<SEC-DOCUMENT>0001558370-22-002737.txt : 20220303
<SEC-HEADER>0001558370-22-002737.hdr.sgml : 20220303
<ACCEPTANCE-DATETIME>20220303083056
ACCESSION NUMBER:		0001558370-22-002737
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		76
CONFORMED PERIOD OF REPORT:	20211231
FILED AS OF DATE:		20220303
DATE AS OF CHANGE:		20220303

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GLYCOMIMETICS INC
		CENTRAL INDEX KEY:			0001253689
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36177
		FILM NUMBER:		22706823

	BUSINESS ADDRESS:	
		STREET 1:		9708 MEDICAL CENTER DRIVE
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		240-243-1201

	MAIL ADDRESS:	
		STREET 1:		9708 MEDICAL CENTER DRIVE
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>glyc-20211231x10k.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 9.6.8042.36810 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 3/3/2022 9:43:43 AM -->
      <!-- iXBRL Library version: 1.0.8042.36816 -->
      <!-- iXBRL Service Job ID: aadc6129-8983-4b30-b4d0-66cca4462be1 -->

  <html xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:glyc="http://glyc.com/20211231" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" xs:nil="true" contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg" name="us-gaap:PreferredStockValue" id="Hidden_AohGR0nW002QcT8etMek_g"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" xs:nil="true" contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug" name="us-gaap:PreferredStockValue" id="Hidden_lfO8cH2MMk2_I8IAXtcv_A"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA" contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" id="Hidden_MfMzt5EkcE6WyYk_4iXzTA">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA" contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" id="Hidden_Us4mRLs5Bk2WaaRS3U7X_A">0</ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" name="dei:DocumentTransitionReport" id="Hidden_FTQh-1T6wkWx-NAQScPX7w">false</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" xs:nil="true" contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" id="Hidden_1YfPvGN8zkuxUetSrMELxA"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" xs:nil="true" contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" id="Hidden_kVVzvEvEd0Oo7zjJJdtzug"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_o6l_rGctYUCSP0KoHptHcQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_rwWrHnExKUCRbPb1Yq_1sA" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" id="Hidden_UfZmMD43P0CtU_nlwGEAYQ">0.02083</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_o6l_rGctYUCSP0KoHptHcQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_CA7rUR2n0UOR1-1JwC42kw" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" id="Hidden_MpFfxPM_9Uq0Hhwoua9x4Q">0.02083</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA" contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member_qc5DeeGdL02LALGoxVJG1g" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" id="Hidden_CPAQxqLmSEmNCmGKblFleQ">93465</ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" name="dei:DocumentAnnualReport" id="Hidden_rd4W_6vNeUy0QPLJGSkzqw">true</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" name="dei:EntityCentralIndexKey" id="Tc_bn5rYJWae0SuCoIaQ0T21w_1_1">0001253689</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" name="dei:CurrentFiscalYearEndDate" id="Tc_zNAgcWt2MUaqIOR4CXpFvA_2_1">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" name="dei:DocumentFiscalYearFocus" id="Tc_rDB8md6t7kWgYTo0G7uf1Q_3_1">2021</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" name="dei:DocumentFiscalPeriodFocus" id="Tc_7iMRKNx_nEOVEGnQzUcNUA_4_1">FY</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" name="dei:AmendmentFlag" id="Tc_IhPCXx0VSkqBfTEaAdBvgQ_5_1">false</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_IVVJKafY3kC3Yl795hDR_Q" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" id="Hidden_PjW0IYReJEOBmlkEA9fwAA">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_z9rHn4j9ykiEqhZQISwvUg" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" id="Hidden_0K-cDCJPGE66OfPYLaO75Q">0</ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_nwn-Uhn-HEykFqNtdjyqYA" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Hidden_0ma8_vtK80W6jIJz3LC8HQ">P3Y</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_f69ARavam0CDVS574-bG4A" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" id="Hidden_SlkqXUTa902BN1_lOh-bNQ">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_95OGnpM2iEC95hp3bmUctw" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" id="Hidden_J0_R-a98aUG0UaJFpC9ytw">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_IVVJKafY3kC3Yl795hDR_Q" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" id="Hidden_pp31TbLqG02QmTAfILU9Ng">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_z9rHn4j9ykiEqhZQISwvUg" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" id="Hidden_aHGqTOTKFkSZ-89kVrt_QQ">0</ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" id="Hidden_jhM2PXDc_EWMY9qaiYQkSQ">true</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_pure_o6l_rGctYUCSP0KoHptHcQ" contextRef="Duration_9_1_2019_To_9_30_2019_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_f8x-KvJQqk2NsjV18XCxTA" decimals="4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" id="Hidden_PGLZbIA_j0-ItwYMfmgcfA">0.3330</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_o6l_rGctYUCSP0KoHptHcQ" contextRef="Duration_9_1_2019_To_9_30_2019_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_tVHL8khK70GIJ-0r9ACJmA" decimals="4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" id="Hidden_BnTvpBXF9EKtCoC_jLU41A">0.6670</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_6ZVfdDCn5UCsvmo46quH_A" contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member_qc5DeeGdL02LALGoxVJG1g" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" id="Hidden_fSABMxeS7UGMQu4eqOoECg">2.00</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_o6l_rGctYUCSP0KoHptHcQ" contextRef="Duration_1_1_2020_To_1_31_2020_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_Ni5UYq-FH06wJXsy0UsclA" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" id="Hidden_CUsjKSRwVk28fq-bDbXrTw">0.25</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA" contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_LKZji1LDq0-yY11lTQsw3g">52313894</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA" contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_ATYOkIk1MEWEdr2__-2oAw">49017622</ix:nonFraction><ix:nonNumeric contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg" name="us-gaap:LeasePracticalExpedientLessorSingleLeaseComponent" id="Hidden_FRgasz_JB0WJUBzD7HF5EA">true</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToTerminate" id="Hidden_1CXabvkwwUuyuzuDaxMsGQ">true</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_pure_o6l_rGctYUCSP0KoHptHcQ" contextRef="Duration_8_1_2021_To_8_31_2021_us-gaap_AwardTypeAxis_glyc_StockOptionsVestingBasedOnPerformanceMember_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_us-gaap_VestingAxis_glyc_VestingUponFDApprovalMember_1pzmNqmNIEmcFmcgorK24A" decimals="4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" id="Hidden_wFFEp6_-yEedIq15Qcrr0w">0.0500</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_o6l_rGctYUCSP0KoHptHcQ" contextRef="Duration_8_1_2021_To_8_31_2021_us-gaap_AwardTypeAxis_glyc_StockOptionsVestingBasedOnPerformanceMember_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_us-gaap_VestingAxis_glyc_VestingUponFirstCommercialSaleMember_vwx6019QKE62DfP2NevoGw" decimals="4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" id="Hidden_Asb0-jwP3ku8JnmG256I7Q">0.0500</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_6ZVfdDCn5UCsvmo46quH_A" sign="-" contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_gp9IuoM4PUq4Jbf5O9pHjA">1.23</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_6ZVfdDCn5UCsvmo46quH_A" sign="-" contextRef="Duration_1_1_2020_To_12_31_2020_n4dAyZdoqEGSie7qc7FpOQ" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_Jnxrdg2Yn0eKClwdHM9Lig">1.12</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_6ZVfdDCn5UCsvmo46quH_A" sign="-" contextRef="Duration_1_1_2019_To_12_31_2019_pmIpEVmd-kmwrLI0XOvIXQ" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_q-I2yQGv7E6NBmp35fa9Vg">1.34</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA" contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" decimals="INF" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_swbcvcGXEUi9_zTi-LxYfg">51453204</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA" contextRef="Duration_1_1_2020_To_12_31_2020_n4dAyZdoqEGSie7qc7FpOQ" decimals="INF" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_xmX3kUCKa0WljNSAu7PGyw">45721139</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA" contextRef="Duration_1_1_2019_To_12_31_2019_pmIpEVmd-kmwrLI0XOvIXQ" decimals="INF" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_aKsQ3aGgBUW6Oqk4LHr7uw">43254782</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="glyc-20211231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="As_Of_12_31_2021_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_D-pk4UYBwUG2J1DzykZ-HQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_TaxCreditCarryforwardAxis_us-gaap_GeneralBusinessMember_ecyj2U3Yt0Wb9cFTtDT3zQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:GeneralBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_1_1_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_glyc_AtMarketOffering2020Member_G7FlJg156E25J7h_zCeUTQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">glyc:AtMarketOffering2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_glyc_AtMarketOffering2017Member_MrvCJyh9ZEiM2EnDxi7KcA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">glyc:AtMarketOffering2017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_cJJA3MCcxUCEbi4HdRpkhQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_7RS26_kETEqvpbTdEEcRHQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_bpFOniAZWESSLirIldcb9A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_fkG-U4OFgECm1zMTvyySFw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_9jiZRJgwUkmiTr7-zEU_pg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ZGf_JC8_7kO1YJVHBI1tHQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_hWu3exZUdEGAkwWw4npmMw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_YBdCsD1cyEWKXTeBpB1Qvw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_T9wbnfgz4EGnt4Ls-f124g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_JRdAbPca-UyPJvyJT5-3gQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_y9GDd_Gl4EG3z9w6EbLWoQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Aswh0QD8T06Z70c7oH6rxw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_glyc_AtMarketOffering2020Member_s7mbdwTmt0uPTw6bugEC2A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">glyc:AtMarketOffering2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_glyc_AtMarketOffering2017Member_m0ia7emTp0-S4cX7E9JaOQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">glyc:AtMarketOffering2017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_0GYTC9bcFEKmU7vQ3oHIOA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityInducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_NttqVJp3_kWhhS50-PEXsg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityIncentivePlan2013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member_qc5DeeGdL02LALGoxVJG1g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:StockIncentivePlan2003Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member_CPK9V-Op3UaIxCwH7D8lOQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:StockIncentivePlan2003Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_NxJ0kAmhLEq77boNzSrSDA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityInducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_6XsGrPnc8UiemnfhfN3QiA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityIncentivePlan2013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_8_1_2021_To_8_31_2021_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_BlzQN5DfO0-Ob94oAMtNUQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityInducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-01</xbrli:startDate><xbrli:endDate>2021-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_1_2021_To_8_31_2021_us-gaap_AwardTypeAxis_glyc_StockOptionsVestingBasedOnPerformanceMember_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_1HlplHgnqkyMSMXLECvRKw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">glyc:StockOptionsVestingBasedOnPerformanceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityInducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-01</xbrli:startDate><xbrli:endDate>2021-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_31_2020_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_1T-jaCj3OkSylxW_fFHbkQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityInducementPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_1_31_2022_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_kGIqsGlMMESnv3YKbnouEg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityInducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_1_31_2020_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_OL9RAaPvWESWUYV6Drys3g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityInducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_v6BAgvQ6UUWIq_blSFIw4Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityIncentivePlan2013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_TvjyyCwqk0mi8fnukedXiQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityIncentivePlan2013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_LNH3eNmn5kWst66eRhnJGQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityIncentivePlan2013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_1_2021_To_8_31_2021_us-gaap_AwardTypeAxis_glyc_StockOptionsVestingBasedOnPerformanceMember_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_us-gaap_VestingAxis_glyc_VestingUponFirstCommercialSaleMember_vwx6019QKE62DfP2NevoGw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">glyc:StockOptionsVestingBasedOnPerformanceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityInducementPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">glyc:VestingUponFirstCommercialSaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-01</xbrli:startDate><xbrli:endDate>2021-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_1_2021_To_8_31_2021_us-gaap_AwardTypeAxis_glyc_StockOptionsVestingBasedOnPerformanceMember_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_us-gaap_VestingAxis_glyc_VestingUponFDApprovalMember_1pzmNqmNIEmcFmcgorK24A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">glyc:StockOptionsVestingBasedOnPerformanceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityInducementPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">glyc:VestingUponFDApprovalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-01</xbrli:startDate><xbrli:endDate>2021-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_rwWrHnExKUCRbPb1Yq_1sA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:StockIncentivePlan2003Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_cofTMv8PCkK6kTIv_T7Wfg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:StockIncentivePlan2003Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_CA7rUR2n0UOR1-1JwC42kw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityIncentivePlan2013Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_oJ50QEhRZ06VPJ26jZEX3Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityIncentivePlan2013Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_1_2019_To_9_30_2019_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_tVHL8khK70GIJ-0r9ACJmA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityIncentivePlan2013Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_1_2019_To_9_30_2019_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_f8x-KvJQqk2NsjV18XCxTA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityIncentivePlan2013Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_1_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_LrXUfN_p-k2RD7cVXcpvfg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityIncentivePlan2013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_1_2019_To_9_30_2019_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_GTVLQ6MzkE-5qigN7ZgeAg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityIncentivePlan2013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_31_2016_srt_StatementGeographicalAxis_glyc_RockvilleMarylandMember_pHaqdBt7jEqRRIagvedypQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">glyc:RockvilleMarylandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_glyc_AtMarketOffering2020Member_-Fh8SrRC9kSsK069fXrH7w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">glyc:AtMarketOffering2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_glyc_AtMarketOffering2020Member_3hZx0NV1dUGxHj4ixh_xdQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">glyc:AtMarketOffering2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_glyc_AtMarketOffering2017Member_xegFN2MRVUeT2e9ks4eOqg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">glyc:AtMarketOffering2017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_caWo07x0RkeYTz7JqqtihQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_XpvrdhTYnU29K3NXwMZg1w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_VeLLEDcIU0adJ4R_8YWwWQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_nwn-Uhn-HEykFqNtdjyqYA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_glyc_LaboratoryEquipmentMember_18gz3PWP5EGrxYtLQQjCmA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">glyc:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_S4Ib7npi4k2n67LEOrpyzw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_Ct0n8oNDQk-VdEoHy-ji7Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_MyBLeUpbCEad5R76PvA7Qw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_NuJWpFqva06fY6gG06su4A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_glyc_LaboratoryEquipmentMember_ZNg--URu-Um0dMbV5peuIw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">glyc:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_vsNg25IaXU2FJMsaQjaLLw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_7L-ZBeUo20ymuDm-db_BBA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_F-fa25zb1EKNL4wYhdv86w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_mVfAbQ5Nbkmu-wiL5cukOg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_glyc_LaboratoryEquipmentMember_nghKysTWSECvGe85266cdw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">glyc:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member_63yRM8kz2kC7BUq4_p_EHA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:StockIncentivePlan2003Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member_5mpVmM87DESzmaMO4y48HQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:StockIncentivePlan2003Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_8PxguNi7E0SE41ALnvi46Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityIncentivePlan2013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_glyc_FederalAndStateAuthoritiesMember_onB_QxVk6kiCCtMYcUAFbg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">glyc:FederalAndStateAuthoritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_j3ehB3FRnke0I31qV9waCw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_s0Ld-3ryuEyoCl6QFxcQJQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_u9sxIh2gcUepx9OR8uIffA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_jja2ssufsk-400-VxFX0dA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_xN1YQshF5Eu9AMf6bQK4Kw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_bi2yzHjMgEqMF9n2Whpj0Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityIncentivePlan2013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_hGgbCUWxnEO5H7nrY_ZOdA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityIncentivePlan2013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_K6ogEy0tQUqO5CmxYBaQzw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityInducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_F6fULr1eMk6oFlHq__Rahw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityIncentivePlan2013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_GhGdoDUAg0O8Z5VKpubXGw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityInducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_Bhd-nQulWU6ZbQQpkblCKw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MaximumMember_w9j8fZvT2UmDwuBnDsgAcw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MaximumMember_dvu4YMBVCkmKgIY5AJuxZA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_lBnwqvQJ-keVmMK3ebV7mA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_LWXbJD-mPkKObqFgUzRVCw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_z9rHn4j9ykiEqhZQISwvUg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_95OGnpM2iEC95hp3bmUctw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_IVVJKafY3kC3Yl795hDR_Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_f69ARavam0CDVS574-bG4A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_glyc_EmployeeStockOptionsAndRestrictedStockUnitsMember_XfZ7v3VAVk-r9VvuNg_XkA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">glyc:EmployeeStockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_glyc_EmployeeStockOptionsAndRestrictedStockUnitsMember_13b9WUxP7EmEaDz7Hl3AmA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">glyc:EmployeeStockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_glyc_EmployeeStockOptionsAndRestrictedStockUnitsMember_Iay9lDc4RUKcxJLhHUjHTg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">glyc:EmployeeStockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_-ABYVM1ePU6I7iAmO9SKmA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_el_OTs7LDkKYMO80TqWrEQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_6th964nOQ0eXBwdN5dw1YA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_z6e36_7PHUuO7wy1SUfrUg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_To7IkJ452EedOpj-Vpzb4Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_rmnCOBDJHkyNTT0GXfj6Mg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_srt_CounterpartyNameAxis_glyc_ApollomicMember__UsntURv-UWFpyJ1frsxHw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">glyc:ApollomicMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Ci6hS_fKd0SPY1WJAb_gGg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_w7tJ7ePME0abPNOD4nmo0g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_5fUBPR76oEmKbes-wtXqbw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cGTT67gulkyrZ4UjnAS9fA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_LwiWCcw92Ui_-9wG0O1diw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_rTR9aq2hpUuLpaRVLeM3fw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_1_2021_To_8_31_2021_us-gaap_AwardTypeAxis_glyc_StockOptionsVestingBasedOnServiceMember_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_pYIDtpqKaEq0Rg2wBD-AaA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">glyc:StockOptionsVestingBasedOnServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityInducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-01</xbrli:startDate><xbrli:endDate>2021-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_glyc_StockOptionsVestingBasedOnPerformanceMember_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_fMP2VYCGhESofSQXDZURMQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">glyc:StockOptionsVestingBasedOnPerformanceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityInducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member_jeH3ukS87UGj2TpOqDjAFA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:StockIncentivePlan2003Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_eZd6RRkvHUKXyt8ofzDQvA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityIncentivePlan2013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_1_31_2020_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_Ni5UYq-FH06wJXsy0UsclA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityInducementPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_glyc_ApollomicMember_u1SJvvGvK0azW3aP0YW7WQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">glyc:ApollomicMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_9_2014_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_d0xG-7CT90iIt0iDg2j1hA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityIncentivePlan2013Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2014-01-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_9_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_glyc_ApollomicMember_fv4inACjoUWDFNulm8LqCA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">glyc:ApollomicMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_n4dAyZdoqEGSie7qc7FpOQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_pmIpEVmd-kmwrLI0XOvIXQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_glyc_AtMarketOffering2020Member_MXBe8LOc-0ysVhlt9Db4Nw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">glyc:AtMarketOffering2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_7_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_glyc_AtMarketOffering2020Member_d7OWn4p530G-EwtpM2jaYA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">glyc:AtMarketOffering2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_7_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_glyc_AtMarketOffering2020Member_OCkznGqV5UKSXhPF0KDe9w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">glyc:AtMarketOffering2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_28_2017_srt_RangeAxis_srt_MaximumMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_glyc_AtMarketOffering2017Member_1BZR7Z0Sy0OeJz_78Y1Cmg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">glyc:AtMarketOffering2017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-09-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_srt_CounterpartyNameAxis_glyc_ApollomicMember_srt_RangeAxis_srt_MaximumMember_jz80Uqp0xkifz7ggXf9mng"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">glyc:ApollomicMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021__Tn0d_2t2kmK0aVp6UxXyQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_28_2022_D_WA6nW5zUak74Vcq9-xqg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_pure_o6l_rGctYUCSP0KoHptHcQ"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_lease_pZ3IxEbMMU6Abz8KmKdkfQ"><xbrli:measure>glyc:lease</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_item_g-Qg15KDVUyxut40CeCIjQ"><xbrli:measure>glyc:item</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_installment_ezhGoeeUrke0O6iEcwxJow"><xbrli:measure>glyc:installment</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_6ZVfdDCn5UCsvmo46quH_A"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit_Standard_segment_SDPUnB8SLEWaCbvZFtu_Hw"><xbrli:measure>glyc:segment</xbrli:measure></xbrli:unit></ix:resources></ix:header></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;min-height:28.8pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:10.35pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;line-height:1.19;text-align:center;border-top:1px solid #000000;margin:0pt 0pt 1pt 0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;line-height:1.19;text-align:center;border-top:1.0pt solid #000000;margin:0pt;">&#160;</p><a id="_b21ddc66_b927_41e4_99cb_d4f41cd7628c"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:4pt 0pt 0pt 0pt;"><b style="font-size:16pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:16pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">WASHINGTON, D.C. 20549</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:9.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:16pt;text-align:center;margin:3pt 0pt 0pt 0pt;"><b style="font-weight:bold;">FORM </b><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" name="dei:DocumentType" id="Narr_Mvgk89Me4UyLSoNgypOeRA"><b style="font-weight:bold;">10-K</b></ix:nonNumeric></p><div style="font-family:'Times New Roman','Times','serif';font-size:9.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:3pt 0pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_rd4W_6vNeUy0QPLJGSkzqw;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">A</b></span><b style="font-weight:bold;">NNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><span style="-sec-ix-hidden:Hidden_FTQh-1T6wkWx-NAQScPX7w;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">O</b></span><b style="font-weight:bold;">F THE SECURITIES EXCHANGE ACT OF 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:3pt 0pt 0pt 0pt;"><b style="font-size:9pt;font-weight:bold;">For the fiscal year ended </b><ix:nonNumeric format="ixt:datemonthdayyearen" contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" name="dei:DocumentPeriodEndDate" id="Narr_2Pb9bzYoQEaSPp8E3Ndjzw"><b style="font-size:9pt;font-weight:bold;">December&#160;31, 2021</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:3pt 0pt 0pt 0pt;"><b style="font-size:9pt;font-weight:bold;">Commission file number </b><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" name="dei:EntityFileNumber" id="Narr_n7t3DOrsp0mryWYXOlvEkA"><b style="font-size:9pt;font-weight:bold;">001-36177</b></ix:nonNumeric></p><div style="font-family:'Times New Roman','Times','serif';font-size:9.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:22pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" name="dei:EntityRegistrantName" id="Narr_MRseQ0peM0G9Hq2hea6V4w"><b style="font-weight:bold;">GlycoMimetics, Inc.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Exact name of Registrant as specified in its charter)</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:9.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p><a id="_26b9ffa2_6d16_4481_ac79_8429bf03ccf2"></a><a id="Tc_1bijig7aWkuB9wst7WgypQ_2_0"></a><a id="Tc_Ah7-0E_J3kCSbaW_cGYg4Q_2_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:50.08%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:49.91%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:50.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" name="dei:EntityIncorporationStateCountryCode" id="Tc_-cSm5UjVEEKp6HAtKvtphQ_1_0"><b style="font-size:9pt;font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:49.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" name="dei:EntityTaxIdentificationNumber" id="Tc_ARbYdd5ivE-tMYgWuTbiyQ_1_1"><b style="font-size:9pt;font-weight:bold;">06-1686563</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:50.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">(State or other jurisdiction of</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;text-indent:-7.2pt;margin:0pt 0pt 1pt 0pt;"><b style="font-weight:bold;">incorporation or organization)</b></p></td><td style="vertical-align:top;width:49.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(IRS Employer</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 1pt 0pt;"><b style="font-weight:bold;">Identification No.)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p><a id="_9ebdb9c4_667a_4d71_a51c_68171887adfb"></a><a id="Tc_GuAAYhm7hE6my8xSgn1QmQ_1_0"></a><a id="Tc_nqQ8v-uxDEe5xPyO1rzFjQ_2_0"></a><a id="Tc_64r6eGhjuk2e5XfXI6Hb9g_2_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:50.4%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:49.59%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:50.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" name="dei:EntityAddressAddressLine1" id="Narr_G99nmOirgkSvBSeHlUxh1g"><b style="font-size:9pt;font-weight:bold;">9708 Medical Center Drive</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:-7.2pt;margin:0pt 0pt 1pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" name="dei:EntityAddressCityOrTown" id="Narr_uNpuW5IHrEOmGt0_teMvQA"><b style="font-size:9pt;font-weight:bold;">Rockville</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">, </b><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" name="dei:EntityAddressStateOrProvince" id="Narr_w3DHqVJS_0yB99Pd3kRKkQ"><b style="font-size:9pt;font-weight:bold;">Maryland</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:49.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" name="dei:EntityAddressPostalZipCode" id="Tc_-MZDa9MEoEqkoaeidVHIwg_1_1"><b style="font-size:9pt;font-weight:bold;">20850</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:50.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">(Address of principal executive offices)</b></p></td><td style="vertical-align:top;width:49.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Zip Code)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:3pt 0pt 0pt 0pt;"><b style="font-size:9pt;font-weight:bold;">Registrant&#8217;s telephone number, including area code: (</b><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" name="dei:CityAreaCode" id="Narr_5qk-2IMbKEWePj0g4TSTBg"><b style="font-size:9pt;font-weight:bold;">240</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">)&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" name="dei:LocalPhoneNumber" id="Narr_VEMPwRNcykqlfMZe8yt2MQ"><b style="font-size:9pt;font-weight:bold;">243-1201</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:3pt 0pt 0pt 0pt;"><b style="font-weight:bold;">Securities registered pursuant to Section&#160;12(b) of the Act:</b></p><a id="_85ee624a_78f9_4184_8755_f43e4034428a"></a><a id="Tc_20NqRdmXKUm3tEmIWFAmpg_1_0"></a><a id="Tc_NHMBMNtYXkidXNUg_2LVzA_1_1"></a><a id="Tc_5uu5iguGhUu0sf-quu627w_1_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:90.84%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:36.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:26.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:36.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:36.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-bottom:1pt;text-align:center;border-bottom:1px solid #000000;margin:3pt 0pt 0pt 0pt;"><b style="font-weight:bold;">Title of Each Class:</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:26.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-bottom:1pt;text-align:center;border-bottom:1px solid #000000;margin:3pt 0pt 0pt 0pt;"><b style="font-weight:bold;">Trading Symbol:</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:36.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-bottom:1pt;text-align:center;border-bottom:1px solid #000000;margin:3pt 0pt 0pt 0pt;"><b style="font-weight:bold;">Name of Each Exchange on which Registered</b></p></th></tr><tr><td style="vertical-align:top;width:36.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" name="dei:Security12bTitle" id="Tc_nNNG2W3zmE2sp42KKEYcng_2_0"><b style="font-size:7pt;font-weight:bold;">Common Stock, $0.001 par value</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:26.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" name="dei:TradingSymbol" id="Tc_Sc-kimo2Kk-TM2gietEkFw_2_1"><b style="font-size:7pt;font-weight:bold;">GLYC</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:36.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" name="dei:SecurityExchangeName" id="Tc_kS8yI1gS50uAjNdtb2j1Mw_2_2"><b style="font-size:7pt;font-weight:bold;">The Nasdaq Stock Market</b></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Securities registered pursuant to Section&#160;12(g) of the Act: None</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:9.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:3pt 0pt 0pt 0pt;"><span style="font-size:9pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span><span style="font-size:9pt;">&#160;&#160;&#160;&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" name="dei:EntityWellKnownSeasonedIssuer" id="Narr_RFDAEPo4y0mI2zuvVqZC8Q"><span style="font-size:9pt;">No</span></ix:nonNumeric><span style="font-size:9pt;">&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:3pt 0pt 0pt 0pt;"><span style="font-size:9pt;">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d) of the Act.&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span><span style="font-size:9pt;">&#160;&#160;&#160;&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" name="dei:EntityVoluntaryFilers" id="Narr_kg2zn7rgwkGShtYu7ddK4Q"><span style="font-size:9pt;">No</span></ix:nonNumeric><span style="font-size:9pt;">&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:3pt 0pt 0pt 0pt;"><span style="font-size:9pt;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" name="dei:EntityCurrentReportingStatus" id="Narr_f8w32ef9G0KMtyjQZFV7Ag"><span style="font-size:9pt;">Yes</span></ix:nonNumeric><span style="font-size:9pt;">&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span><span style="font-size:9pt;">&#160;&#160;&#160;&#160;No&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:3pt 0pt 0pt 0pt;"><span style="font-size:9pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" name="dei:EntityInteractiveDataCurrent" id="Narr_z3ku3-DIDkuZL8-v5hWDiw"><span style="font-size:9pt;">Yes</span></ix:nonNumeric><span style="font-size:9pt;">&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span><span style="font-size:9pt;">&#160;&#160;&#160;&#160;No&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-indent:24.5pt;margin:3pt 0pt 3pt 0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or emerging growth company. See definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer&#8221;, &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p><a id="_1b6f44ad_fadc_4dc0_927b_9d03862b09bd"></a><a id="Tc_WZESmm1xsEquisqycKMLNQ_1_0"></a><a id="Tc_1yxqktCF4E2lUsQVrZKNPQ_1_1"></a><a id="Tc_U4_YLFrt50SzItBzI9WUtA_1_2"></a><a id="Tc_prf507chj0KMzUDk-heJJw_1_3"></a><a id="Tc_yqF_ThSuq0GQEppDFSW_9w_2_1"></a><a id="Tc_T_Hu8GtEaUKMokqgvkdtew_2_2"></a><a id="Tc_-ytbRL5OzUGisT2WKgPJCg_3_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">Large Accelerated Filer</p></td><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">Accelerated Filer</p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td></tr><tr><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:entityfilercategoryen" contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" name="dei:EntityFilerCategory" id="Tc_Ziwsum_nYU-Vvvvi7U0e6A_2_0"><span style="font-size:9pt;">Non-accelerated Filer</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9746;</span></p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">Smaller Reporting Company</p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" name="dei:EntitySmallBusiness" id="Tc_VgD0cKybh0yNrMC9OnUUtw_2_3"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">Emerging Growth Company</p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" name="dei:EntityEmergingGrowthCompany" id="Tc_816N5PBaNE-Nfd_Enyfr_g_3_3"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-indent:24.5pt;margin:3pt 0pt 0pt 0pt;"><span style="white-space:pre-wrap;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:3pt 0pt 0pt 0pt;"><span style="font-size:9pt;white-space:pre-wrap;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.  </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" name="dei:IcfrAuditorAttestationFlag" id="Narr_HEi-2NYQSUmq0xAkZPH3tQ"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:3pt 0pt 0pt 0pt;"><span style="font-size:9pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;Yes&#160;</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" name="dei:EntityShellCompany" id="Narr_ZfRjmE3eT0Oc9051v_AuFg"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric><span style="font-size:9pt;">&#160;&#160;&#160;No&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-indent:24.5pt;margin:3pt 0pt 0pt 0pt;">As of June&#160;30, 2021, the last business day of the registrant&#8217;s last completed second quarter, the aggregate market value of the Common Stock held by non-affiliates of the registrant was approximately $<ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" format="ixt:numdotdecimal" scale="6" contextRef="As_Of_6_30_2021__Tn0d_2t2kmK0aVp6UxXyQ" decimals="-5" name="dei:EntityPublicFloat" id="Narr_2d-ZLaLElkWC_GVi_vbUkw">117.5</ix:nonFraction> million based on the closing price of the registrant&#8217;s Common Stock, as reported by the Nasdaq Global Market, on such date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-indent:24.5pt;margin:3pt 0pt 3pt 0pt;">At February 28, 2022, <ix:nonFraction unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA" format="ixt:numdotdecimal" scale="0" contextRef="As_Of_2_28_2022_D_WA6nW5zUak74Vcq9-xqg" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" id="Narr_OIGXmf0JX0CpvKlhHDZG6A">52,313,894</ix:nonFraction> shares of GlycoMimetics, Inc.&#8217;s Common Stock, $0.001 par value per share, were outstanding. </p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.43;text-align:center;margin:0pt;"><b style="font-weight:bold;">DOCUMENTS INCORPORATED BY REFERENCE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.43;text-indent:18pt;margin:0pt 0pt 3pt 0pt;">Portions of GlycoMimetics, Inc.&#8217;s definitive proxy statement, to be filed pursuant to Regulation&#160;14A under the Securities Exchange Act of 1934, for its 2022 Annual Meeting of Stockholders are incorporated by reference in Part&#160;III of this Form&#160;10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;line-height:1.19;text-align:center;border-top:1px solid #000000;margin:0pt 0pt 1pt 0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;line-height:1.19;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;line-height:1pt;margin-top:1pt;visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_d311fc5b_5162_4d15_b06b_99506754bc44"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">This Annual Report on Form 10-K, or this Annual Report, contains forward-looking statements within the meaning of Section&#160;27A of the Securities Act of 1933, as amended, and Section&#160;21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, that involve substantial risks and uncertainties. The forward-looking statements are contained principally in Part I, Item&#160;1. &#8220;Business,&#8221; Part I, Item&#160;1A. &#8220;Risk Factors,&#8221; and Part II, Item&#160;7. &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; but are also contained elsewhere in this Annual Report. In some cases, you can identify forward-looking statements by the words &#8220;may,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;objective,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;potential,&#8221; &#8220;continue&#8221; and &#8220;ongoing,&#8221; or the negative of these terms, or other comparable terminology intended to identify statements about the future. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this Annual Report, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. Forward-looking statements include statements about: </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:31.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our plans to develop and commercialize our glycomimetic drug candidates; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:31.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our and our collaborators&#8217; ongoing and planned clinical trials for our drug candidates uproleselan and GMI-1359, including the timing of initiation of and enrollment in the trials, the timing of availability of data from the trials and the anticipated results of the trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:31.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing of and our ability to obtain and maintain regulatory approvals for our drug candidates; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:31.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the clinical utility of our drug candidates; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:31.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our commercialization, marketing and manufacturing capabilities and strategy; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:31.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our intellectual property position; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:31.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to identify additional drug candidates with significant commercial potential that are consistent with our commercial objectives; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:31.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our estimates regarding future revenues, expenses and needs for additional financing; and</span></td></tr></table><div style="margin-top:6pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:31.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our beliefs that our capital resources will be sufficient to meet our anticipated cash requirements into the second quarter of 2023. </span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">You should refer to Item 1A. &#8220;Risk Factors&#8221; section of this Annual Report for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. As a result of these factors, we cannot assure you that the forward-looking statements in this Annual Report will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this Annual Report. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">RISK FACTOR SUMMARY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Our business is subject to numerous risks. You should carefully consider the following risks, as well as general economic and business risks, and all of the other information contained in this Annual Report, together with any other documents we file with the SEC. Any of the following risks could have a material adverse effect on our business, operating results and financial condition and cause the trading price of our common stock to decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Among these important risks are the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have incurred significant losses since our inception. We expect to continue to incur losses over the next several years and may never achieve or maintain profitability. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We will need substantial additional funding to pursue our business objectives. If we are unable to raise capital when needed, we may not be able to continue as a going concern and could be forced to delay, reduce or eliminate our drug development programs or potential commercialization efforts.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our drug candidates. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have only one drug candidate in a late-stage clinical trial. If we or our collaborators are unable to commercialize our drug candidates or experience significant delays in doing so, our business will be materially harmed. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Clinical drug development involves a lengthy and expensive process, with an uncertain outcome. We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our drug candidates. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our business could be adversely affected by the effects of health epidemics or pandemics, including the ongoing COVID-19 pandemic, in regions where we or third parties on whom we rely have significant manufacturing facilities, clinical trial sites or other business operations. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If serious adverse or unacceptable side effects are identified during the development of our drug candidates, we may need to abandon or limit the development of some of our drug candidates. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We may expend our limited resources to pursue a particular drug candidate or indication and fail to capitalize on drug candidates or indications that may be more profitable or for which there is a greater likelihood of success. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our success depends in part on current and future collaborations. If we are unable to maintain any of these collaborations, or if these collaborations are not successful, our business could be adversely affected. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We expect to rely on third parties to conduct our future clinical trials for drug candidates, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We contract with third parties for the manufacturing of our drug candidates for preclinical and clinical testing and expect to continue to do so for commercialization. This reliance on third parties increases the risk that we will not have sufficient quantities of our drug candidates or drugs, or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We, or our third-party manufacturers, may be unable to successfully scale-up manufacturing of our drug candidates in sufficient quality and quantity, which would delay or prevent us from conducting our ongoing and planned clinical trials and developing our drug candidates. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Even if any of our drug candidates receives marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We face substantial competition, which may result in others discovering, developing or commercializing drugs before or more successfully than we do. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If we are unable to obtain and maintain patent protection for our drug candidates, or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize drug candidates similar or identical to ours, and our ability to successfully commercialize our drug candidates may be impaired. </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If we or our collaborators are not able to obtain, or if there are delays in obtaining, required regulatory approvals, we or they will not be able to commercialize our drug candidates and our ability to generate revenue will be materially impaired. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Even though we have obtained Orphan Drug designation for several of our drug candidates, we may not be able to obtain orphan drug marketing exclusivity for these or any of our other drug candidates. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The FDA fast track designation and additional Breakthrough Therapy designation for uproleselan may not actually lead to a faster development or regulatory review or approval process. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Failure to obtain marketing approval in international jurisdictions would prevent our drug candidates from being marketed abroad. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">A variety of risks associated with developing and marketing our drug candidates internationally could hurt our business. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Any drug candidate for which we obtain marketing approval could be subject to post-marketing restrictions or recall or withdrawal from the market, and we may therefore be subject to penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our drug candidates, when and if any of them are approved. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Recently enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our drug candidates and affect the prices we may obtain. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Governments outside the United States tend to impose strict price controls, which may adversely affect our revenue, if any. </span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_b10888ae_18b8_404b_87a9_455e7be187f1"></a><a id="Toc"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">TABLE OF CONTENTS</b></p><a id="ITEM6"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:middle;width:3.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:middle;width:10.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:middle;width:79.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:middle;width:7.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></th></tr><tr><td colspan="2" style="vertical-align:top;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:79.61%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;line-height:2pt;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 1pt 0pt;"><b style="font-weight:bold;">Page</b></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#PARTI_62679"><b style="font-style:normal;font-weight:bold;">PART&#160;I </b></a> </p></td><td style="vertical-align:top;width:79.61%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;line-height:2pt;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;border-top:1px solid #000000;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">1</p></td></tr><tr><td style="vertical-align:top;width:3.09%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;line-height:2pt;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM1BUSINESS_704658"><span style="font-style:normal;font-weight:normal;">ITEM&#160;1.</span></a></p></td><td style="vertical-align:top;width:79.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#ITEM1BUSINESS_704658"><span style="font-style:normal;font-weight:normal;">BUSINESS</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">1</p></td></tr><tr><td style="vertical-align:top;width:3.09%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;line-height:2pt;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM1ARISKFACTORS_618694"><span style="font-style:normal;font-weight:normal;">ITEM&#160;1A.</span></a></p></td><td style="vertical-align:top;width:79.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#ITEM1ARISKFACTORS_618694"><span style="font-style:normal;font-weight:normal;">RISK FACTORS</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">26</p></td></tr><tr><td style="vertical-align:top;width:3.09%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;line-height:2pt;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM1BUNRESOLVEDSTAFFCOMMENTS_434071"><span style="font-style:normal;font-weight:normal;">ITEM&#160;1B.</span></a></p></td><td style="vertical-align:top;width:79.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#ITEM1BUNRESOLVEDSTAFFCOMMENTS_434071"><span style="font-style:normal;font-weight:normal;">UNRESOLVED STAFF COMMENTS</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">52</p></td></tr><tr><td style="vertical-align:top;width:3.09%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;line-height:2pt;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM2PROPERTIES_674160"><span style="font-style:normal;font-weight:normal;">ITEM&#160;2.</span></a></p></td><td style="vertical-align:top;width:79.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#ITEM2PROPERTIES_674160"><span style="font-style:normal;font-weight:normal;">PROPERTIES</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">52</p></td></tr><tr><td style="vertical-align:top;width:3.09%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;line-height:2pt;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM3LEGALPROCEEDINGS_697974"><span style="font-style:normal;font-weight:normal;">ITEM&#160;3.</span></a></p></td><td style="vertical-align:top;width:79.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#ITEM3LEGALPROCEEDINGS_697974"><span style="font-style:normal;font-weight:normal;">LEGAL PROCEEDINGS</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">52</p></td></tr><tr><td style="vertical-align:top;width:3.09%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;line-height:2pt;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM4MINESAFETYDISCLOSURES_857992"><span style="font-style:normal;font-weight:normal;">ITEM&#160;4.</span></a></p></td><td style="vertical-align:top;width:79.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#ITEM4MINESAFETYDISCLOSURES_857992"><span style="font-style:normal;font-weight:normal;">MINE SAFETY DISCLOSURES</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">53</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#PARTII_834"><b style="font-style:normal;font-weight:bold;">PART&#160;II </b></a> </p></td><td style="vertical-align:top;width:79.61%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">53</p></td></tr><tr><td style="vertical-align:top;width:3.09%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;line-height:2pt;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM5MARKETFORREGISTRANTSCOMMONEQUITY_65"><span style="font-style:normal;font-weight:normal;">ITEM&#160;5.</span></a></p></td><td style="vertical-align:top;width:79.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#ITEM5MARKETFORREGISTRANTSCOMMONEQUITY_65"><span style="font-style:normal;font-weight:normal;">MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">53</p></td></tr><tr><td style="vertical-align:top;width:3.09%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;line-height:2pt;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM6RESERVED_84617"><span style="font-style:normal;font-weight:normal;">ITEM&#160;6.</span></a></p></td><td style="vertical-align:top;width:79.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM6RESERVED_84617"><span style="font-style:normal;font-weight:normal;">[RESERVED]</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">54</p></td></tr><tr><td style="vertical-align:top;width:3.09%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;line-height:2pt;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM7MDA"><span style="font-style:normal;font-weight:normal;">ITEM&#160;7.</span></a></p></td><td style="vertical-align:top;width:79.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#ITEM7MDA"><span style="font-style:normal;font-weight:normal;">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">55</p></td></tr><tr><td style="vertical-align:top;width:3.09%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;line-height:2pt;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM7AQUANTITATIVEANDQUALITATIVE_860953"><span style="font-style:normal;font-weight:normal;">ITEM&#160;7A.</span></a></p></td><td style="vertical-align:top;width:79.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#ITEM7AQUANTITATIVEANDQUALITATIVE_860953"><span style="font-style:normal;font-weight:normal;">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">65</p></td></tr><tr><td style="vertical-align:top;width:3.09%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;line-height:2pt;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM8FINANCIALSTATEMENTSANDSUPPLEMENTARY"><span style="font-style:normal;font-weight:normal;">ITEM&#160;8.</span></a></p></td><td style="vertical-align:top;width:79.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#ITEM8FINANCIALSTATEMENTSANDSUPPLEMENTARY"><span style="font-style:normal;font-weight:normal;">FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">65</p></td></tr><tr><td style="vertical-align:top;width:3.09%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;line-height:2pt;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM9CHANGESINANDDISAGREEMENTSWITHACCOUN"><span style="font-style:normal;font-weight:normal;">ITEM&#160;9.</span></a></p></td><td style="vertical-align:top;width:79.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#ITEM9CHANGESINANDDISAGREEMENTSWITHACCOUN"><span style="font-style:normal;font-weight:normal;">CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">65</p></td></tr><tr><td style="vertical-align:top;width:3.09%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;line-height:2pt;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM9ACONTROLSANDPROCEDURES_712204"><span style="font-style:normal;font-weight:normal;">ITEM&#160;9A.</span></a></p></td><td style="vertical-align:top;width:79.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#ITEM9ACONTROLSANDPROCEDURES_712204"><span style="font-style:normal;font-weight:normal;">CONTROLS AND PROCEDURES</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">66</p></td></tr><tr><td style="vertical-align:top;width:3.09%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;line-height:2pt;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM9BOTHERINFORMATION_45602"><span style="font-style:normal;font-weight:normal;">ITEM&#160;9B.</span></a></p></td><td style="vertical-align:top;width:79.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#ITEM9BOTHERINFORMATION_45602"><span style="font-style:normal;font-weight:normal;">OTHER INFORMATION</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">66</p></td></tr><tr><td style="vertical-align:top;width:3.09%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;line-height:2pt;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM9CDISCLOSUREREGARDINGFOREIGNJURISDIC"><span style="font-style:normal;font-weight:normal;">ITEM&#160;9C.</span></a></p></td><td style="vertical-align:top;width:79.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#ITEM9CDISCLOSUREREGARDINGFOREIGNJURISDIC"><span style="font-style:normal;font-weight:normal;text-transform:uppercase;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">66</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#PARTIII_655348"><b style="font-style:normal;font-weight:bold;">PART&#160;III</b></a></p></td><td style="vertical-align:top;width:79.61%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">67</p></td></tr><tr><td style="vertical-align:top;width:3.09%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;line-height:2pt;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM10DIRECTORSEXECUTIVEOFFICERSANDCORPO"><span style="font-style:normal;font-weight:normal;">ITEM&#160;10.</span></a></p></td><td style="vertical-align:top;width:79.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#ITEM10DIRECTORSEXECUTIVEOFFICERSANDCORPO"><span style="font-style:normal;font-weight:normal;">DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">67</p></td></tr><tr><td style="vertical-align:top;width:3.09%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;line-height:2pt;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM11EXECUTIVECOMPENSATION_298012"><span style="font-style:normal;font-weight:normal;">ITEM&#160;11.</span></a></p></td><td style="vertical-align:top;width:79.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#ITEM11EXECUTIVECOMPENSATION_298012"><span style="font-style:normal;font-weight:normal;">EXECUTIVE COMPENSATION</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">67</p></td></tr><tr><td style="vertical-align:top;width:3.09%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;line-height:2pt;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM12SECURITYOWNERSHIPOFCERTAINBENEFICI"><span style="font-style:normal;font-weight:normal;">ITEM&#160;12.</span></a></p></td><td style="vertical-align:top;width:79.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#ITEM12SECURITYOWNERSHIPOFCERTAINBENEFICI"><span style="font-style:normal;font-weight:normal;">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">67</p></td></tr><tr><td style="vertical-align:top;width:3.09%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;line-height:2pt;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM13CERTAINRELATIONSHIPSANDRELATEDTRAN"><span style="font-style:normal;font-weight:normal;">ITEM&#160;13.</span></a></p></td><td style="vertical-align:top;width:79.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#ITEM13CERTAINRELATIONSHIPSANDRELATEDTRAN"><span style="font-style:normal;font-weight:normal;">CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">67</p></td></tr><tr><td style="vertical-align:top;width:3.09%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;line-height:2pt;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM14PRINCIPALACCOUNTINGFEESANDSERVICES"><span style="font-style:normal;font-weight:normal;">ITEM&#160;14.</span></a></p></td><td style="vertical-align:top;width:79.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#ITEM14PRINCIPALACCOUNTINGFEESANDSERVICES"><span style="font-style:normal;font-weight:normal;">PRINCIPAL ACCOUNTING FEES AND SERVICES</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">67</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PARTIV_600453"><b style="font-style:normal;font-weight:bold;">PART&#160;IV</b></a></p></td><td style="vertical-align:top;width:79.61%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">68</p></td></tr><tr><td style="vertical-align:top;width:3.09%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;line-height:2pt;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM15EXHIBITSANDFINANCIALSTATEMENTSCHED"><span style="font-style:normal;font-weight:normal;">ITEM&#160;15.</span></a></p></td><td style="vertical-align:top;width:79.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#ITEM15EXHIBITSANDFINANCIALSTATEMENTSCHED"><span style="font-style:normal;font-weight:normal;">EXHIBITS, FINANCIAL STATEMENT SCHEDULES</span></a> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">68</p></td></tr><tr><td style="vertical-align:top;width:3.09%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;line-height:2pt;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM16FORM10KSUMMARY"><span style="font-style:normal;font-weight:normal;">ITEM&#160;16.</span></a></p></td><td style="vertical-align:top;width:79.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#ITEM16FORM10KSUMMARY"><span style="font-style:normal;font-weight:normal;">FORM 10-K SUMMARY</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">70</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:92.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#SIGNATURES_192363"><b style="font-style:normal;font-weight:bold;">SIGNATURES </b></a><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">71</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:92.75%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">i</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_99339ffc_dfaa_4a48_9bfd_d6e8e50fcb6e"></a><a id="PARTI_62679"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">PART </b><b style="font-weight:bold;">I</b></p><a id="ITEM1BUSINESS_704658"></a><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:54pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;"><b style="font-weight:bold;">ITEM&#160; 1.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;"><b style="font-weight:bold;">BUSINES</b><b style="font-weight:bold;">S </b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Company Overview </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">We are a clinical-stage biotechnology company focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. We are developing a pipeline of proprietary glycomimetics, which are small molecules that mimic the structure of carbohydrates involved in important biological processes, to inhibit disease-related functions of carbohydrates such as the roles they play in inflammation, cancer and infection. We believe this represents an innovative approach to drug discovery to treat a wide range of diseases. We are focusing our efforts on drug candidates for diseases that we believe will qualify for Orphan Drug designation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Our proprietary glycomimetics platform is based on our expertise in carbohydrate chemistry and our understanding of the role carbohydrates play in key biological processes. Most human proteins are modified by the addition of complex carbohydrate structures to the surface of such proteins, which affects the functions of the proteins and their interactions with other molecules. Our research and development efforts have focused on drug candidates targeting selectins, which are proteins that serve as adhesion molecules and bind to carbohydrates that are involved in the inflammatory component and progression of a wide range of diseases, including hematologic disorders, cancer and cardiovascular disease. For example, we believe that members of the selectin family play a key role in tumor metastasis and resistance to chemotherapy. Inhibiting specific carbohydrates from binding to selectins has long been viewed as a potentially attractive approach for therapeutic intervention. The ability to successfully develop drug-like carbohydrate compounds that inhibit binding with selectins, known as selectin antagonists, has historically been limited by their potency and the complexities of carbohydrate chemistry. We believe our expertise in the rational design of potent glycomimetic antagonists with drug-like properties and in carbohydrate chemistry enables us to identify highly effective selectin antagonists and other glycomimetics that may inhibit the disease-related functions of certain carbohydrates in order to develop novel drug candidates to address orphan diseases with high unmet medical need.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Overview of Our Drug Candidates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27pt;margin:0pt 0pt 6pt 0pt;">Our current drug candidates are summarized below. We have retained the worldwide development and commercialization rights to each of our drug candidates, except with respect to uproleselan and GMI-1687, for which we have exclusively licensed development and commercialization rights to Apollomics (Hong Kong) Limited, or Apollomics, in Mainland China, Hong Kong, Macau and Taiwan, collectively referred to as Greater China.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Uproleselan </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">We are developing uproleselan, a specific E-selectin inhibitor, to be used in combination with chemotherapy to treat patients with acute myeloid leukemia, or AML, a life-threatening hematologic cancer, and potentially other hematologic cancers. Uproleselan has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration, or FDA, for the treatment of adults with relapsed or refractory AML. In addition, uproleselan has received Orphan Drug designation from the FDA and the European Commission for the treatment of AML.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">E-selectin plays a critical role in binding cancer cells within vascular niches in the bone marrow, which prevents the cells from entering circulation where they can be more readily killed by chemotherapy. In animal studies, uproleselan mobilized AML cancer cells out of the bone marrow, making them more sensitive to chemotherapy. In these studies, tumor burden was significantly reduced in the animals treated with a combination of chemotherapy and uproleselan as compared to animals treated with chemotherapy alone. In addition, the combination of uproleselan with chemotherapy resulted in improved survival rates for the treated animals compared to chemotherapy alone. In other animal studies, uproleselan appeared to also protect normal cells from some of the side effects of chemotherapy. Common side effects of chemotherapy include bone marrow toxicity resulting in neutropenia, which is an abnormally low number of neutrophils, the white blood cells that serve as the primary defense against infection, and mucositis, which is the inflammation and sloughing of the mucous membranes lining the digestive tract. Animals treated with uproleselan and chemotherapy had less severe neutropenia and mucositis and lower bone marrow toxicity as compared to animals treated with chemotherapy alone. We believe that treatment with uproleselan results in lower bone marrow toxicity due to its inhibition of E-selectin, which inhibition makes stem cells in the bone marrow divide less frequently, thereby protecting them from chemotherapy agents that target rapidly dividing cells.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">We completed an initial Phase 1 trial in healthy volunteers for uproleselan and in 2017 we completed enrollment in a Phase 1/2 clinical trial in patients with either relapsed/refractory or de novo/secondary AML. Final e<span style="background:#ffffff;">fficacy and safety data from this Phase 1/2 trial were published in the journal&#160;</span><i style="font-style:italic;">BLOOD</i> in September 2021<span style="background:#ffffff;">, with scientists highlighting an enhanced depth of response following addition of uproleselan to salvage therapy, as indicated by the </span>high remission rates observed in the trial compared to historical experience with salvage chemotherapy alone and 69% rate of <span style="background:#ffffff;">minimal residual disease, or MRD, negativity in evaluable trial participants with relapsed/refractory AML. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27pt;margin:0pt;">In 2018, we dosed the first patient in a Phase 3 clinical trial to evaluate uproleselan in adults with relapsed/refractory AML. In November 2021, we completed enrollment in this Phase 3 clinical trial and expect to report top-line data from this pivotal trial after year-end 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">In May 2018, we signed a Cooperative Research and Development Agreement, or CRADA, with the NCI, part of the National Institutes of Health. Under the terms of the CRADA, we are collaborating with both the NCI and the Alliance for Clinical Trials in Oncology to conduct a randomized, controlled clinical trial evaluating the addition of uproleselan to a standard cytarabine/daunorubicin chemotherapy regimen (7&amp;3) in older adults with previously untreated AML who are eligible for intensive chemotherapy. The first patient in this Phase 2/3 NCI-sponsored trial was dosed in April 2019. Completion of enrollment of the Phase 2 portion, which occurred in December 2021, sets the stage for a planned interim analysis that will evaluate event-free survival and whether the pre-specified threshold for continuing to Phase 3 has been met. The trial may also provide support for regulatory filings if the results of the planned interim analysis are positive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">GMI-1359</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">We are also developing a drug candidate, GMI-1359, that simultaneously targets both E-selectin and a chemokine receptor known as CXCR4. Since E-selectin and CXCR4 are implicated in the retention of cancer cells in the bone and bone marrow, we believe that targeting both E-selectin and CXCR4 with a single compound could improve efficacy in the treatment of cancers that affect the bone and bone marrow, including solid tumors that have a propensity to metastasize to bone. Following a Phase 1 randomized, double-blind, placebo-controlled, single-dose escalation trial of GMI-1359 in healthy volunteers, we conducted a Phase 1b trial of GMI-1359 at Duke University Cancer Center in hormone receptor positive, or HR+, breast cancer patients whose tumors had spread to bone. The goal of this dose escalation trial was to evaluate safety, pharmacokinetics (PK) and pharmacodynamics (PD). Interim data from this Phase 1b study were presented at the American Association of Cancer Research<span style="background:#ffffff;">&#160;</span><span style="background:#ffffff;">(AACR) 2021 Annual Meeting, with</span> clear evidence of dual antagonism on both E-selectin and CXCR4, key PD markers of biologic activity, being observed for participants treated with GMI-1359. Based on activity levels observed in the trial, we are evaluating potential indications for future development where these overlapping functions play key roles, as well as the funding requirement for any potential development opportunities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">Most recently, at the <span style="background:#ffffff;">63</span><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">rd</sup><span style="background:#ffffff;">&#160;</span>American Society of Hematology<span style="background:#ffffff;">&#160;(ASH) Annual Meeting and Exposition in 2021, </span>we presented preclinical data showing that FLT3 inhibitors, such as <span style="background:#ffffff;">quizartinib and sorafenib, upregulate the expression of E-selectin ligands and CXCR4, thereby increasing adhesion to protective niches in the bone marrow microenvironment and inducing chemoresistance. Using</span><span style="background:#ffffff;"> cells from a relapsed AML patient treated with a FLT3 inhibitor in a murine model, the addition of GMI-1359 to quizartinib broke chemoresistance, which led to a significant reduction in leukemic burden and a statistically significant doubling of median survival time from 79 to 158 days (p&lt;0.0001).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">In January 2020, the FDA granted GMI-1359 Orphan Drug designation and Rare Pediatric Disease designation for the treatment of osteosarcoma, a rare cancer affecting approximately 900 adolescents each year in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">GMI-1687</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">We have rationally designed an innovative antagonist of E-selectin, GMI-1687, that could be suitable for subcutaneous administration. Initially developed as a potential life-cycle extension to uproleselan, when given by subcutaneous injection in animal models, GMI-1687 has been observed to have equivalent activity to uproleselan, but at an approximately 1,000-fold lower dose. We believe that GMI-1687 could be developed to broaden the clinical usefulness of an E-selectin antagonist to conditions where outpatient treatment is preferred or required. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">In September 2020 at the virtual meeting of the Foundation for Sickle Cell Disease Research, or FSCDR, we gave an oral presentation on an abstract containing data on GMI-1687, which included data from a preclinical model showing the drug candidate&#8217;s potential as a subcutaneously administered treatment for vaso-occlusive crisis, or VOC, a common complication of sickle cell disease, or SCD. We are currently conducting activities and studies with GMI-1687 to support our planned submission in the first half of 2022 of an investigational new drug application, or IND, to the FDA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Galectin Antagonists</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">Galectin-3 is a carbohydrate-binding protein whose expression has been shown to play a central role in fibrosis and cancer. Galectin-3 has been linked to a number of biologic processes including inflammation, aberrant cell activation and proliferation (macrophages, neutrophils, and mast cells), fibrogenesis and ultimately, organ dysfunction. Experimental data have implicated galectin-3 in a variety of diseases across a number of organ systems, including liver, kidney, lung, eye and heart. Current research also indicates that galectin-3 has important roles in modulating the immune and inflammatory response to cancer that contributes to neoplastic transformation, tumor cell survival, angiogenesis and metastasis. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">Applying our understanding of carbohydrate biology and chemistry, we have rationally designed several high-potency, selective, small-molecule glycomimetic antagonists of galectin-3, including a potential candidate that has demonstrated oral bioavailability. In our preclinical studies, our galectin-3 antagonists have augmented antitumor activity of checkpoint inhibitors and prevented fibrosis following organ damage, which we believe makes them promising therapeutic targets for further evaluation and development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Our Strategy </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">Our goal is to be the leader in the discovery, development and commercialization of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Leveraging the potentially broad applicability of our proprietary glycomimetics platform, our initial focus is to internally develop and advance orphan drug candidates targeted at hematologic cancers and other diseases, and to out-license any drug candidates we may develop that are targeted at larger market opportunities. The key elements of our strategy are to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Complete clinical development of and obtain regulatory approval for uproleselan for the treatment of adults with relapsed/refractory AML. </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Building on positive Phase 1/2 clinical trial results, we recently completed enrollment in a randomized, double-blind, placebo-controlled Phase 3 clinical trial to evaluate uproleselan in adults with relapsed/refractory AML. Trial design was aligned with guidance received from the FDA. In this single pivotal trial, we enrolled 388 adult patients with relapsed or refractory AML at centers in the United States, Canada, Europe and Australia. Based on discussions with our external statisticians, we expect to report preliminary data from the trial after year-end 2022. If the results from this Phase 3 clinical trial are positive, we plan to apply for regulatory approval from the FDA and potentially the European Medicines Agency, or EMA.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Explore the potential use of uproleselan in other AML patient populations through third-party collaborations. </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We are currently collaborating with the National Cancer Institute (NCI) on a Phase 2/3 clinical trial of uproleselan in previously untreated older adults with AML who are fit for intensive chemotherapy. Under the terms of our collaboration, the NCI may fund additional research, including clinical trials of pediatric patients with AML as well as preclinical experiments and clinical trials evaluating alternative chemotherapy regimens.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Expand the potential use of our E-selectin inhibitors (uproleselan and GMI-1687) in other select territories through out-licensing arrangements. </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In January 2020, we entered into a</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">n exclusive collaboration and license agreement with Apollomics for the development and commercialization of uproleselan and GMI-1687 in Greater China. Apollomics will be responsible at its cost for clinical development and commercialization of uproleselan in Greater China, and will work with us to advance the preclinical and clinical development of GMI-1687. We have also entered into separate agreements to provide clinical and commercial supplies of uproleselan and GMI-1687 to Apollomics, and we retain all rights for both compounds in the rest of the world.</span></td></tr></table><div style="margin-top:6pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Advance the development of GMI-1687 for the treatment of acute VOC and hematologic malignancies. </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We plan to develop our selectin inhibitors for the treatment of acute VOC in patients with SCD and as a life-cycle extension to uproleselan in additional hematologic malignancies. </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">We are currently conducting IND-enabling activities with GMI-1687 to support </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our planned submission of an IND for the treatment of acute VOC to the FDA in the first half of 2022.</span></td></tr></table><div style="margin-top:6pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Seek to advance the clinical development of GMI-1359 for the treatment of cancers that affect the bone and bone marrow. </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have recently ended a Phase 1b trial of GMI-1359 in HR+ breast cancer patients whose tumors have spread to bone to evaluate dose escalation as well as safety, PK and PD markers of biologic activity. Based on activity levels observed in the trial, we are evaluating potential indications for future development where these overlapping functions of CXCR4 and e-selectin play key roles, as well as the funding requirement for any potential development opportunities.</span></td></tr></table><div style="margin-top:6pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Apply our insights and our glycomimetics platform to other carbohydrate targets beyond selectins</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. We have identified additional opportunities where carbohydrates play critical roles in disease processes and where we believe we can apply our platform to create targeted glycomimetic drugs. We have designed inhibitors that specifically block the binding of galectin-3 to carbohydrate structures. We have identified a highly potent galectin-3 compound that could be administered orally and plan to conduct additional preclinical studies to further characterize the effects of galectin-3 inhibitors on inflammation and fibrosis, as well as immune processes. </span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Our Platform </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Our proprietary glycomimetics platform is based on our expertise in carbohydrate chemistry and our understanding of the role carbohydrates play in key biological processes. Carbohydrate structures on cell surfaces are responsible for complex carbohydrate-protein binding interactions. Inhibiting these binding interactions affects the functions of these proteins and their interactions with other molecules. We believe our expertise enables us to design specific glycomimetic molecules that can mimic carbohydrate structures and thereby inhibit their disease-related functions. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Our initial focus is on selectin antagonists, which we believe have the potential to address unmet medical needs in a number of orphan and large market opportunities. Selectins have been shown to play a key role in a wide range of diseases, including hematologic disorders, inflammatory diseases, infection, cancer and cardiovascular disease. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Our initial drug design efforts are focused on a naturally occurring, three-dimensional complex carbohydrate core structure known as the Lewis structure. This core structure is naturally modified in a variety of ways to form many different functional carbohydrates. These variations determine the biological functions of the carbohydrates, including functions related to conditions defined above. Accordingly, we believe that this structure provides the foundation for the design of glycomimetic drug candidates that could be used to address a variety of diseases.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Once we identify a carbohydrate structure involved in a disease pathway, we design molecules that mimic that carbohydrate structure and inhibit its disease-related functions by binding to the carbohydrate&#8217;s target receptor, thereby blocking the binding by the native carbohydrate itself. For example, one of the naturally modified Lewis structures binds to selectins, which play a key role in adhesion of AML blasts to the vasculature of the bone marrow. Uproleselan mimics that carbohydrate structure and accordingly binds to selectins, which we believe thereby inhibits the adhesion of AML blasts and renders them more susceptible to killing with cytotoxic chemotherapies. In addition, our glycomimetic molecules are designed to have greater affinity to the carbohydrate&#8217;s target receptor than does the native carbohydrate. This means that the glycomimetic molecules possess stronger intermolecular forces between themselves and the target receptors, and thus &#8220;outcompete&#8221; the native carbohydrates in binding to the relevant target receptors, thereby inhibiting their disease-related functions. Using our glycomimetics platform, we have designed and synthesized a proprietary library of these structures targeting different biological processes. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Our glycomimetics platform includes intellectual property, know-how, expertise, proprietary biological information and biochemical assays, all of which support the rational design of potent glycomimetic compounds. These include: </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Know-how to successfully mimic the Lewis structure, which is common to a number of functional carbohydrates. </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:212.19pt;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Use of empirical methods to determine critical interactions between variations of a particular functional carbohydrate and its target molecule. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Application of the empirically determined bioactive structure of the functional carbohydrate for docking into the binding area of the crystal structure of the target molecule.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Expertise in stabilizing the bioactive core of glycomimetic compounds and increasing the number of interaction contact points to improve affinity. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Experience and technology in synthetic organic chemistry required for the specialized synthesis of carbohydrates and their modifications. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Proprietary assays to determine the binding characteristics, inhibitory activity and biological activity of glycomimetic compounds. </span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Our Pipeline</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:0pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"><span style="font-size:10pt;">We have discovered our drug candidates internally through a rational drug design approach that couples our expertise in carbohydrate chemistry with our knowledge of carbohydrate biology. We are actively developing glycomimetic drug candidates based on this expertise. Our drug candidates and their target indications and development status are summarized in the chart below.</span><span style="text-decoration-color:#000000;background:#000000;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><img src="glyc-20211231x10k006.jpg" alt="Graphic" style="display:inline-block;height:212.19pt;width:486pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Uproleselan &#8212;Targeting the Bone Marrow Microenvironment to Treat Hematologic Cancers</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">We are developing uproleselan, a specific E-selectin antagonist, to be used adjunctively with standard chemotherapy to treat AML and other hematologic cancers. We believe that uproleselan may be used as first-line treatment for elderly patients with AML or for patients with relapsed or refractory AML. Uproleselan targets interactions between cancer cells and the bone marrow microenvironment. In preclinical studies, combining uproleselan with chemotherapy made cancer cells more sensitive to chemotherapy. In other preclinical studies, uproleselan also reduced some of the toxic effects of chemotherapy, including neutropenia and mucositis, on normal cells.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Uproleselan received Orphan Drug designation from the FDA in 2015 for the treatment of patients with AML. In 2016, uproleselan received Fast Track designation from the FDA for the treatment of adult patients with relapsed or refractory AML and elderly patients aged 60&#160;years or older with AML. In 2017, uproleselan received Breakthrough Therapy designation from the FDA for the treatment of adult patients with relapsed or refractory AML. In 2017, the European Commission, based on a favorable recommendation from the EMA Committee for Orphan Medicinal Products, granted Orphan Designation for uproleselan for the treatment of patients with AML. In January 2021, the China National Medical Products Administration Center for Drug Evaluation granted Breakthrough Therapy designation to uproleselan for the treatment of relapsed/refractory AML.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Acute Myeloid Leukemia</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">AML, a hematologic cancer that is characterized by the rapid growth of abnormal white blood cells that accumulate in the bone marrow and interfere with the production of normal blood cells, is a relatively rare disease, but one that accounts for the largest number of annual deaths from leukemia in the United States. According to the Surveillance, Epidemiology, and End Results Program managed by the NCI, there were an estimated 20,240 new cases of AML diagnosed in 2021 in the United States. AML caused an estimated 11,400 deaths in 2021 in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">AML is more commonly present in elderly patients, with a median age at diagnosis of 68 years old according to the NCI. In a review published in the <i style="font-style:italic;">Journal of Clinical Oncology</i>, the median overall survival of patients 60 years old or older was nine months. The overall five-year relative survival rate for all AML patients from 2011 to 2017 was 29.5%. Relative survival is a statistical measure of net survival that is calculated by comparing observed survival with expected survival from a comparable set of people who do not have AML, in order to measure the excess mortality that is associated with the AML diagnosis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">A number of published studies indicate that only some AML patients who receive chemotherapy achieve a complete response, which is defined as the disappearance of all signs of AML, and that most patients with a complete response will eventually relapse. Patients who do not enter remission are referred to as refractory, meaning that they are resistant to the chemotherapy treatment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">We believe there is a need for new treatment options for elderly patients with AML, as well as those AML patients who relapse or develop refractory disease. Most AML patients with relapsed or refractory disease have limited established treatment options and, accordingly, may be referred for participation in clinical studies of potential new therapies. For patients who elect not to participate or are unable to participate, treatment options typically include chemotherapy regimens, hypomethylating agents and supportive care. Further, many elderly patients with AML are too frail to undergo chemotherapy as a result of other medical conditions, and may only be able to tolerate pain comfort or control measures. Without treatment, however, AML is uniformly fatal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><i style="font-style:italic;">Role of E-selectin in AML</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">E-selectin has been shown to play important roles in the progression of AML and its contribution to cell extrinsic chemoresistance. This has been observed in several studies, which have shown that levels of E-selectin correlate with tumor infiltration and relapse in AML. We therefore believe that our E-selectin antagonist, uproleselan, has the potential to improve the current treatment of patients with AML.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Uproleselan Preclinical Development</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Leukemia cells can bind to E-selectin in the bone marrow where they are relatively protected from the effects of chemotherapy. This phenomenon is now known as environment-mediated drug resistance, or EMDR. We believe that E-selectin inhibition disrupts the cell adhesion involved in EMDR and mobilizes blasts out of the bone marrow and into the bloodstream, making them more susceptible to chemotherapy. We believe that this mechanism of action may allow uproleselan to improve chemotherapy response rates, duration of remission and, ultimately, survival in patients with hematologic cancers such as AML.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">In one in vivo study in a mouse model of AML, combining uproleselan with chemotherapy, mobilized AML blast cells and significantly reduced tumor burden as compared to treatment with chemotherapy alone. In an in vitro study, AML cells once bound to E-selectin were more resistant to chemotherapy. In a related study, when treated with uproleselan, the resistance of such cells to chemotherapy was reduced. Tumor cells of patients who have relapsed AML, when tested in the laboratory, bound significantly higher levels of E-selectin than tumor cells of patients at initial diagnosis. Additional preclinical studies in mouse models of AML, in which E-selectin was observed to be upregulated, suggest that AML cells binding to E-selectin have increased chemo-resistance. This is due to the induction of tumor cell survival signaling pathways as a consequence of E-selectin binding. This effect within the bone marrow microenvironment is unique to E-selectin as compared to other vascular adhesion molecules and can be blocked by uproleselan. The results of these preclinical studies were published in the journal Nature Communications in April 2020, and we believe the findings provide important information about how treatment with uproleselan may improve sensitivity to chemotherapy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">As uproleselan disrupts the interactions between cancer cells and bone marrow microenvironment, its mechanism of action is not limited to a single tumor type. In addition to our studies in AML, we have also tested the drug candidate </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">in other cancer models. In in vivo studies involving animal models of multiple myeloma, chronic myelogenous leukemia and acute lymphoblastic leukemia, uproleselan, as an adjunct to standard-of-care chemotherapy, decreased tumor burden and improved survival over chemotherapy alone.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">In addition to its anti-tumor effects, uproleselan, in animal models, has shown protection against some of the toxicities of chemotherapy. In particular, animals treated with uproleselan in combination with chemotherapy had less severe neutropenia and mucositis and lower bone marrow toxicity as compared to animals treated with chemotherapy alone. We believe that treatment with uproleselan results in lower bone marrow toxicity due to its inhibition of E-selectin, thereby making hematopoietic stem cells divide less frequently and protecting them from chemotherapy agents that target rapidly dividing cells. Hematopoietic stem cells are blood cells that give rise to all other types of blood cells and are heavily concentrated in the bone marrow. Based on these reductions in some of the toxicities of chemotherapy, we are evaluating these effects as secondary efficacy endpoints in our clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><i style="font-style:italic;">Expanding the Utility of E-selectin antagonists</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">At the 2018 annual ASH meeting, we reported on the preclinical development of a highly potent antagonist of E-selectin, GMI-1687, which demonstrated significant activity in animal models previously reported for uproleselan but at an approximately 1,000-fold lower dose. This level of activity was obtained following injections under the skin and could alleviate the need for intravenous infusions. Based on these compound characteristics, we believe GMI-1687 could potentially be used in outpatient settings where an E-selectin antagonist has therapeutic relevance. We are currently conducting IND-enabling studies of GMI-1687 and plan to file an IND in the first half of 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">In 2020, we reported on expanded preclinical studies with GMI-1687 in which the subcutaneous administration of GMI-1687 was effective in restoring blood flow in occluded blood vessels in two mouse models of SCD. We believe that these data support our planned development of GMI-1687 for subcutaneous use and self-administration with the potential for use in the early intervention of VOC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Uproleselan Clinical Trials</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">In 2014, we completed a Phase 1 trial of uproleselan in healthy volunteers. The single-site Phase 1 trial was a randomized, double-blind, placebo-controlled, single ascending intravenous dose trial. In the trial, we evaluated the safety, tolerability and PK of uproleselan. Twenty-eight healthy adult subjects were enrolled in cohorts to receive study drug at three dose levels. In the trial, we observed that the subjects tolerated uproleselan well, and that the PK for uproleselan was consistent with what was predicted based on preclinical data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">In 2015, we commenced a multinational Phase 1/2, open-label trial of uproleselan as an adjunct to standard chemotherapy in patients with AML. This trial in males and females with AML was conducted at a number of academic institutions in the United States, Ireland and Australia. The trial consisted of two parts. In the Phase 1 portion, escalation testing was performed to determine a recommended uproleselan dose in combination with standard chemotherapy to be used in the Phase 2 portion. In the Phase 2 portion of the trial, dose expansion was performed at the recommended dose of 10 mg/kg uproleselan in combination with standard chemotherapy. The primary objective of the trial was to evaluate the safety of uproleselan in combination with chemotherapy. Secondary objectives were to characterize PK and PD and to observe anti-leukemic activity. A total of 19 patients with relapsed or refractory AML were enrolled and dosed with a single cycle of treatment with uproleselan and chemotherapy in the Phase 1 portion of the trial. In the Phase 2 portion, one cohort of 25 patients over 60 years of age with newly diagnosed AML and a second cohort of 47 patients with relapsed or refractory AML were enrolled. Unlike in the Phase 1 portion, some of the patients in the Phase 2 portion were eligible to receive multiple cycles of uproleselan with chemotherapy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">In December 2018, we presented final efficacy and correlative results from the Phase 1/2 trial at the annual ASH <span style="background:#ffffff;">meeting</span>. Key highlights from the Phase 1/2 clinical data include the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Relapsed/Refractory (R/R) AML Cohort: There were 66 patients in the R/R cohort, of which 54 were in the recommended Phase 2 dose (RP2D) group. At the RP2D, CR (complete remission)/CRi (complete remission with incomplete blood count recovery) rate was 41%, median overall survival, or OS, was 8.8 months (95% CI 5.7-11.4) and 69% of evaluable patients (11/16) achieved minimal residual disease, or MRD, negativity as assessed by either flow and/or DNA-based methods such as reverse transcription polymerase chain reaction (RT-PCR). OS will be the primary outcome measure in our ongoing Phase 3 trial in relapsed/refractory AML patients. In historical controls, OS of approximately 5.2-5.4 months has been observed in this population with this treatment approach. If we are able to achieve OS results in the Phase 3 trial comparable to those observed </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">in the Phase 1/2 clinical trial, it could be a significant improvement over the results observed in these historical controls.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Newly Diagnosed AML Cohort: At the RP2D, CR/CRi rate was 72%, median overall survival was 12.6 months (95% CI 9.9-not reached), event-free survival (EFS) was 9.2 months (95% CI 3.0-12.6) and 56% of evaluable patients (5 out of 9) achieved MRD negativity as assessed by either flow and/or DNA-based methods such as RT-PCR. Of note, the EFS data (primary outcome measure for the interim analysis in the&#160;NCI-sponsored clinical trial in newly diagnosed AML patients) compares favorably to a range of 2.0-6.5 months for EFS in historical controls, which generally included lower risk patient populations than those treated in our Phase 1/2 trial.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">An analysis of E-selectin ligand expression on leukemic cells demonstrated that detectable levels were present on leukemic blasts for every patient tested, providing clinical evidence of biological relevance of the E-selectin ligand in this disease setting. In bone marrow samples, leukemic stem cell expression of E-selectin ligand correlated with leukemic blast E-selectin ligand expression (p&lt;0.0001), consistent with the hypothesis that E-selectin-mediated interactions are a mechanism of chemoresistance. Additionally, investigators assessed the association between baseline E-selectin ligand expression on leukemic blasts and clinical outcomes using a log-rank test. In the R/R cohort of patients treated with uproleselan and evaluated for E-selectin ligand expression at baseline, this analysis demonstrated that &#8805;10% E-selectin ligand expression was correlated with prolonged survival (p&lt;0.01) compared to &lt;10% E-selectin ligand expression. We believe this observation is important because in patients not treated with uproleselan the scientific literature has instead observed that high levels of E-selectin ligand correlated with a worse clinical prognosis. The addition of uproleselan in our study appears to have reversed this trend toward worsened prognosis, and we believe this result may be achieved through the restoration of chemosensitivity.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Based on these results, we are conducting a randomized, double-blind, placebo-controlled Phase 3 clinical trial to evaluate uproleselan in individuals with relapsed/refractory AML, with a trial design aligned with guidance received from the FDA. The primary efficacy endpoint is overall survival, and the FDA has advised us that data on overall survival will not need to be censored for transplant in the primary efficacy analysis, meaning that patients who proceed to transplant will continue to be included as part of the survival analysis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">All patients are being treated with standard chemotherapy of either MEC (mitoxantrone, etoposide and cytarabine) or FAI (fludarabine, cytarabine and idarubicin), with approximately half of the patients randomized to receive uproleselan in addition to chemotherapy. Patients receiving uproleselan are dosed for one day prior to initiation of chemotherapy, twice a day through the chemotherapy regimen, and then for two days after the end of chemotherapy, which was the same schedule as in the Phase 2 portion of the Phase 1/2 trial. The dose regimen is fixed, rather than weight-based, which we believe simplifies administration, and we are offering up to three cycles of consolidation therapy in both arms of the trial for patients who achieve remission. We believe that multiple cycles of treatment in patients who respond may drive an even deeper response in patients treated with uproleselan. If this is the case, it could lengthen the duration of remission with potential for additional benefit on survival. Key secondary endpoints of the Phase 3 trial include the incidence of severe mucositis and remission rate, which will be assessed in a hierarchical fashion to provide supportive data. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Enrollment in this pivotal trial began in the fourth quarter of 2018, and we completed enrollment of the trial with a total of 388 patients in November 2021 at centers in the United States, Canada, Europe and Australia. Based on discussions with our external statisticians who are overseeing the results from the trial, we expect to report preliminary data from this trial after year-end 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">In 2018, we signed a CRADA with the NCI. Under the terms of the CRADA, we are collaborating with both the NCI and the Alliance for Clinical Trials in Oncology to conduct a Phase 2/3 randomized, controlled clinical trial testing the addition of uproleselan to a standard cytarabine/daunorubicin chemotherapy regimen (7&amp;3) in older adults with previously untreated AML who are fit for intensive chemotherapy. Following completion of enrollment of the Phase 2 portion of the study, which occurred in December 2021, there will be an interim analysis of EFS. The full trial is expected to enroll approximately 670 patients with a primary endpoint is overall survival, which is defined as the time from the date of randomization to death from any cause. Under the terms of the CRADA, the NCI may also fund additional research, including clinical trials involving pediatric patients with AML as well as preclinical experiments and clinical trials evaluating alternative populations and chemotherapy regimens. We will supply uproleselan as well as </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">provide financial support to augment data analysis and monitoring for the Phase 2/3 program. Completion of enrollment now sets the stage for a planned evaluation of the Phase 2 portion of the trial to determine whether the prespecified threshold for continuing to Phase 3 has been met based on EFS results.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Uproleselan is also being studied in multiple investigator-sponsored trials (ISTs). In May 2021, clinicians at the Washington University School of Medicine in St. Louis dosed the first patient in a Phase 2 IST evaluating uproleselan as a prophylactic agent to reduce gastrointestinal (GI) toxicities and improve clinical outcomes in patients receiving high-dose melphalan in autologous hematopoietic cell transplantation (auto-HCT) for multiple myeloma. Up to 50 patients will be enrolled, and we anticipate a preliminary/interim data readout from the trial in 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">In July 2021, clinicians at&#160;the University of California (UC) Davis Comprehensive Cancer Center&#160;initiated dosing of the first patient in a clinical study of uproleselan combined with venetoclax and azacitidine for the treatment of older or unfit patients with treatment-na&#239;ve AML. The goal of the two-part IST is first to determine a recommended Phase 2 dose, and then to explore efficacy in a dose expansion cohort. We are providing uproleselan for the IST. Up to 31 patients will be enrolled, and a preliminary/interim readout is expected in 2022. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">In July 2021, clinicians at the University of Texas MD Anderson Cancer Center treated the first patient in a Phase 1b/2 study evaluating uproleselan, added to cladribine plus low dose cytarabine, in patients with treated secondary AML (ts-AML). Considered a distinct high-risk subset of AML with an adverse prognosis, ts-AML is defined as AML arising from a previously treated antecedent myeloid neoplasm (myelodysplastic syndrome or myeloproliferative neoplasm).We are providing uproleselan for the IST. The Phase 1b/2 single-arm trial is enrolling patients 18 years or older, with a diagnosis of ts-AML who have not received therapy for their AML. Clinicians plan to enroll approximately 25 patients in the trial and a preliminary/interim readout is expected in 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">In November 2021, clinicians at the University of Michigan initiated dosing of the first patient in a clinical study of uproleselan in patients with severe COVID-19 pneumonia. Soluble E-selectin is a significant biomarker for acute respiratory distress syndrome (ARDS). Soluble E-selectin also has pro-inflammatory properties further releasing cytokines and promoting its synthesis and the continued influx of neutrophils. The goal of the study is to evaluate the safety of uproleselan in this patient population to determine if treatment with E-selectin inhibitors can reduce the progression of ARDS. Clinicians plan to enroll approximately 15 patients in the trial and a preliminary/interim readout is expected in 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">GMI-1359 - Drug Candidate Targeting E-selectin and CXCR4</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">The chemokine CXCR4 has emerged as an important pro-inflammatory cytokine that is involved in cell migration throughout the body. Like E-selectin, tumor cells may also use the CXCR4 cellular pathway, contributing to chemoresistance, metastatic disease and ultimately decreased survival. We are developing GMI-1359 that simultaneously targets both E-selectin and CXCR4. Since E-selectin and CXCR4 are implicated in keeping cancer cells in the bone marrow, we believe that targeting both E-selectin and CXCR4 with a single compound could improve efficacy in the treatment of cancers that affect the bone marrow, such as hematologic cancers, including AML and multiple myeloma, metastases of certain solid tumors, such as breast and prostate cancer, and primary tumors of the bone such as osteosarcoma, a rare cancer affecting about 900 adolescents a year in the United States, as compared to targeting CXCR4 alone.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Leukemic cells and circulating tumor cells derived from adenocarcinomas home to and are retained in the bone marrow via defined sinusoidal vascular gateways that express E-selectin and soluble mediators such as C-X-C motif chemokine 12 (CXCL12, also known as stem cell-derived factor 1). This homing and retention occurs through an interaction with E-selectin ligands and the chemokine receptor for CXCL12, CXCR4, which is expressed on tumor cells. Interrupting E-selectin-mediated cell activation, adhesion and homing and CXCR4-mediated homing and cell migration and retention may be synergistic and could have therapeutic benefit in many malignancies with unmet medical need. We believe the use of an E-selectin/CXCR4 dual antagonist as an adjunct to chemotherapy and possibly immunotherapy could improve response and remission rates, remission duration, and, ultimately, survival, particularly in malignancies where bone involvement is a primary hallmark of cancer growth and metastasis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">In one in vivo mouse model of bone metastatic prostate carcinoma, combining GMI-1359 with docetaxel significantly reduced tumor burden and attenuated bone destruction compared to docetaxel alone. In two mouse models of primary osteosarcoma, administration of GMI-1359 resulted in inhibition of both tumor growth and spread to the lung. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">These results were presented during the 2015 and 2018 meetings of the American Association of Cancer Research. In both mouse models, GMI-1359 showed single agent activity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">GMI-1359 has completed a Phase 1 single-dose escalation trial in healthy volunteers. In this trial, volunteer participants received a single injection of GMI-1359, after which they were evaluated for safety, tolerability, PK and PD. This randomized, double-blind, placebo-controlled, dose-escalation trial was conducted at a single site in the United States. GMI-1359 was generally well tolerated in this trial, with no subjects experiencing serious adverse events. We initiated a Phase 1b trial of GMI-1359 in the fourth quarter of 2019 at the Duke University Cancer Center in HR+ breast cancer patients whose tumors have spread to bone. The trial evaluated safety and PK and PD markers of biologic activity in these patients. The first patient was dosed in January 2020, and the trial ended in the fourth quarter of 2021. Evidence of on-target effects of GMI-1359 was observed in patients, including CD34+ mobilization and decreased soluble E-selectin levels following drug dosing. This data was presented during the 2021 meeting of the American Association of Cancer Research. In January 2020, the FDA granted GMI-1359 Orphan Drug designation and Rare Pediatric Disease designation for the treatment of osteosarcoma. Based on activity levels observed in the trial, we are evaluating potential indications for future development where these overlapping functions play key roles, as well as the funding requirement for any potential development opportunities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">GMI-1687</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">We have rationally designed an innovative antagonist of E-selectin, GMI-1687, that could be suitable for subcutaneous administration. Initially developed as a potential life-cycle extension to uproleselan, when given by subcutaneous injection in animal models, GMI-1687 has been observed to have equivalent activity to uproleselan, but at an approximately 1,000-fold lower dose. We believe that GMI-1687 could be developed to broaden the clinical usefulness of an E-selectin antagonist to conditions where outpatient treatment is preferred or required. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">In September 2020 at the virtual meeting of the FSCDR, we gave an oral presentation on an abstract containing data on GMI-1687, which included data from a preclinical model showing the drug candidate&#8217;s potential as a subcutaneously administered treatment for VOC, a common complication of SCD. We are currently conducting activities and studies with GMI-1687 to support our planned submission of an IND to the FDA in the first half of 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Galectin Inhibitors</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Using our glycomimetics platform, we have designed galectin-3 inhibitors that specifically block the binding of galectin-3 to carbohydrate structures. Galectin-3 is a protein that is known to play critical roles in many pathological processes, including fibrosis, checkpoints in T-cell exhaustion during cancer immunotherapy, chemotherapy resistance and cardiovascular disease. We continue to optimize these compounds and conduct additional preclinical experiments to further characterize the effects of our galectin-3 inhibitors on immune processes, fibrotic-associated disease progression and to determine if these compounds can be orally bioavailable. One such compound, GMI-2093, has been observed to be 30% bioavailable through oral administration. Another compound, GMI-1757, is a dual antagonist of both E-selectin and galectin-3 and inhibited thrombus formation in a vena cava model and fibrosis in a corneal neovascularization model. These results were presented at ASH in 2018.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our Collaboration and License Agreement with Apollomics for Uproleselan and GMI-1687</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">In January 2020, we entered into an exclusive collaboration and license agreement with Apollomics for the development and commercialization of uproleselan and GMI-1687 for all fields and all uses in Greater China. Apollomics will be responsible for all clinical development and commercialization activities in&#160;Greater China. We and Apollomics will also collaborate to advance the preclinical and clinical development of GMI-1687. As part of the agreement, we&#160;received an upfront cash payment&#160;of&#160;$9.0 million&#160;and will be eligible to receive potential milestone payments totaling approximately&#160;$180.0 million based on the achievement of specified development, regulatory and commercial milestones, as well as tiered royalties ranging from the high single digits to 15% based on net sales. In September 2020, we received a non-refundable $1.0 million development milestone payment upon acceptance by Chinese regulatory authorities of a Phase 3 bridging study design to support registration in China. Apollomics will be responsible for all costs related to development, regulatory approvals and commercialization in Greater China for </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">uproleselan and GMI-1687. We&#160;retain all rights for both compounds in the rest of the world and have agreed to supply uproleselan and GMI-1687 to Apollomics pursuant to clinical and commercial supply agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27pt;margin:0pt 0pt 6pt 0pt;">In June 2020, we entered into a clinical supply agreement with Apollomics under which we will manufacture and supply uproleselan product to Apollomics at agreed upon prices. Apollomics has the option to begin manufacture after appropriate material transfer requirements are met. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">In September 2020, the China National Medical Products Administration (NMPA)&#160;Center for Drug Evaluation (CDE) granted IND approval for uproleselan (also referred to as APL-106), enabling the initiation of a Phase 1 PK and tolerability study. The IND approval also includes acceptance of a Phase 3 bridging study of APL-106 in combination with chemotherapy in relapsed/refractory AML. In January 2021, APL-106 was granted Breakthrough Therapy designation from the China NMPA CDE for the treatment of relapsed/refractory acute myeloid leukemia. In March 2021, Apollomics enrolled the first patient in the Phase 1 study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">We and Apollomics have established a joint development committee to oversee activities under the collaboration and license agreement. The collaboration and license agreement will terminate on a region-by-region basis upon the expiration of the royalty term for each region, unless earlier terminated by either party. Either party may terminate the collaboration and license agreement upon prior written notice, subject to specified conditions, including uncured material breach, or upon bankruptcy or insolvency of the other party. Apollomics may terminate the collaboration and license agreement upon prior written notice for any reason.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Intellectual Property</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27pt;margin:0pt 0pt 6pt 0pt;">We strive to protect the intellectual property that we believe is important to our business, including seeking and maintaining patent protection intended to cover the composition of matter of our drug candidates and their methods of use. We have issued patents which cover uproleselan and methods of use that are expected to expire between 2032 and 2033. In addition, we have several pending patent applications covering uproleselan and/or methods of using it, the last expiring of which, if issued, currently would be predicted to expire in 2041. We also have an issued patent covering GMI-1359 and methods of use that is expected to expire in 2036. In addition, we have several pending patent applications covering GMI-1359 and/or methods of using it, the last expiring of which, if issued, currently would be predicted to expire in 2041. We also have an issued patent covering GMI-1687 that is expected to expire in 2037. In addition, we have several pending patent applications covering GMI-1687 and/or methods of using it, the last expiring of which, if issued, currently would be predicted to expire in 2041. We also have several pending patent applications directed to our lead galectin antagonist compounds and their methods of use, the last of which, if issued, currently would be predicted to expire in 2041. We also rely on trade secret protection for our confidential and proprietary information and careful monitoring of such information to protect aspects of our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27pt;margin:0pt 0pt 6pt 0pt;">Our success will depend significantly on our ability to obtain and maintain patent and other proprietary protection for commercially important inventions and know-how related to our business, defend and enforce our patents, preserve the confidentiality of our trade secrets and operate without infringing the valid and enforceable patents and other proprietary rights of third parties. We also rely on know-how and continuing technological innovation to develop, strengthen and maintain our proprietary position in the field of glycomimetics.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">A third party may hold intellectual property, including patent rights that are important or necessary to the development of our drug candidates. It may be necessary for us to use the patented or proprietary technology of third parties to commercialize our drug candidates, in which case we would be required to obtain a license from these third parties. If we are not able to obtain such a license, or are not able to obtain such a license on commercially reasonable terms, our business could be materially harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">We plan to continue to expand our intellectual property estate by filing patent applications directed to additional glycomimetic compounds and their derivatives, compositions and formulations containing them and methods of using them. Additionally, we will seek patent protection in the United States and internationally for novel compositions of matter covering the compounds and their use in a variety of therapies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">The patent positions of biotechnology companies like us are generally uncertain and involve complex legal, scientific and factual questions. In addition, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance, including where a reissue application is filed in relation to an issued patent to correct issues or errors arising during prosecution that may render claims of the issued patent either wholly or partially invalid or unenforceable. Consequently, we do not know whether any of our drug </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">candidates will be protectable or remain protected by enforceable patents. We cannot predict whether the patent applications we are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient proprietary protection from competitors. Any patents that we hold may be challenged, circumvented or invalidated by third parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Because patent applications in the United States and certain other jurisdictions are maintained in secrecy for 18 months, and since publication of discoveries in the scientific or patent literature often lags behind actual discoveries, we cannot be certain of the priority of inventions covered by pending patent applications. Moreover, we may have to participate in interference proceedings declared by the U.S. Patent and Trademark Office, or USPTO, or a foreign patent office to determine priority of invention or in post-grant challenge proceedings, such as oppositions, that challenge priority of invention or other features of patentability. Such proceedings could result in substantial cost, even if the eventual outcome is favorable to us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Manufacturing</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">We do not have any manufacturing facilities or personnel. We currently rely, and expect to continue to rely, on third parties for the manufacturing of our drug candidates for preclinical and clinical testing, as well as for commercial manufacturing if our drug candidates receive marketing approval. We anticipate continuing to manage process development, scale-up and manufacturing under contracts with third parties. For uproleselan, we expect a significant increase in manufacturing as we prepare for potential regulatory filings for marketing approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">All of our drug candidates are small molecules and are manufactured in reliable and reproducible synthetic processes from readily available starting materials. The chemistry does not require unusual equipment in the manufacturing process. We expect to continue to develop drug candidates that can be produced cost-effectively at contract manufacturing facilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Commercialization</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">We have not yet established a sales, marketing or drug distribution infrastructure. We generally expect to retain commercial rights in the United States for our current drug candidates, all of which are still in preclinical or clinical development. We believe that it will be possible for us to access the U.S. market for those drug candidates through a focused, specialized, key account sales force. With respect to uproleselan and GMI-1687, we have granted Apollomics exclusive commercialization rights in Greater China, and we may grant similar rights to third parties for our drug candidates in other jurisdictions around the world.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Subject to receiving marketing approvals, we expect to commence commercialization activities by building or outsourcing a focused sales, marketing and key account management organization in the United States to sell our drugs. We believe that such an organization will be able to target the community of physicians who are the key specialists in treating the patient populations for which our drug candidates are being developed. Outside the United States, we expect to enter into distribution and other marketing arrangements with third parties for any of our drug candidates that obtain marketing approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">We also plan to build a marketing and sales management organization to create and implement marketing strategies for any drugs that we market through our own sales organization and to oversee and support our sales force. The responsibilities of the marketing organization would include developing educational initiatives with respect to approved drugs and establishing relationships with thought leaders in relevant fields of medicine.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Competition</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">The key competitive factors affecting the success of all of our drug candidates, if approved, are likely to be their safety, efficacy, convenience, price, the level of generic competition and the availability of coverage and reimbursement from government and other third-party payors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.5pt;margin:0pt;">As the treatment landscape for AML changes, there is substantial risk that uproleselan might not provide additional benefit over other existing therapies. A key consideration in the treatment of relapsed/refractory AML patients is the patient&#8217;s suitability for intensive salvage chemotherapy. The patient population being studied in our ongoing Phase 3 clinical trial of uproleselan includes AML patients deemed able to tolerate salvage chemotherapy. While there is no commonly accepted single standard approach for salvage chemotherapy, existing options for the treatment of relapsed/refractory AML patients who can tolerate salvage chemotherapy include cytarabine-based combinations. In addition, we are aware of several other products and product candidates that are commercially available or are in </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">development as potential treatment options for AML patients. Some of the patient populations being studied for these product candidates in development overlap with the patient population being studied in our Phase 3 clinical trial of uproleselan. The existence of established treatment options and the development of competing therapies for relapsed/refractory AML patients could negatively impact our ability to successfully commercialize uproleselan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.5pt;margin:0pt 0pt 6pt 0pt;">The following therapies have been approved by the FDA for the treatment of AML:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">RYDAPT&#174; (midostaurin), an oral prescription medicine commercialized by Novartis to be used in combination with certain chemotherapy medicines to treat adults with newly diagnosed AML who have a defect in a gene called FLT3;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">IDHIFA&#174; (enasidenib), a prescription medicine commercialized by Celgene intended to treat people with AML with an isocitrate dehydrogenase-2 (IDH2) mutation whose disease has come back or has not improved after previous treatments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">VYXEOS</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">TM</sup><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> (daunorubicin and cytarabine), commercialized by Jazz Pharmaceuticals, which is indicated for the treatment of adults with newly-diagnosed therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">MYLOTARG</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">TM</sup><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> (</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">gemtuzumab ozogamicin</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">), commercialized by Pfizer, which is indicated for the treatment </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">for the treatment of newly-diagnosed CD33-positive AML in adults (in combination with daunorubicin and cytarabine) and for treatment of relapsed or refractory CD33-positive AML in adults and in pediatric patients aged 2 years and older as a stand-alone treatment;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">TIBSOVO&#174;</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;"> </sup><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ivosidenib), a prescription medicine commercialized by Agios intended to treat people with AML with an isocitrate dehydrogenase-1 (IDH1) mutation whose disease has come back or has not improved after previous treatments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">XOSPATA&#174; (gilteritinib), an oral prescription medicine commercialized by Astellas intended to treat people with AML with a FLT3 gene mutation whose disease has come back or has not improved after previous treatments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">DAURISMO (glasdigib), an oral prescription medicine commercialized by Pfizer to be used in combination with low-dose cytarabine, for the treatment of newly-diagnosed AML in adult patients who are &#8805;75 years old or who have comorbidities that preclude use of intensive induction chemotherapy; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">VENCLEXTA&#174; (venetoclax), an oral prescription medicine commercialized by AbbVie/Genentech to be used </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">in combination with azacitidine, or decitabine, or low-dose cytarabine to treat adults with newly-diagnosed AML who </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">are either 75 years of age or older, or have other medical conditions that prevent the use of standard chemotherapy; and </span></td></tr></table><div style="margin-top:6pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ONUREG&#174; (Azacitidine), an oral prescription medicine for continued treatment of adult patients with AML who achieved CR or CRi following intensive induction chemotherapy and are not able to complete intensive curative therapy.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.5pt;margin:0pt 0pt 6pt 0pt;">While many chemotherapies and targeted therapies, either approved or in development for hematologic malignancies, will likely be complementary to uproleselan, there are also therapies in development that could be directly competitive with uproleselan. In particular, Pfizer has recently initiated Phase 1 development of an E-selectin antibody <span style="background:#ffffff;">(PF-07209326).</span> While the initial target indication for this biologic is SCD, it is possible Pfizer could expand development to AML and other hematologic malignancies. Additionally, there are a number of CXCR4 antagonists in clinical development that target <span style="background:#ffffff;">the bone marrow microenvironment in order to mobilize and sensitize cancer cells to chemotherapy or other therapies, including candidates developed by </span>Sanofi-Aventis <span style="background:#ffffff;">(Mozobil), Bristol Myers Squibb (BMS-936564), NOXXON Pharma (NOX-A12), Eli Lilly (LY2510924) and BioLine RX (BL-8040).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">Many of the companies against which we are competing, or against which we may compete in the future, have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved drugs than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early stage companies may also prove to be significant </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Government Regulation and Product Approval</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Government authorities in the United States, at the federal, state and local levels, and in other countries, extensively regulate, among other things, the research, development, testing, manufacture, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing, import and export of pharmaceutical products, such as those we are developing. The processes for obtaining regulatory approvals in the United States and in foreign countries, along with subsequent compliance with applicable statutes and regulations, require the expenditure of substantial time and financial resources.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">United States Government Regulation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">In the United States, the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act, or FDCA, and its implementing regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable United States requirements at any time during the drug development process, approval process or after approval, may subject an applicant to a variety of administrative or judicial sanctions, such as the FDA&#8217;s refusal to approve pending new drug applications, or NDAs, withdrawal of an approval, imposition of a clinical hold, issuance of warning or untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement or civil or criminal penalties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">The process required by the FDA before a drug may be marketed in the United States generally involves:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">completion of preclinical laboratory tests, animal studies and formulation studies in compliance with the FDA&#8217;s good laboratory practice, or GLP, regulations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">submission to the FDA of an IND, which must become effective before human clinical trials may begin;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">approval by an independent institutional review board, or IRB, at each clinical site before each trial may be initiated;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">performance of human clinical trials, including adequate and well-controlled clinical trials, in accordance with good clinical practices, or GCP, to establish the safety and efficacy of the proposed drug for each indication;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">submission to the FDA of an NDA;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">satisfactory completion of an FDA advisory committee review, if applicable;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the product is produced to assess compliance with current good manufacturing practices, or cGMP, and to assure that the facilities, methods and controls are adequate to preserve the drug&#8217;s identity, strength, quality and purity, as well as satisfactory completion of an FDA inspection of selected clinical sites to determine GCP compliance; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">FDA review and approval of the NDA.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 24.45pt;"><i style="font-style:italic;">Preclinical Studies</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Preclinical studies include laboratory evaluation of product chemistry, toxicity and formulation, as well as animal studies to assess potential safety and efficacy. An IND sponsor must submit the results of the preclinical studies, together with manufacturing information, analytical data and any available clinical data or literature, among other things, to the FDA as part of an IND. Some preclinical testing may continue even after the IND is submitted. An IND automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to one or more proposed clinical trials and places the clinical trial on a clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. As a result, submission of an IND may not result in the FDA allowing clinical trials to commence.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 24.45pt;"><i style="font-style:italic;">Clinical Trials</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Clinical trials involve the administration of the investigational new drug to human subjects under the supervision of qualified investigators in accordance with GCP requirements, which include the requirement that all research subjects provide their informed consent in writing for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the trial, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND. In addition, an IRB at each institution participating in the clinical trial must review and approve the plan for any clinical trial before it commences at that institution, and the IRB must continue to oversee the clinical trial while it is being conducted. Information about certain clinical trials must be submitted within specific timeframes to the National Institutes of Health, or NIH, for public dissemination on their ClinicalTrials.gov website.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Human clinical trials are typically conducted in three sequential phases, which may overlap or be combined. In Phase 1, the drug is initially introduced into healthy human subjects or patients with the target disease or condition and tested for safety, dosage tolerance, absorption, metabolism, distribution, excretion and, if possible, to gain an initial indication of its effectiveness. In Phase 2, the drug typically is administered to a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage. In Phase 3, the drug is administered to an expanded patient population, generally at geographically dispersed clinical trial sites, in well-controlled clinical trials to generate enough data to statistically evaluate the safety and efficacy of the product for approval, to establish the overall risk-benefit profile of the product and to provide adequate information for the labeling of the product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Progress reports detailing the results of the clinical trials must be submitted, at least annually, to the FDA, and more frequently if serious adverse events occur. Phase 1, Phase 2 and Phase 3 clinical trials may not be completed successfully within any specified period, or at all. Furthermore, the FDA or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements, or if the drug has been associated with unexpected serious harm to patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">A sponsor may request a Special Protocol Assessment, or SPA, the purpose of which is to reach agreement with the FDA on the Phase 3 clinical trial protocol design and analysis that will form the primary basis of an efficacy claim. According to the FDA&#8217;s published guidance on the SPA process, a sponsor that meets the prerequisites may make a specific request for an SPA and provide information regarding the design and size of the proposed clinical trial. The FDA is supposed to evaluate the protocol within 45 days of the request to assess whether the protocol design and planned analysis of the trial are acceptable to support regulatory approval of the product candidate with respect to effectiveness of the indication studied, and that evaluation may result in discussions and a request for additional information. An SPA request must be made before the proposed trial begins, and all open issues must be resolved before the trial begins for an SPA to be approved. If a written agreement is reached, it will be documented in an SPA letter or the minutes of a meeting between the sponsor and the FDA and made part of the administrative record.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Even if the FDA agrees to the design, execution and analyses proposed in protocols reviewed under the SPA process, the FDA may revoke or alter its agreement under the following circumstances:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">public health concerns emerge that were unrecognized at the time of the protocol assessment, or the director of the review division determines that a substantial scientific issue essential to determining safety or efficacy has been identified after testing has begun;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a sponsor fails to follow a protocol that was agreed upon with the FDA; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the relevant data, assumptions, or information provided by the sponsor in a request for SPA change are found to be false statements or misstatements, or are found to omit relevant facts.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">A documented SPA may be modified, and such modification will be deemed binding on the FDA review division, except under the circumstances described above, if the FDA and the sponsor agree in writing to modify the protocol and such modification is intended to improve the study. An SPA, however, does not guarantee that a trial will be successful.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 24.5pt;"><i style="font-style:italic;">Marketing Approval</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Assuming successful completion of the required clinical testing, the results of the preclinical and clinical studies, together with detailed information relating to the product&#8217;s chemistry, manufacture, controls and proposed labeling, among other things, are submitted to the FDA as part of an NDA requesting approval to market the product for one or more indications. In most cases, the submission of an NDA is subject to a substantial application user fee. Under the Prescription Drug User Fee Act, or PDUFA, guidelines that are currently in effect, the FDA has agreed to certain performance goals regarding the timing of its review of an application.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">In addition, under the Pediatric Research Equity Act, an NDA or supplement to an NDA must contain data that are adequate to assess the safety and effectiveness of the drug for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data until after approval of the product for use in adults, or full or partial waivers from the pediatric data requirements. Unless otherwise required by regulation, the pediatric data requirements do not apply to products with orphan designation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">The FDA also may require submission of a risk evaluation and mitigation strategy, or REMS, plan to mitigate any identified or suspected serious risks. The REMS plan could include medication guides, physician communication plans, assessment plans and elements to assure safe use, such as restricted distribution methods, patient registries or other risk minimization tools.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">The FDA conducts a preliminary review of all NDAs within the first 60 days after submission, before accepting them for filing, to determine whether they are sufficiently complete to permit substantive review. The FDA may request additional information rather than accept an NDA for filing. In this event, the application must be resubmitted with the additional information. The resubmitted application is also subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth substantive review. The FDA reviews an NDA to determine, among other things, whether the drug is safe and effective and whether the facility in which it is manufactured, processed, packaged or held meets standards designed to assure the product&#8217;s continued safety, quality and purity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">The FDA typically refers questions regarding novel drugs to an external advisory committee. An advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Before approving an NDA, the FDA typically will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA, the FDA will typically inspect one or more clinical trial sites to assure compliance with GCP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">The testing and approval process for an NDA requires substantial time, effort and financial resources, and could take several years to complete. Data obtained from preclinical and clinical testing are not always conclusive and may be susceptible to varying interpretations, which could delay, limit or prevent regulatory approval. The FDA may not grant approval of an NDA on a timely basis, or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">After evaluating the NDA and all related information, including the advisory committee recommendation, if any, and inspection reports regarding the manufacturing facilities and clinical trial sites, the FDA may issue an approval letter, or, in some cases, a complete response letter. A complete response letter generally contains a statement of specific conditions that must be met in order to secure final approval of the NDA and may require additional clinical or preclinical testing in order for the FDA to reconsider the application. Even with submission of this additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. If and when those conditions have been met to the FDA&#8217;s satisfaction, the FDA will typically issue an approval letter. An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 24.45pt;"><i style="font-style:italic;">Special FDA Expedited Review and Approval Programs</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">The FDA has various programs, including fast track designation, accelerated approval, priority review, and breakthrough therapy designation, which are intended to expedite or simplify the process for the development and the FDA review of drugs that are intended for the treatment of serious or life threatening diseases or conditions and demonstrate the potential to address unmet medical needs. The purpose of these programs is to provide important new drugs to patients earlier than under standard FDA review procedures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">To be eligible for a fast track designation, the FDA must determine, based on the request of a sponsor, that a product is intended to treat a serious or life-threatening disease or condition and demonstrates the potential to address an unmet medical need. The FDA will determine that a product will fill an unmet medical need if it will provide a therapy where none exists or provide a therapy that may be potentially superior to existing therapy based on efficacy or safety factors. The FDA may review sections of the NDA for a fast track product on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the NDA, the FDA agrees to accept sections of the NDA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">The FDA may give a priority review designation to drugs that offer major advances in treatment, or provide a treatment where no adequate therapy exists. A priority review means that the goal for the FDA to review an application is six months, rather than the standard review of ten months under current PDUFA guidelines. These six and ten month review periods are measured from the &#8220;filing&#8221; date rather than the receipt date for NDAs for new molecular entities, which typically adds approximately two months to the timeline for review and decision from the date of submission. Most products that are eligible for fast track designation are also likely to be considered appropriate to receive a priority review.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">In addition, products studied for their safety and effectiveness in treating serious or life-threatening illnesses and that provide meaningful therapeutic benefit over existing treatments may be eligible for accelerated approval and may be approved on the basis of adequate and well-controlled clinical trials establishing that the drug product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity or prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA may require a sponsor of a drug receiving accelerated approval to perform post-marketing studies to verify and describe the predicted effect on irreversible morbidity or mortality or other clinical endpoint, and the drug may be subject to accelerated withdrawal procedures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">A sponsor can also request designation of a product candidate as a &#8220;breakthrough therapy.&#8221; A breakthrough therapy is defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. Drugs designated as breakthrough therapies are also eligible for accelerated approval. The FDA must take certain actions, such as holding timely meetings and providing advice, intended to expedite the development and review of an application for approval of a breakthrough therapy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. We may explore some of these opportunities for our product candidates as appropriate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 24.45pt;"><i style="font-style:italic;">Post-Approval Requirements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Drugs manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion and reporting of adverse experiences with the product. After approval, most changes to the approved product, such as adding new indications, manufacturing changes or other labeling claims, are subject to further testing requirements and prior FDA review and approval. There also are continuing annual user fee requirements for any marketed products, as well as application fees for supplemental applications with clinical data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">Even if the FDA approves a product, it may limit the approved indications for use of the product, require that contraindications, warnings or precautions be included in the product labeling, including a boxed warning, require that </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">post-approval studies, including Phase 4 clinical trials, be conducted to further assess a drug&#8217;s safety after approval, require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution restrictions or other risk management mechanisms under a REMS, which can materially affect the potential market and profitability of the product. The FDA may prevent or limit further marketing of a product based on the results of post-marketing studies or surveillance programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">In addition, drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and state agencies, and are subject to periodic unannounced inspections by the FDA and these state agencies for compliance with cGMP requirements. Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting and documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain cGMP compliance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in mandatory revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fines, warning letters or holds on post-approval clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of product license approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product seizure or detention, or refusal to permit the import or export of products; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">injunctions or the imposition of civil or criminal penalties.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Although physicians, in the practice of medicine, may prescribe approved drugs for unapproved indications, pharmaceutical companies generally are required to promote their drug products only for the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability. However, physicians may, in their independent medical judgment, prescribe legally available products for off-label uses. The FDA does not regulate the behavior of physicians in their choice of treatments but the FDA does restrict manufacturer&#8217;s communications on the subject of off-label use of their products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">In addition, the distribution of prescription pharmaceutical products is subject to the Prescription Drug Marketing Act, or PDMA, which regulates the distribution of drugs and drug samples at the federal level, and sets minimum standards for the registration and regulation of drug distributors by the states. Both the PDMA and state laws limit the distribution of prescription pharmaceutical product samples and impose requirements to ensure accountability in distribution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 24.45pt;"><i style="font-style:italic;">Federal and State Fraud and Abuse, Data Privacy and Security, and Transparency Laws and Regulations</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">In addition to FDA restrictions on marketing of pharmaceutical products, federal and state healthcare laws and regulations restrict business practices in the biopharmaceutical industry. These laws include, but are not limited to, anti-kickback and false claims laws and regulations, data privacy and security, and transparency laws and regulations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">The federal Anti-Kickback Statute prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving remuneration to induce or in return for purchasing, leasing, ordering or arranging for or </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">recommending the purchase, lease or order of any item or service reimbursable under Medicare, Medicaid or other federal healthcare programs. The term &#8220;remuneration&#8221; has been broadly interpreted to include anything of value. The Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on one hand and prescribers, purchasers and formulary managers on the other. Although there are a number of statutory exemptions and regulatory safe harbors protecting some common activities from prosecution, the exemptions and safe harbors are drawn narrowly and require strict compliance in order to offer protection. Practices that involve remuneration that may be alleged to be intended to induce prescribing, purchases or recommendations may be subject to scrutiny if they do not qualify for an exemption or safe harbor. Several courts have interpreted the statute&#8217;s intent requirement to mean that if any one purpose of an arrangement involving remuneration is to induce referrals of federal healthcare covered business, the statute has been violated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">The reach of the federal Anti-Kickback Statute was also broadened by the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively PPACA, which, among other things, amended the intent requirement of the federal Anti-Kickback Statute such that a person or entity no longer needs to have actual knowledge of this statute or specific intent to violate it in order to have committed a violation. In addition, PPACA provides that the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act or the civil monetary penalties statute, which imposes penalties against any person or entity who is determined to have presented or caused to be presented a claim to a federal health program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Federal false claims laws, including the federal civil False Claims Act, prohibit any person or entity from knowingly presenting, or causing to be presented, a false claim for payment to the federal government or knowingly making, using or causing to be made or used a false record or statement material to a false or fraudulent claim to the federal government. A claim includes &#8220;any request or demand&#8221; for money or property presented to the U.S. government. Pharmaceutical and other healthcare companies have been prosecuted under these laws for, among other things, allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product. Companies also have been prosecuted for causing false claims to be submitted because of the companies&#8217; marketing of products for unapproved, and thus non-reimbursable, uses. The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, created additional federal criminal statutes that prohibit, among other things, knowingly and willfully executing a scheme to defraud any healthcare benefit program, including private third-party payors and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Also, many states have similar fraud and abuse statutes or regulations that apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payor.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">In addition, we may be subject to data privacy and security regulation by both the federal government and the states in which we conduct our business. HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and their respective implementing regulations, including the Final HIPAA Omnibus Rule published on January&#160;25, 2013, imposes specified requirements on certain types of individuals and entities relating to the privacy, security and transmission of individually identifiable health information. Among other things, HITECH makes HIPAA&#8217;s security standards directly applicable to &#8220;business associates,&#8221; defined as independent contractors or agents of covered entities that create, receive, maintain or transmit protected health information in connection with providing a service for or on behalf of a covered entity. HITECH also increased the civil and criminal penalties that may be imposed against covered entities, business associates and possibly other persons, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorney&#8217;s fees and costs associated with pursuing federal civil actions. In addition, state laws govern the privacy and security of health information in certain circumstances, many of which are not pre-empted by HIPAA, differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">The federal Physician Payments Sunshine Act requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with specific exceptions, to report annually to the Centers for Medicare &amp; Medicaid Services, or CMS, information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), other healthcare professionals (such as physician assistants and nurse practitioners) and </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">teaching hospitals, and applicable manufacturers and applicable group purchasing organizations to report annually to CMS ownership and investment interests held by the physicians and their immediate family members.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">We may also be subject to state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, as well as state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Because of the breadth of these laws and the narrowness of available statutory and regulatory exemptions, it is possible that some of our business activities could be subject to challenge under one or more of such laws. If our operations are found to be in violation of any of the federal and state laws described above or any other governmental regulations that apply to us, we may be subject to penalties, including administrative, criminal and significant civil monetary penalties, damages, fines, disgorgement, imprisonment, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, contractual damages, reputational harm, diminished profits and future earnings, disgorgement, exclusion from participation in government healthcare programs and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. To the extent that any of our products are sold in a foreign country, we may be subject to similar foreign laws and regulations, which may include, for instance, applicable post-marketing requirements, including safety surveillance, anti-fraud and abuse laws and implementation of corporate compliance programs and reporting of payments or transfers of value to healthcare professionals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 24.5pt;"><i style="font-style:italic;">Coverage and Reimbursement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">The future commercial success of our drug candidates or any of our collaborators&#8217; ability to commercialize any approved drug candidates successfully will depend in part on the extent to which governmental payor programs at the federal and state levels, including Medicare and Medicaid, private health insurers and other third-party payors provide coverage for and establish adequate reimbursement levels for our drug candidates. Government health administration authorities, private health insurers and other organizations generally decide which drugs they will pay for and establish reimbursement levels for healthcare. In particular, in the United States, private health insurers and other third-party payors often provide reimbursement for products and services based on the level at which the government, through the Medicare or Medicaid programs, provides reimbursement for such treatments. In the United States, the European Union, or EU, and other potentially significant markets for our drug candidates, government authorities and third party payors are increasingly attempting to limit or regulate the price of medical products and services, particularly for new and innovative products and therapies, which often has resulted in average selling prices lower than they would otherwise be. Further, the increased emphasis on managed healthcare in the United States and on country and regional pricing and reimbursement controls in the EU will put additional pressure on product pricing, reimbursement and usage, which may adversely affect our future product sales and results of operations. These pressures can arise from rules and practices of managed care groups, judicial decisions and laws and regulations related to Medicare, Medicaid and healthcare reform, pharmaceutical coverage and reimbursement policies and pricing in general.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">Third-party payors are increasingly imposing additional requirements and restrictions on coverage and limiting reimbursement levels for medical products. For example, federal and state governments reimburse covered prescription drugs at varying rates generally below average wholesale price. These restrictions and limitations influence the purchase of healthcare services and products. Third-party payors may limit coverage to specific drug products on an approved list, or formulary, which might not include all of the FDA-approved drug products for a particular indication. Third-party payors are increasingly challenging the price and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety and efficacy. We may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of our products, in addition to the costs required to obtain the FDA approvals. Our drug candidates may not be considered medically necessary or cost-effective. A payor&#8217;s decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved. Further, one payor&#8217;s determination to provide coverage for a drug product does not assure that other payors will also provide coverage for the drug product. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in drug development. Legislative proposals to reform healthcare or reduce costs under government insurance programs may result in lower reimbursement for our drugs and drug candidates or exclusion of our drugs and drug candidates from coverage. The cost containment measures that healthcare payors and providers are instituting and any healthcare reform could significantly reduce our </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">revenues from the sale of any approved drug candidates. We cannot provide any assurances that we will be able to obtain and maintain third party coverage or adequate reimbursement for our drug candidates in whole or in part.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 24.5pt;"><i style="font-style:italic;">Impact of Healthcare Reform on our Business</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">The United States and some foreign jurisdictions are considering enacting or have enacted a number of additional legislative and regulatory proposals to change the healthcare system in ways that could affect our ability to sell our products profitably. Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts, which include major legislative initiatives to reduce the cost of care through changes in the healthcare system, including limits on the pricing, coverage, and reimbursement of pharmaceutical and biopharmaceutical products, especially under government-funded health care programs, and increased governmental control of drug pricing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">There have been several U.S. government initiatives over the past few years to fund and incentivize certain comparative effectiveness research, including creation of the Patient-Centered Outcomes Research Institute under PPACA. Although the results of the comparative effectiveness studies are not intended to mandate coverage policies for public or private payors, it is not clear what effect, if any, the research will have on the sales of any product, if any such product or the condition that it is intended to treat is the subject of a study. It is also possible that comparative effectiveness research demonstrating benefits in a competitor&#8217;s product could adversely affect the sales of our product candidates. If third-party payors do not consider our drug candidates to be cost-effective compared to other available therapies, they may not cover our drug candidates, once approved, as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow us to sell our drugs on a profitable basis. PPACA became law in March 2010 and substantially changed the way healthcare is financed by both governmental and private insurers. Among other measures that may have an impact on our business, PPACA established an annual, nondeductible fee on any entity that manufactures or imports specified branded prescription drugs and biologic agents; a new Medicare Part D coverage gap discount program; and a new formula that increases the rebates a manufacturer must pay under the Medicaid Drug Rebate Program. Additionally, PPACA extends manufacturers&#8217; Medicaid rebate liability, expands eligibility criteria for Medicaid programs, and expands entities eligible for discounts under the Public Health Service pharmaceutical pricing program. There remain judicial and Congressional challenges to certain aspects of PPACA, as well as efforts by the executive branch at various times to repeal or replace certain aspects of the PPACA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Since January 2017, two Executive Orders were signed that were designed to delay the implementation of any certain provisions of the PPACA or otherwise circumvent some of the requirements for health insurance mandated by the PPACA. Concurrently, Congress has considered legislation that would repeal or repeal and replace all or part of the PPACA. While Congress has not passed comprehensive repeal legislation, two bills affecting the implementation of certain taxes under the PPACA have been signed into law. The Tax Cuts and Jobs Act of 2017 includes a provision repealing, effective January 1, 2019, the tax-based shared responsibility payment imposed by the PPACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual mandate&#8221;. In addition, the 2020 federal spending package permanently eliminated, effective January 1, 2020, the PPACA-mandated &#8220;Cadillac&#8221; tax on high-cost employer-sponsored health coverage and medical device tax and, effective January 1, 2021, also eliminates the health insurer tax. The Bipartisan Budget Act of 2018, or the BBA, among other things, amended the ACA, effective January&#160;1, 2019, to increase from 50&#160;percent to 70&#160;percent the point-of-sale discount that is owed by pharmaceutical manufacturers who participate in Medicare Part D and to close the coverage gap in most Medicare drug plans, commonly referred to as the &#8220;donut hole.&#8221; For example, on June 17, 2021, the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. Thus, the ACA will remain in effect in its current form. Further, prior to the U.S. Supreme Court ruling, on January 28, 2021, President Biden issued an executive order to initiate a special enrollment period for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructs certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. It is unclear how any such challenges and healthcare reform measures of the Biden administration will impact ACA and our business. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">In addition, there has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. Specifically, there have been several recent U.S. Congressional inquiries and proposed </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">federal and proposed and enacted state legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. At the federal level, the Trump administration used several means to propose implementing drug pricing reform, including through federal budget proposals, executive orders and policy initiatives. For example, on July 24, 2020 and September 13, 2020, the Trump administration announced several executive orders related to prescription drug pricing that seek to implement several of the administration&#8217;s proposals. As a result, the FDA released a final rule and guidance on September 24, 2020, providing guidance for states to build and submit importation plans for drugs from Canada. Further, on November 20, 2020, the U.S. Department of Health and Human Services finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The implementation of the rule has been delayed by the Biden administration from January 1, 2022 to January 1, 2023 in response to ongoing litigation. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers, the implementation of which have also been delayed pending review by the Biden administration until January 1, 2023. On November 20, 2020, the Centers for Medicare &amp; Medicaid Services, or CMS, issued an interim final rule implementing President Trump&#8217;s Most Favored Nation executive order, which would tie Medicare Part B payments for certain physician-administered drugs to the lowest price paid in other economically advanced countries. As a result of litigation challenging the Most Favored Nation model, on December 27, 2021, CMS published a final rule that rescinded the Most Favored Nation model interim final rule. In July 2021, the Biden administration released an executive order, &#8220;Promoting Competition in the American Economy,&#8221; with multiple provisions aimed at prescription drugs. In response to Biden&#8217;s executive order, on September 9, 2021, HHS released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue to advance these principles. No legislation or administrative actions have been finalized to implement these principles. In addition, Congress is considering drug pricing as part of other reform initiatives. At the state level, legislatures are increasingly passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">As a result of PPACA, Medicare payments are increasingly tied to quality of care and value measures, and reporting of related data by providers such as physicians and hospitals. So called &#8220;value based reimbursement&#8221; measures may present challenges as well as potential opportunities for biopharmaceutical manufacturers. Medicare incentives for providers meeting certain quality measures may ultimately prove beneficial for manufacturers that are able to establish that their products may help providers to meet such measures. However, manufacturers&#8217; ability to market their drug products based on quality or value is highly regulated and not always permissible. In addition, the potentially decreased Medicare reimbursement to those providers that fail to adequately comply with quality reporting requirements could translate to decreased resources available to purchase products and may negatively impact marketing or utilization of our drug candidates if they are approved for marketing. We cannot predict at this time what impact, if any, the longer-term shift towards value based reimbursement will have on any of our drug candidates in either the Medicare program, or in any other third party payor programs that may similarly tie payment to provider quality.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">In addition, other legislative changes have been proposed and adopted since PPACA was enacted. In August 2011, the President signed into law the Budget Control Act of 2011, as amended, which, among other things, created the Joint Select Committee on Deficit Reduction to recommend proposals in spending reductions to Congress. The Joint Select Committee on Deficit Reduction did not achieve its targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, triggering the legislation&#8217;s automatic reductions to several government programs. These reductions include aggregate reductions to Medicare payments to providers of up to 2% per fiscal year, which began in 2013 and, following passage of the Bipartisan Budget Act of 2015, will continue through 2031, except for a temporary suspension from May 1, 2020 through March 31, 2022 due to the COVID-19 pandemic, unless additional Congressional action is taken. Under current legislation, the actual reduction in Medicare payments will vary from 1% in 2022 to up to 3% in the final fiscal year of this sequester. On March 11, 2021, President Biden signed the American Rescue Plan Act of 2021 into law, which eliminates the statutory Medicaid drug rebate cap, currently set at 100% of a drug&#8217;s average manufacturer price, for single source and innovator multiple source drugs, beginning January 1, 2024. In January 2013, President Obama signed into law the American Taxpayer Relief Act of 2012, which, among other things, reduced Medicare payments to several providers and increased the statute of limitations period for the government to recover </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">overpayments to providers from three to five years. Additional legislative proposals to reform healthcare and government insurance programs, along with the trend toward managed healthcare in the United States, could influence the purchase of medicines and reduce reimbursement and/or coverage of our product candidates, if approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 24.5pt;"><i style="font-style:italic;">Exclusivity and Approval of Competing Products</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"><i style="font-style:italic;">Hatch-Waxman Patent Listing</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">In seeking approval for a drug through an NDA, applicants are required to list with the FDA each patent with claims that cover the applicant&#8217;s product or a method of using the product. Upon approval of a drug, each of the patents listed in the application for the drug is then published in the FDA&#8217;s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book. Drugs listed in the Orange Book can, in turn, be cited by potential competitors in support of approval of an abbreviated new drug application, or ANDA, or 505(b)(2) NDA. Generally, an ANDA provides for marketing of a drug product that has the same active ingredients in the same strengths, dosage form and route of administration as the listed drug and has been shown to be bioequivalent through <i style="font-style:italic;">in vitro </i>or <i style="font-style:italic;">in vivo </i>testing or otherwise to the listed drug. ANDA applicants are not required to conduct or submit results of preclinical or clinical tests to prove the safety or efficacy of their drug product, other than the requirement for bioequivalence testing. Drugs approved in this way are commonly referred to as &#8220;generic equivalents&#8221; to the listed drug, and can often be substituted by pharmacists under prescriptions written for the original listed drug. 505(b)(2) NDAs generally are submitted for changes to a previously approved drug product, such as a new dosage form or indication.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">The ANDA or 505(b)(2) NDA applicant is required to certify to the FDA concerning any patents listed for the approved product in the FDA&#8217;s Orange Book, except for patents covering methods of use for which the ANDA applicant is not seeking approval. Specifically, the applicant must certify with respect to each patent that:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the required patent information has not been filed;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the listed patent has expired;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the listed patent has not expired, but will expire on a particular date and approval is sought after patent expiration; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the listed patent is invalid, unenforceable or will not be infringed by the new product.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Generally, the ANDA or 505(b)(2) NDA cannot be approved until all listed patents have expired, except when the ANDA or 505(b)(2) NDA applicant challenges a listed drug. A certification that the proposed product will not infringe the already approved product&#8217;s listed patents or that such patents are invalid or unenforceable is called a Paragraph IV certification. If the applicant does not challenge the listed patents or indicate that it is not seeking approval of a patented method of use, the ANDA or 505(b)(2) NDA application will not be approved until all the listed patents claiming the referenced product have expired.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">If the ANDA or 505(b)(2) NDA applicant has provided a Paragraph IV certification to the FDA, the applicant must also send notice of the Paragraph IV certification to the NDA and patent holders once the application has been accepted for filing by the FDA. The NDA and patent holders may then initiate a patent infringement lawsuit in response to the notice of the Paragraph IV certification. The filing of a patent infringement lawsuit within 45 days after the receipt of notice of the Paragraph IV certification automatically prevents the FDA from approving the ANDA or 505(b)(2) NDA until the earlier of 30 months, expiration of the patent, settlement of the lawsuit or a decision in the infringement case that is favorable to the ANDA applicant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"><i style="font-style:italic;">Hatch-Waxman Non-Patent Exclusivity</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Market and data exclusivity provisions under the FDCA also can delay the submission or the approval of certain applications for competing products. The FDCA provides a five-year period of non-patent data exclusivity within the United States to the first applicant to gain approval of an NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the activity of the drug substance. During the exclusivity period, the FDA may not accept for review an ANDA or a 505(b)(2) NDA submitted by another company that contains the previously approved active moiety. However, an ANDA or 505(b)(2) NDA may be submitted after four years if it contains a certification of patent invalidity or noninfringement.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">The FDCA also provides three years of marketing exclusivity for an NDA, 505(b)(2) NDA or supplement to an existing NDA or 505(b)(2) NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant, are deemed by the FDA to be essential to the approval of the application or supplement. Three-year exclusivity may be awarded for changes to a previously approved drug product, such as new indications, dosages, strengths or dosage forms of an existing drug. This three-year exclusivity covers only the conditions of use associated with the new clinical investigations and, as a general matter, does not prohibit the FDA from approving ANDAs or 505(b)(2) NDAs for generic versions of the original, unmodified drug product. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA; however, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"><i style="font-style:italic;">Orphan Drug Exclusivity</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biological product intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States and for which there is no reasonable expectation that the cost of developing and making a drug or biological product available in the United States for this type of disease or condition will be recovered from sales of the product. Orphan designation must be requested before submitting an NDA or biologics license application. Orphan designation does not convey any advantage in or shorten the duration of the regulatory review and approval process. We have received Orphan Drug designation for uproleselan and GMI-1359, as well as for our prior drug candidate rivipansel, and we intend to seek Orphan Drug designation and exclusivity for our other drug candidates whenever it is available.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">If a product that has orphan designation subsequently receives the first FDA approval for such drug for the disease or condition for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications to market the same drug or biological product for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan exclusivity. Competitors, however, may receive approval of different products for the indication for which the orphan product has exclusivity or obtain approval for the same product but for a different indication for which the orphan product has exclusivity. If a drug or biological product designated as an orphan product receives marketing approval for an indication broader than what is designated, it may not be entitled to orphan product exclusivity. Orphan drug status in the EU has similar, but not identical, benefits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"><i style="font-style:italic;">Pediatric Exclusivity</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Pediatric exclusivity is another type of non-patent marketing exclusivity in the United States and, if granted, provides for the attachment of an additional six months of marketing protection to the term of any existing regulatory exclusivity, including the non-patent and orphan drug exclusivity periods described above. This six-month exclusivity may be granted if an NDA sponsor submits pediatric data that fairly respond to a written request from the FDA for such data. The data do not need to show the product to be effective in the pediatric population studied; rather, if the clinical trial is deemed to fairly respond to the FDA&#8217;s request, the additional protection is granted. If reports of requested pediatric studies are submitted to and accepted by FDA within the statutory time limits, whatever statutory or regulatory periods of exclusivity or Orange Book listed patent protection cover the drug are extended by six months. This is not a patent term extension, but it effectively extends the regulatory period during which the FDA cannot approve an ANDA or 505(b)(2) application owing to regulatory exclusivity or listed patents. If any of our drug candidates is approved, we anticipate seeking pediatric exclusivity when it is appropriate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Foreign Regulation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">In order to market any product outside of the United States, we would need to comply with numerous and varying regulatory requirements of other countries regarding safety and efficacy and governing, among other things, clinical trials, marketing authorization, commercial sales and distribution of our drug candidates. For example, in the EU, we must obtain authorization of a clinical trial application, or CTA, in each member state in which we intend to conduct a clinical trial. Whether or not we obtain FDA approval for a drug, we would need to obtain the necessary approvals by the comparable regulatory authorities of foreign countries before we can commence clinical trials or marketing of the drug in those countries. The approval process varies from country to country and can involve additional product testing and additional administrative review periods. The time required to obtain approval in other countries might differ from and be longer than that required to obtain FDA approval. Regulatory approval in one country does not ensure regulatory </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">approval in another, but a failure or delay in obtaining regulatory approval in one country may negatively impact the regulatory process in others.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Employees and Human Capital Resources</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">As of December&#160;31, 2021, we had 52 employees, all of whom are full-time and located in the United States. None of our employees is represented by a labor union or covered by a collective bargaining agreement. We consider our relationship with our employees to be good.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing and new employees. The principal purposes of our equity incentive plans are to attract, retain and reward high performing employees through the granting of equity-based compensation awards in order to increase shareholder value and the success of our company by motivating employees to perform to the best of their abilities and achieve our company objectives. We monitor our compensation, benefits, and exit interview data and make changes as needed to enable the ongoing recruitment and selection of talented new employees, as well as to retain existing talent. Our Core Values underpin our mission on how we build our drug development pipeline, and how we establish relationships with employees, patients, healthcare providers, researchers and stakeholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Legal Proceedings</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">We are not currently a party to any material legal proceedings, and we are not aware of any pending or threatened legal proceeding against us that we believe could have a material adverse effect on our business, operating results or financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Corporate Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">We were incorporated under the laws of the State of Delaware in April 2003 and commenced operations in May 2003. Our principal executive offices are located at 9708 Medical Center Drive, Rockville, Maryland 20850. Our telephone number is (240) 243-1201.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">&#8220;GlycoMimetics,&#8221; the GlycoMimetics logo and other trademarks or service marks of GlycoMimetics, Inc. appearing in this Annual Report are the property of GlycoMimetics, Inc. This Annual Report contains additional trade names, trademarks and service marks of others, which are the property of their respective owners.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Available Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Our internet website address is www.glycomimetics.com. In addition to the information contained in this Annual Report, information about us can be found on our website. Our website and information included in or linked to our website are not part of this Annual Report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">Our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, are available free of charge through our website as soon as reasonably practicable after they are electronically filed with or furnished to the Securities and Exchange Commission, or SEC. Additionally the SEC maintains an internet site that contains reports, proxy and information statements and other information. The address of the SEC&#8217;s website is www.sec.gov.</p><a id="_e83768b3_c81f_4ea0_a40d_b04c91d69201"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 6pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="ITEM1ARISKFACTORS_618694"></a><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:54pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;"><b style="font-weight:bold;">ITEM&#160;1A. </b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;"><b style="font-weight:bold;">RISK FACTORS</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><i style="font-style:italic;">Our business is subject to numerous risks. You should carefully consider the following risks, as well as general economic and business risks, and all of the other information contained in this Annual Report, together with any other documents we file with the SEC. Any of the following risks could have a material adverse effect on our business, operating results and financial condition and cause the trading price of our common stock to decline.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Risks Related to Our Financial Position and Capital Needs</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">We have incurred significant losses since our inception. We expect to continue to incur losses over the next several years and may never achieve or maintain profitability. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">We have incurred significant losses since our inception in 2003 and, as of December 31, 2021, we had an accumulated deficit of $372.9 million. In recent years, we have financed our operations with proceeds from registered public offerings of our common stock and upfront and milestone payments under our license and collaboration agreements. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">We have devoted substantially all of our financial resources and efforts to research and development, including preclinical studies and clinical trials. We are still in the early stages of development of our drug candidates, and we have not completed development of any drugs. We expect to continue to incur significant expenses and operating losses over the next several years. Our net losses may fluctuate significantly from quarter to quarter and year to year. We anticipate that our expenses will increase substantially and our negative cash flows from operating activities will continue over the next 12 months and beyond as we:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">conduct our ongoing clinical trials and initiate additional clinical trials of our drug candidates, including the completion of our planned Phase 3 clinical trial of uproleselan;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">continue the research and preclinical development of our drug candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seek to discover and develop additional drug candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seek regulatory approvals for any drug candidates that successfully complete clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ultimately establish a sales, marketing and distribution infrastructure and scale up external manufacturing capabilities to commercialize any drugs for which we may obtain regulatory approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">maintain, expand and protect our intellectual property portfolio;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">hire additional clinical, quality control, regulatory and scientific personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">add operational, financial and management information systems and personnel, including personnel to support our drug development and planned future commercialization efforts; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">incur legal, accounting, insurance and other expenses in operating as public company.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">To become and remain profitable, we must succeed in developing and eventually commercializing drugs that generate significant revenue. This will require us to be successful in a range of challenging activities, including completing preclinical testing and clinical trials of our drug candidates, obtaining regulatory approval for these drug candidates and manufacturing and commercializing any drugs for which we may obtain regulatory approval, as well as discovering additional drug candidates. We are only in the preliminary stages of most of these activities. We may never succeed in these activities and, even if we do, may never generate revenue that is significant enough to achieve profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">In the case of uproleselan and GMI-1687, our ability to generate revenue is partially dependent upon the achievement of development, regulatory and commercial milestones and sales sufficient to generate royalties under our license agreement with Apollomics, and the achievement of such milestones is largely out of our control. If Apollomics fails, or chooses not to continue, to further develop, to seek regulatory approval for or to commercialize uproleselan in Greater China, our ability to generate revenue with respect to uproleselan may be significantly reduced or eliminated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">Because of the numerous risks and uncertainties associated with drug development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. If we are </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">required by regulatory authorities to perform studies in addition to those currently expected, or if there are any delays in completing our clinical trials or the development of any of our drug candidates, our expenses could increase.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would depress the value of our company and could impair our ability to raise capital, expand our business, maintain our research and development efforts or even continue our operations. A decline in the value of our company could also result in significant harm to our financial position and adversely affect our stock price.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">We will need substantial additional funding to pursue our business objectives. If we are unable to raise capital when needed, we may not be able to continue as a going concern and could be forced to delay, reduce or eliminate our drug development programs or potential commercialization efforts.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">We believe that our cash and cash equivalents as of December 31, 2021 will enable us to fund our operating expenses and capital expenditure requirements into the second quarter of 2023. However, we will need to obtain substantial additional funding in connection with our continuing operations. Our future capital requirements will depend on many factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope, progress, results and costs of preclinical development, laboratory testing and clinical trials for our drug candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number and development requirements of other drug candidates that we may pursue;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs, timing and outcome of regulatory review of our drug candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs and timing of future commercialization activities, including product manufacturing, marketing, sales and distribution, for any of our drug candidates for which we receive marketing approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the revenue, if any, received from commercial sales of our drug candidates for which we receive marketing approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the extent to which we acquire or in-license other drug candidates and technologies.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Our management must periodically evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about our ability to continue as a going concern. Based on our current cash position, our ongoing significant operating losses and the fact that we do not have any committed sources of revenue or cash flows other than potential payments from our license and collaboration agreements, management believes that, given our current cash position, there is substantial doubt about our ability to continue as a going concern beyond the date that is one year from the date that the financial statements included in this Annual Report were issued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Identifying potential drug candidates and conducting preclinical testing and clinical trials is a time-consuming, expensive and uncertain process that takes years to complete, and we or any current or future collaborators may never generate the necessary data or results required to obtain regulatory approval and achieve product sales. In addition, our drug candidates, if approved, may not achieve commercial success. Our commercial revenue, if any, will be derived from the sale of drugs that we do not expect to be commercially available for several years, if at all. Accordingly, our ability to fund our operations is dependent upon management&#8217;s plans, which include raising additional capital in the near term primarily through a combination of equity and debt financings, collaborations and strategic alliances. There can be no assurances that new financings or other transactions will be available to us on commercially acceptable terms, or at all. Our ability to raise additional capital may also be adversely impacted by global economic conditions and disruptions to and volatility in the credit and financial markets in the United States and worldwide resulting from the ongoing COVID-19 pandemic. If we are unable to raise capital to fund our operations when needed or on attractive terms, we could be forced to delay, reduce the scope of or eliminate our research and development programs or any future commercialization efforts, which would have a material adverse effect on our business, financial condition, results of operations and ability to operate as a going concern. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our drug candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Until such time, if ever, as we can generate substantial revenue from the sale of our drugs, we expect to finance our cash needs through a combination of equity offerings, debt financings and license and development agreements. We do not currently have any committed external source of funds other than possible milestone payments and possible royalties under our license agreement with Apollomics. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that could adversely affect your rights as a common stockholder. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may be required to relinquish valuable rights to our research programs or drug candidates or grant licenses on terms that may not be favorable to us or that may be at less than the full potential value of such rights. If we are unable to raise additional funds through equity or debt financings or other arrangements with third parties when needed, we may be required to delay, limit, reduce or terminate our drug development or future commercialization efforts or grant rights to third parties to develop and market drug candidates that we would otherwise prefer to develop and market ourselves. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our operating history may make it difficult for you to evaluate the success of our business to date and to assess our future viability.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">We commenced operations in 2003, and our operations to date have been largely focused on raising capital, developing our expertise in carbohydrate chemistry and knowledge of carbohydrate biology, identifying potential drug candidates, undertaking preclinical studies and conducting clinical trials. We have not yet demonstrated our ability to successfully complete later stage clinical trials, obtain regulatory approvals, manufacture a commercial scale drug, or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful commercialization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">We may encounter unforeseen expenses, difficulties, complications, delays and other known or unknown factors in achieving our business objectives. We will need to transition at some point from a company with a research and development focus to a company capable of supporting commercial activities. We may not be successful in such a transition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">We expect our financial condition and operating results to continue to fluctuate significantly from quarter to quarter and year to year due to a variety of factors, many of which are beyond our control. Accordingly, you should not rely upon the results of any quarterly or annual periods as indications of future operating performance</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our ability to use net operating losses to offset future taxable income may be subject to limitations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">As of December 31, 2021, we had federal and state net operating loss carryforwards of $290.0 million, research and development tax credit carryforwards of $10.3 million and $37.7 million of orphan drug tax credit carryforwards. The federal and state net operating loss carryforwards will begin to expire, if not utilized, beginning in 2026, the research and development tax credits in 2023 and the orphan drug tax credit in 2033. These net operating loss and tax credit carryforwards could expire unused and be unavailable to offset future income tax liabilities. Under federal income tax laws, federal net operating losses incurred in 2018 and in future years may be carried forward indefinitely, but the deductibility of such federal net operating losses is limited.&#160;In addition, under Section 382 of the Internal Revenue Code of 1986, as amended, and corresponding provisions of state law, if a corporation undergoes an &#8220;ownership change,&#8221; which is generally defined as a greater than 50% change, by value, in its equity ownership over a three-year period, the corporation&#8217;s ability to use its pre-change net operating loss carryforwards and other pre-change tax attributes to offset its post-change income or taxes may be limited. We could experience ownership changes in the future that would limit our ability to use our net operating loss carryforwards.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Risks Related to the Discovery and Development of Our Drug Candidates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our research and development is focused on discovering and developing novel glycomimetic drugs, and we are taking an innovative approach to discovering and developing drugs, which may never lead to marketable drugs.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">A key element of our strategy is to use and expand our platform to build a pipeline of novel glycomimetic drug candidates and progress these drug candidates through clinical development for the treatment of a variety of diseases. The discovery of therapeutic drugs based on molecules that mimic the structure of carbohydrates is an emerging field, and the scientific discoveries that form the basis for our efforts to discover and develop drug candidates are relatively new. The scientific evidence to support the feasibility of developing drug candidates based on these discoveries is both preliminary and limited. Although our research and development efforts to date have resulted in a pipeline of glycomimetic drug candidates, we may not be able to develop drug candidates that are safe and effective. Even if we are successful in continuing to build our pipeline, the potential drug candidates that we identify may not be suitable for clinical development, including as a result of being shown to have harmful side effects or other characteristics that indicate that they are unlikely to be drugs that will receive marketing approval and achieve market acceptance. If we do not successfully develop and commercialize drug candidates based upon our glycomimetics platform, we will not be able to obtain product revenue in future periods, which likely would result in significant harm to our financial position and adversely affect our stock price.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">We have only one drug candidate in a late-stage clinical trial. All of our other drug candidates are still in Phase 1 clinical trials or in preclinical development. If we or our collaborators are unable to commercialize our drug candidates or experience significant delays in doing so, our business will be materially harmed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Uproleselan is our only drug candidate that is in a Phase 2 or Phase 3 clinical trial. Our other drug candidates are still in Phase 1 clinical trials or in preclinical development. We have not completed the development of any drug candidates, we currently generate no revenue from the sale of any drugs and we may never be able to develop a marketable drug. We have invested substantially all of our efforts and financial resources in the development of our glycomimetics platform, the identification of potential drug candidates using that platform and the development of our drug candidates. Our ability to generate revenue from our other drug candidates, which we do not expect to occur for many years, if ever, will depend heavily on their successful development and eventual commercialization. The success of those drug candidates will depend on several factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">successful completion of preclinical studies and clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">receipt of marketing approvals from applicable regulatory authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining and maintaining patent and trade secret protection and regulatory exclusivity for our drug candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">making arrangements with third-party manufacturers for, or establishing, commercial manufacturing capabilities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">launching commercial sales of the drugs, if and when approved, whether alone or in collaboration with others;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acceptance of the drugs, if and when approved, by patients, the medical community and third-party payors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">effectively competing with other therapies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining and maintaining healthcare coverage and adequate reimbursement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">protecting our rights in our intellectual property portfolio; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">maintaining a continued acceptable safety profile of the drugs following approval.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">If we do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize our drug candidates, which would materially harm our business.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Clinical drug development involves a lengthy and expensive process, with an uncertain outcome. We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our drug candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">The risk of failure of our drug candidates is high. It is impossible to predict when or if any of our drug candidates will prove safe or effective in humans or will receive regulatory approval. Before obtaining marketing approval from regulatory authorities for the sale of any drug candidate, we or a collaborator must complete preclinical development and then conduct extensive clinical trials to demonstrate the safety and efficacy of the drug candidate in humans. Clinical testing is expensive, difficult to design and implement, can take many years to complete and is uncertain as to outcome. A failure of one or more clinical trials can occur at any stage of development. The outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results. In addition, changes in patient treatment options over time may make the relevance of historical control data for a given indication less relevant to the drug candidate being studied, which could impact the success of the trial or, even if successful, the desirability of a successful drug candidate versus other available treatment options. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their drug candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their drugs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">We or our current or future collaborators may experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent our or their ability to receive marketing approval or commercialize our drug candidates, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulators or institutional review boards may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may experience delays in reaching, or fail to reach, agreement on acceptable clinical trial contracts or clinical trial protocols with prospective trial sites;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical trials of our drug candidates may produce negative or inconclusive results, including failure to demonstrate statistical significance, and we may decide, or regulators may require us, to conduct additional clinical trials or abandon drug development programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number of patients required for clinical trials of our drug candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate or participants may drop out of these clinical trials at a higher rate than we anticipate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulators or institutional review boards may require that we or our investigators suspend or terminate clinical research for various reasons, including noncompliance with regulatory requirements or a finding that the participants are being exposed to unacceptable health risks;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost of clinical trials of our drug candidates may be greater than we anticipate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the supply or quality of our drug candidates or other materials necessary to conduct clinical trials of our drug candidates may be insufficient or inadequate; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our drug candidates may have undesirable side effects or other unexpected characteristics, causing us or our investigators, regulators or institutional review boards to suspend or terminate the trials.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">If we are required to conduct additional clinical trials or other testing of our drug candidates beyond those that we currently contemplate, if we are unable to successfully complete clinical trials of our drug candidates or other testing, if the results of these clinical trials or tests are not positive or are only modestly positive or if there are safety concerns, we may:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">be delayed in obtaining marketing approval for our drug candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">not obtain marketing approval at all;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtain approval for indications or patient populations that are not as broad as intended or desired;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtain approval with labeling that includes significant use or distribution restrictions or safety warnings;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">be subject to additional post-marketing testing requirements; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">have the drug removed from the market after obtaining marketing approval.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Our drug development costs will also increase if we experience delays in testing or marketing approvals. We do not know whether any of our preclinical studies or clinical trials will begin as planned, will need to be restructured or will be completed on schedule, or at all. Significant preclinical study or clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our drug candidates or allow our competitors to bring drugs to market before we do, and thereby impair our ability to successfully commercialize our drug candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our business could be adversely affected by the effects of health epidemics or pandemics, including the ongoing COVID-19 pandemic, in regions where we or third parties on whom we rely have significant manufacturing facilities, clinical trial sites or other business operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Our business could be adversely affected by health epidemics or pandemics in regions where we have concentrations of clinical trial sites or other business operations, and could cause significant disruption in the operations of third-party collaborators, manufacturers and CROs upon whom we rely. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">In response to the ongoing COVID-19 pandemic, in 2020 we implemented a work-from-home policy for most of our employees, and we have recently adopted a hybrid home-office work policy. The effects of our policy may negatively impact productivity, disrupt our business and delay our clinical programs and timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on our ability to conduct our business in the ordinary course. These and similar, and perhaps more severe, disruptions in our operations could negatively impact our business, operating results and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Quarantines, shelter-in-place, stay-at-home, executive and similar government orders&#8212;or the perception that such orders, shutdowns or other restrictions on the conduct of business operations could occur&#8212;related to COVID-19 or other infectious diseases, could impact personnel at third-party manufacturing facilities in the United States and other countries, or the availability or cost of materials, which would disrupt our supply chain. For example, any manufacturing supply interruption of uproleselan, which is currently manufactured at facilities in Switzerland and China, could adversely affect our ability to conduct ongoing and future clinical trials of uproleselan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">In addition, our clinical trials may be affected by the COVID-19 pandemic due to prioritization of hospital resources toward the COVID-19 pandemic. Some patients may not be able to comply with clinical trial protocols if quarantines impede patient movement or interrupt healthcare services. Similarly, the pandemic may impact our ability to recruit and retain patients and principal investigators and site staff who, as healthcare providers, may have heightened exposure to COVID-19 and adversely impact our clinical trial operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">The spread of COVID-19, which has caused a broad impact globally, may materially affect us economically. While the potential economic impact brought by, and the duration of, the COVID-19 pandemic may be difficult to assess or predict, a further prolonged pandemic could result in significant disruption of global financial markets, reducing our ability to access capital, which could in the future negatively affect our liquidity. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">The global pandemic of COVID-19 continues to rapidly evolve. The ultimate impact of the COVID-19 pandemic or a similar health epidemic is highly uncertain and subject to change. We do not yet know the full extent of potential delays or impacts on our business, our clinical trials, healthcare systems or the global economy as a whole. However, these effects could have a material impact on our operations, and we will continue to monitor the situation closely.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">If serious adverse or unacceptable side effects are identified during the development of our drug candidates, we may need to abandon or limit the development of some of our drug candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">If our drug candidates are associated with undesirable side effects in clinical trials or have characteristics that are unexpected, we may need to abandon their development or limit their development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. Many drug candidates that initially showed promise in early stage testing have later been found to cause side effects that prevented their further development.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may expend our limited resources to pursue a particular drug candidate or indication and fail to capitalize on drug candidates or indications that may be more profitable or for which there is a greater likelihood of success.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Because we have limited financial and management resources, we focus on a limited number of research programs and drug candidates. As a result, we may forego or delay pursuit of opportunities with other drug candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial drugs or profitable market opportunities. Our spending on current and future research and development programs and drug candidates for specific indications may not yield any commercially viable drugs. If we do not accurately evaluate the commercial potential or target market for a particular drug candidate, we may relinquish valuable rights to that drug candidate through collaboration, licensing or other arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Risks Related to Our Dependence on Third Parties</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our success depends in part on current and future collaborations. If we are unable to maintain any of these collaborations, or if these collaborations are not successful, our business could be adversely affected.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">We have limited capabilities for drug development and do not yet have any capabilities for sales, marketing or distribution. We cannot assure you that our current or future collaborators will develop our drug candidates in a timely manner, or at all, or, if regulatory approval for a drug candidate is achieved, that such collaborator will successfully commercialize the candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Any collaborations we might enter into may pose a number of risks, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may not perform their obligations as expected;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may not pursue the commercialization of any drug candidates that achieve regulatory approval or may elect not to pursue, continue or renew development or commercialization of drug candidates based on clinical trial results, changes in such collaborators&#8217; strategic focus or available funding or external factors, such as an acquisition, that divert resources or create competing priorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a drug candidate, repeat or conduct new clinical trials or require a new formulation of a drug candidate for clinical testing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators could experience delays in initiating or conducting clinical trials for any number of reasons;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators could independently develop, or develop with third parties, drugs that compete directly or indirectly with our drugs or drug candidates if such collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">drug candidates discovered in collaboration with us may be viewed by our collaborators as competitive with their own drug candidates or drugs, which may cause such collaborators to cease to devote resources to the commercialization of our drug candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a collaborator with marketing and distribution rights to one or more of our drug candidates that achieve regulatory approval may not commit sufficient resources to the marketing and distribution of such drug or drugs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disagreements with collaborators, including disagreements over proprietary rights, contract interpretation or the preferred course of development, might cause delays or termination of the research, development or commercialization of drug candidates, might lead to additional responsibilities for us with respect to drug candidates or might result in litigation or arbitration, any of which would be time consuming and expensive;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may not properly maintain or defend our or their intellectual property rights or may use our or their proprietary information in such a way as to invite litigation that could jeopardize or invalidate such intellectual property or proprietary information or expose us to potential litigation;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborations may be terminated for the convenience of the collaborator and, if terminated, we could be required to raise additional capital to pursue further development or commercialization of the applicable drug candidates.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">If any collaborations we might enter into do not result in the successful development and commercialization of drugs, or if one of our collaborators terminates its agreement with us, we may not receive any future research funding or milestone or royalty payments under the collaboration. For example, in February 2020, Pfizer terminated its license agreement with us for the worldwide development and commercialization of our prior drug candidate rivipansel, thereby eliminating our right to receive any future development or commercialization milestones or royalty payments for sales of that drug candidate. In addition, even if we are eligible to receive any such payments from a collaborator, they could be substantially delayed. If we do not receive the funding we expect under these agreements, the development of our drug candidates could be delayed and we may need additional resources to develop our drug candidates. All of the risks relating to drug development, regulatory approval and commercialization described in this report also apply to the activities of our collaborators.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">If a current or future collaborator of ours is involved in a business combination, the collaborator might deemphasize or terminate development or commercialization of any drug candidate licensed to it by us. If one of our collaborators terminates its agreement with us, we may find it more difficult to attract new collaborators and our reputation in the business and financial communities could be adversely affected. We may in the future determine to collaborate with pharmaceutical and biotechnology companies for their development and potential commercialization of our drug candidates. We face significant competition in seeking appropriate collaborators. Our ability to reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of a collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. If we are unable to reach agreements with suitable collaborators on a timely basis, on acceptable terms, or at all, we may have to curtail the development of a drug candidate, reduce or delay its development or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to fund and undertake development or commercialization activities on our own, we may need to obtain additional expertise and additional capital, which may not be available to us on acceptable terms or at all. If we fail to enter into collaborations and do not have sufficient funds or expertise to undertake the necessary development and commercialization activities, we may not be able to further develop our drug candidates or bring them to market, which would impair our business prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">We expect to rely on third parties to conduct our future clinical trials for drug candidates, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">We have engaged a third-party contract research organization, or CRO, to conduct our ongoing and planned clinical trials for uproleselan and expect to engage CROs with respect to any of our other drug candidates that may progress to clinical development. We expect to continue to rely on third parties, such as CROs, clinical data management organizations, medical institutions and clinical investigators, to conduct those clinical trials. Agreements with such third parties might terminate for a variety of reasons, including a failure to perform by the third parties. If we need to enter into alternative arrangements, that would delay our drug development activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Our reliance on these third parties for research and development activities will reduce our control over these activities, but will not relieve us of our responsibilities. For example, we will remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. Moreover, the FDA requires us to comply with standards, commonly referred to as good clinical practices, or GCPs, for conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected. We also are required to register ongoing clinical trials and post the results of completed clinical trials on a government-sponsored database, ClinicalTrials.gov, within specified timeframes. Failure to do so can result in fines, adverse publicity and significant civil and criminal sanctions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">Furthermore, these third parties may also have relationships with other entities, some of which may be our competitors. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">conduct our clinical trials in accordance with regulatory requirements or our stated protocols, we will not be able to obtain, or may be delayed in obtaining, marketing approvals for our drug candidates and will not be able to, or may be delayed in our efforts to, successfully commercialize our drug candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">We also expect to rely on other third parties to store and distribute drug supplies for our clinical trials. Any performance failure on the part of our distributors could delay clinical development or marketing approval of our drug candidates or commercialization of our drugs, producing additional losses and depriving us of potential revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">We contract with third parties for the manufacturing of our drug candidates for preclinical and clinical testing and expect to continue to do so for commercialization. This reliance on third parties increases the risk that we will not have sufficient quantities of our drug candidates or drugs, or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">We do not have any manufacturing facilities or personnel. We rely, and expect to continue to rely, on third parties for the manufacturing of our drug candidates for preclinical and clinical testing, as well as for commercial manufacture if any of our drug candidates receives marketing approval. Disruption to our supply arrangements may arise from unforeseeable events that impact such third parties, including the ongoing COVID-19 pandemic. Our reliance on third parties increases the risk that we will not have sufficient quantities of our drug candidates or drugs, or such quantities at an acceptable cost or quality, which could delay, prevent or impair our ability to timely conduct our clinical trials or our other development or commercialization efforts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">We also expect to rely on third-party manufacturers or third-party collaborators for the manufacturing of commercial supply of any other drug candidates for which we or our collaborators obtain marketing approval. We may be unable to establish any agreements with third-party manufacturers or to do so on acceptable terms. Even if we are able to establish agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reliance on the third party for regulatory compliance and quality assurance;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the possible breach of the manufacturing agreement by the third party;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the possible misappropriation of our proprietary information, including our trade secrets and know-how; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the possible termination or non-renewal of the agreement by the third party at a time that is costly or inconvenient for us.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Third-party manufacturers may not be able to comply with current good manufacturing practices, or cGMP, regulations or similar regulatory requirements outside the United States. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of drug candidates or drugs, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our drugs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">In addition, in the event that any of our third-party manufacturers fails to comply with such requirements or to perform its obligations to us in relation to quality, timing or otherwise, or if our supply of components or other materials becomes limited or interrupted for other reasons, we may be forced to manufacture the materials ourselves, for which we currently do not have the capabilities or resources, or enter into an agreement with another third party, which we may not be able to do on commercially reasonable terms, if at all. We do not currently have arrangements in place for redundant supply or a second source for bulk drug substance. If our current contract manufacturers cannot perform as agreed, we may be required to replace such manufacturers and we may incur added costs and delays in identifying and qualifying any such replacement. Any replacement of our manufacturers could require significant effort and expertise because there may be a limited number of qualified replacements. If we are required to change manufacturers for any reason, we will be required to verify that the new manufacturer maintains facilities and procedures that comply with quality standards and with all applicable regulations and guidelines. The delays associated with the verification of a new manufacturer could negatively affect our ability to develop our drug candidates in a timely manner or within budget.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Our current and anticipated future dependence upon others for the manufacturing of our drug candidates or drugs may adversely affect our future profit margins and our ability to commercialize any drugs that receive marketing approval on a timely and competitive basis.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">34</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">We, or our third-party manufacturers, may be unable to successfully scale-up manufacturing of our drug candidates in sufficient quality and quantity, which would delay or prevent us from conducting our ongoing and planned clinical trials and developing our drug candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">In order to conduct our ongoing and planned clinical trials of our drug candidates, we will need to manufacture them in large quantities. We, or our manufacturing partners, may be unable to successfully increase the manufacturing capacity for any of our drug candidates in a timely or cost-effective manner, or at all. In addition, quality issues may arise during scale-up activities. If we or our manufacturing partners are unable to successfully scale up the manufacture of our drug candidates in sufficient quality and quantity, the development, testing and clinical trials of that drug candidate may be delayed or become infeasible, and marketing approval or commercial launch of any resulting drug may be delayed or not obtained, which could significantly harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Risks Related to the Commercialization of Our Drug Candidates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Even if any of our drug candidates receives marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">If any of our drug candidates receives marketing approval, it may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payors and others in the medical community. If our drug candidates do not achieve an adequate level of acceptance, we may not generate significant revenue from drug sales and we may not become profitable. The degree of market acceptance of our drug candidates, if approved for commercial sale, will depend on a number of factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the efficacy and potential advantages compared to alternative treatments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to offer our drugs for sale at competitive prices;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the convenience and ease of administration compared to alternative treatments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the strength of marketing and distribution support;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the availability of third-party coverage and adequate reimbursement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the prevalence and severity of any side effects; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any restrictions on the use of our drugs together with other medications.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we are unable to establish sales, marketing and distribution capabilities for our drug candidates, we may not be successful in commercializing those drug candidates if and when they are approved.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">We do not have a sales or marketing infrastructure and have no experience in the sale, marketing or distribution of pharmaceutical drugs. To achieve commercial success for any drug candidate for which we may obtain marketing approval, we will need to establish a sales and marketing organization to market or co-promote such drugs. There are risks involved with establishing our own sales, marketing and distribution capabilities. For example, recruiting and training a sales force is expensive and time consuming and could delay any product launch. If the commercial launch of a drug candidate for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Factors that may inhibit our efforts to commercialize our drugs on our own include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our inability to recruit, train and retain adequate numbers of effective sales and marketing personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the inability of sales personnel to obtain access to physicians or persuade adequate numbers of physicians to prescribe any future drugs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the lack of complementary drugs to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more products; and</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">35</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">unforeseen costs and expenses associated with creating an independent sales and marketing organization.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">If we are unable to establish our own sales, marketing and distribution capabilities and enter into arrangements with third parties to perform these services, our revenue and our profitability, if any, are likely to be lower than if we were to sell, market and distribute any drugs that we develop ourselves. In addition, we may not be successful in entering into arrangements with third parties to sell, market and distribute our drug candidates or may be unable to do so on terms that are favorable to us. We likely will have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our drugs effectively. If we do not establish sales, marketing and distribution capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in commercializing our drug candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">We face substantial competition, which may result in others discovering, developing or commercializing drugs before or more successfully than we do.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">The development and commercialization of new drugs is highly competitive. We face competition with respect to our current drug candidates, and we will face competition with respect to any drug candidates that we may seek to develop or commercialize in the future, from major pharmaceutical companies, specialty pharmaceutical companies, biotechnology companies, academic institutions, governmental agencies and public and private research institutions. Should any competitors&#8217; drug candidates receive regulatory or marketing approval prior to ours, they may establish a strong market position and be difficult to displace or diminish the need for our drug candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">The key competitive factors affecting the success of all of our drug candidates, if approved, are likely to be their safety, efficacy, convenience, price, the level of generic competition and the availability of coverage and reimbursement from government and other third-party payors. As described above under &#8220;Business&#8212;Competition,&#8221; we expect that our drug candidates will compete with approved therapies and those currently in development by other companies. To the extent that competitive drugs or drug candidates developed by others are successful in treating our target indications, it could reduce the market opportunity for our drug candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Many of the companies against which we are competing, or against which we may compete in the future, have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved drugs than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize drugs that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any drugs that we may develop. Our competitors also may obtain FDA or other regulatory approval for their drugs more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">In addition, because we have no patents with respect to our glycomimetics platform, our competitors may use our methods, or acquire similar expertise, in order to develop glycomimetic drug candidates and progress these drug candidates through clinical development and commercialization, which could impair our ability to successfully commercialize our drug candidates or otherwise limit our commercial opportunities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Even if we or our collaborators are able to commercialize any of our drug candidates, the drugs may become subject to unfavorable pricing regulations or third-party coverage and reimbursement policies.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">Our and our collaborators&#8217; ability to commercialize any of our drug candidates successfully will depend, in part, on the extent to which coverage and adequate reimbursement for these drugs and related treatments will be available from government payor programs at the federal and state levels authorities, including Medicare and Medicaid, private health insurers, managed care plans and other organizations. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">36</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">for particular medications. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for drugs. Coverage and reimbursement may not be available for any drug that we or our collaborators commercialize and, even if these are available, the level of reimbursement may not be satisfactory. Inadequate reimbursement levels may adversely affect the demand for, or the price of, any drug candidate for which we or our collaborators obtain marketing approval. Obtaining and maintaining adequate reimbursement for our drugs may be difficult. We may be required to conduct expensive pharmacoeconomic studies to justify coverage and reimbursement or the level of reimbursement relative to other therapies. If coverage and adequate reimbursement are not available or reimbursement is available only to limited levels, we or our collaborators may not be able to successfully commercialize any drug candidates for which marketing approval is obtained.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">There may be significant delays in obtaining coverage and reimbursement for newly approved drugs, and coverage may be more limited than the indications for which the drug is approved by the FDA or similar regulatory authorities outside the United States. Moreover, eligibility for coverage and reimbursement does not imply that a drug will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution expenses. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Reimbursement rates may vary according to the use of the drug and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost drugs and may be incorporated into existing payments for other services. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement policies. However, one payor&#8217;s determination to provide coverage for a drug does not assure that other payors will also provide coverage for the drug. Our or our collaborators&#8217; inability to promptly obtain coverage and adequate reimbursement rates from both government-funded and private payors for any approved drugs that we develop could adversely affect our operating results, our ability to raise capital needed to commercialize drugs and our overall financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">The regulations that govern marketing approvals, pricing, coverage and reimbursement for new drugs vary widely from country to country. Current and future legislation may significantly change the approval requirements in ways that could involve additional costs and cause delays in obtaining approvals. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or licensing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we or our collaborators might obtain marketing approval for a drug in a particular country, but then be subject to price regulations that delay commercial launch of the drug, possibly for lengthy time periods, and negatively impact our ability to generate revenue from the sale of the drug in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more drug candidates, even if our drug candidates obtain marketing approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">There can be no assurance that our drug candidates, if they are approved for sale in the United States or in other countries, will be considered medically reasonable and necessary for a specific indication, that they will be considered cost-effective by third-party payors, that coverage or an adequate level of reimbursement will be available or that third-party payors&#8217; reimbursement policies will not adversely affect our ability to sell our drug candidates profitably if they are approved for sale.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of any drugs that we may develop.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">We face an inherent risk of product liability exposure related to the testing of our drug candidates in human clinical trials, and will face an even greater risk if we commercially sell any drugs that we may develop. If we cannot successfully defend ourselves against claims that our drug candidates or drugs caused injuries, we will incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">decreased demand for any drug candidates or drugs that we may develop;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">injury to our reputation and significant negative media attention;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">withdrawal of clinical trial participants;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">significant costs to defend the related litigation;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">37</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">substantial monetary awards paid to trial participants or patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">loss of revenue;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reduced resources of our management to pursue our business strategy; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the inability to commercialize any drugs that we may develop.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">We carry clinical trial insurance coverage in an amount that we believe is sufficient in relation to our clinical trials being conducted in the United States and in foreign countries where we have or plan to have sites as part of our clinical trials for uproleselan. The use of our drug candidates in clinical trials may result in liability claims for which our current insurance would not be adequate to cover all liabilities that we may incur. In addition, we may need to increase our insurance coverage as we expand our clinical trials or if we commence commercialization of our drug candidates. Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Risks Related to Our Intellectual Property</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we are unable to obtain and maintain patent protection for our drug candidates, or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize drug candidates similar or identical to ours, and our ability to successfully commercialize our drug candidates may be impaired.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Our success depends in large part on our ability to obtain and maintain patent protection in the United States and other countries with respect to our drug candidates. We seek to protect our proprietary position by filing patent applications in the United States and abroad related to our drug candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">The patent prosecution process is expensive and time consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. We may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the rights to patents licensed to third parties. Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation. In addition, the laws of foreign countries may not protect our rights to the same extent as the laws of the United States, or vice versa. For example, European patent law restricts the patentability of methods of treatment of the human body more than U.S. law does. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing or, in some cases, not at all. Therefore, we cannot know with certainty whether we were the first to make the inventions claimed in our patents or pending patent applications, or that we were the first to file for patent protection of such inventions. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued that protect our drug candidates, in whole or in part, or which effectively prevent others from commercializing competitive drug candidates. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Recent patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. On September&#160;16, 2011, the Leahy-Smith America Invents Act, or the Leahy-Smith Act, was signed into law. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted and may also affect patent litigation. The U.S. Patent and Trademark Office recently developed new regulations and procedures to govern administration of the Leahy-Smith Act, and many of the substantive changes to patent law associated with the Leahy-Smith Act, and in particular, the first to file provisions, became effective on March&#160;16, 2013. Accordingly, it is not clear what, if any, impact the Leahy-Smith Act will have on the operation of our business. However, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business and financial condition.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">38</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Moreover, we may be subject to a third-party preissuance submission of prior art to the U.S. Patent and Trademark Office, or become involved in opposition, derivation, reexamination, <i style="font-style:italic;">inter partes</i> review, post-grant review or interference proceedings challenging our patent rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our drug candidates and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize drugs without infringing third-party patent rights. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future drug candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Even if our patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors from competing with us or otherwise provide us with any competitive advantage. Our competitors may be able to circumvent our patents by developing similar or alternative drug candidates in a non-infringing manner.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">In addition, the issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our patents may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical drug candidates, or limit the duration of the patent protection of our drug candidates. Given the amount of time required for the development, testing and regulatory review of new drug candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing drugs similar or identical to ours.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time consuming and unsuccessful.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Competitors may infringe our issued patents or other intellectual property. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time consuming. Any claims we assert against perceived infringers could provoke these parties to assert counterclaims against us alleging that we infringe their patents. In addition, in a patent infringement proceeding, a court may decide that a patent of ours is invalid or unenforceable, in whole or in part, construe the patent&#8217;s claims narrowly or refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology. An adverse result in any litigation proceeding could put one or more of our patents at risk of being invalidated or interpreted narrowly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may need to license intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">A third party may hold intellectual property, including patent, rights that are important or necessary to the development of our drug candidates. It may be necessary for us to use patented or proprietary technology of third parties to commercialize our drug candidates, in which case we would be required to obtain a license from these third parties on commercially reasonable terms, or our business could be harmed, possibly materially.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Our commercial success depends upon our ability, and the ability of our collaborators, to develop, manufacture, market and sell our drug candidates without infringing the proprietary rights of third parties. There is considerable intellectual property litigation in the biotechnology and pharmaceutical industries. We may become party to, or threatened with, future adversarial proceedings or litigation regarding intellectual property rights with respect to our drug candidates, including interference or derivation proceedings before the U.S. Patent and Trademark Office. Third parties may assert infringement claims against us based on existing patents or patents that may be granted in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">If we are found to infringe a third party&#8217;s intellectual property rights, we could be required to obtain a license from such third party to continue developing and marketing our drug candidates. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. We could be forced, including by court order, to cease commercializing the infringing drug. In addition, we could be found liable for monetary damages, including treble damages and attorneys&#8217; fees if we are found to have willfully infringed a patent. A finding of infringement could prevent us from commercializing our drug candidates or force us to cease some of our business </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">39</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">operations. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may be subject to claims by third parties asserting that we or our employees have misappropriated their intellectual property, or claiming ownership of what we regard as our own intellectual property.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Many of our employees were previously employed at universities or other biotechnology or pharmaceutical companies. Although we try to ensure that our employees do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that these employees or we have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such employee&#8217;s former employer. Litigation may be necessary to defend against these claims.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">In addition, while it is our policy to require our employees and contractors who may be involved in the development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact develops intellectual property that we regard as our own. Our and their assignment agreements may not be self-executing or may be breached, and we may be forced to bring claims against third parties, or defend claims they may bring against us, to determine the ownership of what we regard as our intellectual property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in prosecuting or defending against such claims, litigation could result in substantial costs and be a distraction to management.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses, and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise our ability to compete in the marketplace.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">In addition to seeking patents for our drug candidates, we also rely on trade secrets, including unpatented know-how, technology and other proprietary information, to maintain our competitive position. For example, our platform is based on trade secrets that consist largely of expertise in carbohydrate chemistry and knowledge of carbohydrate biology. We do not believe that we can obtain patent protection for our platform. Thus, our competitors may use our methods, or acquire similar expertise, in order to develop glycomimetic drug candidates and progress these drug candidates through clinical development and commercialization, which could impair our ability to successfully commercialize our drug candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">We seek to protect our trade secrets, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, contract manufacturers, consultants, advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive position would be harmed.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">40</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Risks Related to Regulatory Approval of Our Drug Candidates and Other Legal Compliance Matters</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we or our collaborators are not able to obtain, or if there are delays in obtaining, required regulatory approvals, we or they will not be able to commercialize our drug candidates and our ability to generate revenue will be materially impaired.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Our drug candidates and the activities associated with their development and commercialization, including their design, testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale and distribution, are subject to comprehensive regulation by the FDA and other regulatory agencies in the United States and by the EMA and similar regulatory authorities outside the United States. Failure to obtain marketing approval for a drug candidate will prevent us or our collaborators from commercializing the drug candidate. We have not received approval to market any of our drug candidates from regulatory authorities in any jurisdiction. We have only limited experience in filing and supporting the applications necessary to gain marketing approvals and expect to rely on third-party CROs to assist us in this process. Securing marketing approval requires the submission of extensive preclinical and clinical data and supporting information to regulatory authorities for each therapeutic indication to establish the drug candidate&#8217;s safety and efficacy. Securing marketing approval also requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities by, applicable regulatory authorities. Our drug candidates may not be effective, may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude our ability to obtain marketing approval or prevent or limit commercial use. If any of our drug candidates receives marketing approval, the accompanying label may limit the approved use of our drug, which could limit sales of the drug.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">The process of obtaining marketing approvals, both in the United States and abroad, is expensive and may take many years if additional clinical trials are required, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the drug candidates involved. Changes in marketing approval policies during the development period, changes in or the enactment of additional statutes or regulations or changes in regulatory review for each submitted drug application may cause delays in the approval or rejection of an application. Regulatory authorities have substantial discretion in the approval process and may refuse to accept any application, or may decide that our data are insufficient for approval and require additional preclinical, clinical or other studies. In addition, varying interpretations of the data obtained from preclinical and clinical testing could delay, limit or prevent marketing approval of a drug candidate. Any marketing approval we ultimately obtain may be limited or subject to restrictions or post-approval commitments that render the approved drug not commercially viable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">If we experience delays in obtaining approval or if we fail to obtain approval of our drug candidates, the commercial prospects for our drug candidates may be harmed and our ability to generate revenue will be materially impaired.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Even though we have obtained Orphan Drug designation for several of our drug candidates, we may not be able to obtain orphan drug marketing exclusivity for these or any of our other drug candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Regulatory authorities in some jurisdictions, including the United States and the European Union, or EU, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a drug as an orphan drug if it is intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals annually in the United States. We have obtained Orphan Drug designation from the FDA for uproleselan for the treatment of AML, as well as for GMI-1359 for the treatment of osteosarcoma. However, in order to obtain marketing exclusivity in a particular jurisdiction, we must receive the first marketing approval of the drug for its intended indication. In addition, the orphan designation does not convey any advantage in, or shorten the duration of, the regulatory review or approval process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Generally, if a drug with an orphan designation subsequently receives the first marketing approval for the indication for which it has such designation, the drug is entitled to a period of marketing exclusivity, which precludes the FDA or the EMA from approving another marketing application for the same drug for the same indication for that time period. The applicable period is seven years in the United States and 10 years in the EU. The EU exclusivity period can be reduced to six years if a drug no longer meets the criteria for orphan designation or if the drug is sufficiently profitable so that market exclusivity is no longer justified. Orphan drug exclusivity may be lost if the FDA or the EMA determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the drug to meet the needs of patients with the rare disease or condition.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">41</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Even if we obtain orphan drug exclusivity for a drug candidate, that exclusivity may not effectively protect the candidate from competition because different drugs can be approved for the same condition. Even after an orphan drug is approved, the FDA can subsequently approve another drug with the same active moiety for the same condition if the FDA concludes that the later drug is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">The FDA fast track designation and additional breakthrough therapy designation for uproleselan may not actually lead to a faster development or regulatory review or approval process.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">If a drug is intended for the treatment of a serious or life-threatening disease or condition and the drug demonstrates the potential to address unmet medical needs for this disease or condition, the drug sponsor may apply for the FDA fast track designation. If fast track designation is obtained, the FDA may initiate review of sections of a new drug application, or NDA, before the application is complete. This &#8220;rolling review&#8221; is available if the applicant provides, and the FDA approves, a schedule for submission of the individual sections of the application.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Although we have obtained a fast track designation from the FDA for uproleselan to treat AML and breakthrough therapy designation for uproleselan to treat AML, we may not experience a faster development process, review or approval compared to conventional FDA procedures. Our fast track designation may be withdrawn by the FDA if it believes that the designation is no longer supported by data from our clinical development programs. Our fast track designation does not guarantee that we will qualify for or be able to take advantage of the expedited review procedures or that we will ultimately obtain regulatory approval of uproleselan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Failure to obtain marketing approval in international jurisdictions would prevent our drug candidates from being marketed abroad.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">In order to market and sell our drugs in the EU and any other jurisdictions, we or our collaborators must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and can involve additional testing. The time required to obtain approval may differ substantially from that required to obtain FDA approval. The regulatory approval process outside the United States generally includes all of the risks associated with obtaining FDA approval. In addition, in many countries outside the United States, it is required that the drug be approved for reimbursement before it can be approved for sale in that country. We or our collaborators may not obtain approvals from regulatory authorities outside the United States on a timely basis, if at all. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one regulatory authority outside the United States does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA. However, failure to obtain approval in one jurisdiction may impact our ability to obtain approval elsewhere. We or our collaborators may not be able to file for marketing approvals and may not receive necessary approvals to commercialize our drugs in any market.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">A variety of risks associated with developing and marketing our drug candidates internationally could hurt our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">We or our collaborators may seek regulatory approval for uproleselan and our other drug candidates outside of the United States and, accordingly, we expect that we will be subject to additional risks related to operating in foreign countries if we obtain the necessary approvals, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">differing regulatory requirements in foreign countries;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the potential for so-called parallel importing, which is what happens when a local seller, faced with high or higher local prices, opts to import goods from a foreign market with low or lower prices rather than buying them locally;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">unexpected changes in tariffs, trade barriers, price and exchange controls and other regulatory requirements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">economic weakness, including inflation or political instability in particular foreign economies and markets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">foreign taxes, including withholding of payroll taxes;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and other obligations related to doing business in another country;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">42</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">difficulties staffing and managing foreign operations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">workforce uncertainty in countries where labor unrest is more common than in the United States;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential liability under the Foreign Corrupt Practices Act or comparable foreign regulations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">challenges enforcing our contractual and intellectual property rights, especially in foreign countries that do not respect and protect intellectual property rights to the same extent as the United States;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">business interruptions resulting from pandemic, epidemic or disease outbreaks or geo-political actions, including war and terrorism.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Pursuant to the terms of our collaboration and license agreement, Apollomics is responsible for the clinical development and commercialization of uproleselan and GMI-1687 in Greater China. The continuation of COVID-19 in China could have a material adverse effect on Apollomics&#8217; ability to develop these drug candidates in a timely manner due to disruptions in the region, travel restrictions, temporary closures of businesses and suspension of services and supplies. Any such delay or disruptions in clinical development could result in the delay of any potential milestone payments to us under the license and collaboration agreement, which could have a material adverse effect on our financial position and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Any drug candidate for which we obtain marketing approval could be subject to post-marketing restrictions or recall or withdrawal from the market, and we may therefore be subject to penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our drug candidates, when and if any of them are approved.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Any drug candidate for which we obtain marketing approval, along with manufacturing processes, post-approval clinical data, labeling, advertising and promotional activities for such drug candidate, will be subject to continual requirements of and review by the FDA and other regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, registration and listing requirements, cGMP requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of records and documents, requirements regarding the distribution of samples to physicians and recordkeeping. Even if marketing approval of a drug candidate is granted, the approval may be subject to limitations on the indicated uses for which the drug may be marketed or to the conditions of approval, including the requirement to implement a risk evaluation and mitigation strategy. If any of our drug candidates receives marketing approval, the accompanying label may limit the approved use of our drug, which could limit its sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">The FDA may also impose requirements for costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of the drug. The FDA closely regulates the post-approval marketing and promotion of drugs to ensure drugs are marketed only for the approved indications and in accordance with the provisions of the approved labeling. The FDA imposes stringent restrictions on manufacturers&#8217; communications regarding off-label use, and if we do not market our drugs for their approved indications, we may be subject to enforcement action for off-label marketing. Violations of the Federal Food, Drug, and Cosmetic Act relating to the promotion of prescription drugs may lead to investigations alleging violations of federal and state healthcare fraud and abuse laws, as well as state consumer protection laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">In addition, later discovery of previously unknown adverse events or other problems with our drugs, manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may have negative consequences, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on such drugs, manufacturers or manufacturing processes;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on the labeling or marketing of a drug;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on product distribution or use;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">requirements to conduct post-marketing studies or clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">warning letters;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">43</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">recall or withdrawal of the drugs from the market;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refusal to approve pending applications or supplements to approved applications that we submit;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical holds;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fines, restitution or disgorgement of revenue or profit;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">suspension or withdrawal of marketing approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refusal to permit the import or export of our drugs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product seizure; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">injunctions or the imposition of civil or criminal penalties.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Non-compliance with the EU requirements regarding safety monitoring or pharmacovigilance, and with requirements related to the development of drugs for the pediatric population, can also result in significant financial penalties. Similarly, failure to comply with the EU&#8217;s requirements regarding the protection of personal information can also lead to significant penalties and sanctions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our current and future business and relationships with customers and third-party payors in the United States and elsewhere may be subject, directly or indirectly, to applicable anti-kickback, fraud and abuse, false claims, transparency, health information privacy and security and other healthcare laws and regulations, which could expose us to significant penalties, including criminal sanctions, civil penalties, contractual damages, reputational harm, administrative burdens and diminished profits and future earnings.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Healthcare providers and third-party payors in the United States and elsewhere will play a primary role in the recommendation and prescription of any drug candidates for which we obtain marketing approval. Our current and future arrangements with third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations, including, without limitation, the federal Anti-Kickback Statute and the federal False Claims Act, which may constrain the business or financial arrangements and relationships through which we conduct clinical research, sell, market and distribute any drugs for which we obtain marketing approval. In addition, we may be subject to transparency laws and patient data privacy and security regulation by the U.S. federal and state governments and by governments in foreign jurisdictions in which we conduct our business. The applicable federal, state and foreign healthcare laws and regulations that may affect our ability to operate include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under federal healthcare programs, such as Medicare and Medicaid;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">federal civil and criminal false claims laws, including the federal False Claims Act, which impose criminal and civil penalties, including civil whistleblower or qui tam actions, and civil monetary penalty laws that prohibit individuals or entities for knowingly presenting, or causing to be presented, to the federal government, including the Medicare and Medicaid programs, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and their respective implementing regulations, which impose obligations on covered healthcare providers, health plans, and healthcare clearinghouses, as well as their business associates that create, receive, maintain or transmit individually identifiable health information for or on behalf of a covered entity, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;</span></td></tr></table><div style="margin-top:6pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">44</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal Open Payments program, pursuant to the Physician Payments Sunshine Act, which requires manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with specific exceptions, to report annually to the Centers for Medicare&#160;&amp; Medicaid Services, or CMS, information related to &#8220;payments or other transfers of value&#8221; made to physicians, which is defined to include doctors, dentists, optometrists, podiatrists and chiropractors, other healthcare professionals (such as physician assistants and nurse practitioners) and teaching hospitals, and applicable manufacturers and applicable group purchasing organizations to report annually to CMS ownership and investment interests held by the physicians and their immediate family members, with disclosure of such information to be made by CMS on a publicly available website; and</span></td></tr></table><div style="margin-top:6pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers; state and foreign laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government or otherwise restrict payments that may be made to healthcare providers; state and foreign laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; state and local laws requiring the registration of pharmaceutical sales representatives; and state and foreign laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations may involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, including, without limitation, damages, fines, individual imprisonment, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, contractual damages, reputational harm, diminished profits and future earnings, disgorgement, exclusion from participation in government healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations, which could have a material adverse effect on our business. If any of the physicians or other healthcare providers or entities with whom we expect to do business, including our collaborators, is found not to be in compliance with applicable laws, it may be subject to criminal, civil or administrative sanctions, including exclusions from participation in government healthcare programs, which could also materially affect our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Recently enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our drug candidates and affect the prices we may obtain.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">In the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of our drug candidates, restrict or regulate post-approval activities and affect our ability to profitably sell any drug candidates for which we obtain marketing approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts, which include major legislative initiatives to reduce the cost of care through changes in the healthcare system, including limits on the pricing, coverage, and reimbursement of pharmaceutical and biopharmaceutical products, especially under government-funded health care programs, and increased governmental control of drug. In March 2010, President Obama signed into law the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively PPACA, a sweeping law intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, improve quality of care, enhance remedies against fraud and abuse, add new transparency requirements for the healthcare and health insurance industries, impose new taxes and fees on the health industry and impose additional health policy reforms.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">45</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Among the provisions of PPACA of importance to our business and potential drug candidates are:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an annual, nondeductible fee on any entity that manufactures or imports specified branded prescription drugs and biologic agents, apportioned among these entities according to their market share in certain government healthcare programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program to 23.1% and 13.0% of the average manufacturer price for branded and generic drugs, respectively;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expansion of healthcare fraud and abuse laws, including the False Claims Act and the Anti-Kickback Statute, new government investigative powers and enhanced penalties for non-compliance;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a new Medicare Part D coverage gap discount program, in which manufacturers must now agree to offer 70% point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for a manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">extension of a manufacturer&#8217;s Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals and by adding new mandatory eligibility categories for certain individuals with income at or below 133% of the federal poverty level, thereby potentially increasing a manufacturer&#8217;s Medicaid rebate liability;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the new requirements under the federal Open Payments program and its implementing regulations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a new requirement to annually report drug samples that manufacturers and distributors provide to physicians; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">There remain judicial and Congressional challenges to certain aspects of PPACA, as well as efforts by the Trump administration to repeal or replace certain aspects of the PPACA. Since January 2017, President Trump has signed two Executive Orders and other directives designed to delay the implementation of certain provisions of the PPACA or otherwise circumvent some of the requirements for health insurance mandated by the PPACA. Concurrently, Congress has considered legislation that would repeal or repeal and replace all or part of the PPACA. While Congress has not passed comprehensive repeal legislation, several bills affecting the implementation of certain taxes under the ACA have been signed into law. The Tax Cuts and Jobs Act of 2017, or Tax Act, included a provision which repealed, effective January 1, 2019, the tax-based shared responsibility payment imposed by the PPACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual mandate&#8221;. In addition, the 2020 federal spending package permanently eliminates, effective January 1, 2020, the ACA-mandated &#8220;Cadillac&#8221; tax on high-cost employer-sponsored health coverage and medical device tax and, effective January 1, 2021, also eliminates the health insurer tax. The Bipartisan Budget Act of 2018, or the BBA, among other things, amended the ACA, effective January&#160;1, 2019, to increase from 50&#160;percent to 70&#160;percent the point-of-sale discount that is owed by pharmaceutical manufacturers who participate in Medicare Part D and to close the coverage gap in most Medicare drug plans, commonly referred to as the &#8220;donut hole.&#8221; For example, on June 17, 2021, the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. Thus, the ACA will remain in effect in its current form. Further, prior to the U.S. Supreme Court ruling, on January 28, 2021, President Biden issued an executive order to initiate a special enrollment period for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructs certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">46</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">It is unclear how any such challenges and healthcare reform measures of the Biden administration will impact ACA and our business. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">In addition, other legislative changes have been proposed and adopted since PPACA was enacted. These changes include aggregate reductions to Medicare payments to providers of up to 2% per fiscal year, which began in 2013, pursuant to the Budget Control Act of 2011. On March 1, 2013, the President signed an executive order implementing the 2% Medicare payment reductions, and on April&#160;1, 2013, these reductions went into effect. Pursuant to the Bipartisan Budget Act of 2015, these reductions will stay in effect through 2031, except for a temporary suspension from May 1, 2020 through March 31, 2022 due to the COVID-19 pandemic, unless additional Congressional action is taken. Under current legislation, the actual reduction in Medicare payments will vary from 1% in 2022 to up to 3% in the final fiscal year of this sequester. On March 11, 2021, President Biden signed the American Rescue Plan Act of 2021 into law, which eliminates the statutory Medicaid drug rebate cap, currently set at 100% of a drug&#8217;s average manufacturer price, for single source and innovator multiple source drugs, beginning January 1, 2024. In January 2013, President Obama signed into law the American Taxpayer Relief Act of 2012, which, among other things, reduced Medicare payments to several providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. Additional legislative proposals to reform healthcare and government insurance programs, along with the trend toward managed healthcare in the United States, could influence the purchase of medicines and reduce reimbursement and/or coverage of our product candidates, if approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Current and future healthcare reform measures may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved drug. Any reduction in reimbursement from Medicare or other government-funded programs may result in a similar reduction in payments from private payors. There has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. Specifically, there have been several recent U.S. Congressional inquiries and proposed bills designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. At the federal level, the Trump administration used several means to propose implementing drug pricing reform, including through federal budget proposals, executive orders and policy initiatives. For example, on July 24, 2020 and September 13, 2020, the Trump administration announced several executive orders related to prescription drug pricing that seek to implement several of the administration&#8217;s proposals. As a result, the FDA released a final rule and guidance on September 24, 2020, providing guidance for states to build and submit importation plans for drugs from Canada. Further, on November 20, 2020, the U.S. Department of Health and Human Services finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The implementation of the rule has been delayed by the Biden administration from January 1, 2022 to January 1, 2023 in response to ongoing litigation. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers, the implementation of which have also been delayed pending review by the Biden administration until January 1, 2023. On November 20, 2020, the Centers for Medicare &amp; Medicaid Services, or CMS, issued an interim final rule implementing President Trump&#8217;s Most Favored Nation executive order, which would tie Medicare Part B payments for certain physician-administered drugs to the lowest price paid in other economically advanced countries. As a result of litigation challenging the Most Favored Nation model, on December 27, 2021, CMS published a final rule that rescinded the Most Favored Nation model interim final rule. In July 2021, the Biden administration released an executive order, &#8220;Promoting Competition in the American Economy,&#8221; with multiple provisions aimed at prescription drugs. In response to Biden&#8217;s executive order, on September 9, 2021, HHS released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue to advance these principles. No legislation or administrative actions have been finalized to implement these principles. In addition, Congress is considering drug pricing as part of other reform initiatives. At the state level, legislatures are increasingly passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our drugs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for drugs. We cannot be sure whether additional legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of our drug candidates, if any, may be. In addition, increased scrutiny by the U.S. Congress of the FDA&#8217;s </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">47</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and post-marketing testing and other requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Governments outside the United States tend to impose strict price controls, which may adversely affect our revenue, if any.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">In some countries, particularly in the EU, the pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a drug. To obtain coverage and reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our drug candidate to other available therapies. If reimbursement of our drugs is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be harmed, possibly materially.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could harm our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, hazardous or radioactive materials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts. Our failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Risks Related to Employee Matters and Managing Our Growth</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">We are highly dependent on the management, research and development, clinical, financial and business development expertise of Harout Semerjian, our President and Chief Executive Officer; John Magnani, our Senior Vice President of Research and Chief Scientific Officer; Armand Girard, our Senior Vice President and Chief Business Officer; and Brian Hahn, our Senior Vice President of Finance and Chief Financial Officer, as well as the other members of our scientific and clinical teams. In particular, we are dependent upon Dr.&#160;Magnani for key expertise in carbohydrate chemistry and knowledge of carbohydrate biology with respect to our glycomimetics platform, and the loss of his services would materially impair our future drug discovery efforts. Although we have entered into employment agreements with our executive officers, each of them may currently terminate their employment with us at any time. We do not maintain &#8220;key person&#8221; insurance for any of our executives or employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">Recruiting and retaining qualified scientific and clinical personnel and, if we progress the development of our drug pipeline toward scaling up for commercialization, sales and marketing personnel, will also be critical to our success. The loss of the services of our executive officers or other key employees could impede the achievement of our research, development and commercialization objectives and seriously harm our ability to successfully implement our business strategy. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to successfully develop, gain regulatory approval for and commercialize our drug candidates. Competition to hire qualified personnel in our industry is intense, and we may be unable to hire, train, retain or motivate these key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">48</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. If we are unable to continue to attract and retain high quality personnel, our ability to pursue our growth strategy will be limited.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">We expect to expand our development and regulatory capabilities and potentially implement sales, marketing and distribution capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">As our development progresses, we expect to experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of research, drug development, regulatory affairs and, if any of our drug candidates receives marketing approval, sales, marketing and distribution. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Due to our limited financial resources and the limited experience of our management team in managing a company with such anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our employees and employees of our collaborators may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">We and our collaborators are exposed to the risk of employee fraud or other misconduct. Misconduct by employees could include intentional failures to comply with the FDA regulations, to provide accurate information to the FDA, to comply with manufacturing standards we have established, to comply with federal and state healthcare fraud and abuse laws and regulations, to report financial information or data accurately or to disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Employee misconduct could also involve the improper use of individually identifiable information, including, without limitation, information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. We have adopted a code of business conduct and ethics, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent improper activities may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, or any such actions are instituted against any of our collaborators, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions and diminished royalties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">General Risks Related to Ownership of Our Common Stock</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">An active trading market for our common stock may not be sustained.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Although our common stock is listed on The Nasdaq Global Market, we cannot assure you that an active trading market for our shares will be sustained. If an active market for our common stock is not sustained, it may be difficult for investors in our common stock to sell shares without depressing the market price for the shares or to sell the shares at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">The trading price of our common stock has been and is likely to continue to be volatile.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Our stock price from time to time has been volatile. The stock market in general and the market for biopharmaceutical companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, investors may not be able to sell their common stock at or above the price paid for the shares. The market price for our common stock may be influenced by many factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">announcements relating to development, regulatory approvals or commercialization of our drug candidates;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">49</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">actual or anticipated variations in our operating results;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in financial estimates by us or by any securities analysts who might cover our stock;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">conditions or trends in our industry;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in laws or other regulatory actions affecting us or our industry, such as drug pricing and reimbursement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">stock market price and volume fluctuations of comparable companies and, in particular, those that operate in the biopharmaceutical industry;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">announcements by us or our competitors of significant acquisitions, strategic partnerships or divestitures;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">announcements of investigations or regulatory scrutiny of our operations or lawsuits filed against us;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">capital commitments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">investors&#8217; general perception of our company and our business;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disputes concerning our intellectual property or other proprietary rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">recruitment or departure of key personnel; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">sales of our common stock, including sales by our directors and officers or specific stockholders.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">In addition, the stock markets have experienced extreme price and volume fluctuations that have affected and continue to affect the market prices of equity securities of many companies, including recently in connection with the COVID-19 pandemic, which has resulted in volatile stock prices for many companies notwithstanding the lack of a fundamental change in their underlying business models or prospects. These fluctuations have often been unrelated or disproportionate to the operating performance of those companies. Broad market and industry factors, including potentially worsening economic conditions and other adverse effects or developments relating to the COVID-19 pandemic, political, regulatory and other market conditions, may negatively affect the market price of shares of our common stock, regardless of our actual operating performance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">In addition, in the past, stockholders have initiated class action lawsuits against pharmaceutical and biotechnology companies following periods of volatility in the market prices of these companies&#8217; stock. Such litigation, if instituted against us, could cause us to incur substantial costs and divert management&#8217;s attention and resources from our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business or our market, our stock price and trading volume could decline.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">The trading market for our common stock is influenced by the research and reports that equity research analysts publish about us and our business. We have only limited research coverage by equity research analysts. Equity research analysts may elect not to initiate or continue to provide research coverage of our common stock, and such lack of research coverage may adversely affect the market price of our common stock. Even if we have equity research analyst coverage, we will not have any control over the analysts or the content and opinions included in their reports. The price of our stock could decline if one or more equity research analysts downgrade our stock or issue other unfavorable commentary or research. If one or more equity research analysts ceases coverage of our company or fails to publish reports on us regularly, demand for our stock could decrease, which in turn could cause our stock price or trading volume to decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">The issuance of additional stock in connection with financings, acquisitions, investments, our stock incentive plan, our employee stock purchase plan or otherwise will dilute all other stockholders.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Our certificate of incorporation authorizes us to issue up to 100,000,000 shares of common stock and up to 5,000,000 shares of preferred stock with such rights and preferences as may be determined by our board of directors. Subject to compliance with applicable rules and regulations, we may issue our shares of common stock or securities convertible into our common stock from time to time in connection with a financing, acquisition, investment, our stock incentive plan, our employee stock purchase plan or otherwise. Any such issuance could result in substantial dilution to our existing stockholders and cause the trading price of our common stock to decline.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">50</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">If a substantial number of our total outstanding shares are sold into the market, or if the market perceives that such sales may occur, it could cause the market price of our common stock to drop significantly, even if our business is doing well.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Sales of a substantial number of shares of our common stock in the public market could occur at any time. If our stockholders sell, or if the market perceives that our stockholders intend to sell, substantial amounts of our common stock in the public market, the market price of our common stock could decline significantly. All of our outstanding shares of common stock are available for sale in the public market, subject only to the restrictions of Rule 144 under the Securities Act in the case of our affiliates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">In addition, we have filed registration statements on Form S-8 registering the issuance of shares of common stock subject to options or other equity awards issued or reserved for future issuance under our equity incentive plans. Shares registered under these registration statements are available for sale in the public market subject to vesting arrangements and exercise of options, as well as Rule 144 in the case of our affiliates. If these additional shares are sold, or if it is perceived that they will be sold, in the public market, the trading price of our common stock could decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Provisions in our corporate charter documents and under Delaware law may prevent or frustrate attempts by our stockholders to change our management and hinder efforts to acquire a controlling interest in us, and the market price of our common stock may be lower as a result.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">There are provisions in our certificate of incorporation and bylaws that may make it difficult for a third party to acquire, or attempt to acquire, control of our company, even if a change in control was considered favorable by some or all of our stockholders. For example, our board of directors has the authority to issue up to 5,000,000 shares of preferred stock. The board of directors can fix the price, rights, preferences, privileges and restrictions of the preferred stock without any further vote or action by our stockholders. The issuance of shares of preferred stock may delay or prevent a change in control transaction. As a result, the market price of our common stock and the voting and other rights of our stockholders may be adversely affected. An issuance of shares of preferred stock may result in the loss of voting control to other stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Our charter documents also contain other provisions that could have an anti-takeover effect, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">only one of our three classes of directors is elected each year;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">stockholders are not entitled to remove directors other than by a 66 2/3% vote and only for cause;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">stockholders are not permitted to take actions by written consent;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">stockholders cannot call a special meeting of stockholders; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">stockholders must give advance notice to nominate directors or submit proposals for consideration at stockholder meetings.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">In addition, we are subject to the anti-takeover provisions of Section 203 of the Delaware General Corporation Law, which regulates corporate acquisitions by prohibiting Delaware corporations from engaging in specified business combinations with particular stockholders of those companies. These provisions could discourage potential acquisition proposals and could delay or prevent a change in control transaction. They could also have the effect of discouraging others from making tender offers for our common stock, including transactions that may be in your best interests. These provisions may also prevent changes in our management or limit the price that investors are willing to pay for our stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Our certificate of incorporation also provides that the Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between us and our stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we fail to maintain proper and effective internal controls, our ability to produce accurate financial statements on a timely basis could be impaired.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">We are subject to the reporting requirements of the Securities Exchange Act of 1934, the Sarbanes-Oxley Act of 2002, the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 and the rules and regulations of The Nasdaq Global Market. The Sarbanes-Oxley Act requires, among other things, that we maintain effective disclosure controls and procedures and internal control over financial reporting and perform system and process evaluation and testing of our internal control over financial reporting to allow management to report on the effectiveness of our internal </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">51</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">control over financial reporting. This requires that we incur substantial additional professional fees and internal costs to expand our accounting and finance functions and that we expend significant management efforts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">We may in the future discover areas of our internal financial and accounting controls and procedures that need improvement. Our internal control over financial reporting will not prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud will be detected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">If we are unable to maintain proper and effective internal controls in the future, we may not be able to produce timely and accurate financial statements, and we may conclude that our internal controls over financial reporting are not effective. If that were to happen, the market price of our stock could decline and we could be subject to sanctions or investigations by Nasdaq, the SEC or other regulatory authorities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">We do not anticipate paying any cash dividends on our common stock in the foreseeable future and our stock may not appreciate in value.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">We have not declared or paid cash dividends on our common stock to date. We currently intend to retain our future earnings, if any, to fund the development and growth of our business. In addition, the terms of any future debt agreements may preclude us from paying dividends. There is no guarantee that shares of our common stock will appreciate in value or that the price at which our stockholders have purchased their shares will be able to be maintained.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">We incur increased costs and demands upon management as a result of being a public company.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">As a public company listed in the United States, we incur, and will continue to incur now that we have ceased to be an &#8220;emerging growth company,&#8221; significant legal, accounting and other costs. These costs could negatively affect our financial results. In addition, changing laws, regulations and standards relating to corporate governance and public disclosure, including regulations implemented by the SEC and Nasdaq, may increase legal and financial compliance costs and make some activities more time-consuming. These laws, regulations and standards are subject to varying interpretations and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">We intend to invest resources to comply with evolving laws, regulations and standards, and this investment may result in increased general and administrative expenses and a diversion of management&#8217;s time and attention from revenue-generating activities to compliance activities. If we do not comply with new laws, regulations and standards, regulatory authorities may initiate legal proceedings against us and our business may be harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">Failure to comply with these rules might also make it more difficult for us to obtain some types of insurance, including director and officer liability insurance, and we might be forced to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. The impact of these events could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, on committees of our board of directors or as members of senior management.</p><a id="_cf772829_49a7_46e5_a711_59614becad19"></a><a id="ITEM1BUNRESOLVEDSTAFFCOMMENTS_434071"></a><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:54pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;"><b style="font-weight:bold;">ITEM&#160; 1B.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;"><b style="font-weight:bold;">UNRESOLVED STAFF COMMENT</b><b style="font-weight:bold;">S</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">None.</p><a id="_c04dc647_6b77_4401_8ec4_1d5901a0ad7d"></a><a id="ITEM2PROPERTIES_674160"></a><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:54pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;"><b style="font-weight:bold;">ITEM&#160;2.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;"><b style="font-weight:bold;">PROPERTIE</b><b style="font-weight:bold;">S</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">Our principal offices occupy approximately 42,000 square feet of leased office space in Rockville, Maryland, pursuant to a lease agreement that expires in October 2023. We believe that our properties are generally in good condition, well maintained, suitable and adequate to carry on our business. We believe our capital resources are sufficient to lease any additional facilities required to meet our expected growth needs. </p><a id="_d8398efa_71e0_442a_a4c9_0b9a08baf170"></a><a id="ITEM3LEGALPROCEEDINGS_697974"></a><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:54pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:6pt;"><b style="font-weight:bold;">ITEM&#160; 3.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:6pt;"><b style="font-weight:bold;">LEGAL PROCEEDING</b><b style="font-weight:bold;">S</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">From time to time, we are subject to litigation and claims arising in the ordinary course of business. We are not currently a party to any material legal proceedings and we are not aware of any pending or threatened legal proceeding </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">52</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:220.82pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">against us that we believe could have a material adverse effect on our business, operating results, cash flows or financial condition. </p><a id="_35b59741_7b7c_42ab_839a_16ea20c21899"></a><a id="ITEM4MINESAFETYDISCLOSURES_857992"></a><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:54pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;"><b style="font-weight:bold;">ITEM&#160; 4.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;"><b style="font-weight:bold;">MINE SAFETY DISCLOSURE</b><b style="font-weight:bold;">S</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p><a id="_6d786cfa_c00a_4f81_be99_f8131f75843a"></a><a id="PARTII_834"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:55.45pt;text-align:center;text-indent:-55.45pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">PART I</b><b style="font-weight:bold;text-transform:uppercase;">I</b></p><a id="ITEM5MARKETFORREGISTRANTSCOMMONEQUITY_65"></a><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:54pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;"><b style="font-weight:bold;">ITEM&#160; 5.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;"><b style="font-weight:bold;">MARKET FOR REGISTRANT&#8217;S COMMON EQUIT</b><b style="font-weight:bold;">Y, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Market Information for Common Stock</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Our common stock is listed on The Nasdaq Global Market under the symbol &#8220;GLYC.&#8221; </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Dividend Policy</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">We have never declared or paid any dividends on our common stock. We anticipate that we will retain all of our future earnings, if any, for use in the operation and expansion of our business and do not anticipate paying cash dividends in the foreseeable future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Stockholders</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27pt;margin:0pt 0pt 6pt 0pt;">As of February 28, 2022, we had 52,313,894 shares of common stock outstanding held by 24 holders of record. The actual number of stockholders is greater than this number of record holders and includes stockholders who are beneficial owners but whose shares are held in street name by brokers and other nominees. This number of holders of record also does not include stockholders whose shares may be held in trust by other entities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Performance Graph</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">The following graph compares the five-year cumulative total return of our common stock with the Nasdaq Composite Index (U.S.) and the Nasdaq Biotechnology Index. The comparison assumes a $100 investment on December 31, 2016 in our common stock, the stocks comprising the Nasdaq Composite Index, and the stocks comprising the Nasdaq Biotechnology Index, and assumes reinvestment of the full amount of all dividends, if any. Historical stockholder return is not necessarily indicative of the performance to be expected for any future periods.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><b style="font-weight:bold;">Comparison of Cumulative Total Return</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><b style="font-weight:bold;">Among GlycoMimetics, Inc., the Nasdaq Composite Index and the Nasdaq Biotechnology Index</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"><img src="glyc-20211231x10k007.jpg" alt="Graphic" style="display:inline-block;height:220.82pt;width:357pt;" /></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">53</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">The performance graph shall not be deemed to be incorporated by reference by means of any general statement incorporating by reference this Form 10-K into any filing under the Securities Act of 1933, as amended or the Exchange Act, except to the extent that we specifically incorporate such information by reference, and shall not otherwise be deemed filed under such acts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Recent Sales of Unregistered Securities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Purchases of Equity Securities by the Issuer and Affiliated Parties</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">None.</p><a id="_3fea2619_4e11_4399_9361_19b27023d8f9"></a><a id="ITEM6RESERVED_84617"></a><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:54pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;"><b style="font-weight:bold;">ITEM&#160; 6.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;"><b style="font-weight:bold;">[RESERVED]</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">54</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_0fd4b58a_4d6a_462c_84e5_15bc20457233"></a><a id="ITEM7MDA"></a><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:54pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;"><b style="font-weight:bold;">ITEM&#160;7.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;"><b style="font-weight:bold;">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL</b><b style="font-weight:bold;"> CONDITION AND RESULTS OF OPERATIONS</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"><i style="font-style:italic;">You should read the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and the related notes and other financial information included elsewhere in this Annual Report. Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. You should review Item&#160;1A. &#8220;Risk Factors&#8221; and &#8220;Special Note Regarding Forward-Looking Statements&#8221; in this Annual Report for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis</i>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">For the discussion of our financial condition and results of operations and cash flows for the year ended December&#160;31, 2020 compared to the year ended December&#160;31, 2019, please refer to Part II, Item 7, &quot;Management&#39;s Discussion and Analysis of Financial Condition and Results of Operations&quot; in our Annual Report on Form 10-K for the year ended December&#160;31, 2020 filed with the SEC on March 2, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Overview</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">We are a clinical-stage biotechnology company focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. We are developing a pipeline of proprietary glycomimetics, which are small molecules that mimic the structure of carbohydrates involved in important biological processes, to inhibit disease-related functions of carbohydrates such as the roles they play in inflammation, cancer and infection. We believe this represents an innovative approach to drug discovery to treat a wide range of diseases. We are focusing our efforts on drug candidates for diseases that we believe will qualify for orphan drug designation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Our proprietary glycomimetics platform is based on our expertise in carbohydrate chemistry and our understanding of the role carbohydrates play in key biological processes. Most human proteins are modified by the addition of complex carbohydrate structures to the surface of such proteins, which affects the functions of the proteins and their interactions with other molecules. Our initial research and development efforts have focused on drug candidates targeting selectins, which are proteins that serve as adhesion molecules and bind to carbohydrates that are involved in the inflammatory component and progression of a wide range of diseases, including hematologic disorders, cancer and cardiovascular disease. For example, we believe that members of the selectin family play a key role in tumor metastasis and resistance to chemotherapy. Inhibiting specific carbohydrates from binding to selectins has long been viewed as a potentially attractive approach for therapeutic intervention. The ability to successfully develop drug-like carbohydrate compounds that inhibit binding with selectins, known as selectin antagonists, has historically been limited by their potency and the complexities of carbohydrate chemistry. We believe our expertise in the rational design of potent glycomimetic antagonists with drug-like properties and in carbohydrate chemistry enables us to identify highly effective selectin antagonists and other glycomimetics that may inhibit the disease-related functions of certain carbohydrates in order to develop novel drug candidates to address orphan diseases with high unmet medical need.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">Our lead glycomimetic drug candidate, uproleselan, is a specific E-selectin inhibitor that we are developing to be used in combination with chemotherapy to treat patients with acute myeloid leukemia, or AML, a life-threatening hematologic cancer, and potentially other hematologic cancers. In 2021, we completed enrollment of patients in a randomized, double-blind, placebo-controlled Phase 3 pivotal clinical trial to evaluate uproleselan in individuals with relapsed/refractory AML, the design of which was based on guidance received from the U.S. Food and Drug Administration, or FDA. Based on discussions with our external statisticians for the trial, we expect to report preliminary data from the trial after year end 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">We have also entered into a Cooperative Research and Development Agreement, or CRADA, with the National Cancer Institute, or NCI, part of the National Institutes of Health, to conduct a Phase 2/3 randomized, controlled clinical trial testing the addition of uproleselan to a standard chemotherapy regimen. Enrollment of the Phase 2 portion was completed in December 2021. There will be a planned interim analysis that will evaluate event-free survival and whether the pre-specified threshold for continuing to Phase 3 has been met. The trial may also provide support for regulatory filings, if the results of the planned interim analysis are positive.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">55</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Uproleselan is also being studied in multiple investigator-sponsored trials, with data readouts from these trial expected in 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">We have rationally designed an innovative antagonist of E-selectin, GMI-1687, that could be a subcutaneously administered treatment. Initially developed as a potential life-cycle extension to uproleselan, we believe that GMI-1687 could be developed to broaden the clinical usefulness of an E-selectin antagonist to conditions where outpatient treatment is preferred or required. We are currently conducting preclinical activities and studies with GMI-1687 to support our planned submission of an investigational new drug application, or IND, to the FDA in the first half of 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">We are also developing a drug candidate, GMI-1359, that simultaneously targets both E-selectin and a chemokine receptor known as CXCR4. In the fourth quarter of 2021, we ended a Phase 1b trial of GMI-1359 in hormone receptor positive breast cancer patients whose tumors have spread to bone. We are also advancing other preclinical-stage programs, including small-molecule glycomimetic compounds that inhibit the protein galectin-3, that could be an orally administered treatment, which we believe may have potential to be used for the treatment of fibrosis, cancer and cardiovascular disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">We have financed our operations primarily through private placements of our securities, up-front and milestone payments under our license and collaboration agreements and the net proceeds from public offerings of common stock, including sales of common stock under at-the-market sales facilities with Cowen and Company LLC, or Cowen. We have no approved drugs currently available for sale, and substantially all of our revenue to date has been revenue from up-front and milestone payments under license and collaboration agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Since inception, we have incurred significant operating losses. We had an accumulated deficit of $372.9 million as of December 31, 2021 and we expect to continue to incur significant expenses and operating losses over at least the next several years. Our net losses may fluctuate significantly from quarter to quarter and year to year, depending on the timing of our clinical trials and our expenditures on other research and development activities. We anticipate that our expenses will increase substantially as we:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">initiate and conduct our planned clinical trials of uproleselan and GMI-1687, including fulfilling our funding and supply commitments related to the ongoing clinical trials of uproleselan;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">conduct NDA-enabling activities related to manufacture, toxicology and clinical pharmacology for our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">manufacture additional uproleselan drug supplies for validation and prepare for commercialization;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seek to discover and develop additional drug candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seek regulatory approvals for any drug candidates that successfully complete clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ultimately establish a sales, marketing and distribution infrastructure and scale up external manufacturing capabilities to commercialize any drug candidates for which we may obtain regulatory approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">maintain, expand and protect our intellectual property portfolio;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">hire additional clinical, quality control, regulatory and scientific personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">maintain sufficient level of insurance including product liability and directors, officers and corporate liability insurance policies; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">add operational, financial and management information systems and personnel, including personnel to support our drug development and potential future commercialization efforts.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">To fund further operations, we will need to raise capital. We may obtain additional financing in the future through the issuance of our common stock, through other equity or debt financings, potentially including the use of our at-the-market sales facility with Cowen, or through collaborations or partnerships with other companies. We may not be able to raise additional capital on terms acceptable to us, or at all, and any failure to raise capital as and when needed could compromise our ability to execute on our business plan. For example, the current global COVID-19 pandemic presents material uncertainty and its disruption of the capital markets may have a material adverse impact on our ability to raise additional capital if we decide to do so. Although it is difficult to predict future liquidity requirements, we believe that our existing cash and cash equivalents will be sufficient to fund our operations into the second quarter of 2023 without </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">56</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">giving effect to potential business development opportunities, such as upfront or milestone payments under license and collaboration agreements, or additional financing activities including the potential sale of common stock. However, our ability to successfully transition to profitability will be dependent upon achieving a level of revenues adequate to support our cost structure. We cannot assure you that we will ever be profitable or generate positive cash flow from operating activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Impact of COVID-19 on Our Business</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">The imposition of &#8220;lockdown,&#8221; &#8220;social distancing&#8221; and &#8220;shelter in place&#8221; directives by state and federal governments in the United States as well as governments in other regions of the world in response to the COVID-19 pandemic, including in locations in which our Phase 3 clinical trial of uproleselan is being conducted, resulted in slowed clinical site initiation, patient recruitment and enrollment rates early in the pandemic. Enrollment rates returned to forecasted rates from the beginning of the lockdowns and we completed enrollment in November 2021. However, we cannot at this time fully assess the effect of the COVID-19 pandemic on our completion of the clinical trial. We continue to closely monitor the COVID-19 situation and any potential impact to our planned activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:14pt 0pt 0pt 0pt;">We have also implemented business continuity plans designed to address and mitigate the impact of the COVID-19 pandemic on our employees and our business. While to date we have experienced limited impacts beyond the earlier delays in recruitment in our ongoing uproleselan Phase 3 clinical trial, given the global economic slowdown, the overall disruption of global healthcare systems and the other risks and uncertainties associated with the pandemic, our business, financial condition, results of operations and growth prospects could be materially adversely affected. We continue to closely monitor the COVID-19 situation as we evolve our business continuity plans and response strategy. In March 2020, our workforce transitioned to working remotely in accordance with federal and state declarations. We have reopened our offices pursuant to a hybrid return to office policy with a focus on employee safety and optimal work environment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Our Collaboration and License Agreements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Apollomics</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">In January 2020, we entered into an exclusive collaboration and license agreement with Apollomics (Hong Kong) Limited, or Apollomics, for the development and commercialization of uproleselan and GMI-1687 in Mainland China, Hong Kong, Macau and Taiwan, also known as Greater China. Under the terms of the agreement, Apollomics will be responsible for clinical development and commercialization in Greater China. We will also collaborate with Apollomics to advance the preclinical and clinical development of GMI-1687. We received an upfront cash payment of $9.0 million and in September 2020 received a $1.0 million development milestone payment. Subject to the terms of the agreement, we will be eligible to receive potential further milestone payments totaling approximately $179.0 million, as well as tiered royalties ranging from the high single digits to 15%, as a percentage of net sales. Apollomics will be responsible for all costs related to development, regulatory approvals, and commercialization activities for uproleselan and GMI-1687 in Greater China, and we and Apollomics expect to enter into clinical and commercial supply agreements with respect to our provision of uproleselan and GMI-1687 to Apollomics. We retain all rights for both compounds in the rest of the world.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">In September 2020, the China National Medical Products Administration (NMPA)&#160;Center for Drug Evaluation (CDE) granted IND approval for uproleselan (also known as APL-106), enabling the initiation of a Phase 1 pharmacokinetics and tolerability study and a planned Phase 3 bridging study of APL-106 in combination with chemotherapy in relapsed/refractory AML. In January 2021, APL-106 was granted Breakthrough Therapy Designation from the China NMPA CDE for the treatment of relapsed/refractory AML. In March 2021, Apollomics enrolled the first patient in the Phase 1 study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27pt;margin:0pt 0pt 6pt 0pt;">In June 2020, we entered into a clinical supply agreement with Apollomics under which we will manufacture and supply uproleselan product to Apollomics at agreed upon prices. Apollomics has the option to begin manufacture after appropriate material transfer requirements are met. During the year ended December 31, 2021, we recognized $1.1 million in revenue from the sale of clinical supplies to Apollomics under the clinical supply agreement. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">57</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Critical Accounting Policies and Significant Judgments and Estimates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Our management&#8217;s discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States, or GAAP. The preparation of these financial statements requires us to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities as of the dates of the balance sheets and the reported amounts of revenue and expenses during the reporting periods. In accordance with GAAP, we base our estimates on historical experience and on various other assumptions that we believe are reasonable under the circumstances at the time such estimates are made. Actual results may differ materially from our estimates and judgments under different assumptions or conditions. We periodically review our estimates in light of changes in circumstances, facts and experience. The effects of material revisions in estimates are reflected in our financial statements prospectively from the date of the change in estimate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">We define our critical accounting policies as those accounting principles generally accepted in the United States that require us to make subjective estimates and judgments about matters that are uncertain and are likely to have a material impact on our financial condition and results of operations, as well as the specific manner in which we apply those principles. While our significant accounting policies are more fully described in Note 3 to our financial statements appearing elsewhere in this Annual Report, we believe the following are the critical accounting policies used in the preparation of our financial statements that require significant judgments and estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Revenue Recognition</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">We apply Accounting Standards Codification, or ASC, Topic 606, <i style="font-style:italic;">Revenue from Contracts with Customers</i>, to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration agreements and financial instruments. Under Topic 606, an entity recognizes revenue when its customer obtains control of promised goods and services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods and services. To determine revenue recognition for an arrangement that an entity determines is within the scope of Topic 606, we perform the following five steps: (i) identify the contract(s) with the customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation in the contract; and (v) recognize revenue when (or as) we satisfy a performance obligation. We only apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer. At contract inception, once the contract is determined to be within the scope of Topic 606, we assess the goods or services promised within each contract and identify, as a performance obligation, and assess whether each promised good or service is distinct. We then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">We enter into licensing agreements which are within the scope of Topic 606, under which we license certain of our product candidates&#8217; rights to third parties. The terms of these arrangements typically include payment of one or more of the following: non-refundable, up-front license fees; development, regulatory and commercial milestone payments; and royalties on net sales of the licensed product. In determining the appropriate amount of revenue to be recognized as we fulfill our obligation under our agreements, we perform the five steps described above. As part of the accounting for these arrangements, we must develop assumptions that require judgment to determine the stand-alone selling price, which may include forecasted revenues, development timelines, reimbursement of personnel costs, discount rates and probabilities of technical and regulatory success.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"><i style="font-style:italic;">Licensing of Intellectual Property: </i>If the license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we will recognize revenue from non-refundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front-fees. We evaluate the measure of progress each reporting period, and, if necessary, adjust the measure of performance and related revenue recognition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"><i style="font-style:italic;">Milestone Payments</i>: At the inception of each arrangement that includes development milestone payments, we evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal will not occur, </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">58</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">the associated milestone value is included in the transaction price. Milestone payments that are not within our control or the licensee&#8217;s control, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, we re-evaluate the probability of achievement of such development milestones and any related constraint, and if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration and other revenues and earnings in their period of adjustment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"><i style="font-style:italic;">Royalties</i>: For arrangements that include sales-based royalties, including milestone payments based on the level of sales, for which the license is deemed to be the predominant item to which royalties relate, we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some of all of the royalty has been allocated has been satisfied (or partially satisfied). To date, we have not recognized any royalty revenue from our license agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"><i style="font-style:italic;">Manufacturing and Supply:</i> Our agreements may include providing clinical and commercial manufacturing products to the counterparties. The services are generally determined to be distinct from the other promises or performance obligations identified in the arrangement. We recognize the transaction price allocated to these services as revenue at a point in time when transfer of control of the related products to the customer occurs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Stock-Based Compensation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">We issue stock-based compensation awards to our employees and non-employee directors, including stock options. We measure stock-based compensation expense related to these awards based on the fair value of the award, utilizing the Black-Scholes-Merton option pricing model, on the date of grant and recognize stock-based compensation expense on a straight-line basis over the requisite service period of the awards, which generally equals the vesting period. We account for forfeitures as they occur. We grant stock options with exercise prices equal to the estimated fair value of our common stock on the date of grant. The Black-Scholes-Merton option pricing model requires the input of various assumptions that require management to apply judgment and make assumptions and estimates, including:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Risk-Free Interest Rate</b>&#8212;The risk-free interest rate assumption is based on observed interest rates for constant maturity U.S. Treasury securities consistent with the expected life of our employee stock options.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Expected Term</b>&#8212;The expected life represents the period of time the stock options are expected to be outstanding and is based on the simplified method. Under the simplified method, the expected life of an option is presumed to be the midpoint between the vesting date and the end of the contractual term. We used the simplified method due to the lack of sufficient historical exercise data to provide a reasonable basis upon which to otherwise estimate the expected life of the stock options.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Expected Volatility&#8212;</b> Volatility is a measure of the amount by which a financial variable such as share price has fluctuated (historical volatility) or is expected to fluctuate (expected volatility) during a period. We base the expected volatility on the historical volatility of our publicly traded common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Expected Dividend Yield</b>&#8212;We have assumed no dividend yield because we do not expect to pay dividends in the future, which is consistent with our history of not paying dividends.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Accruals for Clinical Trial Expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">Clinical trial costs primarily consist of expenses incurred under agreements with contract research organizations (CROs), investigative sites, laboratory testing expenses, data management and consultants that conduct our clinical trials. Clinical trial expenses are a significant component of research and development expenses, and we outsource a significant portion of these clinical trial activities to third parties. The accrual for site and patient costs includes inputs such as estimates of patient enrollment, patient cycles incurred, clinical site activations, estimated project duration and other pass-through costs. These inputs are required to be estimated due to a lag in receiving the actual clinical information from third parties. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected on the balance sheets as prepaid assets or accrued expenses. These third-party agreements are generally cancellable, and related costs are recorded as research and development expenses as incurred. Except for payments made in advance of services, clinical trial costs are expensed as incurred. Non-refundable advance clinical payments for goods or services that will be used or rendered for future research and development </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">59</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">activities are recorded as a prepaid asset and recognized as expense as the related goods are delivered or the related services are performed. When evaluating the adequacy of the accrued expenses, management assessments include: (i) an evaluation by the project manager of the work that has been completed during the period; (ii) measurement of progress prepared internally and/or provided by the third-party service provider; (iii) analyses of data that justify the progress; and (iv)&#160;our judgment. Significant judgments and estimates may be made in determining the accrued balances at the end of any reporting period. Actual results could differ from the estimates made. Our historical clinical accrual estimates have not been materially different from the actual costs. Clinical trial accruals that are due longer than one year are classified as noncurrent accrued expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Components of Operating Results</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Revenue</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">To date, we have not generated any revenue from the sale of our drug candidates and do not expect to generate any revenue from the sale of drugs in the near future. Substantially all of our historical revenue consisted of upfront and milestone payments under license and collaboration agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Research and Development</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Research and development expenses consist of expenses incurred in performing research and development activities, including compensation and benefits for full-time research and development employees, facilities expenses, overhead expenses, cost of laboratory supplies, clinical trial and related clinical manufacturing expenses, fees paid to CROs and other consultants and other outside expenses. Other preclinical research and platform programs include activities related to exploratory efforts, target validation, lead optimization for our earlier programs and our proprietary glycomimetics platform. Our research and development expenses relate primarily to the development of uproleselan and our other drug candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">We do not currently utilize a formal time allocation system to capture expenses on a project-by-project basis because we are organized and record expense by functional department and our employees may allocate time to more than one development project. Accordingly, we only allocate a portion of our research and development expenses by functional area and by drug candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Research and development costs are expensed as incurred. Non-refundable advance payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Research and development activities are central to our business model. Drug candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later stage clinical trials. We expect our research and development expenses to increase over the next several years as we seek to progress uproleselan, GMI-1687 and our other drug candidates into and through clinical development. However, it is difficult to determine with certainty the duration and completion costs of our current or future preclinical studies and clinical trials of our drug candidates, or if, when or to what extent we will generate revenues from the commercialization and sale of any of our drug candidates that obtain regulatory approval. We may never succeed in achieving regulatory approval for any of our drug candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">The duration, costs and timing of clinical trials and development of our drug candidates will depend on a variety of factors that include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">per patient trial costs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number of patients that participate in the trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number of sites included in the trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the countries in which the trial is conducted;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the length of time required to enroll eligible patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number of doses that patients receive;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the drop-out or discontinuation rates of patients;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">60</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential additional safety monitoring or other studies requested by regulatory agencies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the duration of patient follow-up; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the safety and efficacy profile of the drug candidate.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">In addition, the probability of success for each drug candidate will depend on numerous factors, including competition, manufacturing capability and commercial viability. We will determine which programs to pursue and how much to fund each program in response to the scientific and clinical success of each drug candidate, as well as an assessment of each drug candidate&#8217;s commercial potential.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">General and Administrative</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">General and administrative expenses consist primarily of salaries and other related costs, including stock-based compensation, for personnel in executive, finance, accounting, business development and human resources functions. Other significant costs include facility costs not otherwise included in research and development expenses, legal fees relating to patent and corporate matters and fees for accounting and consulting services. We anticipate that our general and administrative expenses will increase in the future as we start to build upon our commercialization efforts for uproleselan and continue to support our research and development activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Interest Income</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Other income consists of interest income earned on our cash and cash equivalents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Results of Operations </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">The following table sets forth our results of operations:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:18.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:57.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:18.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Increase/(Decrease)</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">(dollars in thousands)</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,160</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 10,163</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (9,003)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (89)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:57.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Costs and expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 24pt;">Research and development expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 47,492</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 44,929</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,563</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:57.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 24pt;">General and administrative expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 17,115</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 16,743</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 372</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:57.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 42pt;">Total costs and expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 64,607</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 61,672</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,935</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:57.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (63,447)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (51,509)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (11,938)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 23</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:57.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 20</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 482</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (462)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (96)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:57.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Net loss and comprehensive loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (63,427)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (51,027)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (12,400)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 24</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Revenue</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27pt;margin:0pt 0pt 6pt 0pt;">During the year ended December 2021 and 2020, revenue was $1.2 million and $10.2 million, respectively, all of which was the result of payments received under our license and collaboration agreement with Apollomics for the development and commercialization of uproleselan and GMI-1687 in Greater China. During the year ended December 31, 2021, we recognized $1.1 million in revenue from the sale of clinical supplies to Apollomics under a clinical supply agreement. In January 2020, we recognized $9.0 million in revenue from an upfront milestone payment, and in September 2020, we recognized a $1.0 million clinical development milestone payment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">61</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Research and Development Expense</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">The following table summarizes our research and development expense by functional area:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:56.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:17.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:17.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Increase/(Decrease)</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">(dollars in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Clinical development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 19,689</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 18,321</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,368</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 7</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:56.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Manufacturing and formulation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 12,307</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 9,221</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,086</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 33</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:56.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Contract research services, consulting and other costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,163</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,907</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 256</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 13</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:56.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Laboratory costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,140</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,066</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 74</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:56.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Personnel-related</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 8,978</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 10,467</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1,489)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (14)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:56.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,215</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,947</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (732)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (25)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:56.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Research and development expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 47,492</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 44,929</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,563</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:6pt 0pt 6pt 0pt;">The following table summarizes our research and development expense by drug candidate:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:56.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:56.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:17.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:17.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Increase/(Decrease)</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">(dollars in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:56.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Uproleselan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 29,781</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 27,189</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,592</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 10</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:56.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">GMI-1359</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 555</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 467</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 88</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 19</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:56.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Other research&#160;and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,963</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,859</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,104</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 55</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:56.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Personnel-related and stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 11,193</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 13,414</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (2,221)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (17)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:56.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Research and development expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 47,492</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 44,929</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,563</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">Our research and development expense for the year ended December 31, 2021 increased by $2.6 million compared to the year ended December 31, 2020 primarily due to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">increased clinical trial and development costs related to our ongoing global Phase 3 clinical trial of uproleselan in individuals with relapsed/refractory AML;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 60.5pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">increased manufacturing costs for the uproleselan validation batches; and</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">increased costs for toxicity studies of GMI-1687 included in other research and development in the drug candidate summary table above.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">These increases were partially offset by:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">decreased personnel-related and stock-based compensation due to a lower number of research and development employees.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">General and Administrative Expense</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">The following table sets forth the components of our general and administrative expense:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:56.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:17.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:17.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Increase/(Decrease)</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">(dollars in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Personnel-related</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,788</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6,275</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (487)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (8)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:56.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,872</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,955</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (83)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (2)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:56.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Legal, consulting and other professional expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6,652</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,819</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 833</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 14</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:56.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 803</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 694</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 109</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 16</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:56.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">General and administrative expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 17,115</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 16,743</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 372</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">General and administrative expense increased for the year ended December 31, 2021 by $372,000, or 2%, compared to 2020. Personnel-related expenses decreased due to a reversal of accruals for performance and retention bonuses that our prior Chief Executive Officer was eligible to receive but which were forfeited upon her cessation of </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">62</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">service in that role in 2021. These decreases were offset by higher recruiting, consulting and legal expenses incurred in the year ended December 31, 2021 as compared to 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Interest Income</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">During the year ended December 31, 2021, interest income decreased by $462,000, compared to the same period in 2020, due to lower average cash balances and lower interest rates on those balances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Liquidity and Capital Resources</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Sources of Liquidity</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">We have historically financed our operations primarily through public offerings and private placements of our capital stock, including sales agreements with Cowen, and upfront and milestone payments from our license and collaboration agreements. As of December 31, 2021, we had $90.3 million in cash and cash equivalents. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">In October 2020, we filed a prospectus supplement to a shelf registration statement that we filed in May 2019 and entered into an at-the-market sales agreement, or the 2020 Sales Agreement, with Cowen. Under the 2020 Sales Agreement, we may sell up to $100.0 million of our common stock registered under the shelf registration statement that we filed in May 2019. During the year ended December 31, 2020, we sold 1,024,760 shares of common stock under the 2020 Sales Agreement at a weighted average price of $3.74 per share, for aggregate net proceeds of $3.7 million, after deducting commissions and offering expenses. During the year ended December 31, 2021, we sold an additional 3,092,603 shares of common stock under the 2020 Sales Agreement at a weighted average price of $3.57 per share, for aggregate net proceeds of $10.7 million, after deducting commissions and offering expenses. As of December 31, 2021, we have approximately $85.1 million remaining available to be sold under the terms of the 2020 Sales Agreement. Subsequent to December 31, 2021, there have been no additional sales under the 2020 Sales Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">We entered into a collaboration and license agreement with Apollomics in January 2020 and are potentially eligible to earn milestone payments and royalties under that agreement. In January 2020, Apollomics made an upfront payment to us of $9.0 million. We also received a non-refundable payment of $1.0 million in September 2020 as a clinical development milestone payment. Our ability to earn additional milestone payments and potential royalty payments and their timing will be dependent upon the outcome of Apollomics&#8217; activities and is therefore uncertain at this time. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Funding Requirements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">Our primary uses of capital are, and we expect will continue to be, compensation and related expenses, third-party clinical research and development services, laboratory and related supplies, clinical costs, legal and other regulatory expenses and general overhead costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"><span style="white-space:pre-wrap;">As of December 31, 2021, our significant contractual obligations consisted solely of rent obligations under a non-cancelable lease, as amended, for our current office space in Rockville, Maryland, which has a term through October 2023. Total remaining obligations under this lease as of December 31, 2021 were $2.0 million.  We have no other fixed long-term obligations and we do not have significant capital expenditure requirements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">We have also entered into various agreements for services with third-party vendors, including agreements to conduct clinical trials, to manufacture products, and for consulting and other contracted services. These agreements include cancellable terms and we accrue the costs of these agreements based on estimates of work completed to date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">The successful development of any of our drug candidates is highly uncertain. As such, at this time, we cannot reasonably estimate or know the nature, timing and costs of the efforts that will be necessary to complete the remainder of the development of uproleselan or our other drug candidates. We are also unable to predict when, if ever, material net cash inflows will commence from uproleselan or our other drug candidates. This is due to the numerous risks and uncertainties associated with developing drugs, including the uncertainty of: </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">successful enrollment in, and completion of, clinical trials; </span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 0pt 24.5pt;"><span style="font-size:8.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">receipt of marketing approvals from applicable regulatory authorities; </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">63</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establishing commercial manufacturing capabilities or making arrangements with third-party manufacturers; </span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining and maintaining patent and trade secret protection and regulatory exclusivity for drug candidates; </span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">launching commercial sales of drugs, if and when approved, whether alone or in collaboration with others; and</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining and maintaining healthcare coverage and adequate reimbursement. </span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">A change in the outcome of any of these variables with respect to the development of any of our drug candidates would significantly change the costs and timing associated with the development of that drug candidate. Because our drug candidates are in various stages of clinical and preclinical development and the outcome of these efforts is uncertain, we cannot estimate the actual amounts necessary to successfully complete the development and commercialization of our drug candidates or whether, or when, we may achieve profitability. Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity or debt financings and collaboration arrangements, including our existing license agreement with Apollomics. Except for amounts that we may sell under our 2020 Sales Agreement with Cowen, and Apollomics&#8217; conditional obligations to make milestone and royalty payments to us under our license agreement, we do not have any committed external source of liquidity. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">To the extent that we raise additional capital through the future sale of equity or debt, the ownership interest of our stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our existing common stockholders. If we raise additional funds through the issuance of convertible debt securities, these securities could contain covenants that would restrict our operations. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">We may require additional capital beyond our currently anticipated amounts. Additional capital may not be available on reasonable terms, or at all. If we raise additional funds through collaboration arrangements in the future, we may have to relinquish valuable rights to our drug candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our drug development or future commercialization efforts or grant rights to develop and market drug candidates that we would otherwise prefer to develop and market ourselves. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Going Concern</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">The accompanying financial statements included in this Annual Report have been prepared assuming that we will continue as a going concern within one year after the date that the financial statements are issued. During 2021, we incurred a net loss of $63.4 million and had net cash flows used in operating activities of $57.5 million. At December 31, 2021, we had $90.3 million in cash and cash equivalents and had no committed source of additional funding from either debt or equity financings. Management believes that given our current cash position and forecasted negative cash flows from operating activities over the next twelve months as we continue our product development activities, including the completion of our planned Phase 3 clinical trial of uproleselan, there is substantial doubt about our ability to continue as a going concern beyond the date that is one year from the date that these financial statements are issued, without obtaining additional financing or entering into another form of non-equity or debt arrangement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Outlook</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Based on our research and development plans and our timing expectations related to the progress of our programs, we expect that our existing cash and cash equivalents will enable us to fund our operating expenses and capital expenditure requirements into the second quarter of 2023. We have based this estimate on assumptions that may prove to be wrong, and we could use our capital resources sooner than we expect. Additionally, the process of testing drug candidates in clinical trials is costly, and the timing of progress in these trials is uncertain.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">64</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Cash Flows</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">The following table summarizes our cash flows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:77.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:77.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">(in&#160;thousands)</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Net cash provided by (used in):</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:77.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 24pt;">Operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (57,489)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (39,242)</span></p></td></tr><tr><td style="vertical-align:bottom;width:77.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 24pt;">Investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (15)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (68)</span></p></td></tr><tr><td style="vertical-align:bottom;width:77.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 24pt;">Financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 10,724</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 18,144</span></p></td></tr><tr><td style="vertical-align:bottom;width:77.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Net change in cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (46,780)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (21,166)</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:6pt 0pt 6pt 0pt;">In assessing cash used in operating activities, we consider several principal factors: (i) net loss for the period; (ii) adjustments for non-cash charges including stock-based compensation expense and depreciation and amortization of property and equipment; and (iii) the extent to which receivables, accounts payable and other liabilities, or other working capital components increase or decrease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><i style="font-style:italic;">Operating Activities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Net cash used in operating activities was $57.5 million during the year ended December&#160;31, 2021 compared to $39.2 million during the year ended December&#160;31, 2020. For the years ended December 31, 2021 and 2020, we received $1.1 million and $10.2 million, respectively, in revenue under our agreements with Apollomics for the development and commercialization of uproleselan and GMI-1687 in Greater China. For the year ended December 31, 2021, there was increased spending in clinical development and manufacturing expenses as a result of ongoing costs associated with our uproleselan clinical development programs in our global Phase 3 clinical trial and the NCI-sponsored Phase 2/3 trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><i style="font-style:italic;">Investing Activities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Net cash used in investing activities, consisting of purchases of scientific equipment and computers, was $15,000 for the year ended December 31, 2021 compared to $68,000 during the year ended December 31, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><i style="font-style:italic;">Financing Activities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Net cash provided by financing activities of $10.7 million and $18.1 million during the years ended December 31, 2021 and 2020, respectively, consisted primarily of the net proceeds received from our at-the-market facility with Cowen. During the year ended December 31, 2020, we also received $319,000 in proceeds from stock option exercises. </p><a id="_d9c4f988_2ae7_4a7c_ab34_66f957a7cf54"></a><a id="ITEM7AQUANTITATIVEANDQUALITATIVE_860953"></a><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:54pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;"><b style="font-weight:bold;">ITEM&#160; 7A.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;"><b style="font-weight:bold;">QUANTITATIVE AND QUALITATIV</b><b style="font-weight:bold;">E DISCLOSURES ABOUT MARKET RISK</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">The market risk inherent in our financial instruments and in our financial position represents the potential loss arising from adverse changes in interest rates. As of December 31, 2021 and 2020, we had cash and cash equivalents of $90.3 million and $137.0 million, respectively. We generally hold our cash in interest-bearing money market accounts. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates. Due to the short-term maturities of our cash equivalents and the low risk profile of our investments, an immediate 100 basis point change in interest rates would not have a material effect on the fair market value of our cash equivalents. </p><a id="_7a06ce04_a3b3_455e_ae34_b216beafaf8f"></a><a id="ITEM8FINANCIALSTATEMENTSANDSUPPLEMENTARY"></a><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:55.1pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;"><b style="font-weight:bold;">ITEM&#160;8.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;"><b style="font-weight:bold;">FINANCIAL STATEMENTS AND SUPPLEMENTARY DAT</b><b style="font-weight:bold;">A</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">The financial statements and related financial statement schedules required to be filed are listed in Part IV, Item 15 of this Form 10-K. </p><a id="_62ec6359_0abb_4385_87b5_c8ee10ba7978"></a><a id="ITEM9CHANGESINANDDISAGREEMENTSWITHACCOUN"></a><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:55.1pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:18pt;"><b style="font-weight:bold;">ITEM&#160; 9.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:18pt;"><b style="font-weight:bold;">CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANT</b><b style="font-weight:bold;">S ON ACCOUNTING AND FINANCIAL DISCLOSURE</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">None.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">65</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_ae0c1181_c4c1_4c56_9e29_c53aec8062e4"></a><a id="ITEM9ACONTROLSANDPROCEDURES_712204"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:72pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">ITEM&#160; 9A.</b></span><b style="font-weight:bold;">CONTROLS AND PROCEDURE</b><b style="font-weight:bold;">S</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><i style="font-style:italic;">Evaluation of Disclosure Controls and Procedures</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Under the supervision of and with the participation of our management, including our chief executive officer, who is our principal executive officer, and our chief financial officer, who is our principal financial officer, we conducted an evaluation of the effectiveness of our disclosure controls and procedures as of December 31, 2021, the end of the period covered by this Annual Report. The term &#8220;disclosure controls and procedures,&#8221; as set forth in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, means controls and other procedures of a company that are designed to provide reasonable assurance that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the rules and forms promulgated by the SEC. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company&#8217;s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of December&#160;31, 2021, our chief executive officer and chief financial officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><i style="font-style:italic;">Management&#8217;s Report on Internal Control over Financial Reporting and Attestation Report of the Registered Public Accounting Firm</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Our management is responsible for establishing and maintaining an adequate system of internal control over financial reporting, as defined in the Exchange Act Rule 13a-15(f). Management conducted an assessment of our internal control over financial reporting based on the original framework established in 2013 by the Committee of Sponsoring Organizations of the Treadway Commission in Internal Control&#8212;Integrated Framework. Based on the assessment, management concluded that, as of December 31, 2021, our internal control over financial reporting was effective.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">This Annual Report does not include an attestation report of our registered public accounting firm regarding the effectiveness of internal control over financial reporting as required by Section&#160;404(b) of the Sarbanes-Oxley Act of 2002. Management&#8217;s report was not subject to attestation by our registered public accounting firm pursuant to rules of the SEC that permit smaller reporting companies to provide only management&#8217;s report in this Annual Report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><i style="font-style:italic;">Changes in Internal Control over Financial Reporting</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">There was no change in our internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the quarter ended December 31, 2021 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</p><a id="_f8c8064b_c96a_42d7_b224_c000774f0523"></a><a id="ITEM9BOTHERINFORMATION_45602"></a><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:54pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;"><b style="font-weight:bold;">ITEM&#160;9B.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;"><b style="font-weight:bold;">OTHER INFORMATIO</b><b style="font-weight:bold;">N</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:6pt 0pt 12pt 0pt;">None</p><a id="ITEM9CDISCLOSUREREGARDINGFOREIGNJURISDIC"></a><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:54pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;"><b style="font-weight:bold;">ITEM&#160;9C.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;"><b style="font-weight:bold;text-transform:uppercase;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.3pt;margin:6pt 0pt 0pt 0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">66</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_cd4114d3_59e0_4cb3_8cbc_2a6f78034fcb"></a><a id="PARTIII_655348"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">PART II</b><b style="font-weight:bold;">I</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23pt;margin:0pt 0pt 12pt 0pt;">We will file a definitive proxy statement for our 2022 annual meeting of stockholders, or the 2022 Proxy Statement, with the SEC, pursuant to Regulation 14A, not later than 120 days after the end of our fiscal year. Accordingly, certain information required by Part III has been omitted under General Instruction G(3) to Form 10-K. Only those sections of the 2022 Proxy Statement that specifically address the items set forth herein are incorporated by reference.</p><a id="ITEM10DIRECTORSEXECUTIVEOFFICERSANDCORPO"></a><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:54pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;"><b style="font-weight:bold;">ITEM&#160; 10.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;"><b style="font-weight:bold;">DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANC</b><b style="font-weight:bold;">E</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23pt;margin:0pt 0pt 12pt 0pt;">The information required by Item 10 is hereby incorporated by reference to the relevant information to be included in the 2022 Proxy Statement under the captions &#8220;Information Regarding the Board of Directors and Corporate Governance,&#8221; &#8220;Election of Directors&#8221; and &#8220;Executive Officers.&#8221;</p><a id="_597e171e_b5c2_4395_989d_4b9a366749cc"></a><a id="ITEM11EXECUTIVECOMPENSATION_298012"></a><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:54pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;"><b style="font-weight:bold;">ITEM&#160; 11.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;"><b style="font-weight:bold;">EXECUTIVE COMPENSATIO</b><b style="font-weight:bold;">N</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23pt;margin:0pt 0pt 12pt 0pt;">The information required by Item 11 is hereby incorporated by reference to the relevant information to be included in the 2022 Proxy Statement under the captions &#8220;Executive Compensation&#8221; and &#8220;Non-Employee Director Compensation.&#8221;</p><a id="_216366db_3400_4994_8ffb_dd9eccd2820c"></a><a id="ITEM12SECURITYOWNERSHIPOFCERTAINBENEFICI"></a><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:54pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;"><b style="font-weight:bold;">ITEM&#160;12.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;"><b style="font-weight:bold;">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNER</b><b style="font-weight:bold;">S AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">The information required by Item 12 is hereby incorporated by reference to the relevant information to be included in the 2022 Proxy Statement under the captions &#8220;Security Ownership of Certain Beneficial Owners and Management&#8221; and &#8220;Securities Authorized for Issuance under Equity Compensation Plans.&#8221;</p><a id="_996e01e7_cb11_4fd2_8916_0cc3d814b4a0"></a><a id="ITEM13CERTAINRELATIONSHIPSANDRELATEDTRAN"></a><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:54pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;"><b style="font-weight:bold;">ITEM&#160;13.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;"><b style="font-weight:bold;">CERTAIN RELATIONSHIPS AND RELATED TRANSACTION</b><b style="font-weight:bold;">S, AND DIRECTOR INDEPENDENCE</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23pt;margin:0pt 0pt 12pt 0pt;">The information required by Item 13 is hereby incorporated by reference to the relevant information to be included in the 2022 Proxy Statement under the captions &#8220;Transactions with Related Persons&#8221; and &#8220;Independence of the Board of Directors.&#8221;</p><a id="_afe77666_ab7a_4632_95b8_663bbfc27d82"></a><a id="ITEM14PRINCIPALACCOUNTINGFEESANDSERVICES"></a><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:54pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;"><b style="font-weight:bold;">ITEM&#160; 14.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;"><b style="font-weight:bold;">PRINCIPAL ACCOUNTING FEES AND SERVICE</b><b style="font-weight:bold;">S</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23pt;margin:0pt 0pt 12pt 0pt;">The information required by Item 14 is hereby incorporated by reference to the relevant information to be included in the 2022 Proxy Statement under the caption &#8220;Ratification of Selection of Independent Auditors.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">67</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_c3c26a6d_4406_4980_987e_b8a0db18457b"></a><a id="PARTIV_600453"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">PART I</b><b style="font-weight:bold;">V</b></p><a id="ITEM15EXHIBITSANDFINANCIALSTATEMENTSCHED"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">ITEM&#160; 15.</b>&#8195;<b style="font-weight:bold;">EXHIBITS, FINANCIAL STATEMENT SCHEDULE</b><b style="font-weight:bold;">S</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 6pt 0pt;">(a)&#8195;The following documents are filed as part of this Annual Report on Form 10-K:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 6pt 24.5pt;">(1)&#8195;Financial Statements:</p><div style="padding-left:46.8pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:90%;"><tr style="height:1pt;"><td style="vertical-align:top;width:94.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.71%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:94.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#Report_of_Independent_Registered_Publ_29"><span style="font-style:normal;font-weight:normal;">Report of Ernst&#160;&amp; Young LLP, Independent Registered Public Accounting Firm</span></a><span style="white-space:pre-wrap;">  </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.71%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">73</p></td></tr><tr><td style="vertical-align:top;width:94.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#BalanceSheets_656978"><span style="font-style:normal;font-weight:normal;">Balance Sheets</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.71%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">75</p></td></tr><tr><td style="vertical-align:top;width:94.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#StatementsofOperationsandComprehensive_1"><span style="font-style:normal;font-weight:normal;">Statements of Operations and Comprehensive Loss</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.71%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">76</p></td></tr><tr><td style="vertical-align:top;width:94.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#StatementsofStockholdersEquity_712246"><span style="font-style:normal;font-weight:normal;">Statements of Stockholders&#8217; Equity</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.71%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">77</p></td></tr><tr><td style="vertical-align:top;width:94.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#StatementsofCashFlows_755635"><span style="font-style:normal;font-weight:normal;">Statements of Cash Flows</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.71%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">78</p></td></tr><tr><td style="vertical-align:top;width:94.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#NotestoFinancialStatements_432888"><span style="font-style:normal;font-weight:normal;">Notes to Financial Statements</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.71%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">79</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:6pt 0pt 6pt 24.5pt;">(2)&#8195;Financial Statement Schedules:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 46.1pt;">All financial statement schedules have been omitted because they are not applicable, not required or the information required is shown in the financial statements or the notes thereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 6pt 24.5pt;">(3)&#8195;Exhibits</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:middle;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:middle;width:86.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Number</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:86.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Description of Document</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:top;white-space:nowrap;width:11%;border-top:1px solid #000000;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:top;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:middle;width:86.99%;border-top:1px solid #000000;margin:0pt;padding:0pt;"></th></tr><tr><td style="vertical-align:top;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;3.1(1)</p></td><td style="vertical-align:top;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1253689/000119312514012028/d657730dex31.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Certificate of Incorporation.</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:86.99%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;3.2(2)</p></td><td style="vertical-align:top;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1253689/000119312514012028/d657730dex32.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Bylaws.</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;4.1(3)</p></td><td style="vertical-align:top;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1253689/000119312513421071/d572031dex42.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Specimen stock certificate evidencing shares of Common Stock.</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;4.2(4)</p></td><td style="vertical-align:top;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1253689/000155837020001723/glyc-20191231ex42a9074bd.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Description of Certain of Registrant&#8217;s Securities.</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:86.99%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;10.1+(5)</p></td><td style="vertical-align:top;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1253689/000119312513391443/d572031dex108.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">2003 Stock Incentive Plan, as amended.</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;10.2+(6)</p></td><td style="vertical-align:top;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1253689/000119312513391443/d572031dex109.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Incentive Stock Option Agreement under 2003 Stock Incentive Plan.</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;10.3+(7)</p></td><td style="vertical-align:top;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1253689/000119312513391443/d572031dex1010.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Nonqualified Stock Option Agreement under 2003 Stock Incentive Plan.</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;10.4+(8)</p></td><td style="vertical-align:top;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1253689/000119312513412381/d572031dex1011.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">2013 Equity Incentive Plan.</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;10.5+(9)</p></td><td style="vertical-align:top;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1253689/000119312513412381/d572031dex1012.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Stock Option Grant Notice and Stock Option Agreement under 2013 Equity Incentive Plan.</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;10.6+(10)</p></td><td style="vertical-align:top;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1253689/000119312513412381/d572031dex1013.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement under 2013 Equity Incentive Plan.</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;10.7+(11)</p></td><td style="vertical-align:top;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1253689/000119312513412381/d572031dex1014.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">2013 Employee Stock Purchase Plan.</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;10.8+(12)</p></td><td style="vertical-align:top;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1253689/000119312513412381/d572031dex1015.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Indemnification Agreement.</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;10.9+(13)</p></td><td style="vertical-align:top;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1253689/000155837021014003/glyc-20210930xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Executive Employment Agreement, dated as of August 3, 2021, by and between the Registrant and Harout Semerjian.</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;10.10+(14)</p></td><td style="vertical-align:top;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1253689/000155837019006741/glyc-20190630ex103863aa0.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Executive Employment Agreement, dated as of July 30, 2019, by and between the Registrant and Brian Hahn.</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;10.11+(15)</p></td><td style="vertical-align:top;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1253689/000155837019006741/glyc-20190630ex104084cd4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Executive Employment Agreement, dated as of July 30, 2019, by and between the Registrant and John Magnani.</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;10.12+(16)</p></td><td style="vertical-align:top;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1253689/000155837019006741/glyc-20190630ex1067816da.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Executive Employment Agreement, dated as of July 30, 2019, by and between the Registrant and Armand Girard.</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;10.13+</p></td><td style="vertical-align:top;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="glyc-20211231xex10d13.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consulting Agreement, dated as of August 31, 2021, by and between the Registrant and Rachel King</span></a>.</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;10.14+</p></td><td style="vertical-align:top;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="glyc-20211231xex10d14.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Non-Employee Director Compensation Policy.</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">68</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:5.75pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:middle;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:middle;width:86.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Number</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:86.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Description of Document</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:top;white-space:nowrap;width:11%;border-top:1px solid #000000;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:top;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:middle;width:86.99%;border-top:1px solid #000000;margin:0pt;padding:0pt;"></th></tr><tr><td style="vertical-align:top;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;10.15(17)</p></td><td style="vertical-align:top;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1253689/000119312514281651/d762605dex101.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Lease Agreement, dated July 23, 2014, by and between the Registrant and BMR-Medical Center Drive, LLC.</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;10.16(18)</p></td><td style="vertical-align:top;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1253689/000155837020011405/glyc-20201007xex1d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;background:#ffffff;">Sales Agreement, dated October 7, 2020 by and between the Registrant and Cowen and Company, LLC</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">.</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:86.99%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;10.17(19)</p></td><td style="vertical-align:top;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1253689/000155837016004451/glyc-20160324ex101357c41.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">First Amendment to Lease, dated March 24, 2016, by and between the Registrant and BMR-Medical Center Drive LLC.</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:86.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;10.18*(20)</p></td><td style="vertical-align:top;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:86.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1253689/000155837020001723/glyc-20191231ex1020d5bed.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Collaboration and License Agreement, dated January 2, 2020, by and between the Registrant and Apollomics (Hong Kong) Limited.</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;10.19+</p></td><td style="vertical-align:top;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="glyc-20211231xex10d19.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">GlycoMimetics, Inc. Amended and Restated Inducement Plan dated as of January 21, 2022.</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:86.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;10.20+(21)</p></td><td style="vertical-align:top;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1253689/000155837020001723/glyc-20191231ex10222a5bd.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Stock Option Grant Notice and Stock Option Agreement under the GlycoMimetics, Inc. Inducement Plan.</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:86.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;23.1</p></td><td style="vertical-align:top;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="glyc-20211231xex23d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consent of Ernst &amp; Young LLP, independent registered public accounting firm.</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:86.99%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;24.1</p></td><td style="vertical-align:top;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#SIGNATURES_192363"><span style="font-style:normal;font-weight:normal;">Power of Attorney (contained on signature page hereto)</span></a>.</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:86.99%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;31.1</p></td><td style="vertical-align:top;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="glyc-20211231xex31d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Principal Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) promulgated under the Securities Exchange Act of 1934, as adopted pursuant to section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:86.99%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;31.2</p></td><td style="vertical-align:top;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="glyc-20211231xex31d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Principal Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) promulgated under the Securities Exchange Act of 1934, as adopted pursuant to section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:86.99%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;32.1&#7610;</p></td><td style="vertical-align:top;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="glyc-20211231xex32d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Principal Executive Officer and Principal Financial Officer pursuant to Rules&#160;13a-14(b) and 15d-14(b) promulgated under the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350, as adopted pursuant to section 906 of The Sarbanes-Oxley Act of 2002.</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:86.99%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.INS</p></td><td style="vertical-align:top;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:86.99%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.SCH</p></td><td style="vertical-align:top;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Schema Document</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:86.99%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.CAL</p></td><td style="vertical-align:top;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:86.99%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.DEF</p></td><td style="vertical-align:top;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Definition Linkbase Document</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:86.99%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.LAB</p></td><td style="vertical-align:top;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Label Linkbase Document</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:86.99%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.PRE</p></td><td style="vertical-align:top;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</p></td></tr><tr style="height:5.85pt;"><td style="vertical-align:top;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:86.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">104</p></td><td style="vertical-align:top;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:6pt;">&#7610;</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:6pt;">These certifications are being furnished solely to accompany this Annual Report pursuant to 18 U.S.C. Section&#160;1350, and are not being filed for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended, and are not to be incorporated by reference into any filing of the registrant, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">+</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">Indicates management contract or compensatory plan.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">*</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">Certain portions of this exhibit (indicated by asterisks) have been omitted because they are not material and would likely cause competitive harm to the registrant if publicly disclosed.</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:1.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1.2pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Previously filed as Exhibit 3.1 to the Registrant&#8217;s Current Report on Form 8-K (File No.&#160;001-36177), filed with the Commission on January&#160;15, 2014, and incorporated by reference herein.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Previously filed as Exhibit 3.2 to the Registrant&#8217;s Current Report on Form 8-K (File No.&#160;001-36177), filed with the Commission on January&#160;15, 2014, and incorporated by reference herein.</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">69</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Previously filed as Exhibit 4.2 to Amendment No.&#160;2 to the Registrant&#8217;s Registration Statement on Form S-1 (File&#160;No.&#160;333-191567), filed with the Commission on October&#160;31, 2013, and incorporated by reference herein.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(4)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Previously filed as Exhibit 4.2 to the Registrant&#8217;s Annual Report on Form 10-K (File No. 001-36177), filed with the Commission on February 28, 2020, and incorporated by reference herein.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(5)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Previously filed as Exhibit 10.8 to the Registrant&#8217;s Registration Statement on Form S-1 (File No.&#160;333-191567), filed with the Commission on October&#160;4, 2013, and incorporated by reference herein.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(6)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Previously filed as Exhibit 10.9 to the Registrant&#8217;s Registration Statement on Form S-1 (File No.&#160;333-191567), filed with the Commission on October&#160;4, 2013, and incorporated by reference herein.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(7)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Previously filed as Exhibit 10.10 to the Registrant&#8217;s Registration Statement on Form S-1 (File No.&#160;333-191567), filed with the Commission on October&#160;4, 2013, and incorporated by reference herein.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(8)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Previously filed as Exhibit 10.11 to Amendment No.&#160;1 to the Registrant&#8217;s Registration Statement on Form&#160;S-1 (File&#160;No.&#160;333-191567), filed with the Commission on October&#160;28, 2013, and incorporated by reference herein.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(9)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Previously filed as Exhibit 10.12 to Amendment No.&#160;1 to the Registrant&#8217;s Registration Statement on Form&#160;S-1 (File&#160;No.&#160;333-191567), filed with the Commission on October&#160;28, 2013, and incorporated by reference herein.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(10)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Previously filed as Exhibit 10.13 to Amendment No.&#160;1 to the Registrant&#8217;s Registration Statement on Form&#160;S-1 (File&#160;No.&#160;333-191567), filed with the Commission on October&#160;28, 2013, and incorporated by reference herein.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(11)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Previously filed as Exhibit 10.14 to Amendment No.&#160;1 to the Registrant&#8217;s Registration Statement on Form&#160;S-1 (File&#160;No.&#160;333-191567), filed with the Commission on October&#160;28, 2013, and incorporated by reference herein.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(12)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Previously filed as Exhibit 10.15 to Amendment No.&#160;1 to the Registrant&#8217;s Registration Statement on Form&#160;S-1 (File&#160;No.&#160;333-191567), filed with the Commission on October&#160;28, 2013, and incorporated by reference herein.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(13)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Previously filed as Exhibit 10.1 to the Registrant&#8217;s Quarterly Report on Form 10-Q (File No. 001-36177), filed with the Commission on November 2, 2021, and incorporated by reference herein.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(14)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Previously filed as Exhibit 10.3 to the Registrant&#8217;s Quarterly Report on Form 10-Q (File No. 001-36177), filed with the Commission on August 1, 2019, and incorporated by reference herein.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(15)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Previously filed as Exhibit 10.4 to the Registrant&#8217;s Quarterly Report on Form 10-Q (File No. 001-36177), filed with the Commission on August 1, 2019, and incorporated by reference herein.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(16)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Previously filed as Exhibit 10.6 to the Registrant&#8217;s Quarterly Report on Form 10-Q (File No. 001-36177), filed with the Commission on August 1, 2019, and incorporated by reference herein.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(17)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Previously filed as Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K (File No. 001-36177), filed with the Commission on July 28, 2014, and incorporated by reference herein.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(18)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Previously filed as Exhibit 1.1 to the Registrant&#8217;s Current Report on Form 8-K (File No.&#160;001-36177), filed with the Commission on October 7, 2020, and incorporated by reference herein.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(19)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Previously filed as Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K (File No. 001-36177), filed with the Commission on March 29, 2016, and incorporated by reference herein.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(20)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Previously filed as Exhibit 10.20 to the Registrant&#8217;s Annual Report on Form 10-K (File No. 001-36177), filed with the Commission on February 28, 2020, and incorporated by reference herein.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(21)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Previously filed as Exhibit 10.22 to the Registrant&#8217;s Annual Report on Form 10-K (File No. 001-36177), filed with the Commission on February 28, 2020, and incorporated by reference herein.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><a id="_3424249c_39d4_420b_bc96_dbeb5a9007f6"></a><a id="ITEM16FORM10KSUMMARY"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">ITEM&#160; 16.</b>&#8195;<b style="font-weight:bold;">FORM 10-K SUMMARY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">70</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_3829c3e7_959e_4f7a_b85f_555f7327cbee"></a><a id="SIGNATURES_192363"></a><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">SIGNATURE</b><b style="font-weight:bold;">S</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-indent:24.5pt;margin:0pt 0pt 18pt 0pt;">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:0.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:49.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:3.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:middle;width:46.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">GLYCOMIMETICS, INC.</b></p></td></tr><tr style="height:12pt;"><td style="vertical-align:top;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.7%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:46.29%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:12pt;text-indent:-12pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:46.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;/s/ Harout Semerjian</p><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;line-height:1pt;text-align:center;border-top:1.0pt solid #000000;margin:1pt 0pt 0pt 0pt;"><span style="font-size:9pt;">&#160;</span></p></td></tr><tr><td style="vertical-align:top;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;line-height:2pt;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;line-height:2pt;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.7%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;line-height:2pt;margin:0pt;"><span style="font-size:9pt;">&#160;</span></p></td><td style="vertical-align:bottom;width:46.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;Harout Semerjian</p></td></tr><tr><td style="vertical-align:top;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;line-height:2pt;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;line-height:2pt;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.7%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;line-height:2pt;margin:0pt;"><span style="font-size:9pt;">&#160;</span></p></td><td style="vertical-align:bottom;width:46.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><i style="font-style:italic;">&#160;&#160;President and Chief Executive Officer</i></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:6pt 0pt 12pt 0pt;">March 3, 2022</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Harout Semerjian and Brian M. Hahn, jointly and severally, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign this Annual Report on Form 10-K of GlycoMimetics, Inc., and any or all amendments thereto, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises hereby ratifying and confirming all that said attorneys-in-fact and agents, or his, her or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:38.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1pt;padding-top:1pt;text-align:center;border-top:1.0pt solid #000000;margin:1pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:42.69%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1pt;padding-top:1pt;text-align:center;border-top:1.0pt solid #000000;margin:1pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:18.75%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1pt;padding-top:1pt;text-align:center;border-top:1.0pt solid #000000;margin:1pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:38.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Signature</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1pt;padding-top:1pt;text-align:center;border-top:1.0pt solid #000000;margin:1pt 0pt 0pt 0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:42.69%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1pt;padding-top:1pt;text-align:center;border-top:1.0pt solid #000000;margin:1pt 0pt 0pt 0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:18.75%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Date</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1pt;padding-top:1pt;text-align:center;border-top:1.0pt solid #000000;margin:1pt 0pt 0pt 0pt;">&#160;</p></th></tr><tr><td style="vertical-align:middle;width:38.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:42.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:18.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:38.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">/s/ Harout Semerjian</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1pt;padding-top:1pt;text-align:center;border-top:1.0pt solid #000000;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">Harout Semerjian</p></td><td style="vertical-align:top;width:42.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 7.2pt;">President, Chief Executive Officer and Director</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 7.2pt;"><i style="font-style:italic;">(Principal Executive Officer)</i></p></td><td style="vertical-align:top;white-space:nowrap;width:18.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:6pt 0pt 0pt 0pt;">March 3, 2022</p></td></tr><tr><td style="vertical-align:middle;width:38.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:42.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 7.2pt;"><span style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:18.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:38.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">/s/ Brian M. Hahn</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1pt;padding-top:1pt;text-align:center;border-top:1.0pt solid #000000;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">Brian M. Hahn</p></td><td style="vertical-align:top;width:42.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 7.2pt;">Chief Financial Officer</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 7.2pt;"><i style="font-style:italic;">(Principal Financial Officer and Principal Accounting Officer)</i></p></td><td style="vertical-align:top;white-space:nowrap;width:18.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:6pt 0pt 0pt 0pt;">March 3, 2022</p></td></tr><tr style="height:12.25pt;"><td style="vertical-align:top;width:38.54%;margin:0pt;padding:0pt;"><div style="height:12.25pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:42.69%;margin:0pt;padding:0pt;"><div style="height:12.25pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:6pt 0pt 0pt 7.2pt;"><span style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:18.75%;margin:0pt;padding:0pt;"><div style="height:12.25pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:38.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">/s/ Patricia S. Andrews</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1pt;padding-top:1pt;text-align:center;border-top:1.0pt solid #000000;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">Patricia S. Andrews</p></td><td style="vertical-align:top;width:42.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:6pt 0pt 0pt 7.2pt;">Director</p></td><td style="vertical-align:top;white-space:nowrap;width:18.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:6pt 0pt 0pt 0pt;">March 3, 2022</p></td></tr><tr style="height:12.25pt;"><td style="vertical-align:top;width:38.54%;margin:0pt;padding:0pt;"><div style="height:12.25pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:42.69%;margin:0pt;padding:0pt;"><div style="height:12.25pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:6pt 0pt 0pt 7.2pt;"><span style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:18.75%;margin:0pt;padding:0pt;"><div style="height:12.25pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:38.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">/s/ Mark A. Goldberg, M.D.</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1pt;padding-top:1pt;text-align:center;border-top:1.0pt solid #000000;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">Mark A. Goldberg M.D.</p></td><td style="vertical-align:top;width:42.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:6pt 0pt 0pt 7.2pt;">Director</p></td><td style="vertical-align:top;white-space:nowrap;width:18.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:6pt 0pt 0pt 0pt;">March 3, 2022</p></td></tr><tr style="height:12.25pt;"><td style="vertical-align:top;width:38.54%;margin:0pt;padding:0pt;"><div style="height:12.25pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:42.69%;margin:0pt;padding:0pt;"><div style="height:12.25pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:6pt 0pt 0pt 7.2pt;"><span style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:18.75%;margin:0pt;padding:0pt;"><div style="height:12.25pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:38.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">/s/ Scott T. Jackson</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1pt;padding-top:1pt;text-align:center;border-top:1.0pt solid #000000;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">Scott T. Jackson</p></td><td style="vertical-align:top;width:42.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:6pt 0pt 0pt 7.2pt;">Director</p></td><td style="vertical-align:top;white-space:nowrap;width:18.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:6pt 0pt 0pt 0pt;">March 3, 2022</p></td></tr><tr style="height:12.25pt;"><td style="vertical-align:top;width:38.54%;margin:0pt;padding:0pt;"><div style="height:12.25pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:42.69%;margin:0pt;padding:0pt;"><div style="height:12.25pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:6pt 0pt 0pt 7.2pt;"><span style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:18.75%;margin:0pt;padding:0pt;"><div style="height:12.25pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:38.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">/s/ Daniel M. Junius</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1pt;padding-top:1pt;text-align:center;border-top:1.0pt solid #000000;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">Daniel M. Junius</p></td><td style="vertical-align:top;width:42.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:6pt 0pt 0pt 7.2pt;">Director</p></td><td style="vertical-align:top;white-space:nowrap;width:18.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:6pt 0pt 0pt 0pt;">March 3, 2022</p></td></tr><tr style="height:12.25pt;"><td style="vertical-align:top;width:38.54%;margin:0pt;padding:0pt;"><div style="height:12.25pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:42.69%;margin:0pt;padding:0pt;"><div style="height:12.25pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:6pt 0pt 0pt 7.2pt;"><span style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:18.75%;margin:0pt;padding:0pt;"><div style="height:12.25pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:12.25pt;"><td style="vertical-align:top;width:38.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">/s/ Rachel K. King</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1pt;padding-top:1pt;text-align:center;border-top:1.0pt solid #000000;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">Rachel K. King</p></td><td style="vertical-align:top;width:42.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:6pt 0pt 0pt 7.2pt;">Director</p></td><td style="vertical-align:top;white-space:nowrap;width:18.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:6pt 0pt 0pt 0pt;">March 3, 2022</p></td></tr><tr style="height:12.25pt;"><td style="vertical-align:top;width:38.54%;margin:0pt;padding:0pt;"><div style="height:12.25pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:42.69%;margin:0pt;padding:0pt;"><div style="height:12.25pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:6pt 0pt 0pt 7.2pt;"><span style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:18.75%;margin:0pt;padding:0pt;"><div style="height:12.25pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:12.25pt;"><td style="vertical-align:top;width:38.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">/s/ Scott Koenig, M.D., Ph.D.</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1pt;padding-top:1pt;text-align:center;border-top:1.0pt solid #000000;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">Scott Koenig, M.D., Ph.D.</p></td><td style="vertical-align:top;width:42.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:6pt 0pt 0pt 7.2pt;">Director</p></td><td style="vertical-align:top;white-space:nowrap;width:18.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:6pt 0pt 0pt 0pt;">March 3, 2022</p></td></tr><tr style="height:12.25pt;"><td style="vertical-align:top;width:38.54%;margin:0pt;padding:0pt;"><div style="height:12.25pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:42.69%;margin:0pt;padding:0pt;"><div style="height:12.25pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:6pt 0pt 0pt 7.2pt;"><span style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:18.75%;margin:0pt;padding:0pt;"><div style="height:12.25pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:12.25pt;"><td style="vertical-align:top;width:38.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">/s/ Timothy Pearson</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1pt;padding-top:1pt;text-align:center;border-top:1.0pt solid #000000;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">Timothy Pearson</p></td><td style="vertical-align:top;width:42.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:6pt 0pt 0pt 7.2pt;">Director</p></td><td style="vertical-align:top;white-space:nowrap;width:18.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:6pt 0pt 0pt 0pt;">March 3, 2022</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">71</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_6d200f18_18c5_44a1_8657_189a2bce89e5"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">INDEX TO FINANCIAL STATEMENTS</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:94.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:middle;width:5.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:94.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#Report_of_Independent_Registered_Publ_29"><span style="font-style:normal;font-weight:normal;">Report of Independent Registered Public Accounting Firm</span></a> (PCAOB ID: <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" name="dei:AuditorFirmId" id="Narr_4Slg_fVU-EytiXPY_k0oUQ">42</ix:nonNumeric>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.84%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">73</p></td></tr><tr><td style="vertical-align:top;width:94.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#BalanceSheets_656978"><span style="font-style:normal;font-weight:normal;">Balance Sheets as of December&#160;31, 2021 and 2020</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.84%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">75</p></td></tr><tr><td style="vertical-align:top;width:94.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#StatementsofOperationsandComprehensive_1"><span style="font-style:normal;font-weight:normal;">Statements of Operations and Comprehensive Loss for the years ended December&#160;31, 2021, 2020 and 2019</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.84%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">76</p></td></tr><tr><td style="vertical-align:top;width:94.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#StatementsofStockholdersEquity_712246"><span style="font-style:normal;font-weight:normal;">Statements of Stockholders&#8217; Equity for the years ended December&#160;31, 2021, 2020 and 2019</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.84%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">77</p></td></tr><tr><td style="vertical-align:top;width:94.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#StatementsofCashFlows_755635"><span style="font-style:normal;font-weight:normal;">Statements of Cash Flows for the years ended December&#160;31, 2021, 2020 and 2019</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.84%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">78</p></td></tr><tr><td style="vertical-align:top;width:94.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#NotestoFinancialStatements_432888"><span style="font-style:normal;font-weight:normal;">Notes to Financial Statements</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.84%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">79</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">72</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_573ef978_3a2f_43df_8f8f_fe5aaf9ce1c2"></a><a id="Report_of_Independent_Registered_Publ_29"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Report of Independent Registered Public Accounting Firm</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:6pt;margin:0pt;">To the Shareholders and the Board of Directors of GlycoMimetics, Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Opinion on the Financial Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:6pt;text-align:justify;margin:0pt;">We have audited the accompanying balance sheets of GlycoMimetics, Inc. (the Company) as of December 31, 2021 and 2020, the related statements of operations and comprehensive loss, stockholders&#8217; equity and cash flows for each of the three years in the period ended December 31, 2021, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2021 and 2020, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2021, in conformity with U.S. generally accepted accounting principles.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">The Company&#39;s Ability to Continue as a Going Concern </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:6pt;text-align:justify;margin:0pt;">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company has suffered recurring losses from operations and has stated that substantial doubt exists about the Company&#8217;s ability to continue as a going concern without obtaining additional funding or entering into another form of non-equity or debt arrangement. Management&#39;s evaluation of the events and conditions and management&#8217;s plans regarding these matters are also described in Note 2. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Basis for Opinion</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;">These financial statements are the responsibility of the Company&#39;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#39;s internal control over financial reporting. Accordingly, we express no such opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:6pt;text-align:justify;margin:0pt;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Critical Audit Matter</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:6pt;text-align:justify;margin:0pt;">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the account or disclosure to which it relates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Accrued Clinical Trial Expenses</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:16.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:83.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:16.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 6pt 0pt;"><i style="font-style:italic;">Description of the Matter</i></p></td><td style="vertical-align:top;width:83.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 0pt 36pt;">As discussed in Note 3 to the financial statements, the Company records costs for clinical trial activities based upon estimates of costs incurred through the balance sheet date that have yet to be invoiced by the contract research organizations, investigative sites, and other consultants. The Company&#8217;s accrued expenses of $8.7 million at December 31, 2021 include accrued clinical trial expenses, and the Company&#8217;s research and development costs and </p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">73</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"><tr><td style="vertical-align:top;width:16.12%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:83.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 0pt 36pt;">expenses of $47.5 million for the year ended December 31, 2021 include 2021 clinical trial expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 0pt 36pt;">Auditing the Company&#8217;s accruals for clinical trials was challenging due to the multiple sources of information used to evaluate the Company&#8217;s estimated accruals. In addition, in certain circumstances, the determination of the work that has been completed and measurement of progress during the reporting period required judgment because the timing and pattern of vendor invoicing may not correspond to the level of services provided and there may be delays in receiving clinical information from investigative sites and other consultants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 6pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:16.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 6pt 0pt;"><i style="font-style:italic;">How We Addressed the Matter in Our Audit</i></p></td><td style="vertical-align:top;width:83.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 36pt;">To evaluate the accrual for clinical expenses, our audit procedures included, among others, reading certain contracts with contract research organizations and clinical study sites to evaluate financial and certain other contractual terms, testing the completeness and accuracy of the underlying data used in the estimates, and evaluating the significant assumptions. For example, we evaluated patient enrollment, patient cycles incurred, clinical site activations, estimated project duration, and other pass-through costs, that are used by management to estimate the recorded accruals. We assessed the reasonableness of the significant assumptions. For example, we corroborated the progress of clinical trials with the Company&#8217;s clinical team and inspected information from third parties related to active patient sites and currently enrolled patients. We also examined subsequent invoices from the service providers and cash disbursements to the service providers, to the extent such invoices were received, or payments were made prior to the date that the financial statements were issued.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:18pt 0pt 0pt 0pt;">/s/ <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" name="dei:AuditorName" id="Narr_cJV2QEZ07UKTbDiqDnD9gw">Ernst &amp; Young LLP</ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We have served as the Company&#8217;s auditor since 2011.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" name="dei:AuditorLocation" id="Narr_i0l5_j19r0WsPd7wB0G_Lg">Baltimore, Maryland</ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">March 3, 2022</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">74</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_e4d222f7_fed2_4841_962b_c84c7e9f7ee0"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">GLYCOMIMETICS, INC.</b></p><a id="BalanceSheets_656978"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Balance Sheet</b><b style="font-weight:bold;">s</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><a id="_43498a5b_8c39_43fe_8e09_01120478f0a2"></a><a id="Tc_adqwLi21KkagBKCea9SmKQ_1_2"></a><a id="Tc_gHidygsrO0OQz3660_wx0A_2_2"></a><a id="Tc_5F8ZjLI4N0WI7QbJuy9mkg_2_5"></a><a id="Tc_UEAFu6I7FE6hvHD5OGAGHg_3_0"></a><a id="Tc_3tTgql3ci0WB_erqasWwDA_4_0"></a><a id="Tc_dfpMI2cQ10CBIf9kPTw6Hg_5_0"></a><a id="Tc_wJp5bFMM9EO78POeUIjQoQ_5_2"></a><a id="Tc_MJHD8iqQrkKA0I5VKw81qA_5_5"></a><a id="Tc_JBxFzXxB0k6964EVh_kkrw_6_0"></a><a id="Tc_l5WyzQRkxkGJE8fl3kUctQ_7_0"></a><a id="Tc_PkMK2UGw7E24B6G1a9PCFg_8_0"></a><a id="Tc_S3xiLXl42E-x3xDv2stkaA_9_0"></a><a id="Tc_4Ndc2vZqHkqgTGaybhaW3w_10_0"></a><a id="Tc_30owCSBRZkSYrn8YCvLfvA_11_0"></a><a id="Tc_Qq6b1yBrakyy3ppIaMczig_12_0"></a><a id="Tc_90ZyOqg0DkiYCLWpmhsW1w_12_2"></a><a id="Tc_WPGUo5-bNkmUcqcKqLSGUg_12_5"></a><a id="Tc_NeN-ORG2p0uPlUwwf4Sy_A_13_0"></a><a id="Tc_ZmB5TAQo606boK5ECGCNog_14_0"></a><a id="Tc_SJO263czWEaeD6S36xazMA_15_0"></a><a id="Tc_v09LuzR_OUW7VKnSjUWLfw_15_2"></a><a id="Tc_2hDJ_Sn0vUGeEZ43XLXGIg_15_5"></a><a id="Tc_qedjK68OUkqIdJ5B5osKDA_16_0"></a><a id="Tc_pEV8ZeQ1gEibiO7y8tWm1w_17_0"></a><a id="Tc_vCgPnfeqLEqXB52WuDffyg_18_0"></a><a id="Tc_LMYUFaW3tUy_9RVGKRJgCw_19_0"></a><a id="Tc_4qzWXzFhQECq6Y69HdB3cw_19_3"></a><a id="Tc_aznKu9U-bU2uH-vxs55mJQ_20_0"></a><a id="Tc_9fFjNfUy2kKdjOnX4VWNmA_21_0"></a><a id="Tc_bwXBeMEfwkuK8j30aitoTA_22_0"></a><a id="Tc_2GLCvgFG70C_kTlZm54aRw_23_0"></a><a id="_e27f3ca8_1164_41a6_9875_f9b39ebb6ea0"></a><a id="_e27f3ca8_1164_41a6_9875_f9b39ebb6ea0_2"></a><a id="_e27f3ca8_1164_41a6_9875_f9b39ebb6ea0_3"></a><a id="Tc_vGslLganL02N4drWYoxnfw_24_0"></a><a id="Tc_ULHV1jdv6k2mxpdn2iE1bw_25_0"></a><a id="Tc_4Na1VDbuuUmxn9ww4Z_sjQ_26_0"></a><a id="Tc_AygiwqNaFUeID53bA9vjFQ_27_0"></a><a id="Tc_gDIAmuVeKES2T52GpIJBfQ_28_0"></a><a id="Tc_SdT0E8Gamke4aCkcftbFew_28_2"></a><a id="Tc_ObknEOeN20ubWVHX3cIF7w_28_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="Tc_by2QtiKuDkSVuXHDMMwnAQ_5_3">90,254,890</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="Tc_tQvRZLerRE21siH9XF5cZQ_5_6">137,035,017</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" id="Tc_Nb7aD25F4EigTCpd0CMLwA_6_3">533,804</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" id="Tc_JrKRy_bbYEGdsoNJpSr6JA_6_6">1,238,328</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 42pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="0" id="Tc_rRv0ssoPxUmxskDV58g52Q_7_3">90,788,694</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="0" id="Tc_qc2YuRAXREuyof-U4h05ng_7_6">138,273,345</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="Tc_A9o9FdFwVEGmxk8o9u6n6w_8_3">368,842</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="Tc_BUBK5pGw0EWLuPuJWZe31w_8_6">620,673</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Prepaid research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseNoncurrent" scale="0" id="Tc_1cfVjNmib0-05pDQ51hSPA_9_3">1,560,607</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseNoncurrent" scale="0" id="Tc_bbHz60duwEGz5iHrsBwK6A_9_6">1,560,607</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SecurityDeposit" scale="0" id="Tc_uyl6w_evmUikYBEOk0tWKg_10_3">52,320</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SecurityDeposit" scale="0" id="Tc_gCP3n0gjEkayeAdGukh39A_10_6">52,320</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Operating lease right-of-use asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="Tc_LuX862F040KraDhijKslHA_11_3">1,576,185</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="Tc_SDe6mNO2d0u6sTjleieTiQ_11_6">2,325,224</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 42pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="0" id="Tc_hZVnorkaZkmjFOHM3CagVw_12_3">94,346,648</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="0" id="Tc_YckmtgyC10aDsN-NpqvGhg_12_6">142,832,169</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Liabilities&#160;&amp; stockholders&#8217; equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="0" id="Tc_XYi6wT4RP0esQ_JQLecblg_15_3">2,107,615</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="0" id="Tc_4Qp9Lsag80e8_MwAoIFYWQ_15_6">2,089,939</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" id="Tc_doiSQBQh90WkTM2PyHcacQ_16_3">8,715,368</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" id="Tc_t-kAZiWOQUGx49FVj9BAEQ_16_6">9,439,881</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" id="Tc_HvboW4tvz0OSc5P5eKjiuA_17_3">1,001,407</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" id="Tc_34fIww0fVEaTjyv2BwMLsA_17_6">898,549</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 42pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="0" id="Tc_2V1zqfChMkaSXV_rzRnMRw_18_3">11,824,390</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="0" id="Tc_6vyIoCHEwECh3f3jRRzzaw_18_6">12,428,369</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Noncurrent accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesNoncurrent" scale="0" id="Tc_NAhSY_4B70iPyTkyMz7DMA_19_6">264,329</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Lease liabilities, net of current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" id="Tc_CCGREFzy2U2XZaCDNomZOw_20_3">918,607</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" id="Tc_vfRxXgJtk0aykNY98Ua_tA_20_6">1,920,015</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 42pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="0" id="Tc_p-NJQPEAYEyM__B9wlOuow_21_3">12,742,997</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="0" id="Tc_5oDjAUJ3NkiR8f4gzyKxEg_21_6">14,612,713</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stockholders&#8217; equity:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Preferred stock; $<ix:nonFraction unitRef="Unit_Divide_USD_shares_6ZVfdDCn5UCsvmo46quH_A" contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_nj1vUyoV5EWfHi97DKyN1g"><ix:nonFraction unitRef="Unit_Divide_USD_shares_6ZVfdDCn5UCsvmo46quH_A" contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_OudNm6G4GkSUHAvKNIyctg">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA" contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_3vYQLT1WdUez0TrEstomGA"><ix:nonFraction unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA" contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_nRKB-WRAmUqsjcXdqgGZ5w">5,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA" contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_ni6GWRcDeUuQR47HvRro5Q"><ix:nonFraction unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA" contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_ImlvWSzfVEqU7rR5VWI5-A">no</ix:nonFraction></ix:nonFraction> shares issued and outstanding at December 31, 2021 and December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_AohGR0nW002QcT8etMek_g;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_lfO8cH2MMk2_I8IAXtcv_A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Common stock; $<ix:nonFraction unitRef="Unit_Divide_USD_shares_6ZVfdDCn5UCsvmo46quH_A" contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_YTY_QNy63UaLVyPzagFWjQ"><ix:nonFraction unitRef="Unit_Divide_USD_shares_6ZVfdDCn5UCsvmo46quH_A" contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_64SnlaWZgkmhymOyxp5CvA">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA" contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_fYezCt7O2EWm0FY0r8ygZA"><ix:nonFraction unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA" contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_xZXn3FMZ1UiQ5rNa_26NUA">100,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA" contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_usd9cpTApEOfehB2SyMP7A">52,313,894</ix:nonFraction> shares issued and <span style="-sec-ix-hidden:Hidden_LKZji1LDq0-yY11lTQsw3g;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">outstanding</span></span> at December 31, 2021; <ix:nonFraction unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA" contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_dZdUalxRdk6yj34Wdi-ySg">49,017,622</ix:nonFraction> shares issued and <span style="-sec-ix-hidden:Hidden_ATYOkIk1MEWEdr2__-2oAw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">outstanding</span></span> at December&#160;31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="0" id="Tc_FvmvCOaZ6kmLbNHyIslK8w_24_3">52,314</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="0" id="Tc_gLX4801x1EKJUw59YBtRZA_24_6">49,018</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Additional paid-in capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="0" id="Tc_Zi2xaokhEEq5j8EFxacGuQ_25_3">454,448,327</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="0" id="Tc_Bx3jBG8e1EWw06C8LsHbXQ_25_6">437,639,991</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="0" id="Tc_0mWHa0PSoUO4-3GsBjCVMg_26_3">372,896,990</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="0" id="Tc_NNXTJwGetUu6KLhqfVIJ1w_26_6">309,469,553</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 42pt;">Total stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_rQBNZBradEq3QnNnU-QJdA_27_3">81,603,651</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_CWzhYlxi90m3GIFCD2rRQA_27_6">128,219,456</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total liabilities and stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="Tc_0bBZltap6kidj_RH5Ha6Ng_28_3">94,346,648</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="Tc_w4dY8kuI2E6fXirwjSv30w_28_6">142,832,169</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 0pt 0pt;"><i style="font-style:italic;">See accompanying notes.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">75</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_dfcf6739_16a6_461a_8e19_f8ca0e246f0e"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">GLYCOMIMETICS, INC.</b></p><a id="StatementsofOperationsandComprehensive_1"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Statements of Operations and Comprehensiv</b><b style="font-weight:bold;">e Loss</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><a id="_d988f326_b5f5_4146_9813_c65d3dd69087"></a><a id="Tc_l9QtWRzrEUSB0Rurexxerw_1_2"></a><a id="Tc_O8Nxit2b-0KtFcg_s8aAew_2_2"></a><a id="Tc_zHTlc5gZrUqd1ltXXx3Lmg_2_5"></a><a id="Tc_EBDXhgqYikaSOKqO5JjsFQ_2_8"></a><a id="Tc_eUZc_sKkikytQU-Syt46QQ_3_0"></a><a id="Tc_mRk5fEyTQkq1oZdDA3Wy4w_3_2"></a><a id="Tc_2hQJl-HPnkufVVEjmiS2rA_3_5"></a><a id="Tc_J6--MHVyWUqYJ-bXWmFm0w_3_8"></a><a id="Tc_VHp-rbJwpEKQ3YMgv8BdhQ_3_9"></a><a id="Tc_4jH6J6A_xUCm4jA_JkPURg_5_0"></a><a id="Tc_PzeWE2OEuEy0_rP7GEY4iQ_6_0"></a><a id="Tc_AfmN9ZdNXUSmnpBO0ckFYw_7_0"></a><a id="Tc_76ik6aHsHEm4wvGpX-Sx4g_8_0"></a><a id="Tc_igVdSBFhT0CChrdLfj_GTA_9_0"></a><a id="Tc_VOY7sgIrk0as4KKLUgPKHQ_10_0"></a><a id="Tc_o-QKwAMsfEK5Ipm-h8VQIQ_11_0"></a><a id="Tc_vaQFHZd2m0WjyPYNyX0QDA_11_2"></a><a id="Tc_mPjtjyTkBUmfvDpHzePyJg_11_5"></a><a id="Tc_nQ2PIq6NRk6Yw_sHz3cZcw_11_8"></a><a id="Tc_emUAXo6PW0OEzvh66jVHyw_12_0"></a><a id="Tc_2r_GCHK4CEq1fCYcE_mQFg_12_2"></a><a id="Tc_0LpakzmnOk2kndckgSnxfg_12_5"></a><a id="Tc_mbHD6rhO00OZLqoinKlE1Q_12_8"></a><a id="Tc_063x7QN6BE-xcugHi5Y5uQ_13_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:39.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year&#160;Ended&#160;December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Revenue from collaboration and license agreements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_zaRYvZAgIES8NoHipTnUNw_3_3">1,159,767</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2020_To_12_31_2020_n4dAyZdoqEGSie7qc7FpOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_kE3kRW4ZnE-FxAWlP8QYAw_3_6">10,162,935</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:58.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Costs and expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Research and development expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="Tc_TiOgAXnLUEqxEerF-ZmgKw_6_3">47,491,567</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2020_To_12_31_2020_n4dAyZdoqEGSie7qc7FpOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="Tc_M2yFlzi_l0eRho7Xng2N_A_6_6">44,929,198</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2019_To_12_31_2019_pmIpEVmd-kmwrLI0XOvIXQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="Tc_S_7frFW_5EC-Jq70V4-JIQ_6_9">47,029,264</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">General and administrative expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="Tc_bY66-cMqUUyvOXav0kqKxA_7_3">17,115,405</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2020_To_12_31_2020_n4dAyZdoqEGSie7qc7FpOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="Tc_AvffIQA89kiaV56IqDhUAA_7_6">16,743,127</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2019_To_12_31_2019_pmIpEVmd-kmwrLI0XOvIXQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="Tc_rkHyHLAOz0K5_jh1Zmk-ng_7_9">14,360,038</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 42pt;">Total costs and expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="0" id="Tc_ArrIosHObU-yOuaaC0uF_g_8_3">64,606,972</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2020_To_12_31_2020_n4dAyZdoqEGSie7qc7FpOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="0" id="Tc_oDzyMJxAXEa5WV3XNf6RNQ_8_6">61,672,325</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2019_To_12_31_2019_pmIpEVmd-kmwrLI0XOvIXQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="0" id="Tc_iJyzxgaD0EOI9Py5YdrBuA_8_9">61,389,302</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="0" id="Tc_D4iY-56O_0aW0h0cMzucAw_9_3">63,447,205</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2020_To_12_31_2020_n4dAyZdoqEGSie7qc7FpOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="0" id="Tc_oJK1xAnLTEGkpAK_2QxBrA_9_6">51,509,390</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2019_To_12_31_2019_pmIpEVmd-kmwrLI0XOvIXQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="0" id="Tc_LPZt9bFFFkawmHv3R2rBUA_9_9">61,389,302</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:58.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="0" id="Tc_svoWm4oEt0ySfCJK8cwtBw_10_3">19,768</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2020_To_12_31_2020_n4dAyZdoqEGSie7qc7FpOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="0" id="Tc_fCUEibIodkODC2t0CiCOMQ_10_6">482,487</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2019_To_12_31_2019_pmIpEVmd-kmwrLI0XOvIXQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="0" id="Tc_rQOSb82yTkqyCfBJwt725g_10_9">3,497,391</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss and comprehensive loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" decimals="0" format="ixt:numdotdecimal" name="glyc:NetIncomeLossAndComprehensiveIncomeNetOfTax" sign="-" scale="0" id="Tc_1c710b9D0UKXoApMgKUexw_11_3">63,427,437</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2020_To_12_31_2020_n4dAyZdoqEGSie7qc7FpOQ" decimals="0" format="ixt:numdotdecimal" name="glyc:NetIncomeLossAndComprehensiveIncomeNetOfTax" sign="-" scale="0" id="Tc_JnrnDb3FyUOT3zQQ0hMl7Q_11_6">51,026,903</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2019_To_12_31_2019_pmIpEVmd-kmwrLI0XOvIXQ" decimals="0" format="ixt:numdotdecimal" name="glyc:NetIncomeLossAndComprehensiveIncomeNetOfTax" sign="-" scale="0" id="Tc_V1DVSfb-IE-OUbUcTJ2BNQ_11_9">57,891,911</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:58.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Basic and <span style="-sec-ix-hidden:Hidden_gp9IuoM4PUq4Jbf5O9pHjA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">diluted</span></span> <span style="-sec-ix-hidden:Hidden_Jnxrdg2Yn0eKClwdHM9Lig;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">net</span></span> <span style="-sec-ix-hidden:Hidden_q-I2yQGv7E6NBmp35fa9Vg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">loss</span></span> per common share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_6ZVfdDCn5UCsvmo46quH_A" contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_TfSUmy1UNk-RmYNVQKyDOw_12_3">1.23</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_6ZVfdDCn5UCsvmo46quH_A" contextRef="Duration_1_1_2020_To_12_31_2020_n4dAyZdoqEGSie7qc7FpOQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_RC8_CfUQbUGGWOLmHUoVJw_12_6">1.12</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_6ZVfdDCn5UCsvmo46quH_A" contextRef="Duration_1_1_2019_To_12_31_2019_pmIpEVmd-kmwrLI0XOvIXQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc__62Y06a_m0axHdQwYMageQ_12_9">1.34</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:58.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Basic and <span style="-sec-ix-hidden:Hidden_swbcvcGXEUi9_zTi-LxYfg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">diluted</span></span> weighted-average number of <span style="-sec-ix-hidden:Hidden_xmX3kUCKa0WljNSAu7PGyw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">common</span></span> <span style="-sec-ix-hidden:Hidden_aKsQ3aGgBUW6Oqk4LHr7uw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">shares</span></span> outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA" contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc__cclYlbCaUCVRdNU6AnP0A_13_3">51,453,204</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA" contextRef="Duration_1_1_2020_To_12_31_2020_n4dAyZdoqEGSie7qc7FpOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_vPIiku-lOEmrdMglAMb5Dg_13_6">45,721,139</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA" contextRef="Duration_1_1_2019_To_12_31_2019_pmIpEVmd-kmwrLI0XOvIXQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_RexWe72me0-yu2DNTzX9Tg_13_9">43,254,782</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 0pt 0pt;"><i style="font-style:italic;">See accompanying notes.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">76</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_522a2e8d_5445_4ea1_8c38_7a8f0ace9478"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">GLYCOMIMETICS, INC.</b></p><a id="StatementsofStockholdersEquity_712246"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Statements of Stockholders&#8217; Equit</b><b style="font-weight:bold;">y</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><a id="_2177988d_50a9_4788_be13_4317d8d4dec9"></a><a id="Tc_fBWQM5ZyL02p_yvieCSBNQ_1_7"></a><a id="Tc_43ogi5NGxEeTg1wUen7hGg_1_13"></a><a id="Tc_eE5JT9dzIUmeDcty-ainwg_2_2"></a><a id="Tc_KAYoVfuAuk-vKMQl_95L2w_2_7"></a><a id="Tc_CQ4yBL6aGUO7KWpdKKKztg_2_10"></a><a id="Tc_ExPUONWll069H851ca_iTw_2_13"></a><a id="Tc_-4Da_M767Eijt8_th3iNDQ_3_2"></a><a id="Tc_KuOVCLzLD0-83C0AGc4JYQ_3_4"></a><a id="Tc_pSXcqenR1UWBKNrWc2RmPA_3_7"></a><a id="Tc_0CrVzWLleEG4jvqGmLGu7Q_3_10"></a><a id="Tc_YJhauqQBR0qigbqZeg6s7w_3_13"></a><a id="Tc_j2uqrt_mqU6O6BYtZvhQcg_4_0"></a><a id="Tc_f05cLTqoTUSVZmzP8Yd-6A_4_4"></a><a id="Tc_aZPo3n1RPk2tjAfFqyH4ng_4_7"></a><a id="Tc_hVThNHTr1U6uJtiJcM7Rbg_4_10"></a><a id="Tc_0oXubtRcpE-69rsJgXEU4w_4_13"></a><a id="Tc_QJMttORqVECStaYGzZ-xsQ_5_0"></a><a id="Tc_tutMJzDYeEeO30KWKT0sSg_5_11"></a><a id="Tc_GnDS4C_k1EqtxVcB2HRoVQ_6_0"></a><a id="Tc_eDHxS8GzFk-hUeW2R6iyWw_6_2"></a><a id="Tc_cfmIhRgO3Ea_7JHBEOaQ1Q_6_5"></a><a id="Tc_IgwxK_sbc0WFVohlJo3Oow_6_11"></a><a id="Tc_Lzw5GUELrkSGzRWElFXgyw_7_0"></a><a id="Tc_sPSY-UQ-sEWTr_uXl6H3Jg_7_2"></a><a id="Tc_8_2wGn76RkqmDiQb-yivCw_7_5"></a><a id="Tc_VfFkYOrb-kOdEYN-dXNUYw_7_8"></a><a id="Tc_3WuC8lQCpUisZwIpLAP9-Q_8_0"></a><a id="Tc_Towb2xh8mEGQPGztuN5b3g_9_0"></a><a id="Tc_NXmveFge1kKGK_ooYcqm7w_9_11"></a><a id="Tc_apFRKVEHeUiiuAITpfsSTQ_10_0"></a><a id="Tc_nC7i1SnVX0aXR3o9NUwHDA_10_11"></a><a id="Tc_Yf0mgTF82kq74X26uCscGg_11_0"></a><a id="Tc_irUAHI4D2ECK9JufjVY2QA_11_2"></a><a id="Tc_Cyz7gKsuQ0WuIFjwA12EZw_11_5"></a><a id="Tc_9oB642rXXkqOHi9r3GTK9A_11_11"></a><a id="Tc_gCrhue-E7UWdE58pZKRiQg_12_0"></a><a id="Tc_a04nhGw41kCgprQk58J1yA_12_2"></a><a id="Tc_XOXrN6_uQUmaOjDQ-_KX4g_12_5"></a><a id="Tc_zR8tBtCJe02jcxuJ9nBSsA_12_8"></a><a id="Tc_woNn9zm5ZkW_BUJMAPinaQ_13_0"></a><a id="Tc_I6UpE7kQ1UK08hpToFwWxQ_13_10"></a><a id="Tc_eiUHTADYVU6MMZjB_GoXyQ_13_13"></a><a id="Tc_f2YxAEURuEK6oz_PxPkinQ_14_0"></a><a id="Tc_qMhNk474-kGQi-W2xLpgyw_14_11"></a><a id="Tc_fXwnsXmkykyKN5nJ9jiv3Q_15_0"></a><a id="Tc_syNzwzwyrkOnWWtv5wrb2Q_15_11"></a><a id="Tc_VLfA0FuTXEWTiTmV4Nj5Fw_16_0"></a><a id="Tc_mfO8cs7DWEOI9k6XEJJZJA_16_2"></a><a id="Tc_mzOuVT8j30e48iX_Ou1rYQ_16_5"></a><a id="Tc_s7mL5dLEsUOilwUWPvtAXQ_16_11"></a><a id="Tc_tRnnJmsAZkWH_1ZuaGJ0sw_17_0"></a><a id="Tc_EnNFp9_IgE-6NrNtULEI1w_17_2"></a><a id="Tc_iYcJwASKkUuTb3CoX2E28Q_17_5"></a><a id="Tc_UWSol7EvZUm-g0_Q6FgxLA_17_8"></a><a id="Tc_LBLr_0h2AkuIrhSTDEcsCw_18_0"></a><a id="Tc_O2RrHBVp0UunyTnxggaJCw_18_4"></a><a id="Tc_Nqm_Le2Ddky8tFj_JE6YqQ_18_7"></a><a id="Tc_sD2REqwFxUK3776utwkNPw_18_10"></a><a id="Tc_KzrsRwoGxEiDGIxar7uUOQ_18_13"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:17.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Common&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Paid-In</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stockholders&#8217;</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b>&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b>&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Equity</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Balance at December 31,&#160;2018</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA" contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Aswh0QD8T06Z70c7oH6rxw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_YgAHUPMJX0eHdPGkUigHQw_4_2">43,160,751</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Aswh0QD8T06Z70c7oH6rxw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_jyHxijjC50W04y3W-BSLFg_4_5">43,159</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_YBdCsD1cyEWKXTeBpB1Qvw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_hSyFAVaKB0S86XTCeJmObg_4_8">405,972,075</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_hWu3exZUdEGAkwWw4npmMw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_rM4bICRmHU6_VszBfk5EnA_4_11">200,550,739</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2018_LWXbJD-mPkKObqFgUzRVCw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_WRo2LydFekOa-04XUxAlQg_4_14">205,464,495</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:43.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Exercise of options and vesting of restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_rTR9aq2hpUuLpaRVLeM3fw" decimals="INF" format="ixt:numdotdecimal" name="glyc:StockIssuedDuringPeriodSharesStockOptionsAndRestrictedStockUnitsVesting" scale="0" id="Tc_WkcXO9ZOBEWWKCyLCMPRSg_5_2">306,182</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_rTR9aq2hpUuLpaRVLeM3fw" decimals="0" format="ixt:numdotdecimal" name="glyc:StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsVesting" scale="0" id="Tc_MMwfpZxQC0SHUso4-jNVXA_5_5">306</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_5fUBPR76oEmKbes-wtXqbw" decimals="0" format="ixt:numdotdecimal" name="glyc:StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsVesting" scale="0" id="Tc_TzQDDAVdB0WtMFq0td59HQ_5_8">412,607</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2019_To_12_31_2019_pmIpEVmd-kmwrLI0XOvIXQ" decimals="0" format="ixt:numdotdecimal" name="glyc:StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsVesting" scale="0" id="Tc_UdjLNPygeU2ldxsMlPzAXA_5_14">412,913</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:43.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_5fUBPR76oEmKbes-wtXqbw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_5Z7G7HfQa06wyyyxzwY0zg_6_8">6,215,090</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2019_To_12_31_2019_pmIpEVmd-kmwrLI0XOvIXQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_SqNTp7ratE-febH6uRDxqg_6_14">6,215,090</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:43.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_u9sxIh2gcUepx9OR8uIffA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_-AuQzHswf0a8PelWqbAZmg_7_11">57,891,911</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2019_To_12_31_2019_pmIpEVmd-kmwrLI0XOvIXQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_9AqvEFOgT0q5vDoSDhIm3w_7_14">57,891,911</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:43.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Balance at December 31,&#160;2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_y9GDd_Gl4EG3z9w6EbLWoQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_2UuFdTxYokmLm_QqeKmzbw_8_2">43,466,933</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_y9GDd_Gl4EG3z9w6EbLWoQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_MANB68xq1U6ofkWgD2HPBA_8_5">43,465</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ZGf_JC8_7kO1YJVHBI1tHQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_r8bnXz674kOlp9nepBg4SQ_8_8">412,599,772</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_9jiZRJgwUkmiTr7-zEU_pg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_7tTwUi3uvUSpXBx1ynTLQA_8_11">258,442,650</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2019_lBnwqvQJ-keVmMK3ebV7mA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_lLhO7dLpF0KZr0cVb7L0Ag_8_14">154,200,587</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:43.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Issuance of common stock, net of issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_LwiWCcw92Ui_-9wG0O1diw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_hDnV7JbU5ESqNactCw8RNA_9_2">5,161,502</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_LwiWCcw92Ui_-9wG0O1diw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_SkTxpRmyAEeM6kqIprVIMg_9_5">5,163</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_w7tJ7ePME0abPNOD4nmo0g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_y_T_L78YU0S8Z21Dhe_T2w_9_8">17,819,554</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2020_To_12_31_2020_n4dAyZdoqEGSie7qc7FpOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_tTmvhaXsLU-IVwmUhExTdw_9_14">17,824,717</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:43.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Exercise of options and vesting of restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_LwiWCcw92Ui_-9wG0O1diw" decimals="INF" format="ixt:numdotdecimal" name="glyc:StockIssuedDuringPeriodSharesStockOptionsAndRestrictedStockUnitsVesting" scale="0" id="Tc_2o9OnVo68EOZfjiumEJVQg_10_2">389,187</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_LwiWCcw92Ui_-9wG0O1diw" decimals="0" format="ixt:numdotdecimal" name="glyc:StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsVesting" scale="0" id="Tc_lwHxPW6sPESN5GoTNBhLnA_10_5">390</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_w7tJ7ePME0abPNOD4nmo0g" decimals="0" format="ixt:numdotdecimal" name="glyc:StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsVesting" scale="0" id="Tc_5adj2kvKWUC2-Es3mLa-vw_10_8">318,907</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2020_To_12_31_2020_n4dAyZdoqEGSie7qc7FpOQ" decimals="0" format="ixt:numdotdecimal" name="glyc:StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsVesting" scale="0" id="Tc_q1G_HljOnUqc6N0aic-nQw_10_14">319,297</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:43.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_w7tJ7ePME0abPNOD4nmo0g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_tqv-gUwy60uEKrhiHa7JmA_11_8">6,901,758</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2020_To_12_31_2020_n4dAyZdoqEGSie7qc7FpOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_ZEIxhO4tS0aYlu860R9MjQ_11_14">6,901,758</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:43.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_s0Ld-3ryuEyoCl6QFxcQJQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_jBHmK4XKBUq_J8TtqRzPnA_12_11">51,026,903</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2020_To_12_31_2020_n4dAyZdoqEGSie7qc7FpOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_of8a20Ul_UWzwZ9TZlAl_A_12_14">51,026,903</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:43.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Balance at December 31,&#160;2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_JRdAbPca-UyPJvyJT5-3gQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_hC-wdcinHEKkDCIAYJfp_g_13_2">49,017,622</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_JRdAbPca-UyPJvyJT5-3gQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_coDF9ej9eEaBEu8nNCY-oQ_13_5">49,018</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_fkG-U4OFgECm1zMTvyySFw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_mxJeHEUg2UqC3SgsacIF0Q_13_8">437,639,991</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_bpFOniAZWESSLirIldcb9A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_ipTHaJu6xE-130z9V69Jpw_13_11">309,469,553</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_Ea2WQM-MvkigtjVQzsFpNA_13_14">128,219,456</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:43.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Issuance of common stock, net of issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cGTT67gulkyrZ4UjnAS9fA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_0kN4UtnHo0SlGHksu-s7eQ_14_2">3,092,603</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cGTT67gulkyrZ4UjnAS9fA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_X741DZ7RG0uSo0EKILia2w_14_5">3,092</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Ci6hS_fKd0SPY1WJAb_gGg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_yyMNQBqC1U2Np7vIlCWp6w_14_8">10,696,225</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_w4ElWbVrc0CTqjfj84saGQ_14_14">10,699,317</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:43.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Exercise of options and vesting of restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cGTT67gulkyrZ4UjnAS9fA" decimals="INF" format="ixt:numdotdecimal" name="glyc:StockIssuedDuringPeriodSharesStockOptionsAndRestrictedStockUnitsVesting" scale="0" id="Tc_J1qPY2IS90WMvx-C4g0_Dg_15_2">203,669</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cGTT67gulkyrZ4UjnAS9fA" decimals="0" format="ixt:numdotdecimal" name="glyc:StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsVesting" scale="0" id="Tc_ZKu6AtlFV0mSjvbUysZQ_Q_15_5">204</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Ci6hS_fKd0SPY1WJAb_gGg" decimals="0" format="ixt:numdotdecimal" name="glyc:StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsVesting" scale="0" id="Tc_ShM7DxlmbUmDEehU0tXe6Q_15_8">24,825</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" decimals="0" format="ixt:numdotdecimal" name="glyc:StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsVesting" scale="0" id="Tc_xJouqrCfX0G7FgVm-OT3Yg_15_14">25,029</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:43.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Ci6hS_fKd0SPY1WJAb_gGg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_zSy2HiUjv0GeApkO71dS9Q_16_8">6,087,286</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_b7o_uEKEN0eT3ojoYi5hcA_16_14">6,087,286</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:43.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_j3ehB3FRnke0I31qV9waCw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_41Wt-RVZoUmeGzAuD23Lgg_17_11">63,427,437</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_vkB52Igql0aB0cK4EY2iHQ_17_14">63,427,437</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:43.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Balance at December&#160;31,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_T9wbnfgz4EGnt4Ls-f124g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_C_KF3OKmNUqm7n6C07sbUw_18_2">52,313,894</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_T9wbnfgz4EGnt4Ls-f124g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_wu4zpKtE40q0MEZBojMqZQ_18_5">52,314</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_7RS26_kETEqvpbTdEEcRHQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_8xLhl7mVi0eiV479pE48FA_18_8">454,448,327</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_cJJA3MCcxUCEbi4HdRpkhQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_tdKX1E3tKkiiHZbegt25IA_18_11">372,896,990</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_Nn4wuklaN0GEjN6bTJWpFw_18_14">81,603,651</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 0pt 0pt;"><i style="font-style:italic;">See accompanying notes.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">77</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_69689a57_a41f_4ec5_a66f_a76281e7f84c"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">GLYCOMIMETICS, INC.</b></p><a id="StatementsofCashFlows_755635"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Statements of Cash Flow</b><b style="font-weight:bold;">s</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><a id="_8d93c521_8fc4_40ee_b4c7_7b6e76bccce6"></a><a id="Tc_zTiG3vDFXU2AV7QymiwpOg_1_2"></a><a id="Tc_oRIZCIcjaUOZ1ozq1tul4w_2_2"></a><a id="Tc_hgM1bbnSK0awCYQagReenQ_2_5"></a><a id="Tc_XwgT6yr_30u13SQsASmtOg_2_8"></a><a id="Tc_81z8qvtjl0uZ5539nWz60Q_3_0"></a><a id="Tc_dPaRm9K-YkCl6WiY5fUXmw_4_0"></a><a id="Tc_AUuAabmWK0yL6z_IhlKPZw_4_2"></a><a id="Tc_JrAADyby4E-JezxL-74-CQ_4_5"></a><a id="Tc_BDVmZcKL2UeEarrWW8d6ew_4_8"></a><a id="Tc_0UTumn-HtEecm9izANmqww_5_0"></a><a id="Tc_HFkolJZzoEmeRTzS-XJd7Q_6_0"></a><a id="Tc_lK9nu16SYUyuw53OApsINg_7_0"></a><a id="Tc_7_KvQ9zAj0GPGAel2gVowg_7_6"></a><a id="Tc_nXaF3S8vekaGzMR_EM6SSg_7_9"></a><a id="Tc_E7pVELAtF0CuSoiJHOUY7g_8_0"></a><a id="Tc_FqHsPmmBuU6j1My4lu4JUg_9_0"></a><a id="Tc_WTMMcYlwbkGuMhuB7I-mHA_10_0"></a><a id="Tc_lXzByy1ciUSiPjZOzjZctA_11_0"></a><a id="Tc_ra0y8UItnEeO2rtHHJILyQ_12_0"></a><a id="Tc_LFHh-9ixN0qTodJsaB88KQ_13_0"></a><a id="Tc_ovVQpb-PdEmy4Ie6WjTG9A_14_0"></a><a id="Tc_j0oUfm7o7Eiw75PvW9vSIA_15_0"></a><a id="Tc_8vXbUCMCCky41xI6jpI6fg_17_0"></a><a id="Tc_rlxR_I1yf0uMEfq_KnasZg_18_0"></a><a id="Tc_Hoa2Leay9E-5eVTqMd0oGw_19_0"></a><a id="Tc_X7LkfMxclEaAdMMwHJPhIg_21_0"></a><a id="Tc_jeNXfBIvyUSZnj-OdpGynw_22_0"></a><a id="Tc_lMKtFJs8L0yOqMbav10C9A_22_9"></a><a id="Tc_2wfy2YmLFES6O_kWK7XMmQ_23_0"></a><a id="Tc_E7wfNrzy6k6HcDOpBYrlmA_24_0"></a><a id="Tc_UURFOZrGdUGaLg1Lpo_Gkw_25_0"></a><a id="Tc_VMrsK7m6tkWVoeYNpLA0tA_26_0"></a><a id="Tc_sKht9WASkUKhxFDrfomZhg_27_0"></a><a id="Tc_E5qu_MRqEUSf3j42W2EN8A_27_2"></a><a id="Tc_yHwAo1rYdU2VBEMJZ2vv_Q_27_5"></a><a id="Tc_9RhPYo-48kqHYpqIJGqi9g_27_8"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:41.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year&#160;Ended&#160;December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Operating activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="0" id="Tc_Eb2sqi-IVk6uhbFN0hh8jA_4_3">63,427,437</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2020_To_12_31_2020_n4dAyZdoqEGSie7qc7FpOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="0" id="Tc_6NnHvYkxY0eZqTEEJ5GR5w_4_6">51,026,903</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2019_To_12_31_2019_pmIpEVmd-kmwrLI0XOvIXQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="0" id="Tc_MCEDZ3y3PE2mWB8OfPfR9A_4_9">57,891,911</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:58.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Adjustments to reconcile net loss to net cash used in operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="0" id="Tc_XR8e7zVYd0uBkwgl06Q8pg_6_3">264,600</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2020_To_12_31_2020_n4dAyZdoqEGSie7qc7FpOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="0" id="Tc_8P9aE0Cue0qQW7jI7s9RGw_6_6">270,754</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2019_To_12_31_2019_pmIpEVmd-kmwrLI0XOvIXQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="0" id="Tc_90o3HzZgqkifu7rQTlDkEw_6_9">279,234</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Loss on disposal of assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" sign="-" scale="0" id="Tc_abskKLhTfU-24JcA71XtbA_7_3">2,174</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:58.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Non-cash lease expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="0" id="Tc_6ClQCohvgESC9POQbuzXuw_8_3">749,039</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2020_To_12_31_2020_n4dAyZdoqEGSie7qc7FpOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="0" id="Tc_mRvkkGcO70-c-ld59DQTzQ_8_6">680,845</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2019_To_12_31_2019_pmIpEVmd-kmwrLI0XOvIXQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="0" id="Tc_1OtSdNyTOkOllBLW5Cpbbw_8_9">620,068</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="Tc_gqRxtBLCbEGkVgi0W4uIjw_9_3">6,087,286</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2020_To_12_31_2020_n4dAyZdoqEGSie7qc7FpOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="Tc_EqqaWGodIkm8zcCR6tt1IA_9_6">6,901,758</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2019_To_12_31_2019_pmIpEVmd-kmwrLI0XOvIXQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="Tc_kDk2ehfnZE-ZLahPmGQ3Lg_9_9">6,215,090</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Changes in assets and liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 42pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" sign="-" scale="0" id="Tc_pgVRoW5r8Eql0fidm8Zz3Q_11_3">704,524</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2020_To_12_31_2020_n4dAyZdoqEGSie7qc7FpOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" sign="-" scale="0" id="Tc_aeGguSLCO0-7OeVEINcV-A_11_6">3,087,994</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2019_To_12_31_2019_pmIpEVmd-kmwrLI0XOvIXQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" id="Tc_dPbp7jW2gkqxiUhc8nLFYQ_11_9">2,059,260</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:58.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 42pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="0" id="Tc_HzkQqYAQKE-3B8B5-1xMuA_12_3">17,676</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2020_To_12_31_2020_n4dAyZdoqEGSie7qc7FpOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="0" id="Tc_dP4Dyfv8zEeFo5NKCGIAgA_12_6">654,279</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2019_To_12_31_2019_pmIpEVmd-kmwrLI0XOvIXQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" sign="-" scale="0" id="Tc_N78nxfBibUqSftfTqXQohA_12_9">1,227,919</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:58.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 42pt;">Accrued expenses </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" sign="-" scale="0" id="Tc_Hs_-MgjfuUSMgYCPFnWRRQ_13_3">988,842</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2020_To_12_31_2020_n4dAyZdoqEGSie7qc7FpOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="0" id="Tc_EL1WzHOhIUi2IrlFa0NMgQ_13_6">993,420</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2019_To_12_31_2019_pmIpEVmd-kmwrLI0XOvIXQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="0" id="Tc_rLCrZDLznUGG2jOFC6rhuw_13_9">2,709,986</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 42pt;">Lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" decimals="0" format="ixt:numdotdecimal" name="glyc:IncreaseDecreaseInOperatingLeaseLiabilities" sign="-" scale="0" id="Tc_uBaqSGxsD0igK2SZC-a8Wg_14_3">898,550</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2020_To_12_31_2020_n4dAyZdoqEGSie7qc7FpOQ" decimals="0" format="ixt:numdotdecimal" name="glyc:IncreaseDecreaseInOperatingLeaseLiabilities" sign="-" scale="0" id="Tc_mXdPg-AIyUapmGIqpvq02A_14_6">804,078</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2019_To_12_31_2019_pmIpEVmd-kmwrLI0XOvIXQ" decimals="0" format="ixt:numdotdecimal" name="glyc:IncreaseDecreaseInOperatingLeaseLiabilities" sign="-" scale="0" id="Tc_xZJpylidN0G6-L4nPzaaoQ_14_9">629,427</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:58.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="0" id="Tc_lIxk8k6ntkq8Cx76xRnkiQ_15_3">57,489,530</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2020_To_12_31_2020_n4dAyZdoqEGSie7qc7FpOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="0" id="Tc_dtsxUEctVUqj7q6Tt5wrWg_15_6">39,241,931</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2019_To_12_31_2019_pmIpEVmd-kmwrLI0XOvIXQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="0" id="Tc_PwWBK3MgHkq40dHLx33NuQ_15_9">51,984,139</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:58.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Investing activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Purchases of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" id="Tc_sr90-mbuekeDVfFxAPSjAA_18_3">14,943</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2020_To_12_31_2020_n4dAyZdoqEGSie7qc7FpOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" id="Tc_pHk2GD3H_0-SfTMlXbllEw_18_6">68,507</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2019_To_12_31_2019_pmIpEVmd-kmwrLI0XOvIXQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" id="Tc_a-wPmgFj3Eeibih1oi5K-Q_18_9">144,928</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:58.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net cash used in investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="0" id="Tc_z6zpsdy4iUWdThSDsGCITA_19_3">14,943</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2020_To_12_31_2020_n4dAyZdoqEGSie7qc7FpOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="0" id="Tc_dNKzmISC4EmnzZl7V1dulw_19_6">68,507</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2019_To_12_31_2019_pmIpEVmd-kmwrLI0XOvIXQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="0" id="Tc_XYLAHlr130a2d3zEwzj-7g_19_9">144,928</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:58.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Financing activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Proceeds from issuance of common stock, net of issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" id="Tc_VhtVkuu9oEm1NIhzuTraQA_22_3">10,699,317</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2020_To_12_31_2020_n4dAyZdoqEGSie7qc7FpOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" id="Tc_9xV53S_QaUGOMtEro9DVKQ_22_6">17,824,717</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:58.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Proceeds from exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="0" id="Tc_9RYsJm9zmUCtm-v_nGXUWw_23_3">25,029</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2020_To_12_31_2020_n4dAyZdoqEGSie7qc7FpOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="0" id="Tc_PHMdVPUakk2lLqy7wFqD8Q_23_6">319,297</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2019_To_12_31_2019_pmIpEVmd-kmwrLI0XOvIXQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="0" id="Tc_Wx_Q7-TSCkyvoQj0xBCy8Q_23_9">412,913</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net cash provided by financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="Tc_ZA6Rc8c0Ok2TjVioQ1pnjg_24_3">10,724,346</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2020_To_12_31_2020_n4dAyZdoqEGSie7qc7FpOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="Tc_jtefA2tfgk6ocDGHJSzwrQ_24_6">18,144,014</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2019_To_12_31_2019_pmIpEVmd-kmwrLI0XOvIXQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="Tc_tfqkGP5YYkav4u1wGz61vw_24_9">412,913</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net change in cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="0" id="Tc_ibQsl8ixyUeur6gPoXmhtQ_25_3">46,780,127</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2020_To_12_31_2020_n4dAyZdoqEGSie7qc7FpOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="0" id="Tc_Wajq7EWswUuNLUgCUO8PWA_25_6">21,166,424</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2019_To_12_31_2019_pmIpEVmd-kmwrLI0XOvIXQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="0" id="Tc_xDF8XbpEp0m6rhOHn0MfIA_25_9">51,716,154</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:58.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash and cash equivalents, beginning of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_pfSvQAMBzkG_v0i3NmStpw_26_3">137,035,017</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2019_lBnwqvQJ-keVmMK3ebV7mA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_u1AhWvda9ECCG2ltb-zZBw_26_6">158,201,441</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2018_LWXbJD-mPkKObqFgUzRVCw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_plQ5aT86oEWP4C3bwjtM8g_26_9">209,917,595</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash and cash equivalents, end of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_oaJSlmfPO0yuALx52qY5cw_27_3">90,254,890</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_VpquCqBlXEeWWdGNH3a1pA_27_6">137,035,017</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2019_lBnwqvQJ-keVmMK3ebV7mA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_hlLMHMGTLEGy0NBtImOVQQ_27_9">158,201,441</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">See accompanying notes.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">78</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_8b14f217_79f1_4cee_8fc8_24d5b3faaaac"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">GLYCOMIMETICS, INC.</b></p><a id="NotestoFinancialStatements_432888"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Notes to Financial Statement</b><b style="font-weight:bold;">s</b></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" name="us-gaap:NatureOfOperations" id="Tb_cqVj8YLk50uvSB74WZAuww" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">1. Description of the Business</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">GlycoMimetics, Inc. (the Company), a Delaware corporation headquartered in Rockville, Maryland, was incorporated in 2003. The Company is a clinical stage biotechnology company focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using its expertise in carbohydrate chemistry and knowledge of carbohydrate biology, the Company is developing a pipeline of proprietary glycomimetics that inhibit disease-related functions of carbohydrates, such as the roles they play in inflammation, cancer and infection.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" name="us-gaap:SubstantialDoubtAboutGoingConcernTextBlock" id="Tb_-onKBSKgeUGTMo1PLZqDig" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">2. Going Concern</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern within one year after the date that the financial statements are issued. During 2021, the Company incurred a net loss of $<ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" decimals="-5" format="ixt:numdotdecimal" name="glyc:NetIncomeLossAndComprehensiveIncomeNetOfTax" sign="-" scale="6" id="Narr_MFtCSh6uAkCws4bpJOkRBA">63.4</ix:nonFraction> million and had net cash flows used in operating activities of $<ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="6" id="Narr_DYWKn-RQmU2GOhHA7rY6rQ">57.5</ix:nonFraction> million. At December 31, 2021, the Company had $<ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="Narr_1BRuhAWifEaQnXghrV2FmA">90.3</ix:nonFraction> million in cash and cash equivalents and had no committed source of additional funding from either debt or equity financings. Management believes that given the Company&#8217;s current cash position and forecasted negative cash flows from operating activities over the next twelve months, including the completion of its planned Phase 3 clinical trial of uproleselan, there is substantial doubt about its ability to continue as a going concern after the date that is one year from the date that these financial statements are issued, without obtaining additional financing or entering into another form of non-equity or debt arrangement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">The Company&#8217;s ability to fund its operations is dependent upon management&#8217;s plans, which include raising additional capital in the near term primarily through a combination of equity and debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements and in the longer term, from revenue related to product sales, to the extent its product candidates receive marketing approval and can be commercialized. There can be no assurances that new financings or other transactions will be available to us on commercially acceptable terms, or at all. Also, any collaborations, strategic alliances and marketing, distribution or licensing arrangements may require the Company to give up some or all of its rights to a product or technology, which in some cases may be at less than the full potential value of such rights. If the Company is unable to obtain additional capital, the Company will assess its capital resources and may be required to delay, reduce the scope of or eliminate some or all of our operations, which may have a material adverse effect on our business, financial condition, results of operations and ability to operate as a going concern.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">The financial statements do not include any adjustments that might be necessary if the Company is not able to continue as a going concern.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="Tb_PIyvbO9BwUmteXP95dQEvQ" continuedAt="Tb_PIyvbO9BwUmteXP95dQEvQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">3. Summary of Significant Accounting Policies</b></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="Tb_B10ID10pT0mYWwx3eDMUfA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Basis of Accounting</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">The accompanying financial statements were prepared based on the accrual method of accounting in accordance with U.S. generally accepted accounting principles (GAAP).</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="Tb_uFQFxn30g0q8UtN3l_Nt9g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Segment Information</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in <ix:nonFraction unitRef="Unit_Standard_segment_SDPUnB8SLEWaCbvZFtu_Hw" contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="Narr_lA0QHO9VH0OYxqkk4NDKaA">one</ix:nonFraction> segment, which is the identification and development of glycomimetic compounds.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" name="us-gaap:UseOfEstimates" id="Tb_8qQbnqaUVkOdxeUDEvaKgA" continuedAt="Tb_8qQbnqaUVkOdxeUDEvaKgA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Although actual results could differ from those estimates, management does not believe that such differences would be material.</p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">79</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_c54284d5_068a_4c70_8bcd_53a4285c5ef9"></a><a id="_c54284d5_068a_4c70_8bcd_53a4285c5ef9_2"></a><a id="_c54284d5_068a_4c70_8bcd_53a4285c5ef9_3"></a><a id="_25a37f9c_7df4_4cd2_9890_81b3780b2b89"></a><a id="_25a37f9c_7df4_4cd2_9890_81b3780b2b89_2"></a><a id="_25a37f9c_7df4_4cd2_9890_81b3780b2b89_3"></a><a id="_195b2a0e_2eed_4c9e_9650_d9ae95ec990d"></a><a id="_195b2a0e_2eed_4c9e_9650_d9ae95ec990d_2"></a><a id="_195b2a0e_2eed_4c9e_9650_d9ae95ec990d_3"></a><ix:continuation id="Tb_PIyvbO9BwUmteXP95dQEvQ_cont1" continuedAt="Tb_PIyvbO9BwUmteXP95dQEvQ_cont2"><ix:continuation id="Tb_8qQbnqaUVkOdxeUDEvaKgA_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="Tb_Wp3UvkZT1EiCEguumypT9A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Cash and Cash Equivalents</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Cash and cash equivalents consist of investment in money market funds with commercial banks and financial institutions. The Company considers all investments in highly liquid financial instruments with an original maturity of three months or less at the date of purchase to be cash equivalents. Cash equivalents are stated at amortized cost, plus accrued interest, which approximates fair value.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="Tb_ah5Hp_TPb0ScApbrClh8Kg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Fair Value Measurements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">The Company&#8217;s financial instruments include cash and cash equivalents. The fair values of the financial instruments approximated their carrying values at December 31, 2021 and 2020, due to their short-term maturities. The Company accounts for recurring and nonrecurring fair value measurements in accordance with ASC 820, <i style="font-style:italic;">Fair Value Measurements</i>. ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements. The ASC hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value, and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 1&#8212;Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 2&#8212;Fair value is determined by using inputs, other than Level 1 quoted prices, that are directly and indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models that can be corroborated by observable market data.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 3&#8212;Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity. In instances where the determination of the fair value measurement is based on inputs from different levels of fair value hierarchy, the fair value measurement will fall within the lowest level input that is significant to the fair value measurement in its entirety.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">The Company periodically evaluates financial assets and liabilities subject to fair value measurements to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC 820 hierarchy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">The Company had <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_f69ARavam0CDVS574-bG4A" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="Narr_72j1wDV0wkyG7AOqi3laRA"><ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_95OGnpM2iEC95hp3bmUctw" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="Narr_OwSJMj5hLUKbX2Rf3GfG0A">no</ix:nonFraction></ix:nonFraction> assets or liabilities that were measured using quoted prices for similar assets and liabilities or significant unobservable inputs (Level 2 and Level 3 assets and liabilities, respectively) either on a recurring or non-recurring basis as of December&#160;31, 2021 and 2020. The carrying value of cash held in money market funds of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_jja2ssufsk-400-VxFX0dA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:MoneyMarketFundsAtCarryingValue" scale="6" id="Narr_RrGyHkhNTEGhQh8kVev2eg">88.3</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_xN1YQshF5Eu9AMf6bQK4Kw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:MoneyMarketFundsAtCarryingValue" scale="6" id="Narr_KUzxn9cXykqFKUrEF0AUiQ">135.0</ix:nonFraction> million as of December&#160;31, 2021 and 2020, respectively, is included in cash and cash equivalents and approximates market values based on quoted market prices (Level 1 inputs). The Company did&#160;not transfer any assets measured at fair value on a recurring basis between levels during the&#160;years ended December 31, 2021 and 2020.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" name="us-gaap:ConcentrationRiskCreditRisk" id="Tb_-FQp2mxlG0GlUCgUSGSt8g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Concentration of Credit Risk</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Credit risk represents the risk that the Company would incur a loss if counterparties failed to perform pursuant to the terms of their agreements. Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. Cash and cash equivalents consist of investment in money market funds with major financial institutions in the United States. These deposits and funds may be redeemed upon demand and, therefore, bear minimal risk. The Company does not anticipate any losses on such balances.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="Tb_ubYMg7deDk28mr9l8uQa7w" continuedAt="Tb_ubYMg7deDk28mr9l8uQa7w_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Property and Equipment</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">Property and equipment are recorded at cost and depreciated on a straight-line basis over estimated useful lives ranging from <span style="-sec-ix-hidden:Hidden_0ma8_vtK80W6jIJz3LC8HQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three</span></span> to <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_Bhd-nQulWU6ZbQQpkblCKw" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Narr_MlHxfMKUbkexiIAg6n7AOQ">seven years</ix:nonNumeric>. Upon retirement or disposition of assets, the costs and related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the results of operations. Expenditures for repairs and maintenance are charged to operations as incurred; major replacements that extend the </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">80</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_BdJ_Lx5WF0KI9FodRebGFA_1_2"></a><a id="Tc_MdkuyqzdQUe82UBCPV_5bA_2_0"></a><a id="Tc_DDRJreZQj0q0Y7JTaQU3Cw_3_0"></a><a id="Tc_HLXIt6umUkGSEqJFbZm9pA_4_0"></a><a id="Tc_ABs8MGCFbUG56FN-iz43PQ_5_0"></a><a id="Tc_h9CnJJHIfESuVlz9b002LA_6_0"></a><a id="Tc_hxS0bv66W0mhpaWz309iCw_6_2"></a><ix:continuation id="Tb_PIyvbO9BwUmteXP95dQEvQ_cont2" continuedAt="Tb_PIyvbO9BwUmteXP95dQEvQ_cont3"><ix:continuation id="Tb_ubYMg7deDk28mr9l8uQa7w_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">useful life are capitalized. Depreciation and amortization are computed using the straight-line method over the following estimated useful lives:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" name="glyc:ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" id="Tb_bnQ4jJJUhEShyoSUAxiZ5Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><div style="padding-left:40.5pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:82.39%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:46.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:51.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:46.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ESTIMATED&#160;USEFUL&#160;LIVES</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:46.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_XpvrdhTYnU29K3NXwMZg1w" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Tc_lZCuRFcUekKqRhoF38mnjg_2_2">7 years</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:51.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Laboratory equipment</p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:46.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_glyc_LaboratoryEquipmentMember_18gz3PWP5EGrxYtLQQjCmA" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Tc_1HhmUeZzfEiqTFh9XoL_Gw_3_2">5 years</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:51.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Office equipment</p></td><td style="vertical-align:bottom;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:46.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_caWo07x0RkeYTz7JqqtihQ" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Tc_i69j1PNf_0uUn5WCHafNsw_4_2">5 years</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:51.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Computer equipment</p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:46.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_VeLLEDcIU0adJ4R_8YWwWQ" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Tc_x1J3FDCPakSh88OJKr1tDA_5_2">5 years</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:51.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:46.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.6pt 0pt 0pt;">Shorter&#160;of&#160;lease&#160;term&#160;or&#160;useful&#160; life</p></td></tr></table></div></ix:nonNumeric></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 6pt 0pt;"><span style="font-size:1pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="Tb_kVTV7L88TE-w8lmxbyEU7Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Impairment of Long-Lived Assets</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">The Company periodically assesses the recoverability of the carrying value of its long-lived assets in accordance with the provisions of ASC 360, <i style="font-style:italic;">Property, Plant, and Equipment</i>. ASC 360 requires that long-lived assets and certain identifiable intangible assets be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of the long-lived asset is measured by a comparison of the carrying amount of the asset to future undiscounted net cash flows expected to be generated by the asset. If the carrying value exceeds the sum of undiscounted cash flows, the Company then determines the fair value of the underlying asset. Any impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the estimated fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value, less costs to sell. As of December&#160;31, 2021 and 2020, the Company determined that there were <ix:nonFraction unitRef="Unit_Standard_item_g-Qg15KDVUyxut40CeCIjQ" contextRef="Duration_1_1_2020_To_12_31_2020_n4dAyZdoqEGSie7qc7FpOQ" decimals="0" format="ixt-sec:numwordsen" name="glyc:NumberOfLongLivedAssetsDeterminedToBeImpaired" scale="0" id="Narr_JYSW7gfZmkyoGWd11g48fg"><ix:nonFraction unitRef="Unit_Standard_item_g-Qg15KDVUyxut40CeCIjQ" contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" decimals="0" format="ixt-sec:numwordsen" name="glyc:NumberOfLongLivedAssetsDeterminedToBeImpaired" scale="0" id="Narr_MNmrhJT1-U-qVP_prrHkVw">no</ix:nonFraction></ix:nonFraction> impaired assets and it had <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:AssetsHeldForSaleNotPartOfDisposalGroup" scale="6" id="Narr_s9Jti2ztxEan79ag2BzUSA"><ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:AssetsHeldForSaleNotPartOfDisposalGroup" scale="6" id="Narr_cuMx20tRY0qK59joUD0JTw">no</ix:nonFraction></ix:nonFraction> assets held for sale.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="Tb_5S1U0jsALkOnKG0j-ki_bA" continuedAt="Tb_5S1U0jsALkOnKG0j-ki_bA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Revenue Recognition</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">The Company applies Accounting Standards Codification, or ASC, Topic 606, <i style="font-style:italic;">Revenue from Contracts with Customers </i>(Topic 606), to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. Under Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services in an amount that reflects the consideration which the entity expects to receive in exchange for those goods and services. To determine revenue recognition for arrangements that an entity determines are within the scope of Topic 606, the entity performs the following five steps: (i) identify the contract(s) with the customer(s); (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods and services it transfers to the customer. At contract inception, the Company assesses the goods or services promised within each contract that falls under the scope of Topic 606, determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">The Company enters into licensing agreements which are within the scope of Topic 606, under which it licenses certain of its drug candidates&#8217; rights to third parties. The terms of these arrangements typically include payment of one or more of the following: non-refundable, up-front license fees; development, regulatory and commercial milestone payments; and royalties on net sales of the licensed product, if and when earned. See Note 11 for additional information regarding the Company&#8217;s license agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"><span style="white-space:pre-wrap;"> In determining the appropriate amount of revenue to be recognized as it fulfills its obligation under each of its agreements, the Company performs the five steps under Topic 606 described above. As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price, which may include forecasted revenues, development timelines, reimbursement of personnel costs, discount rates and probabilities of technical and regulatory success.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"><i style="font-style:italic;">Licensing of Intellectual Property: </i>If the license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">81</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_PIyvbO9BwUmteXP95dQEvQ_cont3" continuedAt="Tb_PIyvbO9BwUmteXP95dQEvQ_cont4"><ix:continuation id="Tb_5S1U0jsALkOnKG0j-ki_bA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. The Company evaluates the measure of progress each reporting period, and, if necessary, adjusts the measure of performance and related revenue recognition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"><i style="font-style:italic;">Milestone Payments</i>: At the inception of each arrangement that includes development milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal will not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such development milestones and any related constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration and other revenues and earnings in their period of adjustment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"><i style="font-style:italic;">Royalties</i>: For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue from its license agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"><i style="font-style:italic;">Manufacturing and Supply:&#160;</i>The obligations under the Company&#8217;s agreements may include clinical and commercial manufacturing products to be provided by the Company to the counterparty. The services are generally determined to be distinct from the other promises or performance obligations identified in the arrangement. The Company recognizes the transaction price allocated to these services as revenue at a point in time when transfer of control of the related products to the customer occurs.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="Tb_vX1MskOWfUK4T1B3vBi0Lg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Research and Development Costs</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Except for payments made in advance of services, research and development costs are expensed as incurred. For payments made in advance, the Company recognizes research and development expense as the services are rendered. Research and development costs primarily consist of salaries and related expenses for personnel, laboratory supplies and raw materials, sponsored research, depreciation of laboratory facilities and leasehold improvements, and utilities costs related to research space. Other research and development expenses include fees paid to consultants and outside service providers including clinical research organizations and clinical manufacturing organizations.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" name="glyc:AccrualsForClinicalTrialExpensesPolicyTextBlock" id="Tb_0MCZCZ7s50OArLJVPGwlmA" continuedAt="Tb_0MCZCZ7s50OArLJVPGwlmA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Accruals for Clinical Trial Expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">Clinical trial costs primarily consist of expenses incurred under agreements with contract research organizations (CROs), investigative sites, laboratory testing expenses, data management and consultants that conduct the Company&#39;s clinical trials. Clinical trial expenses are a significant component of research and development expenses, and the Company outsources a significant portion of these clinical trial activities to third parties. The accrual for site and patient costs includes inputs such as estimates of patient enrollment, patient cycles incurred, clinical site activations, estimated project duration and other pass-through costs. These inputs are required to be estimated due to a lag in receiving the actual clinical information from third parties. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected on the balance sheets as a prepaid asset or accrued expenses. These third-party agreements are generally cancellable, and related costs are recorded as research and development expenses as incurred. Except for payments made in advance of services, clinical trial costs are expensed as incurred. Non-refundable advance clinical payments for goods or services that will be used or rendered for future research and development activities are recorded as a prepaid asset and recognized as expense as the related goods are delivered or the related services are performed. When evaluating the adequacy of the accrued expenses, management assessments include: (i) an evaluation by the project manager of the work that has been completed during the period; (ii) measurement of progress prepared internally and/or provided by the third-party service provider; (iii) analyses of data that justify the progress; and (iv)&#160;the Company&#8217;s judgment. Significant judgments and estimates may be made in determining the accrued balances at the end of any reporting period. Actual results could differ from the estimates made. </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">82</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_PIyvbO9BwUmteXP95dQEvQ_cont4" continuedAt="Tb_PIyvbO9BwUmteXP95dQEvQ_cont5"><ix:continuation id="Tb_0MCZCZ7s50OArLJVPGwlmA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">The Company&#8217;s historical clinical accrual estimates have not been materially different from the actual costs. Clinical trial accruals that are due longer than one year are classified as noncurrent accrued expenses.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="Tb_v-NDXr9ZM0ScaN2KDjHRnA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Stock-Based Compensation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Stock-based payments are accounted for in accordance with the provisions of ASC 718, <i style="font-style:italic;">Compensation&#8212;Stock Compensation</i>. The fair value of stock-based payments is estimated, on the date of grant, using the Black-Scholes-Merton model. The resulting fair value is recognized ratably over the requisite service period, which is generally the vesting period of the option. The Company has elected to account for forfeitures as they occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">The Company has elected to use the Black-Scholes-Merton option pricing model to value any options granted. The Company will reconsider use of the Black-Scholes-Merton model if additional information becomes available in the future that indicates another model would be more appropriate or if grants issued in future periods have characteristics that prevent their value from being reasonably estimated using this model.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">A discussion of management&#8217;s methodology for developing some of the assumptions used in the valuation model follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><i style="font-style:italic;">Expected Dividend Yield</i>&#8212;The Company has never declared or paid dividends and has no plans to do so in the foreseeable future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><i style="font-style:italic;">Expected Volatility&#8212;</i>Volatility is a measure of the amount by which a financial variable such as share price has fluctuated (historical volatility) or is expected to fluctuate (expected volatility) during a period. Effective January 1, 2020, the Company bases the expected volatility on the historical volatility of the Company&#8217;s publicly traded common stock. Prior to January 1, 2020, the Company utilized the historical volatilities of a peer group (e.g., several public entities of similar size, complexity, and stage of development), along with the Company&#8217;s historical volatility since its initial public offering, to determine its expected volatility.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><i style="font-style:italic;">Risk-Free Interest Rate</i>&#8212;This is the U.S. Treasury rate for the week of each option grant during the year, having a term that most closely resembles the expected life of the option.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><i style="font-style:italic;">Expected Term</i>&#8212;This is a period of time that the options granted are expected to remain unexercised. Options granted have a maximum term of <ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MaximumMember_dvu4YMBVCkmKgIY5AJuxZA" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_xbpKellvoUGqURWIghfObQ"><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MaximumMember_w9j8fZvT2UmDwuBnDsgAcw" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_F8a-KOm9tk2ec2AivBbs9g"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_Bhd-nQulWU6ZbQQpkblCKw" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_vxDA81EbzUivYlOeCbhy2A">10 years</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric>. The Company estimates the expected life of the option term to be <ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_pmIpEVmd-kmwrLI0XOvIXQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_SGI3wtOBUUew_H1RZXvhqg"><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_n4dAyZdoqEGSie7qc7FpOQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_zYpvaXHliE-p1oUG7FNcOg"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_GS9eaHfBdkem4_zHLEvbZQ">6.25</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric> years. The Company uses a simplified method to calculate the average expected term.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" name="us-gaap:IncomeTaxPolicyTextBlock" id="Tb_lXogQdz0g0CbH8QN5s-g1A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Income Taxes</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">The Company accounts for income taxes using the asset and liability method in accordance with ASC 740,<i style="font-style:italic;"> Income Taxes</i>. Deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and the financial reporting amounts at each year-end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. A valuation allowance is established when necessary to reduce deferred tax assets to the amount expected to be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">The Company accounts for uncertain tax positions pursuant to ASC 740. Financial statement recognition of a tax position taken or expected to be taken in a tax return is determined based on a more-likely-than-not threshold of that tax position being sustained. If the tax position meets this threshold, the benefit to be recognized is measured as the tax benefit having the highest likelihood of being realized upon ultimate settlement with the taxing authority. The Company recognizes interest accrued related to unrecognized tax benefits and penalties in the provision for income taxes.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="Tb_PQdZUBZlIk2jW7QKch1BTQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Comprehensive Loss</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Comprehensive loss comprises net loss and other changes in equity that are excluded from net loss. For the years ended December&#160;31, 2021, 2020 and 2019, the Company&#8217;s net loss was equal to comprehensive loss and, accordingly, no additional disclosure is presented.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" name="glyc:NewAccountingPronouncementsAdoptedPolicyPolicyTextBlock" id="Tb_MZI7_A1VVkqkL5R4Ws9W_g" continuedAt="Tb_MZI7_A1VVkqkL5R4Ws9W_g_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Adopted Accounting Standards</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">In December 2019, the FASB issued ASU 2019-12. ASU 2019-12 removes certain exceptions for recognizing deferred taxes for investments, performing intra-period allocation and calculating income taxes in interim periods. The ASU also adds guidance to reduce complexity in certain areas, including deferred taxes for goodwill and allocating taxes for members of a consolidated group. ASU 2019-12 was effective for all entities for fiscal years beginning after </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">83</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_PIyvbO9BwUmteXP95dQEvQ_cont5"><ix:continuation id="Tb_MZI7_A1VVkqkL5R4Ws9W_g_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">December 15, 2020. As of January 1, 2021, the Company adopted the standard, which did not have a material impact on the Company&#39;s financial statements. </p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Tb_cN_EAx7mmEyZ0oxXFNzDrw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Accounting Standards Not Yet Adopted</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">With the exception of the new standard discussed above, there have been no new accounting pronouncements that have significance, or potential significance, to the Company&#8217;s financial statements.</p></ix:nonNumeric></ix:continuation><a id="Tc_kmcXqmvfakmXdswxsCkmyQ_2_2"></a><a id="Tc_1j9esCCFQkmdL56xlVK_RA_2_4"></a><a id="Tc_z-kCToEquE-LsWlKxVmODg_2_6"></a><a id="Tc_xIncnnuJL0G_7KdDNIpxhQ_3_0"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" name="us-gaap:EarningsPerShareTextBlock" id="Tb_2xDwnLoA0Eyc-VmJzWaFCA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">4. Net Loss Per Share of Common Stock</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Basic net loss per common share is determined by dividing net loss by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per share is computed by dividing net loss by the weighted-average number of common stock equivalents outstanding for the period. The treasury stock method is used to determine the dilutive effect of the Company&#8217;s stock options and restricted stock units (RSUs).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted-average common shares outstanding, as they would be anti-dilutive: </p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="Tb_ncjfVAIBQU6pgzcDTIpZEg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock options and restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_glyc_EmployeeStockOptionsAndRestrictedStockUnitsMember_XfZ7v3VAVk-r9VvuNg_XkA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_Qwe1GQvFJ0qQiGV1iMGkbw_3_2">7,908,122</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_glyc_EmployeeStockOptionsAndRestrictedStockUnitsMember_13b9WUxP7EmEaDz7Hl3AmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_lMthW7YINUSW2Z_hPQBlGQ_3_4">6,143,594</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_glyc_EmployeeStockOptionsAndRestrictedStockUnitsMember_Iay9lDc4RUKcxJLhHUjHTg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_CmsnoAJncEuOUP4xI8vgJg_3_6">5,106,493</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><a id="_9d0d3010_8710_4be6_b87d_798b54b367d7"></a><a id="Tc_p-k-oTLPLEKlGcgZpEbZcg_2_2"></a><a id="Tc_w82mwQxIFESFdFNg9CnVrA_2_5"></a><a id="Tc_bJnx_ygpr0mJzuH2YWn3Kw_3_0"></a><a id="Tc_8U976-bYf06RnXITo2NTvQ_3_2"></a><a id="Tc_YrSb6K6nUk2Wa4zUnSLPKA_3_5"></a><a id="Tc_olKcfrEUukuNkFtlisyj5g_4_0"></a><a id="Tc_hMb_D6dTbUqxLueMLgSBdA_5_0"></a><a id="Tc_L41DPj4Ep0-pmgSY8bdBxQ_6_0"></a><a id="Tc_cq2RsxhDtk-LwwPUS5yJGA_6_2"></a><a id="Tc_m9Kuehl_kECMg5mReXsRNQ_6_5"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" name="us-gaap:OtherCurrentAssetsTextBlock" id="Tb_qS3PJOfYJ0yuw-GvroQkWQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">5. Prepaid Expenses and Other Current Assets</b></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" id="Tb_52BRLZl35EaGAIn91Z7sbg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">The following is a summary of the Company&#8217;s prepaid expenses and other current assets at December 31:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseCurrent" scale="0" id="Tc_LeNYEZM6f0OrtSN-NbFEdw_3_3">273,396</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseCurrent" scale="0" id="Tc_B7iI3ppHjUqpQo6wjGT-pQ_3_6">965,504</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other prepaid expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherPrepaidExpenseCurrent" scale="0" id="Tc_LLnBLMdkO0GbhNrSaLL4ww_4_3">259,061</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherPrepaidExpenseCurrent" scale="0" id="Tc_ay8H-e0X3k-s17u1GGmgWg_4_6">270,675</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherReceivablesNetCurrent" scale="0" id="Tc_YwO0SOdQqUGgJBqU9aYSoQ_5_3">1,347</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherReceivablesNetCurrent" scale="0" id="Tc_a2YaferNgEyUBYcXEXtzRA_5_6">2,149</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" id="Tc_3rUVHvLNZ0GhOa_ZPuC1DA_6_3">533,804</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" id="Tc_1IlLDAuJGU2eXVGDXD3qLw_6_6">1,238,328</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><a id="_9822019e_9af3_41b3_946d_8825684258db"></a><a id="Tc_lr2MRXJYRUyidBSN-83DXA_2_2"></a><a id="Tc_n9amQyzqN0eGu6JFASCzdw_2_5"></a><a id="Tc_YcK8OSkJRUC0CE9pu2Gzfg_3_0"></a><a id="Tc_rSzCUwFTiUCqLM-63QF2SA_3_2"></a><a id="Tc_6sTzdmMf5kyEtSdvnH7aPw_3_5"></a><a id="Tc_SLDuYN1KdEeNJIGPFDi-Aw_4_0"></a><a id="Tc_UIBclCZzu0i1R1yPfHOVgA_5_0"></a><a id="Tc_GSxyYX7CoEWjqi7QwIu3eA_6_0"></a><a id="Tc_enr0q-T1AkmzqMpxsimtyg_7_0"></a><a id="Tc_6WQDIOUcIkSonOoBZETLgQ_8_0"></a><a id="Tc_rh2JiQpUJkifRlr82di9RQ_9_0"></a><a id="Tc_hKRozDNckU6l7HTxGDMmaw_10_0"></a><a id="Tc_ySOVxmEVqkeC6ldrPn4oXQ_10_2"></a><a id="Tc_k5stVp90f0eUedKiY4h8Pw_10_5"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="Tb_joW-RxiDgEugUVOGMZschg" continuedAt="Tb_joW-RxiDgEugUVOGMZschg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">6. Property and Equipment</b></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="Tb_yMMqefQEDUmzwpshvDg1JA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:6pt 0pt 6pt 0pt;">Property and equipment, net consisted of the following at December 31:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_MyBLeUpbCEad5R76PvA7Qw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_k1wwiGNtTkqwRpFOmfaxxQ_3_3">345,712</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_F-fa25zb1EKNL4wYhdv86w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_F83EzidXuUe3wBmf3Ai_rA_3_6">345,712</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Laboratory equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_glyc_LaboratoryEquipmentMember_ZNg--URu-Um0dMbV5peuIw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_O1Aso1stn0SsXHdlnVSYYg_4_3">1,406,346</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_glyc_LaboratoryEquipmentMember_nghKysTWSECvGe85266cdw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_s1kzzGKNhE-2LSC4NPJn-w_4_6">1,446,596</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Office equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_S4Ib7npi4k2n67LEOrpyzw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_ye4duZ9ppkGe3vFt5UJ1Rg_5_3">17,762</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_vsNg25IaXU2FJMsaQjaLLw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_kL0BAnLSSUKkrVYR9o21RA_5_6">16,755</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Computer equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_NuJWpFqva06fY6gG06su4A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_vPkHqcP-UUKPBlwtmMJcfg_6_3">305,784</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_mVfAbQ5Nbkmu-wiL5cukOg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_av83HMYqfUexGn3fV4po2w_6_6">327,776</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_Ct0n8oNDQk-VdEoHy-ji7Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_qKbFFjX7R0CHSqwCDUpllA_7_3">616,133</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_7L-ZBeUo20ymuDm-db_BBA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_ZIhlcKqbP0GGpnE2qCbV9w_7_6">616,133</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_66TWTm2yvUKCIpm08ur3Zw_8_3">2,691,737</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_gAZMrg1TT0uUH3yvL6wSJQ_8_6">2,752,972</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less accumulated depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" id="Tc_MVAnMKNSy0yvyz7oXZocug_9_3">2,322,895</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" id="Tc_Nlrc8froLUKn6iZxwwb2qA_9_6">2,132,299</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="Tc_naxr0zpPC06B_4SntK4oZw_10_3">368,842</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="Tc_ENQSdD1yq0uFOq2zlvklRw_10_6">620,673</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:6pt 0pt 12pt 0pt;">Depreciation of property and equipment totaled $<ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="0" id="Narr_9W3Rn4Sbc0WyG3rgXLiy8w">264,600</ix:nonFraction>, $<ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2020_To_12_31_2020_n4dAyZdoqEGSie7qc7FpOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="0" id="Narr_Oh9vy1zV30625yAkT4jW-w">270,754</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2019_To_12_31_2019_pmIpEVmd-kmwrLI0XOvIXQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="0" id="Narr_h8IS-gvawEOxOXkcl3jOrw">279,234</ix:nonFraction> for the years ended December&#160;31, 2021, 2020 and 2019, respectively.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">84</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_joW-RxiDgEugUVOGMZschg_cont1"></ix:continuation><a id="_d16d66dd_3212_4730_b2fe_bd4927c09692"></a><a id="Tc_BIQpX43cX0uzXXc0-Af4qw_1_2"></a><a id="Tc_-ua7zT9WZkOdPy86kbGXig_1_5"></a><a id="Tc_14l8x6SwTUKqWPgQhd95WQ_2_0"></a><a id="Tc_e8A3S3jr702yO9L83U4ZwQ_2_2"></a><a id="Tc_tR1v4FX190eWAkv2yIyRxQ_2_5"></a><a id="Tc_rOzvgQp-zkyQ9VjqNaxynQ_3_0"></a><a id="Tc_zGQDb5lXtUeihdXseJFhyA_4_0"></a><a id="Tc_48Iriffl40G9RzrYjNjS3w_5_0"></a><a id="Tc_QXTaBApzTEaFzbyooMxg2g_6_0"></a><a id="Tc_o5Uot9OCmEKXxMnMBYqwlA_7_0"></a><a id="Tc_pmx7vlHO8UaCcDBrENVp-w_7_2"></a><a id="Tc_-CPHLK14Okq564lBLEAL3w_7_5"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="Tb_fwtii2lr6kqS5KPt2-unKA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">7. Accrued Expenses</b></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="Tb_s43keHxPI0myngYTsa8riw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:6pt 0pt 6pt 0pt;">The following is a summary of the Company&#8217;s accrued expenses at December 31:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg" decimals="0" format="ixt:numdotdecimal" name="glyc:AccruedResearchAndDevelopmentExpenseCurrent" scale="0" id="Tc_V3tIQEdSA0i5UbF0yUcNNw_2_3">5,824,365</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug" decimals="0" format="ixt:numdotdecimal" name="glyc:AccruedResearchAndDevelopmentExpenseCurrent" scale="0" id="Tc_kjV1sL-kKkGrComvIIgi3w_2_6">5,114,420</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued bonuses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccruedBonusesCurrent" scale="0" id="Tc_zegzQ_-vC0erxvP9_XaOjg_3_3">2,152,302</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccruedBonusesCurrent" scale="0" id="Tc_yS4PrIKrqUaxfLWnUCk8PQ_3_6">3,341,184</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued consulting and other professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="0" id="Tc_8OgWT5mazkKOfhG6Dx0HIw_4_3">299,607</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="0" id="Tc_8357aKFWi06zLeGOCo7Mjg_4_6">194,760</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued employee benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccruedEmployeeBenefitsCurrent" scale="0" id="Tc_GeGTDQawtkOUlf6otFfBxw_5_3">348,752</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccruedEmployeeBenefitsCurrent" scale="0" id="Tc_fv258ssWO0qX-3fK7NmeGA_5_6">569,048</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="0" id="Tc_82gM0GfzWEORdzTUhIKc1g_6_3">90,342</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="0" id="Tc_bp2oN0x8D0yX87BEerT5VA_6_6">220,469</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" id="Tc_LvhJL1fo50OTSYirKMjQHg_7_3">8,715,368</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" id="Tc_CSdwe-xClUGEqI2FPJfjfA_7_6">9,439,881</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" name="us-gaap:LesseeOperatingLeasesTextBlock" id="Tb_-2pSWULU7Uag3bOETResjw" continuedAt="Tb_-2pSWULU7Uag3bOETResjw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">8. Operating Leases</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"><span style="font-size:10pt;">At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the circumstances present. The Company determines a lease exists if the contract conveys the right to control an identified asset for a period of time in exchange for consideration. Control is considered to exist when the lessee has the right to obtain substantially all of the economic benefits from the use of an identified asset as well as direct the right to use of that asset. Leases with a term greater than one year are recognized on the balance sheet as right-of-use assets, lease liabilities and, if applicable, long-term lease liabilities. The Company has elected not to recognize on the balance sheet leases with terms of one year or less on the lease commencement date. If a contract is considered to be a lease, the Company recognizes a lease liability based on the present value of the future lease payments over the expected lease term, with an offsetting entry to recognize a right-of-use asset. The Company has also elected to use the practical expedient and account for each lease component and related non-lease component as one </span><span style="-sec-ix-hidden:Hidden_FRgasz_JB0WJUBzD7HF5EA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">single</span></span><span style="font-size:10pt;"> component. The lease component results in a right-of-use asset being recorded on the balance sheet and amortized as lease expense on a straight-line basis.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.5pt;margin:0pt 0pt 6pt 0pt;">The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a term similar to the term of the lease for which the rate is estimated. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">The Company leases office and research space in Rockville, Maryland under an operating lease with a term from June 15, 2015 through October 31, 2023 (the Lease) that is subject to annual rent increases. The Company has the right to sublease or assign all or a portion of the premises, subject to the conditions set forth in the Lease. The Lease may be terminated early by either the landlord or the Company in certain circumstances. In connection with the Lease, the Company received rent abatement as a lease incentive in the initial year of the Lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">In March 2016, the Company amended the Lease (the Lease Amendment) to lease additional space as of June 1, 2016. In May 2016, the Company also paid a security deposit of $<ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_5_31_2016_srt_StatementGeographicalAxis_glyc_RockvilleMarylandMember_pHaqdBt7jEqRRIagvedypQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SecurityDeposit" scale="0" id="Narr_sseOQMt-RkWSVvwelShcfg">52,320</ix:nonFraction> to be held until the expiration or termination of the Company&#8217;s obligations under the Lease. The term of the Lease Amendment for the additional space continues through October 31, 2023, the same date as for the premises originally leased under the Lease, subject to the Company&#8217;s renewal option set forth in the Lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">The Company identified and applied the following significant assumptions in recognizing the right-of-use asset and corresponding liability for the Lease and Lease Amendment:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Lease term &#8211; The lease term includes both the noncancelable period and, when applicable, </span><span style="-sec-ix-hidden:Hidden_1CXabvkwwUuyuzuDaxMsGQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">cancelable</span></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> option periods where failure to exercise such option would result in an economic penalty. The Company&#8217;s renewal option to </span><span style="-sec-ix-hidden:Hidden_jhM2PXDc_EWMY9qaiYQkSQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">extend</span></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> is not reasonably certain of being exercised as of December 31, 2021.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Incremental borrowing rate &#8211; As the Company&#8217;s lease does not provide an implicit rate, the Company used an incremental borrowing rate (IBR), which is the rate incurred to borrow on a collateralized basis over a term similar to the term of the lease for which the rate is estimated. The Company determined the IBR to be </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_pure_o6l_rGctYUCSP0KoHptHcQ" contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateIncreaseDecrease" scale="-2" id="Narr_E4W7QUQ2TUamu_nk162J1w">8</ix:nonFraction>%</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> based on an estimated rate that considered the Company&#8217;s credit risk in the United States for a collateralized borrowing and lease term similar to the Lease.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"><span style="font-size:10pt;">As of December 31, 2021 the weighted-average remaining lease term was </span><ix:nonNumeric contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="Narr_aCy0j2gGWkKHvifzIED5Cw"><span style="font-size:10pt;">1.8</span></ix:nonNumeric><span style="font-size:10pt;"> years. There were </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_lease_pZ3IxEbMMU6Abz8KmKdkfQ" contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" decimals="0" format="ixt-sec:numwordsen" name="glyc:LesseeOperatingLeaseNumberOfNewLeases" scale="0" id="Narr_5LV12CFYp0W2P2SAtmm4UQ">no</ix:nonFraction></span><span style="font-size:10pt;"> additional operating leases entered into during the year ended December 31, 2021.</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">85</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_YnuHnes_VUOQ4UeR7T0-uw_1_2"></a><a id="Tc_uSmoxzlZBEOxo0hN81iyXA_2_2"></a><a id="Tc_ihkjC0xKr0SzO7XQ3209Sg_2_5"></a><a id="Tc_1s054rQiREaQpC7AuM39eg_2_9"></a><a id="Tc_y1wwEX5b1ky3pbqpQcB8iA_3_0"></a><a id="Tc_DcqgE9AP8UKx0ZwT5IE4Pg_3_2"></a><a id="Tc_-TbF4o_QLU6V2bM8zlSrog_3_5"></a><a id="Tc_n90oRXesB06Z7cj1tg3wYw_3_8"></a><a id="Tc_ZL98fICcME-dAfj4cJVTFg_4_0"></a><a id="Tc__sJZ1lPGy0ySrJvw9XW2_A_5_0"></a><a id="Tc_JXRqt7G8XUiL3Vknfzk_Wg_5_2"></a><a id="Tc_VJmLidwC9USjGUiaj1P49g_5_5"></a><a id="Tc_AwImwu4LYEetsnwlrDxk-g_5_8"></a><a id="Tc_KP1cZ4nNUUSmjWPeeK95KA_7_0"></a><a id="Tc_RysJERcfuUGlEH6J2zHpTQ_8_0"></a><a id="Tc_tPVYsJmtb0iKbvl2BXilsg_8_2"></a><a id="Tc_qEJ3V7-3NUCeeEDeN_sNqA_8_5"></a><a id="Tc_xruTXl3KQUer1zcvvnE48Q_8_8"></a><a id="Tc_9P2O068fb0WlMLu0Dyye9A_1_2"></a><a id="Tc_NhICP_8Ih0O9WMRYjB-fjQ_2_2"></a><a id="Tc_A8VGssIOvka1iCeqFiE8bQ_3_0"></a><a id="Tc_ajiDB5OPiEePzJjSVLHVIA_3_2"></a><a id="Tc_5ZUJAFEQsUOzCmaF61udBg_4_0"></a><a id="Tc_LAMB5-R_AkWVHwFLmFi7qg_5_0"></a><a id="Tc_VKQkdj7CzUmsBtDEfqibbw_6_0"></a><a id="Tc_ljcOah_cRkGpGFs52AVSag_7_0"></a><a id="Tc_BMybXTu_RkKBClFdKWkEgg_8_0"></a><a id="Tc_14cHRN89NUyjWsgbatBBwQ_8_2"></a><ix:continuation id="Tb_-2pSWULU7Uag3bOETResjw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">The components of lease expense and related cash flows were as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" name="us-gaap:LeaseCostTableTextBlock" id="Tb__byZm6gt-0OxMgqdhjmP2Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:34.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating lease cost </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="Tc_mv3NjhGygkKRiAae41Vc0g_3_3">927,957</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2020_To_12_31_2020_n4dAyZdoqEGSie7qc7FpOQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="Tc_W4in4TbQ-kinbu-9Tjg__Q_3_6">927,957</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2019_To_12_31_2019_pmIpEVmd-kmwrLI0XOvIXQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="Tc_Bv0LGIfo0U2Lm3P6ZJxg0A_3_9">927,957</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:64.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Variable lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:VariableLeaseCost" scale="3" id="Tc_GjvRit4WQEW8qjhrPK7uqg_4_3">490,871</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2020_To_12_31_2020_n4dAyZdoqEGSie7qc7FpOQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:VariableLeaseCost" scale="3" id="Tc_86B8-5RGhUG52UL31gtlGg_4_6">593,973</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2019_To_12_31_2019_pmIpEVmd-kmwrLI0XOvIXQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:VariableLeaseCost" scale="3" id="Tc_QHVWm_JtA0uESGuucQ51ww_4_9">465,028</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:64.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total operating lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="Tc_iVRB1nYQG0aNGvOov_QHzw_5_3">1,418,828</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2020_To_12_31_2020_n4dAyZdoqEGSie7qc7FpOQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="Tc_VZmeFm0zLUq6Y8Gz69GQYA_5_6">1,521,930</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2019_To_12_31_2019_pmIpEVmd-kmwrLI0XOvIXQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="Tc_Zds0acymuEWXI9alsYyL7Q_5_9">1,392,985</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:64.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash paid for amounts included in the measurement of lease liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating cash outflows for operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="3" id="Tc_XgL2TKpkzEepH615mQxy_g_8_3">1,077,469</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2020_To_12_31_2020_n4dAyZdoqEGSie7qc7FpOQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="3" id="Tc_jygyTiw97UqsoIqnkisv9Q_8_6">1,051,190</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2019_To_12_31_2019_pmIpEVmd-kmwrLI0XOvIXQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="3" id="Tc_4KDUY2SbT0O5JFQOzydhzA_8_9">941,089</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:6pt 0pt 6pt 0pt;">Maturities of lease liability due under these lease agreements as of December 31, 2021 were as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="Tb_50zI_QdbtEKl3iqx1DFROw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:83.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:83.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Operating Lease</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:83.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Obligation</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:83.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="0" id="Tc_BnFJsUeEq0SS-gmh_OgJkQ_3_3">1,104,356</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:83.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="0" id="Tc_XXon3TelRkW-ZT1GCyLPmA_4_3">940,840</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:83.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg" decimals="0" format="ixt:zerodash" name="glyc:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo" scale="0" id="Tc_dkeAn01ObUW0yhpKK03ukQ_5_3">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:83.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="0" id="Tc_EaCpdzG05kWR4hNIL00Alw_6_3">2,045,196</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:83.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Present value adjustment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="0" id="Tc_rb_Ok2W_wE6Yb3FQMsZ9Yg_7_3">125,182</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:83.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Present value of lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="0" id="Tc_sQSiP7LNmEirLcT0mBKZwg_8_3">1,920,014</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" name="glyc:DisclosureOfStockholdersEquityAndCompensationRelatedCostsShareBasedPaymentsTextBlock" id="Tb_Ohclz55C50-VwnTSfGuopw" continuedAt="Tb_Ohclz55C50-VwnTSfGuopw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">9. Stockholders&#8217; Equity</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Common Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">At-The-Market Equity Offerings</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">On September 28, 2017, the Company entered into an at-the-market sales agreement (the 2017 Sales Agreement) with Cowen and Company, LLC (Cowen) to sell up to $<ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_9_28_2017_srt_RangeAxis_srt_MaximumMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_glyc_AtMarketOffering2017Member_1BZR7Z0Sy0OeJz_78Y1Cmg" decimals="-5" format="ixt:numdotdecimal" name="glyc:CommonStockValueAvailableForSaleUnderAgreement" scale="6" id="Narr_5WF-SRVY006Sc2FCHQMbYg">100.0</ix:nonFraction> million of the Company&#8217;s common stock registered under a shelf registration statement filed with the U.S. Securities and Exchange Commission in September 2017. During the year ended December 31, 2020, the Company issued and sold <ix:nonFraction unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_glyc_AtMarketOffering2017Member_xegFN2MRVUeT2e9ks4eOqg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_7Xm72gEphUCg7AQkyMfyYg">4,136,742</ix:nonFraction> shares of common stock under the 2017 Sales Agreement at a weighted average price per share of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_6ZVfdDCn5UCsvmo46quH_A" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_glyc_AtMarketOffering2017Member_m0ia7emTp0-S4cX7E9JaOQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_32CPf1Snr0ejlTcp3tydlg">3.52</ix:nonFraction>, for aggregate net proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_glyc_AtMarketOffering2017Member_xegFN2MRVUeT2e9ks4eOqg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="Narr_-AOvbSumZ0O8tBbdqQU2FA">14.1</ix:nonFraction> million, after deducting commissions and offering expenses. There were <ix:nonFraction unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_glyc_AtMarketOffering2017Member_MrvCJyh9ZEiM2EnDxi7KcA" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_AaKqxuizlE-pSKd6Xad9Gw">no</ix:nonFraction> shares sold under the 2017 Sales Agreement during the year ended December 31, 2019. The shelf registration statement, under which the shares that could be sold under the 2017 Sales Agreement were registered, expired on October 6, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">On October 7, 2020, the Company filed a prospectus supplement to a shelf registration statement that it filed in May 2019 and entered into a new at-the-market sales agreement (the 2020 Sales Agreement) with Cowen. Under the 2020 Sales Agreement, the Company may sell up to $<ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_10_7_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_glyc_AtMarketOffering2020Member_d7OWn4p530G-EwtpM2jaYA" decimals="-5" format="ixt:numdotdecimal" name="glyc:CommonStockValueAvailableForSaleUnderAgreement" scale="6" id="Narr_VptH9tJQHE2Kkt_iHHkTzw">100.0</ix:nonFraction> million of the Company&#8217;s common stock registered under the shelf registration statement that was filed in May 2019. The 2020 Sales Agreement replaced the 2017 Sales Agreement between the Company and Cowen, and the $<ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_10_7_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_glyc_AtMarketOffering2020Member_OCkznGqV5UKSXhPF0KDe9w" decimals="-5" format="ixt:numdotdecimal" name="glyc:CommonStockValueAvailableForSaleUnderAgreement" scale="6" id="Narr_7RTtM8vWLUa1LDHYYzU8IA">100.0</ix:nonFraction> million that may be sold under the 2020 Sales Agreement excludes any amounts that were sold under the 2017 Sales Agreement. During the year ended December 31, 2020, the Company issued and sold <ix:nonFraction unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_glyc_AtMarketOffering2020Member_3hZx0NV1dUGxHj4ixh_xdQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_SOwR4r8Pd0azWXJK4v5Q8A">1,024,760</ix:nonFraction> shares of common stock under the 2020 Sales Agreement at a weighted average price per share of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_6ZVfdDCn5UCsvmo46quH_A" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_glyc_AtMarketOffering2020Member_s7mbdwTmt0uPTw6bugEC2A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_ioHwWjWlQkSnPaoGEGC8sQ">3.74</ix:nonFraction>, for aggregate net proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_glyc_AtMarketOffering2020Member_3hZx0NV1dUGxHj4ixh_xdQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="Narr_ojq9wzOZhEuW6dposcgbPw">3.7</ix:nonFraction> million, after deducting commissions and offering expenses. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">During the year ended December 31, 2021, the Company issued and sold an additional <ix:nonFraction unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_glyc_AtMarketOffering2020Member_-Fh8SrRC9kSsK069fXrH7w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_7ArEH66oVkitmRSbkNKiQQ">3,092,603</ix:nonFraction> shares of common stock under the 2020 Sales Agreement at a weighted average price per share of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_6ZVfdDCn5UCsvmo46quH_A" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_glyc_AtMarketOffering2020Member_MXBe8LOc-0ysVhlt9Db4Nw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_vxMaHCgXSUyN3NoZ0peNXw">3.57</ix:nonFraction>, for aggregate net proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_glyc_AtMarketOffering2020Member_-Fh8SrRC9kSsK069fXrH7w" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="Narr_BYUI3qvoeU6S95K4Ro4UAw">10.7</ix:nonFraction> million, after deducting commissions and offering expenses. As of December 31, 2021, approximately $<ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_glyc_AtMarketOffering2020Member_MXBe8LOc-0ysVhlt9Db4Nw" decimals="-5" format="ixt:numdotdecimal" name="glyc:CommonStockValueAvailableForSaleUnderAgreement" scale="6" id="Narr_qX3h7svN1UGCrKfoYVHYgg">85.1</ix:nonFraction> million remained available to be sold under the terms of the 2020 Sales Agreement. Subsequent to December 31, 2021 and through the date these financial statements were issued, there have been <ix:nonFraction unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA" contextRef="Duration_1_1_2022_To_1_1_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_glyc_AtMarketOffering2020Member_G7FlJg156E25J7h_zCeUTQ" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_4kptEbljeE-w9IypnfjDpw">no</ix:nonFraction> additional sales under the 2020 Sales Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">2003 Stock Incentive Plan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">The 2003 Stock Incentive Plan (the 2003 Plan) provided for the grant of incentives and nonqualified stock options and restricted stock awards. The exercise price for incentive stock options must be at least equal to the fair value of the </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">86</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_WTI-TBaaakaeG0mAlfB51g_1_7"></a><a id="Tc_QTRrHbePbEuMeWqSiYRmQA_1_9"></a><a id="Tc_vYu-5Pp_ZEC3XEUmmAJF9A_2_4"></a><a id="Tc_lcrpc2_Cmki8Jtv9lOT3pQ_2_7"></a><a id="Tc_vYPRPjl_g0C9IwjZYo8s3g_2_9"></a><a id="Tc_Q-pwBkzj8022ukIRmeyQMA_3_4"></a><a id="Tc_8Kf536sjL0C9xsZIc96Dhg_3_7"></a><a id="Tc_yzontNzdhU6tWmVk66vMEA_3_9"></a><a id="Tc_6eIt9bwmmECyejhAL2RilQ_4_2"></a><a id="Tc_7Ih8XGqBm02O0wOEqQ4kSg_4_4"></a><a id="Tc_JZVw_jvaVk2cfahNHwXIdQ_4_7"></a><a id="Tc_Ij2YbWTLX0axDkNxzH1g8Q_4_9"></a><a id="Tc_5fhDmNC1F0ejowQLSbH_nQ_5_2"></a><a id="Tc_4_6240-TfUm1aFskE500zQ_5_4"></a><a id="Tc_qe37S-wDL0KRSL84md65yA_5_7"></a><a id="Tc_IdjJ18pNwkSH5IsgTa_6dg_5_9"></a><a id="Tc_Sf9K_ZpvAE2LI1Ir2Db14Q_6_0"></a><a id="Tc_uhG7FGbR_0-_FojkFXKfbA_6_4"></a><a id="Tc_AGYBtL3oAUqQBSTP9hFcnQ_7_0"></a><a id="Tc_jxNpQKuWrEuyXYJC79qB3A_8_0"></a><a id="Tc_KaBZMPydR0iPTIu4mqI0yg_8_2"></a><a id="Tc_K1VDvF-4BkaOslRl_J1jNA_8_5"></a><a id="Tc_rcyFmZHH8UiOV-TV8v9bZg_9_0"></a><a id="Tc_ZTV_3pBTwESbTQOF47D0xg_9_9"></a><a id="Tc_Q8swLLvIeEe0LE0QnSBrTQ_9_10"></a><ix:continuation id="Tb_Ohclz55C50-VwnTSfGuopw_cont1" continuedAt="Tb_Ohclz55C50-VwnTSfGuopw_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">common stock on the grant date. Unless otherwise stated in a stock option agreement, <ix:nonFraction unitRef="Unit_Standard_pure_o6l_rGctYUCSP0KoHptHcQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_cofTMv8PCkK6kTIv_T7Wfg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="Narr_EuiMN0RshEq-i0f4owUk0g">25</ix:nonFraction>% of the shares subject to an option grant will vest upon the first anniversary of the vesting start date and thereafter at the rate of one <span style="-sec-ix-hidden:Hidden_UfZmMD43P0CtU_nlwGEAYQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">forty</span></span>-eighth of the option shares per month as of the first day of each month after the first anniversary. Upon termination of employment by reasons other than death, cause, or disability, any vested options shall terminate <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member_jeH3ukS87UGj2TpOqDjAFA" format="ixt-sec:durwordsen" name="glyc:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment" id="Narr_hG_1iw7RmEWJuZBAK1bxMQ">60 days</ix:nonNumeric> after the termination date. Stock options terminate <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member_jeH3ukS87UGj2TpOqDjAFA" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_HtRl2N0VbUyONNIKZHQjjA">10 years</ix:nonNumeric> from the date of grant. The 2003 Plan expired on May&#160;21, 2013.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">A summary of the Company&#8217;s stock option activity under the 2003 Plan for the year ended December 31, 2021 is as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member_jeH3ukS87UGj2TpOqDjAFA" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="Tb_1YvPUJpYe02r1uQwTj1Tag" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">WEIGHTED-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AGGREGATE</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">WEIGHTED-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AVERAGE</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">INTRINSIC</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AVERAGE</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">REMAINING</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">VALUE</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OUTSTANDING</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EXERCISE</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CONTRACTUAL</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(IN</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OPTIONS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">PRICE</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">TERM&#160;(YEARS)</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">THOUSANDS)</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA" contextRef="As_Of_12_31_2020_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member_CPK9V-Op3UaIxCwH7D8lOQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_PNd32rBZ40uNWHjDhfxKMw_6_2">97,250</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_6ZVfdDCn5UCsvmo46quH_A" contextRef="As_Of_12_31_2020_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member_CPK9V-Op3UaIxCwH7D8lOQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_1skJsyiXk0yvEodPPomjCQ_6_5">1.96</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member_63yRM8kz2kC7BUq4_p_EHA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_f_1WQFakhE237PoBAmahGA_6_7"> 1.3</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Options exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member_jeH3ukS87UGj2TpOqDjAFA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_U9n8ftkq6k2mNMl_YqR8Bw_7_2">3,785</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_6ZVfdDCn5UCsvmo46quH_A" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member_jeH3ukS87UGj2TpOqDjAFA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_wtiPwDqC-kuua2mbMS2ubQ_7_5">1.12</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Options forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_CPAQxqLmSEmNCmGKblFleQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Outstanding</span></span>, Vested and Exercisable as of <span style="-sec-ix-hidden:Hidden_fSABMxeS7UGMQu4eqOoECg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">December&#160;31,&#160;2021</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA" contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member_qc5DeeGdL02LALGoxVJG1g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_ZkvlvjeYwUGBizAl_H3-Wg_9_2">93,465</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_6ZVfdDCn5UCsvmo46quH_A" contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member_qc5DeeGdL02LALGoxVJG1g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_9UenKl5-ukaucFQWyRPIkQ_9_5">2.00</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member_jeH3ukS87UGj2TpOqDjAFA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="Tc_Osc96gGX5kakgU9jcJxfkg_9_7"> 0.3</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:6pt 0pt 6pt 0pt;">During 2021, 2020 and 2019 the Company issued <ix:nonFraction unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member_jeH3ukS87UGj2TpOqDjAFA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Narr_D6l4DsgMU0WEE9eUrJ5XZA">3,785</ix:nonFraction>, <ix:nonFraction unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member_63yRM8kz2kC7BUq4_p_EHA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Narr_9AjluZJ0gUyxAHUFBm2QcQ">285,087</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member_5mpVmM87DESzmaMO4y48HQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Narr_1st0rDVn-kuMNdSZyKgSew">284,743</ix:nonFraction> shares of common stock, respectively, in conjunction with exercises of stock options granted under the 2003 Plan. The Company received cash proceeds from the exercise of these stock options of $<ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member_jeH3ukS87UGj2TpOqDjAFA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="0" id="Narr_F4kKfe8YKUmqtKtvayOfgg">4,239</ix:nonFraction>, $<ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member_63yRM8kz2kC7BUq4_p_EHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="0" id="Narr_O0djUbZCsEyMi0rA5tMw2w">319,297</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member_5mpVmM87DESzmaMO4y48HQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="0" id="Narr_-4uC71dLEEi21GdjFOhz8Q">318,912</ix:nonFraction> during 2021, 2020 and 2019, respectively. Total intrinsic value of the options exercised during the years ended December 31, 2021, 2020 and 2019 was $<ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member_jeH3ukS87UGj2TpOqDjAFA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="0" id="Narr_l_hRRwMgiE284Pu7JgjIlg">8,668</ix:nonFraction>, $<ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member_63yRM8kz2kC7BUq4_p_EHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="0" id="Narr_pPO2VMB5O0OMUxpoRUP8JA">921,168</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member_5mpVmM87DESzmaMO4y48HQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="0" id="Narr_Kz6vgnZKbkmEvZXKuv8jqA">924,688</ix:nonFraction>, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">As of December 31, 2021, the options under the 2003 Plan were fully expensed and all options outstanding under the 2003 Plan were fully vested. There were <ix:nonFraction unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member_5mpVmM87DESzmaMO4y48HQ" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_eyOUNIpHDEuwt_NzWIhNkQ"><ix:nonFraction unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member_63yRM8kz2kC7BUq4_p_EHA" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr__KVXk1moKU2d4LqJdEq3Ag"><ix:nonFraction unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member_jeH3ukS87UGj2TpOqDjAFA" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_ZiqrTjjEDkqjCfkqvFL0zA">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> options granted under the 2003 Plan in 2021, 2020 and 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">2013 Equity Incentive Plan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">The Company&#8217;s board of directors adopted, and its stockholders approved, its 2013 Equity Incentive Plan (the 2013 Plan) effective on January 9, 2014. The 2013 Plan provides for the grant of incentive stock options within the meaning of Section&#160;422 of the Internal Revenue Code (the Code), to the Company&#8217;s employees and its parent and subsidiary corporations&#8217; employees, and for the grant of nonstatutory stock options, restricted stock awards, restricted stock unit awards, stock appreciation rights, performance stock awards and other forms of stock compensation to its employees, including officers, consultants and directors. The 2013 Plan also provides for the grant of performance cash awards to the Company&#8217;s employees, consultants and directors. Unless otherwise stated in a stock option agreement, <ix:nonFraction unitRef="Unit_Standard_pure_o6l_rGctYUCSP0KoHptHcQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_oJ50QEhRZ06VPJ26jZEX3Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="Narr_q6mv2u0jpUy0ZtFzjVJUiw">25</ix:nonFraction>% of the shares subject to an option grant will typically vest upon the first anniversary of the vesting start date and thereafter at the rate of one <span style="-sec-ix-hidden:Hidden_MpFfxPM_9Uq0Hhwoua9x4Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">forty</span></span>-eighth of the option shares per month as of the first day of each month after the first anniversary. Upon termination of employment by reasons other than death, cause, or disability, any vested options shall terminate <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_eZd6RRkvHUKXyt8ofzDQvA" format="ixt-sec:durwordsen" name="glyc:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment" id="Narr_QEOkgkbltEuVMGRQeJoazA">90 days</ix:nonNumeric> after the termination date, unless otherwise set forth in a stock option agreement. Stock options generally terminate <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_eZd6RRkvHUKXyt8ofzDQvA" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_6pnRzAnQdE-mkTCJZnYMDw">10 years</ix:nonNumeric> from the date of grant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><i style="font-style:italic;">Authorized Shares</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">The maximum number of shares of common stock that may be issued under the 2013 Plan was <ix:nonFraction unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA" contextRef="As_Of_1_9_2014_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_d0xG-7CT90iIt0iDg2j1hA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_H1tXXdL2l0WfVo0GxbDVNw">1,000,000</ix:nonFraction>&#160;shares, plus any shares subject to stock options or similar awards granted under the 2003 Plan that expire or terminate without having been exercised in full or are forfeited to or repurchased by the Company. The number of shares of common stock reserved for issuance under the 2013 Plan will automatically increase on January&#160;1 of each year, beginning on January&#160;1, 2015 and ending on January&#160;1, 2023, by <ix:nonFraction unitRef="Unit_Standard_pure_o6l_rGctYUCSP0KoHptHcQ" contextRef="As_Of_1_9_2014_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_d0xG-7CT90iIt0iDg2j1hA" decimals="2" format="ixt:numdotdecimal" name="glyc:PercentageOfTotalNumberOfCommonStockOutstandingOnLastBusinessDayOfPriorFiscalYearThatMayAutomaticallyIncreaseUnderPlan" scale="-2" id="Narr_j3BB9QfInEqRv036aZsWvw">3</ix:nonFraction>% of the total number of shares of common stock outstanding on December&#160;31 of the preceding calendar year, or a lesser number of shares as may be determined by the Company&#8217;s board of directors. The maximum number of shares that may be issued pursuant to exercise of incentive stock options under the 2013 Plan is <ix:nonFraction unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA" contextRef="As_Of_1_9_2014_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_d0xG-7CT90iIt0iDg2j1hA" decimals="INF" format="ixt:numdotdecimal" name="glyc:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMaximumSharesIssuedUponExerciseOfIncentiveStockOptions" scale="0" id="Narr_SJuGqMkxIkyK615ZTYe9dw">20,000,000</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">Shares issued under the 2013 Plan may be authorized but unissued or reacquired shares of common stock. Shares subject to stock awards granted under the 2013 Plan that expire or terminate without being exercised in full, or that are paid out in cash rather than in shares, will not reduce the number of shares available for issuance under the 2013 Plan. Additionally, shares issued pursuant to stock awards under the 2013 Plan that the Company repurchases or that are </p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">87</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_oGtg7Yn-A0ScKNCok4IYpg_1_7"></a><a id="Tc_2BhaqZ0A8Equ8wyncYYICQ_1_9"></a><a id="Tc_EleuAgHOAkuGgVDqhxTfAQ_2_4"></a><a id="Tc_RaHj79pYFEaTqmB3_xWfzA_2_7"></a><a id="Tc_BJB-we1lh0OmagNLlDXPTA_2_9"></a><a id="Tc_Te-BxFofe0KTyisWWEGtpw_3_4"></a><a id="Tc_wyevMRTxgEaGKDURVQq4EQ_3_7"></a><a id="Tc_hBrDLrikbUKx88xWdbM0lw_3_9"></a><a id="Tc_IvyJIX3jwE-Of1Kw6ZyjDg_4_2"></a><a id="Tc_YLUGRDzjgEKUYjB5oN2AuQ_4_4"></a><a id="Tc_ntQtRXZ-m0aUtkSb82gOsQ_4_7"></a><a id="Tc_W8oLI0BLFUqQ4IxxNcWeDA_4_9"></a><a id="Tc_h5J-cRblbkubSFb-HdpnOA_5_2"></a><a id="Tc_ev1G6N8hSkyO6UOkjXmw1w_5_4"></a><a id="Tc_Fo7_hNg17USNbPL5jzOsSQ_5_7"></a><a id="Tc_PbdDdojYakK31BRvCcEiLQ_5_9"></a><a id="Tc_Za2GIM5eQUGu-77WAHTbrw_6_0"></a><a id="Tc_VMdZhcWwPE-6NPCslz2JZQ_6_4"></a><a id="Tc_pIeUGGo3Kk6kXLgc_AXDDA_7_0"></a><a id="Tc_Ft2ah6cWY0-P_YTqbUok9w_8_0"></a><a id="Tc_EsZT9lKn3kSSXwJpun4m6Q_8_2"></a><a id="Tc_RlnWU3mwFEKtdOavHHM9ag_8_5"></a><a id="Tc_JAiVB8Cgm0ODjZB0ogPuew_9_0"></a><a id="Tc_iwOy3lG1eki2HQburnZQTA_10_0"></a><a id="Tc_BK-mF0i710eWM4pDOot5hg_10_9"></a><a id="Tc_9z_RlSLKB0-KDlr8t8Q3yQ_10_10"></a><a id="Tc_WmI2lx3-Ek64WMKmVv4WdQ_11_0"></a><a id="Tc_7knEv6jFw0yCoFUOQ1A6Eg_11_10"></a><a id="Tc_1eC69dzd_UC4qmjKpNF5lw_12_0"></a><a id="Tc_F396vQYO8UKxtrNy_0gjkA_12_10"></a><a id="_6a2cdf49_9716_47f2_b295_eca83bf595b2"></a><a id="Tc_F-EQgY1tP0635bN5dXbu7A_1_4"></a><a id="Tc_1ARr7feyWkCuQ-ubvV77XQ_2_2"></a><a id="Tc_TbIULvHm1UiL_5_n4kKGkA_2_4"></a><a id="Tc_MP3II4aqQUya9pgG7sR9LQ_3_2"></a><a id="Tc_MT6y4Nzu50K15AGyvXmhYg_3_4"></a><a id="Tc_XMoth2k3XEGzhT2EU3Wf1A_4_0"></a><a id="Tc_KUeYJCeLI0itzBJSCw-9CQ_4_4"></a><a id="Tc_-xu3mu2-xEy0chut7q0WPw_5_0"></a><a id="Tc_GuBam1lE2kiyoCCLv26F0Q_6_0"></a><a id="Tc_k5EvgUxnbk-6KKKUd95GJA_7_0"></a><a id="Tc_lsX0SI2JxEmGbVHzEHo05g_8_0"></a><ix:continuation id="Tb_Ohclz55C50-VwnTSfGuopw_cont2" continuedAt="Tb_Ohclz55C50-VwnTSfGuopw_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">forfeited, as well as shares reacquired by the Company as consideration for the exercise or purchase price of a stock award or to satisfy tax withholding obligations related to a stock award, will become available for future grant under the 2013 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><i style="font-style:italic;">Stock Options</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">A summary of the Company&#8217;s stock option activity under the 2013 Plan for the year ended December&#160;31, 2021 is as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_eZd6RRkvHUKXyt8ofzDQvA" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="Tb_VUPdjkiiy0-BM53Ut6xjXw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">WEIGHTED-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AGGREGATE</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">WEIGHTED-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AVERAGE</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">INTRINSIC</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AVERAGE</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">REMAINING</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">VALUE</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OUTSTANDING</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EXERCISE</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CONTRACTUAL</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(IN</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OPTIONS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">PRICE</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">TERM&#160;(YEARS)</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">THOUSANDS)</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA" contextRef="As_Of_12_31_2020_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_6XsGrPnc8UiemnfhfN3QiA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_6SbS1cQ_B0q1dIO8IOcu4A_6_2">5,753,211</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_6ZVfdDCn5UCsvmo46quH_A" contextRef="As_Of_12_31_2020_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_6XsGrPnc8UiemnfhfN3QiA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_tg67UBqgWkW6BjxclmAvIw_6_5">8.93</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_NttqVJp3_kWhhS50-PEXsg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_upYDtWrTQ0KyxZbHM93mBw_6_7"> 6.6</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Options granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_eZd6RRkvHUKXyt8ofzDQvA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc__KibyzseyEmul7oWPvfKUA_7_2">898,100</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_6ZVfdDCn5UCsvmo46quH_A" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_eZd6RRkvHUKXyt8ofzDQvA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_ZDIKdCYa0EaqBZ-BYHNzHQ_7_5">3.70</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Options exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Options forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_eZd6RRkvHUKXyt8ofzDQvA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="Tc_3T0N3aTMM02wvMkrgcEAEA_9_2">995,854</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_6ZVfdDCn5UCsvmo46quH_A" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_eZd6RRkvHUKXyt8ofzDQvA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_c5YF6Qfcb0-v0y9vo-VJ-w_9_5">7.89</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA" contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_bi2yzHjMgEqMF9n2Whpj0Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_1QWR-eryHU--kbkVwuzoog_10_2">5,655,457</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_6ZVfdDCn5UCsvmo46quH_A" contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_bi2yzHjMgEqMF9n2Whpj0Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_1m-pxS8MQUq2FlWLDlvmEQ_10_5">8.30</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_eZd6RRkvHUKXyt8ofzDQvA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_qKy8E-MQK06woQYvWnIuMA_10_7">6.0</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested or expected to vest as of December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA" contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_bi2yzHjMgEqMF9n2Whpj0Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" id="Tc_puveDXGAg0S1gHx-6cUbxw_11_2">5,655,457</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_6ZVfdDCn5UCsvmo46quH_A" contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_bi2yzHjMgEqMF9n2Whpj0Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_9xN1-y9a3k61Za9spOuCGQ_11_5">8.30</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_eZd6RRkvHUKXyt8ofzDQvA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="Tc_H7O3kHuowk6qzEM4qPVtEQ_11_7">6.0</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:45.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercisable as of December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA" contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_bi2yzHjMgEqMF9n2Whpj0Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="Tc_yyjaespr3EOnpuxBVrwLvw_12_2">4,118,394</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_6ZVfdDCn5UCsvmo46quH_A" contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_bi2yzHjMgEqMF9n2Whpj0Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Tc_y3dVgcDBw0eDcb_lmjulQQ_12_5">9.43</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_eZd6RRkvHUKXyt8ofzDQvA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="Tc_fZTwlQBFE0GjuuchNWZHaQ_12_7">5.1</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">As of December 31, 2021, there was $<ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_bi2yzHjMgEqMF9n2Whpj0Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="0" id="Narr_KF5o-vvIwUi-fEhwt1zTUg">4,936,519</ix:nonFraction> of total unrecognized compensation expense related to unvested options that will be recognized over a weighted-average period of approximately <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_eZd6RRkvHUKXyt8ofzDQvA" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Narr_31Lg0OattE6e4VEOJD62AA">2.0</ix:nonNumeric> years. The total fair value of options that vested in the years ended December 31, 2021, 2020 and 2019 was $<ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_eZd6RRkvHUKXyt8ofzDQvA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="0" id="Narr_qX-mmXMfBEW-tdrOjaxtvA">5,936,641</ix:nonFraction>, $<ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_NttqVJp3_kWhhS50-PEXsg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="0" id="Narr_or52JQ6OYk2P37JQpF-9nA">7,347,548</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_8PxguNi7E0SE41ALnvi46Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="0" id="Narr_C92_q_AX_0-3ggOGOv6zEQ">6,159,610</ix:nonFraction>, respectively. There were <ix:nonFraction unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_NttqVJp3_kWhhS50-PEXsg" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Narr_88uXqtecvkSwTvntHCN-0w"><ix:nonFraction unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_eZd6RRkvHUKXyt8ofzDQvA" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Narr_HjnBrgi3W0utyWnkgyuXeA">no</ix:nonFraction></ix:nonFraction> options exercised under the 2013 Plan during the years ended December 31, 2021 or 2020. During the year ended December 31, 2019, the Company received cash of $<ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_8PxguNi7E0SE41ALnvi46Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="0" id="Narr_TiMCsJgpGk-Telsq3_BEUw">94,001</ix:nonFraction> and issued <ix:nonFraction unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_8PxguNi7E0SE41ALnvi46Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_EPM5Df7lvUq5bsIz9RG9Ow">16,606</ix:nonFraction> shares of common stock in conjunction with exercises of stock options granted under the 2013 Plan. The intrinsic value of the options exercised for the year ended December 31, 2019 was $<ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_8PxguNi7E0SE41ALnvi46Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="0" id="Narr_RyMAXLBMhUO-Fsr9sDdrpQ">97,429</ix:nonFraction>. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><i style="font-style:italic;">Restricted Stock Units (RSUs)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">A restricted stock unit (RSU) is a stock award that entitles the holder to receive shares of the Company&#8217;s common stock as the award vests. The fair value of each RSU is based on the closing price of the Company&#8217;s common stock on the date of grant. In January 2021, the Company awarded RSUs under the 2013 Plan to all of its employees. The RSUs granted vest over <ix:nonNumeric contextRef="Duration_1_1_2021_To_1_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_LrXUfN_p-k2RD7cVXcpvfg" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_uEfnpdv6I026kWbPuxd-gQ">four years</ix:nonNumeric> in equal installments on each anniversary of the grant date. In September 2019, the Company granted an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA" contextRef="Duration_9_1_2019_To_9_30_2019_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_GTVLQ6MzkE-5qigN7ZgeAg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Narr_tJ5ExGt2eUG9mnjhjWmLoA">332,106</ix:nonFraction> RSUs with service conditions to the Company&#8217;s non-executive employees. The RSUs granted in September 2019 vested over a <ix:nonNumeric contextRef="Duration_9_1_2019_To_9_30_2019_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_GTVLQ6MzkE-5qigN7ZgeAg" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_asvxjGNCME2neohLtFcHCA">two-year</ix:nonNumeric> period, with <span style="-sec-ix-hidden:Hidden_PGLZbIA_j0-ItwYMfmgcfA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span>-third vesting on the first anniversary of the date of grant and the remaining <span style="-sec-ix-hidden:Hidden_BnTvpBXF9EKtCoC_jLU41A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">two</span></span>-thirds vesting on the second anniversary of the date of grant, provided that the employee remained employed with the Company at the applicable vesting date. Compensation expense is recognized on a straight-line basis. As of December 31, 2021, there was $<ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_hGgbCUWxnEO5H7nrY_ZOdA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="0" id="Narr_xCd6pHNCYEqqOPX-OjoZ9w">943,458</ix:nonFraction> of total unrecognized compensation expense associated with these RSU grants that will be recognized over a weighted-average period of approximately <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_F6fULr1eMk6oFlHq__Rahw" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Narr_PeFMo7Se9kyU-P6yvxBfcA">3.0</ix:nonNumeric> years.</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_eZd6RRkvHUKXyt8ofzDQvA" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" id="Tb_d49b3XTibkW7KBeNcW4cew" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">The following is a summary of RSU activity for the 2013 Plan for the year ended December 31, 2021:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Grant Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Underlying RSUs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unvested at December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA" contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_TvjyyCwqk0mi8fnukedXiQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_YTiEEKj1qUa5gIqCE-qkMA_4_2">192,533</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_6ZVfdDCn5UCsvmo46quH_A" contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_TvjyyCwqk0mi8fnukedXiQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_jkyi0JTnUEq4b3_7um77NQ_4_5">4.53</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_LNH3eNmn5kWst66eRhnJGQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Tc_oYinc6NMK0WGFcmFva0gRg_5_2">444,613</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_6ZVfdDCn5UCsvmo46quH_A" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_LNH3eNmn5kWst66eRhnJGQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_KWMFjTtx-kmot9QXJSWN-A_5_5">3.72</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_LNH3eNmn5kWst66eRhnJGQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="Tc_KAH68dx_AE-6uMABzvUwFg_6_2">101,754</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_6ZVfdDCn5UCsvmo46quH_A" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_LNH3eNmn5kWst66eRhnJGQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="Tc_qMDuvCSRqUeLG0zZ4__Rsw_6_5">3.84</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_LNH3eNmn5kWst66eRhnJGQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="Tc_LC0rCm30GEegC5xepMvQJg_7_2">189,792</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_6ZVfdDCn5UCsvmo46quH_A" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_LNH3eNmn5kWst66eRhnJGQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_bEnHFcyOK0q2hkF8MQ5zLg_7_5">4.53</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unvested at December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_v6BAgvQ6UUWIq_blSFIw4Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_JDQUQD280UOWxAw64hlb1g_8_2">345,600</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_6ZVfdDCn5UCsvmo46quH_A" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_v6BAgvQ6UUWIq_blSFIw4Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_4MZOchggYU-1qq9ypHM6-Q_8_5">3.70</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Inducement Plan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">In January 2020, the Company&#8217;s board of directors adopted the GlycoMimetics, Inc. Inducement Plan (the Inducement Plan). The Inducement Plan provides for the grant of nonstatutory stock options, restricted stock awards, restricted stock unit awards, stock appreciation rights and other forms of stock awards to individuals not previously an </p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">88</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_LNJizEC7Zka8KPEJRAekGQ_1_7"></a><a id="Tc_XXiroN-MjUqArE__0g-aOA_1_9"></a><a id="Tc_lCSwfg4q5k-Cv7V2f-T-_g_2_4"></a><a id="Tc_WfTiKRHNsk6ilsLDHQ_4Qw_2_7"></a><a id="Tc_aTOd9ctVmUSprj6eK0reMQ_2_9"></a><a id="Tc_LmDJ3eH8H0uUidKdPt4QLA_3_4"></a><a id="Tc_XUNt8zdt4Ee4l80o98mr5Q_3_7"></a><a id="Tc_KxeZqp9s4EyAY2boEkLmVw_3_9"></a><a id="Tc_cjM7prApp06xdhE2xinZYA_4_2"></a><a id="Tc_tXRLrDNiQkCOIFfcnuuRmA_4_4"></a><a id="Tc_2Jb3h59SB0iyPzMjtBd34w_4_7"></a><a id="Tc_xjiCl3XyP02iZ0DF3WHELw_4_9"></a><a id="Tc__qyAbeyhDEeFvHsfayS_qw_5_2"></a><a id="Tc_j4h1extI70ePlX69S1jwew_5_4"></a><a id="Tc_YfnIZpjXS0GRrSAZufy5lA_5_7"></a><a id="Tc_D49MOWWHp0G2eEpCArODXQ_5_9"></a><a id="Tc_bPRdQ7pUTkGWuJFHyj2V9g_6_0"></a><a id="Tc_neM0rLZ-YUGDWnXbaUTblA_6_4"></a><a id="Tc_u47Q_xoQ6EiAaTOGU8XlQw_7_0"></a><a id="Tc_DBPYCne4tUeXRUoCuyRItQ_8_0"></a><a id="Tc_SUUPrMJuiEeAPzrZ-G2cnA_9_0"></a><a id="Tc_0Si7BwAqL0Kd_LEczuDAeA_10_0"></a><a id="Tc_0a3F97H4kUmAuegA95T02w_10_9"></a><a id="Tc_4XkaeKvGBUKmrudaofUWjg_10_10"></a><a id="Tc_-u77CaDIGkGnvdBQSTTvPg_11_0"></a><a id="Tc_lcGDLXbMyUqnqgkJ3CDOkQ_11_10"></a><a id="Tc_Aa9QVk7-G0yVaJNqH-ccow_12_0"></a><a id="Tc_sxEDEqYTGk6Sncsxeeo3aA_12_10"></a><ix:continuation id="Tb_Ohclz55C50-VwnTSfGuopw_cont3" continuedAt="Tb_Ohclz55C50-VwnTSfGuopw_cont4"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;">employee or director of the Company as an inducement for such individuals to join the Company. Unless otherwise stated in an applicable stock option agreement, </span><span style="-sec-ix-hidden:Hidden_CUsjKSRwVk28fq-bDbXrTw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span><span style="font-size:10pt;">-fourth of the shares subject to an option grant under the Inducement Plan will typically vest upon the first anniversary of the vesting start date, with the balance of the shares vesting in a series of </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_installment_ezhGoeeUrke0O6iEcwxJow" contextRef="Duration_1_1_2020_To_1_31_2020_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_Ni5UYq-FH06wJXsy0UsclA" decimals="INF" format="ixt-sec:numwordsen" name="glyc:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfMonthlyInstallments" scale="0" id="Narr_dYAMbdb7YEeTGLmxvFoCPQ">thirty-six</ix:nonFraction></span><span style="font-size:10pt;"> successive equal monthly installments as of the first day of each month measured from the first anniversary of the vesting start date, subject to the new employee&#8217;s continued service with the Company through the applicable vesting dates. Upon termination of employment by reasons other than death, cause or disability, any vested options will terminate </span><ix:nonNumeric contextRef="Duration_1_1_2020_To_1_31_2020_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_Ni5UYq-FH06wJXsy0UsclA" format="ixt-sec:durwordsen" name="glyc:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment" id="Narr_nTJvaIbL0k-W4l5GG4ttgg"><span style="font-size:10pt;">90 days</span></ix:nonNumeric><span style="font-size:10pt;"> after the termination date, unless otherwise set forth in a stock option agreement. Stock options generally terminate </span><ix:nonNumeric contextRef="Duration_1_1_2020_To_1_31_2020_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_OL9RAaPvWESWUYV6Drys3g" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_pxQYiWSDsUSN8UCY5Ct3Uw"><span style="font-size:10pt;">10 years</span></ix:nonNumeric><span style="font-size:10pt;"> from the date of grant. There were </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA" contextRef="As_Of_1_31_2020_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_1T-jaCj3OkSylxW_fFHbkQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_OJAtGCmjKUC7al7TSE4LKQ">500,000</ix:nonFraction></span><span style="font-size:10pt;"> shares of common stock reserved under the Inducement Plan at its adoption date. In August 2021, the Company&#8217;s board of directors adopted an amendment to the Inducement Plan to increase the number of shares reserved to </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_GhGdoDUAg0O8Z5VKpubXGw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" id="Narr_zsEhyK9nG0qV6_K-U6BPuA">2,000,000</ix:nonFraction></span><span style="font-size:10pt;"> shares, and in January 2022 the Company&#8217;s board of directors adopted an amendment to the Inducement Plan to further increase the number of shares reserved to </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA" contextRef="Duration_1_1_2022_To_1_31_2022_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_kGIqsGlMMESnv3YKbnouEg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" id="Narr_WjN1aFBRMEuLUVzQfoLn1w">3,000,000</ix:nonFraction></span><span style="font-size:10pt;"> shares. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">A summary of the Company&#8217;s stock option activity under the Inducement Plan for the year ended December 31, 2021 is as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_GhGdoDUAg0O8Z5VKpubXGw" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="Tb_pDjtUOwCSUmNDr2v-Xn_Kw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#0000ff;font-size:14pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">WEIGHTED-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AGGREGATE</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">WEIGHTED-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AVERAGE</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">INTRINSIC</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AVERAGE</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">REMAINING</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">VALUE</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OUTSTANDING</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EXERCISE</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CONTRACTUAL</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(IN</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OPTIONS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">PRICE</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">TERM&#160;(YEARS)</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">THOUSANDS)</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA" contextRef="As_Of_12_31_2020_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_NxJ0kAmhLEq77boNzSrSDA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_Dt4ESSR1I02cgScS-_BhAw_6_2">100,600</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_6ZVfdDCn5UCsvmo46quH_A" contextRef="As_Of_12_31_2020_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_NxJ0kAmhLEq77boNzSrSDA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_cXi06vDx-UOrBcorXgn7TQ_6_5">3.09</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_0GYTC9bcFEKmU7vQ3oHIOA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_E2DIj0cQmkS_4yyssA5tNg_6_7"> 9.5</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Options granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_GhGdoDUAg0O8Z5VKpubXGw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_VRPAuBFw_k2J3-7QMEK32w_7_2">1,747,600</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_6ZVfdDCn5UCsvmo46quH_A" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_GhGdoDUAg0O8Z5VKpubXGw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_nG2F162atUOZBQ2aANgC5Q_7_5">2.02</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Options exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_GhGdoDUAg0O8Z5VKpubXGw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_HtH23ot7N0m5GrvqEFfqsA_8_2">10,092</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_6ZVfdDCn5UCsvmo46quH_A" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_GhGdoDUAg0O8Z5VKpubXGw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_asTZgoDU6ESP6OfmzECoKA_8_5">2.06</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Options forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_GhGdoDUAg0O8Z5VKpubXGw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="Tc_ofNafTptS02XJqPhm_M9wg_9_2">24,508</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_6ZVfdDCn5UCsvmo46quH_A" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_GhGdoDUAg0O8Z5VKpubXGw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_-qZfOVEzN0eKnBfN2FMkBQ_9_5">2.06</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA" contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_K6ogEy0tQUqO5CmxYBaQzw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_JLAFZIDQbE-HKMk6G1Yzgw_10_2">1,813,600</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_6ZVfdDCn5UCsvmo46quH_A" contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_K6ogEy0tQUqO5CmxYBaQzw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_M4eI31NV40SIQxrqUPFxPg_10_5">2.08</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_GhGdoDUAg0O8Z5VKpubXGw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_wtwpwaDRg0SJvut_N4VHsw_10_7">9.6</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested or expected to vest as of December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA" contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_K6ogEy0tQUqO5CmxYBaQzw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" id="Tc_1ns2SqhMaEaeQdX2xmhSKA_11_2">1,264,400</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_6ZVfdDCn5UCsvmo46quH_A" contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_K6ogEy0tQUqO5CmxYBaQzw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_nJTcz7-a0kC12IBQDAB5gg_11_5">2.10</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_GhGdoDUAg0O8Z5VKpubXGw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="Tc_x4TIOOlagUSEu4uZ9e3k-g_11_7">9.6</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:45.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercisable as of December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA" contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_K6ogEy0tQUqO5CmxYBaQzw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="Tc_uHAOAdUSpEmPabD7xNtOew_12_2">22,879</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_6ZVfdDCn5UCsvmo46quH_A" contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_K6ogEy0tQUqO5CmxYBaQzw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Tc_vc8yX0SDd0KGNNWhhD9LNg_12_5">3.58</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_GhGdoDUAg0O8Z5VKpubXGw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="Tc_m5DVBgCrnkCcThyBSomD7g_12_7">8.6</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:6pt 0pt 6pt 0pt;">As of December 31, 2021, there was $<ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_K6ogEy0tQUqO5CmxYBaQzw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="0" id="Narr_Fmw7xqsp_0-HVjXKPBR0gQ">1,672,270</ix:nonFraction> of total unrecognized compensation expense related to unvested options under the Inducement Plan that will be recognized over a weighted-average period of approximately <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_GhGdoDUAg0O8Z5VKpubXGw" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Narr_gd0xsb8nFUmBPBGj5ST1eA"><span style="white-space:pre-wrap;">3.6</span></ix:nonNumeric><span style="white-space:pre-wrap;"> years. In August 2021, the Company granted stock options to purchase an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA" contextRef="Duration_8_1_2021_To_8_31_2021_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_BlzQN5DfO0-Ob94oAMtNUQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_q6K_9D4DZ0yA1fHPwKPtYA">1,647,600</ix:nonFraction> shares to its new Chief Executive Officer under the Inducement Plan. This consisted of (a) an option to purchase <ix:nonFraction unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA" contextRef="Duration_8_1_2021_To_8_31_2021_us-gaap_AwardTypeAxis_glyc_StockOptionsVestingBasedOnServiceMember_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_pYIDtpqKaEq0Rg2wBD-AaA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_qchedrdUIkayvg_M4L6tCg">1,098,400</ix:nonFraction> shares, subject to vesting as to <ix:nonFraction unitRef="Unit_Standard_pure_o6l_rGctYUCSP0KoHptHcQ" contextRef="Duration_8_1_2021_To_8_31_2021_us-gaap_AwardTypeAxis_glyc_StockOptionsVestingBasedOnServiceMember_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_pYIDtpqKaEq0Rg2wBD-AaA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="Narr_eEklIilKukS1X34sfkaTgw">25</ix:nonFraction>% of the underlying shares on August 3, 2022 and as to the remaining underlying shares in equal monthly installments over </span><ix:nonNumeric contextRef="Duration_8_1_2021_To_8_31_2021_us-gaap_AwardTypeAxis_glyc_StockOptionsVestingBasedOnServiceMember_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_pYIDtpqKaEq0Rg2wBD-AaA" format="ixt-sec:durwordsen" name="glyc:ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingUnderlyingSharesVestPeriod" id="Narr_2PJ3kHWbzEmGr5ADrqRsEg"><span style="white-space:pre-wrap;">36 months</span></ix:nonNumeric><span style="white-space:pre-wrap;"> thereafter, subject to the officer&#8217;s continued service through each such vesting date, and (b) an option to purchase <ix:nonFraction unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA" contextRef="Duration_8_1_2021_To_8_31_2021_us-gaap_AwardTypeAxis_glyc_StockOptionsVestingBasedOnPerformanceMember_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_1HlplHgnqkyMSMXLECvRKw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_CCALcnvHH0alGn9IftgK8Q">549,200</ix:nonFraction> shares that is subject to performance vesting conditions and will vest upon achievement of milestones as follows: (i) </span><span style="-sec-ix-hidden:Hidden_wFFEp6_-yEedIq15Qcrr0w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">one</span></span><span style="white-space:pre-wrap;">-half of the shares will vest upon FDA approval of uproleselan in patients with relapsed/refractory acute myeloid leukemia and (ii) </span><span style="-sec-ix-hidden:Hidden_Asb0-jwP3ku8JnmG256I7Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">one</span></span><span style="white-space:pre-wrap;">-half of the shares will vest upon the first commercial sale of uproleselan in the United States or abroad. The maximum fair value of $<ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_glyc_StockOptionsVestingBasedOnPerformanceMember_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_fMP2VYCGhESofSQXDZURMQ" decimals="0" format="ixt:numdotdecimal" name="glyc:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFairValueOfOptionExcludedFromUnrecognizedCompensationExpense" scale="0" id="Narr_tL-ajuZf3Em8jqdLjlpjkA">798,053</ix:nonFraction> associated with the performance-based option is excluded from the unrecognized compensation expense under the Inducement Plan as the completion of the performance milestones are not probable as of December 31, 2021. The Company will reevaluate at the end of each reporting period the probability that the performance conditions will be achieved and record any compensation cost at that time.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:6pt 0pt 6pt 0pt;">The total fair value of options that vested in the year ended December 31, 2021 was $<ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_GhGdoDUAg0O8Z5VKpubXGw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="0" id="Narr_g5nsJ_AnK0ipdL0PurLboA">73,334</ix:nonFraction>. During the year ended December 31, 2021, the Company received cash of $<ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_GhGdoDUAg0O8Z5VKpubXGw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="0" id="Narr_WeWEus6-ZkqagO27xvUMRg">20,790</ix:nonFraction> and issued <ix:nonFraction unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_GhGdoDUAg0O8Z5VKpubXGw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" scale="0" id="Narr_Na790foF2UKXp-uJtgfnwQ">10,092</ix:nonFraction> shares of common stock in conjunction with exercises of stock options granted under the Inducement Plan. The intrinsic value of the options exercised for the year ended December 31, 2021 was $<ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_GhGdoDUAg0O8Z5VKpubXGw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="3" id="Narr_UNXiWgWch0KE0HSx0xcchA">1,944</ix:nonFraction>. There were <ix:nonFraction unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_0GYTC9bcFEKmU7vQ3oHIOA" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" scale="0" id="Narr_ZykJW2KW40--Rt0Yz6hAGA">no</ix:nonFraction> options vested or exercised under the Inducement Plan during the year ended December 31, 2020.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">89</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_JUE5-BOWFkigkD70CDAUIg_1_2"></a><a id="Tc_3SGIT6OlF0mgSrvMWYTGKg_1_4"></a><a id="Tc_pOmidcusJEWVKkTNdELivA_1_6"></a><a id="Tc_a7gqUhXk9U6W5BXLoBmhHg_2_0"></a><a id="Tc_l5Kp8eYNTkauqBRThNSKrg_2_2"></a><a id="Tc_4uKEZ-UB-0mxqUsyzobFdA_2_4"></a><a id="Tc_kDpNVCWVF0qbwm3NvEqQsQ_2_6"></a><a id="Tc_bjlqeJJog06grnmd8cMByg_3_0"></a><a id="Tc_41zP8HfgyEGkdj0bR9o4oQ_4_0"></a><a id="Tc_p7cXZH2pc0yq2oZnOj-7cg_5_0"></a><a id="Tc_V-9UO0QRy02zt7_S0BkcfQ_2_3"></a><a id="Tc_WRFPs4XfjEqhxka36OTPpA_2_6"></a><a id="Tc_WVCi2kwfo0Sh9Jsh_0XKjg_2_9"></a><a id="Tc_St8nkaYkYUa6yPZ76UkSLA_3_0"></a><a id="Tc_oISZCbG0ukymWx-pTkX0Hw_3_3"></a><a id="Tc_yf564j39MkiwotNrnefNrg_3_6"></a><a id="Tc_BK4vPvvIGE2U_0wGFWJGgA_3_9"></a><a id="Tc_l1bgYCQNOkCNr_tRL8X6kg_4_0"></a><a id="Tc_Fwosw_DCQU2IyD2URhD97A_5_0"></a><a id="Tc_Crrnwk8JBEuZSd8HuiQT-A_5_3"></a><a id="Tc_nRebDjFQkkqqvUzoVOGKOQ_5_6"></a><a id="Tc_vTiuRASBV0iWYrDVnTZeSg_5_9"></a><ix:continuation id="Tb_Ohclz55C50-VwnTSfGuopw_cont4"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">The weighted-average fair value of the options granted under all equity incentive plans during the years ended December&#160;31, 2021, 2020 and 2019 was $<ix:nonFraction unitRef="Unit_Divide_USD_shares_6ZVfdDCn5UCsvmo46quH_A" contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_SxEumOMznU6yWp1SrsCMVw">1.85</ix:nonFraction>, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_6ZVfdDCn5UCsvmo46quH_A" contextRef="Duration_1_1_2020_To_12_31_2020_n4dAyZdoqEGSie7qc7FpOQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_fn7eZtHKeUi2JhEydjsj0Q">3.17</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Divide_USD_shares_6ZVfdDCn5UCsvmo46quH_A" contextRef="Duration_1_1_2019_To_12_31_2019_pmIpEVmd-kmwrLI0XOvIXQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_3gjPD5yu10Oi6NVyXts50g">7.17</ix:nonFraction> per share, respectively, applying the Black-Scholes-Merton option pricing model utilizing the following weighted-average assumptions:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="Tb_I22h4zhFnEupJRCgAepTzA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:41.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:41.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_b8sYwQmH3Uyz9RV2JjF-gA">6.25</ix:nonNumeric> years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_n4dAyZdoqEGSie7qc7FpOQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_4syYGgMN1Ey_tksB5UgD1A">6.25</ix:nonNumeric> years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_pmIpEVmd-kmwrLI0XOvIXQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_a_0fUunemUebeHW80sEvCg">6.25</ix:nonNumeric> years</p></td></tr><tr><td style="vertical-align:bottom;width:41.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_o6l_rGctYUCSP0KoHptHcQ" contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_sovZBhVMDUaIBejvj859IQ_3_2">84.19</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_o6l_rGctYUCSP0KoHptHcQ" contextRef="Duration_1_1_2020_To_12_31_2020_n4dAyZdoqEGSie7qc7FpOQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_jTiOxPmX-0CpwITysLHj4A_3_4">84.40</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_o6l_rGctYUCSP0KoHptHcQ" contextRef="Duration_1_1_2019_To_12_31_2019_pmIpEVmd-kmwrLI0XOvIXQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_TpIZ7v35KEG8fTvIV_qvcQ_3_6">71.15</ix:nonFraction>%</p></td></tr><tr><td style="vertical-align:bottom;width:41.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_o6l_rGctYUCSP0KoHptHcQ" contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_iH0cdVWi70SvhoIPZUFnHQ_4_2">0.78</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_o6l_rGctYUCSP0KoHptHcQ" contextRef="Duration_1_1_2020_To_12_31_2020_n4dAyZdoqEGSie7qc7FpOQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_QL9xOGOlYUW2o2O70HM8oA_4_4">1.41</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_o6l_rGctYUCSP0KoHptHcQ" contextRef="Duration_1_1_2019_To_12_31_2019_pmIpEVmd-kmwrLI0XOvIXQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_Tq4-XMmaoE6obwybodYdNg_4_6">2.54</ix:nonFraction>%</p></td></tr><tr><td style="vertical-align:bottom;width:41.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_o6l_rGctYUCSP0KoHptHcQ" contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_3aCfJuvWaUaQeaIuJ1flkQ_5_2">0</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_o6l_rGctYUCSP0KoHptHcQ" contextRef="Duration_1_1_2020_To_12_31_2020_n4dAyZdoqEGSie7qc7FpOQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_CrIMcDGuP0OTn824WA_YdQ_5_4">0</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_o6l_rGctYUCSP0KoHptHcQ" contextRef="Duration_1_1_2019_To_12_31_2019_pmIpEVmd-kmwrLI0XOvIXQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_y8KOVjazskOqc77WLGlN5w_5_6">0</ix:nonFraction>%</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Total stock-based compensation expense associated with stock options and RSUs was classified as follows on the statement of operations for the years ended December 31:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="Tb_c5eEQujWq0ysdIvWIvhOTQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_-ABYVM1ePU6I7iAmO9SKmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_VvHifmI9dkuG191-TF_vZA_3_4">2,214,848</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_6th964nOQ0eXBwdN5dw1YA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_AOmilZ3W90SDHbmDvuJQGQ_3_7">2,946,952</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_To7IkJ452EedOpj-Vpzb4Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_OB4hmGj-lUicNeVqGsC1Og_3_10">2,402,242</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:51.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_el_OTs7LDkKYMO80TqWrEQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_AQ908MZjZkuH9bwLItTOaw_4_4">3,872,438</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_z6e36_7PHUuO7wy1SUfrUg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_vB1mgQ2-rEem3iEkt86p5g_4_7">3,954,806</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_rmnCOBDJHkyNTT0GXfj6Mg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_EuMrI1zcVU6KhRBHHpa-KA_4_10">3,812,848</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:51.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_AeHp4wwc00uzV2CqzW8Jzw_5_4">6,087,286</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2020_To_12_31_2020_n4dAyZdoqEGSie7qc7FpOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_7KPeGXtly0y0DiuPfhITnA_5_7">6,901,758</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2019_To_12_31_2019_pmIpEVmd-kmwrLI0XOvIXQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_mPVw0Q1aMkuCVC6qNMPuXA_5_10">6,215,090</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><a id="Tc_tc21JlQO4EiqsPSSoVbN4A_1_2"></a><a id="Tc_pVyPa2thTEmOzqI4ne3vXA_1_5"></a><a id="Tc_vV9zFXSKjUq4KSE09dScjA_2_0"></a><a id="Tc_ZxaRnCcPpkiGa0I_eyROpg_3_0"></a><a id="Tc_vBk3Tx__5UyMo5YC620PDg_3_2"></a><a id="Tc_6zErd-E-LU-AIVd_60ELOA_3_5"></a><a id="Tc_D0NSKtx5606b8YeWmhqINA_4_0"></a><a id="Tc_lTD4j-57r0Srk8D5yAvqEw_5_0"></a><a id="Tc_BZ_fhddtKE2P6_wfcmUhMw_6_0"></a><a id="Tc_5CiuHwE06k-5mefKUXUgwg_7_0"></a><a id="Tc_00eSVJ0N3kWvRGKDbGfL6g_8_0"></a><a id="Tc_t7GudzWZdkWTAHOx9K5rGA_9_0"></a><a id="Tc_aF52xNLRsEGIndecTG6aIQ_10_0"></a><a id="Tc_ZGIh1s8XgUmGZgshZczTfg_11_0"></a><a id="Tc__Qq9wQHKoUWXKw5vuDfXaA_12_0"></a><a id="Tc_XPmjYPk0AUGzXe6j02NPTw_13_0"></a><a id="Tc_F3fciug6-kOaPxPoD6R3ow_15_0"></a><a id="Tc_oby3fjHVhEKKCxWbflCX4w_16_0"></a><a id="Tc_KVptGbOiP06K_chu7WtykA_17_0"></a><a id="Tc_VgDxxp4WOU-gc5QfIU_TJw_18_0"></a><a id="Tc_NZveHzJu1k-JVL-7wgsYgA_19_0"></a><a id="Tc_-qKh_8CkGkeSglCiZNljvg_19_2"></a><a id="Tc_hLoWss5evU-awWr9cl6mzA_19_5"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" name="us-gaap:IncomeTaxDisclosureTextBlock" id="Tb_voiIRtFnw0G2H5efJ2udwQ" continuedAt="Tb_voiIRtFnw0G2H5efJ2udwQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">10. Income Taxes</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">The components of the gross deferred tax asset and related valuation allowance at December 31 were as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="Tb_mKFI_sEE30i-ZfDHslEdaw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:2.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:16.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:15.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:0.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:18.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:17.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:normal;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred income tax assets:</p></td><td style="vertical-align:bottom;white-space:normal;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:16.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:15.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Net operating loss carryforward</p></td><td style="vertical-align:bottom;white-space:normal;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:16.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" id="Tc_mVOL93vqlU6IPLyr8GgqJg_3_3">79,788,146</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:15.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" id="Tc_99J0ljTAPU-nzS52HpCOWQ_3_6">63,830,866</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Capitalized start-up costs</p></td><td style="vertical-align:bottom;white-space:normal;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:16.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg" decimals="0" format="ixt:numdotdecimal" name="glyc:DeferredTaxAssetsCapitalizedStartUpCosts" scale="0" id="Tc_N4VTNco2_EarnkNqlsWnxw_4_3">920,516</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:15.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug" decimals="0" format="ixt:numdotdecimal" name="glyc:DeferredTaxAssetsCapitalizedStartUpCosts" scale="0" id="Tc_2BSIZ6DUvECPD8Nf6J_qww_4_6">1,114,309</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Patent amortization</p></td><td style="vertical-align:bottom;white-space:normal;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:16.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg" decimals="0" format="ixt:numdotdecimal" name="glyc:DeferredTaxAssetsPatentAmortization" scale="0" id="Tc_Zj0DkHBagU2kaQ-0KSA2GQ_5_3">73,480</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:15.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug" decimals="0" format="ixt:numdotdecimal" name="glyc:DeferredTaxAssetsPatentAmortization" scale="0" id="Tc_nl3INMKF7ke2U3dEgbXGBg_5_6">88,949</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Research and orphan drug credits</p></td><td style="vertical-align:bottom;white-space:normal;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:16.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg" decimals="0" format="ixt:numdotdecimal" name="glyc:DeferredTaxAssetsResearchAndOrphanDrugCredits" scale="0" id="Tc_OtYPrXZFPEa4Mo0UPFaqpA_6_3">47,976,370</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:15.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug" decimals="0" format="ixt:numdotdecimal" name="glyc:DeferredTaxAssetsResearchAndOrphanDrugCredits" scale="0" id="Tc_Ey-FFNxUC0qjzJzTeUQe-g_6_6">42,008,797</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:normal;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:16.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" scale="0" id="Tc_DoVGgtaXNE-BxxvxVmfyAQ_7_3">7,102,947</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:15.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" scale="0" id="Tc_Mwwmr58W4ES-j0AOETa9gQ_7_6">6,778,569</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:normal;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:16.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg" decimals="0" format="ixt:numdotdecimal" name="glyc:DeferredTaxAssetsTaxDeferredExpenseOperatingLeaseLiabilities" scale="0" id="Tc_tusw-_CnVEa6L78xFISGNQ_8_3">528,340</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:15.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug" decimals="0" format="ixt:numdotdecimal" name="glyc:DeferredTaxAssetsTaxDeferredExpenseOperatingLeaseLiabilities" scale="0" id="Tc_T5Uz3xGWJ0uWv0jeGmmSMw_8_6">775,598</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Accrued bonus</p></td><td style="vertical-align:bottom;white-space:normal;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:16.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg" decimals="0" format="ixt:numdotdecimal" name="glyc:DeferredTaxAssetsAccruedBonus" scale="0" id="Tc_5FeJVF_RwU6RqRQNgbHsdA_9_3">592,260</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:15.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug" decimals="0" format="ixt:numdotdecimal" name="glyc:DeferredTaxAssetsAccruedBonus" scale="0" id="Tc_JoQf4y24iE6ybFCF6_ToUQ_9_6">919,410</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Other</p></td><td style="vertical-align:bottom;white-space:normal;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:16.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOther" scale="0" id="Tc_PYrXCh2zXUmTn_VGVtMdqQ_10_3">209,580</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:15.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOther" scale="0" id="Tc_l9Y2HKoWiUOqTy6ft2_BmQ_10_6">283,751</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 42pt;">Gross deferred income tax assets</p></td><td style="vertical-align:bottom;white-space:normal;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:16.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="0" id="Tc_dBnoXbg_B0S15sur67YVVA_11_3">137,191,639</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:15.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="0" id="Tc_KKH2thgumkuYetZsrAPLbA_11_6">115,800,249</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 42pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:normal;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:16.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" id="Tc_Dy16AHnSs0Ce6KPY2I0Xow_12_3">136,613,829</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:15.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" id="Tc_PQYfgAIsb0mxvC0rPbjZmQ_12_6">115,016,323</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:normal;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 42pt;">Net deferred income tax assets</p></td><td style="vertical-align:bottom;white-space:normal;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:16.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsNet" scale="0" id="Tc_CV4X_3K2bUyorDePQ6_qng_13_3">577,810</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:15.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsNet" scale="0" id="Tc_BSLnTgPen0ms4y2DybJe8A_13_6">783,926</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 42pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:16.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:15.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred income tax liabilities:</p></td><td style="vertical-align:bottom;white-space:normal;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:16.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:15.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Operating lease right-of-use assets</p></td><td style="vertical-align:bottom;white-space:normal;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:16.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg" decimals="0" format="ixt:numdotdecimal" name="glyc:DeferredTaxLiabilitiesTaxDeferredExpenseOperatingLeaseLiabilitiesRightOfUseAssets" scale="0" id="Tc_nhDp2LaVz06e3vJoSxzmSg_16_3">433,727</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:15.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug" decimals="0" format="ixt:numdotdecimal" name="glyc:DeferredTaxLiabilitiesTaxDeferredExpenseOperatingLeaseLiabilitiesRightOfUseAssets" scale="0" id="Tc_Fz2IB8aklk-et3V1H_ZF4w_16_6">639,843</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:normal;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Property and equipment</p></td><td style="vertical-align:bottom;white-space:normal;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:16.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="0" id="Tc_avu4qAHO_UW2VCWMmD0ILg_17_3">144,083</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:15.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="0" id="Tc_wJ8_joiiZUuK9z9CmNVi-w_17_6">144,083</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:normal;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 42pt;">Gross deferred income tax liabilities</p></td><td style="vertical-align:bottom;white-space:normal;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:16.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilities" scale="0" id="Tc_FdWShxjPUUua4QEkAhIgiA_18_3">577,810</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:15.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilities" scale="0" id="Tc_hI4XEb_YxEu89LTIKx6aZA_18_6">783,926</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:normal;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net deferred income tax asset/(liability)</p></td><td style="vertical-align:bottom;white-space:normal;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:16.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_1YfPvGN8zkuxUetSrMELxA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:15.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_kVVzvEvEd0Oo7zjJJdtzug;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:6pt 0pt 6pt 0pt;">Based on the Company&#8217;s operating history and management&#8217;s expectation regarding future profitability, management believes the Company&#8217;s deferred tax assets will not be realizable under ASC 740, <i style="font-style:italic;">Income Taxes</i>. Accordingly, a full valuation allowance has been established as of December 31, 2021 and 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">As of December 31, 2021, the Company had $<ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_glyc_FederalAndStateAuthoritiesMember_onB_QxVk6kiCCtMYcUAFbg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_VyrVpc3W3E-iaPfinwkMoA">290.0</ix:nonFraction> million of U.S. Federal and state net operating losses, $<ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2021_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_D-pk4UYBwUG2J1DzykZ-HQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="Narr_hkjFWkzGCU69MUmjR6llvQ">10.3</ix:nonFraction> million of research and development tax credits and $<ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="As_Of_12_31_2021_us-gaap_TaxCreditCarryforwardAxis_us-gaap_GeneralBusinessMember_ecyj2U3Yt0Wb9cFTtDT3zQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="Narr_V6_Kw3YLlUa14VTG4Y5nEw">37.7</ix:nonFraction> million of orphan drug tax credits available to carry forward. A portion of the net operating loss carryforwards will begin to expire in 2026, the research and development tax credits in 2023 and the orphan drug tax credit in 2033. Under current federal income tax laws, federal net operating losses incurred in 2018 and in future years may be carried forward, indefinitely, but the deductibility of such federal net operating losses is limited.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">The Company&#8217;s tax attributes, including net operating losses and credits, are subject to any ownership changes as defined under Internal Revenue Code Sections 382 and 383. A change in ownership could affect the Company&#8217;s ability </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">90</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_eJhzHnN4fUWTJ_UyG_NE3g_1_2"></a><a id="Tc_Eq0-CBEDNECTSUufN9tT2w_1_4"></a><a id="Tc_HpR8u_0DlEm1de481seIoA_1_6"></a><a id="Tc_bDe-jiGuDky0Xf79wWQdFA_2_0"></a><a id="Tc_pdvR3qU3CkCvI3z5neATzw_2_3"></a><a id="Tc_iY34LiBWykeUa9AdgIIbKQ_2_5"></a><a id="Tc_uNHdvsyez0GjmdAR-vfukw_2_7"></a><a id="Tc_d5yLMLI6qkqzuQ_91F0sAg_3_0"></a><a id="Tc_ppU2JeqcQEavdJByMk8cMw_4_0"></a><a id="Tc_QQzFj20xH0KO2vuAlbfRTg_5_0"></a><a id="Tc_xZjPRXNMwUqAQ5syZQsiTg_6_0"></a><a id="Tc_1BiNEutEukeUUNcmmCaMtQ_7_0"></a><a id="Tc_yBgR2kHCoU2xUSeRdyCyjg_8_0"></a><a id="Tc_vvrJv0q3e0KitaU8MRf3Iw_8_2"></a><a id="Tc_tGaaXbWOyEenfkSx1qugnA_8_3"></a><a id="Tc_WPa3m4RWGU6Rsk5AB5Bp1g_8_4"></a><a id="Tc_QPzKkOrQr0Kbr96rlusslA_8_5"></a><a id="Tc_WPJh-Dwg_kmH77TpunLdxw_8_6"></a><a id="Tc_prrnZqzZ0keLBl-IOsn-Lg_8_7"></a><ix:continuation id="Tb_voiIRtFnw0G2H5efJ2udwQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">to utilize its net operating losses and credits. As of December 31, 2021, the Company does not believe that an ownership change has occurred. Any future ownership changes may cause a limitation on the Company&#8217;s ability to utilize existing tax attributes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">The Company files income tax returns in the U.S. federal jurisdiction and in the State of Maryland. The Company&#8217;s federal income tax returns for tax years 2003 and after remain subject to examination by the U.S. Internal Revenue Service due to tax attributes available to be carried forward to open or future tax years. The Company&#8217;s Maryland income tax returns for the tax years 2006 and thereafter remain subject to examination by the Comptroller of Maryland. In addition, all of the net operating losses, research and development tax credit and orphan drug credit carryforwards that may be used in future years are still subject to adjustment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">The Company did not have unrecognized tax benefits as of December 31, 2021 and 2020, and does not anticipate this to change significantly over the next 12 months. The Company will recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. Reconciliations between the statutory federal income tax rate and the effective income tax rate of income tax expense is as follows as of December 31:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="Tb_UnVQ94czLUWE11eQtW9fFQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:42.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:2.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:14.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:3.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:14.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:3.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:14.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:3.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:42.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:normal;width:14.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:normal;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:normal;width:14.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:normal;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:normal;width:14.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:normal;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:42.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">U.S. Federal statutory tax rate</p></td><td style="vertical-align:bottom;white-space:normal;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:14.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_o6l_rGctYUCSP0KoHptHcQ" contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_F5quWnc3uES62G6XfSgstQ_2_2">21.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:14.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_o6l_rGctYUCSP0KoHptHcQ" contextRef="Duration_1_1_2020_To_12_31_2020_n4dAyZdoqEGSie7qc7FpOQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_fTSnBhtrz0qzNPD8d98RDA_2_4">21.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:14.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_o6l_rGctYUCSP0KoHptHcQ" contextRef="Duration_1_1_2019_To_12_31_2019_pmIpEVmd-kmwrLI0XOvIXQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_uEvTmQ33S0CIqAgAFXcMLg_2_6">21.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:42.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">State taxes</p></td><td style="vertical-align:bottom;white-space:normal;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:14.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_o6l_rGctYUCSP0KoHptHcQ" contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="Tc_7b4DMmM-a0i1hg2Oca1oug_3_2">5.9</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:14.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_o6l_rGctYUCSP0KoHptHcQ" contextRef="Duration_1_1_2020_To_12_31_2020_n4dAyZdoqEGSie7qc7FpOQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="Tc_29yZVNWCL0qTxaBoAnQwVw_3_4">5.7</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:14.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_o6l_rGctYUCSP0KoHptHcQ" contextRef="Duration_1_1_2019_To_12_31_2019_pmIpEVmd-kmwrLI0XOvIXQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="Tc_ezYifR7gN0SGMZlblVgAzg_3_6">5.7</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research credit</p></td><td style="vertical-align:bottom;white-space:normal;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:14.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_o6l_rGctYUCSP0KoHptHcQ" contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="Tc_JBgqZ3Uc_0q6qIbFPPUrBQ_4_2">0.9</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:14.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_o6l_rGctYUCSP0KoHptHcQ" contextRef="Duration_1_1_2020_To_12_31_2020_n4dAyZdoqEGSie7qc7FpOQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="Tc_lbJX3aVJEE-9GsP11zqJ2A_4_4">0.7</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:14.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_o6l_rGctYUCSP0KoHptHcQ" contextRef="Duration_1_1_2019_To_12_31_2019_pmIpEVmd-kmwrLI0XOvIXQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="Tc_WetBXf1rH0mqtioqr8k4fQ_4_6">0.8</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Orphan drug credit</p></td><td style="vertical-align:bottom;white-space:normal;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:14.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_o6l_rGctYUCSP0KoHptHcQ" contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" decimals="3" format="ixt:numdotdecimal" name="glyc:EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent" scale="-2" id="Tc_nfh-aO_Wskan3xEEamJehw_5_2">6.6</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:14.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_o6l_rGctYUCSP0KoHptHcQ" contextRef="Duration_1_1_2020_To_12_31_2020_n4dAyZdoqEGSie7qc7FpOQ" decimals="3" format="ixt:numdotdecimal" name="glyc:EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent" scale="-2" id="Tc_geEvh3Hhtk2ytUhVVqH29w_5_4">9.8</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:14.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_o6l_rGctYUCSP0KoHptHcQ" contextRef="Duration_1_1_2019_To_12_31_2019_pmIpEVmd-kmwrLI0XOvIXQ" decimals="3" format="ixt:numdotdecimal" name="glyc:EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent" scale="-2" id="Tc_jv1x-eWOMkK4D2bIXkqr-w_5_6">8.8</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:normal;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:14.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_o6l_rGctYUCSP0KoHptHcQ" contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" sign="-" scale="-2" id="Tc_7s0N_s0H80qcXP4qZvfy0w_6_2">0.3</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:normal;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:14.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_o6l_rGctYUCSP0KoHptHcQ" contextRef="Duration_1_1_2020_To_12_31_2020_n4dAyZdoqEGSie7qc7FpOQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" scale="-2" id="Tc_eUI1M29hLkOXyhxQqHDnsA_6_4">0.4</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:14.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_o6l_rGctYUCSP0KoHptHcQ" contextRef="Duration_1_1_2019_To_12_31_2019_pmIpEVmd-kmwrLI0XOvIXQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" sign="-" scale="-2" id="Tc_l5rUup43ZkqfD6-hj__rxg_6_6">0.1</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:normal;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:normal;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:14.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_o6l_rGctYUCSP0KoHptHcQ" contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="-2" id="Tc_MgJ91dV200qXkNv67FU1vw_7_2">34.1</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:normal;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:14.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_o6l_rGctYUCSP0KoHptHcQ" contextRef="Duration_1_1_2020_To_12_31_2020_n4dAyZdoqEGSie7qc7FpOQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="-2" id="Tc_VLmTcCrjfEawsS9h_IlT_w_7_4">37.6</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:normal;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:14.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_o6l_rGctYUCSP0KoHptHcQ" contextRef="Duration_1_1_2019_To_12_31_2019_pmIpEVmd-kmwrLI0XOvIXQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="-2" id="Tc_bTJTrT8SjkGu3F-ko86NVA_7_6">36.2</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:normal;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Provision for income taxes</p></td><td style="vertical-align:bottom;white-space:normal;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:14.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:normal;width:14.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:normal;width:14.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" name="glyc:ResearchAndLicenseAgreementTextBlock" id="Tb_Imwu8GL6xU6cxXKrXDtmwg" continuedAt="Tb_Imwu8GL6xU6cxXKrXDtmwg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">11. &#160;Research and License Agreements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Apollomics</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27pt;margin:0pt 0pt 6pt 0pt;">In January 2020, the Company entered into a collaboration and license agreement (the Agreement) with Apollomics (Hong Kong), Limited (Apollomics) for the development, manufacture and commercialization of products derived from two of the Company&#8217;s compounds, GMI-1271 and GMI-1687 (the Products) for therapeutic and prophylactic uses (the Field) in China, Taiwan, Hong Kong and Macau (the Territory). Under the terms of the Agreement, the Company granted Apollomics:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an exclusive license, with the right to sublicense, to develop, manufacture and have manufactured, distribute, market, promote, sell, have sold, offer for sale, import, label, package and otherwise the Products in the Field in the Territory; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a non-exclusive license to conduct preclinical research with respect to Products in the Field outside of the Territory for the purposes of developing such Products for use in the Territory.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27pt;margin:0pt;">In June 2020, the Company and Apollomics entered into a clinical supply agreement pursuant to which the Company will manufacture and supply the Products at agreed upon prices. Apollomics has the option to begin manufacture of the Products after appropriate material transfer requirements are met. During the year ended December 30, 2021, the Company recognized $<ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_glyc_ApollomicMember_u1SJvvGvK0azW3aP0YW7WQ" decimals="-5" format="ixt:numdotdecimal" name="glyc:RevenueReceivedFromSaleOfClinicalSupplies" scale="6" id="Narr_qu2Iy01mqEK7ghM9WdRfnA">1.1</ix:nonFraction> million as revenue from the sale of clinical supplies to Apollomics.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27pt;margin:0pt;">The Company evaluated the Agreement under the provisions of ASC 606 and identified two performance obligations under this revenue arrangement: the (i) delivery of functional licenses and (ii) manufacture and supply of the Products. The initial transaction price consists of a $<ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2020_To_3_31_2020_srt_CounterpartyNameAxis_glyc_ApollomicMember__UsntURv-UWFpyJ1frsxHw" decimals="-5" format="ixt:numdotdecimal" name="glyc:UpFrontPaymentReceived" scale="6" id="Narr_OvRLl3ZLXEGtBpANswgV2w">9.0</ix:nonFraction> million non-refundable up-front payment which was allocated to the delivered functional licenses and recognized in full as revenue in the first quarter of 2020 given that the performance obligation was satisfied upon inception. The Agreement contains various forms of variable consideration, including (i) up to $<ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2020_To_3_31_2020_srt_CounterpartyNameAxis_glyc_ApollomicMember_srt_RangeAxis_srt_MaximumMember_jz80Uqp0xkifz7ggXf9mng" decimals="-5" format="ixt:numdotdecimal" name="glyc:DevelopmentAndRegulatoryApprovalMilestonesClinicalAndRegulatoryEvents" scale="6" id="Narr_rmo959dQpUebSYJYeOZgPA">75.0</ix:nonFraction> million in development milestones based on achievement of certain clinical and regulatory events, (ii) up to $<ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2020_To_3_31_2020_srt_CounterpartyNameAxis_glyc_ApollomicMember_srt_RangeAxis_srt_MaximumMember_jz80Uqp0xkifz7ggXf9mng" decimals="-5" format="ixt:numdotdecimal" name="glyc:AchievementOfSpecifiedNetSalesThresholdsForAllLicensedProducts" scale="6" id="Narr_4ho0UoJGVkq7IWffAnchBQ">105.0</ix:nonFraction> million of sales-based commercial milestones based on achievement of certain annual net sales targets, (iii) sales-based royalties at specified percentages of net sales ranging from the high single digits to <ix:nonFraction unitRef="Unit_Standard_pure_o6l_rGctYUCSP0KoHptHcQ" contextRef="Duration_1_1_2020_To_3_31_2020_srt_CounterpartyNameAxis_glyc_ApollomicMember_srt_RangeAxis_srt_MaximumMember_jz80Uqp0xkifz7ggXf9mng" decimals="2" format="ixt:numdotdecimal" name="glyc:TieredPercentageOfAnnualNetSales" scale="-2" id="Narr_ZrgHpZekR0OYqS3PBoqZaw">15</ix:nonFraction>%, and (iv) manufacture and supply of clinical and commercial Products. The Company has fully constrained the development milestone consideration using the most likely amount method and will recognize that revenue when it is probable that recognition </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">91</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_Imwu8GL6xU6cxXKrXDtmwg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="white-space:pre-wrap;">of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price. In September 2020, the Company received a non-refundable $<ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_9_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_glyc_ApollomicMember_fv4inACjoUWDFNulm8LqCA" decimals="-5" format="ixt:numdotdecimal" name="glyc:MilestoneRevenueRecognized" scale="6" id="Narr_wy8blxrMg0eTJjqw_AGmWw">1.0</ix:nonFraction> million development milestone payment upon acceptance by Chinese regulatory authorities of a Phase 3 bridging study design to support registration in China. The Company recognized this $<ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_9_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_glyc_ApollomicMember_fv4inACjoUWDFNulm8LqCA" decimals="-5" format="ixt:numdotdecimal" name="glyc:MilestoneRevenueRecognized" scale="6" id="Narr_hAJXFyocBk-fYOAYHdF6QA">1.0</ix:nonFraction> million payment as revenue in the quarter ended September 30, 2020. The Company did not recognize any milestone revenue under the Agreement for the year ended December 31, 2021.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27pt;margin:0pt 0pt 6pt 0pt;"><span style="white-space:pre-wrap;"> The Company will recognize revenue related to the sales-based commercial and royalty milestones and royalties at the later of (i) when the related sales occur or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied), as they were determined to relate predominantly to the licenses granted to Apollomics and, therefore, have been excluded from the transaction price. Lastly, the Company has determined that the consideration for the manufacturing and supply is all variable and is fully constrained. Variable consideration allocated to manufacturing and supply will be recognized at a point in time when the Product is delivered and when the title to the Product is transferred to the customer pursuant to the agreement. The Company reassesses the transaction price in each reporting period and upon the occurrence of a change in circumstances or final resolution of any particular event.</span></p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" name="us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock" id="Tb_qFSL-qx6xE-X6XIrjE7awg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">12. Employee Benefit Plan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">The Company has a defined contribution plan under the Internal Revenue Code Section&#160;401(k). This plan covers substantially all employees who meet minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pre-tax basis. For the years ended December 31, 2021, 2020 and 2019, the Company matched <ix:nonFraction unitRef="Unit_Standard_pure_o6l_rGctYUCSP0KoHptHcQ" contextRef="Duration_1_1_2019_To_12_31_2019_pmIpEVmd-kmwrLI0XOvIXQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" scale="-2" id="Narr_ZPaXDh1KaUanw5Rzyqxt1g"><ix:nonFraction unitRef="Unit_Standard_pure_o6l_rGctYUCSP0KoHptHcQ" contextRef="Duration_1_1_2020_To_12_31_2020_n4dAyZdoqEGSie7qc7FpOQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" scale="-2" id="Narr_YOFHt0wZwUOOBe1mgJ63NQ"><ix:nonFraction unitRef="Unit_Standard_pure_o6l_rGctYUCSP0KoHptHcQ" contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" scale="-2" id="Narr_tfV4krDhxEm5aKoqnrbaJw">50</ix:nonFraction></ix:nonFraction></ix:nonFraction>%<span style="white-space:pre-wrap;"> up to the first <ix:nonFraction unitRef="Unit_Standard_pure_o6l_rGctYUCSP0KoHptHcQ" contextRef="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MaximumMember_dvu4YMBVCkmKgIY5AJuxZA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" id="Narr_CasoPUjj4kSXhj6jbuf6bA"><ix:nonFraction unitRef="Unit_Standard_pure_o6l_rGctYUCSP0KoHptHcQ" contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MaximumMember_w9j8fZvT2UmDwuBnDsgAcw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" id="Narr_by1JU7-SD0Su8jRCmIlSKw"><ix:nonFraction unitRef="Unit_Standard_pure_o6l_rGctYUCSP0KoHptHcQ" contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_Bhd-nQulWU6ZbQQpkblCKw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" id="Narr_FYDiHtX18kmnj7HTUInd9g">6</ix:nonFraction></ix:nonFraction></ix:nonFraction>%</span><span style="white-space:pre-wrap;"> of employee contributions. All matching contributions have been paid by the Company. The Company&#8217;s matching contributions vest in full immediately. The total Company matching contributions were approximately $<ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="0" id="Narr_1XMh6z0qYEyncZAYyKtjSw">270,000</ix:nonFraction>, $<ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2020_To_12_31_2020_n4dAyZdoqEGSie7qc7FpOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="0" id="Narr_lD9EdlNXUkqRcMNSVK_Lcw">252,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw" contextRef="Duration_1_1_2019_To_12_31_2019_pmIpEVmd-kmwrLI0XOvIXQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="0" id="Narr_juhJQnPXyEC_EGg5ZVx9Eg">219,000</ix:nonFraction> for the years ended December 31, 2021, 2020 and 2019, respectively. </span></p></ix:nonNumeric><a id="_cp_text_4_25"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA" name="us-gaap:LossContingencyDisclosures" id="Tb_F_lTuqwzl0WkmORIuq8qFw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">13. Risks and Uncertainties</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">COVID-19</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27pt;margin:0pt;">In March 2020, the World Health Organization declared the novel coronavirus disease 2019, or COVID-19, outbreak a pandemic. In order to mitigate the spread of COVID-19, governments have imposed unprecedented restrictions on business operations, travel and gatherings, resulting in a global economic downturn and other adverse economic and societal impacts. The COVID-19 pandemic has also overwhelmed or otherwise led to changes in the operations of many healthcare facilities. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:27pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27pt;margin:0pt;">The impact of the COVID-19 pandemic on the Company&#8217;s business and financial performance is uncertain and depends on various factors, including the duration of the pandemic, government restrictions and other actions, including relief measures and mass vaccination efforts, implemented to address the impact of the pandemic, and resulting impacts on the financial markets and overall economy. The imposition of &#8220;lockdown,&#8221; &#8220;social distancing&#8221; and &#8220;shelter in place&#8221; directives by state and federal governments in the United States as well as governments in other regions of the world in response to the COVID-19 pandemic, including in locations in which its Phase 3 clinical trial of uproleselan is being conducted, resulted in slowed clinical site initiation, patient recruitment and enrollment rates early in the pandemic. Enrollment rates have returned to forecasted levels since the lockdowns. However, COVID-19 infection rates continue to fluctuate, particularly with the emergence of variants, which could negatively affect completion of the trial. The Company is unable to determine the extent of the impact of the pandemic on its operations and financial condition going forward. These developments are highly uncertain and unpredictable, and may materially adversely affect the Company&#8217;s financial position and results of operations. The Company continues to closely monitor the COVID-19 situation and any potential impact to its planned activities.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">92</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.29%;margin-right:10.29%;margin-top:30pt;page-break-after:avoid;width:79.41%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.13
<SEQUENCE>2
<FILENAME>glyc-20211231xex10d13.htm
<DESCRIPTION>EX-10.13
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 3/3/2022 09:44:18 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Exhibit&#160;10.13</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">CONSULTING AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">THIS CONSULTING AGREEMENT </b><font style="font-size:12pt;">(the &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Agreement</font><font style="font-size:12pt;">&#8221;) by and between </font><b style="font-size:12pt;font-weight:bold;">GlycoMimetics, Inc. </b><font style="font-size:12pt;">(&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Client&#8221;</font><font style="font-size:12pt;">) and </font><b style="font-size:12pt;font-weight:bold;">Rachel K. King</b><font style="font-size:12pt;">, an individual (&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Consultant</font><font style="font-size:12pt;">&#8221;) is effective as of August 31, 2021 (the &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Effective Date</font><font style="font-size:12pt;">&#8221;).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">RECITALS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">WHEREAS the parties desire for the Client to engage Consultant to perform the services described herein and for Consultant to provide such services on the terms and conditions described herein; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">WHEREAS, the parties desire to use Consultant&#8217;s independent skill and expertise pursuant to this Agreement as an independent contractor;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;">NOW THEREFORE, in consideration of the promises and mutual agreements contained herein, the parties hereto, intending to be legally bound, agree as follows:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">1.</b></font><b style="font-size:12pt;font-weight:bold;">Engagement of Services.</b><font style="font-size:12pt;"> &#160;Consultant agrees to provide consulting services to include, among other things, strategic business advice, assistance with executive transitions and other services upon request of the Chief Executive Officer (&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Executive</font><font style="font-size:12pt;">&#8221;) of the Client. &#160; Consultant agrees to exercise the highest degree of professionalism and utilize her expertise and creative talents in performing these services. &#160;Consultant agrees to make herself available to perform such consulting services throughout the Consulting Period, up to 20 hours per week &#160;throughout the Consulting Period, and to be reasonably available to meet with the Client at its offices or otherwise.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">2.</b></font><b style="font-size:12pt;font-weight:bold;">Compensation.</b><font style="font-size:12pt;"> &#160;In consideration for the services rendered pursuant to this Agreement and for the assignment of certain of Consultant&#8217;s right, title and interest pursuant hereto, Client will pay Consultant a consulting fee of $23,304.17 per month for services rendered during the Consulting Period to be paid by the 15</font><sup style="font-size:9pt;vertical-align:top;">th </sup><font style="font-size:12pt;">calendar day of each applicable month during the Consulting Period.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">3.</b></font><b style="font-size:12pt;font-weight:bold;">Ownership of Work Product.</b><font style="font-size:12pt;"> &#160;Consultant hereby irrevocably assigns, grants and conveys to Client all right, title and interest now existing or that may exist in the future in and to any document, development, work product, know-how, design, processes, invention, technique, trade secret, or idea, and all intellectual property rights related thereto, that is created by Consultant, to which Consultant contributes, or which relates to Consultant&#8217;s services provided pursuant to this Agreement (the &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Work Product</font><font style="font-size:12pt;">&#8221;), including all copyrights, trademarks and other intellectual property rights (including but not limited to patent rights) relating thereto. &#160;Consultant agrees that any and all Work Product shall be and remain the property of Client. Consultant will immediately disclose to the Client all Work Product. &#160;Consultant agrees to execute, at Client&#8217;s request and expense, all documents and other instruments necessary or desirable to confirm such assignment. &#160;In the event that Consultant does not, for any reason, execute such documents within a reasonable time of Client&#8217;s request, Consultant hereby irrevocably appoints Client as Consultant&#8217;s attorney-in-fact for the purpose of executing such documents on Consultant&#8217;s behalf, which appointment is coupled with an interest. &#160;Consultant</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">shall not attempt to register any works created by Consultant pursuant to this Agreement at the U.S. Copyright Office, the U.S. Patent &amp; Trademark Office, or any foreign copyright, patent, or trademark registry. &#160;Consultant retains no rights in the Work Product and agrees not to challenge Client&#8217;s ownership of the rights embodied in the Work Product. &#160;Consultant further agrees to assist Client in every proper way to enforce Client&#8217;s rights relating to the Work Product in any and all countries, including, but not limited to, executing, verifying and delivering such documents and performing such other acts (including appearing as a witness) as Client may reasonably request for use in obtaining, perfecting, evidencing, sustaining and enforcing Client&#8217;s rights relating to the Work Product.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">4.</b></font><b style="font-size:12pt;font-weight:bold;">Artist</b><b style="font-family:'Times';font-size:12pt;font-weight:bold;">&#8217;</b><b style="font-size:12pt;font-weight:bold;">s, Moral, and Other Rights.</b><font style="font-size:12pt;"> &#160;If Consultant has any rights, including without limitation &#8220;artist&#8217;s rights&#8221; or &#8220;moral rights,&#8221; in the Work Product which cannot be assigned (the &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Non-Assignable Rights</font><font style="font-size:12pt;">&#8221;), Consultant agrees to waive enforcement worldwide of such rights against Client. In the event that Consultant has any such rights that cannot be assigned or waived Consultant hereby grants to Client a royalty-free, paid-up, exclusive, worldwide, irrevocable, perpetual license under the Non-Assignable Rights to (i) use, make, sell, offer to sell, have made, and further sublicense the Work Product, and (ii) reproduce, distribute, create derivative works of, publicly perform and publicly display the Work Product in any medium or format, whether now known or later developed.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">5.</b></font><b style="font-size:12pt;font-weight:bold;">Representations and Warranties.</b><font style="font-size:12pt;"> &#160;Consultant represents and warrants that: (a)&#160;Consultant has the full right and authority to enter into this Agreement and perform her obligations hereunder; (b) Consultant has the right and unrestricted ability to assign the Work Product to Client as set forth in Sections 4 and 5 (including without limitation the right to assign any Work Product created by Consultant&#8217;s employees or contractors); (c) the Work Product has not heretofore been published in its entirety; and (d) the Work Product will not infringe upon any copyright, patent, trademark, right of publicity or privacy, or any other proprietary right of any person, whether contractual, statutory or common law. &#160;Consultant agrees to indemnify Client from any and all damages, costs, claims, expenses or other liability (including reasonable attorneys&#8217; fees) arising from or relating to the breach or alleged breach by Consultant of the representations and warranties set forth in this Section 5.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">6.</b></font><b style="font-size:12pt;font-weight:bold;">Independent Contractor Relationship.</b><font style="font-size:12pt;"> &#160;Consultant is an independent contractor and not an employee of the Client. &#160;Nothing in this Agreement is intended to, or should be construed to, create a partnership, agency, joint venture or employment relationship. &#160;The manner and means by which Consultant chooses to complete the consulting services are in Consultant&#8217;s sole discretion and control. &#160;In completing the consulting services, Consultant agrees to provide her own equipment, tools and other materials at her own expense. &#160;Consultant is not authorized to represent that she is an agent, employee, or legal representative of the Client, but may disclose that she is a member of the Board of Directors, independent of this Agreement. &#160;Consultant is not authorized to make any representation, contract, or commitment on behalf of Client or incur any liabilities or obligations of any kind in the name of or on behalf of the Client. &#160;Consultant shall be free at all times to arrange the time and manner of performance of the consulting services. &#160;Consultant is not required to maintain any schedule of duties or assignments. &#160;Consultant is also not required to provide reports to the Client. &#160;In addition to all other obligations contained herein, Consultant agrees: &#160;(a)&#160;to proceed with diligence and promptness and hereby warrants that such services shall be performed in accordance with the</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">2</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">highest professional standards in the field to the satisfaction of the Client; and (b)&#160;to comply, at Consultant&#8217;s own expense, with the provisions of all state, local, and federal laws, regulations, ordinances, requirements and codes which are applicable to the performance of the services hereunder.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">7.</b></font><b style="font-size:12pt;font-weight:bold;">Consultant&#8217;s Responsibilities.</b><font style="font-size:12pt;"> &#160;As an independent contractor, the mode, manner, method and means used by Consultant in the performance of services shall be of Consultant&#8217;s selection and under the sole control and direction of Consultant. &#160;Consultant shall be responsible for all risks incurred in the operation of Consultant&#8217;s business and shall enjoy all the benefits thereof. &#160;Any persons employed by or subcontracting with Consultant to perform any part of Consultant&#8217;s obligations hereunder shall be under the sole control and direction of Consultant and Consultant shall be solely responsible for all liabilities and expenses thereof. &#160;The Client shall have no right or authority with respect to the selection, control, direction, or compensation of such persons.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">8.</b></font><b style="font-size:12pt;font-weight:bold;">Tax Treatment. </b><font style="font-size:12pt;"> Consultant and the Client agree that the Client will treat Consultant as an independent contractor for purposes of all tax laws (local, state and federal) and file forms consistent with that status. &#160;Consultant agrees, as an independent contractor, that neither she nor her employees are entitled to unemployment benefits in the event this Agreement terminates, or workers&#8217; compensation benefits in the event that Consultant, or any employee of Consultant, is injured in any manner while performing obligations under this Agreement. &#160;Consultant will be solely responsible to pay any and all local, state, and/or federal income, social security and unemployment taxes for Consultant and her employees. &#160;The Client will not withhold any taxes or prepare W-2 Forms for Consultant, but will provide Consultant with a Form 1099, if required by law. &#160;Consultant is solely responsible for, and will timely file, all tax returns and payments required to be filed with, or made to, any federal, state or local tax authority with respect to the performance of services and receipt of fees under this Agreement. Consultant is solely responsible for, and must maintain adequate records of, expenses incurred in the course of performing services under this Agreement, except as provided herein. &#160;No part of Consultant&#8217;s compensation will be subject to withholding by Client for the payment of any social security, federal, state or any other employee payroll taxes. &#160;Client will regularly report amounts paid to Consultant with the appropriate taxing authorities, as required by law.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">9.</b></font><b style="font-size:12pt;font-weight:bold;">No Employee Benefits</b><font style="font-size:12pt;">. &#160;Consultant acknowledges and agrees that neither she nor anyone acting on her behalf shall receive any employee benefits of any kind from the Client as a result of this Agreement. &#160;Consultant (and Consultant&#8217;s agents, employees, and subcontractors) is excluded from participating in any fringe benefit plans or programs as a result of the performance of services under this Agreement, without regard to Consultant&#8217;s independent contractor status. &#160;In addition, Consultant (on behalf of herself and on behalf of Consultant&#8217;s agents, employees, and contractors) waives any and all rights, if any, to participation in any of the Client&#8217;s fringe benefit plans or programs including, but not limited to, health, sickness, accident or dental coverage, life insurance, disability benefits, severance, accidental death and dismemberment coverage, unemployment insurance coverage, workers&#8217; compensation coverage, and pension or 401(k) benefit(s) provided by the Client to its employees. Notwithstanding the foregoing, this Agreement does not amend or abrogate in any manner any benefit continuation or conversion rights provided by the provision of a benefit plan or by law arising out of Consultant&#8217;s previous employment relationship with Client.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">3</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">10.</b></font><b style="font-size:12pt;font-weight:bold;">Expenses and Liabilities</b><font style="font-size:12pt;">. &#160;Consultant agrees that as an independent contractor, she is solely responsible for all expenses (and profits/losses) she incurs in connection with the performance of services. &#160;Consultant understands that she will not be reimbursed for any supplies, equipment, or operating costs, nor will these costs of doing business be defrayed in any way by the Client. &#160;In addition, the Client does not guarantee to Consultant that fees derived from Consultant&#8217;s business will exceed Consultant&#8217;s costs.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">11.</b></font><b style="font-size:12pt;font-weight:bold;">Non-Exclusivity</b><font style="font-size:12pt;">. &#160;The Client reserves the right to engage other consultants to perform services, without giving Consultant a right of first refusal or any other exclusive rights. &#160;Consultant reserves the right to perform services for other persons, provided that the performance of such services do not conflict or interfere with services provided pursuant to or obligations under this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">12.</b></font><b style="font-size:12pt;font-weight:bold;">No Conflict of Interest.</b><font style="font-size:12pt;"> &#160;During the term of this Agreement, unless written permission is given by the Executive, Consultant will not accept work, enter into a contract, or provide services to any third party that provides products or services which compete with the products or services provided by the Client nor may Consultant enter into any agreement or perform any services which would conflict or interfere with the services provided pursuant to or the obligations under this Agreement. &#160;Consultant warrants that there is no other contract or duty on her part that prevents or impedes Consultant&#8217;s performance under this Agreement. &#160;Consultant agrees to indemnify Client from any and all loss or liability incurred by reason of the alleged breach by Consultant of any services agreement with any third party.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">13.</b></font><b style="font-size:12pt;font-weight:bold;">No Solicitation.&#160; </b><font style="font-size:12pt;">During the Consulting Period, and for a period of one (1) year thereafter, Consultant will not, directly or indirectly (whether for compensation or without compensation) (i) recruit, solicit or induce, or attempt to induce, any employee, consultant, or contractor of the Client to terminate their employment, contractual or other relationship with the Client; or (ii) solicit the business of any client or customer of Client other than as expressly directed to by the Client.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">14.</b></font><b style="font-size:12pt;font-weight:bold;">Confidential Information.</b><font style="font-size:12pt;"> &#160;Consultant agrees to hold Client&#8217;s Confidential Information (as defined below) in strict confidence and not to disclose such Confidential Information to any third parties. &#160;Consultant also agrees not to use any of Client&#8217;s Confidential Information for any purpose other than performance of Consultant&#8217;s services hereunder. &#160;&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Confidential Information</font><font style="font-size:12pt;">&#8221; as used in this Agreement shall mean all information disclosed by Client to Consultant, or otherwise, regarding Client or its business obtained by Consultant pursuant to services provided under this Agreement that is not generally known in the Client&#8217;s trade or industry and shall include, without limitation, (a) concepts and ideas relating to the development and distribution of content in any medium or to the current, future and proposed products or services of Client or its subsidiaries or affiliates; (b) trade secrets, drawings, inventions, know-how, software programs, and software source documents; (c) information regarding plans for research, development, new service offerings or products, marketing and selling, business plans, business forecasts, budgets and unpublished financial statements, licenses and distribution arrangements, prices and costs, suppliers and customers; and (d) any information regarding the skills and compensation of employees, contractors or other agents of the Client or its subsidiaries or affiliates. &#160;Confidential Information also includes proprietary or confidential information of any third party who may disclose such information to Client or Consultant in the</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">4</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">course of Client&#8217;s business. &#160;Consultant&#8217;s obligations set forth in this Section shall not apply with respect to any portion of the Confidential Information that Consultant can document by competent proof that such portion: (i) is in the public domain through no fault of Consultant; (ii) has been rightfully independently communicated to Consultant free of any obligation of confidence; or (iii) was developed by Consultant independently of and without reference to any information communicated to Consultant by Client. &#160;In addition, Consultant may disclose Client&#8217;s Confidential Information in response to a valid order by a court or other governmental body, as otherwise required by law. &#160;All Confidential Information furnished to Consultant by Client is the sole and exclusive property of Client or its suppliers or customers. &#160;Upon request by Client, Consultant agrees to promptly deliver to Client the original and any copies of such Confidential Information. &#160;Notwithstanding the foregoing or anything to the contrary in this Agreement or any other agreement between Client and Consultant, nothing in this Agreement shall limit Consultant&#8217;s right to discuss Consultant&#8217;s engagement with the Client or report possible violations of law or regulation with the Equal Employment Opportunity Commission, United States Department of Labor, the National Labor Relations Board, the Securities and Exchange Commission, or other federal government agency or similar state or local agency or to discuss the terms and conditions of Consultant&#8217;s engagement with others to the extent expressly permitted by applicable provisions of law or regulation, including but not limited to &quot;whistleblower&quot; statutes or other similar provisions that protect such disclosure. Further, notwithstanding the foregoing, pursuant to 18 U.S.C. Section 1833(b), Consultant shall not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of a trade secret that: (1) is made in confidence to a Federal, State, or local government official, either directly or indirectly, or to an attorney, and solely for the purpose of reporting or investigating a suspected violation of law; or (2) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">15.</b></font><b style="font-size:12pt;font-weight:bold;">Term and Termination.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">15.1</b></font><b style="font-size:12pt;font-weight:bold;">Term. </b><font style="font-size:12pt;"> The term of this Agreement and the &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Consulting Period</font><font style="font-size:12pt;">&#8221; is for twelve (12) months from the Effective Date set forth above; </font><i style="font-size:12pt;font-style:italic;">provided, however</i><font style="font-size:12pt;">, that the Consulting Period may be renewed and extended by the mutual written agreement of Consultant and an authorized officer of Client.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">15.2</b></font><b style="font-size:12pt;font-weight:bold;">Effect of Termination.</b><font style="font-size:12pt;"> &#160;Upon any termination or expiration of this Agreement, Consultant (i) shall immediately discontinue all use of Client&#8217;s Confidential Information delivered under this Agreement; (ii) shall delete any such Client Confidential Information from Consultant&#8217;s computer storage or any other media, including, but not limited to, online and off-line libraries; and (iii) shall return to Client, or, at Client&#8217;s option, destroy, all copies of such Confidential Information then in Consultant&#8217;s possession.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">15.3</b></font><b style="font-size:12pt;font-weight:bold;">Survival.</b><font style="font-size:12pt;"> &#160;The rights and obligations contained in Sections 3-6, 8-9, 13-14, 15.3 and 16-24 will survive any termination or expiration of this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">16.</b></font><b style="font-size:12pt;font-weight:bold;">Indemnification.</b><font style="font-size:12pt;"> &#160;Consultant shall indemnify and hold harmless the Client and its officers, directors, agents, owners, and employees, for any claims brought or liabilities imposed against the Client by Consultant or any of her employees or by any other party (including private parties, governmental bodies and courts), including claims related to worker&#8217;s compensation,</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">5</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">wage and hour laws, employment taxes, and benefits, and whether relating to Consultant&#8217;s status as an independent contractor, the status of her personnel, or any other matters involving the acts or omissions of Consultant and her personnel. &#160;Indemnification shall be for any and all losses and damages, including costs and attorneys&#8217; fees.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">17.</b></font><b style="font-size:12pt;font-weight:bold;">Insurance.</b><font style="font-size:12pt;"> &#160;Consultant will obtain for herself and her personnel before providing services, at her own expense, General Liability (GL) insurance coverage for consulting services performed under this Agreement and (if available under state law) worker&#8217;s compensation coverage.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">18.</b></font><b style="font-size:12pt;font-weight:bold;">Successors and Assigns.</b><font style="font-size:12pt;"> &#160;Consultant may not subcontract or otherwise delegate her obligations under this Agreement without Client&#8217;s prior written consent. &#160;Client may assign this Agreement. Subject to the foregoing, this Agreement will be for the benefit of Client&#8217;s successors and assigns and will be binding on Consultant&#8217;s subcontractors or delegates.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">19.</b></font><b style="font-size:12pt;font-weight:bold;">Notices.</b><font style="font-size:12pt;"> &#160;Any notice required or permitted by this Agreement shall be in writing and shall be delivered as follows with notice deemed given as indicated: (i) by overnight courier upon written verification of receipt; or (ii) by telecopy or facsimile transmission upon acknowledgment of receipt of electronic transmission. &#160;Notice shall be sent to the addresses set forth below or such other address as either party may specify in writing.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">20.</b></font><b style="font-size:12pt;font-weight:bold;">Governing Law.</b><font style="font-size:12pt;"> &#160;This Agreement shall be governed in all respects by the laws of the State of Maryland, as such laws are applied to agreements entered into and to be performed entirely within Maryland between Maryland residents. &#160;Any suit involving this Agreement shall be brought in a court sitting in Maryland. &#160;The parties agree that venue shall be proper in such courts, and that such courts will have personal jurisdiction over them.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">21.</b></font><b style="font-size:12pt;font-weight:bold;">Severability.</b><font style="font-size:12pt;"> &#160;Should any provisions of this Agreement be held by a court of law to be illegal, invalid or unenforceable, the legality, validity and enforceability of the remaining provisions of this Agreement shall not be affected or impaired thereby.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">22.</b></font><b style="font-size:12pt;font-weight:bold;">Waiver.</b><font style="font-size:12pt;"> &#160;The waiver by Client of a breach of any provision of this Agreement by Consultant shall not operate or be construed as a waiver of any other or subsequent breach by Consultant.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">23.</b></font><b style="font-size:12pt;font-weight:bold;">Injunctive Relief for Breach. </b><font style="font-size:12pt;"> Consultant&#8217;s obligations under this Agreement are of a unique character that gives them particular value; breach of any of such obligations will result in irreparable and continuing damage to Client for which there will be no adequate remedy at law; and, in the event of such breach, Client will be entitled to injunctive relief and/or a decree for specific performance, and such other and further relief as may be proper (including monetary damages if appropriate and attorney&#8217;s fees).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">24.</b></font><b style="font-size:12pt;font-weight:bold;">Entire Agreement. &#160;</b><font style="font-size:12pt;">This Agreement constitutes the entire understanding of the parties relating to the subject matter and supersedes any previous oral or written communications, representations, understanding, or agreement between the parties concerning such subject matter. &#160;This Agreement shall not be changed, modified, supplemented or amended except by express written agreement signed by Consultant and the Client. The parties have entered into separate agreements related to Consultant&#8217;s previous employment relationship with</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">6</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">GlycoMimetics, Inc. These separate agreements govern the previous employment relationship between Consultant and GlycoMimetics, Inc., have or may have provisions that survive termination of Consultant&#8217;s relationship with Client under this Agreement, may be amended or superseded without regard to this Agreement, and are enforceable according to their terms without regard to the enforcement provision of this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">[The remainder of this page is intentionally blank. Signature page follows.]</b></p><p style="display:none;line-height:0pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">7</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">IN WITNESS WHEREOF,</b><font style="font-size:12pt;"> the parties have executed this Agreement effective as of the date first written above.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td colspan="2" style="vertical-align:bottom;width:51.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">&#8220;CLIENT&#8221;</b></p></td><td style="vertical-align:top;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:46.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">&#8220;CONSULTANT&#8221;</b></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:51.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:46.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:51.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">GLYCOMIMETICS, INC.</b></p></td><td style="vertical-align:top;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:46.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">RACHEL K. KING</b></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:51.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:46.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:12.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">By:</font></p></td><td style="vertical-align:bottom;width:38.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">/s/ Brian Hahn</font></p></td><td style="vertical-align:top;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:46.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">/s/ Rachel K. King</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:51.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:46.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:12.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Name (print):</font></p></td><td style="vertical-align:bottom;width:38.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Brian Hahn</font></p></td><td style="vertical-align:top;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Name (print): </font></p></td><td style="vertical-align:bottom;width:34.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Rachel King</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:51.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:46.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:12.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Title:</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;"> </u></p></td><td style="vertical-align:bottom;width:38.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Chief Financial Officer and</font></p></td><td style="vertical-align:top;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Address: </font></p></td><td style="vertical-align:bottom;width:34.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">8009 Spring Road</font></p></td></tr><tr><td style="vertical-align:bottom;width:12.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 33pt;"><font style="font-size:12pt;margin-left:0pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:38.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Senior Vice President</font></p></td><td style="vertical-align:top;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:34.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Cabin John, MD 20818</font></p></td></tr><tr><td style="vertical-align:bottom;width:12.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Telephone:</font></p></td><td style="vertical-align:bottom;width:38.74%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">(301) 417-4254</font></p></td><td style="vertical-align:top;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Tel:</font></p></td><td style="vertical-align:bottom;width:34.15%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">(202) 256-6991</font></p></td></tr><tr><td style="vertical-align:bottom;width:12.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Fax: </font></p></td><td style="vertical-align:bottom;width:38.74%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">(240) 599-7656</font></p></td><td style="vertical-align:top;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Fax: </font></p></td><td style="vertical-align:bottom;width:34.15%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">N/A</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.14
<SEQUENCE>3
<FILENAME>glyc-20211231xex10d14.htm
<DESCRIPTION>EX-10.14
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 3/3/2022 09:44:21 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 10.14</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">GLYCOMIMETICS, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">AMENDED AND RESTATED</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">NON-EMPLOYEE DIRECTOR COMPENSATION POLICY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 9.35pt;"><font style="font-size:11pt;">Each member of the Board of Directors (the </font><font style="font-size:11pt;font-style:italic;font-weight:bold;">&#8220;Board&#8221;</font><font style="font-size:11pt;">) who is not also serving as an employee of GlycoMimetics, Inc. (the </font><font style="font-size:11pt;font-style:italic;font-weight:bold;">&#8220;Company&#8221;</font><font style="font-size:11pt;">) or any of its subsidiaries (each such member, an </font><font style="font-size:11pt;font-style:italic;font-weight:bold;">&#8220;Eligible Director&#8221;</font><font style="font-size:11pt;">) will receive the compensation described in this Amended and Restated Non-Employee Director Compensation Policy for his or her Board service.&#160;&#160;This policy may be amended at any time in the sole discretion of the Board or the Compensation Committee of the Board.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 9pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 9pt;"><b style="font-size:11pt;font-weight:bold;">Annual Cash Compensation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 9pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 9pt;"><font style="font-size:11pt;">The annual cash compensation amount set forth below is payable in equal quarterly installments, payable in arrears on the last day of each fiscal quarter in which the service occurred. If an Eligible Director joins the Board or a committee of the Board at a time other than effective as of the first day of a fiscal quarter, each annual retainer set forth below will be pro-rated based on days served in the applicable fiscal year, with the pro-rated amount paid for the first fiscal quarter in which the Eligible Director provides the service, and regular full quarterly payments thereafter. All annual cash fees are vested upon payment.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 9pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><div style="padding-left:9.35pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:4.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:31.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:59.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:4.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">1.</font></p></td><td colspan="2" style="vertical-align:top;width:36.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Annual Board Service Retainer</u><font style="font-size:11pt;">:</font></p></td><td style="vertical-align:top;width:59.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:4.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">a.</font></p></td><td style="vertical-align:top;width:31.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">All Eligible Directors: $40,000</font></p></td><td style="vertical-align:top;width:59.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:4.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">b.</font></p></td><td colspan="2" style="vertical-align:top;width:90.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Chair of the Board Service Retainer (in addition to Eligible Director Service Retainer): $30,000</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="padding-left:9.35pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:4.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:47.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:43.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:4.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">2.</font></p></td><td colspan="2" style="vertical-align:top;width:52.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Annual Committee (Non-Chair) Member Service Retainer</u><font style="font-size:11pt;">:</font></p></td><td style="vertical-align:top;width:43.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:4.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">a.</font></p></td><td style="vertical-align:top;width:47.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Member of the Audit Committee: $9,000</font></p></td><td style="vertical-align:top;width:43.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:4.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">b.</font></p></td><td colspan="2" style="vertical-align:top;width:90.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Member of the Compensation Committee: $6,000</font></p></td></tr><tr><td style="vertical-align:top;width:4.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">c.</font></p></td><td colspan="2" style="vertical-align:top;width:90.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Member of the Nominating and Corporate Governance Committee: $4,500</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="padding-left:9.35pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:4.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:47.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:43.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:4.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">3.</font></p></td><td colspan="2" style="vertical-align:top;width:52.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Annual Committee Chair Service Retainer</u><font style="font-size:11pt;">:</font></p></td><td style="vertical-align:top;width:43.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:4.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">a.</font></p></td><td style="vertical-align:top;width:47.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Chair of the Audit Committee: $18,000</font></p></td><td style="vertical-align:top;width:43.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:4.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">b.</font></p></td><td colspan="2" style="vertical-align:top;width:90.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Chair of the Compensation Committee: $12,000</font></p></td></tr><tr><td style="vertical-align:top;width:4.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">c.</font></p></td><td colspan="2" style="vertical-align:top;width:90.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Chair of the Nominating and Corporate Governance Committee: $9,000</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 9pt;"><b style="font-size:11pt;font-weight:bold;">Equity Compensation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 9pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 9pt;"><font style="font-size:11pt;">The equity compensation set forth below will be granted under the GlycoMimetics, Inc. 2013 Equity Incentive Plan (the &#8220;</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">Plan</font><font style="font-size:11pt;">&#8221;). Any stock options granted under this policy will be nonstatutory stock options, with an exercise price per share equal to 100% of the Fair Market Value (as defined in the Plan) of the underlying Common Stock on the date of grant, and a term of ten years from the date of grant (subject to earlier termination in connection with a termination of service as provided in the Plan).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 9pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:9.35pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:11pt;min-width:26.65pt;white-space:nowrap;">1.</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Initial Grant</u><font style="font-size:11pt;">: On the date of an Eligible Director&#8217;s initial election to the Board (or if such date is not a market trading day, the first market trading day thereafter), the Eligible Director will be automatically, and without further action by the Board or Compensation Committee of the Board, granted a stock option for 42,000 shares of Common Stock.&#160;&#160;The shares subject to each stock option</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 9pt;"><font style="font-size:11pt;">will vest in three equal installments on the first, second and third anniversary of the date of grant, subject to the Eligible Director&#8217;s Continuous Service (as defined in the Plan) at each vesting date.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 9pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 9.35pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:26.65pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">2.</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Annual Grant</u><font style="font-size:11pt;">: On the date of each annual stockholder meeting of the Company, each Eligible Director who continues to serve as a non-employee member of the Board will be automatically, and without further action by the Board or Compensation Committee of the Board, granted a stock option for 21,000 shares of Common Stock (or an equivalent award of equity in such form as the Board or Compensation Committee of the Board shall determine). The shares subject to each stock option or other equity award granted hereunder will vest in full on the first anniversary of the applicable annual stockholder meeting, subject to the Eligible Director&#8217;s Continuous Service (as defined in the Plan) as of such vesting date.</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.19
<SEQUENCE>4
<FILENAME>glyc-20211231xex10d19.htm
<DESCRIPTION>EX-10.19
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 3/3/2022 09:44:25 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Exhibit 10.19</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:14pt;font-weight:bold;">GLYCOMIMETICS, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:14pt;font-weight:bold;">AMENDED AND RESTATED</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:14pt;font-weight:bold;">INDUCEMENT PLAN</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">1.</b></font><b style="font-size:12pt;font-weight:bold;">GENERAL.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(a)</b></font><b style="font-size:12pt;font-weight:bold;">Eligible Stock Award Recipients. &#160;</b><font style="font-size:12pt;">The only persons eligible to receive grants of Stock Awards under this Plan are individuals who satisfy the standards for inducement grants under Nasdaq Marketplace Rule 5635(c)(4) and the related guidance under Nasdaq IM 5635-1 &#8211; that is, generally, a person not previously an employee or director of the Company, or following a bona fide period of non-employment, as an inducement material to the individual&#8217;s entering into employment with the Company. &#160;Such eligible individuals are referred to in this Plan as &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Eligible Employees</font><font style="font-size:12pt;">&#8221;. These grants will be approved by either the Compensation Committee or a majority of the Company&#8217;s &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Independent Directors</font><font style="font-size:12pt;">&#8221; (as such term is defined by Nasdaq for purposes of Nasdaq Marketplace Rule 5635(c)(4)). We refer to Nasdaq Marketplace Rule 5635(c)(4) and the related guidance under Nasdaq IM 5635-1 as the &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Inducement Award Rules</font><font style="font-size:12pt;">&#8221;.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(b)</b></font><b style="font-size:12pt;font-weight:bold;">Available Stock Awards.</b><font style="font-size:12pt;"> &#160;The Plan provides for the grant of the following Stock Awards: (i) Nonstatutory Stock Options, (ii) Stock Appreciation Rights (iii) Restricted Stock Awards, (iv) Restricted Stock Unit Awards, and (v) Other Stock Awards. As provided in Section 2(a), Stock Awards may be granted only by either the Compensation Committee or a majority of the Independent Directors as required by the Inducement Award Rules. &#160;Incentive Stock Options may not be granted under this Plan.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(c)</b></font><b style="font-size:12pt;font-weight:bold;">General Purpose. &#160;</b><font style="font-size:12pt;">The Company, by means of the Plan, seeks to secure and retain the services of one or more Eligible Employees, to provide incentives for such persons to exert maximum efforts for the success of the Company and any Affiliate, and to provide a means by which such persons may be given an opportunity to benefit from increases in value of the Common Stock through the granting of Stock Awards.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">2.</b></font><b style="font-size:12pt;font-weight:bold;">ADMINISTRATION.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(a)</b></font><b style="font-size:12pt;font-weight:bold;">Administration. &#160;</b><font style="font-size:12pt;">The Compensation Committee shall administer the Plan. &#160;Stock Awards may only be granted by either: (i) the Compensation Committee as composed solely of Independent Directors, (ii) another Committee composed solely of Independent Directors and constituting a majority of the Company&#8217;s Independent Directors, or (iii) at the Board level by a majority of the Company&#8217;s Independent Directors, with non-Independent Directors abstaining. Subject to the foregoing Stock Award approval requirements and the other constraints of the Inducement Award Rules, the Compensation Committee may delegate some of its powers of administration of the Plan to another Committee, as provided in Section 2(c) (and references in this Plan to the Compensation Committee will thereafter be to the applicable Committee).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(b)</b></font><b style="font-size:12pt;font-weight:bold;">Powers of Compensation Committee.</b><font style="font-size:12pt;"> &#160;The Compensation Committee will have the power, subject to, and within the limitations of, the express provisions of the Plan and the Inducement Award Rules, including:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">1</font><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">As approved by the Compensation Committee</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">January 21, 2022</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:12pt;font-weight:bold;min-width:36pt;text-indent:0pt;white-space:nowrap;">(i)</font><font style="font-size:12pt;">To determine: (A) which Eligible Employees will be granted Stock Awards; (B) when and how each Stock Award will be granted; (C) what type of Stock Award will be granted; (D) the provisions of each Stock Award (which need not be identical), including when a person will be permitted to exercise or otherwise receive cash or Common Stock under the Stock Award; (E) the number of shares of Common Stock subject to, or the cash value of, a Stock Award; and (F) the Fair Market Value applicable to a Stock Award; provided, however, that Stock Awards may only be granted by either (1) the Compensation Committee as composed solely of Independent Directors, (2) another Committee composed solely of Independent Directors constituting a majority of the Company&#8217;s Independent Directors, or (3)&#160;at the Board level by a majority of the Company&#39;s Independent Directors, with non-Independent Directors abstaining.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:12pt;font-weight:bold;min-width:36pt;text-indent:0pt;white-space:nowrap;">(ii)</font><font style="font-size:12pt;">To construe and interpret the Plan and Stock Awards granted under it, and to establish, amend and revoke rules and regulations for administration of the Plan and Stock Awards. &#160;The Compensation Committee, in the exercise of these powers, may correct any defect, omission or inconsistency in the Plan or in any Stock Award Agreement, in a manner and to the extent it will deem necessary or expedient to make the Plan or Stock Award fully effective.</font></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman';font-size:12pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(iii)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">To settle all controversies regarding the Plan and Stock Awards granted under it.</font></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:12pt;font-weight:bold;min-width:36pt;text-indent:0pt;white-space:nowrap;">(iv)</font><font style="font-size:12pt;">To accelerate, in whole or in part, the time at which a Stock Award may be exercised or vest (or at which cash or shares of Common Stock may be issued).</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:12pt;font-weight:bold;min-width:36pt;text-indent:0pt;white-space:nowrap;">(v)</font><font style="font-size:12pt;">To suspend or terminate the Plan at any time. &#160;Except as otherwise provided in the Plan or a Stock Award Agreement, suspension or termination of the Plan will not materially impair a Participant&#8217;s rights under his or her then-outstanding Stock Award without his or her written consent except as provided in Section 2(b)(viii) below.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:12pt;font-weight:bold;min-width:36pt;text-indent:0pt;white-space:nowrap;">(vi)</font><font style="font-size:12pt;">To amend the Plan in any respect the Compensation Committee deems necessary or advisable consistent with the Inducement Award Rules, including, without limitation, by adopting amendments relating to certain nonqualified deferred compensation under Section 409A of the Code and/or to make the Plan or Stock Awards granted under the Plan exempt from or compliant with the requirements for nonqualified deferred compensation under Section 409A of the Code, subject to the limitations, if any, of applicable law, and subject to any stockholder approval required under the Inducement Award Rules in connection with such amendment of the Plan. Except as otherwise provided in the Plan or a Stock Award Agreement, no amendment of the Plan will materially impair a Participant&#8217;s rights under an outstanding Stock Award without the Participant&#8217;s written consent.</font></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman';font-size:12pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(vii)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">To approve forms of Stock Award Agreements for use under the Plan.</font></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:12pt;font-weight:bold;min-width:36pt;text-indent:0pt;white-space:nowrap;">(viii)</font><font style="font-size:12pt;">To amend the terms of any one or more Stock Awards, including, but not limited to, amendments to provide terms more favorable to the Participant than previously provided in the Stock Award Agreement, subject to any specified limits in the Plan that are not subject to Compensation Committee discretion, and subject to any stockholder approval required under the Inducement Award Rules in connection with such amendment of a Stock Award;</font></div><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">2</font><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">As approved by the Compensation Committee</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">January 21, 2022</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">provided however, that a Participant&#8217;s rights under any Stock Award will not be impaired by any such amendment unless (A) the Company requests the consent of the affected Participant, and (B) such Participant consents in writing. Notwithstanding the foregoing, (1) a Participant&#8217;s rights will not be deemed to have been impaired by any such amendment if the Compensation Committee, in its sole discretion, determines that the amendment, taken as a whole, does not materially impair the Participant&#8217;s rights, and (2) subject to the limitations of applicable law, if any, the Compensation Committee may amend the terms of any one or more Stock Awards without the affected Participant&#8217;s consent (A) to clarify the manner of exemption from, or to bring the Stock Award into compliance with, Section 409A of the Code or (B) to comply with other applicable laws or listing requirements, including the Inducement Award Rules.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(ix)</b></font><font style="font-size:12pt;">Generally, to exercise such powers and to perform such acts as the Compensation Committee deems necessary or expedient to promote the best interests of the Company and that are not in conflict with the provisions of the Plan or Stock Awards.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(x)</b></font><font style="font-size:12pt;">To adopt such procedures and sub-plans as are necessary or appropriate to permit participation in the Plan by Eligible Employees who are foreign nationals or employed outside the United States (provided that Compensation Committee approval will not be necessary for immaterial modifications to the Plan or any Stock Award Agreement that are required for compliance with the laws of the relevant foreign jurisdiction).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(c)</b></font><b style="font-size:12pt;font-weight:bold;">Delegation to Committee.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(i)</b></font><b style="font-size:12pt;font-weight:bold;">General. &#160;</b><font style="font-size:12pt;">Subject to the Stock Award approval requirements set forth in Section 2(a), the Compensation Committee may delegate some or all of the administration of the Plan to a Committee but only to the extent that such delegation is consistent with the Inducement Award Rules. If administration is delegated to a Committee, the Committee will have, in connection with the administration of the Plan, the powers theretofore possessed by the Compensation Committee that have been delegated to the Committee, including the power to delegate to a subcommittee any of the administrative powers the Committee is authorized to exercise, subject, however, to such resolutions, not inconsistent with the provisions of the Plan, as may be adopted from time to time by the Compensation Committee. The Compensation Committee may retain the authority to concurrently administer the Plan with the Committee and may, at any time, re-vest in the Compensation Committee some or all of the powers previously delegated.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(d)</b></font><b style="font-size:12pt;font-weight:bold;">Effect of Compensation Committee&#8217;s Decision.</b><font style="font-size:12pt;"> All determinations, interpretations and constructions made by the Compensation Committee in good faith will not be subject to review by any person and will be final, binding and conclusive on all persons.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(e)</b></font><b style="font-size:12pt;font-weight:bold;">Cancellation and Re-Grant of Stock Awards.</b><font style="font-size:12pt;"> &#160;Neither the Compensation Committee nor any Committee will have the authority to: (i) reduce the exercise price or strike price of any outstanding Options or SARs under the Plan, or (ii) cancel any outstanding Options or SARs that have an exercise price or strike price greater than the current Fair Market Value in exchange for cash or other Stock Awards under the Plan, unless the stockholders of the Company have approved such an action within twelve months prior to such an event.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">3</font><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">As approved by the Compensation Committee</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">January 21, 2022</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">3.</b></font><b style="font-size:12pt;font-weight:bold;">SHARES SUBJECT TO THE PLAN.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(a)</b></font><b style="font-size:12pt;font-weight:bold;">Share Reserve. &#160;</b><font style="font-size:12pt;">Subject to Section 9(a) relating to Capitalization Adjustments, the aggregate number of shares of Common Stock that may be issued pursuant to Stock Awards from and after the Effective Date will not exceed 3,000,000 shares (the &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Share Reserve</font><font style="font-size:12pt;">&#8221;). &#160;For clarity, the Share Reserve is a limitation on the number of shares of Common Stock that may be issued under the Plan. &#160;Accordingly, this Section 3(a) does not limit the granting of Stock Awards except as provided in Section 7(a). &#160;Shares may be issued in connection with a merger or acquisition as permitted by NASDAQ Listing Rule 5635(c) or, if applicable, NYSE Listed Company Manual Section 303A.08, AMEX Company Guide Section 711 or other applicable rule, and such issuance will not reduce the number of shares available for issuance under the Plan.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(b)</b></font><b style="font-size:12pt;font-weight:bold;">Reversion of Shares to the Share Reserve. &#160;</b><font style="font-size:12pt;">If a Stock Award or any portion thereof (i) expires or otherwise terminates without all of the shares covered by such Stock Award having been issued or (ii) is settled in cash (</font><i style="font-size:12pt;font-style:italic;">i.e.</i><font style="font-size:12pt;">, the Participant receives cash rather than stock), such expiration, termination or settlement will not reduce (or otherwise offset) the number of shares of Common Stock that may be available for issuance under the Plan. &#160;If any shares of Common Stock issued pursuant to a Stock Award are forfeited back to or repurchased by the Company because of the failure to meet a contingency or condition required to vest such shares in the Participant, then the shares that are forfeited or repurchased will revert to and again become available for issuance under the Plan. &#160;Any shares reacquired by the Company in satisfaction of tax withholding obligations on a Stock Award or as consideration for the exercise or purchase price of a Stock Award will again become available for issuance under the Plan.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(c)</b></font><b style="font-size:12pt;font-weight:bold;">Source of Shares.</b><font style="font-size:12pt;"> &#160;The stock issuable under the Plan will be shares of authorized but unissued or reacquired Common Stock, including shares repurchased by the Company on the open market or otherwise.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">4.</b></font><b style="font-size:12pt;font-weight:bold;">ELIGIBILITY.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">Stock Awards may be granted to Eligible Employees; </font><i style="font-size:12pt;font-style:italic;">provided, however</i><font style="font-size:12pt;">, that Stock Awards may not be granted to Eligible Employees who are providing Continuous Service only to any &#8220;parent&#8221; of the Company, as such term is defined in Rule&#160;405 of the Securities Act, unless (i) the stock underlying such Stock Awards is treated as &#8220;service recipient stock&#8221; under Section&#160;409A of the Code (for example, because the Stock Awards are granted pursuant to a corporate transaction such as a spin off transaction), (ii) the Company, in consultation with its legal counsel, has determined that such Stock Awards are otherwise exempt from Section 409A of the Code, or (iii) the Company, in consultation with its legal counsel, has determined that such Stock Awards comply with the distribution requirements of Section&#160;409A of the Code.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">5.</b></font><b style="font-size:12pt;font-weight:bold;">PROVISIONS RELATING TO OPTIONS AND STOCK APPRECIATION RIGHTS.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">Each Option or SAR will be in such form and will contain such terms and conditions as the Compensation Committee deems appropriate. &#160;The provisions of separate Options or SARs need not be identical; </font><i style="font-size:12pt;font-style:italic;">provided, however</i><font style="font-size:12pt;">, that each Stock Award Agreement will conform to</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">4</font><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">As approved by the Compensation Committee</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">January 21, 2022</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(through incorporation of provisions hereof by reference in the applicable Stock Award Agreement or otherwise) the substance of each of the following provisions:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(a)</b></font><b style="font-size:12pt;font-weight:bold;">Term. &#160;</b><font style="font-size:12pt;">No Option or SAR will be exercisable after the expiration of ten years from the date of its grant or such shorter period specified in the Stock Award Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(b)</b></font><b style="font-size:12pt;font-weight:bold;">Exercise Price. &#160;</b><font style="font-size:12pt;">The exercise or strike price of each Option or SAR will be not less than 100% of the Fair Market Value of the Common Stock subject to the Option or SAR on the date the Stock Award is granted. &#160;Each SAR will be denominated in shares of Common Stock equivalents.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(c)</b></font><b style="font-size:12pt;font-weight:bold;">Purchase Price for Options.</b><font style="font-size:12pt;"> &#160;The purchase price of Common Stock acquired pursuant to the exercise of an Option may be paid, to the extent permitted by applicable law and as determined by the Compensation Committee in its sole discretion, by any combination of the methods of payment set forth below. &#160;The Compensation Committee will have the authority to grant Options that do not permit all of the following methods of payment (or that otherwise restrict the ability to use certain methods) and to grant Options that require the consent of the Company to use a particular method of payment. &#160;The permitted methods of payment are as follows:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(i)</b></font><font style="font-size:12pt;">by cash, check, bank draft or money order payable to the Company;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(ii)</b></font><font style="font-size:12pt;">pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board that, prior to the issuance of the stock subject to the Option, results in either the receipt of cash (or check) by the Company or the receipt of irrevocable instructions to pay the aggregate exercise price to the Company from the sales proceeds;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(iii)</b></font><font style="font-size:12pt;">by delivery to the Company (either by actual delivery or attestation) of shares of Common Stock;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(iv)</b></font><font style="font-size:12pt;">by a &#8220;net exercise&#8221; arrangement pursuant to which the Company will reduce the number of shares of Common Stock issuable upon exercise by the largest whole number of shares with a Fair Market Value that does not exceed the aggregate exercise price; </font><i style="font-size:12pt;font-style:italic;">provided, however</i><font style="font-size:12pt;">, that the Company will accept a cash or other payment from the Participant to the extent of any remaining balance of the aggregate exercise price not satisfied by such reduction in the number of whole shares to be issued. &#160;Shares of Common Stock will no longer be subject to an Option and will not be exercisable thereafter to the extent that (A) shares issuable upon exercise are reduced to pay the exercise price pursuant to the &#8220;net exercise,&#8221; (B) shares are delivered to the Participant as a result of such exercise, and (C) shares are withheld to satisfy tax withholding obligations; or</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(v)</b></font><font style="font-size:12pt;">in any other form of legal consideration that may be acceptable to the Compensation Committee and specified in the applicable Stock Award Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(d)</b></font><b style="font-size:12pt;font-weight:bold;">Exercise and Payment of a SAR.</b><font style="font-size:12pt;"> &#160;To exercise any outstanding SAR, the Participant must provide written notice of exercise to the Company in compliance with the provisions of the Stock Appreciation Right Agreement evidencing such SAR. &#160;The appreciation</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">5</font><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">As approved by the Compensation Committee</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">January 21, 2022</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">distribution payable on the exercise of a SAR will be not greater than an amount equal to the excess of (A) the aggregate Fair Market Value (on the date of the exercise of the SAR) of a number of shares of Common Stock equal to the number of Common Stock equivalents in which the Participant is vested under such SAR, and with respect to which the Participant is exercising the SAR on such date, over (B) the aggregate strike price of the number of Common Stock equivalents with respect to which the Participant is exercising the SAR on such date. &#160;The appreciation distribution may be paid in Common Stock, in cash, in any combination of the two or in any other form of consideration, as determined by the Compensation Committee and contained in the Stock Award Agreement evidencing such SAR.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(e)</b></font><b style="font-size:12pt;font-weight:bold;">Transferability of Options and SARs.</b><font style="font-size:12pt;"> &#160;The Compensation Committee may, in its sole discretion, impose such limitations on the transferability of Options and SARs as the Compensation Committee will determine. &#160;In the absence of such a determination by the Compensation Committee to the contrary, the following restrictions on the transferability of Options and SARs will apply:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(i)</b></font><b style="font-size:12pt;font-weight:bold;">Restrictions on Transfer.</b><font style="font-size:12pt;"> &#160;An Option or SAR will not be transferable except by will or by the laws of descent and distribution (or pursuant to subsections (ii) and (iii) below), and will be exercisable during the lifetime of the Participant only by the Participant. &#160;The Compensation Committee may permit transfer of the Option or SAR in a manner that is not prohibited by applicable tax and securities laws. Except as explicitly provided herein, neither an Option nor a SAR may be transferred for consideration.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(ii)</b></font><b style="font-size:12pt;font-weight:bold;">Domestic Relations Orders.</b><font style="font-size:12pt;"> &#160;Subject to the approval of the Compensation Committee or a duly authorized Officer, an Option or SAR may be transferred pursuant to the terms of a domestic relations order, official marital settlement agreement or other divorce or separation instrument.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(iii)</b></font><b style="font-size:12pt;font-weight:bold;">Beneficiary Designation.</b><font style="font-size:12pt;"> &#160;Subject to the approval of the Compensation Committee or a duly authorized Officer, a Participant may, by delivering written notice to the Company, in a form approved by the Company (or the designated broker), designate a third party who, on the death of the Participant, will thereafter be entitled to exercise the Option or SAR and receive the Common Stock or other consideration resulting from such exercise. &#160;In the absence of such a designation, the executor or administrator of the Participant&#8217;s estate will be entitled to exercise the Option or SAR and receive the Common Stock or other consideration resulting from such exercise. However, the Company may prohibit designation of a beneficiary at any time, including due to any conclusion by the Company that such designation would be inconsistent with the provisions of applicable laws.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(f)</b></font><b style="font-size:12pt;font-weight:bold;">Vesting Generally.</b><font style="font-size:12pt;"> &#160;The total number of shares of Common Stock subject to an Option or SAR may vest and become exercisable in periodic installments that may or may not be equal. &#160;The Option or SAR may be subject to such other terms and conditions on the time or times when it may or may not be exercised (which may be based on the satisfaction of performance goals or other criteria) as the Compensation Committee may deem appropriate. &#160;The vesting provisions of individual Options or SARs may vary. &#160;The provisions of this Section 5(f) are subject to any Option or SAR provisions governing the minimum number of shares of Common Stock as to which an Option or SAR may be exercised.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">6</font><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">As approved by the Compensation Committee</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">January 21, 2022</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(g)</b></font><b style="font-size:12pt;font-weight:bold;">Termination of Continuous Service.</b><font style="font-size:12pt;"> &#160;Except as otherwise provided in the applicable Stock Award Agreement or other agreement between the Participant and the Company, if a Participant&#8217;s Continuous Service terminates (other than for Cause and other than upon the Participant&#8217;s death or Disability), the Participant may exercise his or her Option or SAR (to the extent that the Participant was entitled to exercise such Stock Award as of the date of termination of Continuous Service) within the period of time ending on the earlier of (i) the date three months following the termination of the Participant&#8217;s Continuous Service (or such longer or shorter period specified in the applicable Stock Award Agreement), and (ii) the expiration of the term of the Option or SAR as set forth in the Stock Award Agreement. &#160;If, after termination of Continuous Service, the Participant does not exercise his or her Option or SAR (as applicable) within the applicable time frame, the Option or SAR will terminate.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(h)</b></font><b style="font-size:12pt;font-weight:bold;">Extension of Termination Date.</b><font style="font-size:12pt;"> &#160;If the exercise of an Option or SAR following the termination of the Participant&#8217;s Continuous Service (other than for Cause and other than upon the Participant&#8217;s death or Disability) would be prohibited at any time solely because the issuance of shares of Common Stock would violate the registration requirements under the Securities Act, then the Option or SAR will terminate on the earlier of (i) the expiration of a total period of time (that need not be consecutive) equal to the applicable post termination exercise period after the termination of the Participant&#8217;s Continuous Service during which the exercise of the Option or SAR would not be in violation of such registration requirements, and (ii) the expiration of the term of the Option or SAR as set forth in the applicable Stock Award Agreement. &#160;In addition, unless otherwise provided in a Participant&#8217;s Stock Award Agreement, if the sale of any Common Stock received on exercise of an Option or SAR following the termination of the Participant&#8217;s Continuous Service (other than for Cause) would violate the Company&#8217;s insider trading policy, then the Option or SAR will terminate on the earlier of (i) the expiration of a period of months (that need not be consecutive) equal to the applicable post-termination exercise period after the termination of the Participant&#8217;s Continuous Service during which the sale of the Common Stock received upon exercise of the Option or SAR would not be in violation of the Company&#8217;s insider trading policy, or (ii) the expiration of the term of the Option or SAR as set forth in the applicable Stock Award Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(i)</b></font><b style="font-size:12pt;font-weight:bold;">Disability of Participant.</b><font style="font-size:12pt;"> &#160;Except as otherwise provided in the applicable Stock Award Agreement or other agreement between the Participant and the Company, if a Participant&#8217;s Continuous Service terminates as a result of the Participant&#8217;s Disability, the Participant may exercise his or her Option or SAR (to the extent that the Participant was entitled to exercise such Option or SAR as of the date of termination of Continuous Service), but only within such period of time ending on the earlier of (i) the date 12 months following such termination of Continuous Service (or such longer or shorter period specified in the Stock Award Agreement), and (ii) the expiration of the term of the Option or SAR as set forth in the Stock Award Agreement. &#160;If, after termination of Continuous Service, the Participant does not exercise his or her Option or SAR within the applicable time frame, the Option or SAR (as applicable) will terminate.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(j)</b></font><b style="font-size:12pt;font-weight:bold;">Death of Participant.</b><font style="font-size:12pt;"> &#160;Except as otherwise provided in the applicable Stock Award Agreement or other agreement between the Participant and the Company, if (i) a Participant&#8217;s Continuous Service terminates as a result of the Participant&#8217;s death, or (ii) the Participant dies within the period (if any) specified in the Stock Award Agreement for</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">7</font><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">As approved by the Compensation Committee</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">January 21, 2022</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">exercisability after the termination of the Participant&#8217;s Continuous Service for a reason other than death, then the Option or SAR may be exercised (to the extent the Participant was entitled to exercise such Option or SAR as of the date of death) by the Participant&#8217;s estate, by a person who acquired the right to exercise the Option or SAR by bequest or inheritance or by a person designated to exercise the Option or SAR upon the Participant&#8217;s death, but only within the period ending on the earlier of (i) the date 18 months following the date of death</font><font style="font-size:12pt;"> (or such longer or shorter period specified in the Stock Award Agreement), </font><font style="font-size:12pt;">and (ii) the expiration of the term of such Option or SAR as set forth in the Stock Award Agreement. &#160;If, after the Participant&#8217;s death, the Option or SAR is not exercised within the applicable time frame, the Option or SAR will terminate.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(k)</b></font><b style="font-size:12pt;font-weight:bold;">Termination for Cause.</b><font style="font-size:12pt;"> &#160;Except as explicitly provided otherwise in a Participant&#8217;s Stock Award Agreement or other individual written agreement between the Company or any Affiliate and the Participant, if a Participant&#8217;s Continuous Service is terminated for Cause, the Option or SAR will terminate immediately upon such Participant&#8217;s termination of Continuous Service, and the Participant will be prohibited from exercising his or her Option or SAR from and after the date of such termination of Continuous Service.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(l)</b></font><b style="font-size:12pt;font-weight:bold;">Non-Exempt Employees</b><font style="font-size:12pt;">. &#160;If an Option or SAR is granted to an Eligible Employee who is a non-exempt employee for purposes of the Fair Labor Standards Act of 1938, as amended, the Option or SAR will not be first exercisable for any shares of Common Stock until at least six (6) months following the date of grant of the Option or SAR (although the Stock Award may vest prior to such date). Consistent with the provisions of the Worker Economic Opportunity Act, (i) if such non-exempt Employee dies or suffers a Disability, (ii) upon a Corporate Transaction in which such Option or SAR is not assumed, continued, or substituted, (iii) upon a Change in Control, or (iv) upon the Participant&#8217;s retirement (as such term may be defined in the Participant&#8217;s Stock Award Agreement in another agreement between the Participant and the Company, or, if no such definition, in accordance with the Company&#39;s then current employment policies and guidelines), the vested portion of any Options and SARs may be exercised earlier than six months following the date of grant. &#160;The foregoing provision is intended to operate so that any income derived by a non-exempt employee in connection with the exercise or vesting of an Option or SAR will be exempt from his or her regular rate of pay. To the extent permitted and/or required for compliance with the Worker Economic Opportunity Act to ensure that any income derived by a non-exempt employee in connection with the exercise, vesting or issuance of any shares under any other Stock Award will be exempt from the employee&#8217;s regular rate of pay, the provisions of this Section 5(l) will apply to all Stock Awards and are hereby incorporated by reference into such Stock Award Agreements.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">6.</b></font><b style="font-size:12pt;font-weight:bold;">PROVISIONS OF STOCK AWARDS OTHER THAN OPTIONS AND SARS.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(a)</b></font><b style="font-size:12pt;font-weight:bold;">Restricted Stock Awards.</b><font style="font-size:12pt;"> &#160;Each Restricted Stock Award Agreement will be in such form and will contain such terms and conditions as the Compensation Committee will deem appropriate. &#160;To the extent consistent with the Company&#8217;s bylaws, at the Compensation Committee&#8217;s election, shares of Common Stock may be (x) held in book entry form subject to the Company&#8217;s instructions until any restrictions relating to the Restricted Stock Award lapse; or (y)&#160;evidenced by a certificate, which certificate will be held in such form and manner as determined by the Compensation Committee. &#160;The terms and conditions of Restricted Stock</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">8</font><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">As approved by the Compensation Committee</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">January 21, 2022</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">Award Agreements may change from time to time, and the terms and conditions of separate Restricted Stock Award Agreements need not be identical. &#160;Each Restricted Stock Award Agreement will conform to (through incorporation of the provisions hereof by reference in the agreement or otherwise) the substance of each of the following provisions:</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:12pt;font-weight:bold;min-width:36pt;text-indent:0pt;white-space:nowrap;">(i)</font><b style="font-size:12pt;font-weight:bold;">Consideration.</b><font style="font-size:12pt;"> &#160;A Restricted Stock Award may be awarded in consideration for (A) cash, check, bank draft or money order payable to the Company, (B) past services to the Company or an Affiliate, or (C) any other form of legal consideration (including future services) that may be acceptable to the Compensation Committee, in its sole discretion, and permissible under applicable law.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:12pt;font-weight:bold;min-width:36pt;text-indent:0pt;white-space:nowrap;">(ii)</font><b style="font-size:12pt;font-weight:bold;">Vesting. &#160;</b><font style="font-size:12pt;">Shares of Common Stock awarded under the Restricted Stock Award Agreement may be subject to forfeiture to the Company in accordance with a vesting schedule to be determined by the Compensation Committee.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:12pt;font-weight:bold;min-width:36pt;text-indent:0pt;white-space:nowrap;">(iii)</font><b style="font-size:12pt;font-weight:bold;">Termination of Participant&#8217;s Continuous Service.</b><font style="font-size:12pt;"> &#160;If a Participant&#8217;s Continuous Service terminates, the Company may receive through a forfeiture condition or a repurchase right any or all of the shares of Common Stock held by the Participant as of the date of termination of Continuous Service under the terms of the Restricted Stock Award Agreement.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:12pt;font-weight:bold;min-width:36pt;text-indent:0pt;white-space:nowrap;">(iv)</font><b style="font-size:12pt;font-weight:bold;">Transferability.</b><font style="font-size:12pt;"> &#160;Rights to acquire shares of Common Stock under the Restricted Stock Award Agreement will be transferable by the Participant only upon such terms and conditions as are set forth in the Restricted Stock Award Agreement, as the Compensation Committee will determine in its sole discretion, so long as Common Stock awarded under the Restricted Stock Award Agreement remains subject to the terms of the Restricted Stock Award Agreement.</font></div><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(v)</b></font><b style="font-size:12pt;font-weight:bold;">Dividends. &#160;</b><font style="font-size:12pt;">A Restricted Stock Award Agreement may provide that any dividends paid on Restricted Stock will be subject to the same vesting and forfeiture restrictions as apply to the shares subject to the Restricted Stock Award to which they relate.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(b)</b></font><b style="font-size:12pt;font-weight:bold;">Restricted Stock Unit Awards. &#160;</b><font style="font-size:12pt;">Each Restricted Stock Unit Award Agreement will be in such form and will contain such terms and conditions as the Compensation Committee will deem appropriate. &#160;The terms and conditions of Restricted Stock Unit Award Agreements may change from time to time, and the terms and conditions of separate Restricted Stock Unit Award Agreements need not be identical. &#160;Each Restricted Stock Unit Award Agreement will conform to (through incorporation of the provisions hereof by reference in the Agreement or otherwise) the substance of each of the following provisions:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(i)</b></font><b style="font-size:12pt;font-weight:bold;">Consideration.</b><font style="font-size:12pt;"> &#160;At the time of grant of a Restricted Stock Unit Award, the Compensation Committee will determine the consideration, if any, to be paid by the Participant upon delivery of each share of Common Stock subject to the Restricted Stock Unit Award. The consideration to be paid (if any) by the Participant for each share of Common Stock subject to a Restricted Stock Unit Award may be paid in any form of legal consideration that may be acceptable to the Compensation Committee, in its sole discretion, and permissible under applicable law.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">9</font><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">As approved by the Compensation Committee</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">January 21, 2022</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(ii)</b></font><b style="font-size:12pt;font-weight:bold;">Vesting. &#160;</b><font style="font-size:12pt;">At the time of the grant of a Restricted Stock Unit Award, the Compensation Committee may impose such restrictions on or conditions to the vesting of the Restricted Stock Unit Award as it, in its sole discretion, deems appropriate.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(iii)</b></font><b style="font-size:12pt;font-weight:bold;">Payment</b><font style="font-size:12pt;">. &#160;A Restricted Stock Unit Award may be settled by the delivery of shares of Common Stock, their cash equivalent, any combination thereof or in any other form of consideration, as determined by the Compensation Committee and contained in the Restricted Stock Unit Award Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(iv)</b></font><b style="font-size:12pt;font-weight:bold;">Additional Restrictions. &#160;</b><font style="font-size:12pt;">At the time of the grant of a Restricted Stock Unit Award, the Compensation Committee, as it deems appropriate, may impose such restrictions or conditions that delay the delivery of the shares of Common Stock (or their cash equivalent) subject to a Restricted Stock Unit Award to a time after the vesting of such Restricted Stock Unit Award.</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:12pt;font-weight:bold;min-width:36pt;text-indent:0pt;white-space:nowrap;">(v)</font><b style="font-size:12pt;font-weight:bold;">Dividend Equivalents. &#160;</b><font style="font-size:12pt;">Dividend equivalents may be credited in respect of shares of Common Stock covered by a Restricted Stock Unit Award, as determined by the Compensation Committee and contained in the Restricted Stock Unit Award Agreement. &#160;At the sole discretion of the Compensation Committee, such dividend equivalents may be converted into additional shares of Common Stock covered by the Restricted Stock Unit Award in such manner as determined by the Compensation Committee. &#160;Any additional shares covered by the Restricted Stock Unit Award credited by reason of such dividend equivalents will be subject to all of the same terms and conditions of the underlying Restricted Stock Unit Award Agreement to which they relate.</font></div><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(vi)</b></font><b style="font-size:12pt;font-weight:bold;">Termination of Participant&#8217;s Continuous Service. &#160;</b><font style="font-size:12pt;">Except as otherwise provided in the applicable Restricted Stock Unit Award Agreement, such portion of the Restricted Stock Unit Award that has not vested will be forfeited upon the Participant&#8217;s termination of Continuous Service.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(c)</b></font><b style="font-size:12pt;font-weight:bold;">Other Stock Awards</b><font style="font-size:12pt;">. &#160;Other forms of Stock Awards valued in whole or in part by reference to, or otherwise based on, Common Stock, including the appreciation in value thereof (e.g., options or stock rights with an exercise price or strike price less than 100% of the Fair Market Value of the Common Stock at the time of grant) may be granted either alone or in addition to Stock Awards provided for under Section 5 and the preceding provisions of this Section 6. &#160;Subject to the provisions of the Plan, the Compensation Committee will have sole and complete authority to determine the persons to whom and the time or times at which such Other Stock Awards will be granted, the number of shares of Common Stock (or the cash equivalent thereof) to be granted pursuant to such Other Stock Awards and all other terms and conditions of such Other Stock Awards.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">7.</b></font><b style="font-size:12pt;font-weight:bold;">COVENANTS OF THE COMPANY.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(a)</b></font><b style="font-size:12pt;font-weight:bold;">Availability of Shares.</b><font style="font-size:12pt;"> &#160;The Company will keep available at all times the number of shares of Common Stock reasonably required to satisfy then-outstanding Stock Awards.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">10</font><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">As approved by the Compensation Committee</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">January 21, 2022</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(b)</b></font><b style="font-size:12pt;font-weight:bold;">Securities Law Compliance.</b><font style="font-size:12pt;"> &#160;The Company will seek to obtain from each regulatory commission or agency having jurisdiction over the Plan such authority as may be required to grant Stock Awards and to issue and sell shares of Common Stock upon exercise of the Stock Awards; </font><i style="font-size:12pt;font-style:italic;">provided, however</i><font style="font-size:12pt;">, that this undertaking will not require the Company to register under the Securities Act the Plan, any Stock Award or any Common Stock issued or issuable pursuant to any such Stock Award. &#160;If, after reasonable efforts and at a reasonable cost, the Company is unable to obtain from any such regulatory commission or agency the authority that counsel for the Company deems necessary for the lawful issuance and sale of Common Stock under the Plan, the Company will be relieved from any liability for failure to issue and sell Common Stock upon exercise of such Stock Awards unless and until such authority is obtained. A Participant will not be eligible for the grant of a Stock Award or the subsequent issuance of cash or Common Stock pursuant to the Stock Award if such grant or issuance would be in violation of any applicable securities law.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(c)</b></font><b style="font-size:12pt;font-weight:bold;">No Obligation to Notify or Minimize Taxes. &#160;</b><font style="font-size:12pt;">The Company will have no duty or obligation to any Participant to advise such holder as to the time or manner of exercising such Stock Award. &#160;Furthermore, the Company will have no duty or obligation to warn or otherwise advise such holder of a pending termination or expiration of a Stock Award or a possible period in which the Stock Award may not be exercised. &#160;The Company has no duty or obligation to minimize the tax consequences of a Stock Award to the holder of such Stock Award.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">8.</b></font><b style="font-size:12pt;font-weight:bold;">MISCELLANEOUS.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(a)</b></font><b style="font-size:12pt;font-weight:bold;">Use of Proceeds from Sales of Common Stock. &#160;</b><font style="font-size:12pt;">Proceeds from the sale of shares of Common Stock pursuant to Stock Awards will constitute general funds of the Company.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(b)</b></font><b style="font-size:12pt;font-weight:bold;">Corporate Action Constituting Grant of </b><font style="font-size:12pt;">Stock </font><b style="font-size:12pt;font-weight:bold;">Awards.</b><font style="font-size:12pt;"> &#160;Corporate action constituting a grant by the Company of a Stock Award to any Participant will be deemed completed as of the date of such corporate action, unless otherwise determined by the Compensation Committee, regardless of when the instrument, certificate, or letter evidencing the Stock Award is communicated to, or actually received or accepted by, the Participant. &#160;In the event that the corporate records (e.g., Compensation Committee consents, resolutions or minutes) documenting the corporate action constituting the grant contain terms (e.g., exercise price, vesting schedule or number of shares) that are inconsistent with those in the Stock Award Agreement or related grant documents as a result of a clerical error in the papering of the Stock Award Agreement or related grant documents, the corporate records will control and the Participant will have no legally binding right to the incorrect term in the Stock Award Agreement or related grant documents.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(c)</b></font><b style="font-size:12pt;font-weight:bold;">Stockholder Rights.</b><font style="font-size:12pt;"> &#160;No Participant will be deemed to be the holder of, or to have any of the rights of a holder with respect to, any shares of Common Stock subject to a Stock Award unless and until (i) such Participant has satisfied all requirements for exercise of, or the issuance of shares under, the Stock Award pursuant to its terms, and (ii) the issuance of the Common Stock subject to such Stock Award has been entered into the books and records of the Company.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">11</font><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">As approved by the Compensation Committee</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">January 21, 2022</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(d)</b></font><b style="font-size:12pt;font-weight:bold;">No Employment or Other Service Rights.</b><font style="font-size:12pt;"> Nothing in the Plan, any Stock Award Agreement or any other instrument executed thereunder or in connection with any Stock Award granted pursuant thereto will confer upon any Participant any right to continue to serve the Company or an Affiliate in the capacity in effect at the time the Stock Award was granted or will affect the right of the Company or an Affiliate to terminate (i) the employment of an Employee with or without notice and with or without cause, (ii) the service of a Consultant pursuant to the terms of such Consultant&#8217;s agreement with the Company or an Affiliate, or (iii) the service of a Director pursuant to the bylaws of the Company or an Affiliate, and any applicable provisions of the corporate law of the state in which the Company or the Affiliate is incorporated, as the case may be.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(e)</b></font><b style="font-size:12pt;font-weight:bold;">Change in Time Commitment.</b><font style="font-size:12pt;"> &#160;In the event a Participant&#8217;s regular level of time commitment in the performance of his or her services for the Company and any Affiliates is reduced (for example, and without limitation, if the Participant is an Employee of the Company and the Employee has a change in status from a full-time Employee to a part-time Employee or takes an extended leave of absence) after the date of grant of any Stock Award to the Participant, the Compensation Committee has the right in its sole discretion to (x) make a corresponding reduction in the number of shares or cash amount subject to any portion of such Stock Award that is scheduled to vest or become payable after the date of such change in time commitment, and (y) in lieu of or in combination with such a reduction, extend the vesting or payment schedule applicable to such Stock Award. In the event of any such reduction, the Participant will have no right with respect to any portion of the Stock Award that is so reduced.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(f)</b></font><b style="font-size:12pt;font-weight:bold;">Investment Assurances.</b><font style="font-size:12pt;"> &#160;The Company may require a Participant, as a condition of exercising or acquiring Common Stock under any Stock Award, (i) to give written assurances satisfactory to the Company as to the Participant&#8217;s knowledge and experience in financial and business matters and/or to employ a purchaser representative reasonably satisfactory to the Company who is knowledgeable and experienced in financial and business matters and that he or she is capable of evaluating, alone or together with the purchaser representative, the merits and risks of exercising the Stock Award; and (ii) to give written assurances satisfactory to the Company stating that the Participant is acquiring Common Stock subject to the Stock Award for the Participant&#8217;s own account and not with any present intention of selling or otherwise distributing the Common Stock. &#160;The foregoing requirements, and any assurances given pursuant to such requirements, will be inoperative if (A) the issuance of the shares upon the exercise or acquisition of Common Stock under the Stock Award has been registered under a then currently effective registration statement under the Securities Act, or (B) as to any particular requirement, a determination is made by counsel for the Company that such requirement need not be met in the circumstances under the then applicable securities laws. &#160;The Company may, upon advice of counsel to the Company, place legends on stock certificates issued under the Plan as such counsel deems necessary or appropriate in order to comply with applicable securities laws, including, but not limited to, legends restricting the transfer of the Common Stock.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(g)</b></font><b style="font-size:12pt;font-weight:bold;">Withholding Obligations. &#160;</b><font style="font-size:12pt;">Unless prohibited by the terms of a Stock Award Agreement, the Company may, in its sole discretion, satisfy any federal, state or local tax withholding obligation relating to a Stock Award by any of the following means or by a combination of such means: (i) causing the Participant to tender a cash payment; (ii)&#160;&#160;withholding shares of Common Stock from the shares of Common Stock issued or otherwise</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">12</font><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">As approved by the Compensation Committee</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">January 21, 2022</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">issuable to the Participant in connection with the Stock Award; </font><i style="font-size:12pt;font-style:italic;">provided, however, </i><font style="font-size:12pt;">that no shares of Common Stock are withheld with a value exceeding the minimum amount of tax required to be withheld by law (or such lesser amount as may be necessary to avoid classification of the Stock Award as a liability for financial accounting purposes); (iii) withholding cash from a Stock Award settled in cash; (iv) withholding payment from any amounts otherwise payable to the Participant; or (v) by such other method as may be set forth in the Stock Award Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(h)</b></font><b style="font-size:12pt;font-weight:bold;">Electronic Delivery</b><font style="font-size:12pt;">. &#160;Any reference herein to a &#8220;written&#8221; agreement or document will include any agreement or document delivered electronically, filed publicly at www.sec.gov (or any successor website thereto) or posted on the Company&#8217;s intranet (or other shared electronic medium controlled by the Company to which the Participant has access).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(i)</b></font><b style="font-size:12pt;font-weight:bold;">Deferrals.</b><font style="font-size:12pt;"> &#160;To the extent permitted by applicable law, the Compensation Committee, in its sole discretion, may determine that the delivery of Common Stock or the payment of cash, upon the exercise, vesting or settlement of all or a portion of any Stock Award may be deferred and may establish programs and procedures for deferral elections to be made by Participants. &#160;Deferrals by Participants will be made in accordance with Section 409A of the Code. Consistent with Section 409A of the Code, the Compensation Committee may provide for distributions while a Participant is still an employee or otherwise providing services to the Company. &#160;The Compensation Committee is authorized to make deferrals of Stock Awards and determine when, and in what annual percentages, Participants may receive payments, including lump sum payments, following the Participant&#8217;s termination of Continuous Service, and implement such other terms and conditions consistent with the provisions of the Plan and in accordance with applicable law.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(j)</b></font><b style="font-size:12pt;font-weight:bold;">Compliance with Section 409A. &#160;</b><font style="font-size:12pt;">Unless otherwise expressly provided for in a Stock Award Agreement, the Plan and Stock Award Agreements will be interpreted to the greatest extent possible in a manner that makes the Plan and the Stock Awards granted hereunder exempt from Section 409A of the Code, and, to the extent not so exempt, in compliance with Section 409A of the Code. &#160;If the Compensation Committee determines that any Stock Award granted hereunder is not exempt from and is therefore subject to Section 409A of the Code, the Stock Award Agreement evidencing such Stock Award will incorporate the terms and conditions necessary to avoid the consequences specified in Section 409A(a)(1) of the Code, and to the extent a Stock Award Agreement is silent on terms necessary for compliance, such terms are hereby incorporated by reference into the Stock Award Agreement. &#160;Notwithstanding anything to the contrary in this Plan (and unless the Stock Award Agreement specifically provides otherwise), if the shares of Common Stock are publicly traded, and if a Participant holding a Stock Award that constitutes &#8220;deferred compensation&#8221; under Section 409A of the Code is a &#8220;specified employee&#8221; for purposes of Section 409A of the Code, no distribution or payment of any amount that is due because of a &#8220;separation from service&#8221; (as defined in Section 409A of the Code without regard to alternative definitions thereunder) will be issued or paid before the date that is six months following the date of such Participant&#8217;s &#8220;separation from service&#8221; or, if earlier, the date of the Participant&#8217;s death, unless such distribution or payment can be made in a manner that complies with Section 409A of the Code, and any amounts so deferred will be paid in a lump sum on the day after such six month period elapses, with the balance paid thereafter on the original schedule.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">13</font><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">As approved by the Compensation Committee</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">January 21, 2022</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(k)</b></font><b style="font-size:12pt;font-weight:bold;">Clawback/Recovery</b><font style="font-size:12pt;">. &#160;All Stock Awards granted under the Plan will be subject to recoupment in accordance with any clawback policy that the Company is required to adopt pursuant to the listing standards of any national securities exchange or association on which the Company&#8217;s securities are listed or as is otherwise required by the Dodd-Frank Wall Street Reform and Consumer Protection Act or other applicable law. In addition, the Compensation Committee may impose such other clawback, recovery or recoupment provisions in a Stock Award Agreement as the Compensation Committee determines necessary or appropriate, including but not limited to a reacquisition right in respect of previously acquired shares of Common Stock or other cash or property upon the occurrence of Cause. &#160;No recovery of compensation under such a clawback policy will be an event giving rise to a right to resign for &#8220;good reason&#8221; or &#8220;constructive termination&#8221; (or similar term) under any agreement with the Company.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">9.</b></font><b style="font-size:12pt;font-weight:bold;">ADJUSTMENTS UPON CHANGES IN COMMON STOCK; OTHER CORPORATE EVENTS.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(a)</b></font><b style="font-size:12pt;font-weight:bold;">Capitalization Adjustments</b><font style="font-size:12pt;">. &#160;In the event of a Capitalization Adjustment, the Compensation Committee will appropriately and proportionately adjust: (i) the class(es) and maximum number of securities subject to the Plan pursuant to Section 3(a) and (ii) the class(es) and number of securities and price per share of stock subject to outstanding Stock Awards. &#160;The Compensation Committee will make such adjustments, and its determination will be final, binding and conclusive.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(b)</b></font><b style="font-size:12pt;font-weight:bold;">Dissolution or Liquidation</b><font style="font-size:12pt;">. &#160;Except as otherwise provided in the Stock Award Agreement, in the event of a dissolution or liquidation of the Company, all outstanding Stock Awards (other than Stock Awards consisting of vested and outstanding shares of Common Stock not subject to a forfeiture condition or the Company&#8217;s right of repurchase) will terminate immediately prior to the completion of such dissolution or liquidation, and the shares of Common Stock subject to the Company&#8217;s repurchase rights or subject to a forfeiture condition may be repurchased or reacquired by the Company notwithstanding the fact that the holder of such Stock Award is providing Continuous Service; </font><i style="font-size:12pt;font-style:italic;">provided, however</i><font style="font-size:12pt;">, that the Compensation Committee may, in its sole discretion, cause some or all Stock Awards to become fully vested, exercisable and/or no longer subject to repurchase or forfeiture (to the extent such Stock Awards have not previously expired or terminated) before the dissolution or liquidation is completed but contingent on its completion.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(c)</b></font><b style="font-size:12pt;font-weight:bold;">Corporate Transaction.</b><font style="font-size:12pt;"> &#160;The following provisions will apply to Stock Awards in the event of a Corporate Transaction unless otherwise provided in the instrument evidencing the Stock Award or any other written agreement between the Company or any Affiliate and the Participant or unless otherwise expressly provided by the Compensation Committee at the time of grant of a Stock Award. &#160;In the event of a Corporate Transaction, then, notwithstanding any other provision of the Plan, the Compensation Committee will take one or more of the following actions with respect to Stock Awards, contingent upon the closing or completion of the Corporate Transaction:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(i)</b></font><font style="font-size:12pt;">arrange for the surviving corporation or acquiring corporation (or the surviving or acquiring corporation&#8217;s parent company) to assume or continue the Stock Award or to substitute a similar stock award for the Stock Award (including, but not limited to, an award to</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">14</font><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">As approved by the Compensation Committee</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">January 21, 2022</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">acquire the same consideration paid to the stockholders of the Company pursuant to the Corporate Transaction);</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(ii)</b></font><font style="font-size:12pt;">arrange for the assignment of any reacquisition or repurchase rights held by the Company in respect of Common Stock issued pursuant to the Stock Award to the surviving corporation or acquiring corporation (or the surviving or acquiring corporation&#8217;s parent company);</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(iii)</b></font><font style="font-size:12pt;">accelerate the vesting, in whole or in part, of the Stock Award (and, if applicable, the time at which the Stock Award may be exercised) to a date prior to the effective time of such Corporate Transaction as the Compensation Committee will determine (or, if the Compensation Committee will not determine such a date, to the date that is five days prior to the effective date of the Corporate Transaction), with such Stock Award terminating if not exercised (if applicable) at or prior to the effective time of the Corporate Transaction;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(iv)</b></font><font style="font-size:12pt;">arrange for the lapse, in whole or in part, of any reacquisition or repurchase rights held by the Company with respect to the Stock Award;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(v)</b></font><font style="font-size:12pt;">cancel or arrange for the cancellation of the Stock Award, to the extent not vested or not exercised prior to the effective time of the Corporate Transaction, in exchange for such cash consideration, if any, as the Compensation Committee, in its sole discretion, may consider appropriate; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(vi)</b></font><font style="font-size:12pt;">make a payment, in such form as may be determined by the Compensation Committee equal to the excess, if any, of (A) the value of the property the Participant would have received upon the exercise of the Stock Award immediately prior to the effective time of the Corporate Transaction, over (B) any exercise price payable by such holder in connection with such exercise.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">The Compensation Committee need not take the same action or actions with respect to all Stock Awards or portions thereof or with respect to all Participants. The Compensation Committee may take different actions with respect to the vested and unvested portions of a Stock Award.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(d)</b></font><b style="font-size:12pt;font-weight:bold;">Change in Control.</b><font style="font-size:12pt;"> &#160;A Stock Award may be subject to additional acceleration of vesting and exercisability upon or after a Change in Control as may be provided in the Stock Award Agreement for such Stock Award or as may be provided in any other written agreement between the Company or any Affiliate and the Participant, but in the absence of such provision, no such acceleration will occur.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">10.</b></font><b style="font-size:12pt;font-weight:bold;">PLAN TERM; EARLIER TERMINATION OR SUSPENSION OF THE PLAN.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">The Compensation Committee may suspend or terminate the Plan at any time. &#160;No Stock Awards may be granted under the Plan while the Plan is suspended or after it is terminated.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">11.</b></font><b style="font-size:12pt;font-weight:bold;">EFFECTIVE DATE OF PLAN.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">The Plan will become effective on the Effective Date.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">15</font><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">As approved by the Compensation Committee</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">January 21, 2022</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">12.</b></font><b style="font-size:12pt;font-weight:bold;">CHOICE OF LAW.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">The law of the State of Delaware will govern all questions concerning the construction, validity and interpretation of the Plan, without regard to that state&#8217;s conflict of laws rules.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">13.</b></font><b style="font-size:12pt;font-weight:bold;">DEFINITIONS. &#160;</b><font style="font-size:12pt;">As used in the Plan, the following definitions will apply to the capitalized terms indicated below:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(a)</b></font><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Affiliate</font><font style="font-size:12pt;">&#8221; means, at the time of determination, any &#8220;parent&#8221; or &#8220;subsidiary&#8221; of the Company as such terms are defined in Rule 405 of the Securities Act. &#160;The Compensation Committee will have the authority to determine the time or times at which &#8220;parent&#8221; or &#8220;subsidiary&#8221; status is determined within the foregoing definition.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(b)</b></font><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Award</font><font style="font-size:12pt;">&#8221; means a Stock Award.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(c)</b></font><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Award Agreement</font><font style="font-size:12pt;">&#8221; means a Stock Award Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(d)</b></font><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Board</font><font style="font-size:12pt;">&#8221; means the Board of Directors of the Company.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(e)</b></font><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Capital Stock</font><font style="font-size:12pt;">&#8221; means each and every class of common stock of the Company, regardless of the number of votes per share.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(f)</b></font><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Capitalization Adjustment</font><font style="font-size:12pt;">&#8221; means any change that is made in, or other events that occur with respect to, the Common Stock subject to the Plan or subject to any Stock Award after the Effective Date without the receipt of consideration by the Company through merger, consolidation, reorganization, recapitalization, reincorporation, stock dividend, dividend in property other than cash, large nonrecurring cash dividend, stock split, reverse stock split, liquidating dividend, combination of shares, exchange of shares, change in corporate structure or any similar equity restructuring transaction, as that term is used in Statement of Financial Accounting Standards Board Accounting Standards Codification Topic 718 (or any successor thereto). &#160;Notwithstanding the foregoing, the conversion of any convertible securities of the Company will not be treated as a Capitalization Adjustment.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(g)</b></font><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Cause</font><font style="font-size:12pt;">&#8221; will have the meaning ascribed to such term in any written agreement between the Participant and the Company defining such term and, in the absence of such agreement, such term means, with respect to a Participant, the occurrence of any of the following events: &#160;(i) such Participant&#8217;s conviction of any felony or any crime involving fraud; (ii) such Participant&#8217;s participation (whether by affirmative act or omission) in a fraud or felonious act against the Company and/or its Affiliates; (iii) conduct by such Participant which, based upon a good faith and reasonable factual investigation by the Company (or, if such Participant is an Officer, by the Board or Compensation Committee), demonstrates such Participant&#8217;s unfitness to serve; (iv) such Participant&#8217;s violation of any statutory or fiduciary duty, or duty of loyalty owed to the Company and/or its Affiliates and which has a material adverse effect on the Company and/or its Affiliates; (v) such Participant&#8217;s violation of state or federal law in connection with such Participant&#8217;s performance of such Participant&#8217;s job which has a material adverse effect on the Company and/or its Affiliates; (vi) breach of any material term of any contract between such Participant and the Company and/or its Affiliates; and (vii) such Participant&#8217;s violation of any</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">16</font><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">As approved by the Compensation Committee</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">January 21, 2022</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">material Company policy. &#160;Notwithstanding the foregoing, such Participant&#8217;s death or Disability shall not constitute Cause as set forth herein. &#160;The determination that a termination of the Participant&#8217;s Continuous Service is either for Cause or without Cause will be made by the Board or Compensation Committee, as applicable, in its sole and exclusive judgment and discretion. &#160;Any determination by the Company that the Continuous Service of a Participant was terminated with or without Cause for the purposes of outstanding Stock Awards held by such Participant will have no effect upon any determination of the rights or obligations of the Company or such Participant for any other purpose.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(h)</b></font><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Change in Control</font><font style="font-size:12pt;">&#8221; means the occurrence, in a single transaction or in a series of related transactions, of any one or more of the following events:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(i)</b></font><font style="font-size:12pt;">any Exchange Act Person becomes the Owner, directly or indirectly, of securities of the Company representing more than 50% of the combined voting power of the Company&#8217;s then outstanding securities other than by virtue of a merger, consolidation or similar transaction. &#160;Notwithstanding the foregoing, a Change in Control will not be deemed to occur (A) on account of the acquisition of securities of the Company directly from the Company, (B) on account of the acquisition of securities of the Company by an investor, any affiliate thereof or any other Exchange Act Person that acquires the Company&#8217;s securities in a transaction or series of related transactions the primary purpose of which is to obtain financing for the Company through the issuance of equity securities, (C) on account of the acquisition of securities of the Company by any individual who is, on the Effective Date, either an executive officer or a Director (either, a &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Registration Investor</font><font style="font-size:12pt;">&#8221;) and/or any entity in which a Registration Investor has a direct or indirect interest (whether in the form of voting rights or participation in profits or capital contributions) of more than 50% (collectively, the &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Registration Entities</font><font style="font-size:12pt;">&#8221; ) or on account of the Registration Entities continuing to hold shares that come to represent more than 50% of the combined voting power of the Company&#8217;s then outstanding securities as a result of the conversion of any class of the Company&#8217;s securities into another class of the Company&#8217;s securities having a different number of votes per share pursuant to the conversion provisions set forth in the Company&#8217;s Amended and Restated Certificate of Incorporation; &#160;or (D) solely because the level of Ownership held by any Exchange Act Person (the &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Subject Person</font><font style="font-size:12pt;">&#8221;) exceeds the designated percentage threshold of the outstanding voting securities as a result of a repurchase or other acquisition of voting securities by the Company reducing the number of shares outstanding, provided that if a Change in Control would occur (but for the operation of this sentence) as a result of the acquisition of voting securities by the Company, and after such share acquisition, the Subject Person becomes the Owner of any additional voting securities that, assuming the repurchase or other acquisition had not occurred, increases the percentage of the then outstanding voting securities Owned by the Subject Person over the designated percentage threshold, then a Change in Control will be deemed to occur;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(ii)</b></font><font style="font-size:12pt;">there is consummated a merger, consolidation or similar transaction involving (directly or indirectly) the Company and, immediately after the consummation of such merger, consolidation or similar transaction, the stockholders of the Company immediately prior thereto do not Own, directly or indirectly, either (A) outstanding voting securities representing more than 50% of the combined outstanding voting power of the surviving Entity in such merger, consolidation or similar transaction or (B) more than 50% of the combined outstanding voting power of the parent of the surviving Entity in such merger, consolidation or similar</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">17</font><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">As approved by the Compensation Committee</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">January 21, 2022</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">transaction, in each case in substantially the same proportions as their Ownership of the outstanding voting securities of the Company immediately prior to such transaction; </font><i style="font-size:12pt;font-style:italic;">provided, however</i><font style="font-size:12pt;">, that a merger, consolidation or similar transaction will not constitute a Change in Control under this prong of the definition if the outstanding voting securities representing more than 50% of the combined voting power of the surviving Entity or its parent are owned by the </font><font style="font-size:12pt;">Registration</font><font style="font-size:12pt;"> Entities;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(iii)</b></font><font style="font-size:12pt;">there is consummated a sale, lease, exclusive license or other disposition of all or substantially all of the consolidated assets of the Company and its Subsidiaries, other than a sale, lease, license or other disposition of all or substantially all of the consolidated assets of the Company and its Subsidiaries to an Entity, more than fifty percent (50%) of the combined voting power of the voting securities of which are Owned by stockholders of the Company in substantially the same proportions as their Ownership of the outstanding voting securities of the Company immediately prior to such sale, lease, license or other disposition; </font><i style="font-size:12pt;font-style:italic;">provided, however</i><font style="font-size:12pt;">, that a sale, lease, exclusive license or other disposition of all or substantially all of the consolidated assets of the Company and its Subsidiaries will not constitute a Change in Control under this prong of the definition if the outstanding voting securities representing more than 50% of the combined voting power of the acquiring Entity or its parent are owned by the </font><font style="font-size:12pt;">Registration</font><font style="font-size:12pt;"> Entities; or</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(iv)</b></font><font style="font-size:12pt;">individuals who, on the date the Plan is adopted by the Compensation Committee, are members of the Board (the &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Incumbent Board</font><font style="font-size:12pt;">&#8221;) cease for any reason to constitute at least a majority of the members of the Board; </font><i style="font-size:12pt;font-style:italic;">provided, however</i><font style="font-size:12pt;">, that if the appointment or election (or nomination for election) of any new Board member was approved or recommended by a majority vote of the members of the Incumbent Board then still in office, such new member will, for purposes of this Plan, be considered as a member of the Incumbent Board.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">Notwithstanding the foregoing definition or any other provision of this Plan, the term Change in Control will not include a sale of assets, merger or other transaction effected exclusively for the purpose of changing the domicile of the Company and the definition of Change in Control (or any analogous term) in an individual written agreement between the Company or any Affiliate and the Participant will supersede the foregoing definition with respect to Stock Awards subject to such agreement; </font><i style="font-size:12pt;font-style:italic;">provided, however</i><font style="font-size:12pt;">, that if no definition of Change in Control or any analogous term is set forth in such an individual written agreement, the foregoing definition will apply.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(i)</b></font><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Code</font><font style="font-size:12pt;">&#8221; means the Internal Revenue Code of 1986, as amended, including any applicable regulations and guidance thereunder.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(j)</b></font><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Committee</font><font style="font-size:12pt;">&#8221; means a committee of one or more Directors to whom authority has been delegated by the Compensation Committee in accordance with Section 2(c). &#160;Authority to grant Awards may only be deleted to a Committee comprised of a majority of the Company&#8217;s Independent Directors.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(k)</b></font><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Common Stock</font><font style="font-size:12pt;">&#8221; means, as of the Effective Date, the common stock of the Company, having 1 vote per share.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">18</font><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">As approved by the Compensation Committee</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">January 21, 2022</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(l)</b></font><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Company</font><font style="font-size:12pt;">&#8221; means GlycoMimetics, Inc., a Delaware corporation.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(m)</b></font><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Compensation Committee</font><font style="font-size:12pt;">&#8221; means the Compensation Committee of the Board as composed solely of Independent Directors.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(n)</b></font><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Consultant</font><font style="font-size:12pt;">&#8221; means any person, including an advisor, who is (i) engaged by the Company or an Affiliate to render consulting or advisory services and is compensated for such services, or (ii) serving as a member of the board of directors of an Affiliate and is compensated for such services. &#160;However, service solely as a Director, or payment of a fee for such service, will not cause a Director to be considered a &#8220;Consultant&#8221; for purposes of the Plan. Notwithstanding the foregoing, a person is treated as a Consultant under this Plan only if a Form S-8 Registration Statement under the Securities Act is available to register either the offer or the sale of the Company&#8217;s securities to such person.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(o)</b></font><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Continuous Service</font><font style="font-size:12pt;">&#8221; means that the Participant&#8217;s service with the Company or an Affiliate, whether as an Employee, Director or Consultant, is not interrupted or terminated. &#160;A change in the capacity in which the Participant renders service to the Company or an Affiliate as an Employee, Consultant or Director or a change in the entity for which the Participant renders such service, provided that there is no interruption or termination of the Participant&#8217;s service with the Company or an Affiliate, will not terminate a Participant&#8217;s Continuous Service ; </font><i style="font-size:12pt;font-style:italic;">provided, however</i><font style="font-size:12pt;">, that if the Entity for which a Participant is rendering services ceases to qualify as an Affiliate, as determined by the Compensation Committee, in its sole discretion, such Participant&#8217;s Continuous Service will be considered to have terminated on the date such Entity ceases to qualify as an Affiliate. &#160;To the extent permitted by law, the Compensation Committee or the chief executive officer of the Company, in that party&#8217;s sole discretion, may determine whether Continuous Service will be considered interrupted in the case of (i) any leave of absence approved by the Compensation Committee or chief executive officer, including sick leave, military leave or any other personal leave, or (ii) transfers between the Company, an Affiliate, or their successors. &#160;Notwithstanding the foregoing, a leave of absence will be treated as Continuous Service for purposes of vesting in a Stock Award only to such extent as may be provided in the Company&#8217;s leave of absence policy, in the written terms of any leave of absence agreement or policy applicable to the Participant, or as otherwise required by law.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(p)</b></font><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Corporate Transaction</font><font style="font-size:12pt;">&#8221; means the consummation, in a single transaction or in a series of related transactions, of any one or more of the following events:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(i)</b></font><font style="font-size:12pt;">a sale or other disposition of all or substantially all, as determined by the Compensation Committee, in its sole discretion, of the consolidated assets of the Company and its Subsidiaries;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(ii)</b></font><font style="font-size:12pt;">a sale or other disposition of at least 90% of the outstanding securities of the Company;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(iii)</b></font><font style="font-size:12pt;">a merger, consolidation or similar transaction following which the Company is not the surviving corporation; or</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">19</font><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">As approved by the Compensation Committee</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">January 21, 2022</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(iv)</b></font><font style="font-size:12pt;">a merger, consolidation or similar transaction following which the Company is the surviving corporation but the shares of Common Stock outstanding immediately preceding the merger, consolidation or similar transaction are converted or exchanged by virtue of the merger, consolidation or similar transaction into other property, whether in the form of securities, cash or otherwise.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(q)</b></font><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Director</font><font style="font-size:12pt;">&#8221; means a member of the Board.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(r)</b></font><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Disability</font><font style="font-size:12pt;">&#8221; means, with respect to a Participant, &#160;the inability of such Participant to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment that can be expected to result in death or that has lasted or can be expected to last for a continuous period of not less than 12 months, as provided in Sections 22(e)(3) and 409A(a)(2)(c)(i) of the Code, and will be determined by the Compensation Committee on the basis of such medical evidence as the Compensation Committee deems warranted under the circumstances.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(s)</b></font><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Effective Date</font><font style="font-size:12pt;">&#8221; means January 22, 2020, the date the Compensation Committee approved the Plan.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(t)</b></font><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Eligible Employee</font><font style="font-size:12pt;">&#8221; has the meaning set forth in Section 1(a).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(u)</b></font><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Employee</font><font style="font-size:12pt;">&#8221; means any person employed by the Company or an Affiliate. &#160;However, service solely as a Director, or payment of a fee for such services, will not cause a Director to be considered an &#8220;Employee&#8221; for purposes of the Plan.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(v)</b></font><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Entity</font><font style="font-size:12pt;">&#8221; means a corporation, partnership, limited liability company or other entity.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(w)</b></font><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Exchange Act</font><font style="font-size:12pt;">&#8221; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(x)</b></font><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Exchange Act Person</font><font style="font-size:12pt;">&#8221; means any natural person, Entity or &#8220;group&#8221; (within the meaning of Section 13(d) or 14(d) of the Exchange Act), except that &#8220;Exchange Act Person&#8221; will not include (i) the Company or any Subsidiary of the Company, (ii) any employee benefit plan of the Company or any Subsidiary of the Company or any trustee or other fiduciary holding securities under an employee benefit plan of the Company or any Subsidiary of the Company, (iii) an underwriter temporarily holding securities pursuant to a registered public offering of such securities, (iv) an Entity Owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as their Ownership of stock of the Company; or (v) any natural person, Entity or &#8220;group&#8221; (within the meaning of Section 13(d) or 14(d) of the Exchange Act) that, as of the Effective Date, is the Owner, directly or indirectly, of securities of the Company representing more than 50% of the combined voting power of the Company&#8217;s then outstanding securities.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(y)</b></font><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Fair Market Value</font><font style="font-size:12pt;">&#8221; means, as of any date, the value of the Common Stock determined as follows:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">20</font><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">As approved by the Compensation Committee</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">January 21, 2022</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:12pt;font-weight:bold;min-width:36pt;text-indent:0pt;white-space:nowrap;">(i)</font><font style="font-size:12pt;">If the Common Stock is listed on any established stock exchange or traded on any established market, the Fair Market Value of a share of Common Stock will be, unless otherwise determined by the Compensation Committee, </font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">the closing sales price</b><font style="font-size:12pt;"> for such stock as quoted on such exchange or market (or the exchange or market with the greatest volume of trading in the Common Stock) </font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">on the date of determination</b><font style="font-size:12pt;">, as reported in a source the Compensation Committee deems reliable.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:12pt;font-weight:bold;min-width:36pt;text-indent:0pt;white-space:nowrap;">(ii)</font><font style="font-size:12pt;">Unless otherwise provided by the Compensation Committee, if there is no closing sales price for the Common Stock on the date of determination, then the Fair Market Value will be the closing selling price on the last preceding date for which such quotation exists.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:12pt;font-weight:bold;min-width:36pt;text-indent:0pt;white-space:nowrap;">(iii)</font><font style="font-size:12pt;">In the absence of such markets for the Common Stock, the Fair Market Value will be determined by the Compensation Committee in good faith and in a manner that complies with Sections 409A of the Code.</font></div><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(z)</b></font><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Incentive Stock Option</font><font style="font-size:12pt;">&#8221; means an option that is intended to be, and qualifies as, an &#8220;incentive stock option&#8221; within the meaning of Section 422 of the Code.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(aa)</b></font><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Independent Director</font><font style="font-size:12pt;">&#8221; has the meaning set forth in Section 1(a).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(bb)</b></font><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Inducement Award Rules</font><font style="font-size:12pt;">&#8221; has the meaning set forth in Section 1(a).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(cc)</b></font><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Non-Employee Director</font><font style="font-size:12pt;">&#8221; means a Director who either (i) is not a current employee or officer of the Company or an Affiliate, does not receive compensation, either directly or indirectly, from the Company or an Affiliate for services rendered as a consultant or in any capacity other than as a Director (except for an amount as to which disclosure would not be required under Item 404(a) of Regulation S-K promulgated pursuant to the Securities Act (&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Regulation S-K</font><font style="font-size:12pt;">&#8221;)), does not possess an interest in any other transaction for which disclosure would be required under Item 404(a) of Regulation S-K, and is not engaged in a business relationship for which disclosure would be required pursuant to Item&#160;404(b) of Regulation S-K; or (ii) is otherwise considered a &#8220;non-employee director&#8221; for purposes of Rule 16b-3.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(dd)</b></font><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Nonstatutory Stock Option</font><font style="font-size:12pt;">&#8221; means any option granted pursuant to Section 5 of the Plan that does not qualify as an Incentive Stock Option.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(ee)</b></font><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Officer</font><font style="font-size:12pt;">&#8221; means a person who is an officer of the Company within the meaning of Section&#160;16 of the Exchange Act.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(ff)</b></font><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Option</font><font style="font-size:12pt;">&#8221; means a Nonstatutory Stock Option to purchase shares of Common Stock granted pursuant to the Plan.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(gg)</b></font><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Option Agreement</font><font style="font-size:12pt;">&#8221; means a written agreement between the Company and an Optionholder evidencing the terms and conditions of an Option grant. &#160;Each Option Agreement will be subject to the terms and conditions of the Plan.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(hh)</b></font><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Optionholder</font><font style="font-size:12pt;">&#8221; means a person to whom an Option is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding Option.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">21</font><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">As approved by the Compensation Committee</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">January 21, 2022</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(ii)</b></font><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Other Stock Award</font><font style="font-size:12pt;">&#8221; means an award based in whole or in part by reference to the Common Stock which is granted pursuant to the terms and conditions of Section 6(c).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(jj)</b></font><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Other Stock Award Agreement</font><font style="font-size:12pt;">&#8221; means a written agreement between the Company and a holder of an Other Stock Award evidencing the terms and conditions of an Other Stock Award grant. &#160;Each Other Stock Award Agreement will be subject to the terms and conditions of the Plan.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(kk)</b></font><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Own,</font><font style="font-size:12pt;">&#8221; &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Owned,</font><font style="font-size:12pt;">&#8221; &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Owner,</font><font style="font-size:12pt;">&#8221; &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Ownership</font><font style="font-size:12pt;">&#8221; means a person or Entity will be deemed to &#8220;Own,&#8221; to have &#8220;Owned,&#8221; to be the &#8220;Owner&#8221; of, or to have acquired &#8220;Ownership&#8221; of securities if such person or Entity, directly or indirectly, through any contract, arrangement, understanding, relationship or otherwise, has or shares voting power, which includes the power to vote or to direct the voting, with respect to such securities.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(ll)</b></font><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Participant</font><font style="font-size:12pt;">&#8221; means a person to whom a Stock Award is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding Stock Award.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(mm)</b></font><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Plan</font><font style="font-size:12pt;">&#8221; means this GlycoMimetics, Inc. Inducement Plan.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(nn)</b></font><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Restricted Stock Award</font><font style="font-size:12pt;">&#8221; means an award of shares of Common Stock which is granted pursuant to the terms and conditions of Section 6(a).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(oo)</b></font><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Restricted Stock Award Agreement</font><font style="font-size:12pt;">&#8221; means a written agreement between the Company and a holder of a Restricted Stock Award evidencing the terms and conditions of a Restricted Stock Award grant. &#160;Each Restricted Stock Award Agreement will be subject to the terms and conditions of the Plan.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(pp)</b></font><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Restricted Stock Unit Award</font><font style="font-size:12pt;">&#8221; means a right to receive shares of Common Stock which is granted pursuant to the terms and conditions of Section 6(b).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(qq)</b></font><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Restricted Stock Unit Award Agreement</font><font style="font-size:12pt;">&#8221; means a written agreement between the Company and a holder of a Restricted Stock Unit Award evidencing the terms and conditions of a Restricted Stock Unit Award grant. &#160;Each Restricted Stock Unit Award Agreement will be subject to the terms and conditions of the Plan.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(rr)</b></font><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Rule 16b-3</font><font style="font-size:12pt;">&#8221; means Rule 16b-3 promulgated under the Exchange Act or any successor to Rule 16b-3, as in effect from time to time.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(ss)</b></font><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Securities Act</font><font style="font-size:12pt;">&#8221; means the Securities Act of 1933, as amended.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(tt)</b></font><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Stock Appreciation Right</font><font style="font-size:12pt;">&#8221; or &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">SAR</font><font style="font-size:12pt;">&#8221; means a right to receive the appreciation on Common Stock that is granted pursuant to the terms and conditions of Section 5.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(uu)</b></font><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Stock Appreciation Right Agreement</font><font style="font-size:12pt;">&#8221; means a written agreement between the Company and a holder of a Stock Appreciation Right evidencing the terms and conditions of a Stock Appreciation Right grant. &#160;Each Stock Appreciation Right Agreement will be subject to the terms and conditions of the Plan.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">22</font><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">As approved by the Compensation Committee</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">January 21, 2022</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(vv)</b></font><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Stock Award</font><font style="font-size:12pt;">&#8221; means any right to receive Common Stock granted under the Plan, including a Nonstatutory Stock Option, a Restricted Stock Award, a Restricted Stock Unit Award, a Stock Appreciation Right or any Other Stock Award.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(ww)</b></font><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Stock Award Agreement</font><font style="font-size:12pt;">&#8221; means a written agreement between the Company and a Participant evidencing the terms and conditions of a Stock Award grant. &#160;Each Stock Award Agreement will be subject to the terms and conditions of the Plan.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(xx)</b></font><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Subsidiary</font><font style="font-size:12pt;">&#8221; means, with respect to the Company, (i) any corporation of which more than 50% of the outstanding capital stock having ordinary voting power to elect a majority of the board of directors of such corporation (irrespective of whether, at the time, stock of any other class or classes of such corporation will have or might have voting power by reason of the happening of any contingency) is at the time, directly or indirectly, Owned by the Company, and (ii) any partnership, limited liability company or other entity in which the Company has a direct or indirect interest (whether in the form of voting or participation in profits or capital contribution) of more than 50%.</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">23</font><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">As approved by the Compensation Committee</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">January 21, 2022</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>glyc-20211231xex23d1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 3/3/2022 09:44:27 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Exhibit 23.1 </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:9pt 0pt 0pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;white-space:pre-wrap;">Consent of Independent Registered Public Accounting Firm   </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">We consent to the incorporation by reference in the following Registration Statements:</font></p><div style="margin-top:12pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Arial';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:justify;">Registration Statement (Form S-8 No. 333-193317) pertaining to the 2003 Stock Incentive Plan, as amended, 2013 Equity Incentive Plan and 2013 Employee Stock Purchase Plan of GlycoMimetics, Inc.,</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Arial';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:justify;">Registration Statement (Form S-8 No. 333-206166) pertaining to the 2013 Equity Incentive Plan and 2013 Employee Stock Purchase Plan of GlycoMimetics, Inc.,</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Arial';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:justify;">Registration Statement (Form S-8 No. 333-209814) pertaining to the 2013 Equity Incentive Plan and 2013 Employee Stock Purchase Plan of GlycoMimetics, Inc.,</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Arial';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(4)</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:justify;">Registration Statement (Form S-8 No. 333-216366) pertaining to the 2013 Equity Incentive Plan and 2013 Employee Stock Purchase Plan of GlycoMimetics, Inc.,</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Arial';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(5)</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:justify;">Registration Statement (Form S-8 No. 333-223462) pertaining to the 2013 Equity Incentive Plan and 2013 Employee Stock Purchase Plan of GlycoMimetics, Inc., </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Arial';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(6)</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:justify;">Registration Statement (Form S-8 No. 333-230117) pertaining to the 2013 Equity Incentive Plan and 2013 Employee Stock Purchase Plan of GlycoMimetics, Inc.,</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Arial';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(7)</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:justify;">Registration Statement (Form S-3 No. 333-231577) of GlycoMimetics, Inc.,</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Arial';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(8)</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:justify;">Registration Statement (Form S-8 No. 333-236754) pertaining to the 2013 Equity Incentive Plan, 2013 Employee Stock Purchase Plan, and Inducement Plan of GlycoMimetics, Inc.; and</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Arial';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(9)</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:justify;">Registration Statement (Form S-8 No. 333-253788) pertaining to the 2013 Equity Incentive Plan and 2013 Employee Stock Purchase Plan of GlycoMimetics, Inc.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"><font style="color:#333333;font-family:'Arial','Helvetica','sans-serif';">of our report dated March 3, 2022, with respect to the financial statements of GlycoMimetics, Inc. included in this Annual Report (Form 10-K) of GlycoMimetics, Inc. for the year ended December 31, 2021.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">/s/ Ernst &amp; Young LLP</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Baltimore, Maryland</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">March 3, 2022</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.29%;margin-right:10.29%;margin-top:30pt;page-break-after:avoid;width:79.41%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>glyc-20211231xex31d1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 3/3/2022 09:44:30 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-weight:bold;">EXHIBIT 31.1 </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:12pt 0pt 0pt 0pt;"><b style="font-weight:bold;">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;">I, Harout Semerjian, certify that: </p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:6pt;"><font style="font-size:10pt;">1.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:6pt;"><font style="font-size:10pt;">I have reviewed this annual report on Form 10-K of GlycoMimetics, Inc. (the &#8220;registrant&#8221;); </font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:6pt;"><font style="font-size:10pt;">2.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:6pt;"><font style="font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:6pt;"><font style="font-size:10pt;">3.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:6pt;"><font style="font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:6pt;"><font style="font-size:10pt;">4.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:6pt;"><font style="font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: </font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 24.45pt;">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 24.45pt;">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 24.45pt;">(c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 24.45pt;">(d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and </p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:6pt;"><font style="font-size:10pt;">5.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:6pt;"><font style="font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions): </font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 24.45pt;">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 24.45pt;">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 0pt 24.5pt;"><font style="margin-bottom:5pt;margin-left:0pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Date: March 3, 2022 </p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td colspan="2" style="vertical-align:middle;width:100%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">/s/ Harout Semerjian</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Harout Semerjian</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">President&#160;&amp; Chief Executive Officer</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">(principal executive officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>glyc-20211231xex31d2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 3/3/2022 09:44:33 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-weight:bold;">EXHIBIT 31.2 </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:12pt 0pt 0pt 0pt;"><b style="font-weight:bold;">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;">I, Brian M. Hahn, certify that: </p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:6pt;"><font style="font-size:10pt;">1.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:6pt;"><font style="font-size:10pt;">I have reviewed this annual report on Form 10-K of GlycoMimetics, Inc. (the &#8220;registrant&#8221;); </font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:6pt;"><font style="font-size:10pt;">2.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:6pt;"><font style="font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:6pt;"><font style="font-size:10pt;">3.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:6pt;"><font style="font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:6pt;"><font style="font-size:10pt;">4.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:6pt;"><font style="font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: </font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 24.45pt;">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 24.45pt;">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 24.45pt;">(c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 24.45pt;">(d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and </p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:6pt;"><font style="font-size:10pt;">5.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:6pt;"><font style="font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions): </font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 24.45pt;">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 24.45pt;">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 0pt 24.45pt;"><font style="margin-bottom:5pt;margin-left:0pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Date: March 3, 2022</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td colspan="2" style="vertical-align:middle;width:100%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">/s/ Brian M. Hahn</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:12pt;text-indent:-12pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:12pt;text-indent:-12pt;margin:0pt;">Brian M. Hahn</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:12pt;text-indent:-12pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:12pt;text-indent:-12pt;margin:0pt;">Chief Financial Officer and Senior Vice President</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:12pt;text-indent:-12pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:12pt;text-indent:-12pt;margin:0pt;">(principal financial officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>glyc-20211231xex32d1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 3/3/2022 09:44:36 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-weight:bold;">EXHIBIT 32.1 </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:12pt 0pt 0pt 0pt;"><b style="font-weight:bold;">CERTIFICATIONS OF </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">PURSUANT TO 18 U.S.C. SECTION 1350, </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">AS ADOPTED PURSUANT TO </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and Section&#160;1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167;1350), Harout Semerjian, Chief Executive Officer of GlycoMimetics, Inc. (the &#8220;Company&#8221;), and Brian M. Hahn, Chief Financial Officer and Senior Vice President of the Company, each hereby certifies that, to the best of his or her knowledge: </p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:24.45pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:6pt;"><font style="font-size:10pt;">1.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:6pt;"><font style="font-size:10pt;">The Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2021 (the &#8220;Annual Report&#8221;), to which this Certification is attached as Exhibit 32.1, fully complies with the requirements of Section&#160;13(a) or Section&#160;15(d) of the Exchange Act, and </font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:24.45pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:6pt;"><font style="font-size:10pt;">2.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:6pt;"><font style="font-size:10pt;">The information contained in the Annual Report fairly presents, in all material respects, the financial condition of the Company as of the end of the period covered by the Annual Report and results of operations of the Company for the periods covered by the Annual Report. </font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;"><b style="font-weight:bold;">In Witness Whereof, </b>the undersigned have set their hands hereto as of the 3<sup style="font-size:7.5pt;vertical-align:top;">rd</sup> day of March 2022. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:middle;width:13.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:middle;width:43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td></tr><tr><td style="vertical-align:middle;width:43%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:13.99%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:43%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">/s/ Harout Semerjian</p><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;line-height:1pt;text-align:center;border-top:1.0pt solid #000000;margin:1pt 0pt 0pt 0pt;"><font style="font-size:10pt;">&#160;</font></p></td><td style="vertical-align:bottom;width:13.99%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;line-height:2pt;margin:0pt;"><font style="font-size:10pt;">&#160;</font></p></td><td style="vertical-align:bottom;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">/s/ Brian M. Hahn</p><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;line-height:1pt;text-align:center;border-top:1.0pt solid #000000;margin:1pt 0pt 0pt 0pt;"><font style="font-size:10pt;">&#160;</font></p></td></tr><tr><td style="vertical-align:top;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Harout Semerjian</p></td><td style="vertical-align:bottom;width:13.99%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;line-height:2pt;margin:0pt;"><font style="font-size:10pt;">&#160;</font></p></td><td style="vertical-align:bottom;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Brian M. Hahn</p></td></tr><tr><td style="vertical-align:top;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">President&#160;&amp; Chief Executive Officer</p></td><td style="vertical-align:bottom;width:13.99%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;line-height:2pt;margin:0pt;"><font style="font-size:10pt;">&#160;</font></p></td><td style="vertical-align:bottom;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Chief Financial Officer and Senior Vice President</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:12.25pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:14pt;"><font style="font-size:10pt;">*</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:14pt;"><font style="font-size:10pt;">This certification accompanies the Form 10-K to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of GlycoMimetics, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-K), irrespective of any general incorporation language contained in such filing. </font></p></td></tr></table></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>glyc-20211231x10k006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 glyc-20211231x10k006.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &I \P# 2(  A$! Q$!_\0
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M&TE5/F*=V"N&_P!D]?RH?UK^9_>P2H]D=-_:=Y_S\/1_:=Y_S\/7*IXH22=
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MJG)PV.PK:T/0=.\3V/BM[:\U2^74XTB^W7<"113.B_(\04#.TX^8CJ*]3HH
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M%>D.P5-B$AG+<*-H;)/88(_.HI=.D@6(RRPIYB+(H)/W3T/2FN%\M>TW]_\
MP!/B;,UJX+[CIO[>T[_GN?\ OAO\*/[>T[_GN?\ OAO\*Y2]LY+&Y:WE9#(O
M#!3G!JO6D>$L!)74G]YE+BW'Q=G%?<>@:?XRTO3C(6$\WF8QY:=,>N2/6KO_
M  L;2?\ GUO?^^$_^*KS*BO3P^28:C34(WT\S@J\18RI-RT^X]PTK4H=7TZ*
M]@5UCDS@2  \$CL3Z5=KGO!'_(IV?U?_ -#:NAKQ*L5&I**Z,^NP\W4HQG+=
MI!11169L%%%% !1110 4444 %%%% "45QOCKQA=^%7L1;6T,WV@2;O,SQMV]
M,?6N0_X6_JO_ $#K/\V_QK>&&J3CS11QU<=1I2<)/4]BHKQW_A;^J_\ 0.L_
MS;_&C_A;^J_] ZS_ #;_ !J_J=;L9_VGAN_X'L5%>._\+?U7_H'6?YM_C1_P
MM_5?^@=9_FW^-'U.MV#^T\-W_ ]BHKQW_A;^J_\ 0.L_S;_&C_A;^J_] ZS_
M #;_ !H^IUNP?VGAN_X'L5%>._\ "W]5_P"@=9_FW^-'_"W]5_Z!UG^;?XT?
M4ZW8/[3PW?\  ]BHKQW_ (6_JO\ T#K/\V_QH_X6_JO_ $#K/\V_QH^IUNP?
MVGAN_P"![%17CO\ PM_5?^@=9_FW^-'_  M_5?\ H'6?YM_C1]3K=@_M/#=_
MP/8J2O'O^%OZK_T#K/\ -O\ &C_A;^J_] ZS_-O\:/J=;L']IX;O^![%17DE
MI\6=3GF*-IUK@([<,PY"DC^50?\ "W]5_P"@=9_FW^-'U.MV'_:6'[_@>Q45
MX[_PM_5?^@=9_FW^-'_"W]5_Z!UG^;?XT?4ZW87]IX;O^![%17CO_"W]5_Z!
MUG^;?XT?\+?U7_H'6?YM_C1]3K=@_M/#=_P/8J*\=_X6_JO_ $#K/\V_QH_X
M6_JO_0.L_P V_P :/J=;L']IX;O^![%17CO_  M_5?\ H'6?YM_C1_PM_5?^
M@=9_FW^-'U.MV#^T\-W_  /8J*\=_P"%OZK_ - ZS_-O\:/^%OZK_P! ZS_-
MO\:/J=;L']IX;O\ @>Q45X[_ ,+?U7_H'6?YM_C1_P +?U7_ *!UG^;?XT?4
MZW8/[3PW?\#V*BO'?^%OZK_T#K/\V_QH_P"%OZK_ - ZS_-O\:/J=;L']IX;
MO^![%17CO_"W]5_Z!UG^;?XT?\+?U7_H'6?YM_C1]3K=@_M/#=_P/8J*\=_X
M6_JO_0.L_P V_P :/^%OZK_T#K/\V_QH^IUNP?VGAN_X'L5%>._\+?U7_H'6
M?YM_C1_PM_5?^@=9_FW^-'U.MV#^T\-W_ ]BHKQW_A;^J_\ 0.L_S;_&C_A;
M^J_] ZS_ #;_ !H^IUNP?VGAN_X'L5%>._\ "W]5_P"@=9_FW^-'_"W]5_Z!
MUG^;?XT?4ZW8/[3PW?\  ]BHKQW_ (6_JO\ T#K/\V_QH_X6_JO_ $#K/\V_
MQH^IUNP?VGAN_P"![":\$^,G_(ZP_P#7DG_H3UM?\+?U7_H'6?YM_C7(>*O$
MT?B#48[^^TV,S>7Y7[N5E& 21Q^)K6CAZE.?-)&&(QE&M#D@]3DJ*T/M>G?]
M S_R8;_"C[7IW_0,_P#)AO\ "NN_D<'*NYGUIZ3JD>G1WL,MNTT5Y#Y+A9-C
M ;@V0<'T]*9]KT[_ *!G_DPW^%)]KT[_ *!G_DPW^%)ZJS0UH[IFO/XO>YN(
M));/"PSM*HCG9& ,21J PY! 0'/<]1BEO_%=OJK8OM'BEBCE,L"+,4P2H5MY
M ^8$JK'&TY'7FL?[7IW_ $#/_)AO\*/M>G?] S_R8;_"HY(]B_:2_F-$^*&\
MF5TM E_+9BR>X$AP8Q@9"8X;:%&<XXSC-:$OCVXGU&*Z>S"!+1[=EAE*$LXP
MTF[!PQP.QKG_ +7IW_0,_P#)AO\ "C[7IW_0,_\ )AO\*.2/8%4DOM&WI_C:
M73(1!#;22QFY:>0W,^]W#1["N[:".F01R*QI]7DFT.'2BK>3#<O.A9R<!@!M
MQTXP3^)IGVO3O^@9_P"3#?X4?:]._P"@9_Y,-_A344G>PG.35G(FTG7)=*U>
MPU#R(9#9G*HJ+'NXQR0.3[G-7-/\7ZA8QS!\7$DAAVM+@A5C8MMVXQ@Y-9YN
MM."J?[,//_3PW^%)]KT[_H&?^3#?X4-)[H%*4=I&O=>+?M-FMNL%W!Y<TLT?
ME7G&7;=\P*G=@^]+%XM@CUS^V!I"?;9)&DG<3MABR%2%&,*,DGG<?>L;[7IW
M_0,_\F&_PH^UZ=_T#/\ R8;_  I<D>PW4EW-C2?%_P#8=N8;"S=5#2NC23[F
M4O&J=0H'&W/2KU[\1)[W._3855V3S%#G#*(GB91QQD.?I7-?:]._Z!G_ ),-
M_A1]KT[_ *!G_DPW^%')&][#]K-*W,:-EXF728I5TJP2W>0Q$RRN)6^1BW.Y
M<9)P<@#&T<=26:MK]MJME';OI[PF&29X3'/\J^8Y;!!4YQTZBJ/VO3O^@9_Y
M,-_A2?:]._Z!G_DPW^%-15[V%SRM:Z*%%7_M>G?] S_R8;_"E^UZ=_T#/_)A
MO\*N[[&7*NYGT^.-I7"J,DU=^UZ=_P! S_R8;_"MF/\ LZW+"/3SUZF8YJHI
MR>Q%1J*W*%O;K;IQRQZFIJN?:;+_ )\/_(QH^TV7_/A_Y&-=2=E9(X9*[NY+
M\2G15S[39?\ /A_Y&-'VFR_Y\/\ R,:.9]A<B[HIT5<^TV7_ #X?^1C1]ILO
M^?#_ ,C&CF?8.1=T4Z*N?:;+_GP_\C&C[19?\^'_ )&-',^P<B[H33;]M.O%
MN%0.-K(Z$XW*RE3^AJY'JMG'9W-FM@ZP7 CW%9_GRA)R25(YW=@.E5/M%E_S
MX?\ D8TY;BR9P/L'4X_UQJ))/5I_U\S2,FE927]?(W;7QO<V,D36]JJJ@B0J
MTF=Z(&&#QWW?@0*KW'BHWEG]BN;(/:X7*K+M;<K%@0<<<,0>/RK(^TV7_/A_
MY&-'VFR_Y\/_ ",:A487ORO^OF:.O4MR\ZM_7D:J^*2EG]@CL(8['RI(S"#D
MY<YW!F!.1A<?2L_5]1BU2[:[%N\4SA0_[T,IPH7@;1CIZFHOM-E_SX?^1C1]
MILO^?#_R,:J,(Q=U%D2J2DN5R5OZ\BG15S[39?\ /A_Y&-'VFR_Y\/\ R,:T
MYGV,N1=T4Z*N?:;+_GP_\C&C[39?\^'_ )&-',^P<B[HIT5<^TV7_/A_Y&-'
MVFR_Y\/_ ",:.9]@Y%W13HJZ+BR(/^@=!_SV-)]ILO\ GP_\C&CG?8.1=U^)
M3HJY]ILO^?#_ ,C&C[39?\^'_D8T<S[!R+NBG15S[39?\^'_ )&-'VFR_P"?
M#_R,:.9]@Y%W13HJY]ILO^?#_P C&C[39?\ /A_Y&-',^P<B[HIT5<^TV7_/
MA_Y&-'VFR_Y\/_(QHYGV#D7=?B0V]NT[[1P.Y]*V(HDAC"J./7UJK%JMO$@1
M-/4#_KJU7;2_M[A6)L@N/24UO3FET=_E_F<M:E*6O,K?/_(*<C;)%;KM(-3>
M?;?\^G_D4T>?:_\ /I_Y%-;.3:MRO\/\SF4$G=27X_Y'0#QG.5*RV<<@W%N7
MZ_/N&>.W JB/$5P5+/$C3F)XS+@#(9@W0#'!S]<UF^?:_P#/I_Y%-'GVO_/I
M_P"137,L-26T'_7S.N6+KRWJ+^OD:W_"3RA94%LGE3R;YHRV5<%0I'MTR/2J
M=[J@O+>&)DE3RHDB $WR$+W*XZ_C57S[7_GT_P#(IH\^U_Y]/_(IJE1IQ=U!
M_P!?,F6(JR5G-?U\A;^[-_?S73($,C9*@YQ5:K'GVO\ SZ?^131Y]K_SY_\
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M%=!R!1110 4444 %%%% !3H_]8OU%-IT?^L7ZBD]AQW&T444Q!1110 4444
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MS6E2FI:IF .U=S-%;W6M:[93V=FEE:0L\;QVT<9C<$!!N4 G<3MP<YS7.?\
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M803QTZ\UE_V+XM^Q_8_[,UO[+_SP\B79US]W&.O-2MI_C5T"-::^R+C"F.;
MQTIZ=T+7LSHM*TO2M2U#38ULX$N;6R62>,H"EQ&T1.XCNRL1GV(]*S=2MX;#
M3);ZRLK9ITBLU<M;K(L:/#DMM((!9@!N([^]8Z:!XICF69-)UA9%7:KBWE#
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M\^5Q_P!^F_PKTX=!0!#.,;?QJ&IKC^'\:YOQ7K,^BZ=!) T41GN$@:XF&8X
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MB@ HHHH **** "BBB@ HHHH BE_UD'^__P"RFI:BE_UD'^^?_06J6@ HHHH
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MN((@D:RX^^)0<;<\\FN]LHYHK"WCN9!).D2K(X_B8 9/YU/10 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 5GVI_XF]\/]S_T$5H5FVQ_XG=\/]S_ -!% &E1110 4444 %%%
M% !1110 4444 11_Z^;ZC^52U%'_ *^;ZC^52T %%%% !1110 4444 %%%%
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M: N-\E/3]:/)3T_6GY&*,T ,\E/3]:/)3T_6GT9H 9Y*>GZT>2GI^M/HSQ0
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M -^D_P#B:/\ A,_$'_00/_?I/_B:/[)K]T'^L.%[,]<\E/3]:/)3T_6O(_\
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M;6/R[..:T!)(!9I%W.<?[ .!^= %&R\-:WI.I:G/INJ6*07UTUP8YK1F*Y[
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MV:7_ (3_ $3^_-_W[-;?5\1_*SE^N8-?;B=#]AM/^?6'_OV*/L-I_P ^L/\
MW[%<]_PGVB?WYO\ OV:/^$^T3^_-_P!^S1]7Q'\K#Z[@_P">)T/V&T_Y]8?^
M_8H^PVG_ #ZP_P#?L5SW_"?:)_?F_P"_9H_X3[1/[\W_ '[-'U?$?RL/KN#_
M )XG0_8;3_GUA_[]BC[#:?\ /K#_ -^Q7/?\)]HG]^;_ +]FC_A/M$_OS?\
M?LT?5\1_*P^NX/\ GB=#]AM/^?6'_OV*/L-I_P ^L/\ W[%<]_PGVB?WYO\
MOV:/^$^T3^_-_P!^S1]7Q'\K#Z[@_P">)MQV5KY\W^C0]O\ EF/2IOL-I_SZ
MP_\ ?L5S2>.]%$TK%YL-C'[L^E2?\)]HG]^;_OV:/J^(_E8?7<'_ #Q.A^PV
MG_/K#_W[%'V&T_Y]8?\ OV*Y[_A/M$_OS?\ ?LT?\)]HG]^;_OV:/J^(_E8?
M7<'_ #Q.A^PVG_/K#_W[%'V&T_Y]8?\ OV*Y[_A/M$_OS?\ ?LT?\)]HG]^;
M_OV:/J^(_E8?7<'_ #Q.A^PVG_/K#_W[%'V&T_Y]8?\ OV*Y[_A/M$_OS?\
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MDC#*<@U-10!0M; Q:G>7TKAI9@D: =$C7.!]=S,3]1Z5?HHH **** "BBB@
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MR^(M,ABAD:=R)8S*JK"[,$'5F4#*@>^*@U3Q18V%M*\3_:)416"HK%/FZ;G
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MPJT;?)SY\H_X$/?V]_T%=2S#$K[7X(X7E&">\/Q?^9PW_"M#_P!!8?\ @/\
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MQ_M#GI[>WZT"V(S^_F/XCV]O;]31_:.)_F_(/[&P7\GXO_,X;_A6A_Z"P_\
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M>65MK;6>E3:@S:Q<!EBEC0ISU.\C]*M26,=C\5(I0\\S3Z=+(_F/N/W^%7L
M.PH [&#4K&Y>9(+VVE:#_6JDJL8_][!X_&H8-<TFY29[?5+*5(5W2M'.C!!Z
MM@\#ZUYA'/IJ:K?7&@!#;7.CS*888-LEEC&?, .6)8'KR,\<513RAH6H:=#>
MZ;<V,-K;3F_BL_+&0PQ#*4!)R <YY&#F@#V>VNK>\@6>UGBGA;[LD3AE/T(X
MJ:N$^&YE>;Q!,L5O%927@,*6K[H0VWYMAP 1]WD"N[H **** "BBB@ HHHH
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MS_<_$/\ 5O\ Z>?@>(T5[KE/^?9O^^12;DVD_9GX[;1[_P"'ZT?VS_<_$/\
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M^?6@3D_\LI!^'T_Q_0T 345 ;@@9\F7Z8IQF(./*D_+Z_P"'ZB@"6BH?//\
MSRD_*@3D[?W4G/MTZ?X_H: )J*A$Y/\ RRD_*@SD*3Y,O';'U_P_44 $_P#K
M+?\ ZZ?^RM4U5)ICYL \M_\ 6?G\K?GTJ43G_GE)^7^?\B@":BH1<' /E2<]
ML=.G^/Z&CSS_ ,\9.GI0!-14)G."?)DX]NO7_#]11YQSCRI/RH FHJ$3D_\
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MK_A^HH FHJ'SS_SRD_*I>M "T45CZ_K\>B16ZK;R75Y=R>5;6T9 ,C8SR3P
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MZBB\'W\<42RRPA4>V9BC$G$<3HV!CDY88J^6GKJ9<];30Z$^*=%!(:]Q\C2
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M="')35D%%%%9FP56L!BPMAC&(EXQCL.W:K-5[''V"VQC'E+TSZ>] %BBBB@
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ML1RK8SC/I4F*1%5%"J  .  .E.J#0BEMX9]GG1))L8.FY0=K#H1Z&I-M+10
MF!1BEHH 3%&!2T4 )BEHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 10_ZV?C_ ):#L?[JU+44/^LG_P"N@[G^ZM2T %%%% !1110
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M?RH ;13MC?W3^5&QO[I_*@!M%.V-_=/Y4;&_NG\J &T4[8W]T_E1L;^Z?RH
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M44 %%%% !1110 4444 %%%% "&N9E'_%2WG':/M_LUT]>0^.Q_Q6<W_7*/\
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M "BBB@"&8?O(.,_/Z9_A/Y5-4,X_>V_'23TS_"WY5-0 4444 %%%% !1110
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M%Q'I?F1RMIJ@>660 +@]57@<"NL%>=:'K6O+XDL[36KR:VN)Y)DEM;BW"Q.
M 5-NZK\V,\Y-6[6/66\<W&D/XDOFMH+6.YYBARQ+$%3\G3CZT =WFBO-['6]
M?@\56]KJ][-:M-=R1_9[BW MY8_X?)D53ENG!/>O2* "BBB@ K-\02R0>'=1
MFB=DD2VD964X((4\BM*H+RUCOK*:TFSY4R&-\'!P1@TT[,F2NFD<I'<R6GAR
M?4)+'5$>.TW[[B^++(<#IME8@]\X%&G:SJ,$-_=S*LMG'J'E?/(2ZJQ4?+VP
M"PX^M=+<:9;W.E-ILNXV[1>40#SMQCK5*+PS8Q2NRO<&-YA.\#29C9QT)'X
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MYX2_D/\ &IATZ?G0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M HHHH **** "LV 9U:[/NO\ Z"*TJHVX_P")E>'_ &E_]!% %ZBBB@ HHHH
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M?7Q?IFU@^\2HH+QKAF!)4%< YR"PZX!YQ5ZXU"X6Z6WMK022>3YSB679M&<
M# .3U]O>@#2HKGQXI@%XUK+;R1R^=Y49)RKX* \CN/,''ZT]/%>GO9S7.V=4
MB",V\*ORMG:V2<8.#WS0!NT52L[];R2153:%5)$.<[D89!]NA&/:KM !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 54MQ_IM
MV?\ ;7_T$5;JO!_Q]77^^/\ T$4 6**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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$@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>glyc-20211231x10k007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 glyc-20211231x10k007.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &_ M(# 2(  A$! Q$!_\0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*** "BBB@ HJGJLU]!ILTNFVR7-VH_=Q.VT,<^M<E_;?C_\ Z%>T_P# A?\
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M 4444 %%%% !1110 4444 %06EG;V,+16T8CC:624@$G+NY=SSZLQ/XU/10
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MWO&*AE8$(.Q/U/%;M*4)12;6XXSC)M)[!1114E!1110 4444 %%%% !1110
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M%KK>EV][;NN)4#%-V2A[@_0U?LY<G/;0S]K#G]G?7<T:***@T"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ Z52_M?3/^@C:?]_U_
MQJ34+NWLK":>ZF2&)5.7=L 5\JUR8G$^QLDKW/H,DR19DIRE)QY;=+WO<]MU
MS7;[QCJ3^'?#<A2T!Q>WXZ!>Z@_YS]*[/0=!LO#NF1V-C'A%Y=S]YV[DFN>^
M%<4:>!+5U10[R2%V Y;#D<_A7:5I1CS)5);O\#ES.K[*3P5)6A!M><FM+O\
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M>I:5=+<6TG 8<$'N".QK2H **** "BBB@ HHHH **** "BBB@ HHHH ****
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MFEMT9Q]"1F@#SOX,>!=.T[PM9:]?::#K=SND\Z<;F123MVY^[\N.>O->KT@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHIKNL:,[D!5!))["@!U%<[I/BI-4:XF%C=16 @%S:W3QX6XBP"6'I
MU& >2.:6#QA92Z2=3>SOX+4JC1-+" 9BYPH0 DDG(_.@#H:*S=)UNVU<W,<4
M<\-Q;.$G@G3:Z$C(R/0@\&M*@"CI/_'I+_U]3_\ HUJO51TG_CTE_P"OJ?\
M]&M5Z@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"C
MJ>CZ?K,*0ZA;)<1H=RJQ. ?PJC:^#O#]E=1W-MI<,<T3!D=2V0?SK<HJU5FE
MRINQ#I0D^9Q5PHHHJ"PHHHH K:A8P:G836=R@:*92K"N-\%WT^CZG<^$]18^
M9 2]H[?QQ]<#^==W7'^.]$GNK2'6M-RNIZ<?,0J.74<D>_T^M=.'DI7I2V?X
M/H<N(BXVK0W7XKJ=A165X<UR#Q#HL%_#@%AB1,_<<=16K6$HN+<7NCHC)3BI
M1V84452U35K+1K)[N^G6*)?7JQ] .YI).3LAMJ*NRV[K&C.[!449+$X %>4R
M?$D0^.7F,COI"CR=J<Y_VP/K^E:.-:^(<O/F:;X?!Z='G'^'Z?6KW_"I_#O]
M^^_[^C_XFO0HQH4;JN[M]%T_X)YU:=>O9T%9+J^O_ .ETKQ'I&M*#I]_#,V,
MF/=AQ_P$\UJ5R-[\-] NH8Q%%);3QJ )X6PQ([D=,_3%4/[+\:^'^;#44U:V
M7I%<_?Q]?_KU@Z5*?\.5O)_YFZJUH?Q(7\U_EO\ F=[17$6_Q%AMI5M]>TVY
MTV;IN92R'Z&M:3QKH27=G M]%(+K.)%8;4Q_>]*B6&JQ?PFD<51DOB.AHKD=
M1^(FBVDOD69EU"Y/ CMEW9/UJA]K\<>(/^/:WAT:U;^.3YI,?Y]J:PL[7E[J
M\_ZN3+%4[VA[S\M?^ =I>ZA9Z= 9KVZAMXQ_%*X4?K7F?C#XD1/-:PZ%<.RQ
M2B264 J'QT49[5T%G\.+!IQ=:U=W.J7/<S.0O^/ZTMS\+O#MS<R3$74>]L[(
MY%55]@-O2NB@\+3E>;<OEH<]=8NK"T$H_/4U="\8Z-KL<:P7D:7+ 9@D.UL^
M@SU_"M^N-'PQ\."R:W\J<MG*S&3YU_$#&/J*J?V)XO\ #G.D:F-3M%Z6]U]X
M#T!_^O64J=";_=2MZ_YFL:M>"_>QOZ?Y?Y'>T5Q5I\0[>&86NO6-QI=QTRZD
MH?H:Z&;Q%I,%I#=&^A:":18D=&# L>@K*5"I%V:-H8BE-74C4HHHK$V"BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ ILFX1OL4,^#M5C@$^A-.HH X+P[
M97JWLLFFZ//INEQQS0SZ;<W0>&67=P(DRPC4'=TV@YZ'M3;PG?/=&^TS0X='
MB@,$BZ<DL86X='R3A"54X. >_?BO2:* .?T&PO1K.KZS?6WV1[[R8X[<NKLJ
M1J1EBN1DEFZ$\ 5MW%LER@61I0 <_NY6C/YJ14M% &?HR".Q=%+$+<3@;F+'
M_6MU)Y-:%4=)_P"/27_KZG_]&M5Z@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MM_SRO?\ P!F_^(J_10!G+K=FS,JK>%EX8"RFR._/RT[^U[;_ )Y7O_@#-_\
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M!F_^(JV\*2212,,M$2R^Q((_D:DH H?VO;?\\KW_ , 9O_B*/[7MO^>5[_X
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M[.*-I)%O$1069FLI@ !U).VM&HYX4N;>2"49CD0HP]01@T 5/[7MO^>5[_X
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M)52VT9)RQ   ]ZY-G,KZCXJTB\ECOX&_T_3;X[4:-5 ,3#D*P )5QQDG.0:
M-'0/&L-W<RV.H3Q-.+GR(;B")Q#+E00,GH>2,9[5V%<=X>T5=2QJ\XU"WM)K
MC[9!IET(P(W('SG W>X4GBNQH *I:Q?MI>CWM\D#W#V\+2B%/O/@9Q46L:NN
MDP1$6\MS<3R"*""(@-(W7&6( X]37*L'U6_O-;TZZGL-<LU59;"].V/RP.8W
M )!5N2''0^HR" 3Z+XYBEO;BTU.XMWVO$(KFUBD\K+C.QB1P1Q_WT.E=K7#Z
M#IB>)&EUJ2/4+&PO98[EM.F\O9+(J*H?@;@ORKQG!V@]#SW% !39'V(S8+$
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MC4K>/$>N")&,<9'R[P?^6G; X/7VKK],T^'2M-M["WW&*! BESECZDGU)YH
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M:Y\N0XSM(/0XZ=C7*ZI'H/\ 9)\4Q^8+Z#583>R3KB9$DF6.2%Q_<$;D8Z<
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MK+!$D8=B[!1C+'J3[TEU+)!:3310F:1$++$#@N0.F?>GRS10*&FE2-20H+L
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MC 'W!H MZ3I%_>:E:ZKJ5[97<<-L\,4MM&5-RCXYDR<=N@XY)KJ5544*JA5
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M&TF;3[K2KD"0P74I$M@7);*A0<C.2%.,'H<5UVFZ5::9&WD0H)I<&>4* TK
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MX8<@$>AZ?C5Y@2I ;:2.".U><ZIHMUX1NSJ^CW-G;R+:>3)]H1Y9-3F+!OF
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MR5?28D8M%"5VF0-G"CC)7;CGKFNPT"QNM.TF*SO'21X"T<<@ZM&#\N??&,T
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A@C1%R20J@9)ZGCO4M% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>11
<FILENAME>glyc-20211231.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8042.36810 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/3/2022 9:43:53 AM-->
<!--Modified on: 3/3/2022 9:43:53 AM-->
<xsd:schema targetNamespace="http://glyc.com/20211231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:glyc="http://glyc.com/20211231" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:srt-roles="http://fasb.org/srt-roles/2021-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:attributeFormDefault="unqualified" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dei="http://xbrl.sec.gov/dei/2021q4">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://glyc.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/StatementBalanceSheets" id="StatementBalanceSheets">
        <link:definition>00100 - Statement - Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/StatementStatementsOfOperationsAndComprehensiveLoss" id="StatementStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>00200 - Statement - Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/StatementStatementsOfCashFlows" id="StatementStatementsOfCashFlows">
        <link:definition>00400 - Statement - Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails" id="DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails">
        <link:definition>40501 - Disclosure - Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosurePropertyAndEquipmentDetails" id="DisclosurePropertyAndEquipmentDetails">
        <link:definition>40601 - Disclosure - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureOperatingLeasesMaturitiesOfLeaseLiabilityDetailsCalc2" id="DisclosureOperatingLeasesMaturitiesOfLeaseLiabilityDetailsCalc2">
        <link:definition>40603 - Disclosure - Operating leases - Maturities of lease liability (Details) Calc 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails" id="DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails">
        <link:definition>40701 - Disclosure - Accrued Expenses - Summary of Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureOperatingLeasesComponentsOfLeaseExpenseDetails" id="DisclosureOperatingLeasesComponentsOfLeaseExpenseDetails">
        <link:definition>40802 - Disclosure - Operating Leases - Components of lease expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureOperatingLeasesMaturitiesOfLeaseLiabilityDetails" id="DisclosureOperatingLeasesMaturitiesOfLeaseLiabilityDetails">
        <link:definition>40803 - Disclosure - Operating Leases - Maturities of lease liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureIncomeTaxesScheduleOfGrossDeferredTaxAssetAndRelatedValuationAllowanceDetail" id="DisclosureIncomeTaxesScheduleOfGrossDeferredTaxAssetAndRelatedValuationAllowanceDetail">
        <link:definition>41001 - Disclosure - Income Taxes - Schedule of Gross Deferred Tax Asset and Related Valuation Allowance (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureIncomeTaxesReconciliationBetweenStatutoryFederalIncomeTaxRateAndEffectiveIncomeTaxRateDetail" id="DisclosureIncomeTaxesReconciliationBetweenStatutoryFederalIncomeTaxRateAndEffectiveIncomeTaxRateDetail">
        <link:definition>41003 - Disclosure - Income Taxes - Reconciliation Between Statutory Federal Income Tax Rate and Effective Income Tax Rate (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/StatementStatementsOfStockholdersEquity" id="StatementStatementsOfStockholdersEquity">
        <link:definition>00300 - Statement - Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureStockholdersEquityTables" id="DisclosureStockholdersEquityTables">
        <link:definition>30903 - Disclosure - Stockholders Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails">
        <link:definition>40302 - Disclosure - Summary of Significant Accounting Policies - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails">
        <link:definition>40303 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails">
        <link:definition>40305 - Disclosure - Summary of Significant Accounting Policies - Stock-Based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureNetLossPerCommonShareDetails" id="DisclosureNetLossPerCommonShareDetails">
        <link:definition>40401 - Disclosure - Net Loss Per Common Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureOperatingLeasesDetails" id="DisclosureOperatingLeasesDetails">
        <link:definition>40801 - Disclosure - Operating Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureStockholdersEquityEquityOfferingsDetails" id="DisclosureStockholdersEquityEquityOfferingsDetails">
        <link:definition>40901 - Disclosure - Stockholders' Equity - Equity Offerings (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureStockholdersEquityIncentivePlansDetails" id="DisclosureStockholdersEquityIncentivePlansDetails">
        <link:definition>40903 - Disclosure - Stockholders' Equity - Incentive Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureStockholdersEquityCompanySStockOptionActivityDetails" id="DisclosureStockholdersEquityCompanySStockOptionActivityDetails">
        <link:definition>40904 - Disclosure - Stockholders' Equity - Company's Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureStockholdersEquitySummaryOfRsuActivityDetails" id="DisclosureStockholdersEquitySummaryOfRsuActivityDetails">
        <link:definition>40905 - Disclosure - Stockholders' Equity - Summary of RSU Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureStockholdersEquityInducementPlanDetails" id="DisclosureStockholdersEquityInducementPlanDetails">
        <link:definition>40906 - Disclosure - Stockholders' Equity - Inducement Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureStockholdersEquityInducementPlanStockOptionActivityDetails" id="DisclosureStockholdersEquityInducementPlanStockOptionActivityDetails">
        <link:definition>40907 - Disclosure - Stockholders' Equity - Inducement Plan - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureStockholdersEquityWeightedAverageAssumptionsDetails" id="DisclosureStockholdersEquityWeightedAverageAssumptionsDetails">
        <link:definition>40908 - Disclosure - Stockholders' Equity - Weighted-Average assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails" id="DisclosureStockholdersEquityStockBasedCompensationExpenseDetails">
        <link:definition>40909 - Disclosure - Stockholders' Equity - Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureIncomeTaxesNolsAndCarryforwardsDetail" id="DisclosureIncomeTaxesNolsAndCarryforwardsDetail">
        <link:definition>41002 - Disclosure - Income Taxes - NOLs and carryforwards (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureResearchAndLicenseAgreementsDetails" id="DisclosureResearchAndLicenseAgreementsDetails">
        <link:definition>41101 - Disclosure - Research and License Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureEmployeeBenefitPlanDetail" id="DisclosureEmployeeBenefitPlanDetail">
        <link:definition>41201 - Disclosure - Employee Benefit Plan (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/StatementBalanceSheetsParenthetical" id="StatementBalanceSheetsParenthetical">
        <link:definition>00105 - Statement - Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureDescriptionOfBusiness" id="DisclosureDescriptionOfBusiness">
        <link:definition>10101 - Disclosure - Description of the Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureGoingConcern" id="DisclosureGoingConcern">
        <link:definition>10201 - Disclosure - Going Concern</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPolicies" id="DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>10301 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureNetLossPerShareOfCommonStock" id="DisclosureNetLossPerShareOfCommonStock">
        <link:definition>10401 - Disclosure - Net Loss Per Share of Common Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets" id="DisclosurePrepaidExpensesAndOtherCurrentAssets">
        <link:definition>10501 - Disclosure - Prepaid Expenses and Other Current Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosurePropertyAndEquipment" id="DisclosurePropertyAndEquipment">
        <link:definition>10601 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureAccruedExpenses" id="DisclosureAccruedExpenses">
        <link:definition>10701 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureOperatingLeases" id="DisclosureOperatingLeases">
        <link:definition>10801 - Disclosure - Operating Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureStockholdersEquity" id="DisclosureStockholdersEquity">
        <link:definition>10901 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>11001 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureResearchAndLicenseAgreements" id="DisclosureResearchAndLicenseAgreements">
        <link:definition>11101 - Disclosure - Research and License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureEmployeeBenefitPlan" id="DisclosureEmployeeBenefitPlan">
        <link:definition>11201 - Disclosure - Employee Benefit Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureRisksAndUncertainties" id="DisclosureRisksAndUncertainties">
        <link:definition>11301 - Disclosure - Risks and Uncertainties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>20202 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" id="DisclosureSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>30303 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureNetLossPerShareOfCommonStockTables" id="DisclosureNetLossPerShareOfCommonStockTables">
        <link:definition>30403 - Disclosure - Net Loss Per Share of Common Stock (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" id="DisclosurePrepaidExpensesAndOtherCurrentAssetsTables">
        <link:definition>30503 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosurePropertyAndEquipmentTables" id="DisclosurePropertyAndEquipmentTables">
        <link:definition>30603 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureAccruedExpensesTables" id="DisclosureAccruedExpensesTables">
        <link:definition>30703 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureOperatingLeasesTables" id="DisclosureOperatingLeasesTables">
        <link:definition>30803 - Disclosure - Operating Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureIncomeTaxesTables" id="DisclosureIncomeTaxesTables">
        <link:definition>31003 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureGoingConcernDetails" id="DisclosureGoingConcernDetails">
        <link:definition>40201 - Disclosure - Going Concern (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesSegmentInformationDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesSegmentInformationDetails">
        <link:definition>40301 - Disclosure - Summary of Significant Accounting Policies - Segment Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesImpairmentOfLongLivedAssetsDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesImpairmentOfLongLivedAssetsDetails">
        <link:definition>40304 - Disclosure - Summary of Significant Accounting Policies - Impairment of Long-Lived Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="glyc-20211231_pre.xml" xlink:title="Presentation Links, all" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="glyc-20211231_cal.xml" xlink:title="Calculation Links, all" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="glyc-20211231_def.xml" xlink:title="Definition Links, all" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="glyc-20211231_lab.xml" xlink:title="Label Links, all" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
  <xsd:element id="glyc_AccruedResearchAndDevelopmentExpenseCurrent" name="AccruedResearchAndDevelopmentExpenseCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="glyc_DeferredTaxAssetsCapitalizedStartUpCosts" name="DeferredTaxAssetsCapitalizedStartUpCosts" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="glyc_DeferredTaxAssetsPatentAmortization" name="DeferredTaxAssetsPatentAmortization" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element name="LaboratoryEquipmentMember" id="glyc_LaboratoryEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMaximumSharesIssuedUponExerciseOfIncentiveStockOptions" id="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMaximumSharesIssuedUponExerciseOfIncentiveStockOptions" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="instant" />
  <xsd:element id="glyc_EmployeeStockOptionsAndRestrictedStockUnitsMember" name="EmployeeStockOptionsAndRestrictedStockUnitsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="glyc_DisclosureOfStockholdersEquityAndCompensationRelatedCostsShareBasedPaymentsTextBlock" name="DisclosureOfStockholdersEquityAndCompensationRelatedCostsShareBasedPaymentsTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="glyc_PercentageOfTotalNumberOfCommonStockOutstandingOnLastBusinessDayOfPriorFiscalYearThatMayAutomaticallyIncreaseUnderPlan" name="PercentageOfTotalNumberOfCommonStockOutstandingOnLastBusinessDayOfPriorFiscalYearThatMayAutomaticallyIncreaseUnderPlan" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="glyc_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment" name="SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="glyc_EquityIncentivePlan2013Member" name="EquityIncentivePlan2013Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="glyc_StockIncentivePlan2003Member" name="StockIncentivePlan2003Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="glyc_ArrangementsAndNonarrangementTransactionsLineItems" name="ArrangementsAndNonarrangementTransactionsLineItems" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="glyc_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent" name="EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedSharesDisclosureAbstract" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedSharesDisclosureAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="glyc_NumberOfLongLivedAssetsDeterminedToBeImpaired" name="NumberOfLongLivedAssetsDeterminedToBeImpaired" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="glyc_ResearchAndLicenseAgreementTextBlock" name="ResearchAndLicenseAgreementTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="glyc_FederalAndStateAuthoritiesMember" name="FederalAndStateAuthoritiesMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="glyc_CommonStockValueAvailableForSaleUnderAgreement" name="CommonStockValueAvailableForSaleUnderAgreement" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="glyc_DeferredTaxAssetsResearchAndOrphanDrugCredits" name="DeferredTaxAssetsResearchAndOrphanDrugCredits" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="glyc_ResearchAndLicenseAgreementsAbstract" name="ResearchAndLicenseAgreementsAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="glyc_UpFrontPaymentReceived" name="UpFrontPaymentReceived" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="glyc_NewAccountingPronouncementsAdoptedPolicyPolicyTextBlock" name="NewAccountingPronouncementsAdoptedPolicyPolicyTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="glyc_AtMarketOffering2017Member" name="AtMarketOffering2017Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="glyc_LesseeOperatingLeaseNumberOfNewLeases" name="LesseeOperatingLeaseNumberOfNewLeases" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="glyc_IncreaseDecreaseInOperatingLeaseLiabilities" name="IncreaseDecreaseInOperatingLeaseLiabilities" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="glyc_RockvilleMarylandMember" name="RockvilleMarylandMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="glyc_DeferredTaxAssetsAccruedBonus" name="DeferredTaxAssetsAccruedBonus" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="glyc_ApollomicMember" name="ApollomicMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="glyc_AchievementOfSpecifiedNetSalesThresholdsForAllLicensedProducts" name="AchievementOfSpecifiedNetSalesThresholdsForAllLicensedProducts" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="glyc_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" name="ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="glyc_TieredPercentageOfAnnualNetSales" name="TieredPercentageOfAnnualNetSales" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="glyc_DeferredTaxAssetsTaxDeferredExpenseOperatingLeaseLiabilities" name="DeferredTaxAssetsTaxDeferredExpenseOperatingLeaseLiabilities" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="glyc_DeferredTaxLiabilitiesTaxDeferredExpenseOperatingLeaseLiabilitiesRightOfUseAssets" name="DeferredTaxLiabilitiesTaxDeferredExpenseOperatingLeaseLiabilitiesRightOfUseAssets" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="glyc_DevelopmentAndRegulatoryApprovalMilestonesClinicalAndRegulatoryEvents" name="DevelopmentAndRegulatoryApprovalMilestonesClinicalAndRegulatoryEvents" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="glyc_EquityInducementPlanMember" name="EquityInducementPlanMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfMonthlyInstallments" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfMonthlyInstallments" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="glyc_AtMarketOffering2020Member" name="AtMarketOffering2020Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="glyc_StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsVesting" name="StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsVesting" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="glyc_StockIssuedDuringPeriodSharesStockOptionsAndRestrictedStockUnitsVesting" name="StockIssuedDuringPeriodSharesStockOptionsAndRestrictedStockUnitsVesting" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="glyc_NetIncomeLossAndComprehensiveIncomeNetOfTax" name="NetIncomeLossAndComprehensiveIncomeNetOfTax" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="glyc_MilestoneRevenueRecognized" name="MilestoneRevenueRecognized" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="glyc_AccrualsForClinicalTrialExpensesPolicyTextBlock" name="AccrualsForClinicalTrialExpensesPolicyTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element name="StockOptionsVestingBasedOnServiceMember" id="glyc_StockOptionsVestingBasedOnServiceMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="StockOptionsVestingBasedOnPerformanceMember" id="glyc_StockOptionsVestingBasedOnPerformanceMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="VestingUponFirstCommercialSaleMember" id="glyc_VestingUponFirstCommercialSaleMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="VestingUponFDApprovalMember" id="glyc_VestingUponFDApprovalMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFairValueOfOptionExcludedFromUnrecognizedCompensationExpense" id="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFairValueOfOptionExcludedFromUnrecognizedCompensationExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="GoingConcernAbstract" id="glyc_GoingConcernAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingUnderlyingSharesVestPeriod" id="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingUnderlyingSharesVestPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="RevenueReceivedFromSaleOfClinicalSupplies" id="glyc_RevenueReceivedFromSaleOfClinicalSupplies" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo" id="glyc_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>12
<FILENAME>glyc-20211231_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8042.36810 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/3/2022 9:43:53 AM-->
<!--Modified on: 3/3/2022 9:43:53 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="glyc-20211231.xsd#StatementBalanceSheets" roleURI="http://glyc.com/role/StatementBalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="glyc-20211231.xsd#StatementStatementsOfOperationsAndComprehensiveLoss" roleURI="http://glyc.com/role/StatementStatementsOfOperationsAndComprehensiveLoss" />
  <roleRef xlink:type="simple" xlink:href="glyc-20211231.xsd#StatementStatementsOfCashFlows" roleURI="http://glyc.com/role/StatementStatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="glyc-20211231.xsd#DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails" roleURI="http://glyc.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails" />
  <roleRef xlink:type="simple" xlink:href="glyc-20211231.xsd#DisclosurePropertyAndEquipmentDetails" roleURI="http://glyc.com/role/DisclosurePropertyAndEquipmentDetails" />
  <roleRef xlink:type="simple" xlink:href="glyc-20211231.xsd#DisclosureOperatingLeasesMaturitiesOfLeaseLiabilityDetailsCalc2" roleURI="http://glyc.com/role/DisclosureOperatingLeasesMaturitiesOfLeaseLiabilityDetailsCalc2" />
  <roleRef xlink:type="simple" xlink:href="glyc-20211231.xsd#DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails" roleURI="http://glyc.com/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails" />
  <roleRef xlink:type="simple" xlink:href="glyc-20211231.xsd#DisclosureOperatingLeasesComponentsOfLeaseExpenseDetails" roleURI="http://glyc.com/role/DisclosureOperatingLeasesComponentsOfLeaseExpenseDetails" />
  <roleRef xlink:type="simple" xlink:href="glyc-20211231.xsd#DisclosureOperatingLeasesMaturitiesOfLeaseLiabilityDetails" roleURI="http://glyc.com/role/DisclosureOperatingLeasesMaturitiesOfLeaseLiabilityDetails" />
  <roleRef xlink:type="simple" xlink:href="glyc-20211231.xsd#DisclosureIncomeTaxesScheduleOfGrossDeferredTaxAssetAndRelatedValuationAllowanceDetail" roleURI="http://glyc.com/role/DisclosureIncomeTaxesScheduleOfGrossDeferredTaxAssetAndRelatedValuationAllowanceDetail" />
  <roleRef xlink:type="simple" xlink:href="glyc-20211231.xsd#DisclosureIncomeTaxesReconciliationBetweenStatutoryFederalIncomeTaxRateAndEffectiveIncomeTaxRateDetail" roleURI="http://glyc.com/role/DisclosureIncomeTaxesReconciliationBetweenStatutoryFederalIncomeTaxRateAndEffectiveIncomeTaxRateDetail" />
  <link:roleRef roleURI="http://glyc.com/role/DisclosureStockholdersEquityCompanySStockOptionActivityDetails" xlink:type="simple" xlink:href="glyc-20211231.xsd#DisclosureStockholdersEquityCompanySStockOptionActivityDetails" />
  <link:roleRef roleURI="http://glyc.com/role/DisclosureStockholdersEquityWeightedAverageAssumptionsDetails" xlink:type="simple" xlink:href="glyc-20211231.xsd#DisclosureStockholdersEquityWeightedAverageAssumptionsDetails" />
  <link:roleRef roleURI="http://glyc.com/role/DisclosureStockholdersEquitySummaryOfRsuActivityDetails" xlink:type="simple" xlink:href="glyc-20211231.xsd#DisclosureStockholdersEquitySummaryOfRsuActivityDetails" />
  <link:roleRef roleURI="http://glyc.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="glyc-20211231.xsd#DisclosureStockholdersEquityStockBasedCompensationExpenseDetails" />
  <calculationLink xlink:role="http://glyc.com/role/StatementBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - Balance Sheets">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_637417323404412620" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_637818974327694094" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets_637417323404412620" xlink:to="us-gaap_AssetsCurrent_637818974327694094" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637818974327694094" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637818974327694094" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637818974327694094" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637818974327704095" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637818974327694094" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637818974327704095" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637818974327704095" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets_637417323404412620" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637818974327704095" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="us-gaap_PrepaidExpenseNoncurrent_637818974327704095" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets_637417323404412620" xlink:to="us-gaap_PrepaidExpenseNoncurrent_637818974327704095" order="3" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit_637818974327704095" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets_637417323404412620" xlink:to="us-gaap_SecurityDeposit_637818974327704095" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_637818974327704095" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets_637417323404412620" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_637818974327704095" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_637417323514923670" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_637818974327704095" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity_637417323514923670" xlink:to="us-gaap_Liabilities_637818974327704095" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_637818974327704095" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637818974327704095" xlink:to="us-gaap_LiabilitiesCurrent_637818974327704095" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_637818974327704095" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637818974327704095" xlink:to="us-gaap_AccountsPayableCurrent_637818974327704095" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_637818974327704095" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637818974327704095" xlink:to="us-gaap_AccruedLiabilitiesCurrent_637818974327704095" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_637818974327714093" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637818974327704095" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_637818974327714093" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_637818974327714093" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637818974327704095" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_637818974327714093" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent_637818974327714093" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637818974327704095" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent_637818974327714093" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637818974327714093" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity_637417323514923670" xlink:to="us-gaap_StockholdersEquity_637818974327714093" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_637818974327714093" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637818974327714093" xlink:to="us-gaap_PreferredStockValue_637818974327714093" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_637818974327714093" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637818974327714093" xlink:to="us-gaap_CommonStockValue_637818974327714093" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_637818974327714093" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637818974327714093" xlink:to="us-gaap_AdditionalPaidInCapital_637818974327714093" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_637818974327714093" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637818974327714093" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_637818974327714093" order="4" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://glyc.com/role/StatementStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" xlink:title="00200 - Statement - Statements of Operations and Comprehensive Loss">
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_NetIncomeLossAndComprehensiveIncomeNetOfTax" xlink:label="glyc_NetIncomeLossAndComprehensiveIncomeNetOfTax" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_637818974327724095" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="glyc_NetIncomeLossAndComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OperatingIncomeLoss_637818974327724095" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_637818974327724095" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_637818974327724095" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_637818974327724095" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_637818974327724095" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_637818974327724095" xlink:to="us-gaap_OperatingExpenses_637818974327724095" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_637818974327724095" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_637818974327724095" xlink:to="us-gaap_ResearchAndDevelopmentExpense_637818974327724095" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_637818974327724095" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_637818974327724095" xlink:to="us-gaap_GeneralAndAdministrativeExpense_637818974327724095" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_637818974327724095" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="glyc_NetIncomeLossAndComprehensiveIncomeNetOfTax" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet_637818974327724095" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://glyc.com/role/StatementStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - Statements of Cash Flows">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_637818974327724095" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_637818974327724095" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_637818974327724095" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637818974327724095" xlink:to="us-gaap_ProfitLoss_637818974327724095" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_637818974327724095" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637818974327724095" xlink:to="us-gaap_Depreciation_637818974327724095" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_637818974327734092" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637818974327724095" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_637818974327734092" order="3" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_637818974327734092" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637818974327724095" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_637818974327734092" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_637818974327734092" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637818974327724095" xlink:to="us-gaap_ShareBasedCompensation_637818974327734092" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637818974327734092" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637818974327724095" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637818974327734092" order="6" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_637818974327734092" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637818974327724095" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_637818974327734092" order="7" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_637818974327734092" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637818974327724095" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_637818974327734092" order="8" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:label="glyc_IncreaseDecreaseInOperatingLeaseLiabilities_637818974327734092" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637818974327724095" xlink:to="glyc_IncreaseDecreaseInOperatingLeaseLiabilities_637818974327734092" order="9" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_637818974327734092" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_637818974327734092" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637818974327734092" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637818974327734092" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637818974327734092" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_637818974327734092" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_637818974327734092" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_637818974327744094" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637818974327734092" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_637818974327744094" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_637818974327744094" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637818974327734092" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_637818974327744094" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://glyc.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637418094388261276" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent_637818974327744094" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637418094388261276" xlink:to="us-gaap_PrepaidExpenseCurrent_637818974327744094" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent_637818974327744094" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637418094388261276" xlink:to="us-gaap_OtherReceivablesNetCurrent_637818974327744094" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_637818974327744094" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637418094388261276" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_637818974327744094" order="3" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://glyc.com/role/DisclosurePropertyAndEquipmentDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Property and Equipment (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_637818974327744094" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_637818974327744094" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_637818974327744094" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_637818974327744094" order="2" use="optional" weight="-1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://glyc.com/role/DisclosureOperatingLeasesMaturitiesOfLeaseLiabilityDetailsCalc2" xlink:type="extended" xlink:title="40603 - Disclosure - Operating leases - Maturities of lease liability (Details) Calc 2">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_637818974327754094" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_637818974327754094" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_637818974327754094" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability_637818974327754094" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://glyc.com/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Accrued Expenses - Summary of Accrued Expenses (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_637418096260978529" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_AccruedResearchAndDevelopmentExpenseCurrent" xlink:label="glyc_AccruedResearchAndDevelopmentExpenseCurrent_637818974327754094" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent_637418096260978529" xlink:to="glyc_AccruedResearchAndDevelopmentExpenseCurrent_637818974327754094" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="us-gaap_AccruedBonusesCurrent_637818974327754094" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent_637418096260978529" xlink:to="us-gaap_AccruedBonusesCurrent_637818974327754094" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_637818974327754094" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent_637418096260978529" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_637818974327754094" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_637818974327754094" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent_637418096260978529" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent_637818974327754094" order="4" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_637818974327754094" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent_637418096260978529" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_637818974327754094" order="5" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://glyc.com/role/DisclosureOperatingLeasesComponentsOfLeaseExpenseDetails" xlink:type="extended" xlink:title="40802 - Disclosure - Operating Leases - Components of lease expense (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost_637818974327764094" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_OperatingLeaseCost_637818974327764094" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost_637818974327764094" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_VariableLeaseCost_637818974327764094" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://glyc.com/role/DisclosureOperatingLeasesMaturitiesOfLeaseLiabilityDetails" xlink:type="extended" xlink:title="40803 - Disclosure - Operating Leases - Maturities of lease liability (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_637818974327764094" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_637818974327764094" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_637818974327764094" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_637818974327764094" order="2" use="optional" weight="1" priority="1" />
  </calculationLink>
  <calculationLink xlink:role="http://glyc.com/role/DisclosureIncomeTaxesScheduleOfGrossDeferredTaxAssetAndRelatedValuationAllowanceDetail" xlink:type="extended" xlink:title="41001 - Disclosure - Income Taxes - Schedule of Gross Deferred Tax Asset and Related Valuation Allowance (Detail)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_637418104302822633" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet_637818974327764094" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet_637418104302822633" xlink:to="us-gaap_DeferredTaxAssetsNet_637818974327764094" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_637818974327764094" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet_637818974327764094" xlink:to="us-gaap_DeferredTaxAssetsGross_637818974327764094" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_637818974327764094" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637818974327764094" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_637818974327764094" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_DeferredTaxAssetsCapitalizedStartUpCosts" xlink:label="glyc_DeferredTaxAssetsCapitalizedStartUpCosts_637818974327764094" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637818974327764094" xlink:to="glyc_DeferredTaxAssetsCapitalizedStartUpCosts_637818974327764094" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_DeferredTaxAssetsPatentAmortization" xlink:label="glyc_DeferredTaxAssetsPatentAmortization_637818974327764094" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637818974327764094" xlink:to="glyc_DeferredTaxAssetsPatentAmortization_637818974327764094" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_DeferredTaxAssetsResearchAndOrphanDrugCredits" xlink:label="glyc_DeferredTaxAssetsResearchAndOrphanDrugCredits_637818974327774093" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637818974327764094" xlink:to="glyc_DeferredTaxAssetsResearchAndOrphanDrugCredits_637818974327774093" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_DeferredTaxAssetsTaxDeferredExpenseOperatingLeaseLiabilities" xlink:label="glyc_DeferredTaxAssetsTaxDeferredExpenseOperatingLeaseLiabilities_637818974327774093" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637818974327764094" xlink:to="glyc_DeferredTaxAssetsTaxDeferredExpenseOperatingLeaseLiabilities_637818974327774093" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_637818974327774093" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637818974327764094" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_637818974327774093" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_DeferredTaxAssetsAccruedBonus" xlink:label="glyc_DeferredTaxAssetsAccruedBonus_637818974327774093" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637818974327764094" xlink:to="glyc_DeferredTaxAssetsAccruedBonus_637818974327774093" order="7" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther_637818974327774093" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637818974327764094" xlink:to="us-gaap_DeferredTaxAssetsOther_637818974327774093" order="8" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_637818974327774093" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet_637818974327764094" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_637818974327774093" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_637818974327774093" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet_637418104302822633" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_637818974327774093" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_DeferredTaxLiabilitiesTaxDeferredExpenseOperatingLeaseLiabilitiesRightOfUseAssets" xlink:label="glyc_DeferredTaxLiabilitiesTaxDeferredExpenseOperatingLeaseLiabilitiesRightOfUseAssets_637818974327774093" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities_637818974327774093" xlink:to="glyc_DeferredTaxLiabilitiesTaxDeferredExpenseOperatingLeaseLiabilitiesRightOfUseAssets_637818974327774093" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_637818974327774093" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities_637818974327774093" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_637818974327774093" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://glyc.com/role/DisclosureIncomeTaxesReconciliationBetweenStatutoryFederalIncomeTaxRateAndEffectiveIncomeTaxRateDetail" xlink:type="extended" xlink:title="41003 - Disclosure - Income Taxes - Reconciliation Between Statutory Federal Income Tax Rate and Effective Income Tax Rate (Detail)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_637818974327784095" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_637818974327784095" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_637818974327784095" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_637818974327784095" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_637818974327784095" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_637818974327784095" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent" xlink:label="glyc_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent_637818974327784095" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="glyc_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent_637818974327784095" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_637818974327784095" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_637818974327784095" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_637818974327784095" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_637818974327784095" order="6" use="optional" weight="1" priority="2" />
  </calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>13
<FILENAME>glyc-20211231_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8042.36810 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/3/2022 9:43:53 AM-->
<!--Modified on: 3/3/2022 9:43:54 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="glyc-20211231.xsd#StatementStatementsOfStockholdersEquity" roleURI="http://glyc.com/role/StatementStatementsOfStockholdersEquity" />
  <roleRef xlink:type="simple" xlink:href="glyc-20211231.xsd#DisclosureStockholdersEquityTables" roleURI="http://glyc.com/role/DisclosureStockholdersEquityTables" />
  <roleRef xlink:type="simple" xlink:href="glyc-20211231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails" roleURI="http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails" />
  <roleRef xlink:type="simple" xlink:href="glyc-20211231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" roleURI="http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" />
  <roleRef xlink:type="simple" xlink:href="glyc-20211231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails" roleURI="http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails" />
  <roleRef xlink:type="simple" xlink:href="glyc-20211231.xsd#DisclosureNetLossPerCommonShareDetails" roleURI="http://glyc.com/role/DisclosureNetLossPerCommonShareDetails" />
  <roleRef xlink:type="simple" xlink:href="glyc-20211231.xsd#DisclosurePropertyAndEquipmentDetails" roleURI="http://glyc.com/role/DisclosurePropertyAndEquipmentDetails" />
  <roleRef xlink:type="simple" xlink:href="glyc-20211231.xsd#DisclosureOperatingLeasesDetails" roleURI="http://glyc.com/role/DisclosureOperatingLeasesDetails" />
  <roleRef xlink:type="simple" xlink:href="glyc-20211231.xsd#DisclosureStockholdersEquityEquityOfferingsDetails" roleURI="http://glyc.com/role/DisclosureStockholdersEquityEquityOfferingsDetails" />
  <roleRef xlink:type="simple" xlink:href="glyc-20211231.xsd#DisclosureStockholdersEquityIncentivePlansDetails" roleURI="http://glyc.com/role/DisclosureStockholdersEquityIncentivePlansDetails" />
  <roleRef xlink:type="simple" xlink:href="glyc-20211231.xsd#DisclosureStockholdersEquityCompanySStockOptionActivityDetails" roleURI="http://glyc.com/role/DisclosureStockholdersEquityCompanySStockOptionActivityDetails" />
  <roleRef xlink:type="simple" xlink:href="glyc-20211231.xsd#DisclosureStockholdersEquitySummaryOfRsuActivityDetails" roleURI="http://glyc.com/role/DisclosureStockholdersEquitySummaryOfRsuActivityDetails" />
  <roleRef xlink:type="simple" xlink:href="glyc-20211231.xsd#DisclosureStockholdersEquityInducementPlanDetails" roleURI="http://glyc.com/role/DisclosureStockholdersEquityInducementPlanDetails" />
  <roleRef xlink:type="simple" xlink:href="glyc-20211231.xsd#DisclosureStockholdersEquityInducementPlanStockOptionActivityDetails" roleURI="http://glyc.com/role/DisclosureStockholdersEquityInducementPlanStockOptionActivityDetails" />
  <roleRef xlink:type="simple" xlink:href="glyc-20211231.xsd#DisclosureStockholdersEquityStockBasedCompensationExpenseDetails" roleURI="http://glyc.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails" />
  <roleRef xlink:type="simple" xlink:href="glyc-20211231.xsd#DisclosureIncomeTaxesNolsAndCarryforwardsDetail" roleURI="http://glyc.com/role/DisclosureIncomeTaxesNolsAndCarryforwardsDetail" />
  <roleRef xlink:type="simple" xlink:href="glyc-20211231.xsd#DisclosureResearchAndLicenseAgreementsDetails" roleURI="http://glyc.com/role/DisclosureResearchAndLicenseAgreementsDetails" />
  <roleRef xlink:type="simple" xlink:href="glyc-20211231.xsd#DisclosureEmployeeBenefitPlanDetail" roleURI="http://glyc.com/role/DisclosureEmployeeBenefitPlanDetail" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:roleRef roleURI="http://glyc.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:href="glyc-20211231.xsd#DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" />
  <link:roleRef xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd#eedm" roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended" xlink:title="Extensible Enumeration Domain Members" />
  <link:definitionLink xlink:role="http://glyc.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="extended" xlink:title="99900 - Disclosure - Standard And Custom Axis Domain Defaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_1" xlink:title="us-gaap_StatementEquityComponentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_1" xlink:title="us-gaap_EquityComponentDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementEquityComponentsAxis_1" xlink:to="us-gaap_EquityComponentDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementEquityComponentsAxis_1 To us-gaap_EquityComponentDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis_1" xlink:title="srt_CumulativeEffectPeriodOfAdoptionAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain_1" xlink:title="srt_CumulativeEffectPeriodOfAdoptionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis_1" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_CumulativeEffectPeriodOfAdoptionAxis_1 To srt_CumulativeEffectPeriodOfAdoptionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_1" xlink:title="us-gaap_PlanNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_1" xlink:title="us-gaap_PlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PlanNameAxis_1" xlink:to="us-gaap_PlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PlanNameAxis_1 To us-gaap_PlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:title="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" xlink:title="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByFairValueHierarchyLevelAxis_1 To us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_1" xlink:title="srt_RangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_1" xlink:title="srt_RangeMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RangeAxis_1" xlink:to="srt_RangeMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RangeAxis_1 To srt_RangeMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_1" xlink:title="us-gaap_AntidilutiveSecuritiesNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1 To us-gaap_AntidilutiveSecuritiesNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:title="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:title="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PropertyPlantAndEquipmentByTypeAxis_1 To us-gaap_PropertyPlantAndEquipmentTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_1" xlink:title="srt_StatementGeographicalAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_1" xlink:title="srt_SegmentGeographicalDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementGeographicalAxis_1" xlink:to="srt_SegmentGeographicalDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementGeographicalAxis_1 To srt_SegmentGeographicalDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:title="us-gaap_SubsidiarySaleOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_1" xlink:title="us-gaap_SaleOfStockNameOfTransactionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsidiarySaleOfStockAxis_1 To us-gaap_SaleOfStockNameOfTransactionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_1" xlink:title="us-gaap_VestingAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_1" xlink:title="us-gaap_VestingDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_VestingAxis_1" xlink:to="us-gaap_VestingDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_VestingAxis_1 To us-gaap_VestingDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_1" xlink:title="us-gaap_AwardTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AwardTypeAxis_1" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AwardTypeAxis_1 To us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis_1" xlink:title="us-gaap_GranteeStatusAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain_1" xlink:title="us-gaap_GranteeStatusDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_GranteeStatusAxis_1" xlink:to="us-gaap_GranteeStatusDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_GranteeStatusAxis_1 To us-gaap_GranteeStatusDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_1" xlink:title="us-gaap_IncomeStatementLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_1" xlink:title="us-gaap_IncomeStatementLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeStatementLocationAxis_1" xlink:to="us-gaap_IncomeStatementLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeStatementLocationAxis_1 To us-gaap_IncomeStatementLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_1" xlink:title="srt_CounterpartyNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_1" xlink:title="srt_RepurchaseAgreementCounterpartyNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_CounterpartyNameAxis_1" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_CounterpartyNameAxis_1 To srt_RepurchaseAgreementCounterpartyNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_1" xlink:title="us-gaap_IncomeTaxAuthorityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_1" xlink:title="us-gaap_IncomeTaxAuthorityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeTaxAuthorityAxis_1" xlink:to="us-gaap_IncomeTaxAuthorityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeTaxAuthorityAxis_1 To us-gaap_IncomeTaxAuthorityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis_1" xlink:title="us-gaap_TaxCreditCarryforwardAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_1" xlink:title="us-gaap_TaxCreditCarryforwardNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_TaxCreditCarryforwardAxis_1" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_TaxCreditCarryforwardAxis_1 To us-gaap_TaxCreditCarryforwardNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_1" xlink:title="us-gaap_SubsequentEventTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_1" xlink:title="us-gaap_SubsequentEventTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsequentEventTypeAxis_1" xlink:to="us-gaap_SubsequentEventTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsequentEventTypeAxis_1 To us-gaap_SubsequentEventTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_1" xlink:title="srt_TitleOfIndividualAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" xlink:title="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_TitleOfIndividualAxis_1" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_TitleOfIndividualAxis_1 To srt_TitleOfIndividualWithRelationshipToEntityDomain_1" order="1" />
  </link:definitionLink>
  <definitionLink xlink:role="http://glyc.com/role/StatementStatementsOfStockholdersEquity" xlink:type="extended" xlink:title="00300 - Statement - Statements of Stockholders' Equity">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsVesting" xlink:label="glyc_StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsVesting" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="glyc_StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsVesting" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_StockIssuedDuringPeriodSharesStockOptionsAndRestrictedStockUnitsVesting" xlink:label="glyc_StockIssuedDuringPeriodSharesStockOptionsAndRestrictedStockUnitsVesting" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="glyc_StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsVesting" xlink:to="glyc_StockIssuedDuringPeriodSharesStockOptionsAndRestrictedStockUnitsVesting" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://glyc.com/role/DisclosureStockholdersEquityTables" xlink:type="extended" xlink:title="30903 - Disclosure - Stockholders Equity (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_StockIncentivePlan2003Member" xlink:label="glyc_StockIncentivePlan2003Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="glyc_StockIncentivePlan2003Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_EquityIncentivePlan2013Member" xlink:label="glyc_EquityIncentivePlan2013Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PlanNameDomain" xlink:to="glyc_EquityIncentivePlan2013Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_EquityInducementPlanMember" xlink:label="glyc_EquityInducementPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PlanNameDomain" xlink:to="glyc_EquityInducementPlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails" xlink:type="extended" xlink:title="40302 - Disclosure - Summary of Significant Accounting Policies - Fair Value Measurements (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_MoneyMarketFundsAtCarryingValue" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" xlink:type="extended" xlink:title="40303 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_LaboratoryEquipmentMember" xlink:label="glyc_LaboratoryEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="glyc_LaboratoryEquipmentMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails" xlink:type="extended" xlink:title="40305 - Disclosure - Summary of Significant Accounting Policies - Stock-Based Compensation (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="us-gaap_DefinedContributionPlanTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="srt_RangeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://glyc.com/role/DisclosureNetLossPerCommonShareDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Net Loss Per Common Share (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_EmployeeStockOptionsAndRestrictedStockUnitsMember" xlink:label="glyc_EmployeeStockOptionsAndRestrictedStockUnitsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="glyc_EmployeeStockOptionsAndRestrictedStockUnitsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://glyc.com/role/DisclosurePropertyAndEquipmentDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Property and Equipment (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_LaboratoryEquipmentMember" xlink:label="glyc_LaboratoryEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="glyc_LaboratoryEquipmentMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://glyc.com/role/DisclosureOperatingLeasesDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Operating Leases (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_StatementGeographicalAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_RockvilleMarylandMember" xlink:label="glyc_RockvilleMarylandMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_SegmentGeographicalDomain" xlink:to="glyc_RockvilleMarylandMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:label="us-gaap_LesseeOperatingLeaseDescriptionAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDescriptionAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasePracticalExpedientLessorSingleLeaseComponent" xlink:label="us-gaap_LeasePracticalExpedientLessorSingleLeaseComponent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:to="us-gaap_LeasePracticalExpedientLessorSingleLeaseComponent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:to="us-gaap_SecurityDeposit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:label="us-gaap_DebtInstrumentInterestRateIncreaseDecrease" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:to="us-gaap_DebtInstrumentInterestRateIncreaseDecrease" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_LesseeOperatingLeaseNumberOfNewLeases" xlink:label="glyc_LesseeOperatingLeaseNumberOfNewLeases" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:to="glyc_LesseeOperatingLeaseNumberOfNewLeases" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://glyc.com/role/DisclosureStockholdersEquityEquityOfferingsDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Stockholders' Equity - Equity Offerings (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_AtMarketOffering2017Member" xlink:label="glyc_AtMarketOffering2017Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="glyc_AtMarketOffering2017Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_AtMarketOffering2020Member" xlink:label="glyc_AtMarketOffering2020Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="glyc_AtMarketOffering2020Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityNoteAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_CommonStockValueAvailableForSaleUnderAgreement" xlink:label="glyc_CommonStockValueAvailableForSaleUnderAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="glyc_CommonStockValueAvailableForSaleUnderAgreement" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://glyc.com/role/DisclosureStockholdersEquityIncentivePlansDetails" xlink:type="extended" xlink:title="40903 - Disclosure - Stockholders' Equity - Incentive Plans (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_StockIncentivePlan2003Member" xlink:label="glyc_StockIncentivePlan2003Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="glyc_StockIncentivePlan2003Member" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_EquityIncentivePlan2013Member" xlink:label="glyc_EquityIncentivePlan2013Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PlanNameDomain" xlink:to="glyc_EquityIncentivePlan2013Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VestingAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfMonthlyInstallments" xlink:label="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfMonthlyInstallments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfMonthlyInstallments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment" xlink:label="glyc_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="glyc_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedSharesDisclosureAbstract" xlink:label="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedSharesDisclosureAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedSharesDisclosureAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedSharesDisclosureAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_PercentageOfTotalNumberOfCommonStockOutstandingOnLastBusinessDayOfPriorFiscalYearThatMayAutomaticallyIncreaseUnderPlan" xlink:label="glyc_PercentageOfTotalNumberOfCommonStockOutstandingOnLastBusinessDayOfPriorFiscalYearThatMayAutomaticallyIncreaseUnderPlan" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedSharesDisclosureAbstract" xlink:to="glyc_PercentageOfTotalNumberOfCommonStockOutstandingOnLastBusinessDayOfPriorFiscalYearThatMayAutomaticallyIncreaseUnderPlan" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMaximumSharesIssuedUponExerciseOfIncentiveStockOptions" xlink:label="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMaximumSharesIssuedUponExerciseOfIncentiveStockOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedSharesDisclosureAbstract" xlink:to="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMaximumSharesIssuedUponExerciseOfIncentiveStockOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedSharesDisclosureAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://glyc.com/role/DisclosureStockholdersEquityCompanySStockOptionActivityDetails" xlink:type="extended" xlink:title="40904 - Disclosure - Stockholders' Equity - Company's Stock Option Activity (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_StockIncentivePlan2003Member" xlink:label="glyc_StockIncentivePlan2003Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="glyc_StockIncentivePlan2003Member" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_EquityIncentivePlan2013Member" xlink:label="glyc_EquityIncentivePlan2013Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PlanNameDomain" xlink:to="glyc_EquityIncentivePlan2013Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://glyc.com/role/DisclosureStockholdersEquitySummaryOfRsuActivityDetails" xlink:type="extended" xlink:title="40905 - Disclosure - Stockholders' Equity - Summary of RSU Activity (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_EquityIncentivePlan2013Member" xlink:label="glyc_EquityIncentivePlan2013Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="glyc_EquityIncentivePlan2013Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_GranteeStatusAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://glyc.com/role/DisclosureStockholdersEquityInducementPlanDetails" xlink:type="extended" xlink:title="40906 - Disclosure - Stockholders' Equity - Inducement Plan (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_EquityInducementPlanMember" xlink:label="glyc_EquityInducementPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="glyc_EquityInducementPlanMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_VestingUponFDApprovalMember" xlink:label="glyc_VestingUponFDApprovalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_VestingDomain" xlink:to="glyc_VestingUponFDApprovalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_VestingUponFirstCommercialSaleMember" xlink:label="glyc_VestingUponFirstCommercialSaleMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_VestingDomain" xlink:to="glyc_VestingUponFirstCommercialSaleMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefExecutiveOfficerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_StockOptionsVestingBasedOnServiceMember" xlink:label="glyc_StockOptionsVestingBasedOnServiceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="glyc_StockOptionsVestingBasedOnServiceMember" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_StockOptionsVestingBasedOnPerformanceMember" xlink:label="glyc_StockOptionsVestingBasedOnPerformanceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="glyc_StockOptionsVestingBasedOnPerformanceMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingUnderlyingSharesVestPeriod" xlink:label="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingUnderlyingSharesVestPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingUnderlyingSharesVestPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfMonthlyInstallments" xlink:label="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfMonthlyInstallments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfMonthlyInstallments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment" xlink:label="glyc_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="glyc_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFairValueOfOptionExcludedFromUnrecognizedCompensationExpense" xlink:label="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFairValueOfOptionExcludedFromUnrecognizedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFairValueOfOptionExcludedFromUnrecognizedCompensationExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://glyc.com/role/DisclosureStockholdersEquityInducementPlanStockOptionActivityDetails" xlink:type="extended" xlink:title="40907 - Disclosure - Stockholders' Equity - Inducement Plan - Stock Option Activity (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_EquityInducementPlanMember" xlink:label="glyc_EquityInducementPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="glyc_EquityInducementPlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://glyc.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails" xlink:type="extended" xlink:title="40909 - Disclosure - Stockholders' Equity - Stock-Based Compensation Expense (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://glyc.com/role/DisclosureIncomeTaxesNolsAndCarryforwardsDetail" xlink:type="extended" xlink:title="41002 - Disclosure - Income Taxes - NOLs and carryforwards (Detail)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardTable" xlink:label="us-gaap_TaxCreditCarryforwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_TaxCreditCarryforwardTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_FederalAndStateAuthoritiesMember" xlink:label="glyc_FederalAndStateAuthoritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="glyc_FederalAndStateAuthoritiesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_TaxCreditCarryforwardTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralBusinessMember" xlink:label="us-gaap_GeneralBusinessMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_GeneralBusinessMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems" xlink:label="us-gaap_TaxCreditCarryforwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="us-gaap_TaxCreditCarryforwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://glyc.com/role/DisclosureResearchAndLicenseAgreementsDetails" xlink:type="extended" xlink:title="41101 - Disclosure - Research and License Agreements (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_ApollomicMember" xlink:label="glyc_ApollomicMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="glyc_ApollomicMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_ArrangementsAndNonarrangementTransactionsLineItems" xlink:label="glyc_ArrangementsAndNonarrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="glyc_ArrangementsAndNonarrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_RevenueReceivedFromSaleOfClinicalSupplies" xlink:label="glyc_RevenueReceivedFromSaleOfClinicalSupplies" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="glyc_ArrangementsAndNonarrangementTransactionsLineItems" xlink:to="glyc_RevenueReceivedFromSaleOfClinicalSupplies" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_UpFrontPaymentReceived" xlink:label="glyc_UpFrontPaymentReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="glyc_ArrangementsAndNonarrangementTransactionsLineItems" xlink:to="glyc_UpFrontPaymentReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_DevelopmentAndRegulatoryApprovalMilestonesClinicalAndRegulatoryEvents" xlink:label="glyc_DevelopmentAndRegulatoryApprovalMilestonesClinicalAndRegulatoryEvents" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="glyc_ArrangementsAndNonarrangementTransactionsLineItems" xlink:to="glyc_DevelopmentAndRegulatoryApprovalMilestonesClinicalAndRegulatoryEvents" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_AchievementOfSpecifiedNetSalesThresholdsForAllLicensedProducts" xlink:label="glyc_AchievementOfSpecifiedNetSalesThresholdsForAllLicensedProducts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="glyc_ArrangementsAndNonarrangementTransactionsLineItems" xlink:to="glyc_AchievementOfSpecifiedNetSalesThresholdsForAllLicensedProducts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_MilestoneRevenueRecognized" xlink:label="glyc_MilestoneRevenueRecognized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="glyc_ArrangementsAndNonarrangementTransactionsLineItems" xlink:to="glyc_MilestoneRevenueRecognized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_TieredPercentageOfAnnualNetSales" xlink:label="glyc_TieredPercentageOfAnnualNetSales" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="glyc_ArrangementsAndNonarrangementTransactionsLineItems" xlink:to="glyc_TieredPercentageOfAnnualNetSales" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://glyc.com/role/DisclosureEmployeeBenefitPlanDetail" xlink:type="extended" xlink:title="41201 - Disclosure - Employee Benefit Plan (Detail)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="us-gaap_DefinedContributionPlanTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" priority="1" use="optional" />
  </definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>14
<FILENAME>glyc-20211231_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8042.36810 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/3/2022 9:43:53 AM-->
<!--Modified on: 3/3/2022 9:43:53 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Document and Entity Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US">ICFR Auditor Attestation Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US">Auditor Firm ID</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="dei_AuditorName" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US">Auditor Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US">Auditor Location</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Balance Sheets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="us-gaap_PrepaidExpenseNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseNoncurrent" xlink:to="us-gaap_PrepaidExpenseNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseNoncurrent_lbl" xml:lang="en-US">Prepaid Expense, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseNoncurrent_lbl" xml:lang="en-US">Prepaid research and development expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDeposit" xlink:to="us-gaap_SecurityDeposit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SecurityDeposit_lbl" xml:lang="en-US">Security Deposit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SecurityDeposit_lbl" xml:lang="en-US">Deposits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right-of-use asset</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities &amp; stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating Lease, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent_lbl" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent_lbl" xml:lang="en-US">Noncurrent accrued expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Lease liabilities, net of current portion</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders' equity:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock; $0.001 par value; 5,000,000 shares authorized, no shares issued and outstanding at December 31, 2021 and December 31, 2020</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock; $0.001 par value; 100,000,000 shares authorized; 52,313,894 shares issued and outstanding at December 31, 2021; 49,017,622 shares issued and outstanding at December 31, 2020</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional Paid in Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred Stock, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Statements of Operations and Comprehensive Loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xml:lang="en-US">Revenue from Contract with Customer, Including Assessed Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xml:lang="en-US">Revenue from collaboration and license agreements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingCostsAndExpensesAbstract" xlink:label="us-gaap_OperatingCostsAndExpensesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_OperatingCostsAndExpensesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingCostsAndExpensesAbstract_lbl" xml:lang="en-US">Operating Costs and Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingCostsAndExpensesAbstract_lbl" xml:lang="en-US">Costs and expenses:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General And Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total costs and expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xml:lang="en-US">Interest Income (Expense), Nonoperating, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xml:lang="en-US">Interest income</label>
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_NetIncomeLossAndComprehensiveIncomeNetOfTax" xlink:label="glyc_NetIncomeLossAndComprehensiveIncomeNetOfTax" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_NetIncomeLossAndComprehensiveIncomeNetOfTax" xlink:to="glyc_NetIncomeLossAndComprehensiveIncomeNetOfTax_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_NetIncomeLossAndComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">The portion of profit or loss and comprehensive income for the period, net of income taxes, which is attributable to the parent.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_NetIncomeLossAndComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Net Income Loss And Comprehensive Income Net Of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="glyc_NetIncomeLossAndComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="glyc_NetIncomeLossAndComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Net loss and comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Earnings Per Share, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Basic net loss per common share (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Earnings Per Share, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Diluted net loss per common share (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Basic weighted-average number of common shares outstanding (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Diluted weighted-average number of common shares outstanding (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Statements of Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-In Capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance, shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of common stock, net of issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of common stock, net of issuance costs, shares</label>
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsVesting" xlink:label="glyc_StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsVesting" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsVesting" xlink:to="glyc_StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsVesting_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsVesting_lbl" xml:lang="en-US">The value of share options and vesting of stock units exercised during the current period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsVesting_lbl" xml:lang="en-US">Stock Issued During Period Value Stock Options And Restricted Stock Units Vesting</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsVesting_lbl" xml:lang="en-US">Exercise of options and vesting of restricted stock units</label>
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_StockIssuedDuringPeriodSharesStockOptionsAndRestrictedStockUnitsVesting" xlink:label="glyc_StockIssuedDuringPeriodSharesStockOptionsAndRestrictedStockUnitsVesting" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_StockIssuedDuringPeriodSharesStockOptionsAndRestrictedStockUnitsVesting" xlink:to="glyc_StockIssuedDuringPeriodSharesStockOptionsAndRestrictedStockUnitsVesting_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_StockIssuedDuringPeriodSharesStockOptionsAndRestrictedStockUnitsVesting_lbl" xml:lang="en-US">Number of share options and vesting of stock units exercised during the current period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_StockIssuedDuringPeriodSharesStockOptionsAndRestrictedStockUnitsVesting_lbl" xml:lang="en-US">Stock Issued During Period Shares Stock Options And Restricted Stock Units Vesting</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_StockIssuedDuringPeriodSharesStockOptionsAndRestrictedStockUnitsVesting_lbl" xml:lang="en-US">Exercise of options and vesting of restricted stock units, shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Exercise of options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Options exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Shares issued from exercise of stock options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Options exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Exercise of options, shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statements of Cash Flows</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation of property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US">Loss on disposal of assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xml:lang="en-US">Operating Lease Right Of Use Asset Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xml:lang="en-US">Non-cash lease expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in assets and liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Accrued expenses</label>
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:label="glyc_IncreaseDecreaseInOperatingLeaseLiabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:to="glyc_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" xml:lang="en-US">The increase (decrease) during the reporting period in the operating lease liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" xml:lang="en-US">Increase Decrease In Operating Lease Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="glyc_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" xml:lang="en-US">Lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash flows used in operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Investing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchases of property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Financing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from issuance of common stock, net of issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl" xml:lang="en-US">Proceeds from Issuance of Shares under Incentive and Share-based Compensation Plans, Including Stock Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl" xml:lang="en-US">Proceeds from exercise of stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net change in cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash and cash equivalents, end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash and cash equivalents, beginning of period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Description of the Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US">Nature of Operations [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US">Description of the Business</label>
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_GoingConcernAbstract" xlink:label="glyc_GoingConcernAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_GoingConcernAbstract" xlink:to="glyc_GoingConcernAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_GoingConcernAbstract_lbl" xml:lang="en-US">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_GoingConcernAbstract_lbl" xml:lang="en-US">Going Concern</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl" xml:lang="en-US">Substantial Doubt about Going Concern [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl" xml:lang="en-US">Going Concern</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Summary of Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Summary of Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" xml:lang="en-US">Net Loss Per Share of Common Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">Earnings Per Share [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">Net Loss Per Share of Common Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl" xml:lang="en-US">Prepaid Expenses and Other Current Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentAssetsTextBlock" xlink:label="us-gaap_OtherCurrentAssetsTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentAssetsTextBlock" xlink:to="us-gaap_OtherCurrentAssetsTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCurrentAssetsTextBlock_lbl" xml:lang="en-US">Other Current Assets [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherCurrentAssetsTextBlock_lbl" xml:lang="en-US">Prepaid Expenses and Other Current Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property and Equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">Property and Equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US">Accrued Expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">Accrued Expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesAbstract_lbl" xml:lang="en-US">Operating Leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">Lessee, Operating Leases [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">Operating Leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_DisclosureOfStockholdersEquityAndCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="glyc_DisclosureOfStockholdersEquityAndCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_DisclosureOfStockholdersEquityAndCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="glyc_DisclosureOfStockholdersEquityAndCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_DisclosureOfStockholdersEquityAndCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">This note contains 1) the entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income and 2) the entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_DisclosureOfStockholdersEquityAndCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Disclosure Of Stockholders Equity And Compensation Related Costs Share Based Payments Text Block</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_DisclosureOfStockholdersEquityAndCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_ResearchAndLicenseAgreementsAbstract" xlink:label="glyc_ResearchAndLicenseAgreementsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_ResearchAndLicenseAgreementsAbstract" xlink:to="glyc_ResearchAndLicenseAgreementsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_ResearchAndLicenseAgreementsAbstract_lbl" xml:lang="en-US">n/a</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_ResearchAndLicenseAgreementsAbstract_lbl" xml:lang="en-US">Research and License Agreements</label>
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_ResearchAndLicenseAgreementTextBlock" xlink:label="glyc_ResearchAndLicenseAgreementTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_ResearchAndLicenseAgreementTextBlock" xlink:to="glyc_ResearchAndLicenseAgreementTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_ResearchAndLicenseAgreementTextBlock_lbl" xml:lang="en-US">The entire disclosure for research services and license agreements, including contracts and arrangements to be performed by or for others. Includes contingent payment receivables or liabilities for achievement of specific milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_ResearchAndLicenseAgreementTextBlock_lbl" xml:lang="en-US">Research And License Agreement Text Block</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_ResearchAndLicenseAgreementTextBlock_lbl" xml:lang="en-US">Research and License Agreements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xml:lang="en-US">Employee Benefit Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock_lbl" xml:lang="en-US">Compensation and Employee Benefit Plans, Other than Share-based Compensation [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock_lbl" xml:lang="en-US">Employee Benefit Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyAbstract" xlink:label="us-gaap_LossContingencyAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyAbstract" xlink:to="us-gaap_LossContingencyAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingencyAbstract_lbl" xml:lang="en-US">Risks and Uncertainties</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyDisclosures" xlink:label="us-gaap_LossContingencyDisclosures" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyDisclosures" xlink:to="us-gaap_LossContingencyDisclosures_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingencyDisclosures_lbl" xml:lang="en-US">Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LossContingencyDisclosures_lbl" xml:lang="en-US">Risks and Uncertainties</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Accounting</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segment Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentration of Credit Risk</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property and Equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment of Long-Lived Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Costs</label>
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_AccrualsForClinicalTrialExpensesPolicyTextBlock" xlink:label="glyc_AccrualsForClinicalTrialExpensesPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_AccrualsForClinicalTrialExpensesPolicyTextBlock" xlink:to="glyc_AccrualsForClinicalTrialExpensesPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_AccrualsForClinicalTrialExpensesPolicyTextBlock_lbl" xml:lang="en-US">Disclosure of accounting policy for Accruals for Clinical Trial Expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_AccrualsForClinicalTrialExpensesPolicyTextBlock_lbl" xml:lang="en-US">Accruals For Clinical Trial Expenses [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_AccrualsForClinicalTrialExpensesPolicyTextBlock_lbl" xml:lang="en-US">Accruals for Clinical Trial Expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Stock-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US">Comprehensive Loss</label>
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_NewAccountingPronouncementsAdoptedPolicyPolicyTextBlock" xlink:label="glyc_NewAccountingPronouncementsAdoptedPolicyPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_NewAccountingPronouncementsAdoptedPolicyPolicyTextBlock" xlink:to="glyc_NewAccountingPronouncementsAdoptedPolicyPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_NewAccountingPronouncementsAdoptedPolicyPolicyTextBlock_lbl" xml:lang="en-US">Disclosure of accounting policy pertaining to new accounting pronouncements that have been adopted during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_NewAccountingPronouncementsAdoptedPolicyPolicyTextBlock_lbl" xml:lang="en-US">New Accounting Pronouncements Adopted Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_NewAccountingPronouncementsAdoptedPolicyPolicyTextBlock_lbl" xml:lang="en-US">Adopted Accounting Standards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Accounting Standards Not Yet Adopted</label>
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:label="glyc_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:to="glyc_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock_lbl" xml:lang="en-US">Tabular disclosure of the useful life of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock_lbl" xml:lang="en-US">Schedule Of Property Plant And Equipment Useful Life [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock_lbl" xml:lang="en-US">Schedule of Property and Equipment Estimated Useful Lives</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Potentially dilutive securities outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Summary of Prepaid Expenses and Other Current Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Summary of Property and Equipment useful lives</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Summary of Accrued Expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">Lease, Cost [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">Components of lease expense and related cash flows</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Maturities of lease liabilities due</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US">Plan Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_StockIncentivePlan2003Member" xlink:label="glyc_StockIncentivePlan2003Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_StockIncentivePlan2003Member" xlink:to="glyc_StockIncentivePlan2003Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_StockIncentivePlan2003Member_lbl" xml:lang="en-US">Pertains to the 2003 Stock Incentive Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_StockIncentivePlan2003Member_lbl" xml:lang="en-US">2003 Stock Incentive Plan</label>
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_EquityIncentivePlan2013Member" xlink:label="glyc_EquityIncentivePlan2013Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_EquityIncentivePlan2013Member" xlink:to="glyc_EquityIncentivePlan2013Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_EquityIncentivePlan2013Member_lbl" xml:lang="en-US">Pertaining to the 2013 Equity Incentive Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_EquityIncentivePlan2013Member_lbl" xml:lang="en-US">2013 Equity Incentive Plan</label>
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_EquityInducementPlanMember" xlink:label="glyc_EquityInducementPlanMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_EquityInducementPlanMember" xlink:to="glyc_EquityInducementPlanMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_EquityInducementPlanMember_lbl" xml:lang="en-US">Represents information relating to inducement plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_EquityInducementPlanMember_lbl" xml:lang="en-US">Inducement Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Company's Stock Option Activity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl" xml:lang="en-US">Summary of RSU Activity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Weighted-Average Fair Value of Options Granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US">Stock-Based Compensation Expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Gross Deferred Tax Asset and Related Valuation Allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of Reconciliations Between Statutory Federal Income Tax Rate and Effective Income Tax Rate of Income Tax Expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US">Number Of Operating Segments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US">Number of operating segments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Level 1</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Level 2</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Level 3</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US">Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US">Assets, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US">Assets measured at fair value levels 2 or 3</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xml:lang="en-US">Financial and Nonfinancial Liabilities, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xml:lang="en-US">Liabilities measured at fair value levels 2 or 3</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsAtCarryingValue" xlink:to="us-gaap_MoneyMarketFundsAtCarryingValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue_lbl" xml:lang="en-US">Money Market Funds, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue_lbl" xml:lang="en-US">Carrying value of cash held in money market fund</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Range [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Range [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US">Furniture and Fixtures</label>
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_LaboratoryEquipmentMember" xlink:label="glyc_LaboratoryEquipmentMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_LaboratoryEquipmentMember" xlink:to="glyc_LaboratoryEquipmentMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_LaboratoryEquipmentMember_lbl" xml:lang="en-US">Laboratory equipment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_LaboratoryEquipmentMember_lbl" xml:lang="en-US">Laboratory Equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xml:lang="en-US">Office Equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US">Computer Equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Property and Equipment estimated useful lives</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwillAbstract" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwillAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwillAbstract" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwillAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwillAbstract_lbl" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill) [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwillAbstract_lbl" xml:lang="en-US">Impairment of Long-Lived Assets</label>
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_NumberOfLongLivedAssetsDeterminedToBeImpaired" xlink:label="glyc_NumberOfLongLivedAssetsDeterminedToBeImpaired" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_NumberOfLongLivedAssetsDeterminedToBeImpaired" xlink:to="glyc_NumberOfLongLivedAssetsDeterminedToBeImpaired_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_NumberOfLongLivedAssetsDeterminedToBeImpaired_lbl" xml:lang="en-US">Represents the number of long-lived assets determined to be impaired.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_NumberOfLongLivedAssetsDeterminedToBeImpaired_lbl" xml:lang="en-US">Number Of Long Lived Assets Determined To Be Impaired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_NumberOfLongLivedAssetsDeterminedToBeImpaired_lbl" xml:lang="en-US">Number of long-lived assets determined to be impaired</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup" xlink:label="us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup" xlink:to="us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup_lbl" xml:lang="en-US">Assets Held-for-sale, Not Part of Disposal Group</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup_lbl" xml:lang="en-US">Assets held for sale</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="us-gaap_DefinedContributionPlanTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="us-gaap_DefinedContributionPlanTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanTable_lbl" xml:lang="en-US">Defined Contribution Plan [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanDisclosureLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems_lbl" xml:lang="en-US">Defined Contribution Plan Disclosure [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems_lbl" xml:lang="en-US">Defined Contribution Plan Disclosure</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award Expiration Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Expiration period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_EmployeeStockOptionsAndRestrictedStockUnitsMember" xlink:label="glyc_EmployeeStockOptionsAndRestrictedStockUnitsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_EmployeeStockOptionsAndRestrictedStockUnitsMember" xlink:to="glyc_EmployeeStockOptionsAndRestrictedStockUnitsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_EmployeeStockOptionsAndRestrictedStockUnitsMember_lbl" xml:lang="en-US">n/a</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_EmployeeStockOptionsAndRestrictedStockUnitsMember_lbl" xml:lang="en-US">Stock options and restricted stock units</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Anti-dilutive securities excluded from computation of earnings per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Anti-dilutive securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid Expense, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid research and development expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xml:lang="en-US">Other Prepaid Expense, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xml:lang="en-US">Other prepaid expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl" xml:lang="en-US">Other Receivables, Net, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl" xml:lang="en-US">Other receivables</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold Improvements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Less accumulated depreciation</label>
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_AccruedResearchAndDevelopmentExpenseCurrent" xlink:label="glyc_AccruedResearchAndDevelopmentExpenseCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_AccruedResearchAndDevelopmentExpenseCurrent" xlink:to="glyc_AccruedResearchAndDevelopmentExpenseCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_AccruedResearchAndDevelopmentExpenseCurrent_lbl" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_AccruedResearchAndDevelopmentExpenseCurrent_lbl" xml:lang="en-US">Accrued Research And Development Expense Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_AccruedResearchAndDevelopmentExpenseCurrent_lbl" xml:lang="en-US">Accrued research and development expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="us-gaap_AccruedBonusesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedBonusesCurrent" xlink:to="us-gaap_AccruedBonusesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedBonusesCurrent_lbl" xml:lang="en-US">Accrued Bonuses, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedBonusesCurrent_lbl" xml:lang="en-US">Accrued bonuses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US">Accrued Professional Fees, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US">Accrued consulting and other professional fees</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" xml:lang="en-US">Accrued Employee Benefits, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" xml:lang="en-US">Accrued employee benefits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Other Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Other accrued expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xml:lang="en-US">Lessee, Lease, Description [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US">Geographical [Domain]</label>
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_RockvilleMarylandMember" xlink:label="glyc_RockvilleMarylandMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_RockvilleMarylandMember" xlink:to="glyc_RockvilleMarylandMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_RockvilleMarylandMember_lbl" xml:lang="en-US">Pertaining to Rockville, Maryland.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_RockvilleMarylandMember_lbl" xml:lang="en-US">Rockville, Maryland</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xml:lang="en-US">Lessee, Lease, Description [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:label="us-gaap_LesseeOperatingLeaseDescriptionAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:to="us-gaap_LesseeOperatingLeaseDescriptionAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseDescriptionAbstract_lbl" xml:lang="en-US">Lessee, Operating Lease, Description [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseDescriptionAbstract_lbl" xml:lang="en-US">Operating leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasePracticalExpedientLessorSingleLeaseComponent" xlink:label="us-gaap_LeasePracticalExpedientLessorSingleLeaseComponent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasePracticalExpedientLessorSingleLeaseComponent" xlink:to="us-gaap_LeasePracticalExpedientLessorSingleLeaseComponent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasePracticalExpedientLessorSingleLeaseComponent_lbl" xml:lang="en-US">Lease, Practical Expedient, Lessor Single Lease Component [true false]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xml:lang="en-US">Lessee, Operating Lease, Existence of Option to Extend [true false]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate_lbl" xml:lang="en-US">Lessee, Operating Lease, Existence of Option to Terminate [true false]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:label="us-gaap_DebtInstrumentInterestRateIncreaseDecrease" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:to="us-gaap_DebtInstrumentInterestRateIncreaseDecrease_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateIncreaseDecrease_lbl" xml:lang="en-US">Debt Instrument, Interest Rate, Increase (Decrease)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateIncreaseDecrease_lbl" xml:lang="en-US">Incremental borrowing rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</label>
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_LesseeOperatingLeaseNumberOfNewLeases" xlink:label="glyc_LesseeOperatingLeaseNumberOfNewLeases" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_LesseeOperatingLeaseNumberOfNewLeases" xlink:to="glyc_LesseeOperatingLeaseNumberOfNewLeases_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_LesseeOperatingLeaseNumberOfNewLeases_lbl" xml:lang="en-US">Represents the number of additional operating leases entered into during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_LesseeOperatingLeaseNumberOfNewLeases_lbl" xml:lang="en-US">Lessee Operating Lease Number Of New Leases</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_LesseeOperatingLeaseNumberOfNewLeases_lbl" xml:lang="en-US">Number of additional operating leases entered during the period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCostAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostAbstract_lbl" xml:lang="en-US">Lease, Cost [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCostAbstract_lbl" xml:lang="en-US">Components of lease expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Operating Lease, Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Operating lease cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VariableLeaseCost_lbl" xml:lang="en-US">Variable Lease, Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_VariableLeaseCost_lbl" xml:lang="en-US">Variable lease cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US">Lease, Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US">Total operating lease cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:label="us-gaap_CashFlowOperatingActivitiesLesseeAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:to="us-gaap_CashFlowOperatingActivitiesLesseeAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowOperatingActivitiesLesseeAbstract_lbl" xml:lang="en-US">Cash Flow, Operating Activities, Lessee [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFlowOperatingActivitiesLesseeAbstract_lbl" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating Lease, Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating cash outflows from operating leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US">Operating Lease Liabilities, Payments Due [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US">Maturities of lease liability due</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2022</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2023</label>
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo" xlink:label="glyc_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo" xlink:to="glyc_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo_lbl" xml:lang="en-US">Amount of lessee's undiscounted obligation for lease payment for operating lease due after second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo_lbl" xml:lang="en-US">Lessee Operating Lease Liability Payments Due After Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo_lbl" xml:lang="en-US">Thereafter</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Present value adjustment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Operating Lease, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Present value of lease payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_AtMarketOffering2017Member" xlink:label="glyc_AtMarketOffering2017Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_AtMarketOffering2017Member" xlink:to="glyc_AtMarketOffering2017Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_AtMarketOffering2017Member_lbl" xml:lang="en-US">Pertains to the sale of common stock under an at-the-market sales agreement under a shelf registration statement filed in September 2017.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_AtMarketOffering2017Member_lbl" xml:lang="en-US">At Market Offering 2017 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_AtMarketOffering2017Member_lbl" xml:lang="en-US">2017 Sales Agreement</label>
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_AtMarketOffering2020Member" xlink:label="glyc_AtMarketOffering2020Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_AtMarketOffering2020Member" xlink:to="glyc_AtMarketOffering2020Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_AtMarketOffering2020Member_lbl" xml:lang="en-US">Pertains to the sale of common stock under an at-the-market sales agreement under a shelf registration statement filed in October 2020.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_AtMarketOffering2020Member_lbl" xml:lang="en-US">At Market Offering 2020 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_AtMarketOffering2020Member_lbl" xml:lang="en-US">2020 Sales Agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US">Equity offerings</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Shares Issued, Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Price per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US">Aggregate net proceeds from stock sale</label>
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_CommonStockValueAvailableForSaleUnderAgreement" xlink:label="glyc_CommonStockValueAvailableForSaleUnderAgreement" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_CommonStockValueAvailableForSaleUnderAgreement" xlink:to="glyc_CommonStockValueAvailableForSaleUnderAgreement_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_CommonStockValueAvailableForSaleUnderAgreement_lbl" xml:lang="en-US">Amount of common stock remaining available to be sold under the terms of the agreement at the end of the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_CommonStockValueAvailableForSaleUnderAgreement_lbl" xml:lang="en-US">Common Stock Value Available For Sale Under Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_CommonStockValueAvailableForSaleUnderAgreement_lbl" xml:lang="en-US">Common stock available for sale under agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingAxis_lbl" xml:lang="en-US">Vesting [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingDomain_lbl" xml:lang="en-US">Vesting [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xml:lang="en-US">Upon first anniversary of start date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xml:lang="en-US">Each month after the first anniversary</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_lbl" xml:lang="en-US">Incentive plans</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US">Percent of shares subject to option grant that will vest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US">Vesting percentage</label>
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfMonthlyInstallments" xlink:label="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfMonthlyInstallments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfMonthlyInstallments" xlink:to="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfMonthlyInstallments_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfMonthlyInstallments_lbl" xml:lang="en-US">Number of monthly installments for Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition. Includes, but is not limited to, combination of market, performance or service condition.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfMonthlyInstallments_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Number of Monthly Installments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfMonthlyInstallments_lbl" xml:lang="en-US">Number of monthly installments</label>
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment" xlink:label="glyc_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment" xlink:to="glyc_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment_lbl" xml:lang="en-US">Period from date of termination of employment by reasons other than death, cause, or disability that any vested options shall expire, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment_lbl" xml:lang="en-US">Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period After Termination Of Employment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment_lbl" xml:lang="en-US">Period from date of termination that any vested options shall expire</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Unrecognized compensation expense related to unvested options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Period for unrecognized compensation expense related to unvested options yet has not been recognized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US">Share-based compensation arrangement by share-based payment award options exercises in period total intrinsic value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US">Intrinsic value of options exercised</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Cash proceeds from exercise of stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xml:lang="en-US">Fair value of shares vested</label>
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedSharesDisclosureAbstract" xlink:label="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedSharesDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedSharesDisclosureAbstract" xlink:to="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedSharesDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedSharesDisclosureAbstract_lbl" xml:lang="en-US">n/a</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedSharesDisclosureAbstract_lbl" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Authorized Shares Disclosure Abstract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedSharesDisclosureAbstract_lbl" xml:lang="en-US">Authorized shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US">Common stock authorized</label>
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_PercentageOfTotalNumberOfCommonStockOutstandingOnLastBusinessDayOfPriorFiscalYearThatMayAutomaticallyIncreaseUnderPlan" xlink:label="glyc_PercentageOfTotalNumberOfCommonStockOutstandingOnLastBusinessDayOfPriorFiscalYearThatMayAutomaticallyIncreaseUnderPlan" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_PercentageOfTotalNumberOfCommonStockOutstandingOnLastBusinessDayOfPriorFiscalYearThatMayAutomaticallyIncreaseUnderPlan" xlink:to="glyc_PercentageOfTotalNumberOfCommonStockOutstandingOnLastBusinessDayOfPriorFiscalYearThatMayAutomaticallyIncreaseUnderPlan_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_PercentageOfTotalNumberOfCommonStockOutstandingOnLastBusinessDayOfPriorFiscalYearThatMayAutomaticallyIncreaseUnderPlan_lbl" xml:lang="en-US">Total automatic increase in number of shares of common stock reserved for issuance under the Plan on January 1 of each year, as a percent of the total number of common stock outstanding at December 31 of the prior year.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_PercentageOfTotalNumberOfCommonStockOutstandingOnLastBusinessDayOfPriorFiscalYearThatMayAutomaticallyIncreaseUnderPlan_lbl" xml:lang="en-US">Percentage Of Total Number Of Common Stock Outstanding On Last Business Day Of Prior Fiscal Year That May Automatically Increase Under Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_PercentageOfTotalNumberOfCommonStockOutstandingOnLastBusinessDayOfPriorFiscalYearThatMayAutomaticallyIncreaseUnderPlan_lbl" xml:lang="en-US">Automatic increase in number of shares reserved for issuance as a percentage of the total common stock outstanding at the end of the prior year</label>
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMaximumSharesIssuedUponExerciseOfIncentiveStockOptions" xlink:label="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMaximumSharesIssuedUponExerciseOfIncentiveStockOptions" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMaximumSharesIssuedUponExerciseOfIncentiveStockOptions" xlink:to="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMaximumSharesIssuedUponExerciseOfIncentiveStockOptions_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMaximumSharesIssuedUponExerciseOfIncentiveStockOptions_lbl" xml:lang="en-US">Share based compensation arrangement by share based payment award number of maximum shares issued upon exercise of incentive stock options.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMaximumSharesIssuedUponExerciseOfIncentiveStockOptions_lbl" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Number Of Maximum Shares Issued Upon Exercise Of Incentive Stock Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMaximumSharesIssuedUponExerciseOfIncentiveStockOptions_lbl" xml:lang="en-US">Maximum number of shares that may be issued pursuant to exercise of incentive stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US">Increase in number of shares of common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US">OUTSTANDING OPTIONS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Outstanding at end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Outstanding at beginning of period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Options granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Stock options granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Options forfeited</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US">WEIGHTED-AVERAGE EXERCISE PRICE</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Outstanding at end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Outstanding at beginning of period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Options granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Options exercised</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Options forfeited</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_lbl" xml:lang="en-US">VESTED AND EXPECTED TO VEST</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Outstanding options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted-Average Exercise Price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted-Average Remaining Contractual Term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US">ADDITIONAL DISCLOSURES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Outstanding options exercisable at end of period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted-average exercise price exercisable at end of period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted-average contractual term outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted-average contractual term (years) exercisable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US">Equity Award [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">RSU [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">RSU</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GranteeStatusAxis_lbl" xml:lang="en-US">Grantee Status [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_GranteeStatusDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GranteeStatusDomain_lbl" xml:lang="en-US">Grantee Status [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl" xml:lang="en-US">Non-executive employees</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_lbl" xml:lang="en-US">On the second anniversary of the date of grant</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US">Restricted Stock Units information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Vesting period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xml:lang="en-US">Unrecognized compensation expense related to unvested service RSUs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xml:lang="en-US">Unrecognized compensation expense related to unvested options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xml:lang="en-US">NUMBER OF SHARES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Unvested at end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Unvested at beginning of period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US">Forfeited</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Vested</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xml:lang="en-US">WEIGHTED-AVERAGE GRANT DATE FAIR VALUE</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Unvested at end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Unvested at beginning of period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Forfeited</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Vested</label>
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_VestingUponFDApprovalMember" xlink:label="glyc_VestingUponFDApprovalMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_VestingUponFDApprovalMember" xlink:to="glyc_VestingUponFDApprovalMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_VestingUponFDApprovalMember_lbl" xml:lang="en-US">Vesting upon FDA approval of uproleselan in patients with relapsed/refractory acute myeloid leukemia.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_VestingUponFDApprovalMember_lbl" xml:lang="en-US">Vesting upon FDA Approval</label>
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_VestingUponFirstCommercialSaleMember" xlink:label="glyc_VestingUponFirstCommercialSaleMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_VestingUponFirstCommercialSaleMember" xlink:to="glyc_VestingUponFirstCommercialSaleMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_VestingUponFirstCommercialSaleMember_lbl" xml:lang="en-US">Vesting upon the first commercial sale of uproleselan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_VestingUponFirstCommercialSaleMember_lbl" xml:lang="en-US">Vesting upon First Commercial Sale</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US">Title of Individual [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xml:lang="en-US">Chief Executive Officer</label>
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_StockOptionsVestingBasedOnServiceMember" xlink:label="glyc_StockOptionsVestingBasedOnServiceMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_StockOptionsVestingBasedOnServiceMember" xlink:to="glyc_StockOptionsVestingBasedOnServiceMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_StockOptionsVestingBasedOnServiceMember_lbl" xml:lang="en-US">Represents a stock option award with vesting based on length of service.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_StockOptionsVestingBasedOnServiceMember_lbl" xml:lang="en-US">Stock options vesting based on service</label>
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_StockOptionsVestingBasedOnPerformanceMember" xlink:label="glyc_StockOptionsVestingBasedOnPerformanceMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_StockOptionsVestingBasedOnPerformanceMember" xlink:to="glyc_StockOptionsVestingBasedOnPerformanceMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_StockOptionsVestingBasedOnPerformanceMember_lbl" xml:lang="en-US">Represents a stock option award with vesting based on achievement of performance conditions.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_StockOptionsVestingBasedOnPerformanceMember_lbl" xml:lang="en-US">Stock options vesting based on performance</label>
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingUnderlyingSharesVestPeriod" xlink:label="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingUnderlyingSharesVestPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingUnderlyingSharesVestPeriod" xlink:to="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingUnderlyingSharesVestPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingUnderlyingSharesVestPeriod_lbl" xml:lang="en-US">Period remaining underlying shares vest, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingUnderlyingSharesVestPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Remaining Underlying Shares Vest Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingUnderlyingSharesVestPeriod_lbl" xml:lang="en-US">Period remaining underlying shares vest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xml:lang="en-US">Common stock shares issued</label>
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFairValueOfOptionExcludedFromUnrecognizedCompensationExpense" xlink:label="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFairValueOfOptionExcludedFromUnrecognizedCompensationExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFairValueOfOptionExcludedFromUnrecognizedCompensationExpense" xlink:to="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFairValueOfOptionExcludedFromUnrecognizedCompensationExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFairValueOfOptionExcludedFromUnrecognizedCompensationExpense_lbl" xml:lang="en-US">Maximum fair value of option excluded from the unrecognized compensation expense under the share based payment arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFairValueOfOptionExcludedFromUnrecognizedCompensationExpense_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Fair Value Of Option Excluded From Unrecognized Compensation Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFairValueOfOptionExcludedFromUnrecognizedCompensationExpense_lbl" xml:lang="en-US">Maximum fair value of option excluded from the unrecognized compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted-average fair value of the options granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xml:lang="en-US">Weighted-average assumptions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected volatility</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Expected dividend yield</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US">Income Statement Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and Administrative Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and Administrative Expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US">Stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Allocated Share-based Compensation Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Total stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xml:lang="en-US">Components of Deferred Tax Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xml:lang="en-US">Deferred income tax assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforward</label>
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_DeferredTaxAssetsCapitalizedStartUpCosts" xlink:label="glyc_DeferredTaxAssetsCapitalizedStartUpCosts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_DeferredTaxAssetsCapitalizedStartUpCosts" xlink:to="glyc_DeferredTaxAssetsCapitalizedStartUpCosts_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_DeferredTaxAssetsCapitalizedStartUpCosts_lbl" xml:lang="en-US">Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences capitalized start up costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_DeferredTaxAssetsCapitalizedStartUpCosts_lbl" xml:lang="en-US">Deferred Tax Assets Capitalized Start Up Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_DeferredTaxAssetsCapitalizedStartUpCosts_lbl" xml:lang="en-US">Capitalized start-up costs</label>
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_DeferredTaxAssetsPatentAmortization" xlink:label="glyc_DeferredTaxAssetsPatentAmortization" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_DeferredTaxAssetsPatentAmortization" xlink:to="glyc_DeferredTaxAssetsPatentAmortization_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_DeferredTaxAssetsPatentAmortization_lbl" xml:lang="en-US">Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences patent amortization.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_DeferredTaxAssetsPatentAmortization_lbl" xml:lang="en-US">Deferred Tax Assets Patent Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_DeferredTaxAssetsPatentAmortization_lbl" xml:lang="en-US">Patent amortization</label>
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_DeferredTaxAssetsResearchAndOrphanDrugCredits" xlink:label="glyc_DeferredTaxAssetsResearchAndOrphanDrugCredits" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_DeferredTaxAssetsResearchAndOrphanDrugCredits" xlink:to="glyc_DeferredTaxAssetsResearchAndOrphanDrugCredits_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_DeferredTaxAssetsResearchAndOrphanDrugCredits_lbl" xml:lang="en-US">Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from research and orphan drug credits.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_DeferredTaxAssetsResearchAndOrphanDrugCredits_lbl" xml:lang="en-US">Deferred Tax Assets Research And Orphan Drug Credits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_DeferredTaxAssetsResearchAndOrphanDrugCredits_lbl" xml:lang="en-US">Research and orphan drug credits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl" xml:lang="en-US">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_DeferredTaxAssetsTaxDeferredExpenseOperatingLeaseLiabilities" xlink:label="glyc_DeferredTaxAssetsTaxDeferredExpenseOperatingLeaseLiabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_DeferredTaxAssetsTaxDeferredExpenseOperatingLeaseLiabilities" xlink:to="glyc_DeferredTaxAssetsTaxDeferredExpenseOperatingLeaseLiabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_DeferredTaxAssetsTaxDeferredExpenseOperatingLeaseLiabilities_lbl" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from operating lease liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_DeferredTaxAssetsTaxDeferredExpenseOperatingLeaseLiabilities_lbl" xml:lang="en-US">Deferred Tax Assets Tax Deferred Expense Operating Lease Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_DeferredTaxAssetsTaxDeferredExpenseOperatingLeaseLiabilities_lbl" xml:lang="en-US">Operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_DeferredTaxAssetsAccruedBonus" xlink:label="glyc_DeferredTaxAssetsAccruedBonus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_DeferredTaxAssetsAccruedBonus" xlink:to="glyc_DeferredTaxAssetsAccruedBonus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_DeferredTaxAssetsAccruedBonus_lbl" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from Accrued bonus.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_DeferredTaxAssetsAccruedBonus_lbl" xml:lang="en-US">Deferred Tax Assets, Accrued Bonus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_DeferredTaxAssetsAccruedBonus_lbl" xml:lang="en-US">Accrued bonus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US">Deferred Tax Assets, Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US">Other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Deferred Tax Assets, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Gross deferred income tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Net deferred income tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl" xml:lang="en-US">Components of Deferred Tax Liabilities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl" xml:lang="en-US">Deferred tax liabilities:</label>
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_DeferredTaxLiabilitiesTaxDeferredExpenseOperatingLeaseLiabilitiesRightOfUseAssets" xlink:label="glyc_DeferredTaxLiabilitiesTaxDeferredExpenseOperatingLeaseLiabilitiesRightOfUseAssets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_DeferredTaxLiabilitiesTaxDeferredExpenseOperatingLeaseLiabilitiesRightOfUseAssets" xlink:to="glyc_DeferredTaxLiabilitiesTaxDeferredExpenseOperatingLeaseLiabilitiesRightOfUseAssets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_DeferredTaxLiabilitiesTaxDeferredExpenseOperatingLeaseLiabilitiesRightOfUseAssets_lbl" xml:lang="en-US">Amount of deferred tax liability attributable to taxable temporary differences from operating lease right-of-use assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_DeferredTaxLiabilitiesTaxDeferredExpenseOperatingLeaseLiabilitiesRightOfUseAssets_lbl" xml:lang="en-US">Deferred Tax Liabilities Tax Deferred Expense Operating Lease Liabilities Right Of Use Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="glyc_DeferredTaxLiabilitiesTaxDeferredExpenseOperatingLeaseLiabilitiesRightOfUseAssets_lbl" xml:lang="en-US">Operating lease right-of-use assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xml:lang="en-US">Property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US">Deferred Tax Liabilities, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US">Gross deferred income tax liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US">Deferred Tax Assets, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US">Net deferred income tax asset/(liability)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardTable" xlink:label="us-gaap_TaxCreditCarryforwardTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardTable" xlink:to="us-gaap_TaxCreditCarryforwardTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardTable_lbl" xml:lang="en-US">Tax Credit Carryforward [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US">Income Tax Authority [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US">Income Tax Authority [Domain]</label>
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_FederalAndStateAuthoritiesMember" xlink:label="glyc_FederalAndStateAuthoritiesMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_FederalAndStateAuthoritiesMember" xlink:to="glyc_FederalAndStateAuthoritiesMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_FederalAndStateAuthoritiesMember_lbl" xml:lang="en-US">Designated tax department of the U. S. government and the designated tax department of the state government entitled to levy and collect income taxes.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_FederalAndStateAuthoritiesMember_lbl" xml:lang="en-US">U.S. Federal And State</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xml:lang="en-US">Tax Credit Carryforward [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchMember_lbl" xml:lang="en-US">Research Tax Credit Carryforward [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralBusinessMember" xlink:label="us-gaap_GeneralBusinessMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralBusinessMember" xlink:to="us-gaap_GeneralBusinessMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralBusinessMember_lbl" xml:lang="en-US">General Business Tax Credit Carryforward [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralBusinessMember_lbl" xml:lang="en-US">General Business Tax Credit Carryforward</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems" xlink:label="us-gaap_TaxCreditCarryforwardLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="us-gaap_TaxCreditCarryforwardLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardLineItems_lbl" xml:lang="en-US">Tax Credit Carryforward [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxCreditCarryforwardLineItems_lbl" xml:lang="en-US">Tax Credit Carryforward</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating losses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US">Tax Credit Carryforward, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US">Tax credits available to carry forward</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">U.S. Federal statutory tax rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xml:lang="en-US">Research credit</label>
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent" xlink:label="glyc_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent" xlink:to="glyc_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent_lbl" xml:lang="en-US">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to orphan drug tax credit.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation Tax Credit Orphan Drug Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent_lbl" xml:lang="en-US">Orphan drug credit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" xml:lang="en-US">Other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Provision for income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_lbl" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CounterpartyNameAxis_lbl" xml:lang="en-US">Counterparty Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US">Counterparty Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_ApollomicMember" xlink:label="glyc_ApollomicMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_ApollomicMember" xlink:to="glyc_ApollomicMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_ApollomicMember_lbl" xml:lang="en-US">Represents the information pertaining to Apollomic.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_ApollomicMember_lbl" xml:lang="en-US">Apollomics, Inc.</label>
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_ArrangementsAndNonarrangementTransactionsLineItems" xlink:label="glyc_ArrangementsAndNonarrangementTransactionsLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_ArrangementsAndNonarrangementTransactionsLineItems" xlink:to="glyc_ArrangementsAndNonarrangementTransactionsLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_ArrangementsAndNonarrangementTransactionsLineItems_lbl" xml:lang="en-US">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_ArrangementsAndNonarrangementTransactionsLineItems_lbl" xml:lang="en-US">Research And License Agreements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_ArrangementsAndNonarrangementTransactionsLineItems_lbl" xml:lang="en-US">Research and License Agreements</label>
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_RevenueReceivedFromSaleOfClinicalSupplies" xlink:label="glyc_RevenueReceivedFromSaleOfClinicalSupplies" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_RevenueReceivedFromSaleOfClinicalSupplies" xlink:to="glyc_RevenueReceivedFromSaleOfClinicalSupplies_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_RevenueReceivedFromSaleOfClinicalSupplies_lbl" xml:lang="en-US">The amount of revenue from the sale of clinical supplies.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_RevenueReceivedFromSaleOfClinicalSupplies_lbl" xml:lang="en-US">Revenue Received From Sale Of Clinical Supplies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_RevenueReceivedFromSaleOfClinicalSupplies_lbl" xml:lang="en-US">Revenue from sale of clinical supplies</label>
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_UpFrontPaymentReceived" xlink:label="glyc_UpFrontPaymentReceived" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_UpFrontPaymentReceived" xlink:to="glyc_UpFrontPaymentReceived_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_UpFrontPaymentReceived_lbl" xml:lang="en-US">Amount of up-front payment received under terms of the agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_UpFrontPaymentReceived_lbl" xml:lang="en-US">Up Front Payment Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_UpFrontPaymentReceived_lbl" xml:lang="en-US">Up-front payment received</label>
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_DevelopmentAndRegulatoryApprovalMilestonesClinicalAndRegulatoryEvents" xlink:label="glyc_DevelopmentAndRegulatoryApprovalMilestonesClinicalAndRegulatoryEvents" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_DevelopmentAndRegulatoryApprovalMilestonesClinicalAndRegulatoryEvents" xlink:to="glyc_DevelopmentAndRegulatoryApprovalMilestonesClinicalAndRegulatoryEvents_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_DevelopmentAndRegulatoryApprovalMilestonesClinicalAndRegulatoryEvents_lbl" xml:lang="en-US">The amount of development and regulatory specific approval milestones based on achievement of certain clinical and regulatory events.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_DevelopmentAndRegulatoryApprovalMilestonesClinicalAndRegulatoryEvents_lbl" xml:lang="en-US">Development And Regulatory Approval Milestones Clinical And Regulatory Events</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_DevelopmentAndRegulatoryApprovalMilestonesClinicalAndRegulatoryEvents_lbl" xml:lang="en-US">Milestones based on achievement of certain clinical and regulatory events</label>
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_AchievementOfSpecifiedNetSalesThresholdsForAllLicensedProducts" xlink:label="glyc_AchievementOfSpecifiedNetSalesThresholdsForAllLicensedProducts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_AchievementOfSpecifiedNetSalesThresholdsForAllLicensedProducts" xlink:to="glyc_AchievementOfSpecifiedNetSalesThresholdsForAllLicensedProducts_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_AchievementOfSpecifiedNetSalesThresholdsForAllLicensedProducts_lbl" xml:lang="en-US">The amount of revenue to be received upon the achievement of specified net sales thresholds for all licensed products.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_AchievementOfSpecifiedNetSalesThresholdsForAllLicensedProducts_lbl" xml:lang="en-US">Achievement of Specified Net Sales Thresholds for all Licensed Products</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_AchievementOfSpecifiedNetSalesThresholdsForAllLicensedProducts_lbl" xml:lang="en-US">Milestone payment upon achievement of specified net sales thresholds for all licensed products</label>
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_MilestoneRevenueRecognized" xlink:label="glyc_MilestoneRevenueRecognized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_MilestoneRevenueRecognized" xlink:to="glyc_MilestoneRevenueRecognized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_MilestoneRevenueRecognized_lbl" xml:lang="en-US">The milestone revenue recognized.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_MilestoneRevenueRecognized_lbl" xml:lang="en-US">Milestone Revenue Recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_MilestoneRevenueRecognized_lbl" xml:lang="en-US">Milestone revenue recognized based on achievement of certain clinical and regulatory events</label>
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_TieredPercentageOfAnnualNetSales" xlink:label="glyc_TieredPercentageOfAnnualNetSales" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_TieredPercentageOfAnnualNetSales" xlink:to="glyc_TieredPercentageOfAnnualNetSales_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_TieredPercentageOfAnnualNetSales_lbl" xml:lang="en-US">The entitled royalty payments to be received based on a tiered percentage of annual net sales.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_TieredPercentageOfAnnualNetSales_lbl" xml:lang="en-US">Tiered Percentage Of Annual Net Sales</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_TieredPercentageOfAnnualNetSales_lbl" xml:lang="en-US">Tiered percentage of annual net sales</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xml:lang="en-US">Company matching contribution percentage</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xml:lang="en-US">Percent of employee contributions the company contributes a matching contribution</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xml:lang="en-US">Defined Contribution Plan, Employer Discretionary Contribution Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xml:lang="en-US">Employer match contribution</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>15
<FILENAME>glyc-20211231_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8042.36810 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/3/2022 9:43:53 AM-->
<!--Modified on: 3/3/2022 9:43:53 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="glyc-20211231.xsd#DocumentDocumentAndEntityInformation" roleURI="http://glyc.com/role/DocumentDocumentAndEntityInformation" />
  <roleRef xlink:type="simple" xlink:href="glyc-20211231.xsd#StatementBalanceSheets" roleURI="http://glyc.com/role/StatementBalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="glyc-20211231.xsd#StatementBalanceSheetsParenthetical" roleURI="http://glyc.com/role/StatementBalanceSheetsParenthetical" />
  <roleRef xlink:type="simple" xlink:href="glyc-20211231.xsd#StatementStatementsOfOperationsAndComprehensiveLoss" roleURI="http://glyc.com/role/StatementStatementsOfOperationsAndComprehensiveLoss" />
  <roleRef xlink:type="simple" xlink:href="glyc-20211231.xsd#StatementStatementsOfStockholdersEquity" roleURI="http://glyc.com/role/StatementStatementsOfStockholdersEquity" />
  <roleRef xlink:type="simple" xlink:href="glyc-20211231.xsd#StatementStatementsOfCashFlows" roleURI="http://glyc.com/role/StatementStatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="glyc-20211231.xsd#DisclosureDescriptionOfBusiness" roleURI="http://glyc.com/role/DisclosureDescriptionOfBusiness" />
  <roleRef xlink:type="simple" xlink:href="glyc-20211231.xsd#DisclosureGoingConcern" roleURI="http://glyc.com/role/DisclosureGoingConcern" />
  <roleRef xlink:type="simple" xlink:href="glyc-20211231.xsd#DisclosureSummaryOfSignificantAccountingPolicies" roleURI="http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPolicies" />
  <roleRef xlink:type="simple" xlink:href="glyc-20211231.xsd#DisclosureNetLossPerShareOfCommonStock" roleURI="http://glyc.com/role/DisclosureNetLossPerShareOfCommonStock" />
  <roleRef xlink:type="simple" xlink:href="glyc-20211231.xsd#DisclosurePrepaidExpensesAndOtherCurrentAssets" roleURI="http://glyc.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets" />
  <roleRef xlink:type="simple" xlink:href="glyc-20211231.xsd#DisclosurePropertyAndEquipment" roleURI="http://glyc.com/role/DisclosurePropertyAndEquipment" />
  <roleRef xlink:type="simple" xlink:href="glyc-20211231.xsd#DisclosureAccruedExpenses" roleURI="http://glyc.com/role/DisclosureAccruedExpenses" />
  <roleRef xlink:type="simple" xlink:href="glyc-20211231.xsd#DisclosureOperatingLeases" roleURI="http://glyc.com/role/DisclosureOperatingLeases" />
  <roleRef xlink:type="simple" xlink:href="glyc-20211231.xsd#DisclosureStockholdersEquity" roleURI="http://glyc.com/role/DisclosureStockholdersEquity" />
  <roleRef xlink:type="simple" xlink:href="glyc-20211231.xsd#DisclosureIncomeTaxes" roleURI="http://glyc.com/role/DisclosureIncomeTaxes" />
  <roleRef xlink:type="simple" xlink:href="glyc-20211231.xsd#DisclosureResearchAndLicenseAgreements" roleURI="http://glyc.com/role/DisclosureResearchAndLicenseAgreements" />
  <roleRef xlink:type="simple" xlink:href="glyc-20211231.xsd#DisclosureEmployeeBenefitPlan" roleURI="http://glyc.com/role/DisclosureEmployeeBenefitPlan" />
  <roleRef xlink:type="simple" xlink:href="glyc-20211231.xsd#DisclosureRisksAndUncertainties" roleURI="http://glyc.com/role/DisclosureRisksAndUncertainties" />
  <roleRef xlink:type="simple" xlink:href="glyc-20211231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" />
  <roleRef xlink:type="simple" xlink:href="glyc-20211231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesTables" roleURI="http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" />
  <roleRef xlink:type="simple" xlink:href="glyc-20211231.xsd#DisclosureNetLossPerShareOfCommonStockTables" roleURI="http://glyc.com/role/DisclosureNetLossPerShareOfCommonStockTables" />
  <roleRef xlink:type="simple" xlink:href="glyc-20211231.xsd#DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" roleURI="http://glyc.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" />
  <roleRef xlink:type="simple" xlink:href="glyc-20211231.xsd#DisclosurePropertyAndEquipmentTables" roleURI="http://glyc.com/role/DisclosurePropertyAndEquipmentTables" />
  <roleRef xlink:type="simple" xlink:href="glyc-20211231.xsd#DisclosureAccruedExpensesTables" roleURI="http://glyc.com/role/DisclosureAccruedExpensesTables" />
  <roleRef xlink:type="simple" xlink:href="glyc-20211231.xsd#DisclosureOperatingLeasesTables" roleURI="http://glyc.com/role/DisclosureOperatingLeasesTables" />
  <roleRef xlink:type="simple" xlink:href="glyc-20211231.xsd#DisclosureStockholdersEquityTables" roleURI="http://glyc.com/role/DisclosureStockholdersEquityTables" />
  <roleRef xlink:type="simple" xlink:href="glyc-20211231.xsd#DisclosureIncomeTaxesTables" roleURI="http://glyc.com/role/DisclosureIncomeTaxesTables" />
  <roleRef xlink:type="simple" xlink:href="glyc-20211231.xsd#DisclosureGoingConcernDetails" roleURI="http://glyc.com/role/DisclosureGoingConcernDetails" />
  <roleRef xlink:type="simple" xlink:href="glyc-20211231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesSegmentInformationDetails" roleURI="http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesSegmentInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="glyc-20211231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails" roleURI="http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails" />
  <roleRef xlink:type="simple" xlink:href="glyc-20211231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" roleURI="http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" />
  <roleRef xlink:type="simple" xlink:href="glyc-20211231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesImpairmentOfLongLivedAssetsDetails" roleURI="http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesImpairmentOfLongLivedAssetsDetails" />
  <roleRef xlink:type="simple" xlink:href="glyc-20211231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails" roleURI="http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails" />
  <roleRef xlink:type="simple" xlink:href="glyc-20211231.xsd#DisclosureNetLossPerCommonShareDetails" roleURI="http://glyc.com/role/DisclosureNetLossPerCommonShareDetails" />
  <roleRef xlink:type="simple" xlink:href="glyc-20211231.xsd#DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails" roleURI="http://glyc.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails" />
  <roleRef xlink:type="simple" xlink:href="glyc-20211231.xsd#DisclosurePropertyAndEquipmentDetails" roleURI="http://glyc.com/role/DisclosurePropertyAndEquipmentDetails" />
  <roleRef xlink:type="simple" xlink:href="glyc-20211231.xsd#DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails" roleURI="http://glyc.com/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails" />
  <roleRef xlink:type="simple" xlink:href="glyc-20211231.xsd#DisclosureOperatingLeasesDetails" roleURI="http://glyc.com/role/DisclosureOperatingLeasesDetails" />
  <roleRef xlink:type="simple" xlink:href="glyc-20211231.xsd#DisclosureOperatingLeasesComponentsOfLeaseExpenseDetails" roleURI="http://glyc.com/role/DisclosureOperatingLeasesComponentsOfLeaseExpenseDetails" />
  <roleRef xlink:type="simple" xlink:href="glyc-20211231.xsd#DisclosureOperatingLeasesMaturitiesOfLeaseLiabilityDetails" roleURI="http://glyc.com/role/DisclosureOperatingLeasesMaturitiesOfLeaseLiabilityDetails" />
  <roleRef xlink:type="simple" xlink:href="glyc-20211231.xsd#DisclosureStockholdersEquityEquityOfferingsDetails" roleURI="http://glyc.com/role/DisclosureStockholdersEquityEquityOfferingsDetails" />
  <roleRef xlink:type="simple" xlink:href="glyc-20211231.xsd#DisclosureStockholdersEquityIncentivePlansDetails" roleURI="http://glyc.com/role/DisclosureStockholdersEquityIncentivePlansDetails" />
  <roleRef xlink:type="simple" xlink:href="glyc-20211231.xsd#DisclosureStockholdersEquityCompanySStockOptionActivityDetails" roleURI="http://glyc.com/role/DisclosureStockholdersEquityCompanySStockOptionActivityDetails" />
  <roleRef xlink:type="simple" xlink:href="glyc-20211231.xsd#DisclosureStockholdersEquitySummaryOfRsuActivityDetails" roleURI="http://glyc.com/role/DisclosureStockholdersEquitySummaryOfRsuActivityDetails" />
  <roleRef xlink:type="simple" xlink:href="glyc-20211231.xsd#DisclosureStockholdersEquityInducementPlanDetails" roleURI="http://glyc.com/role/DisclosureStockholdersEquityInducementPlanDetails" />
  <roleRef xlink:type="simple" xlink:href="glyc-20211231.xsd#DisclosureStockholdersEquityInducementPlanStockOptionActivityDetails" roleURI="http://glyc.com/role/DisclosureStockholdersEquityInducementPlanStockOptionActivityDetails" />
  <roleRef xlink:type="simple" xlink:href="glyc-20211231.xsd#DisclosureStockholdersEquityWeightedAverageAssumptionsDetails" roleURI="http://glyc.com/role/DisclosureStockholdersEquityWeightedAverageAssumptionsDetails" />
  <roleRef xlink:type="simple" xlink:href="glyc-20211231.xsd#DisclosureStockholdersEquityStockBasedCompensationExpenseDetails" roleURI="http://glyc.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails" />
  <roleRef xlink:type="simple" xlink:href="glyc-20211231.xsd#DisclosureIncomeTaxesScheduleOfGrossDeferredTaxAssetAndRelatedValuationAllowanceDetail" roleURI="http://glyc.com/role/DisclosureIncomeTaxesScheduleOfGrossDeferredTaxAssetAndRelatedValuationAllowanceDetail" />
  <roleRef xlink:type="simple" xlink:href="glyc-20211231.xsd#DisclosureIncomeTaxesNolsAndCarryforwardsDetail" roleURI="http://glyc.com/role/DisclosureIncomeTaxesNolsAndCarryforwardsDetail" />
  <roleRef xlink:type="simple" xlink:href="glyc-20211231.xsd#DisclosureIncomeTaxesReconciliationBetweenStatutoryFederalIncomeTaxRateAndEffectiveIncomeTaxRateDetail" roleURI="http://glyc.com/role/DisclosureIncomeTaxesReconciliationBetweenStatutoryFederalIncomeTaxRateAndEffectiveIncomeTaxRateDetail" />
  <roleRef xlink:type="simple" xlink:href="glyc-20211231.xsd#DisclosureResearchAndLicenseAgreementsDetails" roleURI="http://glyc.com/role/DisclosureResearchAndLicenseAgreementsDetails" />
  <roleRef xlink:type="simple" xlink:href="glyc-20211231.xsd#DisclosureEmployeeBenefitPlanDetail" roleURI="http://glyc.com/role/DisclosureEmployeeBenefitPlanDetail" />
  <presentationLink xlink:role="http://glyc.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType_637818974328254099" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType_637818974328254099" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport_637818974328254099" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport_637818974328254099" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_637818974328264098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport_637818974328264098" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_637818974328264098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_637818974328264098" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_637818974328264098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber_637818974328264098" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_637818974328264098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName_637818974328264098" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_637818974328264098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_637818974328264098" order="7" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_637818974328264098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_637818974328264098" order="8" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_637818974328264098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_637818974328264098" order="9" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_637818974328264098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_637818974328264098" order="10" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_637818974328264098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_637818974328264098" order="11" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_637818974328264098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_637818974328264098" order="12" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_637818974328264098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode_637818974328264098" order="13" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_637818974328264098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber_637818974328264098" order="14" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_637818974328264098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle_637818974328264098" order="15" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_637818974328264098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol_637818974328264098" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_637818974328274099" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName_637818974328274099" order="17" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer_637818974328274099" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer_637818974328274099" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers_637818974328274099" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers_637818974328274099" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_637818974328274099" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus_637818974328274099" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_637818974328274099" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent_637818974328274099" order="21" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_637818974328274099" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory_637818974328274099" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_637818974328274099" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness_637818974328274099" order="23" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_637818974328274099" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_637818974328274099" order="24" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_637818974328274099" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany_637818974328274099" order="25" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag_637818974328274099" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag_637818974328274099" order="26" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat_637818974328284101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat_637818974328284101" order="27" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_637818974328284101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_637818974328284101" order="28" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_637818974328284101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus_637818974328284101" order="29" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_637818974328284101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_637818974328284101" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_637818974328284101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey_637818974328284101" order="31" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_637818974328284101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate_637818974328284101" order="32" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_637818974328284101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag_637818974328284101" order="33" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId_637818974328284101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId_637818974328284101" order="34" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="dei_AuditorName_637818974328294105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName_637818974328294105" order="35" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation_637818974328294105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation_637818974328294105" order="36" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/StatementBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - Balance Sheets">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_637818974328294105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract_637818974328294105" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_637818974328294105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637818974328294105" xlink:to="us-gaap_AssetsCurrentAbstract_637818974328294105" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637818974328294105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637818974328294105" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637818974328294105" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637818974328294105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637818974328294105" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637818974328294105" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_637818974328294105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637818974328294105" xlink:to="us-gaap_AssetsCurrent_637818974328294105" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637818974328294105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637818974328294105" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637818974328294105" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="us-gaap_PrepaidExpenseNoncurrent_637818974328294105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637818974328294105" xlink:to="us-gaap_PrepaidExpenseNoncurrent_637818974328294105" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit_637818974328294105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637818974328294105" xlink:to="us-gaap_SecurityDeposit_637818974328294105" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_637818974328304115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637818974328294105" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_637818974328304115" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_637818974328304115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637818974328294105" xlink:to="us-gaap_Assets_637818974328304115" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637818974328304115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637818974328304115" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_637818974328304115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637818974328304115" xlink:to="us-gaap_LiabilitiesCurrentAbstract_637818974328304115" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_637818974328304115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637818974328304115" xlink:to="us-gaap_AccountsPayableCurrent_637818974328304115" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_637818974328304115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637818974328304115" xlink:to="us-gaap_AccruedLiabilitiesCurrent_637818974328304115" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_637818974328304115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637818974328304115" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_637818974328304115" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_637818974328304115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637818974328304115" xlink:to="us-gaap_LiabilitiesCurrent_637818974328304115" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent_637818974328304115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637818974328304115" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent_637818974328304115" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_637818974328304115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637818974328304115" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_637818974328304115" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_637818974328304115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637818974328304115" xlink:to="us-gaap_Liabilities_637818974328304115" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_637818974328304115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637818974328304115" xlink:to="us-gaap_StockholdersEquityAbstract_637818974328304115" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_637818974328314102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637818974328304115" xlink:to="us-gaap_PreferredStockValue_637818974328314102" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_637818974328314102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637818974328304115" xlink:to="us-gaap_CommonStockValue_637818974328314102" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_637818974328314102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637818974328304115" xlink:to="us-gaap_AdditionalPaidInCapital_637818974328314102" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_637818974328314102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637818974328304115" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_637818974328314102" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637818974328314102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637818974328304115" xlink:to="us-gaap_StockholdersEquity_637818974328314102" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_637818974328314102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637818974328304115" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_637818974328314102" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/StatementBalanceSheetsParenthetical" xlink:type="extended" xlink:title="00105 - Statement - Balance Sheets (Parenthetical)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_637818974328314102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_637818974328314102" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_637818974328314102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized_637818974328314102" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_637818974328324101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued_637818974328324101" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_637818974328324101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding_637818974328324101" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_637818974328324101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_637818974328324101" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_637818974328324101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized_637818974328324101" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_637818974328324101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued_637818974328324101" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_637818974328324101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding_637818974328324101" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/StatementStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" xlink:title="00200 - Statement - Statements of Operations and Comprehensive Loss">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_637818974328324101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_637818974328324101" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingCostsAndExpensesAbstract" xlink:label="us-gaap_OperatingCostsAndExpensesAbstract_637818974328324101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingCostsAndExpensesAbstract_637818974328324101" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_637818974328324101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract_637818974328324101" xlink:to="us-gaap_ResearchAndDevelopmentExpense_637818974328324101" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_637818974328324101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract_637818974328324101" xlink:to="us-gaap_GeneralAndAdministrativeExpense_637818974328324101" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_637818974328324101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract_637818974328324101" xlink:to="us-gaap_OperatingExpenses_637818974328324101" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_637818974328324101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss_637818974328324101" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_637818974328324101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet_637818974328324101" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_NetIncomeLossAndComprehensiveIncomeNetOfTax" xlink:label="glyc_NetIncomeLossAndComprehensiveIncomeNetOfTax_637818974328324101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="glyc_NetIncomeLossAndComprehensiveIncomeNetOfTax_637818974328324101" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_637818974328334101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic_637818974328334101" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_637818974328334101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted_637818974328334101" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_637818974328334101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_637818974328334101" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_637818974328334101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_637818974328334101" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/StatementStatementsOfStockholdersEquity" xlink:type="extended" xlink:title="00300 - Statement - Statements of Stockholders' Equity">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="StatementOfStockholdersEquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637818974328334101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable_637818974328334101" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_637818974328334101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637818974328334101" xlink:to="us-gaap_StatementEquityComponentsAxis_637818974328334101" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_637818974328334101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637818974328334101" xlink:to="us-gaap_CommonStockMember_637818974328334101" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_637818974328334101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637818974328334101" xlink:to="us-gaap_AdditionalPaidInCapitalMember_637818974328334101" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_637818974328334101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637818974328334101" xlink:to="us-gaap_RetainedEarningsMember_637818974328334101" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637818974328334101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637818974328334101" xlink:to="us-gaap_EquityComponentDomain_637818974328334101" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637818974328334101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637818974328334101" xlink:to="us-gaap_StatementLineItems_637818974328334101" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637818974328334101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637818974328334101" xlink:to="us-gaap_StockholdersEquity_637818974328334101" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_637818974328344100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637818974328334101" xlink:to="us-gaap_SharesOutstanding_637818974328344100" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_637818974328344100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637818974328334101" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_637818974328344100" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637818974328344100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues_637818974328344100" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637818974328344100" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsVesting" xlink:label="glyc_StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsVesting_637818974328344100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637818974328334101" xlink:to="glyc_StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsVesting_637818974328344100" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_StockIssuedDuringPeriodSharesStockOptionsAndRestrictedStockUnitsVesting" xlink:label="glyc_StockIssuedDuringPeriodSharesStockOptionsAndRestrictedStockUnitsVesting_637818974328344100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsVesting_637818974328344100" xlink:to="glyc_StockIssuedDuringPeriodSharesStockOptionsAndRestrictedStockUnitsVesting_637818974328344100" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_637818974328344100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637818974328334101" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_637818974328344100" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637818974328344100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_637818974328344100" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637818974328344100" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_637818974328344100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637818974328334101" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_637818974328344100" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637818974328344100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637818974328334101" xlink:to="us-gaap_NetIncomeLoss_637818974328344100" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637818974328344100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637818974328334101" xlink:to="us-gaap_StockholdersEquity_637818974328344100" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_6378189743283441001" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637818974328334101" xlink:to="us-gaap_SharesOutstanding_6378189743283441001" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/StatementStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - Statements of Cash Flows">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637818974328354099" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637818974328354099" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_637818974328354099" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637818974328354099" xlink:to="us-gaap_ProfitLoss_637818974328354099" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637818974328354099" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637818974328354099" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637818974328354099" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_637818974328354099" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637818974328354099" xlink:to="us-gaap_Depreciation_637818974328354099" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_637818974328354099" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637818974328354099" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_637818974328354099" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_637818974328354099" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637818974328354099" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_637818974328354099" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_637818974328354099" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637818974328354099" xlink:to="us-gaap_ShareBasedCompensation_637818974328354099" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637818974328354099" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637818974328354099" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637818974328354099" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637818974328354099" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637818974328354099" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637818974328354099" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_637818974328354099" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637818974328354099" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_637818974328354099" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_637818974328354099" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637818974328354099" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_637818974328354099" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:label="glyc_IncreaseDecreaseInOperatingLeaseLiabilities_637818974328354099" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637818974328354099" xlink:to="glyc_IncreaseDecreaseInOperatingLeaseLiabilities_637818974328354099" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_637818974328354099" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637818974328354099" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_637818974328354099" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637818974328364101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637818974328364101" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637818974328364101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637818974328364101" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637818974328364101" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_637818974328364101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637818974328364101" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_637818974328364101" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637818974328364101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637818974328364101" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_637818974328364101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637818974328364101" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_637818974328364101" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_637818974328364101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637818974328364101" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_637818974328364101" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_637818974328364101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637818974328364101" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_637818974328364101" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637818974328364101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637818974328364101" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637818974328364101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637818974328364101" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6378189743283641011" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6378189743283641011" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureDescriptionOfBusiness" xlink:type="extended" xlink:title="10101 - Disclosure - Description of the Business">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations_637818974328374100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NatureOfOperations_637818974328374100" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureGoingConcern" xlink:type="extended" xlink:title="10201 - Disclosure - Going Concern">
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_GoingConcernAbstract" xlink:label="glyc_GoingConcernAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_637818974328374100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_GoingConcernAbstract" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_637818974328374100" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="extended" xlink:title="10301 - Disclosure - Summary of Significant Accounting Policies">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_637818974328374100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_637818974328374100" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="9" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureNetLossPerShareOfCommonStock" xlink:type="extended" xlink:title="10401 - Disclosure - Net Loss Per Share of Common Stock">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock_637818974328374100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock_637818974328374100" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets" xlink:type="extended" xlink:title="10501 - Disclosure - Prepaid Expenses and Other Current Assets">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentAssetsTextBlock" xlink:label="us-gaap_OtherCurrentAssetsTextBlock_637818974328384101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_OtherCurrentAssetsTextBlock_637818974328384101" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosurePropertyAndEquipment" xlink:type="extended" xlink:title="10601 - Disclosure - Property and Equipment">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_637818974328384101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_637818974328384101" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureAccruedExpenses" xlink:type="extended" xlink:title="10701 - Disclosure - Accrued Expenses">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_637818974328384101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_637818974328384101" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureOperatingLeases" xlink:type="extended" xlink:title="10801 - Disclosure - Operating Leases">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_637818974328384101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_637818974328384101" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureStockholdersEquity" xlink:type="extended" xlink:title="10901 - Disclosure - Stockholders' Equity">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_DisclosureOfStockholdersEquityAndCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="glyc_DisclosureOfStockholdersEquityAndCompensationRelatedCostsShareBasedPaymentsTextBlock_637818974328384101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="glyc_DisclosureOfStockholdersEquityAndCompensationRelatedCostsShareBasedPaymentsTextBlock_637818974328384101" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureIncomeTaxes" xlink:type="extended" xlink:title="11001 - Disclosure - Income Taxes">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_637818974328394100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_637818974328394100" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureResearchAndLicenseAgreements" xlink:type="extended" xlink:title="11101 - Disclosure - Research and License Agreements">
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_ResearchAndLicenseAgreementsAbstract" xlink:label="glyc_ResearchAndLicenseAgreementsAbstract" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_ResearchAndLicenseAgreementTextBlock" xlink:label="glyc_ResearchAndLicenseAgreementTextBlock_637818974328394100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_ResearchAndLicenseAgreementsAbstract" xlink:to="glyc_ResearchAndLicenseAgreementTextBlock_637818974328394100" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureEmployeeBenefitPlan" xlink:type="extended" xlink:title="11201 - Disclosure - Employee Benefit Plan">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock_637818974328394100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock_637818974328394100" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureRisksAndUncertainties" xlink:type="extended" xlink:title="11301 - Disclosure - Risks and Uncertainties">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyAbstract" xlink:label="us-gaap_LossContingencyAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyDisclosures" xlink:label="us-gaap_LossContingencyDisclosures_637818974328394100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingencyAbstract" xlink:to="us-gaap_LossContingencyDisclosures_637818974328394100" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="20202 - Disclosure - Summary of Significant Accounting Policies (Policies)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_637818974328404100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_637818974328404100" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_637818974328404100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_637818974328404100" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_637818974328404100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates_637818974328404100" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_637818974328404100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_637818974328404100" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_637818974328404100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_637818974328404100" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk_637818974328404100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk_637818974328404100" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_637818974328404100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_637818974328404100" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_637818974328404100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_637818974328404100" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_637818974328404100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_637818974328404100" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_637818974328404100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_637818974328404100" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_AccrualsForClinicalTrialExpensesPolicyTextBlock" xlink:label="glyc_AccrualsForClinicalTrialExpensesPolicyTextBlock_637818974328404100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="glyc_AccrualsForClinicalTrialExpensesPolicyTextBlock_637818974328404100" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_637818974328404100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_637818974328404100" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_637818974328404100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_637818974328404100" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_637818974328404100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_637818974328404100" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_NewAccountingPronouncementsAdoptedPolicyPolicyTextBlock" xlink:label="glyc_NewAccountingPronouncementsAdoptedPolicyPolicyTextBlock_637818974328414101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="glyc_NewAccountingPronouncementsAdoptedPolicyPolicyTextBlock_637818974328414101" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_637818974328414101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_637818974328414101" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="9" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" xlink:title="30303 - Disclosure - Summary of Significant Accounting Policies (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:label="glyc_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock_637818974328414101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="glyc_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock_637818974328414101" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureNetLossPerShareOfCommonStockTables" xlink:type="extended" xlink:title="30403 - Disclosure - Net Loss Per Share of Common Stock (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_637818974328414101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_637818974328414101" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" xlink:type="extended" xlink:title="30503 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_637818974328414101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_637818974328414101" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosurePropertyAndEquipmentTables" xlink:type="extended" xlink:title="30603 - Disclosure - Property and Equipment (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_637818974328424101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_637818974328424101" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureAccruedExpensesTables" xlink:type="extended" xlink:title="30703 - Disclosure - Accrued Expenses (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_637818974328424101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_637818974328424101" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureOperatingLeasesTables" xlink:type="extended" xlink:title="30803 - Disclosure - Operating Leases (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock_637818974328424101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock_637818974328424101" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_637818974328424101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_637818974328424101" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureStockholdersEquityTables" xlink:type="extended" xlink:title="30903 - Disclosure - Stockholders Equity (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637818974328424101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="us-gaap_StatementTable_637818974328424101" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_637818974328424101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637818974328424101" xlink:to="us-gaap_PlanNameAxis_637818974328424101" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_637818974328434102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_637818974328424101" xlink:to="us-gaap_PlanNameDomain_637818974328434102" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_StockIncentivePlan2003Member" xlink:label="glyc_StockIncentivePlan2003Member_637818974328434102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637818974328434102" xlink:to="glyc_StockIncentivePlan2003Member_637818974328434102" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_EquityIncentivePlan2013Member" xlink:label="glyc_EquityIncentivePlan2013Member_637818974328434102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637818974328434102" xlink:to="glyc_EquityIncentivePlan2013Member_637818974328434102" order="2" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_EquityInducementPlanMember" xlink:label="glyc_EquityInducementPlanMember_637818974328434102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637818974328434102" xlink:to="glyc_EquityInducementPlanMember_637818974328434102" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637818974328434102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637818974328424101" xlink:to="us-gaap_StatementLineItems_637818974328434102" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_637818974328434102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637818974328434102" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_637818974328434102" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_637818974328434102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637818974328434102" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_637818974328434102" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_637818974328434102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637818974328434102" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_637818974328434102" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_637818974328434102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637818974328434102" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_637818974328434102" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureIncomeTaxesTables" xlink:type="extended" xlink:title="31003 - Disclosure - Income Taxes (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_637818974328434102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_637818974328434102" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_637818974328434102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_637818974328434102" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureGoingConcernDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Going Concern (Details)">
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_GoingConcernAbstract" xlink:label="glyc_GoingConcernAbstract_1" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_NetIncomeLossAndComprehensiveIncomeNetOfTax" xlink:label="glyc_NetIncomeLossAndComprehensiveIncomeNetOfTax_637818974328444101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_GoingConcernAbstract_1" xlink:to="glyc_NetIncomeLossAndComprehensiveIncomeNetOfTax_637818974328444101" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_637818974328444101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_GoingConcernAbstract_1" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_637818974328444101" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637818974328444101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_GoingConcernAbstract_1" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637818974328444101" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesSegmentInformationDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Summary of Significant Accounting Policies - Segment Information (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments_637818974328444101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NumberOfOperatingSegments_637818974328444101" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails" xlink:type="extended" xlink:title="40302 - Disclosure - Summary of Significant Accounting Policies - Fair Value Measurements (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637818974328444101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637818974328444101" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_637818974328444101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637818974328444101" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_637818974328444101" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637818974328444101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_637818974328444101" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637818974328444101" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member_637818974328444101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637818974328444101" xlink:to="us-gaap_FairValueInputsLevel1Member_637818974328444101" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member_637818974328444101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637818974328444101" xlink:to="us-gaap_FairValueInputsLevel2Member_637818974328444101" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member_637818974328454102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637818974328444101" xlink:to="us-gaap_FairValueInputsLevel3Member_637818974328454102" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_637818974328454102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637818974328444101" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_637818974328454102" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure_637818974328454102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_637818974328454102" xlink:to="us-gaap_AssetsFairValueDisclosure_637818974328454102" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_637818974328454102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_637818974328454102" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_637818974328454102" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue_637818974328454102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_637818974328454102" xlink:to="us-gaap_MoneyMarketFundsAtCarryingValue_637818974328454102" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" xlink:type="extended" xlink:title="40303 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637818974328454102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637818974328454102" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637818974328454102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637818974328454102" xlink:to="srt_RangeAxis_637818974328454102" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637818974328454102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637818974328454102" xlink:to="srt_RangeMember_637818974328454102" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_637818974328454102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637818974328454102" xlink:to="srt_MinimumMember_637818974328454102" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637818974328454102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637818974328454102" xlink:to="srt_MaximumMember_637818974328454102" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637818974328454102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637818974328454102" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637818974328454102" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_637818974328454102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637818974328454102" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_637818974328454102" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember_637818974328454102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637818974328454102" xlink:to="us-gaap_FurnitureAndFixturesMember_637818974328454102" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_LaboratoryEquipmentMember" xlink:label="glyc_LaboratoryEquipmentMember_637818974328464103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637818974328454102" xlink:to="glyc_LaboratoryEquipmentMember_637818974328464103" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember_637818974328464103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637818974328454102" xlink:to="us-gaap_OfficeEquipmentMember_637818974328464103" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember_637818974328464103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637818974328454102" xlink:to="us-gaap_ComputerEquipmentMember_637818974328464103" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_637818974328464103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637818974328454102" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_637818974328464103" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_637818974328464103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_637818974328464103" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_637818974328464103" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesImpairmentOfLongLivedAssetsDetails" xlink:type="extended" xlink:title="40304 - Disclosure - Summary of Significant Accounting Policies - Impairment of Long-Lived Assets (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwillAbstract" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwillAbstract_637818974328464103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwillAbstract_637818974328464103" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_NumberOfLongLivedAssetsDeterminedToBeImpaired" xlink:label="glyc_NumberOfLongLivedAssetsDeterminedToBeImpaired_637818974328464103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwillAbstract_637818974328464103" xlink:to="glyc_NumberOfLongLivedAssetsDeterminedToBeImpaired_637818974328464103" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup" xlink:label="us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup_637818974328464103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwillAbstract_637818974328464103" xlink:to="us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup_637818974328464103" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails" xlink:type="extended" xlink:title="40305 - Disclosure - Summary of Significant Accounting Policies - Stock-Based Compensation (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="us-gaap_DefinedContributionPlanTable_637818974328544102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DefinedContributionPlanTable_637818974328544102" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637818974328544102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanTable_637818974328544102" xlink:to="srt_RangeAxis_637818974328544102" order="1" use="optional" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637818974328544102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637818974328544102" xlink:to="srt_RangeMember_637818974328544102" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637818974328544102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637818974328544102" xlink:to="srt_MaximumMember_637818974328544102" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems_637818974328544102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanTable_637818974328544102" xlink:to="us-gaap_DefinedContributionPlanDisclosureLineItems_637818974328544102" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_637818974328544102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems_637818974328544102" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_637818974328544102" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_637818974328544102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems_637818974328544102" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_637818974328544102" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureNetLossPerCommonShareDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Net Loss Per Common Share (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637818974328554104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637818974328554104" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_637818974328554104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637818974328554104" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_637818974328554104" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_637818974328554104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_637818974328554104" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_637818974328554104" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_EmployeeStockOptionsAndRestrictedStockUnitsMember" xlink:label="glyc_EmployeeStockOptionsAndRestrictedStockUnitsMember_637818974328554104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_637818974328554104" xlink:to="glyc_EmployeeStockOptionsAndRestrictedStockUnitsMember_637818974328554104" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_637818974328554104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637818974328554104" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_637818974328554104" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_637818974328554104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_637818974328554104" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_637818974328554104" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent_637818974328554104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent_637818974328554104" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_637818974328554104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_637818974328554104" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent_637818974328554104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_OtherReceivablesNetCurrent_637818974328554104" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637818974328554104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637818974328554104" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosurePropertyAndEquipmentDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Property and Equipment (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="PropertyPlantAndEquipmentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637818974328554104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637818974328554104" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637818974328554104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637818974328554104" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637818974328554104" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_637818974328564105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637818974328554104" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_637818974328564105" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember_637818974328564105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637818974328564105" xlink:to="us-gaap_FurnitureAndFixturesMember_637818974328564105" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_LaboratoryEquipmentMember" xlink:label="glyc_LaboratoryEquipmentMember_637818974328564105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637818974328564105" xlink:to="glyc_LaboratoryEquipmentMember_637818974328564105" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember_637818974328564105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637818974328564105" xlink:to="us-gaap_OfficeEquipmentMember_637818974328564105" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember_637818974328564105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637818974328564105" xlink:to="us-gaap_ComputerEquipmentMember_637818974328564105" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember_637818974328564105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637818974328564105" xlink:to="us-gaap_LeaseholdImprovementsMember_637818974328564105" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_637818974328564105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637818974328554104" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_637818974328564105" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_637818974328564105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_637818974328564105" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_637818974328564105" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_637818974328564105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_637818974328564105" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_637818974328564105" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637818974328564105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_637818974328564105" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637818974328564105" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_637818974328564105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637818974328554104" xlink:to="us-gaap_Depreciation_637818974328564105" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Accrued Expenses - Summary of Accrued Expenses (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_AccruedResearchAndDevelopmentExpenseCurrent" xlink:label="glyc_AccruedResearchAndDevelopmentExpenseCurrent_637818974328564105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="glyc_AccruedResearchAndDevelopmentExpenseCurrent_637818974328564105" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="us-gaap_AccruedBonusesCurrent_637818974328574104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedBonusesCurrent_637818974328574104" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_637818974328574104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_637818974328574104" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_637818974328574104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent_637818974328574104" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_637818974328574104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_637818974328574104" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_637818974328574104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent_637818974328574104" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureOperatingLeasesDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Operating Leases (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable_637818974328574104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable_637818974328574104" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_637818974328574104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_637818974328574104" xlink:to="srt_StatementGeographicalAxis_637818974328574104" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_637818974328574104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis_637818974328574104" xlink:to="srt_SegmentGeographicalDomain_637818974328574104" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_RockvilleMarylandMember" xlink:label="glyc_RockvilleMarylandMember_637818974328574104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_637818974328574104" xlink:to="glyc_RockvilleMarylandMember_637818974328574104" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_637818974328574104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_637818974328574104" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_637818974328574104" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:label="us-gaap_LesseeOperatingLeaseDescriptionAbstract_637818974328574104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_637818974328574104" xlink:to="us-gaap_LesseeOperatingLeaseDescriptionAbstract_637818974328574104" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasePracticalExpedientLessorSingleLeaseComponent" xlink:label="us-gaap_LeasePracticalExpedientLessorSingleLeaseComponent_637818974328574104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseDescriptionAbstract_637818974328574104" xlink:to="us-gaap_LeasePracticalExpedientLessorSingleLeaseComponent_637818974328574104" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit_637818974328574104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseDescriptionAbstract_637818974328574104" xlink:to="us-gaap_SecurityDeposit_637818974328574104" order="2" use="optional" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_637818974328584102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseDescriptionAbstract_637818974328574104" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_637818974328584102" order="3" use="optional" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate_637818974328584102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseDescriptionAbstract_637818974328574104" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate_637818974328584102" order="4" use="optional" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:label="us-gaap_DebtInstrumentInterestRateIncreaseDecrease_637818974328584102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseDescriptionAbstract_637818974328574104" xlink:to="us-gaap_DebtInstrumentInterestRateIncreaseDecrease_637818974328584102" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_637818974328584102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseDescriptionAbstract_637818974328574104" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_637818974328584102" order="6" use="optional" priority="4" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_LesseeOperatingLeaseNumberOfNewLeases" xlink:label="glyc_LesseeOperatingLeaseNumberOfNewLeases_637818974328584102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseDescriptionAbstract_637818974328574104" xlink:to="glyc_LesseeOperatingLeaseNumberOfNewLeases_637818974328584102" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureOperatingLeasesComponentsOfLeaseExpenseDetails" xlink:type="extended" xlink:title="40802 - Disclosure - Operating Leases - Components of lease expense (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract_637818974328584102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostAbstract_637818974328584102" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost_637818974328584102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract_637818974328584102" xlink:to="us-gaap_OperatingLeaseCost_637818974328584102" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost_637818974328584102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract_637818974328584102" xlink:to="us-gaap_VariableLeaseCost_637818974328584102" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost_637818974328584102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract_637818974328584102" xlink:to="us-gaap_LeaseCost_637818974328584102" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:label="us-gaap_CashFlowOperatingActivitiesLesseeAbstract_637818974328584102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_CashFlowOperatingActivitiesLesseeAbstract_637818974328584102" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments_637818974328584102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowOperatingActivitiesLesseeAbstract_637818974328584102" xlink:to="us-gaap_OperatingLeasePayments_637818974328584102" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureOperatingLeasesMaturitiesOfLeaseLiabilityDetails" xlink:type="extended" xlink:title="40803 - Disclosure - Operating Leases - Maturities of lease liability (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_637818974328594104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_637818974328594104" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_637818974328594104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_637818974328594104" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_637818974328594104" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_637818974328594104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_637818974328594104" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_637818974328594104" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo" xlink:label="glyc_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo_637818974328594104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_637818974328594104" xlink:to="glyc_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo_637818974328594104" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_637818974328594104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_637818974328594104" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_637818974328594104" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_637818974328594104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_637818974328594104" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_637818974328594104" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_637818974328594104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_637818974328594104" xlink:to="us-gaap_OperatingLeaseLiability_637818974328594104" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureStockholdersEquityEquityOfferingsDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Stockholders' Equity - Equity Offerings (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637818974328594104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="us-gaap_StatementTable_637818974328594104" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_637818974328594104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637818974328594104" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_637818974328594104" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_637818974328594104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_637818974328594104" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_637818974328594104" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_AtMarketOffering2017Member" xlink:label="glyc_AtMarketOffering2017Member_637818974328594104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637818974328594104" xlink:to="glyc_AtMarketOffering2017Member_637818974328594104" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_AtMarketOffering2020Member" xlink:label="glyc_AtMarketOffering2020Member_637818974328594104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637818974328594104" xlink:to="glyc_AtMarketOffering2020Member_637818974328594104" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_637818974328594104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637818974328594104" xlink:to="us-gaap_StatementEquityComponentsAxis_637818974328594104" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637818974328604103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637818974328594104" xlink:to="us-gaap_EquityComponentDomain_637818974328604103" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_637818974328604103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_637818974328604103" xlink:to="us-gaap_CommonStockMember_637818974328604103" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637818974328604103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637818974328594104" xlink:to="srt_RangeAxis_637818974328604103" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637818974328604103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637818974328604103" xlink:to="srt_RangeMember_637818974328604103" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637818974328604103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637818974328604103" xlink:to="srt_MaximumMember_637818974328604103" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_637818974328604103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637818974328594104" xlink:to="us-gaap_SubsequentEventTypeAxis_637818974328604103" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_637818974328604103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_637818974328604103" xlink:to="us-gaap_SubsequentEventTypeDomain_637818974328604103" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_637818974328604103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_637818974328604103" xlink:to="us-gaap_SubsequentEventMember_637818974328604103" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637818974328604103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637818974328594104" xlink:to="us-gaap_StatementLineItems_637818974328604103" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract_637818974328604103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637818974328604103" xlink:to="us-gaap_StockholdersEquityNoteAbstract_637818974328604103" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637818974328604103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract_637818974328604103" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637818974328604103" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_637818974328604103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract_637818974328604103" xlink:to="us-gaap_SharesIssuedPricePerShare_637818974328604103" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_637818974328604103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract_637818974328604103" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_637818974328604103" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_CommonStockValueAvailableForSaleUnderAgreement" xlink:label="glyc_CommonStockValueAvailableForSaleUnderAgreement_637818974328614102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract_637818974328604103" xlink:to="glyc_CommonStockValueAvailableForSaleUnderAgreement_637818974328614102" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureStockholdersEquityIncentivePlansDetails" xlink:type="extended" xlink:title="40903 - Disclosure - Stockholders' Equity - Incentive Plans (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract_636123922648061023" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637818974328614102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract_636123922648061023" xlink:to="us-gaap_StatementTable_637818974328614102" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_637818974328614102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637818974328614102" xlink:to="us-gaap_StatementEquityComponentsAxis_637818974328614102" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637818974328614102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637818974328614102" xlink:to="us-gaap_EquityComponentDomain_637818974328614102" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_637818974328614102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_637818974328614102" xlink:to="us-gaap_CommonStockMember_637818974328614102" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_637818974328614102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637818974328614102" xlink:to="us-gaap_PlanNameAxis_637818974328614102" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_637818974328614102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_637818974328614102" xlink:to="us-gaap_PlanNameDomain_637818974328614102" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_StockIncentivePlan2003Member" xlink:label="glyc_StockIncentivePlan2003Member_637818974328614102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637818974328614102" xlink:to="glyc_StockIncentivePlan2003Member_637818974328614102" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_EquityIncentivePlan2013Member" xlink:label="glyc_EquityIncentivePlan2013Member_637818974328614102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637818974328614102" xlink:to="glyc_EquityIncentivePlan2013Member_637818974328614102" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_637818974328614102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637818974328614102" xlink:to="us-gaap_VestingAxis_637818974328614102" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_637818974328614102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis_637818974328614102" xlink:to="us-gaap_VestingDomain_637818974328614102" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_637818974328624103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_637818974328614102" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_637818974328624103" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_637818974328624103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_637818974328614102" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_637818974328624103" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637818974328624103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637818974328614102" xlink:to="srt_RangeAxis_637818974328624103" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637818974328624103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637818974328624103" xlink:to="srt_RangeMember_637818974328624103" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637818974328624103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637818974328624103" xlink:to="srt_MaximumMember_637818974328624103" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637818974328624103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637818974328614102" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637818974328624103" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_637818974328624103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637818974328624103" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_637818974328624103" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_637818974328624103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_637818974328624103" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_637818974328624103" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfMonthlyInstallments" xlink:label="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfMonthlyInstallments_637818974328624103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_637818974328624103" xlink:to="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfMonthlyInstallments_637818974328624103" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment" xlink:label="glyc_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment_637818974328624103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_637818974328624103" xlink:to="glyc_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment_637818974328624103" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_637818974328624103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_637818974328624103" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_637818974328624103" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_637818974328624103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_637818974328624103" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_637818974328624103" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_637818974328634104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_637818974328624103" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_637818974328634104" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_637818974328634104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_637818974328624103" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_637818974328634104" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_637818974328634104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_637818974328624103" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_637818974328634104" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637818974328634104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_637818974328624103" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637818974328634104" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_637818974328634104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_637818974328624103" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_637818974328634104" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedSharesDisclosureAbstract" xlink:label="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedSharesDisclosureAbstract_637818974328634104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_637818974328624103" xlink:to="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedSharesDisclosureAbstract_637818974328634104" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_637818974328634104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedSharesDisclosureAbstract_637818974328634104" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_637818974328634104" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_PercentageOfTotalNumberOfCommonStockOutstandingOnLastBusinessDayOfPriorFiscalYearThatMayAutomaticallyIncreaseUnderPlan" xlink:label="glyc_PercentageOfTotalNumberOfCommonStockOutstandingOnLastBusinessDayOfPriorFiscalYearThatMayAutomaticallyIncreaseUnderPlan_637818974328634104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedSharesDisclosureAbstract_637818974328634104" xlink:to="glyc_PercentageOfTotalNumberOfCommonStockOutstandingOnLastBusinessDayOfPriorFiscalYearThatMayAutomaticallyIncreaseUnderPlan_637818974328634104" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMaximumSharesIssuedUponExerciseOfIncentiveStockOptions" xlink:label="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMaximumSharesIssuedUponExerciseOfIncentiveStockOptions_637818974328634104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedSharesDisclosureAbstract_637818974328634104" xlink:to="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMaximumSharesIssuedUponExerciseOfIncentiveStockOptions_637818974328634104" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_637818974328644103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedSharesDisclosureAbstract_637818974328634104" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_637818974328644103" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureStockholdersEquityCompanySStockOptionActivityDetails" xlink:type="extended" xlink:title="40904 - Disclosure - Stockholders' Equity - Company's Stock Option Activity (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637818974328644103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637818974328644103" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_637818974328644103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637818974328644103" xlink:to="us-gaap_PlanNameAxis_637818974328644103" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_637818974328644103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_637818974328644103" xlink:to="us-gaap_PlanNameDomain_637818974328644103" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_StockIncentivePlan2003Member" xlink:label="glyc_StockIncentivePlan2003Member_637818974328644103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637818974328644103" xlink:to="glyc_StockIncentivePlan2003Member_637818974328644103" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_EquityIncentivePlan2013Member" xlink:label="glyc_EquityIncentivePlan2013Member_637818974328644103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637818974328644103" xlink:to="glyc_EquityIncentivePlan2013Member_637818974328644103" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637818974328644103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637818974328644103" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637818974328644103" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637818974328644103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637818974328644103" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637818974328644103" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637818974328644103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637818974328644103" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637818974328644103" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637818974328654102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637818974328644103" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637818974328654102" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637818974328654102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637818974328644103" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637818974328654102" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_637818974328654102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637818974328644103" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_637818974328654102" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637818974328654102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637818974328644103" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637818974328654102" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637818974328654102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637818974328644103" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637818974328654102" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637818974328654102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637818974328654102" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637818974328654102" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_637818974328654102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637818974328654102" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_637818974328654102" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_637818974328654102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637818974328654102" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_637818974328654102" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_637818974328654102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637818974328654102" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_637818974328654102" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6378189743286541021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637818974328654102" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6378189743286541021" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_637818974328654102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637818974328644103" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_637818974328654102" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_637818974328654102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_637818974328654102" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_637818974328654102" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_637818974328664106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_637818974328654102" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_637818974328664106" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_637818974328664106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_637818974328654102" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_637818974328664106" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637818974328664106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637818974328644103" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637818974328664106" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_637818974328664106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637818974328664106" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_637818974328664106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_637818974328664106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637818974328664106" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_637818974328664106" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_637818974328664106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637818974328664106" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_637818974328664106" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_637818974328664106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637818974328664106" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_637818974328664106" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureStockholdersEquitySummaryOfRsuActivityDetails" xlink:type="extended" xlink:title="40905 - Disclosure - Stockholders' Equity - Summary of RSU Activity (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637818974328674105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637818974328674105" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_637818974328674105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637818974328674105" xlink:to="us-gaap_AwardTypeAxis_637818974328674105" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637818974328674105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_637818974328674105" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637818974328674105" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_637818974328674105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637818974328674105" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_637818974328674105" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_637818974328674105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637818974328674105" xlink:to="us-gaap_PlanNameAxis_637818974328674105" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_637818974328674105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_637818974328674105" xlink:to="us-gaap_PlanNameDomain_637818974328674105" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_EquityIncentivePlan2013Member" xlink:label="glyc_EquityIncentivePlan2013Member_637818974328674105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637818974328674105" xlink:to="glyc_EquityIncentivePlan2013Member_637818974328674105" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis_637818974328674105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637818974328674105" xlink:to="us-gaap_GranteeStatusAxis_637818974328674105" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain_637818974328674105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis_637818974328674105" xlink:to="us-gaap_GranteeStatusDomain_637818974328674105" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember_637818974328674105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusDomain_637818974328674105" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember_637818974328674105" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_637818974328674105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637818974328674105" xlink:to="us-gaap_VestingAxis_637818974328674105" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_637818974328674105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis_637818974328674105" xlink:to="us-gaap_VestingDomain_637818974328674105" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_637818974328674105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_637818974328674105" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_637818974328674105" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_637818974328674105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_637818974328674105" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_637818974328674105" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637818974328684105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637818974328674105" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637818974328684105" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_637818974328684105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637818974328684105" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_637818974328684105" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_637818974328684105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_637818974328684105" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_637818974328684105" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_637818974328684105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_637818974328684105" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_637818974328684105" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_637818974328684105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_637818974328684105" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_637818974328684105" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_637818974328684105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_637818974328684105" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_637818974328684105" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_637818974328684105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637818974328684105" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_637818974328684105" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_637818974328684105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_637818974328684105" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_637818974328684105" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_637818974328684105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_637818974328684105" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_637818974328684105" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_637818974328684105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_637818974328684105" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_637818974328684105" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_637818974328684105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_637818974328684105" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_637818974328684105" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_637818974328694105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_637818974328684105" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_637818974328694105" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_637818974328694105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637818974328684105" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_637818974328694105" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_637818974328694105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_637818974328694105" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_637818974328694105" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_637818974328694105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_637818974328694105" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_637818974328694105" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_637818974328694105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_637818974328694105" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_637818974328694105" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_637818974328694105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_637818974328694105" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_637818974328694105" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6378189743286941051" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_637818974328694105" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6378189743286941051" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureStockholdersEquityInducementPlanDetails" xlink:type="extended" xlink:title="40906 - Disclosure - Stockholders' Equity - Inducement Plan (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637818974328704103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637818974328704103" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_637818974328704103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637818974328704103" xlink:to="us-gaap_StatementEquityComponentsAxis_637818974328704103" order="1" use="optional" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637818974328704103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637818974328704103" xlink:to="us-gaap_EquityComponentDomain_637818974328704103" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_637818974328704103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_637818974328704103" xlink:to="us-gaap_CommonStockMember_637818974328704103" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_637818974328704103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637818974328704103" xlink:to="us-gaap_PlanNameAxis_637818974328704103" order="2" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_637818974328704103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_637818974328704103" xlink:to="us-gaap_PlanNameDomain_637818974328704103" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_EquityInducementPlanMember" xlink:label="glyc_EquityInducementPlanMember_637818974328704103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637818974328704103" xlink:to="glyc_EquityInducementPlanMember_637818974328704103" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_637818974328704103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637818974328704103" xlink:to="us-gaap_VestingAxis_637818974328704103" order="3" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_637818974328704103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis_637818974328704103" xlink:to="us-gaap_VestingDomain_637818974328704103" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_637818974328704103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_637818974328704103" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_637818974328704103" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_637818974328704103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_637818974328704103" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_637818974328704103" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_VestingUponFDApprovalMember" xlink:label="glyc_VestingUponFDApprovalMember_637818974328704103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_637818974328704103" xlink:to="glyc_VestingUponFDApprovalMember_637818974328704103" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_VestingUponFirstCommercialSaleMember" xlink:label="glyc_VestingUponFirstCommercialSaleMember_637818974328704103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_637818974328704103" xlink:to="glyc_VestingUponFirstCommercialSaleMember_637818974328704103" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_637818974328714103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637818974328704103" xlink:to="srt_TitleOfIndividualAxis_637818974328714103" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_637818974328714103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_637818974328714103" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_637818974328714103" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember_637818974328714103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_637818974328714103" xlink:to="srt_ChiefExecutiveOfficerMember_637818974328714103" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_637818974328714103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637818974328704103" xlink:to="us-gaap_AwardTypeAxis_637818974328714103" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637818974328714103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_637818974328714103" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637818974328714103" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_StockOptionsVestingBasedOnServiceMember" xlink:label="glyc_StockOptionsVestingBasedOnServiceMember_637818974328714103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637818974328714103" xlink:to="glyc_StockOptionsVestingBasedOnServiceMember_637818974328714103" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_StockOptionsVestingBasedOnPerformanceMember" xlink:label="glyc_StockOptionsVestingBasedOnPerformanceMember_637818974328714103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637818974328714103" xlink:to="glyc_StockOptionsVestingBasedOnPerformanceMember_637818974328714103" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637818974328714103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637818974328704103" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637818974328714103" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_637818974328714103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637818974328714103" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_637818974328714103" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingUnderlyingSharesVestPeriod" xlink:label="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingUnderlyingSharesVestPeriod_637818974328714103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637818974328714103" xlink:to="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingUnderlyingSharesVestPeriod_637818974328714103" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfMonthlyInstallments" xlink:label="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfMonthlyInstallments_637818974328714103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637818974328714103" xlink:to="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfMonthlyInstallments_637818974328714103" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment" xlink:label="glyc_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment_637818974328724104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637818974328714103" xlink:to="glyc_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment_637818974328724104" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_637818974328724104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637818974328714103" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_637818974328724104" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_637818974328724104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637818974328714103" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_637818974328724104" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_637818974328724104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637818974328714103" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_637818974328724104" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_637818974328724104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637818974328714103" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_637818974328724104" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_637818974328724104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637818974328714103" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_637818974328724104" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_637818974328724104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637818974328714103" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_637818974328724104" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_637818974328724104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637818974328714103" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_637818974328724104" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_637818974328734105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637818974328714103" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_637818974328734105" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637818974328734105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637818974328714103" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637818974328734105" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_637818974328734105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637818974328714103" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_637818974328734105" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637818974328734105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637818974328714103" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637818974328734105" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFairValueOfOptionExcludedFromUnrecognizedCompensationExpense" xlink:label="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFairValueOfOptionExcludedFromUnrecognizedCompensationExpense_637818974328734105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637818974328714103" xlink:to="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFairValueOfOptionExcludedFromUnrecognizedCompensationExpense_637818974328734105" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureStockholdersEquityInducementPlanStockOptionActivityDetails" xlink:type="extended" xlink:title="40907 - Disclosure - Stockholders' Equity - Inducement Plan - Stock Option Activity (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract_637305793802408714" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637818974328734105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract_637305793802408714" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637818974328734105" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_637818974328744104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637818974328734105" xlink:to="us-gaap_PlanNameAxis_637818974328744104" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_637818974328744104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_637818974328744104" xlink:to="us-gaap_PlanNameDomain_637818974328744104" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_EquityInducementPlanMember" xlink:label="glyc_EquityInducementPlanMember_637818974328744104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637818974328744104" xlink:to="glyc_EquityInducementPlanMember_637818974328744104" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637818974328744104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637818974328734105" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637818974328744104" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637818974328744104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637818974328744104" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637818974328744104" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637818974328744104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637818974328744104" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637818974328744104" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637818974328744104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637818974328744104" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637818974328744104" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637818974328744104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637818974328744104" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637818974328744104" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_637818974328744104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637818974328744104" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_637818974328744104" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6378189743287441041" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637818974328744104" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6378189743287441041" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637818974328744104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637818974328744104" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637818974328744104" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637818974328744104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637818974328744104" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637818974328744104" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_637818974328744104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637818974328744104" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_637818974328744104" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_637818974328744104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637818974328744104" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_637818974328744104" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_637818974328754104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637818974328744104" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_637818974328754104" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637818974328754104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637818974328744104" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637818974328754104" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_637818974328754104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637818974328744104" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_637818974328754104" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_637818974328754104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_637818974328754104" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_637818974328754104" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_637818974328754104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_637818974328754104" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_637818974328754104" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_637818974328754104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_637818974328754104" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_637818974328754104" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637818974328754104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637818974328744104" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637818974328754104" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_637818974328754104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637818974328754104" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_637818974328754104" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_637818974328754104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637818974328754104" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_637818974328754104" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_637818974328754104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637818974328754104" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_637818974328754104" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_637818974328764105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637818974328754104" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_637818974328764105" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureStockholdersEquityWeightedAverageAssumptionsDetails" xlink:type="extended" xlink:title="40908 - Disclosure - Stockholders' Equity - Weighted-Average assumptions (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_637818974328764105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_637818974328764105" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_637818974328764105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_637818974328764105" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_637818974328764105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_637818974328764105" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_637818974328764105" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_637818974328764105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_637818974328764105" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_637818974328764105" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_637818974328764105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_637818974328764105" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_637818974328764105" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_637818974328764105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_637818974328764105" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_637818974328764105" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails" xlink:type="extended" xlink:title="40909 - Disclosure - Stockholders' Equity - Stock-Based Compensation Expense (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_637818974328764105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_637818974328764105" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_637818974328764105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_637818974328764105" xlink:to="us-gaap_IncomeStatementLocationAxis_637818974328764105" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_637818974328774106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_637818974328764105" xlink:to="us-gaap_IncomeStatementLocationDomain_637818974328774106" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_637818974328774106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637818974328774106" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_637818974328774106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_637818974328774106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637818974328774106" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_637818974328774106" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_637818974328774106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_637818974328764105" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_637818974328774106" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_637818974328774106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_637818974328774106" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_637818974328774106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureIncomeTaxesScheduleOfGrossDeferredTaxAssetAndRelatedValuationAllowanceDetail" xlink:type="extended" xlink:title="41001 - Disclosure - Income Taxes - Schedule of Gross Deferred Tax Asset and Related Valuation Allowance (Detail)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637818974328774106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637818974328774106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_637818974328774106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637818974328774106" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_637818974328774106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_DeferredTaxAssetsCapitalizedStartUpCosts" xlink:label="glyc_DeferredTaxAssetsCapitalizedStartUpCosts_637818974328774106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637818974328774106" xlink:to="glyc_DeferredTaxAssetsCapitalizedStartUpCosts_637818974328774106" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_DeferredTaxAssetsPatentAmortization" xlink:label="glyc_DeferredTaxAssetsPatentAmortization_637818974328774106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637818974328774106" xlink:to="glyc_DeferredTaxAssetsPatentAmortization_637818974328774106" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_DeferredTaxAssetsResearchAndOrphanDrugCredits" xlink:label="glyc_DeferredTaxAssetsResearchAndOrphanDrugCredits_637818974328774106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637818974328774106" xlink:to="glyc_DeferredTaxAssetsResearchAndOrphanDrugCredits_637818974328774106" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_637818974328774106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637818974328774106" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_637818974328774106" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_DeferredTaxAssetsTaxDeferredExpenseOperatingLeaseLiabilities" xlink:label="glyc_DeferredTaxAssetsTaxDeferredExpenseOperatingLeaseLiabilities_637818974328774106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637818974328774106" xlink:to="glyc_DeferredTaxAssetsTaxDeferredExpenseOperatingLeaseLiabilities_637818974328774106" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_DeferredTaxAssetsAccruedBonus" xlink:label="glyc_DeferredTaxAssetsAccruedBonus_637818974328774106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637818974328774106" xlink:to="glyc_DeferredTaxAssetsAccruedBonus_637818974328774106" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther_637818974328784105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637818974328774106" xlink:to="us-gaap_DeferredTaxAssetsOther_637818974328784105" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_637818974328784105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637818974328774106" xlink:to="us-gaap_DeferredTaxAssetsGross_637818974328784105" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_637818974328784105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637818974328774106" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_637818974328784105" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet_637818974328784105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet_637818974328784105" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_637818974328784105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_637818974328784105" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_DeferredTaxLiabilitiesTaxDeferredExpenseOperatingLeaseLiabilitiesRightOfUseAssets" xlink:label="glyc_DeferredTaxLiabilitiesTaxDeferredExpenseOperatingLeaseLiabilitiesRightOfUseAssets_637818974328784105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_637818974328784105" xlink:to="glyc_DeferredTaxLiabilitiesTaxDeferredExpenseOperatingLeaseLiabilitiesRightOfUseAssets_637818974328784105" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_637818974328784105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_637818974328784105" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_637818974328784105" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_637818974328784105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_637818974328784105" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_637818974328784105" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_637818974328784105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_637818974328784105" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureIncomeTaxesNolsAndCarryforwardsDetail" xlink:type="extended" xlink:title="41002 - Disclosure - Income Taxes - NOLs and carryforwards (Detail)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardTable" xlink:label="us-gaap_TaxCreditCarryforwardTable_637818974328784105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_TaxCreditCarryforwardTable_637818974328784105" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_637818974328794106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardTable_637818974328784105" xlink:to="us-gaap_IncomeTaxAuthorityAxis_637818974328794106" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_637818974328794106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis_637818974328794106" xlink:to="us-gaap_IncomeTaxAuthorityDomain_637818974328794106" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_FederalAndStateAuthoritiesMember" xlink:label="glyc_FederalAndStateAuthoritiesMember_637818974328794106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_637818974328794106" xlink:to="glyc_FederalAndStateAuthoritiesMember_637818974328794106" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis_637818974328794106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardTable_637818974328784105" xlink:to="us-gaap_TaxCreditCarryforwardAxis_637818974328794106" order="2" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_637818974328794106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis_637818974328794106" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_637818974328794106" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember_637818974328794106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain_637818974328794106" xlink:to="us-gaap_ResearchMember_637818974328794106" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralBusinessMember" xlink:label="us-gaap_GeneralBusinessMember_637818974328794106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain_637818974328794106" xlink:to="us-gaap_GeneralBusinessMember_637818974328794106" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems" xlink:label="us-gaap_TaxCreditCarryforwardLineItems_637818974328794106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardTable_637818974328784105" xlink:to="us-gaap_TaxCreditCarryforwardLineItems_637818974328794106" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards_637818974328794106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardLineItems_637818974328794106" xlink:to="us-gaap_OperatingLossCarryforwards_637818974328794106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount_637818974328794106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardLineItems_637818974328794106" xlink:to="us-gaap_TaxCreditCarryforwardAmount_637818974328794106" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureIncomeTaxesReconciliationBetweenStatutoryFederalIncomeTaxRateAndEffectiveIncomeTaxRateDetail" xlink:type="extended" xlink:title="41003 - Disclosure - Income Taxes - Reconciliation Between Statutory Federal Income Tax Rate and Effective Income Tax Rate (Detail)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_637818974328794106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_637818974328794106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_637818974328794106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_637818974328794106" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_637818974328804106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_637818974328804106" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent" xlink:label="glyc_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent_637818974328804106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="glyc_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent_637818974328804106" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_637818974328804106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_637818974328804106" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_637818974328804106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_637818974328804106" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_637818974328804106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_637818974328804106" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="8" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureResearchAndLicenseAgreementsDetails" xlink:type="extended" xlink:title="41101 - Disclosure - Research and License Agreements (Details)">
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_ResearchAndLicenseAgreementsAbstract" xlink:label="glyc_ResearchAndLicenseAgreementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_637818974328804106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_ResearchAndLicenseAgreementsAbstract" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_637818974328804106" order="1" use="optional" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_637818974328804106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_637818974328804106" xlink:to="srt_CounterpartyNameAxis_637818974328804106" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_637818974328804106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_637818974328804106" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_637818974328804106" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_ApollomicMember" xlink:label="glyc_ApollomicMember_637818974328804106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_637818974328804106" xlink:to="glyc_ApollomicMember_637818974328804106" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637818974328804106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_637818974328804106" xlink:to="srt_RangeAxis_637818974328804106" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637818974328804106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637818974328804106" xlink:to="srt_RangeMember_637818974328804106" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637818974328804106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637818974328804106" xlink:to="srt_MaximumMember_637818974328804106" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_ArrangementsAndNonarrangementTransactionsLineItems" xlink:label="glyc_ArrangementsAndNonarrangementTransactionsLineItems_637818974328804106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_637818974328804106" xlink:to="glyc_ArrangementsAndNonarrangementTransactionsLineItems_637818974328804106" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_RevenueReceivedFromSaleOfClinicalSupplies" xlink:label="glyc_RevenueReceivedFromSaleOfClinicalSupplies_637818974328814105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_ArrangementsAndNonarrangementTransactionsLineItems_637818974328804106" xlink:to="glyc_RevenueReceivedFromSaleOfClinicalSupplies_637818974328814105" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_UpFrontPaymentReceived" xlink:label="glyc_UpFrontPaymentReceived_637818974328814105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_ArrangementsAndNonarrangementTransactionsLineItems_637818974328804106" xlink:to="glyc_UpFrontPaymentReceived_637818974328814105" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_DevelopmentAndRegulatoryApprovalMilestonesClinicalAndRegulatoryEvents" xlink:label="glyc_DevelopmentAndRegulatoryApprovalMilestonesClinicalAndRegulatoryEvents_637818974328814105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_ArrangementsAndNonarrangementTransactionsLineItems_637818974328804106" xlink:to="glyc_DevelopmentAndRegulatoryApprovalMilestonesClinicalAndRegulatoryEvents_637818974328814105" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_AchievementOfSpecifiedNetSalesThresholdsForAllLicensedProducts" xlink:label="glyc_AchievementOfSpecifiedNetSalesThresholdsForAllLicensedProducts_637818974328814105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_ArrangementsAndNonarrangementTransactionsLineItems_637818974328804106" xlink:to="glyc_AchievementOfSpecifiedNetSalesThresholdsForAllLicensedProducts_637818974328814105" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_MilestoneRevenueRecognized" xlink:label="glyc_MilestoneRevenueRecognized_637818974328814105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_ArrangementsAndNonarrangementTransactionsLineItems_637818974328804106" xlink:to="glyc_MilestoneRevenueRecognized_637818974328814105" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="glyc-20211231.xsd#glyc_TieredPercentageOfAnnualNetSales" xlink:label="glyc_TieredPercentageOfAnnualNetSales_637818974328814105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_ArrangementsAndNonarrangementTransactionsLineItems_637818974328804106" xlink:to="glyc_TieredPercentageOfAnnualNetSales_637818974328814105" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureEmployeeBenefitPlanDetail" xlink:type="extended" xlink:title="41201 - Disclosure - Employee Benefit Plan (Detail)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="us-gaap_DefinedContributionPlanTable_637818974328814105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanTable_637818974328814105" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637818974328814105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanTable_637818974328814105" xlink:to="srt_RangeAxis_637818974328814105" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637818974328814105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637818974328814105" xlink:to="srt_RangeMember_637818974328814105" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637818974328814105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637818974328814105" xlink:to="srt_MaximumMember_637818974328814105" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems_637818974328814105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanTable_637818974328814105" xlink:to="us-gaap_DefinedContributionPlanDisclosureLineItems_637818974328814105" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_637818974328814105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems_637818974328814105" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_637818974328814105" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_637818974328824105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems_637818974328814105" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_637818974328824105" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_637818974328824105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems_637818974328814105" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_637818974328824105" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140248076943304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Feb. 28, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">GlycoMimetics, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">06-1686563<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">9708 Medical Center Drive<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Rockville<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">20850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">243-1201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">GLYC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 117.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,313,894<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001253689<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Baltimore, Maryland<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140248078546360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 90,254,890<span></span>
</td>
<td class="nump">$ 137,035,017<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">533,804<span></span>
</td>
<td class="nump">1,238,328<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">90,788,694<span></span>
</td>
<td class="nump">138,273,345<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">368,842<span></span>
</td>
<td class="nump">620,673<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseNoncurrent', window );">Prepaid research and development expenses</a></td>
<td class="nump">1,560,607<span></span>
</td>
<td class="nump">1,560,607<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Deposits</a></td>
<td class="nump">52,320<span></span>
</td>
<td class="nump">52,320<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">1,576,185<span></span>
</td>
<td class="nump">2,325,224<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">94,346,648<span></span>
</td>
<td class="nump">142,832,169<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">2,107,615<span></span>
</td>
<td class="nump">2,089,939<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">8,715,368<span></span>
</td>
<td class="nump">9,439,881<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liabilities</a></td>
<td class="nump">1,001,407<span></span>
</td>
<td class="nump">898,549<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">11,824,390<span></span>
</td>
<td class="nump">12,428,369<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent', window );">Noncurrent accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">264,329<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liabilities, net of current portion</a></td>
<td class="nump">918,607<span></span>
</td>
<td class="nump">1,920,015<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">12,742,997<span></span>
</td>
<td class="nump">14,612,713<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock; $0.001 par value; 5,000,000 shares authorized, no shares issued and outstanding at December 31, 2021 and December 31, 2020</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock; $0.001 par value; 100,000,000 shares authorized; 52,313,894 shares issued and outstanding at December 31, 2021; 49,017,622 shares issued and outstanding at December 31, 2020</a></td>
<td class="nump">52,314<span></span>
</td>
<td class="nump">49,018<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">454,448,327<span></span>
</td>
<td class="nump">437,639,991<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(372,896,990)<span></span>
</td>
<td class="num">(309,469,553)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">81,603,651<span></span>
</td>
<td class="nump">128,219,456<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 94,346,648<span></span>
</td>
<td class="nump">$ 142,832,169<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due after one year (or beyond the operating cycle if longer), including liabilities for compensation costs, fringe benefits other than pension and postretirement obligations, rent, contractual rights and obligations, and statutory obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8,17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140248076853560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Balance Sheets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">52,313,894<span></span>
</td>
<td class="nump">49,017,622<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">52,313,894<span></span>
</td>
<td class="nump">49,017,622<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140248077070792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Operations and Comprehensive Loss - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Statements of Operations and Comprehensive Loss</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue from collaboration and license agreements</a></td>
<td class="nump">$ 1,159,767<span></span>
</td>
<td class="nump">$ 10,162,935<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">47,491,567<span></span>
</td>
<td class="nump">44,929,198<span></span>
</td>
<td class="nump">$ 47,029,264<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expense</a></td>
<td class="nump">17,115,405<span></span>
</td>
<td class="nump">16,743,127<span></span>
</td>
<td class="nump">14,360,038<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total costs and expenses</a></td>
<td class="nump">64,606,972<span></span>
</td>
<td class="nump">61,672,325<span></span>
</td>
<td class="nump">61,389,302<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(63,447,205)<span></span>
</td>
<td class="num">(51,509,390)<span></span>
</td>
<td class="num">(61,389,302)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest income</a></td>
<td class="nump">19,768<span></span>
</td>
<td class="nump">482,487<span></span>
</td>
<td class="nump">3,497,391<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glyc_NetIncomeLossAndComprehensiveIncomeNetOfTax', window );">Net loss and comprehensive loss</a></td>
<td class="num">$ (63,427,437)<span></span>
</td>
<td class="num">$ (51,026,903)<span></span>
</td>
<td class="num">$ (57,891,911)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per common share (in dollars per share)</a></td>
<td class="num">$ (1.23)<span></span>
</td>
<td class="num">$ (1.12)<span></span>
</td>
<td class="num">$ (1.34)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per common share (in dollars per share)</a></td>
<td class="num">$ (1.23)<span></span>
</td>
<td class="num">$ (1.12)<span></span>
</td>
<td class="num">$ (1.34)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic weighted-average number of common shares outstanding (in shares)</a></td>
<td class="nump">51,453,204<span></span>
</td>
<td class="nump">45,721,139<span></span>
</td>
<td class="nump">43,254,782<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted weighted-average number of common shares outstanding (in shares)</a></td>
<td class="nump">51,453,204<span></span>
</td>
<td class="nump">45,721,139<span></span>
</td>
<td class="nump">43,254,782<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_NetIncomeLossAndComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss and comprehensive income for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_NetIncomeLossAndComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingCostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140248076132104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statements of Stockholders' Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2018</a></td>
<td class="nump">$ 43,159<span></span>
</td>
<td class="nump">$ 405,972,075<span></span>
</td>
<td class="num">$ (200,550,739)<span></span>
</td>
<td class="nump">$ 205,464,495<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2018</a></td>
<td class="nump">43,160,751<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glyc_StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsVesting', window );">Exercise of options and vesting of restricted stock units</a></td>
<td class="nump">$ 306<span></span>
</td>
<td class="nump">412,607<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">412,913<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glyc_StockIssuedDuringPeriodSharesStockOptionsAndRestrictedStockUnitsVesting', window );">Exercise of options and vesting of restricted stock units, shares</a></td>
<td class="nump">306,182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,215,090<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,215,090<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(57,891,911)<span></span>
</td>
<td class="num">(57,891,911)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 43,465<span></span>
</td>
<td class="nump">412,599,772<span></span>
</td>
<td class="num">(258,442,650)<span></span>
</td>
<td class="nump">154,200,587<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2019</a></td>
<td class="nump">43,466,933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of issuance costs</a></td>
<td class="nump">$ 5,163<span></span>
</td>
<td class="nump">17,819,554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,824,717<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs, shares</a></td>
<td class="nump">5,161,502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glyc_StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsVesting', window );">Exercise of options and vesting of restricted stock units</a></td>
<td class="nump">$ 390<span></span>
</td>
<td class="nump">318,907<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">319,297<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glyc_StockIssuedDuringPeriodSharesStockOptionsAndRestrictedStockUnitsVesting', window );">Exercise of options and vesting of restricted stock units, shares</a></td>
<td class="nump">389,187<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,901,758<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,901,758<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(51,026,903)<span></span>
</td>
<td class="num">(51,026,903)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 49,018<span></span>
</td>
<td class="nump">437,639,991<span></span>
</td>
<td class="num">(309,469,553)<span></span>
</td>
<td class="nump">128,219,456<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2020</a></td>
<td class="nump">49,017,622<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of issuance costs</a></td>
<td class="nump">$ 3,092<span></span>
</td>
<td class="nump">10,696,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,699,317<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs, shares</a></td>
<td class="nump">3,092,603<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glyc_StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsVesting', window );">Exercise of options and vesting of restricted stock units</a></td>
<td class="nump">$ 204<span></span>
</td>
<td class="nump">24,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,029<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glyc_StockIssuedDuringPeriodSharesStockOptionsAndRestrictedStockUnitsVesting', window );">Exercise of options and vesting of restricted stock units, shares</a></td>
<td class="nump">203,669<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,087,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,087,286<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(63,427,437)<span></span>
</td>
<td class="num">(63,427,437)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 52,314<span></span>
</td>
<td class="nump">$ 454,448,327<span></span>
</td>
<td class="num">$ (372,896,990)<span></span>
</td>
<td class="nump">$ 81,603,651<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2021</a></td>
<td class="nump">52,313,894<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_StockIssuedDuringPeriodSharesStockOptionsAndRestrictedStockUnitsVesting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options and vesting of stock units exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_StockIssuedDuringPeriodSharesStockOptionsAndRestrictedStockUnitsVesting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsVesting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of share options and vesting of stock units exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsVesting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140248076094888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (63,427,437)<span></span>
</td>
<td class="num">$ (51,026,903)<span></span>
</td>
<td class="num">$ (57,891,911)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">264,600<span></span>
</td>
<td class="nump">270,754<span></span>
</td>
<td class="nump">279,234<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of assets</a></td>
<td class="nump">2,174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Non-cash lease expense</a></td>
<td class="nump">749,039<span></span>
</td>
<td class="nump">680,845<span></span>
</td>
<td class="nump">620,068<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">6,087,286<span></span>
</td>
<td class="nump">6,901,758<span></span>
</td>
<td class="nump">6,215,090<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">704,524<span></span>
</td>
<td class="nump">3,087,994<span></span>
</td>
<td class="num">(2,059,260)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">17,676<span></span>
</td>
<td class="nump">654,279<span></span>
</td>
<td class="num">(1,227,919)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="num">(988,842)<span></span>
</td>
<td class="nump">993,420<span></span>
</td>
<td class="nump">2,709,986<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glyc_IncreaseDecreaseInOperatingLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="num">(898,550)<span></span>
</td>
<td class="num">(804,078)<span></span>
</td>
<td class="num">(629,427)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(57,489,530)<span></span>
</td>
<td class="num">(39,241,931)<span></span>
</td>
<td class="num">(51,984,139)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(14,943)<span></span>
</td>
<td class="num">(68,507)<span></span>
</td>
<td class="num">(144,928)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(14,943)<span></span>
</td>
<td class="num">(68,507)<span></span>
</td>
<td class="num">(144,928)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of issuance costs</a></td>
<td class="nump">10,699,317<span></span>
</td>
<td class="nump">17,824,717<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">25,029<span></span>
</td>
<td class="nump">319,297<span></span>
</td>
<td class="nump">412,913<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">10,724,346<span></span>
</td>
<td class="nump">18,144,014<span></span>
</td>
<td class="nump">412,913<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash and cash equivalents</a></td>
<td class="num">(46,780,127)<span></span>
</td>
<td class="num">(21,166,424)<span></span>
</td>
<td class="num">(51,716,154)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of period</a></td>
<td class="nump">137,035,017<span></span>
</td>
<td class="nump">158,201,441<span></span>
</td>
<td class="nump">209,917,595<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of period</a></td>
<td class="nump">$ 90,254,890<span></span>
</td>
<td class="nump">$ 137,035,017<span></span>
</td>
<td class="nump">$ 158,201,441<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_IncreaseDecreaseInOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_IncreaseDecreaseInOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140248080911960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of the Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Description of the Business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Description of the Business</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">1. Description of the Business</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">GlycoMimetics, Inc. (the Company), a Delaware corporation headquartered in Rockville, Maryland, was incorporated in 2003. The Company is a clinical stage biotechnology company focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using its expertise in carbohydrate chemistry and knowledge of carbohydrate biology, the Company is developing a pipeline of proprietary glycomimetics that inhibit disease-related functions of carbohydrates, such as the roles they play in inflammation, cancer and infection.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140248078654520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Going Concern<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glyc_GoingConcernAbstract', window );"><strong>Going Concern</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock', window );">Going Concern</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">2. Going Concern</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern within one year after the date that the financial statements are issued. During 2021, the Company incurred a net loss of $63.4 million and had net cash flows used in operating activities of $57.5 million. At December 31, 2021, the Company had $90.3 million in cash and cash equivalents and had no committed source of additional funding from either debt or equity financings. Management believes that given the Company&#8217;s current cash position and forecasted negative cash flows from operating activities over the next twelve months, including the completion of its planned Phase 3 clinical trial of uproleselan, there is substantial doubt about its ability to continue as a going concern after the date that is one year from the date that these financial statements are issued, without obtaining additional financing or entering into another form of non-equity or debt arrangement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">The Company&#8217;s ability to fund its operations is dependent upon management&#8217;s plans, which include raising additional capital in the near term primarily through a combination of equity and debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements and in the longer term, from revenue related to product sales, to the extent its product candidates receive marketing approval and can be commercialized. There can be no assurances that new financings or other transactions will be available to us on commercially acceptable terms, or at all. Also, any collaborations, strategic alliances and marketing, distribution or licensing arrangements may require the Company to give up some or all of its rights to a product or technology, which in some cases may be at less than the full potential value of such rights. If the Company is unable to obtain additional capital, the Company will assess its capital resources and may be required to delay, reduce the scope of or eliminate some or all of our operations, which may have a material adverse effect on our business, financial condition, results of operations and ability to operate as a going concern.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">The financial statements do not include any adjustments that might be necessary if the Company is not able to continue as a going concern.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_GoingConcernAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_GoingConcernAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 40<br> -URI http://asc.fasb.org/subtopic&amp;trid=51888271<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubstantialDoubtAboutGoingConcernTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140248080914200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">3. Summary of Significant Accounting Policies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Basis of Accounting</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">The accompanying financial statements were prepared based on the accrual method of accounting in accordance with U.S. generally accepted accounting principles (GAAP).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Segment Information</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one segment, which is the identification and development of glycomimetic compounds.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Although actual results could differ from those estimates, management does not believe that such differences would be material.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Cash and Cash Equivalents</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Cash and cash equivalents consist of investment in money market funds with commercial banks and financial institutions. The Company considers all investments in highly liquid financial instruments with an original maturity of three months or less at the date of purchase to be cash equivalents. Cash equivalents are stated at amortized cost, plus accrued interest, which approximates fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Fair Value Measurements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">The Company&#8217;s financial instruments include cash and cash equivalents. The fair values of the financial instruments approximated their carrying values at December 31, 2021 and 2020, due to their short-term maturities. The Company accounts for recurring and nonrecurring fair value measurements in accordance with ASC 820, <i style="font-style:italic;">Fair Value Measurements</i>. ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements. The ASC hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value, and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 1&#8212;Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 2&#8212;Fair value is determined by using inputs, other than Level 1 quoted prices, that are directly and indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models that can be corroborated by observable market data.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 3&#8212;Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity. In instances where the determination of the fair value measurement is based on inputs from different levels of fair value hierarchy, the fair value measurement will fall within the lowest level input that is significant to the fair value measurement in its entirety.</span></td></tr></table><div style="margin-top:6pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">The Company periodically evaluates financial assets and liabilities subject to fair value measurements to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC 820 hierarchy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">The Company had no assets or liabilities that were measured using quoted prices for similar assets and liabilities or significant unobservable inputs (Level 2 and Level 3 assets and liabilities, respectively) either on a recurring or non-recurring basis as of December&#160;31, 2021 and 2020. The carrying value of cash held in money market funds of approximately $88.3 million and $135.0 million as of December&#160;31, 2021 and 2020, respectively, is included in cash and cash equivalents and approximates market values based on quoted market prices (Level 1 inputs). The Company did&#160;not transfer any assets measured at fair value on a recurring basis between levels during the&#160;years ended December 31, 2021 and 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Concentration of Credit Risk</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Credit risk represents the risk that the Company would incur a loss if counterparties failed to perform pursuant to the terms of their agreements. Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. Cash and cash equivalents consist of investment in money market funds with major financial institutions in the United States. These deposits and funds may be redeemed upon demand and, therefore, bear minimal risk. The Company does not anticipate any losses on such balances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Property and Equipment</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">Property and equipment are recorded at cost and depreciated on a straight-line basis over estimated useful lives ranging from <span style="-sec-ix-hidden:Hidden_0ma8_vtK80W6jIJz3LC8HQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three</span></span> to seven years. Upon retirement or disposition of assets, the costs and related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the results of operations. Expenditures for repairs and maintenance are charged to operations as incurred; major replacements that extend the </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">useful life are capitalized. Depreciation and amortization are computed using the straight-line method over the following estimated useful lives:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><div style="padding-left:40.5pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:82.39%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:46.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:51.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:46.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ESTIMATED&#160;USEFUL&#160;LIVES</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:46.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">7 years</p></td></tr><tr><td style="vertical-align:bottom;width:51.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Laboratory equipment</p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:46.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">5 years</p></td></tr><tr><td style="vertical-align:bottom;width:51.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Office equipment</p></td><td style="vertical-align:bottom;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:46.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">5 years</p></td></tr><tr><td style="vertical-align:bottom;width:51.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Computer equipment</p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:46.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">5 years</p></td></tr><tr><td style="vertical-align:bottom;width:51.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:46.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.6pt 0pt 0pt;">Shorter&#160;of&#160;lease&#160;term&#160;or&#160;useful&#160; life</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 6pt 0pt;"><span style="font-size:1pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Impairment of Long-Lived Assets</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">The Company periodically assesses the recoverability of the carrying value of its long-lived assets in accordance with the provisions of ASC 360, <i style="font-style:italic;">Property, Plant, and Equipment</i>. ASC 360 requires that long-lived assets and certain identifiable intangible assets be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of the long-lived asset is measured by a comparison of the carrying amount of the asset to future undiscounted net cash flows expected to be generated by the asset. If the carrying value exceeds the sum of undiscounted cash flows, the Company then determines the fair value of the underlying asset. Any impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the estimated fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value, less costs to sell. As of December&#160;31, 2021 and 2020, the Company determined that there were no impaired assets and it had no assets held for sale.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Revenue Recognition</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">The Company applies Accounting Standards Codification, or ASC, Topic 606, <i style="font-style:italic;">Revenue from Contracts with Customers </i>(Topic 606), to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. Under Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services in an amount that reflects the consideration which the entity expects to receive in exchange for those goods and services. To determine revenue recognition for arrangements that an entity determines are within the scope of Topic 606, the entity performs the following five steps: (i) identify the contract(s) with the customer(s); (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods and services it transfers to the customer. At contract inception, the Company assesses the goods or services promised within each contract that falls under the scope of Topic 606, determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">The Company enters into licensing agreements which are within the scope of Topic 606, under which it licenses certain of its drug candidates&#8217; rights to third parties. The terms of these arrangements typically include payment of one or more of the following: non-refundable, up-front license fees; development, regulatory and commercial milestone payments; and royalties on net sales of the licensed product, if and when earned. See Note 11 for additional information regarding the Company&#8217;s license agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"><span style="white-space:pre-wrap;"> In determining the appropriate amount of revenue to be recognized as it fulfills its obligation under each of its agreements, the Company performs the five steps under Topic 606 described above. As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price, which may include forecasted revenues, development timelines, reimbursement of personnel costs, discount rates and probabilities of technical and regulatory success.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"><i style="font-style:italic;">Licensing of Intellectual Property: </i>If the license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. The Company evaluates the measure of progress each reporting period, and, if necessary, adjusts the measure of performance and related revenue recognition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"><i style="font-style:italic;">Milestone Payments</i>: At the inception of each arrangement that includes development milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal will not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such development milestones and any related constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration and other revenues and earnings in their period of adjustment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"><i style="font-style:italic;">Royalties</i>: For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue from its license agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"><i style="font-style:italic;">Manufacturing and Supply:&#160;</i>The obligations under the Company&#8217;s agreements may include clinical and commercial manufacturing products to be provided by the Company to the counterparty. The services are generally determined to be distinct from the other promises or performance obligations identified in the arrangement. The Company recognizes the transaction price allocated to these services as revenue at a point in time when transfer of control of the related products to the customer occurs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Research and Development Costs</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Except for payments made in advance of services, research and development costs are expensed as incurred. For payments made in advance, the Company recognizes research and development expense as the services are rendered. Research and development costs primarily consist of salaries and related expenses for personnel, laboratory supplies and raw materials, sponsored research, depreciation of laboratory facilities and leasehold improvements, and utilities costs related to research space. Other research and development expenses include fees paid to consultants and outside service providers including clinical research organizations and clinical manufacturing organizations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Accruals for Clinical Trial Expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">Clinical trial costs primarily consist of expenses incurred under agreements with contract research organizations (CROs), investigative sites, laboratory testing expenses, data management and consultants that conduct the Company's clinical trials. Clinical trial expenses are a significant component of research and development expenses, and the Company outsources a significant portion of these clinical trial activities to third parties. The accrual for site and patient costs includes inputs such as estimates of patient enrollment, patient cycles incurred, clinical site activations, estimated project duration and other pass-through costs. These inputs are required to be estimated due to a lag in receiving the actual clinical information from third parties. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected on the balance sheets as a prepaid asset or accrued expenses. These third-party agreements are generally cancellable, and related costs are recorded as research and development expenses as incurred. Except for payments made in advance of services, clinical trial costs are expensed as incurred. Non-refundable advance clinical payments for goods or services that will be used or rendered for future research and development activities are recorded as a prepaid asset and recognized as expense as the related goods are delivered or the related services are performed. When evaluating the adequacy of the accrued expenses, management assessments include: (i) an evaluation by the project manager of the work that has been completed during the period; (ii) measurement of progress prepared internally and/or provided by the third-party service provider; (iii) analyses of data that justify the progress; and (iv)&#160;the Company&#8217;s judgment. Significant judgments and estimates may be made in determining the accrued balances at the end of any reporting period. Actual results could differ from the estimates made. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">The Company&#8217;s historical clinical accrual estimates have not been materially different from the actual costs. Clinical trial accruals that are due longer than one year are classified as noncurrent accrued expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Stock-Based Compensation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Stock-based payments are accounted for in accordance with the provisions of ASC 718, <i style="font-style:italic;">Compensation&#8212;Stock Compensation</i>. The fair value of stock-based payments is estimated, on the date of grant, using the Black-Scholes-Merton model. The resulting fair value is recognized ratably over the requisite service period, which is generally the vesting period of the option. The Company has elected to account for forfeitures as they occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">The Company has elected to use the Black-Scholes-Merton option pricing model to value any options granted. The Company will reconsider use of the Black-Scholes-Merton model if additional information becomes available in the future that indicates another model would be more appropriate or if grants issued in future periods have characteristics that prevent their value from being reasonably estimated using this model.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">A discussion of management&#8217;s methodology for developing some of the assumptions used in the valuation model follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><i style="font-style:italic;">Expected Dividend Yield</i>&#8212;The Company has never declared or paid dividends and has no plans to do so in the foreseeable future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><i style="font-style:italic;">Expected Volatility&#8212;</i>Volatility is a measure of the amount by which a financial variable such as share price has fluctuated (historical volatility) or is expected to fluctuate (expected volatility) during a period. Effective January 1, 2020, the Company bases the expected volatility on the historical volatility of the Company&#8217;s publicly traded common stock. Prior to January 1, 2020, the Company utilized the historical volatilities of a peer group (e.g., several public entities of similar size, complexity, and stage of development), along with the Company&#8217;s historical volatility since its initial public offering, to determine its expected volatility.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><i style="font-style:italic;">Risk-Free Interest Rate</i>&#8212;This is the U.S. Treasury rate for the week of each option grant during the year, having a term that most closely resembles the expected life of the option.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><i style="font-style:italic;">Expected Term</i>&#8212;This is a period of time that the options granted are expected to remain unexercised. Options granted have a maximum term of 10 years. The Company estimates the expected life of the option term to be 6.25 years. The Company uses a simplified method to calculate the average expected term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Income Taxes</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">The Company accounts for income taxes using the asset and liability method in accordance with ASC 740,<i style="font-style:italic;"> Income Taxes</i>. Deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and the financial reporting amounts at each year-end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. A valuation allowance is established when necessary to reduce deferred tax assets to the amount expected to be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">The Company accounts for uncertain tax positions pursuant to ASC 740. Financial statement recognition of a tax position taken or expected to be taken in a tax return is determined based on a more-likely-than-not threshold of that tax position being sustained. If the tax position meets this threshold, the benefit to be recognized is measured as the tax benefit having the highest likelihood of being realized upon ultimate settlement with the taxing authority. The Company recognizes interest accrued related to unrecognized tax benefits and penalties in the provision for income taxes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Comprehensive Loss</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Comprehensive loss comprises net loss and other changes in equity that are excluded from net loss. For the years ended December&#160;31, 2021, 2020 and 2019, the Company&#8217;s net loss was equal to comprehensive loss and, accordingly, no additional disclosure is presented.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Adopted Accounting Standards</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">In December 2019, the FASB issued ASU 2019-12. ASU 2019-12 removes certain exceptions for recognizing deferred taxes for investments, performing intra-period allocation and calculating income taxes in interim periods. The ASU also adds guidance to reduce complexity in certain areas, including deferred taxes for goodwill and allocating taxes for members of a consolidated group. ASU 2019-12 was effective for all entities for fiscal years beginning after </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">December 15, 2020. As of January 1, 2021, the Company adopted the standard, which did not have a material impact on the Company's financial statements. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Accounting Standards Not Yet Adopted</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">With the exception of the new standard discussed above, there have been no new accounting pronouncements that have significance, or potential significance, to the Company&#8217;s financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140248078656456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share of Common Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Net Loss Per Share of Common Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share of Common Stock</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">4. Net Loss Per Share of Common Stock</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Basic net loss per common share is determined by dividing net loss by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per share is computed by dividing net loss by the weighted-average number of common stock equivalents outstanding for the period. The treasury stock method is used to determine the dilutive effect of the Company&#8217;s stock options and restricted stock units (RSUs).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted-average common shares outstanding, as they would be anti-dilutive: </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock options and restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 7,908,122</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 6,143,594</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5,106,493</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140248080872712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Prepaid Expenses and Other Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCurrentAssetsTextBlock', window );">Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">5. Prepaid Expenses and Other Current Assets</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">The following is a summary of the Company&#8217;s prepaid expenses and other current assets at December 31:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 273,396</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 965,504</p></td></tr><tr><td style="vertical-align:bottom;width:71.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other prepaid expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 259,061</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 270,675</p></td></tr><tr><td style="vertical-align:bottom;width:71.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,347</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,149</p></td></tr><tr><td style="vertical-align:bottom;width:71.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 533,804</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,238,328</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140248080895608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">6. Property and Equipment</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:6pt 0pt 6pt 0pt;">Property and equipment, net consisted of the following at December 31:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 345,712</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 345,712</p></td></tr><tr><td style="vertical-align:bottom;width:71.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Laboratory equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,406,346</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,446,596</p></td></tr><tr><td style="vertical-align:bottom;width:71.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Office equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 17,762</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 16,755</p></td></tr><tr><td style="vertical-align:bottom;width:71.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Computer equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 305,784</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 327,776</p></td></tr><tr><td style="vertical-align:bottom;width:71.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 616,133</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 616,133</p></td></tr><tr><td style="vertical-align:bottom;width:71.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,691,737</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,752,972</p></td></tr><tr><td style="vertical-align:bottom;width:71.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less accumulated depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,322,895)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,132,299)</p></td></tr><tr><td style="vertical-align:bottom;width:71.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 368,842</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 620,673</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:6pt 0pt 12pt 0pt;">Depreciation of property and equipment totaled $264,600, $270,754 and $279,234 for the years ended December&#160;31, 2021, 2020 and 2019, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140248080937752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accrued Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">7. Accrued Expenses</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:6pt 0pt 6pt 0pt;">The following is a summary of the Company&#8217;s accrued expenses at December 31:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5,824,365</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5,114,420</p></td></tr><tr><td style="vertical-align:bottom;width:72.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued bonuses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,152,302</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,341,184</p></td></tr><tr><td style="vertical-align:bottom;width:72.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued consulting and other professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 299,607</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 194,760</p></td></tr><tr><td style="vertical-align:bottom;width:72.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued employee benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 348,752</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 569,048</p></td></tr><tr><td style="vertical-align:bottom;width:72.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 90,342</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 220,469</p></td></tr><tr><td style="vertical-align:bottom;width:72.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 8,715,368</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 9,439,881</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140248081009144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Operating Leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">8. Operating Leases</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"><span style="font-size:10pt;">At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the circumstances present. The Company determines a lease exists if the contract conveys the right to control an identified asset for a period of time in exchange for consideration. Control is considered to exist when the lessee has the right to obtain substantially all of the economic benefits from the use of an identified asset as well as direct the right to use of that asset. Leases with a term greater than one year are recognized on the balance sheet as right-of-use assets, lease liabilities and, if applicable, long-term lease liabilities. The Company has elected not to recognize on the balance sheet leases with terms of one year or less on the lease commencement date. If a contract is considered to be a lease, the Company recognizes a lease liability based on the present value of the future lease payments over the expected lease term, with an offsetting entry to recognize a right-of-use asset. The Company has also elected to use the practical expedient and account for each lease component and related non-lease component as one </span><span style="-sec-ix-hidden:Hidden_FRgasz_JB0WJUBzD7HF5EA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">single</span></span><span style="font-size:10pt;"> component. The lease component results in a right-of-use asset being recorded on the balance sheet and amortized as lease expense on a straight-line basis.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.5pt;margin:0pt 0pt 6pt 0pt;">The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a term similar to the term of the lease for which the rate is estimated. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">The Company leases office and research space in Rockville, Maryland under an operating lease with a term from June 15, 2015 through October 31, 2023 (the Lease) that is subject to annual rent increases. The Company has the right to sublease or assign all or a portion of the premises, subject to the conditions set forth in the Lease. The Lease may be terminated early by either the landlord or the Company in certain circumstances. In connection with the Lease, the Company received rent abatement as a lease incentive in the initial year of the Lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">In March 2016, the Company amended the Lease (the Lease Amendment) to lease additional space as of June 1, 2016. In May 2016, the Company also paid a security deposit of $52,320 to be held until the expiration or termination of the Company&#8217;s obligations under the Lease. The term of the Lease Amendment for the additional space continues through October 31, 2023, the same date as for the premises originally leased under the Lease, subject to the Company&#8217;s renewal option set forth in the Lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">The Company identified and applied the following significant assumptions in recognizing the right-of-use asset and corresponding liability for the Lease and Lease Amendment:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Lease term &#8211; The lease term includes both the noncancelable period and, when applicable, </span><span style="-sec-ix-hidden:Hidden_1CXabvkwwUuyuzuDaxMsGQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">cancelable</span></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> option periods where failure to exercise such option would result in an economic penalty. The Company&#8217;s renewal option to </span><span style="-sec-ix-hidden:Hidden_jhM2PXDc_EWMY9qaiYQkSQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">extend</span></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> is not reasonably certain of being exercised as of December 31, 2021.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Incremental borrowing rate &#8211; As the Company&#8217;s lease does not provide an implicit rate, the Company used an incremental borrowing rate (IBR), which is the rate incurred to borrow on a collateralized basis over a term similar to the term of the lease for which the rate is estimated. The Company determined the IBR to be </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8%</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> based on an estimated rate that considered the Company&#8217;s credit risk in the United States for a collateralized borrowing and lease term similar to the Lease.</span></td></tr></table><div style="margin-top:6pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"><span style="font-size:10pt;">As of December 31, 2021 the weighted-average remaining lease term was </span><span style="font-size:10pt;">1.8</span><span style="font-size:10pt;"> years. There were </span><span style="font-size:10pt;">no</span><span style="font-size:10pt;"> additional operating leases entered into during the year ended December 31, 2021.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">The components of lease expense and related cash flows were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:34.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating lease cost </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 927,957</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 927,957</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 927,957</p></td></tr><tr><td style="vertical-align:bottom;width:64.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Variable lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 490,871</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 593,973</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 465,028</p></td></tr><tr><td style="vertical-align:bottom;width:64.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total operating lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,418,828</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,521,930</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,392,985</p></td></tr><tr><td style="vertical-align:bottom;width:64.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash paid for amounts included in the measurement of lease liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating cash outflows for operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,077,469</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,051,190</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 941,089</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:6pt 0pt 6pt 0pt;">Maturities of lease liability due under these lease agreements as of December 31, 2021 were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:83.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:83.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Operating Lease</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:83.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Obligation</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:83.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,104,356</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:83.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 940,840</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:83.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:83.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,045,196</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:83.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Present value adjustment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (125,182)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:83.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Present value of lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,920,014</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140248080966248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glyc_DisclosureOfStockholdersEquityAndCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stockholders' Equity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">9. Stockholders&#8217; Equity</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Common Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">At-The-Market Equity Offerings</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">On September 28, 2017, the Company entered into an at-the-market sales agreement (the 2017 Sales Agreement) with Cowen and Company, LLC (Cowen) to sell up to $100.0 million of the Company&#8217;s common stock registered under a shelf registration statement filed with the U.S. Securities and Exchange Commission in September 2017. During the year ended December 31, 2020, the Company issued and sold 4,136,742 shares of common stock under the 2017 Sales Agreement at a weighted average price per share of $3.52, for aggregate net proceeds of $14.1 million, after deducting commissions and offering expenses. There were no shares sold under the 2017 Sales Agreement during the year ended December 31, 2019. The shelf registration statement, under which the shares that could be sold under the 2017 Sales Agreement were registered, expired on October 6, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">On October 7, 2020, the Company filed a prospectus supplement to a shelf registration statement that it filed in May 2019 and entered into a new at-the-market sales agreement (the 2020 Sales Agreement) with Cowen. Under the 2020 Sales Agreement, the Company may sell up to $100.0 million of the Company&#8217;s common stock registered under the shelf registration statement that was filed in May 2019. The 2020 Sales Agreement replaced the 2017 Sales Agreement between the Company and Cowen, and the $100.0 million that may be sold under the 2020 Sales Agreement excludes any amounts that were sold under the 2017 Sales Agreement. During the year ended December 31, 2020, the Company issued and sold 1,024,760 shares of common stock under the 2020 Sales Agreement at a weighted average price per share of $3.74, for aggregate net proceeds of $3.7 million, after deducting commissions and offering expenses. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">During the year ended December 31, 2021, the Company issued and sold an additional 3,092,603 shares of common stock under the 2020 Sales Agreement at a weighted average price per share of $3.57, for aggregate net proceeds of $10.7 million, after deducting commissions and offering expenses. As of December 31, 2021, approximately $85.1 million remained available to be sold under the terms of the 2020 Sales Agreement. Subsequent to December 31, 2021 and through the date these financial statements were issued, there have been no additional sales under the 2020 Sales Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">2003 Stock Incentive Plan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">The 2003 Stock Incentive Plan (the 2003 Plan) provided for the grant of incentives and nonqualified stock options and restricted stock awards. The exercise price for incentive stock options must be at least equal to the fair value of the </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">common stock on the grant date. Unless otherwise stated in a stock option agreement, 25% of the shares subject to an option grant will vest upon the first anniversary of the vesting start date and thereafter at the rate of one <span style="-sec-ix-hidden:Hidden_UfZmMD43P0CtU_nlwGEAYQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">forty</span></span>-eighth of the option shares per month as of the first day of each month after the first anniversary. Upon termination of employment by reasons other than death, cause, or disability, any vested options shall terminate 60 days after the termination date. Stock options terminate 10 years from the date of grant. The 2003 Plan expired on May&#160;21, 2013.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">A summary of the Company&#8217;s stock option activity under the 2003 Plan for the year ended December 31, 2021 is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">WEIGHTED-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AGGREGATE</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">WEIGHTED-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AVERAGE</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">INTRINSIC</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AVERAGE</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">REMAINING</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">VALUE</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OUTSTANDING</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EXERCISE</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CONTRACTUAL</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(IN</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OPTIONS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">PRICE</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">TERM&#160;(YEARS)</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">THOUSANDS)</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 97,250</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1.96</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Options exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,785)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1.12</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Options forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_CPAQxqLmSEmNCmGKblFleQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Outstanding</span></span>, Vested and Exercisable as of <span style="-sec-ix-hidden:Hidden_fSABMxeS7UGMQu4eqOoECg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">December&#160;31,&#160;2021</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 93,465</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 0.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:6pt 0pt 6pt 0pt;">During 2021, 2020 and 2019 the Company issued 3,785, 285,087 and 284,743 shares of common stock, respectively, in conjunction with exercises of stock options granted under the 2003 Plan. The Company received cash proceeds from the exercise of these stock options of $4,239, $319,297 and $318,912 during 2021, 2020 and 2019, respectively. Total intrinsic value of the options exercised during the years ended December 31, 2021, 2020 and 2019 was $8,668, $921,168 and $924,688, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">As of December 31, 2021, the options under the 2003 Plan were fully expensed and all options outstanding under the 2003 Plan were fully vested. There were no options granted under the 2003 Plan in 2021, 2020 and 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">2013 Equity Incentive Plan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">The Company&#8217;s board of directors adopted, and its stockholders approved, its 2013 Equity Incentive Plan (the 2013 Plan) effective on January 9, 2014. The 2013 Plan provides for the grant of incentive stock options within the meaning of Section&#160;422 of the Internal Revenue Code (the Code), to the Company&#8217;s employees and its parent and subsidiary corporations&#8217; employees, and for the grant of nonstatutory stock options, restricted stock awards, restricted stock unit awards, stock appreciation rights, performance stock awards and other forms of stock compensation to its employees, including officers, consultants and directors. The 2013 Plan also provides for the grant of performance cash awards to the Company&#8217;s employees, consultants and directors. Unless otherwise stated in a stock option agreement, 25% of the shares subject to an option grant will typically vest upon the first anniversary of the vesting start date and thereafter at the rate of one <span style="-sec-ix-hidden:Hidden_MpFfxPM_9Uq0Hhwoua9x4Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">forty</span></span>-eighth of the option shares per month as of the first day of each month after the first anniversary. Upon termination of employment by reasons other than death, cause, or disability, any vested options shall terminate 90 days after the termination date, unless otherwise set forth in a stock option agreement. Stock options generally terminate 10 years from the date of grant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><i style="font-style:italic;">Authorized Shares</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">The maximum number of shares of common stock that may be issued under the 2013 Plan was 1,000,000&#160;shares, plus any shares subject to stock options or similar awards granted under the 2003 Plan that expire or terminate without having been exercised in full or are forfeited to or repurchased by the Company. The number of shares of common stock reserved for issuance under the 2013 Plan will automatically increase on January&#160;1 of each year, beginning on January&#160;1, 2015 and ending on January&#160;1, 2023, by 3% of the total number of shares of common stock outstanding on December&#160;31 of the preceding calendar year, or a lesser number of shares as may be determined by the Company&#8217;s board of directors. The maximum number of shares that may be issued pursuant to exercise of incentive stock options under the 2013 Plan is 20,000,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">Shares issued under the 2013 Plan may be authorized but unissued or reacquired shares of common stock. Shares subject to stock awards granted under the 2013 Plan that expire or terminate without being exercised in full, or that are paid out in cash rather than in shares, will not reduce the number of shares available for issuance under the 2013 Plan. Additionally, shares issued pursuant to stock awards under the 2013 Plan that the Company repurchases or that are </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">forfeited, as well as shares reacquired by the Company as consideration for the exercise or purchase price of a stock award or to satisfy tax withholding obligations related to a stock award, will become available for future grant under the 2013 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><i style="font-style:italic;">Stock Options</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">A summary of the Company&#8217;s stock option activity under the 2013 Plan for the year ended December&#160;31, 2021 is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">WEIGHTED-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AGGREGATE</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">WEIGHTED-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AVERAGE</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">INTRINSIC</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AVERAGE</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">REMAINING</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">VALUE</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OUTSTANDING</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EXERCISE</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CONTRACTUAL</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(IN</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OPTIONS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">PRICE</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">TERM&#160;(YEARS)</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">THOUSANDS)</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5,753,211</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 8.93</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 6.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Options granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 898,100</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3.70</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Options exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Options forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (995,854)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 7.89</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5,655,457</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 8.30</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">6.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested or expected to vest as of December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5,655,457</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 8.30</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">6.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:45.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercisable as of December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4,118,394</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 9.43</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">5.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">As of December 31, 2021, there was $4,936,519 of total unrecognized compensation expense related to unvested options that will be recognized over a weighted-average period of approximately 2.0 years. The total fair value of options that vested in the years ended December 31, 2021, 2020 and 2019 was $5,936,641, $7,347,548 and $6,159,610, respectively. There were no options exercised under the 2013 Plan during the years ended December 31, 2021 or 2020. During the year ended December 31, 2019, the Company received cash of $94,001 and issued 16,606 shares of common stock in conjunction with exercises of stock options granted under the 2013 Plan. The intrinsic value of the options exercised for the year ended December 31, 2019 was $97,429. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><i style="font-style:italic;">Restricted Stock Units (RSUs)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">A restricted stock unit (RSU) is a stock award that entitles the holder to receive shares of the Company&#8217;s common stock as the award vests. The fair value of each RSU is based on the closing price of the Company&#8217;s common stock on the date of grant. In January 2021, the Company awarded RSUs under the 2013 Plan to all of its employees. The RSUs granted vest over four years in equal installments on each anniversary of the grant date. In September 2019, the Company granted an aggregate of 332,106 RSUs with service conditions to the Company&#8217;s non-executive employees. The RSUs granted in September 2019 vested over a two-year period, with <span style="-sec-ix-hidden:Hidden_PGLZbIA_j0-ItwYMfmgcfA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span>-third vesting on the first anniversary of the date of grant and the remaining <span style="-sec-ix-hidden:Hidden_BnTvpBXF9EKtCoC_jLU41A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">two</span></span>-thirds vesting on the second anniversary of the date of grant, provided that the employee remained employed with the Company at the applicable vesting date. Compensation expense is recognized on a straight-line basis. As of December 31, 2021, there was $943,458 of total unrecognized compensation expense associated with these RSU grants that will be recognized over a weighted-average period of approximately 3.0 years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">The following is a summary of RSU activity for the 2013 Plan for the year ended December 31, 2021:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Grant Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Underlying RSUs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unvested at December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 192,533</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4.53</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 444,613</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3.72</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (101,754)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3.84</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (189,792)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4.53</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unvested at December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 345,600</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3.70</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Inducement Plan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">In January 2020, the Company&#8217;s board of directors adopted the GlycoMimetics, Inc. Inducement Plan (the Inducement Plan). The Inducement Plan provides for the grant of nonstatutory stock options, restricted stock awards, restricted stock unit awards, stock appreciation rights and other forms of stock awards to individuals not previously an </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;">employee or director of the Company as an inducement for such individuals to join the Company. Unless otherwise stated in an applicable stock option agreement, </span><span style="-sec-ix-hidden:Hidden_CUsjKSRwVk28fq-bDbXrTw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span><span style="font-size:10pt;">-fourth of the shares subject to an option grant under the Inducement Plan will typically vest upon the first anniversary of the vesting start date, with the balance of the shares vesting in a series of </span><span style="font-size:10pt;">thirty-six</span><span style="font-size:10pt;"> successive equal monthly installments as of the first day of each month measured from the first anniversary of the vesting start date, subject to the new employee&#8217;s continued service with the Company through the applicable vesting dates. Upon termination of employment by reasons other than death, cause or disability, any vested options will terminate </span><span style="font-size:10pt;">90 days</span><span style="font-size:10pt;"> after the termination date, unless otherwise set forth in a stock option agreement. Stock options generally terminate </span><span style="font-size:10pt;">10 years</span><span style="font-size:10pt;"> from the date of grant. There were </span><span style="font-size:10pt;">500,000</span><span style="font-size:10pt;"> shares of common stock reserved under the Inducement Plan at its adoption date. In August 2021, the Company&#8217;s board of directors adopted an amendment to the Inducement Plan to increase the number of shares reserved to </span><span style="font-size:10pt;">2,000,000</span><span style="font-size:10pt;"> shares, and in January 2022 the Company&#8217;s board of directors adopted an amendment to the Inducement Plan to further increase the number of shares reserved to </span><span style="font-size:10pt;">3,000,000</span><span style="font-size:10pt;"> shares. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">A summary of the Company&#8217;s stock option activity under the Inducement Plan for the year ended December 31, 2021 is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#0000ff;font-size:14pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">WEIGHTED-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AGGREGATE</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">WEIGHTED-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AVERAGE</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">INTRINSIC</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AVERAGE</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">REMAINING</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">VALUE</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OUTSTANDING</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EXERCISE</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CONTRACTUAL</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(IN</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OPTIONS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">PRICE</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">TERM&#160;(YEARS)</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">THOUSANDS)</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 100,600</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3.09</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 9.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Options granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,747,600</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2.02</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Options exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (10,092)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2.06</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Options forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (24,508)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2.06</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,813,600</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2.08</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">9.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested or expected to vest as of December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,264,400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2.10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">9.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:45.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercisable as of December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 22,879</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3.58</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">8.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:6pt 0pt 6pt 0pt;">As of December 31, 2021, there was $1,672,270 of total unrecognized compensation expense related to unvested options under the Inducement Plan that will be recognized over a weighted-average period of approximately <span style="white-space:pre-wrap;">3.6</span><span style="white-space:pre-wrap;"> years. In August 2021, the Company granted stock options to purchase an aggregate of 1,647,600 shares to its new Chief Executive Officer under the Inducement Plan. This consisted of (a) an option to purchase 1,098,400 shares, subject to vesting as to 25% of the underlying shares on August 3, 2022 and as to the remaining underlying shares in equal monthly installments over </span><span style="white-space:pre-wrap;">36 months</span><span style="white-space:pre-wrap;"> thereafter, subject to the officer&#8217;s continued service through each such vesting date, and (b) an option to purchase 549,200 shares that is subject to performance vesting conditions and will vest upon achievement of milestones as follows: (i) </span><span style="-sec-ix-hidden:Hidden_wFFEp6_-yEedIq15Qcrr0w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">one</span></span><span style="white-space:pre-wrap;">-half of the shares will vest upon FDA approval of uproleselan in patients with relapsed/refractory acute myeloid leukemia and (ii) </span><span style="-sec-ix-hidden:Hidden_Asb0-jwP3ku8JnmG256I7Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">one</span></span><span style="white-space:pre-wrap;">-half of the shares will vest upon the first commercial sale of uproleselan in the United States or abroad. The maximum fair value of $798,053 associated with the performance-based option is excluded from the unrecognized compensation expense under the Inducement Plan as the completion of the performance milestones are not probable as of December 31, 2021. The Company will reevaluate at the end of each reporting period the probability that the performance conditions will be achieved and record any compensation cost at that time.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:6pt 0pt 6pt 0pt;">The total fair value of options that vested in the year ended December 31, 2021 was $73,334. During the year ended December 31, 2021, the Company received cash of $20,790 and issued 10,092 shares of common stock in conjunction with exercises of stock options granted under the Inducement Plan. The intrinsic value of the options exercised for the year ended December 31, 2021 was $1,944. There were no options vested or exercised under the Inducement Plan during the year ended December 31, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">The weighted-average fair value of the options granted under all equity incentive plans during the years ended December&#160;31, 2021, 2020 and 2019 was $1.85, $3.17 and $7.17 per share, respectively, applying the Black-Scholes-Merton option pricing model utilizing the following weighted-average assumptions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:41.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:41.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">6.25 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">6.25 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">6.25 years</p></td></tr><tr><td style="vertical-align:bottom;width:41.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">84.19%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">84.40%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">71.15%</p></td></tr><tr><td style="vertical-align:bottom;width:41.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">0.78%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">1.41%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2.54%</p></td></tr><tr><td style="vertical-align:bottom;width:41.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">0%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">0%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">0%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Total stock-based compensation expense associated with stock options and RSUs was classified as follows on the statement of operations for the years ended December 31:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,214,848</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,946,952</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,402,242</p></td></tr><tr><td style="vertical-align:bottom;width:51.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,872,438</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,954,806</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,812,848</p></td></tr><tr><td style="vertical-align:bottom;width:51.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 6,087,286</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 6,901,758</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 6,215,090</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_DisclosureOfStockholdersEquityAndCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This note contains 1) the entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income and 2) the entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_DisclosureOfStockholdersEquityAndCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140248080997240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">10. Income Taxes</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">The components of the gross deferred tax asset and related valuation allowance at December 31 were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:2.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:16.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:15.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:0.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:18.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:17.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:normal;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred income tax assets:</p></td><td style="vertical-align:bottom;white-space:normal;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:16.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:15.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Net operating loss carryforward</p></td><td style="vertical-align:bottom;white-space:normal;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:16.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 79,788,146</p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:15.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 63,830,866</p></td><td style="vertical-align:bottom;white-space:normal;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Capitalized start-up costs</p></td><td style="vertical-align:bottom;white-space:normal;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:16.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 920,516</p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:15.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,114,309</p></td><td style="vertical-align:bottom;white-space:normal;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Patent amortization</p></td><td style="vertical-align:bottom;white-space:normal;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:16.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 73,480</p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:15.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 88,949</p></td><td style="vertical-align:bottom;white-space:normal;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Research and orphan drug credits</p></td><td style="vertical-align:bottom;white-space:normal;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:16.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 47,976,370</p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:15.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 42,008,797</p></td><td style="vertical-align:bottom;white-space:normal;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:normal;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:16.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 7,102,947</p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:15.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 6,778,569</p></td><td style="vertical-align:bottom;white-space:normal;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:normal;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:16.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 528,340</p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:15.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 775,598</p></td><td style="vertical-align:bottom;white-space:normal;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Accrued bonus</p></td><td style="vertical-align:bottom;white-space:normal;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:16.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 592,260</p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:15.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 919,410</p></td><td style="vertical-align:bottom;white-space:normal;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Other</p></td><td style="vertical-align:bottom;white-space:normal;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:16.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 209,580</p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:15.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 283,751</p></td><td style="vertical-align:bottom;white-space:normal;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 42pt;">Gross deferred income tax assets</p></td><td style="vertical-align:bottom;white-space:normal;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:16.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 137,191,639</p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:15.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 115,800,249</p></td><td style="vertical-align:bottom;white-space:normal;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 42pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:normal;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:16.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (136,613,829)</p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:15.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (115,016,323)</p></td><td style="vertical-align:bottom;white-space:normal;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 42pt;">Net deferred income tax assets</p></td><td style="vertical-align:bottom;white-space:normal;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:16.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 577,810</p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:15.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 783,926</p></td><td style="vertical-align:bottom;white-space:normal;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 42pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:16.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:15.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred income tax liabilities:</p></td><td style="vertical-align:bottom;white-space:normal;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:16.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:15.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Operating lease right-of-use assets</p></td><td style="vertical-align:bottom;white-space:normal;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:16.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (433,727)</p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:15.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (639,843)</p></td><td style="vertical-align:bottom;white-space:normal;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Property and equipment</p></td><td style="vertical-align:bottom;white-space:normal;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:16.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (144,083)</p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:15.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (144,083)</p></td><td style="vertical-align:bottom;white-space:normal;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 42pt;">Gross deferred income tax liabilities</p></td><td style="vertical-align:bottom;white-space:normal;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:16.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (577,810)</p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:15.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (783,926)</p></td><td style="vertical-align:bottom;white-space:normal;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net deferred income tax asset/(liability)</p></td><td style="vertical-align:bottom;white-space:normal;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:16.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_1YfPvGN8zkuxUetSrMELxA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:15.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_kVVzvEvEd0Oo7zjJJdtzug;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:6pt 0pt 6pt 0pt;">Based on the Company&#8217;s operating history and management&#8217;s expectation regarding future profitability, management believes the Company&#8217;s deferred tax assets will not be realizable under ASC 740, <i style="font-style:italic;">Income Taxes</i>. Accordingly, a full valuation allowance has been established as of December 31, 2021 and 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">As of December 31, 2021, the Company had $290.0 million of U.S. Federal and state net operating losses, $10.3 million of research and development tax credits and $37.7 million of orphan drug tax credits available to carry forward. A portion of the net operating loss carryforwards will begin to expire in 2026, the research and development tax credits in 2023 and the orphan drug tax credit in 2033. Under current federal income tax laws, federal net operating losses incurred in 2018 and in future years may be carried forward, indefinitely, but the deductibility of such federal net operating losses is limited.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">The Company&#8217;s tax attributes, including net operating losses and credits, are subject to any ownership changes as defined under Internal Revenue Code Sections 382 and 383. A change in ownership could affect the Company&#8217;s ability </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">to utilize its net operating losses and credits. As of December 31, 2021, the Company does not believe that an ownership change has occurred. Any future ownership changes may cause a limitation on the Company&#8217;s ability to utilize existing tax attributes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">The Company files income tax returns in the U.S. federal jurisdiction and in the State of Maryland. The Company&#8217;s federal income tax returns for tax years 2003 and after remain subject to examination by the U.S. Internal Revenue Service due to tax attributes available to be carried forward to open or future tax years. The Company&#8217;s Maryland income tax returns for the tax years 2006 and thereafter remain subject to examination by the Comptroller of Maryland. In addition, all of the net operating losses, research and development tax credit and orphan drug credit carryforwards that may be used in future years are still subject to adjustment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">The Company did not have unrecognized tax benefits as of December 31, 2021 and 2020, and does not anticipate this to change significantly over the next 12 months. The Company will recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. Reconciliations between the statutory federal income tax rate and the effective income tax rate of income tax expense is as follows as of December 31:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:42.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:2.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:14.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:3.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:14.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:3.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:14.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:3.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:42.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:normal;width:14.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:normal;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:normal;width:14.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:normal;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:normal;width:14.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:normal;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:42.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">U.S. Federal statutory tax rate</p></td><td style="vertical-align:bottom;white-space:normal;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:14.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:normal;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:14.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:normal;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:14.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:normal;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:42.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">State taxes</p></td><td style="vertical-align:bottom;white-space:normal;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:14.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5.9</p></td><td style="vertical-align:bottom;white-space:normal;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:14.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5.7</p></td><td style="vertical-align:bottom;white-space:normal;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:14.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5.7</p></td><td style="vertical-align:bottom;white-space:normal;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research credit</p></td><td style="vertical-align:bottom;white-space:normal;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:14.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 0.9</p></td><td style="vertical-align:bottom;white-space:normal;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:14.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 0.7</p></td><td style="vertical-align:bottom;white-space:normal;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:14.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 0.8</p></td><td style="vertical-align:bottom;white-space:normal;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Orphan drug credit</p></td><td style="vertical-align:bottom;white-space:normal;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:14.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 6.6</p></td><td style="vertical-align:bottom;white-space:normal;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:14.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 9.8</p></td><td style="vertical-align:bottom;white-space:normal;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:14.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 8.8</p></td><td style="vertical-align:bottom;white-space:normal;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:normal;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:14.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.3)</p></td><td style="vertical-align:bottom;white-space:normal;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:14.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 0.4</p></td><td style="vertical-align:bottom;white-space:normal;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:14.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.1)</p></td><td style="vertical-align:bottom;white-space:normal;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:normal;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:14.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (34.1)</p></td><td style="vertical-align:bottom;white-space:normal;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:14.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (37.6)</p></td><td style="vertical-align:bottom;white-space:normal;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:14.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (36.2)</p></td><td style="vertical-align:bottom;white-space:normal;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Provision for income taxes</p></td><td style="vertical-align:bottom;white-space:normal;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:14.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:normal;width:14.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:normal;width:14.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140248080969464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research and License Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glyc_ResearchAndLicenseAgreementsAbstract', window );"><strong>Research and License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glyc_ResearchAndLicenseAgreementTextBlock', window );">Research and License Agreements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">11. &#160;Research and License Agreements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Apollomics</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27pt;margin:0pt 0pt 6pt 0pt;">In January 2020, the Company entered into a collaboration and license agreement (the Agreement) with Apollomics (Hong Kong), Limited (Apollomics) for the development, manufacture and commercialization of products derived from two of the Company&#8217;s compounds, GMI-1271 and GMI-1687 (the Products) for therapeutic and prophylactic uses (the Field) in China, Taiwan, Hong Kong and Macau (the Territory). Under the terms of the Agreement, the Company granted Apollomics:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an exclusive license, with the right to sublicense, to develop, manufacture and have manufactured, distribute, market, promote, sell, have sold, offer for sale, import, label, package and otherwise the Products in the Field in the Territory; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a non-exclusive license to conduct preclinical research with respect to Products in the Field outside of the Territory for the purposes of developing such Products for use in the Territory.</span></td></tr></table><div style="margin-top:6pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27pt;margin:0pt;">In June 2020, the Company and Apollomics entered into a clinical supply agreement pursuant to which the Company will manufacture and supply the Products at agreed upon prices. Apollomics has the option to begin manufacture of the Products after appropriate material transfer requirements are met. During the year ended December 30, 2021, the Company recognized $1.1 million as revenue from the sale of clinical supplies to Apollomics.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27pt;margin:0pt;">The Company evaluated the Agreement under the provisions of ASC 606 and identified two performance obligations under this revenue arrangement: the (i) delivery of functional licenses and (ii) manufacture and supply of the Products. The initial transaction price consists of a $9.0 million non-refundable up-front payment which was allocated to the delivered functional licenses and recognized in full as revenue in the first quarter of 2020 given that the performance obligation was satisfied upon inception. The Agreement contains various forms of variable consideration, including (i) up to $75.0 million in development milestones based on achievement of certain clinical and regulatory events, (ii) up to $105.0 million of sales-based commercial milestones based on achievement of certain annual net sales targets, (iii) sales-based royalties at specified percentages of net sales ranging from the high single digits to 15%, and (iv) manufacture and supply of clinical and commercial Products. The Company has fully constrained the development milestone consideration using the most likely amount method and will recognize that revenue when it is probable that recognition </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="white-space:pre-wrap;">of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price. In September 2020, the Company received a non-refundable $1.0 million development milestone payment upon acceptance by Chinese regulatory authorities of a Phase 3 bridging study design to support registration in China. The Company recognized this $1.0 million payment as revenue in the quarter ended September 30, 2020. The Company did not recognize any milestone revenue under the Agreement for the year ended December 31, 2021.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27pt;margin:0pt 0pt 6pt 0pt;"><span style="white-space:pre-wrap;"> The Company will recognize revenue related to the sales-based commercial and royalty milestones and royalties at the later of (i) when the related sales occur or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied), as they were determined to relate predominantly to the licenses granted to Apollomics and, therefore, have been excluded from the transaction price. Lastly, the Company has determined that the consideration for the manufacturing and supply is all variable and is fully constrained. Variable consideration allocated to manufacturing and supply will be recognized at a point in time when the Product is delivered and when the title to the Product is transferred to the customer pursuant to the agreement. The Company reassesses the transaction price in each reporting period and upon the occurrence of a change in circumstances or final resolution of any particular event.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_ResearchAndLicenseAgreementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for research services and license agreements, including contracts and arrangements to be performed by or for others. Includes contingent payment receivables or liabilities for achievement of specific milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_ResearchAndLicenseAgreementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_ResearchAndLicenseAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>n/a</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_ResearchAndLicenseAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140248081012472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Employee Benefit Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock', window );">Employee Benefit Plan</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">12. Employee Benefit Plan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">The Company has a defined contribution plan under the Internal Revenue Code Section&#160;401(k). This plan covers substantially all employees who meet minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pre-tax basis. For the years ended December 31, 2021, 2020 and 2019, the Company matched 50%<span style="white-space:pre-wrap;"> up to the first 6%</span><span style="white-space:pre-wrap;"> of employee contributions. All matching contributions have been paid by the Company. The Company&#8217;s matching contributions vest in full immediately. The total Company matching contributions were approximately $270,000, $252,000 and $219,000 for the years ended December 31, 2021, 2020 and 2019, respectively. </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of an entity's employee compensation and benefit plans, excluding share-based compensation and including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -URI http://asc.fasb.org/topic&amp;trid=2197446<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -URI http://asc.fasb.org/topic&amp;trid=2127225<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140248080911960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Risks and Uncertainties<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAbstract', window );"><strong>Risks and Uncertainties</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDisclosures', window );">Risks and Uncertainties</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">13. Risks and Uncertainties</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">COVID-19</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27pt;margin:0pt;">In March 2020, the World Health Organization declared the novel coronavirus disease 2019, or COVID-19, outbreak a pandemic. In order to mitigate the spread of COVID-19, governments have imposed unprecedented restrictions on business operations, travel and gatherings, resulting in a global economic downturn and other adverse economic and societal impacts. The COVID-19 pandemic has also overwhelmed or otherwise led to changes in the operations of many healthcare facilities. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:27pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27pt;margin:0pt;">The impact of the COVID-19 pandemic on the Company&#8217;s business and financial performance is uncertain and depends on various factors, including the duration of the pandemic, government restrictions and other actions, including relief measures and mass vaccination efforts, implemented to address the impact of the pandemic, and resulting impacts on the financial markets and overall economy. The imposition of &#8220;lockdown,&#8221; &#8220;social distancing&#8221; and &#8220;shelter in place&#8221; directives by state and federal governments in the United States as well as governments in other regions of the world in response to the COVID-19 pandemic, including in locations in which its Phase 3 clinical trial of uproleselan is being conducted, resulted in slowed clinical site initiation, patient recruitment and enrollment rates early in the pandemic. Enrollment rates have returned to forecasted levels since the lockdowns. However, COVID-19 infection rates continue to fluctuate, particularly with the emergence of variants, which could negatively affect completion of the trial. The Company is unable to determine the extent of the impact of the pandemic on its operations and financial condition going forward. These developments are highly uncertain and unpredictable, and may materially adversely affect the Company&#8217;s financial position and results of operations. The Company continues to closely monitor the COVID-19 situation and any potential impact to its planned activities.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for loss and gain contingencies. Describes any existing condition, situation, or set of circumstances involving uncertainty as of the balance sheet date (or prior to issuance of the financial statements) as to a probable or reasonably possible loss incurred by an entity that will ultimately be resolved when one or more future events occur or fail to occur, and typically discloses the amount of loss recorded or a range of possible loss, or an assertion that no reasonable estimate can be made.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 30<br> -URI http://asc.fasb.org/subtopic&amp;trid=2127197<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=2127163<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140248075610776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Accounting</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Basis of Accounting</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">The accompanying financial statements were prepared based on the accrual method of accounting in accordance with U.S. generally accepted accounting principles (GAAP).</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Segment Information</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one segment, which is the identification and development of glycomimetic compounds.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Although actual results could differ from those estimates, management does not believe that such differences would be material.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Cash and Cash Equivalents</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Cash and cash equivalents consist of investment in money market funds with commercial banks and financial institutions. The Company considers all investments in highly liquid financial instruments with an original maturity of three months or less at the date of purchase to be cash equivalents. Cash equivalents are stated at amortized cost, plus accrued interest, which approximates fair value.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Fair Value Measurements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">The Company&#8217;s financial instruments include cash and cash equivalents. The fair values of the financial instruments approximated their carrying values at December 31, 2021 and 2020, due to their short-term maturities. The Company accounts for recurring and nonrecurring fair value measurements in accordance with ASC 820, <i style="font-style:italic;">Fair Value Measurements</i>. ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements. The ASC hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value, and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 1&#8212;Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 2&#8212;Fair value is determined by using inputs, other than Level 1 quoted prices, that are directly and indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models that can be corroborated by observable market data.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 3&#8212;Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity. In instances where the determination of the fair value measurement is based on inputs from different levels of fair value hierarchy, the fair value measurement will fall within the lowest level input that is significant to the fair value measurement in its entirety.</span></td></tr></table><div style="margin-top:6pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">The Company periodically evaluates financial assets and liabilities subject to fair value measurements to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC 820 hierarchy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">The Company had no assets or liabilities that were measured using quoted prices for similar assets and liabilities or significant unobservable inputs (Level 2 and Level 3 assets and liabilities, respectively) either on a recurring or non-recurring basis as of December&#160;31, 2021 and 2020. The carrying value of cash held in money market funds of approximately $88.3 million and $135.0 million as of December&#160;31, 2021 and 2020, respectively, is included in cash and cash equivalents and approximates market values based on quoted market prices (Level 1 inputs). The Company did&#160;not transfer any assets measured at fair value on a recurring basis between levels during the&#160;years ended December 31, 2021 and 2020.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Concentration of Credit Risk</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Credit risk represents the risk that the Company would incur a loss if counterparties failed to perform pursuant to the terms of their agreements. Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. Cash and cash equivalents consist of investment in money market funds with major financial institutions in the United States. These deposits and funds may be redeemed upon demand and, therefore, bear minimal risk. The Company does not anticipate any losses on such balances.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Property and Equipment</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">Property and equipment are recorded at cost and depreciated on a straight-line basis over estimated useful lives ranging from <span style="-sec-ix-hidden:Hidden_0ma8_vtK80W6jIJz3LC8HQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three</span></span> to seven years. Upon retirement or disposition of assets, the costs and related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the results of operations. Expenditures for repairs and maintenance are charged to operations as incurred; major replacements that extend the </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">useful life are capitalized. Depreciation and amortization are computed using the straight-line method over the following estimated useful lives:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><div style="padding-left:40.5pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:82.39%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:46.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:51.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:46.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ESTIMATED&#160;USEFUL&#160;LIVES</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:46.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">7 years</p></td></tr><tr><td style="vertical-align:bottom;width:51.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Laboratory equipment</p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:46.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">5 years</p></td></tr><tr><td style="vertical-align:bottom;width:51.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Office equipment</p></td><td style="vertical-align:bottom;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:46.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">5 years</p></td></tr><tr><td style="vertical-align:bottom;width:51.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Computer equipment</p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:46.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">5 years</p></td></tr><tr><td style="vertical-align:bottom;width:51.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:46.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.6pt 0pt 0pt;">Shorter&#160;of&#160;lease&#160;term&#160;or&#160;useful&#160; life</p></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Impairment of Long-Lived Assets</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">The Company periodically assesses the recoverability of the carrying value of its long-lived assets in accordance with the provisions of ASC 360, <i style="font-style:italic;">Property, Plant, and Equipment</i>. ASC 360 requires that long-lived assets and certain identifiable intangible assets be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of the long-lived asset is measured by a comparison of the carrying amount of the asset to future undiscounted net cash flows expected to be generated by the asset. If the carrying value exceeds the sum of undiscounted cash flows, the Company then determines the fair value of the underlying asset. Any impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the estimated fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value, less costs to sell. As of December&#160;31, 2021 and 2020, the Company determined that there were no impaired assets and it had no assets held for sale.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Revenue Recognition</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">The Company applies Accounting Standards Codification, or ASC, Topic 606, <i style="font-style:italic;">Revenue from Contracts with Customers </i>(Topic 606), to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. Under Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services in an amount that reflects the consideration which the entity expects to receive in exchange for those goods and services. To determine revenue recognition for arrangements that an entity determines are within the scope of Topic 606, the entity performs the following five steps: (i) identify the contract(s) with the customer(s); (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods and services it transfers to the customer. At contract inception, the Company assesses the goods or services promised within each contract that falls under the scope of Topic 606, determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">The Company enters into licensing agreements which are within the scope of Topic 606, under which it licenses certain of its drug candidates&#8217; rights to third parties. The terms of these arrangements typically include payment of one or more of the following: non-refundable, up-front license fees; development, regulatory and commercial milestone payments; and royalties on net sales of the licensed product, if and when earned. See Note 11 for additional information regarding the Company&#8217;s license agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"><span style="white-space:pre-wrap;"> In determining the appropriate amount of revenue to be recognized as it fulfills its obligation under each of its agreements, the Company performs the five steps under Topic 606 described above. As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price, which may include forecasted revenues, development timelines, reimbursement of personnel costs, discount rates and probabilities of technical and regulatory success.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"><i style="font-style:italic;">Licensing of Intellectual Property: </i>If the license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. The Company evaluates the measure of progress each reporting period, and, if necessary, adjusts the measure of performance and related revenue recognition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"><i style="font-style:italic;">Milestone Payments</i>: At the inception of each arrangement that includes development milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal will not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such development milestones and any related constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration and other revenues and earnings in their period of adjustment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"><i style="font-style:italic;">Royalties</i>: For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue from its license agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"><i style="font-style:italic;">Manufacturing and Supply:&#160;</i>The obligations under the Company&#8217;s agreements may include clinical and commercial manufacturing products to be provided by the Company to the counterparty. The services are generally determined to be distinct from the other promises or performance obligations identified in the arrangement. The Company recognizes the transaction price allocated to these services as revenue at a point in time when transfer of control of the related products to the customer occurs.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Research and Development Costs</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Except for payments made in advance of services, research and development costs are expensed as incurred. For payments made in advance, the Company recognizes research and development expense as the services are rendered. Research and development costs primarily consist of salaries and related expenses for personnel, laboratory supplies and raw materials, sponsored research, depreciation of laboratory facilities and leasehold improvements, and utilities costs related to research space. Other research and development expenses include fees paid to consultants and outside service providers including clinical research organizations and clinical manufacturing organizations.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glyc_AccrualsForClinicalTrialExpensesPolicyTextBlock', window );">Accruals for Clinical Trial Expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Accruals for Clinical Trial Expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">Clinical trial costs primarily consist of expenses incurred under agreements with contract research organizations (CROs), investigative sites, laboratory testing expenses, data management and consultants that conduct the Company's clinical trials. Clinical trial expenses are a significant component of research and development expenses, and the Company outsources a significant portion of these clinical trial activities to third parties. The accrual for site and patient costs includes inputs such as estimates of patient enrollment, patient cycles incurred, clinical site activations, estimated project duration and other pass-through costs. These inputs are required to be estimated due to a lag in receiving the actual clinical information from third parties. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected on the balance sheets as a prepaid asset or accrued expenses. These third-party agreements are generally cancellable, and related costs are recorded as research and development expenses as incurred. Except for payments made in advance of services, clinical trial costs are expensed as incurred. Non-refundable advance clinical payments for goods or services that will be used or rendered for future research and development activities are recorded as a prepaid asset and recognized as expense as the related goods are delivered or the related services are performed. When evaluating the adequacy of the accrued expenses, management assessments include: (i) an evaluation by the project manager of the work that has been completed during the period; (ii) measurement of progress prepared internally and/or provided by the third-party service provider; (iii) analyses of data that justify the progress; and (iv)&#160;the Company&#8217;s judgment. Significant judgments and estimates may be made in determining the accrued balances at the end of any reporting period. Actual results could differ from the estimates made. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">The Company&#8217;s historical clinical accrual estimates have not been materially different from the actual costs. Clinical trial accruals that are due longer than one year are classified as noncurrent accrued expenses.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Stock-Based Compensation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Stock-based payments are accounted for in accordance with the provisions of ASC 718, <i style="font-style:italic;">Compensation&#8212;Stock Compensation</i>. The fair value of stock-based payments is estimated, on the date of grant, using the Black-Scholes-Merton model. The resulting fair value is recognized ratably over the requisite service period, which is generally the vesting period of the option. The Company has elected to account for forfeitures as they occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">The Company has elected to use the Black-Scholes-Merton option pricing model to value any options granted. The Company will reconsider use of the Black-Scholes-Merton model if additional information becomes available in the future that indicates another model would be more appropriate or if grants issued in future periods have characteristics that prevent their value from being reasonably estimated using this model.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">A discussion of management&#8217;s methodology for developing some of the assumptions used in the valuation model follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><i style="font-style:italic;">Expected Dividend Yield</i>&#8212;The Company has never declared or paid dividends and has no plans to do so in the foreseeable future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><i style="font-style:italic;">Expected Volatility&#8212;</i>Volatility is a measure of the amount by which a financial variable such as share price has fluctuated (historical volatility) or is expected to fluctuate (expected volatility) during a period. Effective January 1, 2020, the Company bases the expected volatility on the historical volatility of the Company&#8217;s publicly traded common stock. Prior to January 1, 2020, the Company utilized the historical volatilities of a peer group (e.g., several public entities of similar size, complexity, and stage of development), along with the Company&#8217;s historical volatility since its initial public offering, to determine its expected volatility.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><i style="font-style:italic;">Risk-Free Interest Rate</i>&#8212;This is the U.S. Treasury rate for the week of each option grant during the year, having a term that most closely resembles the expected life of the option.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><i style="font-style:italic;">Expected Term</i>&#8212;This is a period of time that the options granted are expected to remain unexercised. Options granted have a maximum term of 10 years. The Company estimates the expected life of the option term to be 6.25 years. The Company uses a simplified method to calculate the average expected term.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Income Taxes</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">The Company accounts for income taxes using the asset and liability method in accordance with ASC 740,<i style="font-style:italic;"> Income Taxes</i>. Deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and the financial reporting amounts at each year-end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. A valuation allowance is established when necessary to reduce deferred tax assets to the amount expected to be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">The Company accounts for uncertain tax positions pursuant to ASC 740. Financial statement recognition of a tax position taken or expected to be taken in a tax return is determined based on a more-likely-than-not threshold of that tax position being sustained. If the tax position meets this threshold, the benefit to be recognized is measured as the tax benefit having the highest likelihood of being realized upon ultimate settlement with the taxing authority. The Company recognizes interest accrued related to unrecognized tax benefits and penalties in the provision for income taxes.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Comprehensive Loss</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Comprehensive loss comprises net loss and other changes in equity that are excluded from net loss. For the years ended December&#160;31, 2021, 2020 and 2019, the Company&#8217;s net loss was equal to comprehensive loss and, accordingly, no additional disclosure is presented.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glyc_NewAccountingPronouncementsAdoptedPolicyPolicyTextBlock', window );">Adopted Accounting Standards</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Adopted Accounting Standards</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">In December 2019, the FASB issued ASU 2019-12. ASU 2019-12 removes certain exceptions for recognizing deferred taxes for investments, performing intra-period allocation and calculating income taxes in interim periods. The ASU also adds guidance to reduce complexity in certain areas, including deferred taxes for goodwill and allocating taxes for members of a consolidated group. ASU 2019-12 was effective for all entities for fiscal years beginning after </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">December 15, 2020. As of January 1, 2021, the Company adopted the standard, which did not have a material impact on the Company's financial statements. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Accounting Standards Not Yet Adopted</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Accounting Standards Not Yet Adopted</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">With the exception of the new standard discussed above, there have been no new accounting pronouncements that have significance, or potential significance, to the Company&#8217;s financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_AccrualsForClinicalTrialExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for Accruals for Clinical Trial Expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_AccrualsForClinicalTrialExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_NewAccountingPronouncementsAdoptedPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that have been adopted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_NewAccountingPronouncementsAdoptedPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140248162748328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glyc_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock', window );">Schedule of Property and Equipment Estimated Useful Lives</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><div style="padding-left:40.5pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:82.39%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:46.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:51.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:46.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ESTIMATED&#160;USEFUL&#160;LIVES</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:46.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">7 years</p></td></tr><tr><td style="vertical-align:bottom;width:51.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Laboratory equipment</p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:46.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">5 years</p></td></tr><tr><td style="vertical-align:bottom;width:51.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Office equipment</p></td><td style="vertical-align:bottom;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:46.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">5 years</p></td></tr><tr><td style="vertical-align:bottom;width:51.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Computer equipment</p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:46.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">5 years</p></td></tr><tr><td style="vertical-align:bottom;width:51.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:46.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.6pt 0pt 0pt;">Shorter&#160;of&#160;lease&#160;term&#160;or&#160;useful&#160; life</p></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the useful life of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140248081012472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share of Common Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Net Loss Per Share of Common Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Potentially dilutive securities outstanding</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock options and restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 7,908,122</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 6,143,594</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5,106,493</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140248080896440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Prepaid Expenses and Other Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Summary of Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">The following is a summary of the Company&#8217;s prepaid expenses and other current assets at December 31:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 273,396</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 965,504</p></td></tr><tr><td style="vertical-align:bottom;width:71.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other prepaid expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 259,061</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 270,675</p></td></tr><tr><td style="vertical-align:bottom;width:71.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,347</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,149</p></td></tr><tr><td style="vertical-align:bottom;width:71.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 533,804</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,238,328</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140248080972776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Summary of Property and Equipment useful lives</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:6pt 0pt 6pt 0pt;">Property and equipment, net consisted of the following at December 31:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 345,712</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 345,712</p></td></tr><tr><td style="vertical-align:bottom;width:71.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Laboratory equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,406,346</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,446,596</p></td></tr><tr><td style="vertical-align:bottom;width:71.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Office equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 17,762</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 16,755</p></td></tr><tr><td style="vertical-align:bottom;width:71.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Computer equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 305,784</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 327,776</p></td></tr><tr><td style="vertical-align:bottom;width:71.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 616,133</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 616,133</p></td></tr><tr><td style="vertical-align:bottom;width:71.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,691,737</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,752,972</p></td></tr><tr><td style="vertical-align:bottom;width:71.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less accumulated depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,322,895)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,132,299)</p></td></tr><tr><td style="vertical-align:bottom;width:71.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 368,842</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 620,673</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140248081010808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accrued Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Summary of Accrued Expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:6pt 0pt 6pt 0pt;">The following is a summary of the Company&#8217;s accrued expenses at December 31:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5,824,365</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5,114,420</p></td></tr><tr><td style="vertical-align:bottom;width:72.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued bonuses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,152,302</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,341,184</p></td></tr><tr><td style="vertical-align:bottom;width:72.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued consulting and other professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 299,607</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 194,760</p></td></tr><tr><td style="vertical-align:bottom;width:72.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued employee benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 348,752</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 569,048</p></td></tr><tr><td style="vertical-align:bottom;width:72.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 90,342</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 220,469</p></td></tr><tr><td style="vertical-align:bottom;width:72.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 8,715,368</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 9,439,881</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140248081007304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Components of lease expense and related cash flows</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:34.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating lease cost </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 927,957</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 927,957</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 927,957</p></td></tr><tr><td style="vertical-align:bottom;width:64.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Variable lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 490,871</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 593,973</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 465,028</p></td></tr><tr><td style="vertical-align:bottom;width:64.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total operating lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,418,828</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,521,930</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,392,985</p></td></tr><tr><td style="vertical-align:bottom;width:64.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash paid for amounts included in the measurement of lease liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating cash outflows for operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,077,469</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,051,190</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 941,089</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Maturities of lease liabilities due</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:83.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:83.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Operating Lease</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:83.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Obligation</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:83.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,104,356</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:83.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 940,840</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:83.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:83.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,045,196</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:83.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Present value adjustment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (125,182)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:83.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Present value of lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,920,014</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140248077021704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Weighted-Average Fair Value of Options Granted</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:41.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:41.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">6.25 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">6.25 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">6.25 years</p></td></tr><tr><td style="vertical-align:bottom;width:41.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">84.19%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">84.40%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">71.15%</p></td></tr><tr><td style="vertical-align:bottom;width:41.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">0.78%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">1.41%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2.54%</p></td></tr><tr><td style="vertical-align:bottom;width:41.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">0%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">0%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">0%</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Stock-Based Compensation Expense</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,214,848</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,946,952</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,402,242</p></td></tr><tr><td style="vertical-align:bottom;width:51.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,872,438</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,954,806</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,812,848</p></td></tr><tr><td style="vertical-align:bottom;width:51.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 6,087,286</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 6,901,758</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 6,215,090</p></td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=glyc_StockIncentivePlan2003Member', window );">2003 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Company's Stock Option Activity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">WEIGHTED-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AGGREGATE</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">WEIGHTED-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AVERAGE</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">INTRINSIC</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AVERAGE</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">REMAINING</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">VALUE</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OUTSTANDING</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EXERCISE</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CONTRACTUAL</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(IN</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OPTIONS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">PRICE</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">TERM&#160;(YEARS)</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">THOUSANDS)</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 97,250</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1.96</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Options exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,785)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1.12</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Options forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_CPAQxqLmSEmNCmGKblFleQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Outstanding</span></span>, Vested and Exercisable as of <span style="-sec-ix-hidden:Hidden_fSABMxeS7UGMQu4eqOoECg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">December&#160;31,&#160;2021</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 93,465</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 0.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=glyc_EquityIncentivePlan2013Member', window );">2013 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Company's Stock Option Activity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">WEIGHTED-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AGGREGATE</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">WEIGHTED-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AVERAGE</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">INTRINSIC</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AVERAGE</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">REMAINING</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">VALUE</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OUTSTANDING</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EXERCISE</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CONTRACTUAL</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(IN</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OPTIONS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">PRICE</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">TERM&#160;(YEARS)</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">THOUSANDS)</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5,753,211</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 8.93</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 6.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Options granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 898,100</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3.70</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Options exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Options forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (995,854)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 7.89</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5,655,457</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 8.30</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">6.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested or expected to vest as of December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5,655,457</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 8.30</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">6.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:45.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercisable as of December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4,118,394</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 9.43</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">5.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Summary of RSU Activity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">The following is a summary of RSU activity for the 2013 Plan for the year ended December 31, 2021:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Grant Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Underlying RSUs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unvested at December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 192,533</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4.53</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 444,613</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3.72</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (101,754)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3.84</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (189,792)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4.53</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unvested at December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 345,600</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3.70</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=glyc_EquityInducementPlanMember', window );">Inducement Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Company's Stock Option Activity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#0000ff;font-size:14pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">WEIGHTED-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AGGREGATE</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">WEIGHTED-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AVERAGE</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">INTRINSIC</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AVERAGE</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">REMAINING</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">VALUE</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OUTSTANDING</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EXERCISE</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CONTRACTUAL</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(IN</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OPTIONS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">PRICE</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">TERM&#160;(YEARS)</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">THOUSANDS)</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 100,600</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3.09</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 9.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Options granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,747,600</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2.02</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Options exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (10,092)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2.06</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Options forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (24,508)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2.06</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,813,600</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2.08</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">9.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested or expected to vest as of December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,264,400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2.10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">9.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:45.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercisable as of December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 22,879</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3.58</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">8.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=glyc_StockIncentivePlan2003Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=glyc_StockIncentivePlan2003Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=glyc_EquityIncentivePlan2013Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=glyc_EquityIncentivePlan2013Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=glyc_EquityInducementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=glyc_EquityInducementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140248078619720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Gross Deferred Tax Asset and Related Valuation Allowance</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:2.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:16.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:15.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:0.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:18.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:17.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:normal;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred income tax assets:</p></td><td style="vertical-align:bottom;white-space:normal;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:16.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:15.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Net operating loss carryforward</p></td><td style="vertical-align:bottom;white-space:normal;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:16.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 79,788,146</p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:15.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 63,830,866</p></td><td style="vertical-align:bottom;white-space:normal;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Capitalized start-up costs</p></td><td style="vertical-align:bottom;white-space:normal;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:16.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 920,516</p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:15.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,114,309</p></td><td style="vertical-align:bottom;white-space:normal;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Patent amortization</p></td><td style="vertical-align:bottom;white-space:normal;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:16.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 73,480</p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:15.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 88,949</p></td><td style="vertical-align:bottom;white-space:normal;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Research and orphan drug credits</p></td><td style="vertical-align:bottom;white-space:normal;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:16.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 47,976,370</p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:15.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 42,008,797</p></td><td style="vertical-align:bottom;white-space:normal;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:normal;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:16.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 7,102,947</p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:15.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 6,778,569</p></td><td style="vertical-align:bottom;white-space:normal;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:normal;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:16.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 528,340</p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:15.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 775,598</p></td><td style="vertical-align:bottom;white-space:normal;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Accrued bonus</p></td><td style="vertical-align:bottom;white-space:normal;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:16.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 592,260</p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:15.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 919,410</p></td><td style="vertical-align:bottom;white-space:normal;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Other</p></td><td style="vertical-align:bottom;white-space:normal;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:16.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 209,580</p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:15.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 283,751</p></td><td style="vertical-align:bottom;white-space:normal;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 42pt;">Gross deferred income tax assets</p></td><td style="vertical-align:bottom;white-space:normal;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:16.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 137,191,639</p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:15.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 115,800,249</p></td><td style="vertical-align:bottom;white-space:normal;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 42pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:normal;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:16.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (136,613,829)</p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:15.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (115,016,323)</p></td><td style="vertical-align:bottom;white-space:normal;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 42pt;">Net deferred income tax assets</p></td><td style="vertical-align:bottom;white-space:normal;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:16.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 577,810</p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:15.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 783,926</p></td><td style="vertical-align:bottom;white-space:normal;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 42pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:16.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:15.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred income tax liabilities:</p></td><td style="vertical-align:bottom;white-space:normal;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:16.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:15.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Operating lease right-of-use assets</p></td><td style="vertical-align:bottom;white-space:normal;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:16.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (433,727)</p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:15.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (639,843)</p></td><td style="vertical-align:bottom;white-space:normal;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Property and equipment</p></td><td style="vertical-align:bottom;white-space:normal;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:16.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (144,083)</p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:15.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (144,083)</p></td><td style="vertical-align:bottom;white-space:normal;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 42pt;">Gross deferred income tax liabilities</p></td><td style="vertical-align:bottom;white-space:normal;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:16.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (577,810)</p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:15.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (783,926)</p></td><td style="vertical-align:bottom;white-space:normal;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net deferred income tax asset/(liability)</p></td><td style="vertical-align:bottom;white-space:normal;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:16.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_1YfPvGN8zkuxUetSrMELxA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:15.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_kVVzvEvEd0Oo7zjJJdtzug;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Reconciliations Between Statutory Federal Income Tax Rate and Effective Income Tax Rate of Income Tax Expense</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:42.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:2.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:14.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:3.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:14.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:3.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:14.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:3.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:42.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:normal;width:14.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:normal;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:normal;width:14.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:normal;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:normal;width:14.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:normal;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:42.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">U.S. Federal statutory tax rate</p></td><td style="vertical-align:bottom;white-space:normal;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:14.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:normal;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:14.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:normal;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:14.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:normal;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:42.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">State taxes</p></td><td style="vertical-align:bottom;white-space:normal;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:14.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5.9</p></td><td style="vertical-align:bottom;white-space:normal;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:14.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5.7</p></td><td style="vertical-align:bottom;white-space:normal;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:14.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5.7</p></td><td style="vertical-align:bottom;white-space:normal;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research credit</p></td><td style="vertical-align:bottom;white-space:normal;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:14.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 0.9</p></td><td style="vertical-align:bottom;white-space:normal;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:14.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 0.7</p></td><td style="vertical-align:bottom;white-space:normal;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:14.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 0.8</p></td><td style="vertical-align:bottom;white-space:normal;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Orphan drug credit</p></td><td style="vertical-align:bottom;white-space:normal;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:14.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 6.6</p></td><td style="vertical-align:bottom;white-space:normal;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:14.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 9.8</p></td><td style="vertical-align:bottom;white-space:normal;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:14.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 8.8</p></td><td style="vertical-align:bottom;white-space:normal;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:normal;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:14.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.3)</p></td><td style="vertical-align:bottom;white-space:normal;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:14.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 0.4</p></td><td style="vertical-align:bottom;white-space:normal;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:14.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.1)</p></td><td style="vertical-align:bottom;white-space:normal;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:normal;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:14.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (34.1)</p></td><td style="vertical-align:bottom;white-space:normal;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:14.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (37.6)</p></td><td style="vertical-align:bottom;white-space:normal;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:14.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (36.2)</p></td><td style="vertical-align:bottom;white-space:normal;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Provision for income taxes</p></td><td style="vertical-align:bottom;white-space:normal;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:14.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:normal;width:14.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:normal;width:14.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140248076200104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Going Concern (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glyc_GoingConcernAbstract', window );"><strong>Going Concern</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glyc_NetIncomeLossAndComprehensiveIncomeNetOfTax', window );">Net loss</a></td>
<td class="nump">$ 63,427,437<span></span>
</td>
<td class="nump">$ 51,026,903<span></span>
</td>
<td class="nump">$ 57,891,911<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash flows used in operating activities</a></td>
<td class="nump">57,489,530<span></span>
</td>
<td class="nump">39,241,931<span></span>
</td>
<td class="nump">$ 51,984,139<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 90,254,890<span></span>
</td>
<td class="nump">$ 137,035,017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_GoingConcernAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_GoingConcernAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_NetIncomeLossAndComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss and comprehensive income for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_NetIncomeLossAndComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140248080854264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Segment Information (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140248076155976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Fair Value Measurements (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MoneyMarketFundsAtCarryingValue', window );">Carrying value of cash held in money market fund</a></td>
<td class="nump">$ 88.3<span></span>
</td>
<td class="nump">$ 135.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value levels 2 or 3</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities measured at fair value levels 2 or 3</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value levels 2 or 3</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities measured at fair value levels 2 or 3</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MoneyMarketFundsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MoneyMarketFundsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140248076887688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Property and Equipment (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and Equipment estimated useful lives</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=glyc_LaboratoryEquipmentMember', window );">Laboratory Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and Equipment estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and Equipment estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and Equipment estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and Equipment estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and Equipment estimated useful lives</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=glyc_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=glyc_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140248076799912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Impairment of Long-Lived Assets (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>item</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>item</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Impairment of Long-Lived Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glyc_NumberOfLongLivedAssetsDeterminedToBeImpaired', window );">Number of long-lived assets determined to be impaired | item</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup', window );">Assets held for sale | $</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_NumberOfLongLivedAssetsDeterminedToBeImpaired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of long-lived assets determined to be impaired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_NumberOfLongLivedAssetsDeterminedToBeImpaired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets held-for-sale that are not part of a disposal group.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 15<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123398962&amp;loc=d3e400-110220<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140248077009784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Stock-Based Compensation (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Defined Contribution Plan Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Defined Contribution Plan Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140248076854648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Common Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=glyc_EmployeeStockOptionsAndRestrictedStockUnitsMember', window );">Stock options and restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Anti-dilutive securities excluded from computation of earnings per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities</a></td>
<td class="nump">7,908,122<span></span>
</td>
<td class="nump">6,143,594<span></span>
</td>
<td class="nump">5,106,493<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=glyc_EmployeeStockOptionsAndRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=glyc_EmployeeStockOptionsAndRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140248076874632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Prepaid Expenses and Other Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid research and development expenses</a></td>
<td class="nump">$ 273,396<span></span>
</td>
<td class="nump">$ 965,504<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other prepaid expenses</a></td>
<td class="nump">259,061<span></span>
</td>
<td class="nump">270,675<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="nump">1,347<span></span>
</td>
<td class="nump">2,149<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">$ 533,804<span></span>
</td>
<td class="nump">$ 1,238,328<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123349782&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140248078407320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">$ 2,691,737<span></span>
</td>
<td class="nump">$ 2,752,972<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation</a></td>
<td class="num">(2,322,895)<span></span>
</td>
<td class="num">(2,132,299)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">368,842<span></span>
</td>
<td class="nump">620,673<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation of property and equipment</a></td>
<td class="nump">264,600<span></span>
</td>
<td class="nump">270,754<span></span>
</td>
<td class="nump">$ 279,234<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">345,712<span></span>
</td>
<td class="nump">345,712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=glyc_LaboratoryEquipmentMember', window );">Laboratory Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">1,406,346<span></span>
</td>
<td class="nump">1,446,596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">17,762<span></span>
</td>
<td class="nump">16,755<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">305,784<span></span>
</td>
<td class="nump">327,776<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">$ 616,133<span></span>
</td>
<td class="nump">$ 616,133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=glyc_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=glyc_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140248077184104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses - Summary of Accrued Expenses (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accrued Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glyc_AccruedResearchAndDevelopmentExpenseCurrent', window );">Accrued research and development expenses</a></td>
<td class="nump">$ 5,824,365<span></span>
</td>
<td class="nump">$ 5,114,420<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedBonusesCurrent', window );">Accrued bonuses</a></td>
<td class="nump">2,152,302<span></span>
</td>
<td class="nump">3,341,184<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued consulting and other professional fees</a></td>
<td class="nump">299,607<span></span>
</td>
<td class="nump">194,760<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Accrued employee benefits</a></td>
<td class="nump">348,752<span></span>
</td>
<td class="nump">569,048<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued expenses</a></td>
<td class="nump">90,342<span></span>
</td>
<td class="nump">220,469<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">$ 8,715,368<span></span>
</td>
<td class="nump">$ 9,439,881<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_AccruedResearchAndDevelopmentExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_AccruedResearchAndDevelopmentExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedBonusesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedBonusesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140248076902488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>lease</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescriptionAbstract', window );"><strong>Operating leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasePracticalExpedientLessorSingleLeaseComponent', window );">Lease, Practical Expedient, Lessor Single Lease Component [true false]</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security Deposit</a></td>
<td class="nump">$ 52,320<span></span>
</td>
<td class="nump">$ 52,320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend', window );">Lessee, Operating Lease, Existence of Option to Extend [true false]</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate', window );">Lessee, Operating Lease, Existence of Option to Terminate [true false]</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease', window );">Incremental borrowing rate</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating Lease, Weighted Average Remaining Lease Term</a></td>
<td class="text">1 year 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glyc_LesseeOperatingLeaseNumberOfNewLeases', window );">Number of additional operating leases entered during the period | lease</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=glyc_RockvilleMarylandMember', window );">Rockville, Maryland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescriptionAbstract', window );"><strong>Operating leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security Deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52,320<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_LesseeOperatingLeaseNumberOfNewLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of additional operating leases entered into during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_LesseeOperatingLeaseNumberOfNewLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Incremental percentage increase (decrease) in the stated rate on a debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasePracticalExpedientLessorSingleLeaseComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether practical expedient is elected to account for lease component and nonlease component as single lease component.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL117410129-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasePracticalExpedientLessorSingleLeaseComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDescriptionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDescriptionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to extend operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to terminate operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8,17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=glyc_RockvilleMarylandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=glyc_RockvilleMarylandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140248077019736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases - Components of lease expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Components of lease expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 927,957<span></span>
</td>
<td class="nump">$ 927,957<span></span>
</td>
<td class="nump">$ 927,957<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">490,871<span></span>
</td>
<td class="nump">593,973<span></span>
</td>
<td class="nump">465,028<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total operating lease cost</a></td>
<td class="nump">1,418,828<span></span>
</td>
<td class="nump">1,521,930<span></span>
</td>
<td class="nump">1,392,985<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowOperatingActivitiesLesseeAbstract', window );"><strong>Cash paid for amounts included in the measurement of lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash outflows from operating leases</a></td>
<td class="nump">$ 1,077,469<span></span>
</td>
<td class="nump">$ 1,051,190<span></span>
</td>
<td class="nump">$ 941,089<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowOperatingActivitiesLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowOperatingActivitiesLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140248078822360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Operating Leases - Maturities of lease liability (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Maturities of lease liability due</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 1,104,356<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">940,840<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glyc_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo', window );">Thereafter</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total</a></td>
<td class="nump">2,045,196<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Present value adjustment</a></td>
<td class="num">(125,182)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease payments</a></td>
<td class="nump">$ 1,920,014<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140248075123368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Equity Offerings (Details) - Common Stock - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Oct. 07, 2020</div></th>
<th class="th"><div>Sep. 28, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Equity offerings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,092,603<span></span>
</td>
<td class="nump">5,161,502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=glyc_AtMarketOffering2017Member', window );">2017 Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Equity offerings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,136,742<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Aggregate net proceeds from stock sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=glyc_AtMarketOffering2017Member', window );">2017 Sales Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Equity offerings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glyc_CommonStockValueAvailableForSaleUnderAgreement', window );">Common stock available for sale under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=glyc_AtMarketOffering2020Member', window );">2020 Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Equity offerings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,092,603<span></span>
</td>
<td class="nump">1,024,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.57<span></span>
</td>
<td class="nump">$ 3.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Aggregate net proceeds from stock sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.7<span></span>
</td>
<td class="nump">$ 3.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glyc_CommonStockValueAvailableForSaleUnderAgreement', window );">Common stock available for sale under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 85.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=glyc_AtMarketOffering2020Member', window );">2020 Sales Agreement | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Equity offerings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs, shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=glyc_AtMarketOffering2020Member', window );">2020 Sales Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Equity offerings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glyc_CommonStockValueAvailableForSaleUnderAgreement', window );">Common stock available for sale under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_CommonStockValueAvailableForSaleUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of common stock remaining available to be sold under the terms of the agreement at the end of the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_CommonStockValueAvailableForSaleUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=glyc_AtMarketOffering2017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=glyc_AtMarketOffering2017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=glyc_AtMarketOffering2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=glyc_AtMarketOffering2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140248072766040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Incentive Plans (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jan. 09, 2014</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Incentive plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=glyc_StockIncentivePlan2003Member', window );">2003 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Incentive plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glyc_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment', window );">Period from date of termination that any vested options shall expire</a></td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised</a></td>
<td class="nump">$ 8,668<span></span>
</td>
<td class="nump">$ 921,168<span></span>
</td>
<td class="nump">$ 924,688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Cash proceeds from exercise of stock options</a></td>
<td class="nump">$ 4,239<span></span>
</td>
<td class="nump">$ 319,297<span></span>
</td>
<td class="nump">$ 318,912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares issued from exercise of stock options</a></td>
<td class="nump">3,785<span></span>
</td>
<td class="nump">285,087<span></span>
</td>
<td class="nump">284,743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=glyc_StockIncentivePlan2003Member', window );">2003 Stock Incentive Plan | Upon first anniversary of start date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Incentive plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Percent of shares subject to option grant that will vest</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=glyc_StockIncentivePlan2003Member', window );">2003 Stock Incentive Plan | Each month after the first anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Incentive plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Percent of shares subject to option grant that will vest</a></td>
<td class="nump">2.083%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=glyc_EquityIncentivePlan2013Member', window );">2013 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Incentive plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glyc_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment', window );">Period from date of termination that any vested options shall expire</a></td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense related to unvested options</a></td>
<td class="nump">$ 4,936,519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period for unrecognized compensation expense related to unvested options yet has not been recognized</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 97,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Cash proceeds from exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares issued from exercise of stock options</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of shares vested</a></td>
<td class="nump">$ 5,936,641<span></span>
</td>
<td class="nump">$ 7,347,548<span></span>
</td>
<td class="nump">$ 6,159,610<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=glyc_EquityIncentivePlan2013Member', window );">2013 Equity Incentive Plan | Upon first anniversary of start date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Incentive plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Percent of shares subject to option grant that will vest</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=glyc_EquityIncentivePlan2013Member', window );">2013 Equity Incentive Plan | Each month after the first anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Incentive plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Percent of shares subject to option grant that will vest</a></td>
<td class="nump">2.083%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | 2013 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedSharesDisclosureAbstract', window );"><strong>Authorized shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Common stock authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glyc_PercentageOfTotalNumberOfCommonStockOutstandingOnLastBusinessDayOfPriorFiscalYearThatMayAutomaticallyIncreaseUnderPlan', window );">Automatic increase in number of shares reserved for issuance as a percentage of the total common stock outstanding at the end of the prior year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMaximumSharesIssuedUponExerciseOfIncentiveStockOptions', window );">Maximum number of shares that may be issued pursuant to exercise of incentive stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_PercentageOfTotalNumberOfCommonStockOutstandingOnLastBusinessDayOfPriorFiscalYearThatMayAutomaticallyIncreaseUnderPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total automatic increase in number of shares of common stock reserved for issuance under the Plan on January 1 of each year, as a percent of the total number of common stock outstanding at December 31 of the prior year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_PercentageOfTotalNumberOfCommonStockOutstandingOnLastBusinessDayOfPriorFiscalYearThatMayAutomaticallyIncreaseUnderPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedSharesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>n/a</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedSharesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMaximumSharesIssuedUponExerciseOfIncentiveStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award number of maximum shares issued upon exercise of incentive stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMaximumSharesIssuedUponExerciseOfIncentiveStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from date of termination of employment by reasons other than death, cause, or disability that any vested options shall expire, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=glyc_StockIncentivePlan2003Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=glyc_StockIncentivePlan2003Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=glyc_EquityIncentivePlan2013Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=glyc_EquityIncentivePlan2013Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140248072831112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Company's Stock Option Activity (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=glyc_StockIncentivePlan2003Member', window );">2003 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>OUTSTANDING OPTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at beginning of period</a></td>
<td class="nump">97,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised</a></td>
<td class="num">(3,785)<span></span>
</td>
<td class="num">(285,087)<span></span>
</td>
<td class="num">(284,743)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at end of period</a></td>
<td class="nump">93,465<span></span>
</td>
<td class="nump">97,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>WEIGHTED-AVERAGE EXERCISE PRICE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at beginning of period</a></td>
<td class="nump">$ 1.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options exercised</a></td>
<td class="nump">1.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at end of period</a></td>
<td class="nump">$ 2.00<span></span>
</td>
<td class="nump">$ 1.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract', window );"><strong>VESTED AND EXPECTED TO VEST</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Outstanding options</a></td>
<td class="nump">93,465<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price</a></td>
<td class="nump">$ 2.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>ADDITIONAL DISCLOSURES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-average contractual term outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-average contractual term (years) exercisable</a></td>
<td class="text">3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=glyc_EquityIncentivePlan2013Member', window );">2013 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>OUTSTANDING OPTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at beginning of period</a></td>
<td class="nump">5,753,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted</a></td>
<td class="nump">898,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,606<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options forfeited</a></td>
<td class="num">(995,854)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at end of period</a></td>
<td class="nump">5,655,457<span></span>
</td>
<td class="nump">5,753,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>WEIGHTED-AVERAGE EXERCISE PRICE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at beginning of period</a></td>
<td class="nump">$ 8.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted</a></td>
<td class="nump">3.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Options forfeited</a></td>
<td class="nump">7.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at end of period</a></td>
<td class="nump">$ 8.30<span></span>
</td>
<td class="nump">$ 8.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract', window );"><strong>VESTED AND EXPECTED TO VEST</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Outstanding options</a></td>
<td class="nump">5,655,457<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price</a></td>
<td class="nump">$ 8.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted-Average Remaining Contractual Term</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>ADDITIONAL DISCLOSURES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Outstanding options exercisable at end of period</a></td>
<td class="nump">4,118,394<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted-average exercise price exercisable at end of period</a></td>
<td class="nump">$ 9.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-average contractual term outstanding</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-average contractual term (years) exercisable</a></td>
<td class="text">5 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=glyc_StockIncentivePlan2003Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=glyc_StockIncentivePlan2003Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=glyc_EquityIncentivePlan2013Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=glyc_EquityIncentivePlan2013Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140248078428472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Summary of RSU Activity (Details) - 2013 Equity Incentive Plan - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract', window );"><strong>Restricted Stock Units information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period for unrecognized compensation expense related to unvested options yet has not been recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=glyc_EquityIncentivePlan2013Member', window );">Upon first anniversary of start date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract', window );"><strong>Restricted Stock Units information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSU</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>NUMBER OF SHARES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested at beginning of period</a></td>
<td class="nump">192,533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">192,533<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">444,613<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(101,754)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(189,792)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested at end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">345,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>WEIGHTED-AVERAGE GRANT DATE FAIR VALUE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested at beginning of period</a></td>
<td class="nump">$ 4.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.53<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.72<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.84<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.53<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested at end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.70<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSU | Non-executive employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract', window );"><strong>Restricted Stock Units information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation expense related to unvested service RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 943,458<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period for unrecognized compensation expense related to unvested options yet has not been recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>NUMBER OF SHARES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">332,106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSU | Non-executive employees | Upon first anniversary of start date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract', window );"><strong>Restricted Stock Units information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSU | Non-executive employees | On the second anniversary of the date of grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract', window );"><strong>Restricted Stock Units information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=glyc_EquityIncentivePlan2013Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=glyc_EquityIncentivePlan2013Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140248072519192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Inducement Plan (Details) - Inducement Plan<br></strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jan. 31, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 31, 2020 </div>
<div>installment </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation expense related to unvested options | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,672,270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,944,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Cash proceeds from exercise of stock options | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,790<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period for unrecognized compensation expense related to unvested options yet has not been recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Increase in number of shares of common stock</a></td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Common stock shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,092<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,747,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of shares vested | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 73,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,092<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=glyc_EquityInducementPlanMember', window );">Stock options vesting based on service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingUnderlyingSharesVestPeriod', window );">Period remaining underlying shares vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,098,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=glyc_EquityInducementPlanMember', window );">Stock options vesting based on performance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">549,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFairValueOfOptionExcludedFromUnrecognizedCompensationExpense', window );">Maximum fair value of option excluded from the unrecognized compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 798,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=glyc_EquityInducementPlanMember', window );">Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,647,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=glyc_EquityInducementPlanMember', window );">Upon first anniversary of start date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfMonthlyInstallments', window );">Number of monthly installments | installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glyc_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment', window );">Period from date of termination that any vested options shall expire</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=glyc_EquityInducementPlanMember', window );">Vesting upon FDA Approval | Stock options vesting based on performance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=glyc_EquityInducementPlanMember', window );">Vesting upon First Commercial Sale | Stock options vesting based on performance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Common stock authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfMonthlyInstallments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of monthly installments for Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfMonthlyInstallments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFairValueOfOptionExcludedFromUnrecognizedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum fair value of option excluded from the unrecognized compensation expense under the share based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFairValueOfOptionExcludedFromUnrecognizedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingUnderlyingSharesVestPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period remaining underlying shares vest, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingUnderlyingSharesVestPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from date of termination of employment by reasons other than death, cause, or disability that any vested options shall expire, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=glyc_EquityInducementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=glyc_EquityInducementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=glyc_StockOptionsVestingBasedOnServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=glyc_StockOptionsVestingBasedOnServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=glyc_StockOptionsVestingBasedOnPerformanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=glyc_StockOptionsVestingBasedOnPerformanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=glyc_VestingUponFDApprovalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=glyc_VestingUponFDApprovalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=glyc_VestingUponFirstCommercialSaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=glyc_VestingUponFirstCommercialSaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140248072489384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Inducement Plan - Stock Option Activity (Details) - Inducement Plan - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>OUTSTANDING OPTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at beginning of period</a></td>
<td class="nump">100,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted</a></td>
<td class="nump">1,747,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised</a></td>
<td class="num">(10,092)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options forfeited</a></td>
<td class="num">(24,508)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at end of period</a></td>
<td class="nump">1,813,600<span></span>
</td>
<td class="nump">100,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>WEIGHTED-AVERAGE EXERCISE PRICE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at beginning of period</a></td>
<td class="nump">$ 3.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted</a></td>
<td class="nump">2.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options exercised</a></td>
<td class="nump">2.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Options forfeited</a></td>
<td class="nump">2.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at end of period</a></td>
<td class="nump">$ 2.08<span></span>
</td>
<td class="nump">$ 3.09<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract', window );"><strong>VESTED AND EXPECTED TO VEST</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Outstanding options</a></td>
<td class="nump">1,264,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price</a></td>
<td class="nump">$ 2.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted-Average Remaining Contractual Term</a></td>
<td class="text">9 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>ADDITIONAL DISCLOSURES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Outstanding options exercisable at end of period</a></td>
<td class="nump">22,879<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted-average exercise price exercisable at end of period</a></td>
<td class="nump">$ 3.58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-average contractual term outstanding</a></td>
<td class="text">9 years 7 months 6 days<span></span>
</td>
<td class="text">9 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-average contractual term (years) exercisable</a></td>
<td class="text">8 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=glyc_EquityInducementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=glyc_EquityInducementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140248078568520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Weighted-Average assumptions (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value of the options granted</a></td>
<td class="nump">$ 1.85<span></span>
</td>
<td class="nump">$ 3.17<span></span>
</td>
<td class="nump">$ 7.17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Weighted-average assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">84.19%<span></span>
</td>
<td class="nump">84.40%<span></span>
</td>
<td class="nump">71.15%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.78%<span></span>
</td>
<td class="nump">1.41%<span></span>
</td>
<td class="nump">2.54%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140248077023576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Stock-Based Compensation Expense (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 6,087,286<span></span>
</td>
<td class="nump">$ 6,901,758<span></span>
</td>
<td class="nump">$ 6,215,090<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">2,214,848<span></span>
</td>
<td class="nump">2,946,952<span></span>
</td>
<td class="nump">2,402,242<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 3,872,438<span></span>
</td>
<td class="nump">$ 3,954,806<span></span>
</td>
<td class="nump">$ 3,812,848<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140248071990104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Gross Deferred Tax Asset and Related Valuation Allowance (Detail) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred income tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforward</a></td>
<td class="nump">$ 79,788,146<span></span>
</td>
<td class="nump">$ 63,830,866<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glyc_DeferredTaxAssetsCapitalizedStartUpCosts', window );">Capitalized start-up costs</a></td>
<td class="nump">920,516<span></span>
</td>
<td class="nump">1,114,309<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glyc_DeferredTaxAssetsPatentAmortization', window );">Patent amortization</a></td>
<td class="nump">73,480<span></span>
</td>
<td class="nump">88,949<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glyc_DeferredTaxAssetsResearchAndOrphanDrugCredits', window );">Research and orphan drug credits</a></td>
<td class="nump">47,976,370<span></span>
</td>
<td class="nump">42,008,797<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits', window );">Stock-based compensation</a></td>
<td class="nump">7,102,947<span></span>
</td>
<td class="nump">6,778,569<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glyc_DeferredTaxAssetsTaxDeferredExpenseOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="nump">528,340<span></span>
</td>
<td class="nump">775,598<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glyc_DeferredTaxAssetsAccruedBonus', window );">Accrued bonus</a></td>
<td class="nump">592,260<span></span>
</td>
<td class="nump">919,410<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">209,580<span></span>
</td>
<td class="nump">283,751<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred income tax assets</a></td>
<td class="nump">137,191,639<span></span>
</td>
<td class="nump">115,800,249<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(136,613,829)<span></span>
</td>
<td class="num">(115,016,323)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred income tax assets</a></td>
<td class="nump">577,810<span></span>
</td>
<td class="nump">783,926<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glyc_DeferredTaxLiabilitiesTaxDeferredExpenseOperatingLeaseLiabilitiesRightOfUseAssets', window );">Operating lease right-of-use assets</a></td>
<td class="num">(433,727)<span></span>
</td>
<td class="num">(639,843)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="num">(144,083)<span></span>
</td>
<td class="num">(144,083)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Gross deferred income tax liabilities</a></td>
<td class="num">(577,810)<span></span>
</td>
<td class="num">(783,926)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred income tax asset/(liability)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_DeferredTaxAssetsAccruedBonus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from Accrued bonus.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_DeferredTaxAssetsAccruedBonus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_DeferredTaxAssetsCapitalizedStartUpCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences capitalized start up costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_DeferredTaxAssetsCapitalizedStartUpCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_DeferredTaxAssetsPatentAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences patent amortization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_DeferredTaxAssetsPatentAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_DeferredTaxAssetsResearchAndOrphanDrugCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from research and orphan drug credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_DeferredTaxAssetsResearchAndOrphanDrugCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_DeferredTaxAssetsTaxDeferredExpenseOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_DeferredTaxAssetsTaxDeferredExpenseOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_DeferredTaxLiabilitiesTaxDeferredExpenseOperatingLeaseLiabilitiesRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from operating lease right-of-use assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_DeferredTaxLiabilitiesTaxDeferredExpenseOperatingLeaseLiabilitiesRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140248078553320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - NOLs and carryforwards (Detail)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research Tax Credit Carryforward [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credits available to carry forward</a></td>
<td class="nump">$ 10.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_GeneralBusinessMember', window );">General Business Tax Credit Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credits available to carry forward</a></td>
<td class="nump">37.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=glyc_FederalAndStateAuthoritiesMember', window );">U.S. Federal And State</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="nump">$ 290.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_GeneralBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_GeneralBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=glyc_FederalAndStateAuthoritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=glyc_FederalAndStateAuthoritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140248075323144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation Between Statutory Federal Income Tax Rate and Effective Income Tax Rate (Detail)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U.S. Federal statutory tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes</a></td>
<td class="nump">5.90%<span></span>
</td>
<td class="nump">5.70%<span></span>
</td>
<td class="nump">5.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research credit</a></td>
<td class="nump">0.90%<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
<td class="nump">0.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glyc_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent', window );">Orphan drug credit</a></td>
<td class="nump">6.60%<span></span>
</td>
<td class="nump">9.80%<span></span>
</td>
<td class="nump">8.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent', window );">Other</a></td>
<td class="num">(0.30%)<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(34.10%)<span></span>
</td>
<td class="num">(37.60%)<span></span>
</td>
<td class="num">(36.20%)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to orphan drug tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140248072016392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research and License Agreements (Details) - Apollomics, Inc. - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glyc_ArrangementsAndNonarrangementTransactionsLineItems', window );"><strong>Research and License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glyc_RevenueReceivedFromSaleOfClinicalSupplies', window );">Revenue from sale of clinical supplies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glyc_UpFrontPaymentReceived', window );">Up-front payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glyc_MilestoneRevenueRecognized', window );">Milestone revenue recognized based on achievement of certain clinical and regulatory events</a></td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=glyc_ApollomicMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glyc_ArrangementsAndNonarrangementTransactionsLineItems', window );"><strong>Research and License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glyc_DevelopmentAndRegulatoryApprovalMilestonesClinicalAndRegulatoryEvents', window );">Milestones based on achievement of certain clinical and regulatory events</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glyc_AchievementOfSpecifiedNetSalesThresholdsForAllLicensedProducts', window );">Milestone payment upon achievement of specified net sales thresholds for all licensed products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 105.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glyc_TieredPercentageOfAnnualNetSales', window );">Tiered percentage of annual net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_AchievementOfSpecifiedNetSalesThresholdsForAllLicensedProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue to be received upon the achievement of specified net sales thresholds for all licensed products.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_AchievementOfSpecifiedNetSalesThresholdsForAllLicensedProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_ArrangementsAndNonarrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_ArrangementsAndNonarrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_DevelopmentAndRegulatoryApprovalMilestonesClinicalAndRegulatoryEvents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of development and regulatory specific approval milestones based on achievement of certain clinical and regulatory events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_DevelopmentAndRegulatoryApprovalMilestonesClinicalAndRegulatoryEvents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_MilestoneRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The milestone revenue recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_MilestoneRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_RevenueReceivedFromSaleOfClinicalSupplies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue from the sale of clinical supplies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_RevenueReceivedFromSaleOfClinicalSupplies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_TieredPercentageOfAnnualNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entitled royalty payments to be received based on a tiered percentage of annual net sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_TieredPercentageOfAnnualNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_UpFrontPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of up-front payment received under terms of the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_UpFrontPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=glyc_ApollomicMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=glyc_ApollomicMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140248078554440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Defined Contribution Plan Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Company matching contribution percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Employer match contribution</a></td>
<td class="nump">$ 270,000<span></span>
</td>
<td class="nump">$ 252,000<span></span>
</td>
<td class="nump">$ 219,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Defined Contribution Plan Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Percent of employee contributions the company contributes a matching contribution</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>glyc-20211231x10k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:glyc="http://glyc.com/20211231"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="glyc-20211231.xsd" xlink:type="simple"/>
    <context id="As_Of_12_31_2021_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_D-pk4UYBwUG2J1DzykZ-HQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_TaxCreditCarryforwardAxis_us-gaap_GeneralBusinessMember_ecyj2U3Yt0Wb9cFTtDT3zQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:GeneralBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_1_1_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_glyc_AtMarketOffering2020Member_G7FlJg156E25J7h_zCeUTQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">glyc:AtMarketOffering2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-01</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_glyc_AtMarketOffering2017Member_MrvCJyh9ZEiM2EnDxi7KcA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">glyc:AtMarketOffering2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_cJJA3MCcxUCEbi4HdRpkhQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_7RS26_kETEqvpbTdEEcRHQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_bpFOniAZWESSLirIldcb9A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_fkG-U4OFgECm1zMTvyySFw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_9jiZRJgwUkmiTr7-zEU_pg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ZGf_JC8_7kO1YJVHBI1tHQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_hWu3exZUdEGAkwWw4npmMw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_YBdCsD1cyEWKXTeBpB1Qvw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_T9wbnfgz4EGnt4Ls-f124g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_JRdAbPca-UyPJvyJT5-3gQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_y9GDd_Gl4EG3z9w6EbLWoQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Aswh0QD8T06Z70c7oH6rxw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_glyc_AtMarketOffering2020Member_s7mbdwTmt0uPTw6bugEC2A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">glyc:AtMarketOffering2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_glyc_AtMarketOffering2017Member_m0ia7emTp0-S4cX7E9JaOQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">glyc:AtMarketOffering2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_0GYTC9bcFEKmU7vQ3oHIOA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_NttqVJp3_kWhhS50-PEXsg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityIncentivePlan2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member_qc5DeeGdL02LALGoxVJG1g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:StockIncentivePlan2003Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member_CPK9V-Op3UaIxCwH7D8lOQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:StockIncentivePlan2003Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_NxJ0kAmhLEq77boNzSrSDA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_6XsGrPnc8UiemnfhfN3QiA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityIncentivePlan2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_8_1_2021_To_8_31_2021_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_BlzQN5DfO0-Ob94oAMtNUQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="Duration_8_1_2021_To_8_31_2021_us-gaap_AwardTypeAxis_glyc_StockOptionsVestingBasedOnPerformanceMember_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_1HlplHgnqkyMSMXLECvRKw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">glyc:StockOptionsVestingBasedOnPerformanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="As_Of_1_31_2020_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_1T-jaCj3OkSylxW_fFHbkQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityInducementPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_1_31_2022_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_kGIqsGlMMESnv3YKbnouEg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_1_31_2020_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_OL9RAaPvWESWUYV6Drys3g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_v6BAgvQ6UUWIq_blSFIw4Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityIncentivePlan2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_TvjyyCwqk0mi8fnukedXiQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityIncentivePlan2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_LNH3eNmn5kWst66eRhnJGQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityIncentivePlan2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_8_1_2021_To_8_31_2021_us-gaap_AwardTypeAxis_glyc_StockOptionsVestingBasedOnPerformanceMember_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_us-gaap_VestingAxis_glyc_VestingUponFirstCommercialSaleMember_vwx6019QKE62DfP2NevoGw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">glyc:StockOptionsVestingBasedOnPerformanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityInducementPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">glyc:VestingUponFirstCommercialSaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="Duration_8_1_2021_To_8_31_2021_us-gaap_AwardTypeAxis_glyc_StockOptionsVestingBasedOnPerformanceMember_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_us-gaap_VestingAxis_glyc_VestingUponFDApprovalMember_1pzmNqmNIEmcFmcgorK24A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">glyc:StockOptionsVestingBasedOnPerformanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityInducementPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">glyc:VestingUponFDApprovalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_rwWrHnExKUCRbPb1Yq_1sA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:StockIncentivePlan2003Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_cofTMv8PCkK6kTIv_T7Wfg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:StockIncentivePlan2003Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_CA7rUR2n0UOR1-1JwC42kw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityIncentivePlan2013Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_oJ50QEhRZ06VPJ26jZEX3Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityIncentivePlan2013Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_9_1_2019_To_9_30_2019_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_tVHL8khK70GIJ-0r9ACJmA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityIncentivePlan2013Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="Duration_9_1_2019_To_9_30_2019_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_f8x-KvJQqk2NsjV18XCxTA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityIncentivePlan2013Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_1_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_LrXUfN_p-k2RD7cVXcpvfg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityIncentivePlan2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="Duration_9_1_2019_To_9_30_2019_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_GTVLQ6MzkE-5qigN7ZgeAg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityIncentivePlan2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_5_31_2016_srt_StatementGeographicalAxis_glyc_RockvilleMarylandMember_pHaqdBt7jEqRRIagvedypQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">glyc:RockvilleMarylandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-05-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_glyc_AtMarketOffering2020Member_-Fh8SrRC9kSsK069fXrH7w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">glyc:AtMarketOffering2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_glyc_AtMarketOffering2020Member_3hZx0NV1dUGxHj4ixh_xdQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">glyc:AtMarketOffering2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_glyc_AtMarketOffering2017Member_xegFN2MRVUeT2e9ks4eOqg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">glyc:AtMarketOffering2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_caWo07x0RkeYTz7JqqtihQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_XpvrdhTYnU29K3NXwMZg1w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_VeLLEDcIU0adJ4R_8YWwWQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_nwn-Uhn-HEykFqNtdjyqYA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_glyc_LaboratoryEquipmentMember_18gz3PWP5EGrxYtLQQjCmA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">glyc:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_S4Ib7npi4k2n67LEOrpyzw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_Ct0n8oNDQk-VdEoHy-ji7Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_MyBLeUpbCEad5R76PvA7Qw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_NuJWpFqva06fY6gG06su4A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_glyc_LaboratoryEquipmentMember_ZNg--URu-Um0dMbV5peuIw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">glyc:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_vsNg25IaXU2FJMsaQjaLLw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_7L-ZBeUo20ymuDm-db_BBA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_F-fa25zb1EKNL4wYhdv86w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_mVfAbQ5Nbkmu-wiL5cukOg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_glyc_LaboratoryEquipmentMember_nghKysTWSECvGe85266cdw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">glyc:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member_63yRM8kz2kC7BUq4_p_EHA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:StockIncentivePlan2003Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member_5mpVmM87DESzmaMO4y48HQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:StockIncentivePlan2003Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_8PxguNi7E0SE41ALnvi46Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityIncentivePlan2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_glyc_FederalAndStateAuthoritiesMember_onB_QxVk6kiCCtMYcUAFbg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">glyc:FederalAndStateAuthoritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_j3ehB3FRnke0I31qV9waCw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_s0Ld-3ryuEyoCl6QFxcQJQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_u9sxIh2gcUepx9OR8uIffA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_jja2ssufsk-400-VxFX0dA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_xN1YQshF5Eu9AMf6bQK4Kw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_bi2yzHjMgEqMF9n2Whpj0Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityIncentivePlan2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_hGgbCUWxnEO5H7nrY_ZOdA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityIncentivePlan2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_K6ogEy0tQUqO5CmxYBaQzw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_F6fULr1eMk6oFlHq__Rahw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityIncentivePlan2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_GhGdoDUAg0O8Z5VKpubXGw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_Bhd-nQulWU6ZbQQpkblCKw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MaximumMember_w9j8fZvT2UmDwuBnDsgAcw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MaximumMember_dvu4YMBVCkmKgIY5AJuxZA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2019_lBnwqvQJ-keVmMK3ebV7mA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_LWXbJD-mPkKObqFgUzRVCw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_z9rHn4j9ykiEqhZQISwvUg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_95OGnpM2iEC95hp3bmUctw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_IVVJKafY3kC3Yl795hDR_Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_f69ARavam0CDVS574-bG4A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_glyc_EmployeeStockOptionsAndRestrictedStockUnitsMember_XfZ7v3VAVk-r9VvuNg_XkA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">glyc:EmployeeStockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_glyc_EmployeeStockOptionsAndRestrictedStockUnitsMember_13b9WUxP7EmEaDz7Hl3AmA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">glyc:EmployeeStockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_glyc_EmployeeStockOptionsAndRestrictedStockUnitsMember_Iay9lDc4RUKcxJLhHUjHTg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">glyc:EmployeeStockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_-ABYVM1ePU6I7iAmO9SKmA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_el_OTs7LDkKYMO80TqWrEQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_6th964nOQ0eXBwdN5dw1YA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_z6e36_7PHUuO7wy1SUfrUg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_To7IkJ452EedOpj-Vpzb4Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_rmnCOBDJHkyNTT0GXfj6Mg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_srt_CounterpartyNameAxis_glyc_ApollomicMember__UsntURv-UWFpyJ1frsxHw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">glyc:ApollomicMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Ci6hS_fKd0SPY1WJAb_gGg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_w7tJ7ePME0abPNOD4nmo0g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_5fUBPR76oEmKbes-wtXqbw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cGTT67gulkyrZ4UjnAS9fA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_LwiWCcw92Ui_-9wG0O1diw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_rTR9aq2hpUuLpaRVLeM3fw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_8_1_2021_To_8_31_2021_us-gaap_AwardTypeAxis_glyc_StockOptionsVestingBasedOnServiceMember_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_pYIDtpqKaEq0Rg2wBD-AaA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">glyc:StockOptionsVestingBasedOnServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_glyc_StockOptionsVestingBasedOnPerformanceMember_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_fMP2VYCGhESofSQXDZURMQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">glyc:StockOptionsVestingBasedOnPerformanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member_jeH3ukS87UGj2TpOqDjAFA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:StockIncentivePlan2003Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_eZd6RRkvHUKXyt8ofzDQvA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityIncentivePlan2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_1_31_2020_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_Ni5UYq-FH06wJXsy0UsclA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityInducementPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_glyc_ApollomicMember_u1SJvvGvK0azW3aP0YW7WQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">glyc:ApollomicMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_1_9_2014_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_d0xG-7CT90iIt0iDg2j1hA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityIncentivePlan2013Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-01-09</instant>
        </period>
    </context>
    <context id="Duration_9_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_glyc_ApollomicMember_fv4inACjoUWDFNulm8LqCA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">glyc:ApollomicMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_n4dAyZdoqEGSie7qc7FpOQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_pmIpEVmd-kmwrLI0XOvIXQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_glyc_AtMarketOffering2020Member_MXBe8LOc-0ysVhlt9Db4Nw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">glyc:AtMarketOffering2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_10_7_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_glyc_AtMarketOffering2020Member_d7OWn4p530G-EwtpM2jaYA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">glyc:AtMarketOffering2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-07</instant>
        </period>
    </context>
    <context id="As_Of_10_7_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_glyc_AtMarketOffering2020Member_OCkznGqV5UKSXhPF0KDe9w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">glyc:AtMarketOffering2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-07</instant>
        </period>
    </context>
    <context id="As_Of_9_28_2017_srt_RangeAxis_srt_MaximumMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_glyc_AtMarketOffering2017Member_1BZR7Z0Sy0OeJz_78Y1Cmg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">glyc:AtMarketOffering2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-09-28</instant>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_srt_CounterpartyNameAxis_glyc_ApollomicMember_srt_RangeAxis_srt_MaximumMember_jz80Uqp0xkifz7ggXf9mng">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">glyc:ApollomicMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021__Tn0d_2t2kmK0aVp6UxXyQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_2_28_2022_D_WA6nW5zUak74Vcq9-xqg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
        </entity>
        <period>
            <instant>2022-02-28</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <unit id="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Standard_pure_o6l_rGctYUCSP0KoHptHcQ">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Standard_lease_pZ3IxEbMMU6Abz8KmKdkfQ">
        <measure>glyc:lease</measure>
    </unit>
    <unit id="Unit_Standard_item_g-Qg15KDVUyxut40CeCIjQ">
        <measure>glyc:item</measure>
    </unit>
    <unit id="Unit_Standard_installment_ezhGoeeUrke0O6iEcwxJow">
        <measure>glyc:installment</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_6ZVfdDCn5UCsvmo46quH_A">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Standard_segment_SDPUnB8SLEWaCbvZFtu_Hw">
        <measure>glyc:segment</measure>
    </unit>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg"
      id="Hidden_AohGR0nW002QcT8etMek_g"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug"
      id="Hidden_lfO8cH2MMk2_I8IAXtcv_A"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug"
      decimals="INF"
      id="Hidden_MfMzt5EkcE6WyYk_4iXzTA"
      unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg"
      decimals="INF"
      id="Hidden_Us4mRLs5Bk2WaaRS3U7X_A"
      unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA">0</us-gaap:PreferredStockSharesOutstanding>
    <dei:DocumentTransitionReport
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      id="Hidden_FTQh-1T6wkWx-NAQScPX7w">false</dei:DocumentTransitionReport>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg"
      id="Hidden_1YfPvGN8zkuxUetSrMELxA"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug"
      id="Hidden_kVVzvEvEd0Oo7zjJJdtzug"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_rwWrHnExKUCRbPb1Yq_1sA"
      decimals="INF"
      id="Hidden_UfZmMD43P0CtU_nlwGEAYQ"
      unitRef="Unit_Standard_pure_o6l_rGctYUCSP0KoHptHcQ">0.02083</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_CA7rUR2n0UOR1-1JwC42kw"
      decimals="INF"
      id="Hidden_MpFfxPM_9Uq0Hhwoua9x4Q"
      unitRef="Unit_Standard_pure_o6l_rGctYUCSP0KoHptHcQ">0.02083</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member_qc5DeeGdL02LALGoxVJG1g"
      decimals="INF"
      id="Hidden_CPAQxqLmSEmNCmGKblFleQ"
      unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA">93465</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <dei:DocumentAnnualReport
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      id="Hidden_rd4W_6vNeUy0QPLJGSkzqw">true</dei:DocumentAnnualReport>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      id="Tc_bn5rYJWae0SuCoIaQ0T21w_1_1">0001253689</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      id="Tc_zNAgcWt2MUaqIOR4CXpFvA_2_1">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      id="Tc_rDB8md6t7kWgYTo0G7uf1Q_3_1">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      id="Tc_7iMRKNx_nEOVEGnQzUcNUA_4_1">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      id="Tc_IhPCXx0VSkqBfTEaAdBvgQ_5_1">false</dei:AmendmentFlag>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_IVVJKafY3kC3Yl795hDR_Q"
      decimals="-5"
      id="Hidden_PjW0IYReJEOBmlkEA9fwAA"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_z9rHn4j9ykiEqhZQISwvUg"
      decimals="-5"
      id="Hidden_0K-cDCJPGE66OfPYLaO75Q"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_nwn-Uhn-HEykFqNtdjyqYA"
      id="Hidden_0ma8_vtK80W6jIJz3LC8HQ">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_f69ARavam0CDVS574-bG4A"
      decimals="-5"
      id="Hidden_SlkqXUTa902BN1_lOh-bNQ"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_95OGnpM2iEC95hp3bmUctw"
      decimals="-5"
      id="Hidden_J0_R-a98aUG0UaJFpC9ytw"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_IVVJKafY3kC3Yl795hDR_Q"
      decimals="-5"
      id="Hidden_pp31TbLqG02QmTAfILU9Ng"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_z9rHn4j9ykiEqhZQISwvUg"
      decimals="-5"
      id="Hidden_aHGqTOTKFkSZ-89kVrt_QQ"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      id="Hidden_jhM2PXDc_EWMY9qaiYQkSQ">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_9_1_2019_To_9_30_2019_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_f8x-KvJQqk2NsjV18XCxTA"
      decimals="4"
      id="Hidden_PGLZbIA_j0-ItwYMfmgcfA"
      unitRef="Unit_Standard_pure_o6l_rGctYUCSP0KoHptHcQ">0.3330</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_9_1_2019_To_9_30_2019_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_tVHL8khK70GIJ-0r9ACJmA"
      decimals="4"
      id="Hidden_BnTvpBXF9EKtCoC_jLU41A"
      unitRef="Unit_Standard_pure_o6l_rGctYUCSP0KoHptHcQ">0.6670</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member_qc5DeeGdL02LALGoxVJG1g"
      decimals="2"
      id="Hidden_fSABMxeS7UGMQu4eqOoECg"
      unitRef="Unit_Divide_USD_shares_6ZVfdDCn5UCsvmo46quH_A">2.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_1_1_2020_To_1_31_2020_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_Ni5UYq-FH06wJXsy0UsclA"
      decimals="2"
      id="Hidden_CUsjKSRwVk28fq-bDbXrTw"
      unitRef="Unit_Standard_pure_o6l_rGctYUCSP0KoHptHcQ">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg"
      decimals="INF"
      id="Hidden_LKZji1LDq0-yY11lTQsw3g"
      unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA">52313894</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug"
      decimals="INF"
      id="Hidden_ATYOkIk1MEWEdr2__-2oAw"
      unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA">49017622</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:LeasePracticalExpedientLessorSingleLeaseComponent
      contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg"
      id="Hidden_FRgasz_JB0WJUBzD7HF5EA">true</us-gaap:LeasePracticalExpedientLessorSingleLeaseComponent>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToTerminate
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      id="Hidden_1CXabvkwwUuyuzuDaxMsGQ">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToTerminate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_8_1_2021_To_8_31_2021_us-gaap_AwardTypeAxis_glyc_StockOptionsVestingBasedOnPerformanceMember_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_us-gaap_VestingAxis_glyc_VestingUponFDApprovalMember_1pzmNqmNIEmcFmcgorK24A"
      decimals="4"
      id="Hidden_wFFEp6_-yEedIq15Qcrr0w"
      unitRef="Unit_Standard_pure_o6l_rGctYUCSP0KoHptHcQ">0.0500</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_8_1_2021_To_8_31_2021_us-gaap_AwardTypeAxis_glyc_StockOptionsVestingBasedOnPerformanceMember_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_us-gaap_VestingAxis_glyc_VestingUponFirstCommercialSaleMember_vwx6019QKE62DfP2NevoGw"
      decimals="4"
      id="Hidden_Asb0-jwP3ku8JnmG256I7Q"
      unitRef="Unit_Standard_pure_o6l_rGctYUCSP0KoHptHcQ">0.0500</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      decimals="2"
      id="Hidden_gp9IuoM4PUq4Jbf5O9pHjA"
      unitRef="Unit_Divide_USD_shares_6ZVfdDCn5UCsvmo46quH_A">-1.23</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2020_To_12_31_2020_n4dAyZdoqEGSie7qc7FpOQ"
      decimals="2"
      id="Hidden_Jnxrdg2Yn0eKClwdHM9Lig"
      unitRef="Unit_Divide_USD_shares_6ZVfdDCn5UCsvmo46quH_A">-1.12</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2019_To_12_31_2019_pmIpEVmd-kmwrLI0XOvIXQ"
      decimals="2"
      id="Hidden_q-I2yQGv7E6NBmp35fa9Vg"
      unitRef="Unit_Divide_USD_shares_6ZVfdDCn5UCsvmo46quH_A">-1.34</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      decimals="INF"
      id="Hidden_swbcvcGXEUi9_zTi-LxYfg"
      unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA">51453204</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2020_To_12_31_2020_n4dAyZdoqEGSie7qc7FpOQ"
      decimals="INF"
      id="Hidden_xmX3kUCKa0WljNSAu7PGyw"
      unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA">45721139</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2019_To_12_31_2019_pmIpEVmd-kmwrLI0XOvIXQ"
      decimals="INF"
      id="Hidden_aKsQ3aGgBUW6Oqk4LHr7uw"
      unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA">43254782</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <dei:DocumentType
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      id="Narr_Mvgk89Me4UyLSoNgypOeRA">10-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      id="Narr_2Pb9bzYoQEaSPp8E3Ndjzw">2021-12-31</dei:DocumentPeriodEndDate>
    <dei:EntityFileNumber
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      id="Narr_n7t3DOrsp0mryWYXOlvEkA">001-36177</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      id="Narr_MRseQ0peM0G9Hq2hea6V4w">GlycoMimetics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      id="Tc_-cSm5UjVEEKp6HAtKvtphQ_1_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      id="Tc_ARbYdd5ivE-tMYgWuTbiyQ_1_1">06-1686563</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      id="Narr_G99nmOirgkSvBSeHlUxh1g">9708 Medical Center Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      id="Narr_uNpuW5IHrEOmGt0_teMvQA">Rockville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      id="Narr_w3DHqVJS_0yB99Pd3kRKkQ">MD</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      id="Tc_-MZDa9MEoEqkoaeidVHIwg_1_1">20850</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      id="Narr_5qk-2IMbKEWePj0g4TSTBg">240</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      id="Narr_VEMPwRNcykqlfMZe8yt2MQ">243-1201</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      id="Tc_nNNG2W3zmE2sp42KKEYcng_2_0">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      id="Tc_Sc-kimo2Kk-TM2gietEkFw_2_1">GLYC</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      id="Tc_kS8yI1gS50uAjNdtb2j1Mw_2_2">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      id="Narr_RFDAEPo4y0mI2zuvVqZC8Q">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      id="Narr_kg2zn7rgwkGShtYu7ddK4Q">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      id="Narr_f8w32ef9G0KMtyjQZFV7Ag">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      id="Narr_z3ku3-DIDkuZL8-v5hWDiw">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      id="Tc_Ziwsum_nYU-Vvvvi7U0e6A_2_0">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      id="Tc_VgD0cKybh0yNrMC9OnUUtw_2_3">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      id="Tc_816N5PBaNE-Nfd_Enyfr_g_3_3">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      id="Narr_HEi-2NYQSUmq0xAkZPH3tQ">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      id="Narr_ZfRjmE3eT0Oc9051v_AuFg">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="As_Of_6_30_2021__Tn0d_2t2kmK0aVp6UxXyQ"
      decimals="-5"
      id="Narr_2d-ZLaLElkWC_GVi_vbUkw"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">117500000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_2_28_2022_D_WA6nW5zUak74Vcq9-xqg"
      decimals="INF"
      id="Narr_OIGXmf0JX0CpvKlhHDZG6A"
      unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA">52313894</dei:EntityCommonStockSharesOutstanding>
    <dei:AuditorFirmId
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      id="Narr_4Slg_fVU-EytiXPY_k0oUQ">42</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      id="Narr_cJV2QEZ07UKTbDiqDnD9gw">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      id="Narr_i0l5_j19r0WsPd7wB0G_Lg">Baltimore, Maryland</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg"
      decimals="0"
      id="Tc_by2QtiKuDkSVuXHDMMwnAQ_5_3"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">90254890</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug"
      decimals="0"
      id="Tc_tQvRZLerRE21siH9XF5cZQ_5_6"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">137035017</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg"
      decimals="0"
      id="Tc_Nb7aD25F4EigTCpd0CMLwA_6_3"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">533804</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug"
      decimals="0"
      id="Tc_JrKRy_bbYEGdsoNJpSr6JA_6_6"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">1238328</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg"
      decimals="0"
      id="Tc_rRv0ssoPxUmxskDV58g52Q_7_3"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">90788694</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug"
      decimals="0"
      id="Tc_qc2YuRAXREuyof-U4h05ng_7_6"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">138273345</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg"
      decimals="0"
      id="Tc_A9o9FdFwVEGmxk8o9u6n6w_8_3"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">368842</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug"
      decimals="0"
      id="Tc_BUBK5pGw0EWLuPuJWZe31w_8_6"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">620673</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PrepaidExpenseNoncurrent
      contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg"
      decimals="0"
      id="Tc_1cfVjNmib0-05pDQ51hSPA_9_3"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">1560607</us-gaap:PrepaidExpenseNoncurrent>
    <us-gaap:PrepaidExpenseNoncurrent
      contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug"
      decimals="0"
      id="Tc_bbHz60duwEGz5iHrsBwK6A_9_6"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">1560607</us-gaap:PrepaidExpenseNoncurrent>
    <us-gaap:SecurityDeposit
      contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg"
      decimals="0"
      id="Tc_uyl6w_evmUikYBEOk0tWKg_10_3"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">52320</us-gaap:SecurityDeposit>
    <us-gaap:SecurityDeposit
      contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug"
      decimals="0"
      id="Tc_gCP3n0gjEkayeAdGukh39A_10_6"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">52320</us-gaap:SecurityDeposit>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg"
      decimals="0"
      id="Tc_LuX862F040KraDhijKslHA_11_3"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">1576185</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug"
      decimals="0"
      id="Tc_SDe6mNO2d0u6sTjleieTiQ_11_6"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">2325224</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg"
      decimals="0"
      id="Tc_hZVnorkaZkmjFOHM3CagVw_12_3"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">94346648</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug"
      decimals="0"
      id="Tc_YckmtgyC10aDsN-NpqvGhg_12_6"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">142832169</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg"
      decimals="0"
      id="Tc_XYi6wT4RP0esQ_JQLecblg_15_3"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">2107615</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug"
      decimals="0"
      id="Tc_4Qp9Lsag80e8_MwAoIFYWQ_15_6"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">2089939</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg"
      decimals="0"
      id="Tc_doiSQBQh90WkTM2PyHcacQ_16_3"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">8715368</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug"
      decimals="0"
      id="Tc_t-kAZiWOQUGx49FVj9BAEQ_16_6"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">9439881</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg"
      decimals="0"
      id="Tc_HvboW4tvz0OSc5P5eKjiuA_17_3"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">1001407</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug"
      decimals="0"
      id="Tc_34fIww0fVEaTjyv2BwMLsA_17_6"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">898549</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg"
      decimals="0"
      id="Tc_2V1zqfChMkaSXV_rzRnMRw_18_3"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">11824390</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug"
      decimals="0"
      id="Tc_6vyIoCHEwECh3f3jRRzzaw_18_6"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">12428369</us-gaap:LiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug"
      decimals="0"
      id="Tc_NAhSY_4B70iPyTkyMz7DMA_19_6"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">264329</us-gaap:AccountsPayableAndAccruedLiabilitiesNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg"
      decimals="0"
      id="Tc_CCGREFzy2U2XZaCDNomZOw_20_3"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">918607</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug"
      decimals="0"
      id="Tc_vfRxXgJtk0aykNY98Ua_tA_20_6"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">1920015</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg"
      decimals="0"
      id="Tc_p-NJQPEAYEyM__B9wlOuow_21_3"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">12742997</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug"
      decimals="0"
      id="Tc_5oDjAUJ3NkiR8f4gzyKxEg_21_6"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">14612713</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug"
      decimals="INF"
      id="Narr_nj1vUyoV5EWfHi97DKyN1g"
      unitRef="Unit_Divide_USD_shares_6ZVfdDCn5UCsvmo46quH_A">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg"
      decimals="INF"
      id="Narr_OudNm6G4GkSUHAvKNIyctg"
      unitRef="Unit_Divide_USD_shares_6ZVfdDCn5UCsvmo46quH_A">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug"
      decimals="INF"
      id="Narr_3vYQLT1WdUez0TrEstomGA"
      unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg"
      decimals="INF"
      id="Narr_nRKB-WRAmUqsjcXdqgGZ5w"
      unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug"
      decimals="INF"
      id="Narr_ni6GWRcDeUuQR47HvRro5Q"
      unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg"
      decimals="INF"
      id="Narr_ImlvWSzfVEqU7rR5VWI5-A"
      unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug"
      decimals="INF"
      id="Narr_YTY_QNy63UaLVyPzagFWjQ"
      unitRef="Unit_Divide_USD_shares_6ZVfdDCn5UCsvmo46quH_A">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg"
      decimals="INF"
      id="Narr_64SnlaWZgkmhymOyxp5CvA"
      unitRef="Unit_Divide_USD_shares_6ZVfdDCn5UCsvmo46quH_A">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug"
      decimals="INF"
      id="Narr_fYezCt7O2EWm0FY0r8ygZA"
      unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg"
      decimals="INF"
      id="Narr_xZXn3FMZ1UiQ5rNa_26NUA"
      unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg"
      decimals="INF"
      id="Narr_usd9cpTApEOfehB2SyMP7A"
      unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA">52313894</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug"
      decimals="INF"
      id="Narr_dZdUalxRdk6yj34Wdi-ySg"
      unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA">49017622</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg"
      decimals="0"
      id="Tc_FvmvCOaZ6kmLbNHyIslK8w_24_3"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">52314</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug"
      decimals="0"
      id="Tc_gLX4801x1EKJUw59YBtRZA_24_6"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">49018</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg"
      decimals="0"
      id="Tc_Zi2xaokhEEq5j8EFxacGuQ_25_3"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">454448327</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug"
      decimals="0"
      id="Tc_Bx3jBG8e1EWw06C8LsHbXQ_25_6"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">437639991</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg"
      decimals="0"
      id="Tc_0mWHa0PSoUO4-3GsBjCVMg_26_3"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">-372896990</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug"
      decimals="0"
      id="Tc_NNXTJwGetUu6KLhqfVIJ1w_26_6"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">-309469553</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg"
      decimals="0"
      id="Tc_rQBNZBradEq3QnNnU-QJdA_27_3"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">81603651</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug"
      decimals="0"
      id="Tc_CWzhYlxi90m3GIFCD2rRQA_27_6"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">128219456</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg"
      decimals="0"
      id="Tc_0bBZltap6kidj_RH5Ha6Ng_28_3"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">94346648</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug"
      decimals="0"
      id="Tc_w4dY8kuI2E6fXirwjSv30w_28_6"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">142832169</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      decimals="0"
      id="Tc_zaRYvZAgIES8NoHipTnUNw_3_3"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">1159767</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2020_To_12_31_2020_n4dAyZdoqEGSie7qc7FpOQ"
      decimals="0"
      id="Tc_kE3kRW4ZnE-FxAWlP8QYAw_3_6"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">10162935</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      decimals="0"
      id="Tc_TiOgAXnLUEqxEerF-ZmgKw_6_3"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">47491567</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_n4dAyZdoqEGSie7qc7FpOQ"
      decimals="0"
      id="Tc_M2yFlzi_l0eRho7Xng2N_A_6_6"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">44929198</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2019_To_12_31_2019_pmIpEVmd-kmwrLI0XOvIXQ"
      decimals="0"
      id="Tc_S_7frFW_5EC-Jq70V4-JIQ_6_9"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">47029264</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      decimals="0"
      id="Tc_bY66-cMqUUyvOXav0kqKxA_7_3"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">17115405</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_n4dAyZdoqEGSie7qc7FpOQ"
      decimals="0"
      id="Tc_AvffIQA89kiaV56IqDhUAA_7_6"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">16743127</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2019_To_12_31_2019_pmIpEVmd-kmwrLI0XOvIXQ"
      decimals="0"
      id="Tc_rkHyHLAOz0K5_jh1Zmk-ng_7_9"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">14360038</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      decimals="0"
      id="Tc_ArrIosHObU-yOuaaC0uF_g_8_3"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">64606972</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2020_To_12_31_2020_n4dAyZdoqEGSie7qc7FpOQ"
      decimals="0"
      id="Tc_oDzyMJxAXEa5WV3XNf6RNQ_8_6"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">61672325</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2019_To_12_31_2019_pmIpEVmd-kmwrLI0XOvIXQ"
      decimals="0"
      id="Tc_iJyzxgaD0EOI9Py5YdrBuA_8_9"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">61389302</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      decimals="0"
      id="Tc_D4iY-56O_0aW0h0cMzucAw_9_3"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">-63447205</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_n4dAyZdoqEGSie7qc7FpOQ"
      decimals="0"
      id="Tc_oJK1xAnLTEGkpAK_2QxBrA_9_6"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">-51509390</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2019_To_12_31_2019_pmIpEVmd-kmwrLI0XOvIXQ"
      decimals="0"
      id="Tc_LPZt9bFFFkawmHv3R2rBUA_9_9"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">-61389302</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      decimals="0"
      id="Tc_svoWm4oEt0ySfCJK8cwtBw_10_3"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">19768</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="Duration_1_1_2020_To_12_31_2020_n4dAyZdoqEGSie7qc7FpOQ"
      decimals="0"
      id="Tc_fCUEibIodkODC2t0CiCOMQ_10_6"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">482487</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="Duration_1_1_2019_To_12_31_2019_pmIpEVmd-kmwrLI0XOvIXQ"
      decimals="0"
      id="Tc_rQOSb82yTkqyCfBJwt725g_10_9"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">3497391</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <glyc:NetIncomeLossAndComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      decimals="0"
      id="Tc_1c710b9D0UKXoApMgKUexw_11_3"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">-63427437</glyc:NetIncomeLossAndComprehensiveIncomeNetOfTax>
    <glyc:NetIncomeLossAndComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2020_To_12_31_2020_n4dAyZdoqEGSie7qc7FpOQ"
      decimals="0"
      id="Tc_JnrnDb3FyUOT3zQQ0hMl7Q_11_6"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">-51026903</glyc:NetIncomeLossAndComprehensiveIncomeNetOfTax>
    <glyc:NetIncomeLossAndComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2019_To_12_31_2019_pmIpEVmd-kmwrLI0XOvIXQ"
      decimals="0"
      id="Tc_V1DVSfb-IE-OUbUcTJ2BNQ_11_9"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">-57891911</glyc:NetIncomeLossAndComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      decimals="2"
      id="Tc_TfSUmy1UNk-RmYNVQKyDOw_12_3"
      unitRef="Unit_Divide_USD_shares_6ZVfdDCn5UCsvmo46quH_A">-1.23</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2020_To_12_31_2020_n4dAyZdoqEGSie7qc7FpOQ"
      decimals="2"
      id="Tc_RC8_CfUQbUGGWOLmHUoVJw_12_6"
      unitRef="Unit_Divide_USD_shares_6ZVfdDCn5UCsvmo46quH_A">-1.12</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2019_To_12_31_2019_pmIpEVmd-kmwrLI0XOvIXQ"
      decimals="2"
      id="Tc__62Y06a_m0axHdQwYMageQ_12_9"
      unitRef="Unit_Divide_USD_shares_6ZVfdDCn5UCsvmo46quH_A">-1.34</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      decimals="0"
      id="Tc__cclYlbCaUCVRdNU6AnP0A_13_3"
      unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA">51453204</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2020_To_12_31_2020_n4dAyZdoqEGSie7qc7FpOQ"
      decimals="0"
      id="Tc_vPIiku-lOEmrdMglAMb5Dg_13_6"
      unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA">45721139</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2019_To_12_31_2019_pmIpEVmd-kmwrLI0XOvIXQ"
      decimals="0"
      id="Tc_RexWe72me0-yu2DNTzX9Tg_13_9"
      unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA">43254782</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Aswh0QD8T06Z70c7oH6rxw"
      decimals="INF"
      id="Tc_YgAHUPMJX0eHdPGkUigHQw_4_2"
      unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA">43160751</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Aswh0QD8T06Z70c7oH6rxw"
      decimals="0"
      id="Tc_jyHxijjC50W04y3W-BSLFg_4_5"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">43159</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_YBdCsD1cyEWKXTeBpB1Qvw"
      decimals="0"
      id="Tc_hSyFAVaKB0S86XTCeJmObg_4_8"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">405972075</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_hWu3exZUdEGAkwWw4npmMw"
      decimals="0"
      id="Tc_rM4bICRmHU6_VszBfk5EnA_4_11"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">-200550739</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2018_LWXbJD-mPkKObqFgUzRVCw"
      decimals="0"
      id="Tc_WRo2LydFekOa-04XUxAlQg_4_14"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">205464495</us-gaap:StockholdersEquity>
    <glyc:StockIssuedDuringPeriodSharesStockOptionsAndRestrictedStockUnitsVesting
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_rTR9aq2hpUuLpaRVLeM3fw"
      decimals="INF"
      id="Tc_WkcXO9ZOBEWWKCyLCMPRSg_5_2"
      unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA">306182</glyc:StockIssuedDuringPeriodSharesStockOptionsAndRestrictedStockUnitsVesting>
    <glyc:StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsVesting
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_rTR9aq2hpUuLpaRVLeM3fw"
      decimals="0"
      id="Tc_MMwfpZxQC0SHUso4-jNVXA_5_5"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">306</glyc:StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsVesting>
    <glyc:StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsVesting
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_5fUBPR76oEmKbes-wtXqbw"
      decimals="0"
      id="Tc_TzQDDAVdB0WtMFq0td59HQ_5_8"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">412607</glyc:StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsVesting>
    <glyc:StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsVesting
      contextRef="Duration_1_1_2019_To_12_31_2019_pmIpEVmd-kmwrLI0XOvIXQ"
      decimals="0"
      id="Tc_UdjLNPygeU2ldxsMlPzAXA_5_14"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">412913</glyc:StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsVesting>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_5fUBPR76oEmKbes-wtXqbw"
      decimals="0"
      id="Tc_5Z7G7HfQa06wyyyxzwY0zg_6_8"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">6215090</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2019_To_12_31_2019_pmIpEVmd-kmwrLI0XOvIXQ"
      decimals="0"
      id="Tc_SqNTp7ratE-febH6uRDxqg_6_14"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">6215090</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_u9sxIh2gcUepx9OR8uIffA"
      decimals="0"
      id="Tc_-AuQzHswf0a8PelWqbAZmg_7_11"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">-57891911</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2019_To_12_31_2019_pmIpEVmd-kmwrLI0XOvIXQ"
      decimals="0"
      id="Tc_9AqvEFOgT0q5vDoSDhIm3w_7_14"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">-57891911</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_y9GDd_Gl4EG3z9w6EbLWoQ"
      decimals="INF"
      id="Tc_2UuFdTxYokmLm_QqeKmzbw_8_2"
      unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA">43466933</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_y9GDd_Gl4EG3z9w6EbLWoQ"
      decimals="0"
      id="Tc_MANB68xq1U6ofkWgD2HPBA_8_5"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">43465</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ZGf_JC8_7kO1YJVHBI1tHQ"
      decimals="0"
      id="Tc_r8bnXz674kOlp9nepBg4SQ_8_8"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">412599772</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_9jiZRJgwUkmiTr7-zEU_pg"
      decimals="0"
      id="Tc_7tTwUi3uvUSpXBx1ynTLQA_8_11"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">-258442650</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_lBnwqvQJ-keVmMK3ebV7mA"
      decimals="0"
      id="Tc_lLhO7dLpF0KZr0cVb7L0Ag_8_14"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">154200587</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_LwiWCcw92Ui_-9wG0O1diw"
      decimals="INF"
      id="Tc_hDnV7JbU5ESqNactCw8RNA_9_2"
      unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA">5161502</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_LwiWCcw92Ui_-9wG0O1diw"
      decimals="0"
      id="Tc_SkTxpRmyAEeM6kqIprVIMg_9_5"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">5163</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_w7tJ7ePME0abPNOD4nmo0g"
      decimals="0"
      id="Tc_y_T_L78YU0S8Z21Dhe_T2w_9_8"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">17819554</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2020_To_12_31_2020_n4dAyZdoqEGSie7qc7FpOQ"
      decimals="0"
      id="Tc_tTmvhaXsLU-IVwmUhExTdw_9_14"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">17824717</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <glyc:StockIssuedDuringPeriodSharesStockOptionsAndRestrictedStockUnitsVesting
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_LwiWCcw92Ui_-9wG0O1diw"
      decimals="INF"
      id="Tc_2o9OnVo68EOZfjiumEJVQg_10_2"
      unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA">389187</glyc:StockIssuedDuringPeriodSharesStockOptionsAndRestrictedStockUnitsVesting>
    <glyc:StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsVesting
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_LwiWCcw92Ui_-9wG0O1diw"
      decimals="0"
      id="Tc_lwHxPW6sPESN5GoTNBhLnA_10_5"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">390</glyc:StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsVesting>
    <glyc:StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsVesting
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_w7tJ7ePME0abPNOD4nmo0g"
      decimals="0"
      id="Tc_5adj2kvKWUC2-Es3mLa-vw_10_8"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">318907</glyc:StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsVesting>
    <glyc:StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsVesting
      contextRef="Duration_1_1_2020_To_12_31_2020_n4dAyZdoqEGSie7qc7FpOQ"
      decimals="0"
      id="Tc_q1G_HljOnUqc6N0aic-nQw_10_14"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">319297</glyc:StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsVesting>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_w7tJ7ePME0abPNOD4nmo0g"
      decimals="0"
      id="Tc_tqv-gUwy60uEKrhiHa7JmA_11_8"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">6901758</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2020_To_12_31_2020_n4dAyZdoqEGSie7qc7FpOQ"
      decimals="0"
      id="Tc_ZEIxhO4tS0aYlu860R9MjQ_11_14"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">6901758</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_s0Ld-3ryuEyoCl6QFxcQJQ"
      decimals="0"
      id="Tc_jBHmK4XKBUq_J8TtqRzPnA_12_11"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">-51026903</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_n4dAyZdoqEGSie7qc7FpOQ"
      decimals="0"
      id="Tc_of8a20Ul_UWzwZ9TZlAl_A_12_14"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">-51026903</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_JRdAbPca-UyPJvyJT5-3gQ"
      decimals="INF"
      id="Tc_hC-wdcinHEKkDCIAYJfp_g_13_2"
      unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA">49017622</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_JRdAbPca-UyPJvyJT5-3gQ"
      decimals="0"
      id="Tc_coDF9ej9eEaBEu8nNCY-oQ_13_5"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">49018</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_fkG-U4OFgECm1zMTvyySFw"
      decimals="0"
      id="Tc_mxJeHEUg2UqC3SgsacIF0Q_13_8"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">437639991</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_bpFOniAZWESSLirIldcb9A"
      decimals="0"
      id="Tc_ipTHaJu6xE-130z9V69Jpw_13_11"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">-309469553</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug"
      decimals="0"
      id="Tc_Ea2WQM-MvkigtjVQzsFpNA_13_14"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">128219456</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cGTT67gulkyrZ4UjnAS9fA"
      decimals="INF"
      id="Tc_0kN4UtnHo0SlGHksu-s7eQ_14_2"
      unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA">3092603</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cGTT67gulkyrZ4UjnAS9fA"
      decimals="0"
      id="Tc_X741DZ7RG0uSo0EKILia2w_14_5"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">3092</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Ci6hS_fKd0SPY1WJAb_gGg"
      decimals="0"
      id="Tc_yyMNQBqC1U2Np7vIlCWp6w_14_8"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">10696225</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      decimals="0"
      id="Tc_w4ElWbVrc0CTqjfj84saGQ_14_14"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">10699317</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <glyc:StockIssuedDuringPeriodSharesStockOptionsAndRestrictedStockUnitsVesting
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cGTT67gulkyrZ4UjnAS9fA"
      decimals="INF"
      id="Tc_J1qPY2IS90WMvx-C4g0_Dg_15_2"
      unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA">203669</glyc:StockIssuedDuringPeriodSharesStockOptionsAndRestrictedStockUnitsVesting>
    <glyc:StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsVesting
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cGTT67gulkyrZ4UjnAS9fA"
      decimals="0"
      id="Tc_ZKu6AtlFV0mSjvbUysZQ_Q_15_5"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">204</glyc:StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsVesting>
    <glyc:StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsVesting
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Ci6hS_fKd0SPY1WJAb_gGg"
      decimals="0"
      id="Tc_ShM7DxlmbUmDEehU0tXe6Q_15_8"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">24825</glyc:StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsVesting>
    <glyc:StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsVesting
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      decimals="0"
      id="Tc_xJouqrCfX0G7FgVm-OT3Yg_15_14"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">25029</glyc:StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsVesting>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Ci6hS_fKd0SPY1WJAb_gGg"
      decimals="0"
      id="Tc_zSy2HiUjv0GeApkO71dS9Q_16_8"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">6087286</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      decimals="0"
      id="Tc_b7o_uEKEN0eT3ojoYi5hcA_16_14"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">6087286</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_j3ehB3FRnke0I31qV9waCw"
      decimals="0"
      id="Tc_41Wt-RVZoUmeGzAuD23Lgg_17_11"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">-63427437</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      decimals="0"
      id="Tc_vkB52Igql0aB0cK4EY2iHQ_17_14"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">-63427437</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_T9wbnfgz4EGnt4Ls-f124g"
      decimals="INF"
      id="Tc_C_KF3OKmNUqm7n6C07sbUw_18_2"
      unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA">52313894</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_T9wbnfgz4EGnt4Ls-f124g"
      decimals="0"
      id="Tc_wu4zpKtE40q0MEZBojMqZQ_18_5"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">52314</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_7RS26_kETEqvpbTdEEcRHQ"
      decimals="0"
      id="Tc_8xLhl7mVi0eiV479pE48FA_18_8"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">454448327</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_cJJA3MCcxUCEbi4HdRpkhQ"
      decimals="0"
      id="Tc_tdKX1E3tKkiiHZbegt25IA_18_11"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">-372896990</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg"
      decimals="0"
      id="Tc_Nn4wuklaN0GEjN6bTJWpFw_18_14"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">81603651</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      decimals="0"
      id="Tc_Eb2sqi-IVk6uhbFN0hh8jA_4_3"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">-63427437</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_n4dAyZdoqEGSie7qc7FpOQ"
      decimals="0"
      id="Tc_6NnHvYkxY0eZqTEEJ5GR5w_4_6"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">-51026903</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2019_To_12_31_2019_pmIpEVmd-kmwrLI0XOvIXQ"
      decimals="0"
      id="Tc_MCEDZ3y3PE2mWB8OfPfR9A_4_9"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">-57891911</us-gaap:ProfitLoss>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      decimals="0"
      id="Tc_XR8e7zVYd0uBkwgl06Q8pg_6_3"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">264600</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2020_To_12_31_2020_n4dAyZdoqEGSie7qc7FpOQ"
      decimals="0"
      id="Tc_8P9aE0Cue0qQW7jI7s9RGw_6_6"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">270754</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2019_To_12_31_2019_pmIpEVmd-kmwrLI0XOvIXQ"
      decimals="0"
      id="Tc_90o3HzZgqkifu7rQTlDkEw_6_9"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">279234</us-gaap:Depreciation>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      decimals="0"
      id="Tc_abskKLhTfU-24JcA71XtbA_7_3"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">-2174</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      decimals="0"
      id="Tc_6ClQCohvgESC9POQbuzXuw_8_3"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">749039</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_n4dAyZdoqEGSie7qc7FpOQ"
      decimals="0"
      id="Tc_mRvkkGcO70-c-ld59DQTzQ_8_6"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">680845</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="Duration_1_1_2019_To_12_31_2019_pmIpEVmd-kmwrLI0XOvIXQ"
      decimals="0"
      id="Tc_1OtSdNyTOkOllBLW5Cpbbw_8_9"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">620068</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      decimals="0"
      id="Tc_gqRxtBLCbEGkVgi0W4uIjw_9_3"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">6087286</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2020_To_12_31_2020_n4dAyZdoqEGSie7qc7FpOQ"
      decimals="0"
      id="Tc_EqqaWGodIkm8zcCR6tt1IA_9_6"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">6901758</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2019_To_12_31_2019_pmIpEVmd-kmwrLI0XOvIXQ"
      decimals="0"
      id="Tc_kDk2ehfnZE-ZLahPmGQ3Lg_9_9"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">6215090</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      decimals="0"
      id="Tc_pgVRoW5r8Eql0fidm8Zz3Q_11_3"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">-704524</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2020_To_12_31_2020_n4dAyZdoqEGSie7qc7FpOQ"
      decimals="0"
      id="Tc_aeGguSLCO0-7OeVEINcV-A_11_6"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">-3087994</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2019_To_12_31_2019_pmIpEVmd-kmwrLI0XOvIXQ"
      decimals="0"
      id="Tc_dPbp7jW2gkqxiUhc8nLFYQ_11_9"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">2059260</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      decimals="0"
      id="Tc_HzkQqYAQKE-3B8B5-1xMuA_12_3"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">17676</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2020_To_12_31_2020_n4dAyZdoqEGSie7qc7FpOQ"
      decimals="0"
      id="Tc_dP4Dyfv8zEeFo5NKCGIAgA_12_6"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">654279</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2019_To_12_31_2019_pmIpEVmd-kmwrLI0XOvIXQ"
      decimals="0"
      id="Tc_N78nxfBibUqSftfTqXQohA_12_9"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">-1227919</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      decimals="0"
      id="Tc_Hs_-MgjfuUSMgYCPFnWRRQ_13_3"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">-988842</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="Duration_1_1_2020_To_12_31_2020_n4dAyZdoqEGSie7qc7FpOQ"
      decimals="0"
      id="Tc_EL1WzHOhIUi2IrlFa0NMgQ_13_6"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">993420</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="Duration_1_1_2019_To_12_31_2019_pmIpEVmd-kmwrLI0XOvIXQ"
      decimals="0"
      id="Tc_rLCrZDLznUGG2jOFC6rhuw_13_9"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">2709986</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <glyc:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      decimals="0"
      id="Tc_uBaqSGxsD0igK2SZC-a8Wg_14_3"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">-898550</glyc:IncreaseDecreaseInOperatingLeaseLiabilities>
    <glyc:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="Duration_1_1_2020_To_12_31_2020_n4dAyZdoqEGSie7qc7FpOQ"
      decimals="0"
      id="Tc_mXdPg-AIyUapmGIqpvq02A_14_6"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">-804078</glyc:IncreaseDecreaseInOperatingLeaseLiabilities>
    <glyc:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="Duration_1_1_2019_To_12_31_2019_pmIpEVmd-kmwrLI0XOvIXQ"
      decimals="0"
      id="Tc_xZJpylidN0G6-L4nPzaaoQ_14_9"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">-629427</glyc:IncreaseDecreaseInOperatingLeaseLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      decimals="0"
      id="Tc_lIxk8k6ntkq8Cx76xRnkiQ_15_3"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">-57489530</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2020_To_12_31_2020_n4dAyZdoqEGSie7qc7FpOQ"
      decimals="0"
      id="Tc_dtsxUEctVUqj7q6Tt5wrWg_15_6"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">-39241931</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2019_To_12_31_2019_pmIpEVmd-kmwrLI0XOvIXQ"
      decimals="0"
      id="Tc_PwWBK3MgHkq40dHLx33NuQ_15_9"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">-51984139</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      decimals="0"
      id="Tc_sr90-mbuekeDVfFxAPSjAA_18_3"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">14943</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2020_To_12_31_2020_n4dAyZdoqEGSie7qc7FpOQ"
      decimals="0"
      id="Tc_pHk2GD3H_0-SfTMlXbllEw_18_6"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">68507</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2019_To_12_31_2019_pmIpEVmd-kmwrLI0XOvIXQ"
      decimals="0"
      id="Tc_a-wPmgFj3Eeibih1oi5K-Q_18_9"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">144928</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      decimals="0"
      id="Tc_z6zpsdy4iUWdThSDsGCITA_19_3"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">-14943</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2020_To_12_31_2020_n4dAyZdoqEGSie7qc7FpOQ"
      decimals="0"
      id="Tc_dNKzmISC4EmnzZl7V1dulw_19_6"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">-68507</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2019_To_12_31_2019_pmIpEVmd-kmwrLI0XOvIXQ"
      decimals="0"
      id="Tc_XYLAHlr130a2d3zEwzj-7g_19_9"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">-144928</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      decimals="0"
      id="Tc_VhtVkuu9oEm1NIhzuTraQA_22_3"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">10699317</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2020_To_12_31_2020_n4dAyZdoqEGSie7qc7FpOQ"
      decimals="0"
      id="Tc_9xV53S_QaUGOMtEro9DVKQ_22_6"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">17824717</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      decimals="0"
      id="Tc_9RYsJm9zmUCtm-v_nGXUWw_23_3"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">25029</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="Duration_1_1_2020_To_12_31_2020_n4dAyZdoqEGSie7qc7FpOQ"
      decimals="0"
      id="Tc_PHMdVPUakk2lLqy7wFqD8Q_23_6"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">319297</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="Duration_1_1_2019_To_12_31_2019_pmIpEVmd-kmwrLI0XOvIXQ"
      decimals="0"
      id="Tc_Wx_Q7-TSCkyvoQj0xBCy8Q_23_9"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">412913</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      decimals="0"
      id="Tc_ZA6Rc8c0Ok2TjVioQ1pnjg_24_3"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">10724346</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2020_To_12_31_2020_n4dAyZdoqEGSie7qc7FpOQ"
      decimals="0"
      id="Tc_jtefA2tfgk6ocDGHJSzwrQ_24_6"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">18144014</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2019_To_12_31_2019_pmIpEVmd-kmwrLI0XOvIXQ"
      decimals="0"
      id="Tc_tfqkGP5YYkav4u1wGz61vw_24_9"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">412913</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      decimals="0"
      id="Tc_ibQsl8ixyUeur6gPoXmhtQ_25_3"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">-46780127</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2020_To_12_31_2020_n4dAyZdoqEGSie7qc7FpOQ"
      decimals="0"
      id="Tc_Wajq7EWswUuNLUgCUO8PWA_25_6"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">-21166424</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2019_To_12_31_2019_pmIpEVmd-kmwrLI0XOvIXQ"
      decimals="0"
      id="Tc_xDF8XbpEp0m6rhOHn0MfIA_25_9"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">-51716154</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug"
      decimals="0"
      id="Tc_pfSvQAMBzkG_v0i3NmStpw_26_3"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">137035017</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2019_lBnwqvQJ-keVmMK3ebV7mA"
      decimals="0"
      id="Tc_u1AhWvda9ECCG2ltb-zZBw_26_6"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">158201441</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2018_LWXbJD-mPkKObqFgUzRVCw"
      decimals="0"
      id="Tc_plQ5aT86oEWP4C3bwjtM8g_26_9"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">209917595</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg"
      decimals="0"
      id="Tc_oaJSlmfPO0yuALx52qY5cw_27_3"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">90254890</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug"
      decimals="0"
      id="Tc_VpquCqBlXEeWWdGNH3a1pA_27_6"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">137035017</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2019_lBnwqvQJ-keVmMK3ebV7mA"
      decimals="0"
      id="Tc_hlLMHMGTLEGy0NBtImOVQQ_27_9"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">158201441</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:NatureOfOperations
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      id="Tb_cqVj8YLk50uvSB74WZAuww">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;1. Description of the Business&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"&gt;GlycoMimetics, Inc. (the Company), a Delaware corporation headquartered in Rockville, Maryland, was incorporated in 2003. The Company is a clinical stage biotechnology company focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using its expertise in carbohydrate chemistry and knowledge of carbohydrate biology, the Company is developing a pipeline of proprietary glycomimetics that inhibit disease-related functions of carbohydrates, such as the roles they play in inflammation, cancer and infection.&lt;/p&gt;</us-gaap:NatureOfOperations>
    <us-gaap:SubstantialDoubtAboutGoingConcernTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      id="Tb_-onKBSKgeUGTMo1PLZqDig">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2. Going Concern&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"&gt;The accompanying financial statements have been prepared assuming that the Company will continue as a going concern within one year after the date that the financial statements are issued. During 2021, the Company incurred a net loss of $63.4 million and had net cash flows used in operating activities of $57.5 million. At December 31, 2021, the Company had $90.3 million in cash and cash equivalents and had no committed source of additional funding from either debt or equity financings. Management believes that given the Company&#x2019;s current cash position and forecasted negative cash flows from operating activities over the next twelve months, including the completion of its planned Phase 3 clinical trial of uproleselan, there is substantial doubt about its ability to continue as a going concern after the date that is one year from the date that these financial statements are issued, without obtaining additional financing or entering into another form of non-equity or debt arrangement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"&gt;The Company&#x2019;s ability to fund its operations is dependent upon management&#x2019;s plans, which include raising additional capital in the near term primarily through a combination of equity and debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements and in the longer term, from revenue related to product sales, to the extent its product candidates receive marketing approval and can be commercialized. There can be no assurances that new financings or other transactions will be available to us on commercially acceptable terms, or at all. Also, any collaborations, strategic alliances and marketing, distribution or licensing arrangements may require the Company to give up some or all of its rights to a product or technology, which in some cases may be at less than the full potential value of such rights. If the Company is unable to obtain additional capital, the Company will assess its capital resources and may be required to delay, reduce the scope of or eliminate some or all of our operations, which may have a material adverse effect on our business, financial condition, results of operations and ability to operate as a going concern.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"&gt;The financial statements do not include any adjustments that might be necessary if the Company is not able to continue as a going concern.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:SubstantialDoubtAboutGoingConcernTextBlock>
    <glyc:NetIncomeLossAndComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      decimals="-5"
      id="Narr_MFtCSh6uAkCws4bpJOkRBA"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">-63400000</glyc:NetIncomeLossAndComprehensiveIncomeNetOfTax>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      decimals="-5"
      id="Narr_DYWKn-RQmU2GOhHA7rY6rQ"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">-57500000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg"
      decimals="-5"
      id="Narr_1BRuhAWifEaQnXghrV2FmA"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">90300000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      id="Tb_PIyvbO9BwUmteXP95dQEvQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;3. Summary of Significant Accounting Policies&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Basis of Accounting&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"&gt;The accompanying financial statements were prepared based on the accrual method of accounting in accordance with U.S. generally accepted accounting principles (GAAP).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Segment Information&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"&gt;Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one segment, which is the identification and development of glycomimetic compounds.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Although actual results could differ from those estimates, management does not believe that such differences would be material.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"&gt;Cash and cash equivalents consist of investment in money market funds with commercial banks and financial institutions. The Company considers all investments in highly liquid financial instruments with an original maturity of three months or less at the date of purchase to be cash equivalents. Cash equivalents are stated at amortized cost, plus accrued interest, which approximates fair value.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Fair Value Measurements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"&gt;The Company&#x2019;s financial instruments include cash and cash equivalents. The fair values of the financial instruments approximated their carrying values at December 31, 2021 and 2020, due to their short-term maturities. The Company accounts for recurring and nonrecurring fair value measurements in accordance with ASC 820, &lt;i style="font-style:italic;"&gt;Fair Value Measurements&lt;/i&gt;. ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements. The ASC hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value, and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:24.5pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level 1&#x2014;Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:24.5pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level 2&#x2014;Fair value is determined by using inputs, other than Level 1 quoted prices, that are directly and indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models that can be corroborated by observable market data.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:24.5pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level 3&#x2014;Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity. In instances where the determination of the fair value measurement is based on inputs from different levels of fair value hierarchy, the fair value measurement will fall within the lowest level input that is significant to the fair value measurement in its entirety.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:6pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"&gt;The Company periodically evaluates financial assets and liabilities subject to fair value measurements to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC 820 hierarchy.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"&gt;The Company had no assets or liabilities that were measured using quoted prices for similar assets and liabilities or significant unobservable inputs (Level 2 and Level 3 assets and liabilities, respectively) either on a recurring or non-recurring basis as of December&#160;31, 2021 and 2020. The carrying value of cash held in money market funds of approximately $88.3 million and $135.0 million as of December&#160;31, 2021 and 2020, respectively, is included in cash and cash equivalents and approximates market values based on quoted market prices (Level 1 inputs). The Company did&#160;not transfer any assets measured at fair value on a recurring basis between levels during the&#160;years ended December 31, 2021 and 2020.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"&gt;Credit risk represents the risk that the Company would incur a loss if counterparties failed to perform pursuant to the terms of their agreements. Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. Cash and cash equivalents consist of investment in money market funds with major financial institutions in the United States. These deposits and funds may be redeemed upon demand and, therefore, bear minimal risk. The Company does not anticipate any losses on such balances.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Property and Equipment&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"&gt;Property and equipment are recorded at cost and depreciated on a straight-line basis over estimated useful lives ranging from &lt;span style="-sec-ix-hidden:Hidden_0ma8_vtK80W6jIJz3LC8HQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;three&lt;/span&gt;&lt;/span&gt; to seven years. Upon retirement or disposition of assets, the costs and related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the results of operations. Expenditures for repairs and maintenance are charged to operations as incurred; major replacements that extend the &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"&gt;useful life are capitalized. Depreciation and amortization are computed using the straight-line method over the following estimated useful lives:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="padding-left:40.5pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:82.39%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:51.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:46.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:46.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;ESTIMATED&#160;USEFUL&#160;LIVES&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:46.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;7 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:46.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;5 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Office equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:46.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;5 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Computer equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:46.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;5 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:46.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.6pt 0pt 0pt;"&gt;Shorter&#160;of&#160;lease&#160;term&#160;or&#160;useful&#160; life&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 6pt 0pt;"&gt;&lt;span style="font-size:1pt;font-style:italic;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 6pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"&gt;The Company periodically assesses the recoverability of the carrying value of its long-lived assets in accordance with the provisions of ASC 360, &lt;i style="font-style:italic;"&gt;Property, Plant, and Equipment&lt;/i&gt;. ASC 360 requires that long-lived assets and certain identifiable intangible assets be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of the long-lived asset is measured by a comparison of the carrying amount of the asset to future undiscounted net cash flows expected to be generated by the asset. If the carrying value exceeds the sum of undiscounted cash flows, the Company then determines the fair value of the underlying asset. Any impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the estimated fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value, less costs to sell. As of December&#160;31, 2021 and 2020, the Company determined that there were no impaired assets and it had no assets held for sale.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Revenue Recognition&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"&gt;The Company applies Accounting Standards Codification, or ASC, Topic 606, &lt;i style="font-style:italic;"&gt;Revenue from Contracts with Customers &lt;/i&gt;(Topic 606), to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. Under Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services in an amount that reflects the consideration which the entity expects to receive in exchange for those goods and services. To determine revenue recognition for arrangements that an entity determines are within the scope of Topic 606, the entity performs the following five steps: (i) identify the contract(s) with the customer(s); (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods and services it transfers to the customer. At contract inception, the Company assesses the goods or services promised within each contract that falls under the scope of Topic 606, determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"&gt;The Company enters into licensing agreements which are within the scope of Topic 606, under which it licenses certain of its drug candidates&#x2019; rights to third parties. The terms of these arrangements typically include payment of one or more of the following: non-refundable, up-front license fees; development, regulatory and commercial milestone payments; and royalties on net sales of the licensed product, if and when earned. See Note 11 for additional information regarding the Company&#x2019;s license agreements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt; In determining the appropriate amount of revenue to be recognized as it fulfills its obligation under each of its agreements, the Company performs the five steps under Topic 606 described above. As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price, which may include forecasted revenues, development timelines, reimbursement of personnel costs, discount rates and probabilities of technical and regulatory success.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Licensing of Intellectual Property: &lt;/i&gt;If the license to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"&gt;assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. The Company evaluates the measure of progress each reporting period, and, if necessary, adjusts the measure of performance and related revenue recognition.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Milestone Payments&lt;/i&gt;: At the inception of each arrangement that includes development milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal will not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such development milestones and any related constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration and other revenues and earnings in their period of adjustment.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Royalties&lt;/i&gt;: For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue from its license agreements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Manufacturing and Supply:&#160;&lt;/i&gt;The obligations under the Company&#x2019;s agreements may include clinical and commercial manufacturing products to be provided by the Company to the counterparty. The services are generally determined to be distinct from the other promises or performance obligations identified in the arrangement. The Company recognizes the transaction price allocated to these services as revenue at a point in time when transfer of control of the related products to the customer occurs.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Research and Development Costs&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"&gt;Except for payments made in advance of services, research and development costs are expensed as incurred. For payments made in advance, the Company recognizes research and development expense as the services are rendered. Research and development costs primarily consist of salaries and related expenses for personnel, laboratory supplies and raw materials, sponsored research, depreciation of laboratory facilities and leasehold improvements, and utilities costs related to research space. Other research and development expenses include fees paid to consultants and outside service providers including clinical research organizations and clinical manufacturing organizations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Accruals for Clinical Trial Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"&gt;Clinical trial costs primarily consist of expenses incurred under agreements with contract research organizations (CROs), investigative sites, laboratory testing expenses, data management and consultants that conduct the Company's clinical trials. Clinical trial expenses are a significant component of research and development expenses, and the Company outsources a significant portion of these clinical trial activities to third parties. The accrual for site and patient costs includes inputs such as estimates of patient enrollment, patient cycles incurred, clinical site activations, estimated project duration and other pass-through costs. These inputs are required to be estimated due to a lag in receiving the actual clinical information from third parties. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected on the balance sheets as a prepaid asset or accrued expenses. These third-party agreements are generally cancellable, and related costs are recorded as research and development expenses as incurred. Except for payments made in advance of services, clinical trial costs are expensed as incurred. Non-refundable advance clinical payments for goods or services that will be used or rendered for future research and development activities are recorded as a prepaid asset and recognized as expense as the related goods are delivered or the related services are performed. When evaluating the adequacy of the accrued expenses, management assessments include: (i) an evaluation by the project manager of the work that has been completed during the period; (ii) measurement of progress prepared internally and/or provided by the third-party service provider; (iii) analyses of data that justify the progress; and (iv)&#160;the Company&#x2019;s judgment. Significant judgments and estimates may be made in determining the accrued balances at the end of any reporting period. Actual results could differ from the estimates made. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"&gt;The Company&#x2019;s historical clinical accrual estimates have not been materially different from the actual costs. Clinical trial accruals that are due longer than one year are classified as noncurrent accrued expenses.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"&gt;Stock-based payments are accounted for in accordance with the provisions of ASC 718, &lt;i style="font-style:italic;"&gt;Compensation&#x2014;Stock Compensation&lt;/i&gt;. The fair value of stock-based payments is estimated, on the date of grant, using the Black-Scholes-Merton model. The resulting fair value is recognized ratably over the requisite service period, which is generally the vesting period of the option. The Company has elected to account for forfeitures as they occur.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"&gt;The Company has elected to use the Black-Scholes-Merton option pricing model to value any options granted. The Company will reconsider use of the Black-Scholes-Merton model if additional information becomes available in the future that indicates another model would be more appropriate or if grants issued in future periods have characteristics that prevent their value from being reasonably estimated using this model.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"&gt;A discussion of management&#x2019;s methodology for developing some of the assumptions used in the valuation model follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Expected Dividend Yield&lt;/i&gt;&#x2014;The Company has never declared or paid dividends and has no plans to do so in the foreseeable future.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Expected Volatility&#x2014;&lt;/i&gt;Volatility is a measure of the amount by which a financial variable such as share price has fluctuated (historical volatility) or is expected to fluctuate (expected volatility) during a period. Effective January 1, 2020, the Company bases the expected volatility on the historical volatility of the Company&#x2019;s publicly traded common stock. Prior to January 1, 2020, the Company utilized the historical volatilities of a peer group (e.g., several public entities of similar size, complexity, and stage of development), along with the Company&#x2019;s historical volatility since its initial public offering, to determine its expected volatility.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Risk-Free Interest Rate&lt;/i&gt;&#x2014;This is the U.S. Treasury rate for the week of each option grant during the year, having a term that most closely resembles the expected life of the option.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Expected Term&lt;/i&gt;&#x2014;This is a period of time that the options granted are expected to remain unexercised. Options granted have a maximum term of 10 years. The Company estimates the expected life of the option term to be 6.25 years. The Company uses a simplified method to calculate the average expected term.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"&gt;The Company accounts for income taxes using the asset and liability method in accordance with ASC 740,&lt;i style="font-style:italic;"&gt; Income Taxes&lt;/i&gt;. Deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and the financial reporting amounts at each year-end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. A valuation allowance is established when necessary to reduce deferred tax assets to the amount expected to be realized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"&gt;The Company accounts for uncertain tax positions pursuant to ASC 740. Financial statement recognition of a tax position taken or expected to be taken in a tax return is determined based on a more-likely-than-not threshold of that tax position being sustained. If the tax position meets this threshold, the benefit to be recognized is measured as the tax benefit having the highest likelihood of being realized upon ultimate settlement with the taxing authority. The Company recognizes interest accrued related to unrecognized tax benefits and penalties in the provision for income taxes.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Comprehensive Loss&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"&gt;Comprehensive loss comprises net loss and other changes in equity that are excluded from net loss. For the years ended December&#160;31, 2021, 2020 and 2019, the Company&#x2019;s net loss was equal to comprehensive loss and, accordingly, no additional disclosure is presented.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Adopted Accounting Standards&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"&gt;In December 2019, the FASB issued ASU 2019-12. ASU 2019-12 removes certain exceptions for recognizing deferred taxes for investments, performing intra-period allocation and calculating income taxes in interim periods. The ASU also adds guidance to reduce complexity in certain areas, including deferred taxes for goodwill and allocating taxes for members of a consolidated group. ASU 2019-12 was effective for all entities for fiscal years beginning after &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"&gt;December 15, 2020. As of January 1, 2021, the Company adopted the standard, which did not have a material impact on the Company's financial statements. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Accounting Standards Not Yet Adopted&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"&gt;With the exception of the new standard discussed above, there have been no new accounting pronouncements that have significance, or potential significance, to the Company&#x2019;s financial statements.&lt;/p&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      id="Tb_B10ID10pT0mYWwx3eDMUfA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Basis of Accounting&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"&gt;The accompanying financial statements were prepared based on the accrual method of accounting in accordance with U.S. generally accepted accounting principles (GAAP).&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      id="Tb_uFQFxn30g0q8UtN3l_Nt9g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Segment Information&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"&gt;Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one segment, which is the identification and development of glycomimetic compounds.&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      decimals="INF"
      id="Narr_lA0QHO9VH0OYxqkk4NDKaA"
      unitRef="Unit_Standard_segment_SDPUnB8SLEWaCbvZFtu_Hw">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:UseOfEstimates
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      id="Tb_8qQbnqaUVkOdxeUDEvaKgA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Although actual results could differ from those estimates, management does not believe that such differences would be material.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      id="Tb_Wp3UvkZT1EiCEguumypT9A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"&gt;Cash and cash equivalents consist of investment in money market funds with commercial banks and financial institutions. The Company considers all investments in highly liquid financial instruments with an original maturity of three months or less at the date of purchase to be cash equivalents. Cash equivalents are stated at amortized cost, plus accrued interest, which approximates fair value.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      id="Tb_ah5Hp_TPb0ScApbrClh8Kg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Fair Value Measurements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"&gt;The Company&#x2019;s financial instruments include cash and cash equivalents. The fair values of the financial instruments approximated their carrying values at December 31, 2021 and 2020, due to their short-term maturities. The Company accounts for recurring and nonrecurring fair value measurements in accordance with ASC 820, &lt;i style="font-style:italic;"&gt;Fair Value Measurements&lt;/i&gt;. ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements. The ASC hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value, and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:24.5pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level 1&#x2014;Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:24.5pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level 2&#x2014;Fair value is determined by using inputs, other than Level 1 quoted prices, that are directly and indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models that can be corroborated by observable market data.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:24.5pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level 3&#x2014;Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity. In instances where the determination of the fair value measurement is based on inputs from different levels of fair value hierarchy, the fair value measurement will fall within the lowest level input that is significant to the fair value measurement in its entirety.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:6pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"&gt;The Company periodically evaluates financial assets and liabilities subject to fair value measurements to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC 820 hierarchy.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"&gt;The Company had no assets or liabilities that were measured using quoted prices for similar assets and liabilities or significant unobservable inputs (Level 2 and Level 3 assets and liabilities, respectively) either on a recurring or non-recurring basis as of December&#160;31, 2021 and 2020. The carrying value of cash held in money market funds of approximately $88.3 million and $135.0 million as of December&#160;31, 2021 and 2020, respectively, is included in cash and cash equivalents and approximates market values based on quoted market prices (Level 1 inputs). The Company did&#160;not transfer any assets measured at fair value on a recurring basis between levels during the&#160;years ended December 31, 2021 and 2020.&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_f69ARavam0CDVS574-bG4A"
      decimals="-5"
      id="Narr_72j1wDV0wkyG7AOqi3laRA"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_95OGnpM2iEC95hp3bmUctw"
      decimals="-5"
      id="Narr_OwSJMj5hLUKbX2Rf3GfG0A"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_jja2ssufsk-400-VxFX0dA"
      decimals="-5"
      id="Narr_RrGyHkhNTEGhQh8kVev2eg"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">88300000</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_xN1YQshF5Eu9AMf6bQK4Kw"
      decimals="-5"
      id="Narr_KUzxn9cXykqFKUrEF0AUiQ"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">135000000.0</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      id="Tb_-FQp2mxlG0GlUCgUSGSt8g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"&gt;Credit risk represents the risk that the Company would incur a loss if counterparties failed to perform pursuant to the terms of their agreements. Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. Cash and cash equivalents consist of investment in money market funds with major financial institutions in the United States. These deposits and funds may be redeemed upon demand and, therefore, bear minimal risk. The Company does not anticipate any losses on such balances.&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      id="Tb_ubYMg7deDk28mr9l8uQa7w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Property and Equipment&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"&gt;Property and equipment are recorded at cost and depreciated on a straight-line basis over estimated useful lives ranging from &lt;span style="-sec-ix-hidden:Hidden_0ma8_vtK80W6jIJz3LC8HQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;three&lt;/span&gt;&lt;/span&gt; to seven years. Upon retirement or disposition of assets, the costs and related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the results of operations. Expenditures for repairs and maintenance are charged to operations as incurred; major replacements that extend the &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"&gt;useful life are capitalized. Depreciation and amortization are computed using the straight-line method over the following estimated useful lives:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="padding-left:40.5pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:82.39%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:51.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:46.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:46.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;ESTIMATED&#160;USEFUL&#160;LIVES&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:46.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;7 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:46.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;5 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Office equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:46.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;5 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Computer equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:46.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;5 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:46.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.6pt 0pt 0pt;"&gt;Shorter&#160;of&#160;lease&#160;term&#160;or&#160;useful&#160; life&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_Bhd-nQulWU6ZbQQpkblCKw"
      id="Narr_MlHxfMKUbkexiIAg6n7AOQ">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <glyc:ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      id="Tb_bnQ4jJJUhEShyoSUAxiZ5Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="padding-left:40.5pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:82.39%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:51.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:46.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:46.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;ESTIMATED&#160;USEFUL&#160;LIVES&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:46.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;7 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:46.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;5 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Office equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:46.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;5 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Computer equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:46.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;5 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:46.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.6pt 0pt 0pt;"&gt;Shorter&#160;of&#160;lease&#160;term&#160;or&#160;useful&#160; life&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</glyc:ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_XpvrdhTYnU29K3NXwMZg1w"
      id="Tc_lZCuRFcUekKqRhoF38mnjg_2_2">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_glyc_LaboratoryEquipmentMember_18gz3PWP5EGrxYtLQQjCmA"
      id="Tc_1HhmUeZzfEiqTFh9XoL_Gw_3_2">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_caWo07x0RkeYTz7JqqtihQ"
      id="Tc_i69j1PNf_0uUn5WCHafNsw_4_2">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_VeLLEDcIU0adJ4R_8YWwWQ"
      id="Tc_x1J3FDCPakSh88OJKr1tDA_5_2">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      id="Tb_kVTV7L88TE-w8lmxbyEU7Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 6pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"&gt;The Company periodically assesses the recoverability of the carrying value of its long-lived assets in accordance with the provisions of ASC 360, &lt;i style="font-style:italic;"&gt;Property, Plant, and Equipment&lt;/i&gt;. ASC 360 requires that long-lived assets and certain identifiable intangible assets be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of the long-lived asset is measured by a comparison of the carrying amount of the asset to future undiscounted net cash flows expected to be generated by the asset. If the carrying value exceeds the sum of undiscounted cash flows, the Company then determines the fair value of the underlying asset. Any impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the estimated fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value, less costs to sell. As of December&#160;31, 2021 and 2020, the Company determined that there were no impaired assets and it had no assets held for sale.&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <glyc:NumberOfLongLivedAssetsDeterminedToBeImpaired
      contextRef="Duration_1_1_2020_To_12_31_2020_n4dAyZdoqEGSie7qc7FpOQ"
      decimals="0"
      id="Narr_JYSW7gfZmkyoGWd11g48fg"
      unitRef="Unit_Standard_item_g-Qg15KDVUyxut40CeCIjQ">0</glyc:NumberOfLongLivedAssetsDeterminedToBeImpaired>
    <glyc:NumberOfLongLivedAssetsDeterminedToBeImpaired
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      decimals="0"
      id="Narr_MNmrhJT1-U-qVP_prrHkVw"
      unitRef="Unit_Standard_item_g-Qg15KDVUyxut40CeCIjQ">0</glyc:NumberOfLongLivedAssetsDeterminedToBeImpaired>
    <us-gaap:AssetsHeldForSaleNotPartOfDisposalGroup
      contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug"
      decimals="-5"
      id="Narr_s9Jti2ztxEan79ag2BzUSA"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">0</us-gaap:AssetsHeldForSaleNotPartOfDisposalGroup>
    <us-gaap:AssetsHeldForSaleNotPartOfDisposalGroup
      contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg"
      decimals="-5"
      id="Narr_cuMx20tRY0qK59joUD0JTw"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">0</us-gaap:AssetsHeldForSaleNotPartOfDisposalGroup>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      id="Tb_5S1U0jsALkOnKG0j-ki_bA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Revenue Recognition&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"&gt;The Company applies Accounting Standards Codification, or ASC, Topic 606, &lt;i style="font-style:italic;"&gt;Revenue from Contracts with Customers &lt;/i&gt;(Topic 606), to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. Under Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services in an amount that reflects the consideration which the entity expects to receive in exchange for those goods and services. To determine revenue recognition for arrangements that an entity determines are within the scope of Topic 606, the entity performs the following five steps: (i) identify the contract(s) with the customer(s); (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods and services it transfers to the customer. At contract inception, the Company assesses the goods or services promised within each contract that falls under the scope of Topic 606, determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"&gt;The Company enters into licensing agreements which are within the scope of Topic 606, under which it licenses certain of its drug candidates&#x2019; rights to third parties. The terms of these arrangements typically include payment of one or more of the following: non-refundable, up-front license fees; development, regulatory and commercial milestone payments; and royalties on net sales of the licensed product, if and when earned. See Note 11 for additional information regarding the Company&#x2019;s license agreements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt; In determining the appropriate amount of revenue to be recognized as it fulfills its obligation under each of its agreements, the Company performs the five steps under Topic 606 described above. As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price, which may include forecasted revenues, development timelines, reimbursement of personnel costs, discount rates and probabilities of technical and regulatory success.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Licensing of Intellectual Property: &lt;/i&gt;If the license to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"&gt;assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. The Company evaluates the measure of progress each reporting period, and, if necessary, adjusts the measure of performance and related revenue recognition.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Milestone Payments&lt;/i&gt;: At the inception of each arrangement that includes development milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal will not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such development milestones and any related constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration and other revenues and earnings in their period of adjustment.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Royalties&lt;/i&gt;: For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue from its license agreements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Manufacturing and Supply:&#160;&lt;/i&gt;The obligations under the Company&#x2019;s agreements may include clinical and commercial manufacturing products to be provided by the Company to the counterparty. The services are generally determined to be distinct from the other promises or performance obligations identified in the arrangement. The Company recognizes the transaction price allocated to these services as revenue at a point in time when transfer of control of the related products to the customer occurs.&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      id="Tb_vX1MskOWfUK4T1B3vBi0Lg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Research and Development Costs&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"&gt;Except for payments made in advance of services, research and development costs are expensed as incurred. For payments made in advance, the Company recognizes research and development expense as the services are rendered. Research and development costs primarily consist of salaries and related expenses for personnel, laboratory supplies and raw materials, sponsored research, depreciation of laboratory facilities and leasehold improvements, and utilities costs related to research space. Other research and development expenses include fees paid to consultants and outside service providers including clinical research organizations and clinical manufacturing organizations.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <glyc:AccrualsForClinicalTrialExpensesPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      id="Tb_0MCZCZ7s50OArLJVPGwlmA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Accruals for Clinical Trial Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"&gt;Clinical trial costs primarily consist of expenses incurred under agreements with contract research organizations (CROs), investigative sites, laboratory testing expenses, data management and consultants that conduct the Company's clinical trials. Clinical trial expenses are a significant component of research and development expenses, and the Company outsources a significant portion of these clinical trial activities to third parties. The accrual for site and patient costs includes inputs such as estimates of patient enrollment, patient cycles incurred, clinical site activations, estimated project duration and other pass-through costs. These inputs are required to be estimated due to a lag in receiving the actual clinical information from third parties. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected on the balance sheets as a prepaid asset or accrued expenses. These third-party agreements are generally cancellable, and related costs are recorded as research and development expenses as incurred. Except for payments made in advance of services, clinical trial costs are expensed as incurred. Non-refundable advance clinical payments for goods or services that will be used or rendered for future research and development activities are recorded as a prepaid asset and recognized as expense as the related goods are delivered or the related services are performed. When evaluating the adequacy of the accrued expenses, management assessments include: (i) an evaluation by the project manager of the work that has been completed during the period; (ii) measurement of progress prepared internally and/or provided by the third-party service provider; (iii) analyses of data that justify the progress; and (iv)&#160;the Company&#x2019;s judgment. Significant judgments and estimates may be made in determining the accrued balances at the end of any reporting period. Actual results could differ from the estimates made. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"&gt;The Company&#x2019;s historical clinical accrual estimates have not been materially different from the actual costs. Clinical trial accruals that are due longer than one year are classified as noncurrent accrued expenses.&lt;/p&gt;</glyc:AccrualsForClinicalTrialExpensesPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      id="Tb_v-NDXr9ZM0ScaN2KDjHRnA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"&gt;Stock-based payments are accounted for in accordance with the provisions of ASC 718, &lt;i style="font-style:italic;"&gt;Compensation&#x2014;Stock Compensation&lt;/i&gt;. The fair value of stock-based payments is estimated, on the date of grant, using the Black-Scholes-Merton model. The resulting fair value is recognized ratably over the requisite service period, which is generally the vesting period of the option. The Company has elected to account for forfeitures as they occur.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"&gt;The Company has elected to use the Black-Scholes-Merton option pricing model to value any options granted. The Company will reconsider use of the Black-Scholes-Merton model if additional information becomes available in the future that indicates another model would be more appropriate or if grants issued in future periods have characteristics that prevent their value from being reasonably estimated using this model.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"&gt;A discussion of management&#x2019;s methodology for developing some of the assumptions used in the valuation model follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Expected Dividend Yield&lt;/i&gt;&#x2014;The Company has never declared or paid dividends and has no plans to do so in the foreseeable future.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Expected Volatility&#x2014;&lt;/i&gt;Volatility is a measure of the amount by which a financial variable such as share price has fluctuated (historical volatility) or is expected to fluctuate (expected volatility) during a period. Effective January 1, 2020, the Company bases the expected volatility on the historical volatility of the Company&#x2019;s publicly traded common stock. Prior to January 1, 2020, the Company utilized the historical volatilities of a peer group (e.g., several public entities of similar size, complexity, and stage of development), along with the Company&#x2019;s historical volatility since its initial public offering, to determine its expected volatility.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Risk-Free Interest Rate&lt;/i&gt;&#x2014;This is the U.S. Treasury rate for the week of each option grant during the year, having a term that most closely resembles the expected life of the option.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Expected Term&lt;/i&gt;&#x2014;This is a period of time that the options granted are expected to remain unexercised. Options granted have a maximum term of 10 years. The Company estimates the expected life of the option term to be 6.25 years. The Company uses a simplified method to calculate the average expected term.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MaximumMember_dvu4YMBVCkmKgIY5AJuxZA"
      id="Narr_xbpKellvoUGqURWIghfObQ">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MaximumMember_w9j8fZvT2UmDwuBnDsgAcw"
      id="Narr_F8a-KOm9tk2ec2AivBbs9g">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_Bhd-nQulWU6ZbQQpkblCKw"
      id="Narr_vxDA81EbzUivYlOeCbhy2A">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2019_To_12_31_2019_pmIpEVmd-kmwrLI0XOvIXQ"
      id="Narr_SGI3wtOBUUew_H1RZXvhqg">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2020_To_12_31_2020_n4dAyZdoqEGSie7qc7FpOQ"
      id="Narr_zYpvaXHliE-p1oUG7FNcOg">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      id="Narr_GS9eaHfBdkem4_zHLEvbZQ">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      id="Tb_lXogQdz0g0CbH8QN5s-g1A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"&gt;The Company accounts for income taxes using the asset and liability method in accordance with ASC 740,&lt;i style="font-style:italic;"&gt; Income Taxes&lt;/i&gt;. Deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and the financial reporting amounts at each year-end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. A valuation allowance is established when necessary to reduce deferred tax assets to the amount expected to be realized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"&gt;The Company accounts for uncertain tax positions pursuant to ASC 740. Financial statement recognition of a tax position taken or expected to be taken in a tax return is determined based on a more-likely-than-not threshold of that tax position being sustained. If the tax position meets this threshold, the benefit to be recognized is measured as the tax benefit having the highest likelihood of being realized upon ultimate settlement with the taxing authority. The Company recognizes interest accrued related to unrecognized tax benefits and penalties in the provision for income taxes.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      id="Tb_PQdZUBZlIk2jW7QKch1BTQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Comprehensive Loss&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"&gt;Comprehensive loss comprises net loss and other changes in equity that are excluded from net loss. For the years ended December&#160;31, 2021, 2020 and 2019, the Company&#x2019;s net loss was equal to comprehensive loss and, accordingly, no additional disclosure is presented.&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <glyc:NewAccountingPronouncementsAdoptedPolicyPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      id="Tb_MZI7_A1VVkqkL5R4Ws9W_g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Adopted Accounting Standards&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"&gt;In December 2019, the FASB issued ASU 2019-12. ASU 2019-12 removes certain exceptions for recognizing deferred taxes for investments, performing intra-period allocation and calculating income taxes in interim periods. The ASU also adds guidance to reduce complexity in certain areas, including deferred taxes for goodwill and allocating taxes for members of a consolidated group. ASU 2019-12 was effective for all entities for fiscal years beginning after &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"&gt;December 15, 2020. As of January 1, 2021, the Company adopted the standard, which did not have a material impact on the Company's financial statements. &lt;/p&gt;</glyc:NewAccountingPronouncementsAdoptedPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      id="Tb_cN_EAx7mmEyZ0oxXFNzDrw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Accounting Standards Not Yet Adopted&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"&gt;With the exception of the new standard discussed above, there have been no new accounting pronouncements that have significance, or potential significance, to the Company&#x2019;s financial statements.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      id="Tb_2xDwnLoA0Eyc-VmJzWaFCA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;4. Net Loss Per Share of Common Stock&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"&gt;Basic net loss per common share is determined by dividing net loss by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per share is computed by dividing net loss by the weighted-average number of common stock equivalents outstanding for the period. The treasury stock method is used to determine the dilutive effect of the Company&#x2019;s stock options and restricted stock units (RSUs).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"&gt;The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted-average common shares outstanding, as they would be anti-dilutive: &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:63.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Stock options and restricted stock units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 7,908,122&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 6,143,594&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5,106,493&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      id="Tb_ncjfVAIBQU6pgzcDTIpZEg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:63.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Stock options and restricted stock units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 7,908,122&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 6,143,594&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5,106,493&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_glyc_EmployeeStockOptionsAndRestrictedStockUnitsMember_XfZ7v3VAVk-r9VvuNg_XkA"
      decimals="0"
      id="Tc_Qwe1GQvFJ0qQiGV1iMGkbw_3_2"
      unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA">7908122</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_glyc_EmployeeStockOptionsAndRestrictedStockUnitsMember_13b9WUxP7EmEaDz7Hl3AmA"
      decimals="0"
      id="Tc_lMthW7YINUSW2Z_hPQBlGQ_3_4"
      unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA">6143594</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_glyc_EmployeeStockOptionsAndRestrictedStockUnitsMember_Iay9lDc4RUKcxJLhHUjHTg"
      decimals="0"
      id="Tc_CmsnoAJncEuOUP4xI8vgJg_3_6"
      unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA">5106493</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:OtherCurrentAssetsTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      id="Tb_qS3PJOfYJ0yuw-GvroQkWQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;5. Prepaid Expenses and Other Current Assets&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"&gt;The following is a summary of the Company&#x2019;s prepaid expenses and other current assets at December 31:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prepaid research and development expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 273,396&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 965,504&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other prepaid expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 259,061&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 270,675&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other receivables&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,347&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,149&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prepaid expenses and other current assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 533,804&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,238,328&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:OtherCurrentAssetsTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      id="Tb_52BRLZl35EaGAIn91Z7sbg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"&gt;The following is a summary of the Company&#x2019;s prepaid expenses and other current assets at December 31:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prepaid research and development expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 273,396&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 965,504&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other prepaid expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 259,061&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 270,675&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other receivables&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,347&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,149&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prepaid expenses and other current assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 533,804&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,238,328&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg"
      decimals="0"
      id="Tc_LeNYEZM6f0OrtSN-NbFEdw_3_3"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">273396</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug"
      decimals="0"
      id="Tc_B7iI3ppHjUqpQo6wjGT-pQ_3_6"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">965504</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg"
      decimals="0"
      id="Tc_LLnBLMdkO0GbhNrSaLL4ww_4_3"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">259061</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug"
      decimals="0"
      id="Tc_ay8H-e0X3k-s17u1GGmgWg_4_6"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">270675</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg"
      decimals="0"
      id="Tc_YwO0SOdQqUGgJBqU9aYSoQ_5_3"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">1347</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug"
      decimals="0"
      id="Tc_a2YaferNgEyUBYcXEXtzRA_5_6"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">2149</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg"
      decimals="0"
      id="Tc_3rUVHvLNZ0GhOa_ZPuC1DA_6_3"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">533804</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug"
      decimals="0"
      id="Tc_1IlLDAuJGU2eXVGDXD3qLw_6_6"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">1238328</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      id="Tb_joW-RxiDgEugUVOGMZschg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;6. Property and Equipment&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:6pt 0pt 6pt 0pt;"&gt;Property and equipment, net consisted of the following at December 31:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 345,712&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 345,712&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,406,346&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,446,596&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Office equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 17,762&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 16,755&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Computer equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 305,784&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 327,776&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 616,133&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 616,133&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Property and equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,691,737&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,752,972&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Less accumulated depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,322,895)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,132,299)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 368,842&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 620,673&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:6pt 0pt 12pt 0pt;"&gt;Depreciation of property and equipment totaled $264,600, $270,754 and $279,234 for the years ended December&#160;31, 2021, 2020 and 2019, respectively.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      id="Tb_yMMqefQEDUmzwpshvDg1JA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:6pt 0pt 6pt 0pt;"&gt;Property and equipment, net consisted of the following at December 31:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 345,712&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 345,712&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,406,346&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,446,596&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Office equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 17,762&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 16,755&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Computer equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 305,784&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 327,776&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 616,133&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 616,133&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Property and equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,691,737&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,752,972&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Less accumulated depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,322,895)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,132,299)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 368,842&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 620,673&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_MyBLeUpbCEad5R76PvA7Qw"
      decimals="0"
      id="Tc_k1wwiGNtTkqwRpFOmfaxxQ_3_3"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">345712</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_F-fa25zb1EKNL4wYhdv86w"
      decimals="0"
      id="Tc_F83EzidXuUe3wBmf3Ai_rA_3_6"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">345712</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_glyc_LaboratoryEquipmentMember_ZNg--URu-Um0dMbV5peuIw"
      decimals="0"
      id="Tc_O1Aso1stn0SsXHdlnVSYYg_4_3"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">1406346</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_glyc_LaboratoryEquipmentMember_nghKysTWSECvGe85266cdw"
      decimals="0"
      id="Tc_s1kzzGKNhE-2LSC4NPJn-w_4_6"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">1446596</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_S4Ib7npi4k2n67LEOrpyzw"
      decimals="0"
      id="Tc_ye4duZ9ppkGe3vFt5UJ1Rg_5_3"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">17762</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_vsNg25IaXU2FJMsaQjaLLw"
      decimals="0"
      id="Tc_kL0BAnLSSUKkrVYR9o21RA_5_6"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">16755</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_NuJWpFqva06fY6gG06su4A"
      decimals="0"
      id="Tc_vPkHqcP-UUKPBlwtmMJcfg_6_3"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">305784</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_mVfAbQ5Nbkmu-wiL5cukOg"
      decimals="0"
      id="Tc_av83HMYqfUexGn3fV4po2w_6_6"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">327776</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_Ct0n8oNDQk-VdEoHy-ji7Q"
      decimals="0"
      id="Tc_qKbFFjX7R0CHSqwCDUpllA_7_3"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">616133</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_7L-ZBeUo20ymuDm-db_BBA"
      decimals="0"
      id="Tc_ZIhlcKqbP0GGpnE2qCbV9w_7_6"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">616133</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg"
      decimals="0"
      id="Tc_66TWTm2yvUKCIpm08ur3Zw_8_3"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">2691737</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug"
      decimals="0"
      id="Tc_gAZMrg1TT0uUH3yvL6wSJQ_8_6"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">2752972</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg"
      decimals="0"
      id="Tc_MVAnMKNSy0yvyz7oXZocug_9_3"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">2322895</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug"
      decimals="0"
      id="Tc_Nlrc8froLUKn6iZxwwb2qA_9_6"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">2132299</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg"
      decimals="0"
      id="Tc_naxr0zpPC06B_4SntK4oZw_10_3"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">368842</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug"
      decimals="0"
      id="Tc_ENQSdD1yq0uFOq2zlvklRw_10_6"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">620673</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      decimals="0"
      id="Narr_9W3Rn4Sbc0WyG3rgXLiy8w"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">264600</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2020_To_12_31_2020_n4dAyZdoqEGSie7qc7FpOQ"
      decimals="0"
      id="Narr_Oh9vy1zV30625yAkT4jW-w"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">270754</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2019_To_12_31_2019_pmIpEVmd-kmwrLI0XOvIXQ"
      decimals="0"
      id="Narr_h8IS-gvawEOxOXkcl3jOrw"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">279234</us-gaap:Depreciation>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      id="Tb_fwtii2lr6kqS5KPt2-unKA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;7. Accrued Expenses&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:6pt 0pt 6pt 0pt;"&gt;The following is a summary of the Company&#x2019;s accrued expenses at December 31:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued research and development expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5,824,365&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5,114,420&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued bonuses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,152,302&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,341,184&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued consulting and other professional fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 299,607&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 194,760&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued employee benefits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 348,752&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 569,048&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other accrued expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 90,342&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 220,469&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 8,715,368&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 9,439,881&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      id="Tb_s43keHxPI0myngYTsa8riw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:6pt 0pt 6pt 0pt;"&gt;The following is a summary of the Company&#x2019;s accrued expenses at December 31:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued research and development expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5,824,365&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5,114,420&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued bonuses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,152,302&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,341,184&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued consulting and other professional fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 299,607&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 194,760&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued employee benefits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 348,752&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 569,048&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other accrued expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 90,342&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 220,469&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 8,715,368&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 9,439,881&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <glyc:AccruedResearchAndDevelopmentExpenseCurrent
      contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg"
      decimals="0"
      id="Tc_V3tIQEdSA0i5UbF0yUcNNw_2_3"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">5824365</glyc:AccruedResearchAndDevelopmentExpenseCurrent>
    <glyc:AccruedResearchAndDevelopmentExpenseCurrent
      contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug"
      decimals="0"
      id="Tc_kjV1sL-kKkGrComvIIgi3w_2_6"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">5114420</glyc:AccruedResearchAndDevelopmentExpenseCurrent>
    <us-gaap:AccruedBonusesCurrent
      contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg"
      decimals="0"
      id="Tc_zegzQ_-vC0erxvP9_XaOjg_3_3"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">2152302</us-gaap:AccruedBonusesCurrent>
    <us-gaap:AccruedBonusesCurrent
      contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug"
      decimals="0"
      id="Tc_yS4PrIKrqUaxfLWnUCk8PQ_3_6"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">3341184</us-gaap:AccruedBonusesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg"
      decimals="0"
      id="Tc_8OgWT5mazkKOfhG6Dx0HIw_4_3"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">299607</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug"
      decimals="0"
      id="Tc_8357aKFWi06zLeGOCo7Mjg_4_6"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">194760</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg"
      decimals="0"
      id="Tc_GeGTDQawtkOUlf6otFfBxw_5_3"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">348752</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug"
      decimals="0"
      id="Tc_fv258ssWO0qX-3fK7NmeGA_5_6"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">569048</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg"
      decimals="0"
      id="Tc_82gM0GfzWEORdzTUhIKc1g_6_3"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">90342</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug"
      decimals="0"
      id="Tc_bp2oN0x8D0yX87BEerT5VA_6_6"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">220469</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg"
      decimals="0"
      id="Tc_LvhJL1fo50OTSYirKMjQHg_7_3"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">8715368</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug"
      decimals="0"
      id="Tc_CSdwe-xClUGEqI2FPJfjfA_7_6"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">9439881</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      id="Tb_-2pSWULU7Uag3bOETResjw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;8. Operating Leases&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the circumstances present. The Company determines a lease exists if the contract conveys the right to control an identified asset for a period of time in exchange for consideration. Control is considered to exist when the lessee has the right to obtain substantially all of the economic benefits from the use of an identified asset as well as direct the right to use of that asset. Leases with a term greater than one year are recognized on the balance sheet as right-of-use assets, lease liabilities and, if applicable, long-term lease liabilities. The Company has elected not to recognize on the balance sheet leases with terms of one year or less on the lease commencement date. If a contract is considered to be a lease, the Company recognizes a lease liability based on the present value of the future lease payments over the expected lease term, with an offsetting entry to recognize a right-of-use asset. The Company has also elected to use the practical expedient and account for each lease component and related non-lease component as one &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_FRgasz_JB0WJUBzD7HF5EA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;single&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; component. The lease component results in a right-of-use asset being recorded on the balance sheet and amortized as lease expense on a straight-line basis.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.5pt;margin:0pt 0pt 6pt 0pt;"&gt;The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a term similar to the term of the lease for which the rate is estimated. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"&gt;The Company leases office and research space in Rockville, Maryland under an operating lease with a term from June 15, 2015 through October 31, 2023 (the Lease) that is subject to annual rent increases. The Company has the right to sublease or assign all or a portion of the premises, subject to the conditions set forth in the Lease. The Lease may be terminated early by either the landlord or the Company in certain circumstances. In connection with the Lease, the Company received rent abatement as a lease incentive in the initial year of the Lease.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"&gt;In March 2016, the Company amended the Lease (the Lease Amendment) to lease additional space as of June 1, 2016. In May 2016, the Company also paid a security deposit of $52,320 to be held until the expiration or termination of the Company&#x2019;s obligations under the Lease. The term of the Lease Amendment for the additional space continues through October 31, 2023, the same date as for the premises originally leased under the Lease, subject to the Company&#x2019;s renewal option set forth in the Lease.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"&gt;The Company identified and applied the following significant assumptions in recognizing the right-of-use asset and corresponding liability for the Lease and Lease Amendment:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:24.5pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Lease term &#x2013; The lease term includes both the noncancelable period and, when applicable, &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_1CXabvkwwUuyuzuDaxMsGQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;cancelable&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; option periods where failure to exercise such option would result in an economic penalty. The Company&#x2019;s renewal option to &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_jhM2PXDc_EWMY9qaiYQkSQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;extend&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; is not reasonably certain of being exercised as of December 31, 2021.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:24.5pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Incremental borrowing rate &#x2013; As the Company&#x2019;s lease does not provide an implicit rate, the Company used an incremental borrowing rate (IBR), which is the rate incurred to borrow on a collateralized basis over a term similar to the term of the lease for which the rate is estimated. The Company determined the IBR to be &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;8%&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; based on an estimated rate that considered the Company&#x2019;s credit risk in the United States for a collateralized borrowing and lease term similar to the Lease.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:6pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;As of December 31, 2021 the weighted-average remaining lease term was &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;1.8&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; years. There were &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;no&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; additional operating leases entered into during the year ended December 31, 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"&gt;The components of lease expense and related cash flows were as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:64.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:34.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Operating lease cost &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 927,957&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 927,957&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 927,957&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Variable lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 490,871&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 593,973&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 465,028&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total operating lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,418,828&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,521,930&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,392,985&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Operating cash outflows for operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,077,469&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,051,190&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 941,089&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:6pt 0pt 6pt 0pt;"&gt;Maturities of lease liability due under these lease agreements as of December 31, 2021 were as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:83.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:83.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Operating Lease&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:83.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Obligation&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:83.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,104,356&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:83.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 940,840&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:83.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:83.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,045,196&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:83.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Present value adjustment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (125,182)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:83.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Present value of lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,920,014&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:SecurityDeposit
      contextRef="As_Of_5_31_2016_srt_StatementGeographicalAxis_glyc_RockvilleMarylandMember_pHaqdBt7jEqRRIagvedypQ"
      decimals="0"
      id="Narr_sseOQMt-RkWSVvwelShcfg"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">52320</us-gaap:SecurityDeposit>
    <us-gaap:DebtInstrumentInterestRateIncreaseDecrease
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      decimals="2"
      id="Narr_E4W7QUQ2TUamu_nk162J1w"
      unitRef="Unit_Standard_pure_o6l_rGctYUCSP0KoHptHcQ">0.08</us-gaap:DebtInstrumentInterestRateIncreaseDecrease>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg"
      id="Narr_aCy0j2gGWkKHvifzIED5Cw">P1Y9M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <glyc:LesseeOperatingLeaseNumberOfNewLeases
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      decimals="0"
      id="Narr_5LV12CFYp0W2P2SAtmm4UQ"
      unitRef="Unit_Standard_lease_pZ3IxEbMMU6Abz8KmKdkfQ">0</glyc:LesseeOperatingLeaseNumberOfNewLeases>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      id="Tb__byZm6gt-0OxMgqdhjmP2Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:64.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:34.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Operating lease cost &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 927,957&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 927,957&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 927,957&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Variable lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 490,871&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 593,973&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 465,028&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total operating lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,418,828&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,521,930&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,392,985&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Operating cash outflows for operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,077,469&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,051,190&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 941,089&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      decimals="-3"
      id="Tc_mv3NjhGygkKRiAae41Vc0g_3_3"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">927957000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_1_1_2020_To_12_31_2020_n4dAyZdoqEGSie7qc7FpOQ"
      decimals="-3"
      id="Tc_W4in4TbQ-kinbu-9Tjg__Q_3_6"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">927957000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_1_1_2019_To_12_31_2019_pmIpEVmd-kmwrLI0XOvIXQ"
      decimals="-3"
      id="Tc_Bv0LGIfo0U2Lm3P6ZJxg0A_3_9"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">927957000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      decimals="-3"
      id="Tc_GjvRit4WQEW8qjhrPK7uqg_4_3"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">490871000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="Duration_1_1_2020_To_12_31_2020_n4dAyZdoqEGSie7qc7FpOQ"
      decimals="-3"
      id="Tc_86B8-5RGhUG52UL31gtlGg_4_6"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">593973000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="Duration_1_1_2019_To_12_31_2019_pmIpEVmd-kmwrLI0XOvIXQ"
      decimals="-3"
      id="Tc_QHVWm_JtA0uESGuucQ51ww_4_9"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">465028000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      decimals="-3"
      id="Tc_iVRB1nYQG0aNGvOov_QHzw_5_3"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">1418828000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="Duration_1_1_2020_To_12_31_2020_n4dAyZdoqEGSie7qc7FpOQ"
      decimals="-3"
      id="Tc_VZmeFm0zLUq6Y8Gz69GQYA_5_6"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">1521930000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="Duration_1_1_2019_To_12_31_2019_pmIpEVmd-kmwrLI0XOvIXQ"
      decimals="-3"
      id="Tc_Zds0acymuEWXI9alsYyL7Q_5_9"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">1392985000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      decimals="-3"
      id="Tc_XgL2TKpkzEepH615mQxy_g_8_3"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">1077469000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2020_To_12_31_2020_n4dAyZdoqEGSie7qc7FpOQ"
      decimals="-3"
      id="Tc_jygyTiw97UqsoIqnkisv9Q_8_6"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">1051190000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2019_To_12_31_2019_pmIpEVmd-kmwrLI0XOvIXQ"
      decimals="-3"
      id="Tc_4KDUY2SbT0O5JFQOzydhzA_8_9"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">941089000</us-gaap:OperatingLeasePayments>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      id="Tb_50zI_QdbtEKl3iqx1DFROw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:83.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:83.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Operating Lease&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:83.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Obligation&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:83.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,104,356&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:83.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 940,840&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:83.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:83.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,045,196&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:83.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Present value adjustment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (125,182)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:83.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Present value of lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,920,014&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg"
      decimals="0"
      id="Tc_BnFJsUeEq0SS-gmh_OgJkQ_3_3"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">1104356</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg"
      decimals="0"
      id="Tc_XXon3TelRkW-ZT1GCyLPmA_4_3"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">940840</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <glyc:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo
      contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg"
      decimals="0"
      id="Tc_dkeAn01ObUW0yhpKK03ukQ_5_3"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">0</glyc:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg"
      decimals="0"
      id="Tc_EaCpdzG05kWR4hNIL00Alw_6_3"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">2045196</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg"
      decimals="0"
      id="Tc_rb_Ok2W_wE6Yb3FQMsZ9Yg_7_3"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">125182</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg"
      decimals="0"
      id="Tc_sQSiP7LNmEirLcT0mBKZwg_8_3"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">1920014</us-gaap:OperatingLeaseLiability>
    <glyc:DisclosureOfStockholdersEquityAndCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      id="Tb_Ohclz55C50-VwnTSfGuopw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;9. Stockholders&#x2019; Equity&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Common Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;At-The-Market Equity Offerings&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"&gt;On September 28, 2017, the Company entered into an at-the-market sales agreement (the 2017 Sales Agreement) with Cowen and Company, LLC (Cowen) to sell up to $100.0 million of the Company&#x2019;s common stock registered under a shelf registration statement filed with the U.S. Securities and Exchange Commission in September 2017. During the year ended December 31, 2020, the Company issued and sold 4,136,742 shares of common stock under the 2017 Sales Agreement at a weighted average price per share of $3.52, for aggregate net proceeds of $14.1 million, after deducting commissions and offering expenses. There were no shares sold under the 2017 Sales Agreement during the year ended December 31, 2019. The shelf registration statement, under which the shares that could be sold under the 2017 Sales Agreement were registered, expired on October 6, 2020.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"&gt;On October 7, 2020, the Company filed a prospectus supplement to a shelf registration statement that it filed in May 2019 and entered into a new at-the-market sales agreement (the 2020 Sales Agreement) with Cowen. Under the 2020 Sales Agreement, the Company may sell up to $100.0 million of the Company&#x2019;s common stock registered under the shelf registration statement that was filed in May 2019. The 2020 Sales Agreement replaced the 2017 Sales Agreement between the Company and Cowen, and the $100.0 million that may be sold under the 2020 Sales Agreement excludes any amounts that were sold under the 2017 Sales Agreement. During the year ended December 31, 2020, the Company issued and sold 1,024,760 shares of common stock under the 2020 Sales Agreement at a weighted average price per share of $3.74, for aggregate net proceeds of $3.7 million, after deducting commissions and offering expenses. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"&gt;During the year ended December 31, 2021, the Company issued and sold an additional 3,092,603 shares of common stock under the 2020 Sales Agreement at a weighted average price per share of $3.57, for aggregate net proceeds of $10.7 million, after deducting commissions and offering expenses. As of December 31, 2021, approximately $85.1 million remained available to be sold under the terms of the 2020 Sales Agreement. Subsequent to December 31, 2021 and through the date these financial statements were issued, there have been no additional sales under the 2020 Sales Agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;2003 Stock Incentive Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"&gt;The 2003 Stock Incentive Plan (the 2003 Plan) provided for the grant of incentives and nonqualified stock options and restricted stock awards. The exercise price for incentive stock options must be at least equal to the fair value of the &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"&gt;common stock on the grant date. Unless otherwise stated in a stock option agreement, 25% of the shares subject to an option grant will vest upon the first anniversary of the vesting start date and thereafter at the rate of one &lt;span style="-sec-ix-hidden:Hidden_UfZmMD43P0CtU_nlwGEAYQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;forty&lt;/span&gt;&lt;/span&gt;-eighth of the option shares per month as of the first day of each month after the first anniversary. Upon termination of employment by reasons other than death, cause, or disability, any vested options shall terminate 60 days after the termination date. Stock options terminate 10 years from the date of grant. The 2003 Plan expired on May&#160;21, 2013.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"&gt;A summary of the Company&#x2019;s stock option activity under the 2003 Plan for the year ended December 31, 2021 is as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;WEIGHTED-&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;AGGREGATE&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;WEIGHTED-&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;AVERAGE&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;INTRINSIC&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;AVERAGE&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;REMAINING&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;VALUE&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;OUTSTANDING&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EXERCISE&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;CONTRACTUAL&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(IN&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;OPTIONS&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;PRICE&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;TERM&#160;(YEARS)&lt;/b&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;THOUSANDS)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding as of December&#160;31,&#160;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 97,250&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1.96&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"&gt;Options exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,785)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1.12&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"&gt;Options forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_CPAQxqLmSEmNCmGKblFleQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Outstanding&lt;/span&gt;&lt;/span&gt;, Vested and Exercisable as of &lt;span style="-sec-ix-hidden:Hidden_fSABMxeS7UGMQu4eqOoECg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;December&#160;31,&#160;2021&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 93,465&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 0.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:6pt 0pt 6pt 0pt;"&gt;During 2021, 2020 and 2019 the Company issued 3,785, 285,087 and 284,743 shares of common stock, respectively, in conjunction with exercises of stock options granted under the 2003 Plan. The Company received cash proceeds from the exercise of these stock options of $4,239, $319,297 and $318,912 during 2021, 2020 and 2019, respectively. Total intrinsic value of the options exercised during the years ended December 31, 2021, 2020 and 2019 was $8,668, $921,168 and $924,688, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"&gt;As of December 31, 2021, the options under the 2003 Plan were fully expensed and all options outstanding under the 2003 Plan were fully vested. There were no options granted under the 2003 Plan in 2021, 2020 and 2019.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;2013 Equity Incentive Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"&gt;The Company&#x2019;s board of directors adopted, and its stockholders approved, its 2013 Equity Incentive Plan (the 2013 Plan) effective on January 9, 2014. The 2013 Plan provides for the grant of incentive stock options within the meaning of Section&#160;422 of the Internal Revenue Code (the Code), to the Company&#x2019;s employees and its parent and subsidiary corporations&#x2019; employees, and for the grant of nonstatutory stock options, restricted stock awards, restricted stock unit awards, stock appreciation rights, performance stock awards and other forms of stock compensation to its employees, including officers, consultants and directors. The 2013 Plan also provides for the grant of performance cash awards to the Company&#x2019;s employees, consultants and directors. Unless otherwise stated in a stock option agreement, 25% of the shares subject to an option grant will typically vest upon the first anniversary of the vesting start date and thereafter at the rate of one &lt;span style="-sec-ix-hidden:Hidden_MpFfxPM_9Uq0Hhwoua9x4Q;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;forty&lt;/span&gt;&lt;/span&gt;-eighth of the option shares per month as of the first day of each month after the first anniversary. Upon termination of employment by reasons other than death, cause, or disability, any vested options shall terminate 90 days after the termination date, unless otherwise set forth in a stock option agreement. Stock options generally terminate 10 years from the date of grant.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Authorized Shares&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"&gt;The maximum number of shares of common stock that may be issued under the 2013 Plan was 1,000,000&#160;shares, plus any shares subject to stock options or similar awards granted under the 2003 Plan that expire or terminate without having been exercised in full or are forfeited to or repurchased by the Company. The number of shares of common stock reserved for issuance under the 2013 Plan will automatically increase on January&#160;1 of each year, beginning on January&#160;1, 2015 and ending on January&#160;1, 2023, by 3% of the total number of shares of common stock outstanding on December&#160;31 of the preceding calendar year, or a lesser number of shares as may be determined by the Company&#x2019;s board of directors. The maximum number of shares that may be issued pursuant to exercise of incentive stock options under the 2013 Plan is 20,000,000.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"&gt;Shares issued under the 2013 Plan may be authorized but unissued or reacquired shares of common stock. Shares subject to stock awards granted under the 2013 Plan that expire or terminate without being exercised in full, or that are paid out in cash rather than in shares, will not reduce the number of shares available for issuance under the 2013 Plan. Additionally, shares issued pursuant to stock awards under the 2013 Plan that the Company repurchases or that are &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"&gt;forfeited, as well as shares reacquired by the Company as consideration for the exercise or purchase price of a stock award or to satisfy tax withholding obligations related to a stock award, will become available for future grant under the 2013 Plan.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Stock Options&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"&gt;A summary of the Company&#x2019;s stock option activity under the 2013 Plan for the year ended December&#160;31, 2021 is as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:45.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;WEIGHTED-&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;AGGREGATE&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;WEIGHTED-&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;AVERAGE&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;INTRINSIC&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;AVERAGE&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;REMAINING&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;VALUE&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;OUTSTANDING&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EXERCISE&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;CONTRACTUAL&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(IN&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;OPTIONS&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;PRICE&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;TERM&#160;(YEARS)&lt;/b&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;THOUSANDS)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding as of December&#160;31,&#160;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5,753,211&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 8.93&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 6.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"&gt;Options granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 898,100&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3.70&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"&gt;Options exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"&gt;Options forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (995,854)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 7.89&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding as of December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5,655,457&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 8.30&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;6.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Vested or expected to vest as of December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5,655,457&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 8.30&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;6.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercisable as of December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 4,118,394&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 9.43&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;5.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"&gt;As of December 31, 2021, there was $4,936,519 of total unrecognized compensation expense related to unvested options that will be recognized over a weighted-average period of approximately 2.0 years. The total fair value of options that vested in the years ended December 31, 2021, 2020 and 2019 was $5,936,641, $7,347,548 and $6,159,610, respectively. There were no options exercised under the 2013 Plan during the years ended December 31, 2021 or 2020. During the year ended December 31, 2019, the Company received cash of $94,001 and issued 16,606 shares of common stock in conjunction with exercises of stock options granted under the 2013 Plan. The intrinsic value of the options exercised for the year ended December 31, 2019 was $97,429. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Restricted Stock Units (RSUs)&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"&gt;A restricted stock unit (RSU) is a stock award that entitles the holder to receive shares of the Company&#x2019;s common stock as the award vests. The fair value of each RSU is based on the closing price of the Company&#x2019;s common stock on the date of grant. In January 2021, the Company awarded RSUs under the 2013 Plan to all of its employees. The RSUs granted vest over four years in equal installments on each anniversary of the grant date. In September 2019, the Company granted an aggregate of 332,106 RSUs with service conditions to the Company&#x2019;s non-executive employees. The RSUs granted in September 2019 vested over a two-year period, with &lt;span style="-sec-ix-hidden:Hidden_PGLZbIA_j0-ItwYMfmgcfA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;one&lt;/span&gt;&lt;/span&gt;-third vesting on the first anniversary of the date of grant and the remaining &lt;span style="-sec-ix-hidden:Hidden_BnTvpBXF9EKtCoC_jLU41A;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;two&lt;/span&gt;&lt;/span&gt;-thirds vesting on the second anniversary of the date of grant, provided that the employee remained employed with the Company at the applicable vesting date. Compensation expense is recognized on a straight-line basis. As of December 31, 2021, there was $943,458 of total unrecognized compensation expense associated with these RSU grants that will be recognized over a weighted-average period of approximately 3.0 years.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"&gt;The following is a summary of RSU activity for the 2013 Plan for the year ended December 31, 2021:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Grant Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Underlying RSUs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Unvested at December&#160;31,&#160;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 192,533&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 4.53&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 444,613&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3.72&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (101,754)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3.84&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (189,792)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 4.53&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Unvested at December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 345,600&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3.70&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 6pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Inducement Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"&gt;In January 2020, the Company&#x2019;s board of directors adopted the GlycoMimetics, Inc. Inducement Plan (the Inducement Plan). The Inducement Plan provides for the grant of nonstatutory stock options, restricted stock awards, restricted stock unit awards, stock appreciation rights and other forms of stock awards to individuals not previously an &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;"&gt;employee or director of the Company as an inducement for such individuals to join the Company. Unless otherwise stated in an applicable stock option agreement, &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_CUsjKSRwVk28fq-bDbXrTw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;one&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;-fourth of the shares subject to an option grant under the Inducement Plan will typically vest upon the first anniversary of the vesting start date, with the balance of the shares vesting in a series of &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;thirty-six&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; successive equal monthly installments as of the first day of each month measured from the first anniversary of the vesting start date, subject to the new employee&#x2019;s continued service with the Company through the applicable vesting dates. Upon termination of employment by reasons other than death, cause or disability, any vested options will terminate &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;90 days&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; after the termination date, unless otherwise set forth in a stock option agreement. Stock options generally terminate &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;10 years&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; from the date of grant. There were &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;500,000&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; shares of common stock reserved under the Inducement Plan at its adoption date. In August 2021, the Company&#x2019;s board of directors adopted an amendment to the Inducement Plan to increase the number of shares reserved to &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;2,000,000&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; shares, and in January 2022 the Company&#x2019;s board of directors adopted an amendment to the Inducement Plan to further increase the number of shares reserved to &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;3,000,000&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; shares. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"&gt;. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"&gt;A summary of the Company&#x2019;s stock option activity under the Inducement Plan for the year ended December 31, 2021 is as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:45.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#0000ff;font-size:14pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;WEIGHTED-&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;AGGREGATE&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;WEIGHTED-&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;AVERAGE&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;INTRINSIC&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;AVERAGE&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;REMAINING&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;VALUE&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;OUTSTANDING&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EXERCISE&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;CONTRACTUAL&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(IN&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;OPTIONS&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;PRICE&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;TERM&#160;(YEARS)&lt;/b&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;THOUSANDS)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding as of December&#160;31,&#160;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 100,600&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3.09&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 9.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"&gt;Options granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,747,600&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2.02&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"&gt;Options exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (10,092)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2.06&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"&gt;Options forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (24,508)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2.06&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding as of December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,813,600&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2.08&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;9.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Vested or expected to vest as of December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,264,400&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2.10&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;9.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercisable as of December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 22,879&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3.58&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;8.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:6pt 0pt 6pt 0pt;"&gt;As of December 31, 2021, there was $1,672,270 of total unrecognized compensation expense related to unvested options under the Inducement Plan that will be recognized over a weighted-average period of approximately &lt;span style="white-space:pre-wrap;"&gt;3.6&lt;/span&gt;&lt;span style="white-space:pre-wrap;"&gt; years. In August 2021, the Company granted stock options to purchase an aggregate of 1,647,600 shares to its new Chief Executive Officer under the Inducement Plan. This consisted of (a) an option to purchase 1,098,400 shares, subject to vesting as to 25% of the underlying shares on August 3, 2022 and as to the remaining underlying shares in equal monthly installments over &lt;/span&gt;&lt;span style="white-space:pre-wrap;"&gt;36 months&lt;/span&gt;&lt;span style="white-space:pre-wrap;"&gt; thereafter, subject to the officer&#x2019;s continued service through each such vesting date, and (b) an option to purchase 549,200 shares that is subject to performance vesting conditions and will vest upon achievement of milestones as follows: (i) &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_wFFEp6_-yEedIq15Qcrr0w;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;"&gt;one&lt;/span&gt;&lt;/span&gt;&lt;span style="white-space:pre-wrap;"&gt;-half of the shares will vest upon FDA approval of uproleselan in patients with relapsed/refractory acute myeloid leukemia and (ii) &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_Asb0-jwP3ku8JnmG256I7Q;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;"&gt;one&lt;/span&gt;&lt;/span&gt;&lt;span style="white-space:pre-wrap;"&gt;-half of the shares will vest upon the first commercial sale of uproleselan in the United States or abroad. The maximum fair value of $798,053 associated with the performance-based option is excluded from the unrecognized compensation expense under the Inducement Plan as the completion of the performance milestones are not probable as of December 31, 2021. The Company will reevaluate at the end of each reporting period the probability that the performance conditions will be achieved and record any compensation cost at that time.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:6pt 0pt 6pt 0pt;"&gt;The total fair value of options that vested in the year ended December 31, 2021 was $73,334. During the year ended December 31, 2021, the Company received cash of $20,790 and issued 10,092 shares of common stock in conjunction with exercises of stock options granted under the Inducement Plan. The intrinsic value of the options exercised for the year ended December 31, 2021 was $1,944. There were no options vested or exercised under the Inducement Plan during the year ended December 31, 2020.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"&gt;The weighted-average fair value of the options granted under all equity incentive plans during the years ended December&#160;31, 2021, 2020 and 2019 was $1.85, $3.17 and $7.17 per share, respectively, applying the Black-Scholes-Merton option pricing model utilizing the following weighted-average assumptions:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:41.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected term &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;6.25 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;6.25 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;6.25 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;84.19%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;84.40%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;71.15%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;0.78%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;1.41%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;2.54%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;0%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;0%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;0%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"&gt;Total stock-based compensation expense associated with stock options and RSUs was classified as follows on the statement of operations for the years ended December 31:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:51.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,214,848&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,946,952&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,402,242&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;General and administrative expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,872,438&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,954,806&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,812,848&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total stock-based compensation expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 6,087,286&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 6,901,758&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 6,215,090&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</glyc:DisclosureOfStockholdersEquityAndCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <glyc:CommonStockValueAvailableForSaleUnderAgreement
      contextRef="As_Of_9_28_2017_srt_RangeAxis_srt_MaximumMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_glyc_AtMarketOffering2017Member_1BZR7Z0Sy0OeJz_78Y1Cmg"
      decimals="-5"
      id="Narr_5WF-SRVY006Sc2FCHQMbYg"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">100000000.0</glyc:CommonStockValueAvailableForSaleUnderAgreement>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_glyc_AtMarketOffering2017Member_xegFN2MRVUeT2e9ks4eOqg"
      decimals="INF"
      id="Narr_7Xm72gEphUCg7AQkyMfyYg"
      unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA">4136742</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_glyc_AtMarketOffering2017Member_m0ia7emTp0-S4cX7E9JaOQ"
      decimals="2"
      id="Narr_32CPf1Snr0ejlTcp3tydlg"
      unitRef="Unit_Divide_USD_shares_6ZVfdDCn5UCsvmo46quH_A">3.52</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_glyc_AtMarketOffering2017Member_xegFN2MRVUeT2e9ks4eOqg"
      decimals="-5"
      id="Narr_-AOvbSumZ0O8tBbdqQU2FA"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">14100000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_glyc_AtMarketOffering2017Member_MrvCJyh9ZEiM2EnDxi7KcA"
      decimals="INF"
      id="Narr_AaKqxuizlE-pSKd6Xad9Gw"
      unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <glyc:CommonStockValueAvailableForSaleUnderAgreement
      contextRef="As_Of_10_7_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_glyc_AtMarketOffering2020Member_d7OWn4p530G-EwtpM2jaYA"
      decimals="-5"
      id="Narr_VptH9tJQHE2Kkt_iHHkTzw"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">100000000.0</glyc:CommonStockValueAvailableForSaleUnderAgreement>
    <glyc:CommonStockValueAvailableForSaleUnderAgreement
      contextRef="As_Of_10_7_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_glyc_AtMarketOffering2020Member_OCkznGqV5UKSXhPF0KDe9w"
      decimals="-5"
      id="Narr_7RTtM8vWLUa1LDHYYzU8IA"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">100000000.0</glyc:CommonStockValueAvailableForSaleUnderAgreement>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_glyc_AtMarketOffering2020Member_3hZx0NV1dUGxHj4ixh_xdQ"
      decimals="INF"
      id="Narr_SOwR4r8Pd0azWXJK4v5Q8A"
      unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA">1024760</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_glyc_AtMarketOffering2020Member_s7mbdwTmt0uPTw6bugEC2A"
      decimals="2"
      id="Narr_ioHwWjWlQkSnPaoGEGC8sQ"
      unitRef="Unit_Divide_USD_shares_6ZVfdDCn5UCsvmo46quH_A">3.74</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_glyc_AtMarketOffering2020Member_3hZx0NV1dUGxHj4ixh_xdQ"
      decimals="-5"
      id="Narr_ojq9wzOZhEuW6dposcgbPw"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">3700000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_glyc_AtMarketOffering2020Member_-Fh8SrRC9kSsK069fXrH7w"
      decimals="INF"
      id="Narr_7ArEH66oVkitmRSbkNKiQQ"
      unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA">3092603</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_glyc_AtMarketOffering2020Member_MXBe8LOc-0ysVhlt9Db4Nw"
      decimals="2"
      id="Narr_vxMaHCgXSUyN3NoZ0peNXw"
      unitRef="Unit_Divide_USD_shares_6ZVfdDCn5UCsvmo46quH_A">3.57</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_glyc_AtMarketOffering2020Member_-Fh8SrRC9kSsK069fXrH7w"
      decimals="-5"
      id="Narr_BYUI3qvoeU6S95K4Ro4UAw"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">10700000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <glyc:CommonStockValueAvailableForSaleUnderAgreement
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_glyc_AtMarketOffering2020Member_MXBe8LOc-0ysVhlt9Db4Nw"
      decimals="-5"
      id="Narr_qX3h7svN1UGCrKfoYVHYgg"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">85100000</glyc:CommonStockValueAvailableForSaleUnderAgreement>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2022_To_1_1_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_glyc_AtMarketOffering2020Member_G7FlJg156E25J7h_zCeUTQ"
      decimals="INF"
      id="Narr_4kptEbljeE-w9IypnfjDpw"
      unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_cofTMv8PCkK6kTIv_T7Wfg"
      decimals="INF"
      id="Narr_EuiMN0RshEq-i0f4owUk0g"
      unitRef="Unit_Standard_pure_o6l_rGctYUCSP0KoHptHcQ">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <glyc:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member_jeH3ukS87UGj2TpOqDjAFA"
      id="Narr_hG_1iw7RmEWJuZBAK1bxMQ">P60D</glyc:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member_jeH3ukS87UGj2TpOqDjAFA"
      id="Narr_HtRl2N0VbUyONNIKZHQjjA">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member_jeH3ukS87UGj2TpOqDjAFA"
      id="Tb_1YvPUJpYe02r1uQwTj1Tag">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;WEIGHTED-&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;AGGREGATE&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;WEIGHTED-&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;AVERAGE&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;INTRINSIC&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;AVERAGE&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;REMAINING&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;VALUE&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;OUTSTANDING&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EXERCISE&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;CONTRACTUAL&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(IN&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;OPTIONS&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;PRICE&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;TERM&#160;(YEARS)&lt;/b&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;THOUSANDS)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding as of December&#160;31,&#160;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 97,250&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1.96&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"&gt;Options exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,785)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1.12&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"&gt;Options forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_CPAQxqLmSEmNCmGKblFleQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Outstanding&lt;/span&gt;&lt;/span&gt;, Vested and Exercisable as of &lt;span style="-sec-ix-hidden:Hidden_fSABMxeS7UGMQu4eqOoECg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;December&#160;31,&#160;2021&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 93,465&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 0.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2020_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member_CPK9V-Op3UaIxCwH7D8lOQ"
      decimals="INF"
      id="Tc_PNd32rBZ40uNWHjDhfxKMw_6_2"
      unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA">97250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2020_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member_CPK9V-Op3UaIxCwH7D8lOQ"
      decimals="2"
      id="Tc_1skJsyiXk0yvEodPPomjCQ_6_5"
      unitRef="Unit_Divide_USD_shares_6ZVfdDCn5UCsvmo46quH_A">1.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member_63yRM8kz2kC7BUq4_p_EHA"
      id="Tc_f_1WQFakhE237PoBAmahGA_6_7">P1Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member_jeH3ukS87UGj2TpOqDjAFA"
      decimals="INF"
      id="Tc_U9n8ftkq6k2mNMl_YqR8Bw_7_2"
      unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA">3785</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member_jeH3ukS87UGj2TpOqDjAFA"
      decimals="2"
      id="Tc_wtiPwDqC-kuua2mbMS2ubQ_7_5"
      unitRef="Unit_Divide_USD_shares_6ZVfdDCn5UCsvmo46quH_A">1.12</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member_qc5DeeGdL02LALGoxVJG1g"
      decimals="INF"
      id="Tc_ZkvlvjeYwUGBizAl_H3-Wg_9_2"
      unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA">93465</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member_qc5DeeGdL02LALGoxVJG1g"
      decimals="2"
      id="Tc_9UenKl5-ukaucFQWyRPIkQ_9_5"
      unitRef="Unit_Divide_USD_shares_6ZVfdDCn5UCsvmo46quH_A">2.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member_jeH3ukS87UGj2TpOqDjAFA"
      id="Tc_Osc96gGX5kakgU9jcJxfkg_9_7">P0Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member_jeH3ukS87UGj2TpOqDjAFA"
      decimals="INF"
      id="Narr_D6l4DsgMU0WEE9eUrJ5XZA"
      unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA">3785</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member_63yRM8kz2kC7BUq4_p_EHA"
      decimals="INF"
      id="Narr_9AjluZJ0gUyxAHUFBm2QcQ"
      unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA">285087</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member_5mpVmM87DESzmaMO4y48HQ"
      decimals="INF"
      id="Narr_1st0rDVn-kuMNdSZyKgSew"
      unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA">284743</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member_jeH3ukS87UGj2TpOqDjAFA"
      decimals="0"
      id="Narr_F4kKfe8YKUmqtKtvayOfgg"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">4239</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member_63yRM8kz2kC7BUq4_p_EHA"
      decimals="0"
      id="Narr_O0djUbZCsEyMi0rA5tMw2w"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">319297</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member_5mpVmM87DESzmaMO4y48HQ"
      decimals="0"
      id="Narr_-4uC71dLEEi21GdjFOhz8Q"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">318912</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member_jeH3ukS87UGj2TpOqDjAFA"
      decimals="0"
      id="Narr_l_hRRwMgiE284Pu7JgjIlg"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">8668</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member_63yRM8kz2kC7BUq4_p_EHA"
      decimals="0"
      id="Narr_pPO2VMB5O0OMUxpoRUP8JA"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">921168</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member_5mpVmM87DESzmaMO4y48HQ"
      decimals="0"
      id="Narr_Kz6vgnZKbkmEvZXKuv8jqA"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">924688</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member_5mpVmM87DESzmaMO4y48HQ"
      decimals="0"
      id="Narr_eyOUNIpHDEuwt_NzWIhNkQ"
      unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member_63yRM8kz2kC7BUq4_p_EHA"
      decimals="0"
      id="Narr__KVXk1moKU2d4LqJdEq3Ag"
      unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member_jeH3ukS87UGj2TpOqDjAFA"
      decimals="0"
      id="Narr_ZiqrTjjEDkqjCfkqvFL0zA"
      unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_oJ50QEhRZ06VPJ26jZEX3Q"
      decimals="INF"
      id="Narr_q6mv2u0jpUy0ZtFzjVJUiw"
      unitRef="Unit_Standard_pure_o6l_rGctYUCSP0KoHptHcQ">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <glyc:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_eZd6RRkvHUKXyt8ofzDQvA"
      id="Narr_QEOkgkbltEuVMGRQeJoazA">P90D</glyc:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_eZd6RRkvHUKXyt8ofzDQvA"
      id="Narr_6pnRzAnQdE-mkTCJZnYMDw">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_1_9_2014_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_d0xG-7CT90iIt0iDg2j1hA"
      decimals="INF"
      id="Narr_H1tXXdL2l0WfVo0GxbDVNw"
      unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <glyc:PercentageOfTotalNumberOfCommonStockOutstandingOnLastBusinessDayOfPriorFiscalYearThatMayAutomaticallyIncreaseUnderPlan
      contextRef="As_Of_1_9_2014_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_d0xG-7CT90iIt0iDg2j1hA"
      decimals="2"
      id="Narr_j3BB9QfInEqRv036aZsWvw"
      unitRef="Unit_Standard_pure_o6l_rGctYUCSP0KoHptHcQ">0.03</glyc:PercentageOfTotalNumberOfCommonStockOutstandingOnLastBusinessDayOfPriorFiscalYearThatMayAutomaticallyIncreaseUnderPlan>
    <glyc:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMaximumSharesIssuedUponExerciseOfIncentiveStockOptions
      contextRef="As_Of_1_9_2014_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_d0xG-7CT90iIt0iDg2j1hA"
      decimals="INF"
      id="Narr_SJuGqMkxIkyK615ZTYe9dw"
      unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA">20000000</glyc:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMaximumSharesIssuedUponExerciseOfIncentiveStockOptions>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_eZd6RRkvHUKXyt8ofzDQvA"
      id="Tb_VUPdjkiiy0-BM53Ut6xjXw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:45.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;WEIGHTED-&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;AGGREGATE&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;WEIGHTED-&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;AVERAGE&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;INTRINSIC&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;AVERAGE&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;REMAINING&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;VALUE&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;OUTSTANDING&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EXERCISE&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;CONTRACTUAL&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(IN&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;OPTIONS&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;PRICE&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;TERM&#160;(YEARS)&lt;/b&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;THOUSANDS)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding as of December&#160;31,&#160;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5,753,211&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 8.93&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 6.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"&gt;Options granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 898,100&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3.70&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"&gt;Options exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"&gt;Options forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (995,854)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 7.89&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding as of December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5,655,457&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 8.30&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;6.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Vested or expected to vest as of December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5,655,457&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 8.30&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;6.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercisable as of December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 4,118,394&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 9.43&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;5.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2020_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_6XsGrPnc8UiemnfhfN3QiA"
      decimals="INF"
      id="Tc_6SbS1cQ_B0q1dIO8IOcu4A_6_2"
      unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA">5753211</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2020_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_6XsGrPnc8UiemnfhfN3QiA"
      decimals="2"
      id="Tc_tg67UBqgWkW6BjxclmAvIw_6_5"
      unitRef="Unit_Divide_USD_shares_6ZVfdDCn5UCsvmo46quH_A">8.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_NttqVJp3_kWhhS50-PEXsg"
      id="Tc_upYDtWrTQ0KyxZbHM93mBw_6_7">P6Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_eZd6RRkvHUKXyt8ofzDQvA"
      decimals="INF"
      id="Tc__KibyzseyEmul7oWPvfKUA_7_2"
      unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA">898100</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_eZd6RRkvHUKXyt8ofzDQvA"
      decimals="2"
      id="Tc_ZDIKdCYa0EaqBZ-BYHNzHQ_7_5"
      unitRef="Unit_Divide_USD_shares_6ZVfdDCn5UCsvmo46quH_A">3.70</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_eZd6RRkvHUKXyt8ofzDQvA"
      decimals="INF"
      id="Tc_3T0N3aTMM02wvMkrgcEAEA_9_2"
      unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA">995854</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_eZd6RRkvHUKXyt8ofzDQvA"
      decimals="2"
      id="Tc_c5YF6Qfcb0-v0y9vo-VJ-w_9_5"
      unitRef="Unit_Divide_USD_shares_6ZVfdDCn5UCsvmo46quH_A">7.89</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_bi2yzHjMgEqMF9n2Whpj0Q"
      decimals="INF"
      id="Tc_1QWR-eryHU--kbkVwuzoog_10_2"
      unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA">5655457</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_bi2yzHjMgEqMF9n2Whpj0Q"
      decimals="2"
      id="Tc_1m-pxS8MQUq2FlWLDlvmEQ_10_5"
      unitRef="Unit_Divide_USD_shares_6ZVfdDCn5UCsvmo46quH_A">8.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_eZd6RRkvHUKXyt8ofzDQvA"
      id="Tc_qKy8E-MQK06woQYvWnIuMA_10_7">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_bi2yzHjMgEqMF9n2Whpj0Q"
      decimals="INF"
      id="Tc_puveDXGAg0S1gHx-6cUbxw_11_2"
      unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA">5655457</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_bi2yzHjMgEqMF9n2Whpj0Q"
      decimals="2"
      id="Tc_9xN1-y9a3k61Za9spOuCGQ_11_5"
      unitRef="Unit_Divide_USD_shares_6ZVfdDCn5UCsvmo46quH_A">8.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_eZd6RRkvHUKXyt8ofzDQvA"
      id="Tc_H7O3kHuowk6qzEM4qPVtEQ_11_7">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_bi2yzHjMgEqMF9n2Whpj0Q"
      decimals="INF"
      id="Tc_yyjaespr3EOnpuxBVrwLvw_12_2"
      unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA">4118394</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_bi2yzHjMgEqMF9n2Whpj0Q"
      decimals="2"
      id="Tc_y3dVgcDBw0eDcb_lmjulQQ_12_5"
      unitRef="Unit_Divide_USD_shares_6ZVfdDCn5UCsvmo46quH_A">9.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_eZd6RRkvHUKXyt8ofzDQvA"
      id="Tc_fZTwlQBFE0GjuuchNWZHaQ_12_7">P5Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_bi2yzHjMgEqMF9n2Whpj0Q"
      decimals="0"
      id="Narr_KF5o-vvIwUi-fEhwt1zTUg"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">4936519</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_eZd6RRkvHUKXyt8ofzDQvA"
      id="Narr_31Lg0OattE6e4VEOJD62AA">P2Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_eZd6RRkvHUKXyt8ofzDQvA"
      decimals="0"
      id="Narr_qX-mmXMfBEW-tdrOjaxtvA"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">5936641</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_NttqVJp3_kWhhS50-PEXsg"
      decimals="0"
      id="Narr_or52JQ6OYk2P37JQpF-9nA"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">7347548</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_8PxguNi7E0SE41ALnvi46Q"
      decimals="0"
      id="Narr_C92_q_AX_0-3ggOGOv6zEQ"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">6159610</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_NttqVJp3_kWhhS50-PEXsg"
      decimals="INF"
      id="Narr_88uXqtecvkSwTvntHCN-0w"
      unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_eZd6RRkvHUKXyt8ofzDQvA"
      decimals="INF"
      id="Narr_HjnBrgi3W0utyWnkgyuXeA"
      unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_8PxguNi7E0SE41ALnvi46Q"
      decimals="0"
      id="Narr_TiMCsJgpGk-Telsq3_BEUw"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">94001</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_8PxguNi7E0SE41ALnvi46Q"
      decimals="INF"
      id="Narr_EPM5Df7lvUq5bsIz9RG9Ow"
      unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA">16606</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_8PxguNi7E0SE41ALnvi46Q"
      decimals="0"
      id="Narr_RyMAXLBMhUO-Fsr9sDdrpQ"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">97429</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2021_To_1_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_LrXUfN_p-k2RD7cVXcpvfg"
      id="Narr_uEfnpdv6I026kWbPuxd-gQ">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_9_1_2019_To_9_30_2019_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_GTVLQ6MzkE-5qigN7ZgeAg"
      decimals="0"
      id="Narr_tJ5ExGt2eUG9mnjhjWmLoA"
      unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA">332106</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_9_1_2019_To_9_30_2019_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_GTVLQ6MzkE-5qigN7ZgeAg"
      id="Narr_asvxjGNCME2neohLtFcHCA">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_hGgbCUWxnEO5H7nrY_ZOdA"
      decimals="0"
      id="Narr_xCd6pHNCYEqqOPX-OjoZ9w"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">943458</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_F6fULr1eMk6oFlHq__Rahw"
      id="Narr_PeFMo7Se9kyU-P6yvxBfcA">P3Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_eZd6RRkvHUKXyt8ofzDQvA"
      id="Tb_d49b3XTibkW7KBeNcW4cew">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"&gt;The following is a summary of RSU activity for the 2013 Plan for the year ended December 31, 2021:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Grant Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Underlying RSUs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Unvested at December&#160;31,&#160;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 192,533&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 4.53&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 444,613&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3.72&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (101,754)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3.84&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (189,792)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 4.53&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Unvested at December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 345,600&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3.70&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_TvjyyCwqk0mi8fnukedXiQ"
      decimals="0"
      id="Tc_YTiEEKj1qUa5gIqCE-qkMA_4_2"
      unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA">192533</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_TvjyyCwqk0mi8fnukedXiQ"
      decimals="2"
      id="Tc_jkyi0JTnUEq4b3_7um77NQ_4_5"
      unitRef="Unit_Divide_USD_shares_6ZVfdDCn5UCsvmo46quH_A">4.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_LNH3eNmn5kWst66eRhnJGQ"
      decimals="0"
      id="Tc_oYinc6NMK0WGFcmFva0gRg_5_2"
      unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA">444613</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_LNH3eNmn5kWst66eRhnJGQ"
      decimals="2"
      id="Tc_KWMFjTtx-kmot9QXJSWN-A_5_5"
      unitRef="Unit_Divide_USD_shares_6ZVfdDCn5UCsvmo46quH_A">3.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_LNH3eNmn5kWst66eRhnJGQ"
      decimals="0"
      id="Tc_KAH68dx_AE-6uMABzvUwFg_6_2"
      unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA">101754</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_LNH3eNmn5kWst66eRhnJGQ"
      decimals="2"
      id="Tc_qMDuvCSRqUeLG0zZ4__Rsw_6_5"
      unitRef="Unit_Divide_USD_shares_6ZVfdDCn5UCsvmo46quH_A">3.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_LNH3eNmn5kWst66eRhnJGQ"
      decimals="0"
      id="Tc_LC0rCm30GEegC5xepMvQJg_7_2"
      unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA">189792</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_LNH3eNmn5kWst66eRhnJGQ"
      decimals="2"
      id="Tc_bEnHFcyOK0q2hkF8MQ5zLg_7_5"
      unitRef="Unit_Divide_USD_shares_6ZVfdDCn5UCsvmo46quH_A">4.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_v6BAgvQ6UUWIq_blSFIw4Q"
      decimals="0"
      id="Tc_JDQUQD280UOWxAw64hlb1g_8_2"
      unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA">345600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_v6BAgvQ6UUWIq_blSFIw4Q"
      decimals="2"
      id="Tc_4MZOchggYU-1qq9ypHM6-Q_8_5"
      unitRef="Unit_Divide_USD_shares_6ZVfdDCn5UCsvmo46quH_A">3.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <glyc:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfMonthlyInstallments
      contextRef="Duration_1_1_2020_To_1_31_2020_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_Ni5UYq-FH06wJXsy0UsclA"
      decimals="INF"
      id="Narr_dYAMbdb7YEeTGLmxvFoCPQ"
      unitRef="Unit_Standard_installment_ezhGoeeUrke0O6iEcwxJow">36</glyc:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfMonthlyInstallments>
    <glyc:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment
      contextRef="Duration_1_1_2020_To_1_31_2020_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_Ni5UYq-FH06wJXsy0UsclA"
      id="Narr_nTJvaIbL0k-W4l5GG4ttgg">P90D</glyc:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_1_1_2020_To_1_31_2020_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_OL9RAaPvWESWUYV6Drys3g"
      id="Narr_pxQYiWSDsUSN8UCY5Ct3Uw">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_1_31_2020_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_1T-jaCj3OkSylxW_fFHbkQ"
      decimals="INF"
      id="Narr_OJAtGCmjKUC7al7TSE4LKQ"
      unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_GhGdoDUAg0O8Z5VKpubXGw"
      decimals="INF"
      id="Narr_zsEhyK9nG0qV6_K-U6BPuA"
      unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA">2000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="Duration_1_1_2022_To_1_31_2022_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_kGIqsGlMMESnv3YKbnouEg"
      decimals="INF"
      id="Narr_WjN1aFBRMEuLUVzQfoLn1w"
      unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA">3000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_GhGdoDUAg0O8Z5VKpubXGw"
      id="Tb_pDjtUOwCSUmNDr2v-Xn_Kw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:45.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#0000ff;font-size:14pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;WEIGHTED-&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;AGGREGATE&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;WEIGHTED-&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;AVERAGE&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;INTRINSIC&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;AVERAGE&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;REMAINING&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;VALUE&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;OUTSTANDING&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EXERCISE&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;CONTRACTUAL&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(IN&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;OPTIONS&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;PRICE&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;TERM&#160;(YEARS)&lt;/b&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;THOUSANDS)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding as of December&#160;31,&#160;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 100,600&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3.09&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 9.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"&gt;Options granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,747,600&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2.02&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"&gt;Options exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (10,092)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2.06&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"&gt;Options forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (24,508)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2.06&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding as of December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,813,600&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2.08&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;9.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Vested or expected to vest as of December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,264,400&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2.10&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;9.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercisable as of December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 22,879&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3.58&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;8.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2020_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_NxJ0kAmhLEq77boNzSrSDA"
      decimals="INF"
      id="Tc_Dt4ESSR1I02cgScS-_BhAw_6_2"
      unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA">100600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2020_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_NxJ0kAmhLEq77boNzSrSDA"
      decimals="2"
      id="Tc_cXi06vDx-UOrBcorXgn7TQ_6_5"
      unitRef="Unit_Divide_USD_shares_6ZVfdDCn5UCsvmo46quH_A">3.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_0GYTC9bcFEKmU7vQ3oHIOA"
      id="Tc_E2DIj0cQmkS_4yyssA5tNg_6_7">P9Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_GhGdoDUAg0O8Z5VKpubXGw"
      decimals="INF"
      id="Tc_VRPAuBFw_k2J3-7QMEK32w_7_2"
      unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA">1747600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_GhGdoDUAg0O8Z5VKpubXGw"
      decimals="2"
      id="Tc_nG2F162atUOZBQ2aANgC5Q_7_5"
      unitRef="Unit_Divide_USD_shares_6ZVfdDCn5UCsvmo46quH_A">2.02</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_GhGdoDUAg0O8Z5VKpubXGw"
      decimals="INF"
      id="Tc_HtH23ot7N0m5GrvqEFfqsA_8_2"
      unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA">10092</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_GhGdoDUAg0O8Z5VKpubXGw"
      decimals="2"
      id="Tc_asTZgoDU6ESP6OfmzECoKA_8_5"
      unitRef="Unit_Divide_USD_shares_6ZVfdDCn5UCsvmo46quH_A">2.06</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_GhGdoDUAg0O8Z5VKpubXGw"
      decimals="INF"
      id="Tc_ofNafTptS02XJqPhm_M9wg_9_2"
      unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA">24508</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_GhGdoDUAg0O8Z5VKpubXGw"
      decimals="2"
      id="Tc_-qZfOVEzN0eKnBfN2FMkBQ_9_5"
      unitRef="Unit_Divide_USD_shares_6ZVfdDCn5UCsvmo46quH_A">2.06</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_K6ogEy0tQUqO5CmxYBaQzw"
      decimals="INF"
      id="Tc_JLAFZIDQbE-HKMk6G1Yzgw_10_2"
      unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA">1813600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_K6ogEy0tQUqO5CmxYBaQzw"
      decimals="2"
      id="Tc_M4eI31NV40SIQxrqUPFxPg_10_5"
      unitRef="Unit_Divide_USD_shares_6ZVfdDCn5UCsvmo46quH_A">2.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_GhGdoDUAg0O8Z5VKpubXGw"
      id="Tc_wtwpwaDRg0SJvut_N4VHsw_10_7">P9Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_K6ogEy0tQUqO5CmxYBaQzw"
      decimals="INF"
      id="Tc_1ns2SqhMaEaeQdX2xmhSKA_11_2"
      unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA">1264400</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_K6ogEy0tQUqO5CmxYBaQzw"
      decimals="2"
      id="Tc_nJTcz7-a0kC12IBQDAB5gg_11_5"
      unitRef="Unit_Divide_USD_shares_6ZVfdDCn5UCsvmo46quH_A">2.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_GhGdoDUAg0O8Z5VKpubXGw"
      id="Tc_x4TIOOlagUSEu4uZ9e3k-g_11_7">P9Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_K6ogEy0tQUqO5CmxYBaQzw"
      decimals="INF"
      id="Tc_uHAOAdUSpEmPabD7xNtOew_12_2"
      unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA">22879</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_K6ogEy0tQUqO5CmxYBaQzw"
      decimals="2"
      id="Tc_vc8yX0SDd0KGNNWhhD9LNg_12_5"
      unitRef="Unit_Divide_USD_shares_6ZVfdDCn5UCsvmo46quH_A">3.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_GhGdoDUAg0O8Z5VKpubXGw"
      id="Tc_m5DVBgCrnkCcThyBSomD7g_12_7">P8Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_K6ogEy0tQUqO5CmxYBaQzw"
      decimals="0"
      id="Narr_Fmw7xqsp_0-HVjXKPBR0gQ"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">1672270</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_GhGdoDUAg0O8Z5VKpubXGw"
      id="Narr_gd0xsb8nFUmBPBGj5ST1eA">P3Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_8_1_2021_To_8_31_2021_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_BlzQN5DfO0-Ob94oAMtNUQ"
      decimals="INF"
      id="Narr_q6K_9D4DZ0yA1fHPwKPtYA"
      unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA">1647600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_8_1_2021_To_8_31_2021_us-gaap_AwardTypeAxis_glyc_StockOptionsVestingBasedOnServiceMember_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_pYIDtpqKaEq0Rg2wBD-AaA"
      decimals="INF"
      id="Narr_qchedrdUIkayvg_M4L6tCg"
      unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA">1098400</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_8_1_2021_To_8_31_2021_us-gaap_AwardTypeAxis_glyc_StockOptionsVestingBasedOnServiceMember_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_pYIDtpqKaEq0Rg2wBD-AaA"
      decimals="2"
      id="Narr_eEklIilKukS1X34sfkaTgw"
      unitRef="Unit_Standard_pure_o6l_rGctYUCSP0KoHptHcQ">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <glyc:ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingUnderlyingSharesVestPeriod
      contextRef="Duration_8_1_2021_To_8_31_2021_us-gaap_AwardTypeAxis_glyc_StockOptionsVestingBasedOnServiceMember_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_pYIDtpqKaEq0Rg2wBD-AaA"
      id="Narr_2PJ3kHWbzEmGr5ADrqRsEg">P36M</glyc:ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingUnderlyingSharesVestPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_8_1_2021_To_8_31_2021_us-gaap_AwardTypeAxis_glyc_StockOptionsVestingBasedOnPerformanceMember_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_1HlplHgnqkyMSMXLECvRKw"
      decimals="INF"
      id="Narr_CCALcnvHH0alGn9IftgK8Q"
      unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA">549200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <glyc:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFairValueOfOptionExcludedFromUnrecognizedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_glyc_StockOptionsVestingBasedOnPerformanceMember_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_fMP2VYCGhESofSQXDZURMQ"
      decimals="0"
      id="Narr_tL-ajuZf3Em8jqdLjlpjkA"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">798053</glyc:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFairValueOfOptionExcludedFromUnrecognizedCompensationExpense>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_GhGdoDUAg0O8Z5VKpubXGw"
      decimals="0"
      id="Narr_g5nsJ_AnK0ipdL0PurLboA"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">73334</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_GhGdoDUAg0O8Z5VKpubXGw"
      decimals="0"
      id="Narr_WeWEus6-ZkqagO27xvUMRg"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">20790</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_GhGdoDUAg0O8Z5VKpubXGw"
      decimals="INF"
      id="Narr_Na790foF2UKXp-uJtgfnwQ"
      unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA">10092</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_GhGdoDUAg0O8Z5VKpubXGw"
      decimals="-3"
      id="Narr_UNXiWgWch0KE0HSx0xcchA"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">1944000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_0GYTC9bcFEKmU7vQ3oHIOA"
      decimals="INF"
      id="Narr_ZykJW2KW40--Rt0Yz6hAGA"
      unitRef="Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      decimals="2"
      id="Narr_SxEumOMznU6yWp1SrsCMVw"
      unitRef="Unit_Divide_USD_shares_6ZVfdDCn5UCsvmo46quH_A">1.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2020_To_12_31_2020_n4dAyZdoqEGSie7qc7FpOQ"
      decimals="2"
      id="Narr_fn7eZtHKeUi2JhEydjsj0Q"
      unitRef="Unit_Divide_USD_shares_6ZVfdDCn5UCsvmo46quH_A">3.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2019_To_12_31_2019_pmIpEVmd-kmwrLI0XOvIXQ"
      decimals="2"
      id="Narr_3gjPD5yu10Oi6NVyXts50g"
      unitRef="Unit_Divide_USD_shares_6ZVfdDCn5UCsvmo46quH_A">7.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      id="Tb_I22h4zhFnEupJRCgAepTzA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:41.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected term &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;6.25 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;6.25 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;6.25 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;84.19%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;84.40%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;71.15%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;0.78%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;1.41%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;2.54%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;0%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;0%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;0%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      id="Narr_b8sYwQmH3Uyz9RV2JjF-gA">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2020_To_12_31_2020_n4dAyZdoqEGSie7qc7FpOQ"
      id="Narr_4syYGgMN1Ey_tksB5UgD1A">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2019_To_12_31_2019_pmIpEVmd-kmwrLI0XOvIXQ"
      id="Narr_a_0fUunemUebeHW80sEvCg">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      decimals="4"
      id="Tc_sovZBhVMDUaIBejvj859IQ_3_2"
      unitRef="Unit_Standard_pure_o6l_rGctYUCSP0KoHptHcQ">0.8419</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2020_To_12_31_2020_n4dAyZdoqEGSie7qc7FpOQ"
      decimals="4"
      id="Tc_jTiOxPmX-0CpwITysLHj4A_3_4"
      unitRef="Unit_Standard_pure_o6l_rGctYUCSP0KoHptHcQ">0.8440</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2019_To_12_31_2019_pmIpEVmd-kmwrLI0XOvIXQ"
      decimals="4"
      id="Tc_TpIZ7v35KEG8fTvIV_qvcQ_3_6"
      unitRef="Unit_Standard_pure_o6l_rGctYUCSP0KoHptHcQ">0.7115</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      decimals="4"
      id="Tc_iH0cdVWi70SvhoIPZUFnHQ_4_2"
      unitRef="Unit_Standard_pure_o6l_rGctYUCSP0KoHptHcQ">0.0078</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2020_To_12_31_2020_n4dAyZdoqEGSie7qc7FpOQ"
      decimals="4"
      id="Tc_QL9xOGOlYUW2o2O70HM8oA_4_4"
      unitRef="Unit_Standard_pure_o6l_rGctYUCSP0KoHptHcQ">0.0141</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2019_To_12_31_2019_pmIpEVmd-kmwrLI0XOvIXQ"
      decimals="4"
      id="Tc_Tq4-XMmaoE6obwybodYdNg_4_6"
      unitRef="Unit_Standard_pure_o6l_rGctYUCSP0KoHptHcQ">0.0254</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      decimals="2"
      id="Tc_3aCfJuvWaUaQeaIuJ1flkQ_5_2"
      unitRef="Unit_Standard_pure_o6l_rGctYUCSP0KoHptHcQ">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2020_To_12_31_2020_n4dAyZdoqEGSie7qc7FpOQ"
      decimals="2"
      id="Tc_CrIMcDGuP0OTn824WA_YdQ_5_4"
      unitRef="Unit_Standard_pure_o6l_rGctYUCSP0KoHptHcQ">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2019_To_12_31_2019_pmIpEVmd-kmwrLI0XOvIXQ"
      decimals="2"
      id="Tc_y8KOVjazskOqc77WLGlN5w_5_6"
      unitRef="Unit_Standard_pure_o6l_rGctYUCSP0KoHptHcQ">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      id="Tb_c5eEQujWq0ysdIvWIvhOTQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:51.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,214,848&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,946,952&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,402,242&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;General and administrative expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,872,438&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,954,806&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,812,848&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total stock-based compensation expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 6,087,286&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 6,901,758&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 6,215,090&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_-ABYVM1ePU6I7iAmO9SKmA"
      decimals="0"
      id="Tc_VvHifmI9dkuG191-TF_vZA_3_4"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">2214848</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_6th964nOQ0eXBwdN5dw1YA"
      decimals="0"
      id="Tc_AOmilZ3W90SDHbmDvuJQGQ_3_7"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">2946952</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_To7IkJ452EedOpj-Vpzb4Q"
      decimals="0"
      id="Tc_OB4hmGj-lUicNeVqGsC1Og_3_10"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">2402242</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_el_OTs7LDkKYMO80TqWrEQ"
      decimals="0"
      id="Tc_AQ908MZjZkuH9bwLItTOaw_4_4"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">3872438</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_z6e36_7PHUuO7wy1SUfrUg"
      decimals="0"
      id="Tc_vB1mgQ2-rEem3iEkt86p5g_4_7"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">3954806</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_rmnCOBDJHkyNTT0GXfj6Mg"
      decimals="0"
      id="Tc_EuMrI1zcVU6KhRBHHpa-KA_4_10"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">3812848</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      decimals="0"
      id="Tc_AeHp4wwc00uzV2CqzW8Jzw_5_4"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">6087286</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_n4dAyZdoqEGSie7qc7FpOQ"
      decimals="0"
      id="Tc_7KPeGXtly0y0DiuPfhITnA_5_7"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">6901758</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2019_To_12_31_2019_pmIpEVmd-kmwrLI0XOvIXQ"
      decimals="0"
      id="Tc_mPVw0Q1aMkuCVC6qNMPuXA_5_10"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">6215090</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      id="Tb_voiIRtFnw0G2H5efJ2udwQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;10. Income Taxes&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"&gt;The components of the gross deferred tax asset and related valuation allowance at December 31 were as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:59.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:16.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:15.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:0.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:normal;width:18.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:normal;width:17.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:0.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred income tax assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:16.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:15.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"&gt;Net operating loss carryforward&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:16.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 79,788,146&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:15.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 63,830,866&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:0.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"&gt;Capitalized start-up costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:16.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 920,516&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:15.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,114,309&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"&gt;Patent amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:16.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 73,480&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:15.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 88,949&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:0.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"&gt;Research and orphan drug credits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:16.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 47,976,370&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:15.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 42,008,797&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"&gt;Stock-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:16.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 7,102,947&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:15.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 6,778,569&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:0.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"&gt;Operating lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:16.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 528,340&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:15.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 775,598&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"&gt;Accrued bonus&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:16.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 592,260&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:15.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 919,410&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:0.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:16.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 209,580&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:15.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 283,751&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 42pt;"&gt;Gross deferred income tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:16.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 137,191,639&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:15.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 115,800,249&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:0.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 42pt;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:16.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (136,613,829)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:15.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (115,016,323)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 42pt;"&gt;Net deferred income tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:16.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 577,810&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:15.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 783,926&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:0.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 42pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:16.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:15.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred income tax liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:16.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:15.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:0.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"&gt;Operating lease right-of-use assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:16.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (433,727)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:15.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (639,843)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"&gt;Property and equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:16.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (144,083)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:15.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (144,083)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:0.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 42pt;"&gt;Gross deferred income tax liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:16.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (577,810)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:15.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (783,926)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net deferred income tax asset/(liability)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:16.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_1YfPvGN8zkuxUetSrMELxA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:15.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_kVVzvEvEd0Oo7zjJJdtzug;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:0.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:6pt 0pt 6pt 0pt;"&gt;Based on the Company&#x2019;s operating history and management&#x2019;s expectation regarding future profitability, management believes the Company&#x2019;s deferred tax assets will not be realizable under ASC 740, &lt;i style="font-style:italic;"&gt;Income Taxes&lt;/i&gt;. Accordingly, a full valuation allowance has been established as of December 31, 2021 and 2020.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"&gt;As of December 31, 2021, the Company had $290.0 million of U.S. Federal and state net operating losses, $10.3 million of research and development tax credits and $37.7 million of orphan drug tax credits available to carry forward. A portion of the net operating loss carryforwards will begin to expire in 2026, the research and development tax credits in 2023 and the orphan drug tax credit in 2033. Under current federal income tax laws, federal net operating losses incurred in 2018 and in future years may be carried forward, indefinitely, but the deductibility of such federal net operating losses is limited.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"&gt;The Company&#x2019;s tax attributes, including net operating losses and credits, are subject to any ownership changes as defined under Internal Revenue Code Sections 382 and 383. A change in ownership could affect the Company&#x2019;s ability &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"&gt;to utilize its net operating losses and credits. As of December 31, 2021, the Company does not believe that an ownership change has occurred. Any future ownership changes may cause a limitation on the Company&#x2019;s ability to utilize existing tax attributes.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"&gt;The Company files income tax returns in the U.S. federal jurisdiction and in the State of Maryland. The Company&#x2019;s federal income tax returns for tax years 2003 and after remain subject to examination by the U.S. Internal Revenue Service due to tax attributes available to be carried forward to open or future tax years. The Company&#x2019;s Maryland income tax returns for the tax years 2006 and thereafter remain subject to examination by the Comptroller of Maryland. In addition, all of the net operating losses, research and development tax credit and orphan drug credit carryforwards that may be used in future years are still subject to adjustment.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"&gt;The Company did not have unrecognized tax benefits as of December 31, 2021 and 2020, and does not anticipate this to change significantly over the next 12 months. The Company will recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. Reconciliations between the statutory federal income tax rate and the effective income tax rate of income tax expense is as follows as of December 31:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:79.99%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:42.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:14.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:14.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:14.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:42.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:14.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:14.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:14.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:42.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;U.S. Federal statutory tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:14.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:14.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:14.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:42.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;State taxes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:14.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:14.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:14.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:42.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research credit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:14.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 0.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:14.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 0.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:14.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 0.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:42.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Orphan drug credit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:14.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 6.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:14.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 9.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:14.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 8.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:42.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:14.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.3)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:14.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 0.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:14.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:42.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:14.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (34.1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:14.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (37.6)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:14.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (36.2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:42.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Provision for income taxes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:14.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:14.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:14.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      id="Tb_mKFI_sEE30i-ZfDHslEdaw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:59.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:16.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:15.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:0.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:normal;width:18.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:normal;width:17.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:0.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred income tax assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:16.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:15.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"&gt;Net operating loss carryforward&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:16.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 79,788,146&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:15.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 63,830,866&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:0.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"&gt;Capitalized start-up costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:16.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 920,516&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:15.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,114,309&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"&gt;Patent amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:16.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 73,480&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:15.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 88,949&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:0.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"&gt;Research and orphan drug credits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:16.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 47,976,370&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:15.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 42,008,797&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"&gt;Stock-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:16.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 7,102,947&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:15.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 6,778,569&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:0.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"&gt;Operating lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:16.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 528,340&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:15.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 775,598&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"&gt;Accrued bonus&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:16.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 592,260&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:15.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 919,410&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:0.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:16.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 209,580&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:15.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 283,751&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 42pt;"&gt;Gross deferred income tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:16.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 137,191,639&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:15.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 115,800,249&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:0.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 42pt;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:16.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (136,613,829)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:15.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (115,016,323)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 42pt;"&gt;Net deferred income tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:16.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 577,810&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:15.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 783,926&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:0.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 42pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:16.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:15.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred income tax liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:16.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:15.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:0.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"&gt;Operating lease right-of-use assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:16.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (433,727)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:15.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (639,843)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"&gt;Property and equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:16.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (144,083)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:15.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (144,083)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:0.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 42pt;"&gt;Gross deferred income tax liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:16.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (577,810)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:15.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (783,926)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net deferred income tax asset/(liability)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:16.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_1YfPvGN8zkuxUetSrMELxA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:15.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_kVVzvEvEd0Oo7zjJJdtzug;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:0.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg"
      decimals="0"
      id="Tc_mVOL93vqlU6IPLyr8GgqJg_3_3"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">79788146</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug"
      decimals="0"
      id="Tc_99J0ljTAPU-nzS52HpCOWQ_3_6"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">63830866</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <glyc:DeferredTaxAssetsCapitalizedStartUpCosts
      contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg"
      decimals="0"
      id="Tc_N4VTNco2_EarnkNqlsWnxw_4_3"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">920516</glyc:DeferredTaxAssetsCapitalizedStartUpCosts>
    <glyc:DeferredTaxAssetsCapitalizedStartUpCosts
      contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug"
      decimals="0"
      id="Tc_2BSIZ6DUvECPD8Nf6J_qww_4_6"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">1114309</glyc:DeferredTaxAssetsCapitalizedStartUpCosts>
    <glyc:DeferredTaxAssetsPatentAmortization
      contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg"
      decimals="0"
      id="Tc_Zj0DkHBagU2kaQ-0KSA2GQ_5_3"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">73480</glyc:DeferredTaxAssetsPatentAmortization>
    <glyc:DeferredTaxAssetsPatentAmortization
      contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug"
      decimals="0"
      id="Tc_nl3INMKF7ke2U3dEgbXGBg_5_6"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">88949</glyc:DeferredTaxAssetsPatentAmortization>
    <glyc:DeferredTaxAssetsResearchAndOrphanDrugCredits
      contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg"
      decimals="0"
      id="Tc_OtYPrXZFPEa4Mo0UPFaqpA_6_3"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">47976370</glyc:DeferredTaxAssetsResearchAndOrphanDrugCredits>
    <glyc:DeferredTaxAssetsResearchAndOrphanDrugCredits
      contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug"
      decimals="0"
      id="Tc_Ey-FFNxUC0qjzJzTeUQe-g_6_6"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">42008797</glyc:DeferredTaxAssetsResearchAndOrphanDrugCredits>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
      contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg"
      decimals="0"
      id="Tc_DoVGgtaXNE-BxxvxVmfyAQ_7_3"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">7102947</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
      contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug"
      decimals="0"
      id="Tc_Mwwmr58W4ES-j0AOETa9gQ_7_6"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">6778569</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <glyc:DeferredTaxAssetsTaxDeferredExpenseOperatingLeaseLiabilities
      contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg"
      decimals="0"
      id="Tc_tusw-_CnVEa6L78xFISGNQ_8_3"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">528340</glyc:DeferredTaxAssetsTaxDeferredExpenseOperatingLeaseLiabilities>
    <glyc:DeferredTaxAssetsTaxDeferredExpenseOperatingLeaseLiabilities
      contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug"
      decimals="0"
      id="Tc_T5Uz3xGWJ0uWv0jeGmmSMw_8_6"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">775598</glyc:DeferredTaxAssetsTaxDeferredExpenseOperatingLeaseLiabilities>
    <glyc:DeferredTaxAssetsAccruedBonus
      contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg"
      decimals="0"
      id="Tc_5FeJVF_RwU6RqRQNgbHsdA_9_3"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">592260</glyc:DeferredTaxAssetsAccruedBonus>
    <glyc:DeferredTaxAssetsAccruedBonus
      contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug"
      decimals="0"
      id="Tc_JoQf4y24iE6ybFCF6_ToUQ_9_6"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">919410</glyc:DeferredTaxAssetsAccruedBonus>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg"
      decimals="0"
      id="Tc_PYrXCh2zXUmTn_VGVtMdqQ_10_3"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">209580</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug"
      decimals="0"
      id="Tc_l9Y2HKoWiUOqTy6ft2_BmQ_10_6"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">283751</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg"
      decimals="0"
      id="Tc_dBnoXbg_B0S15sur67YVVA_11_3"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">137191639</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug"
      decimals="0"
      id="Tc_KKH2thgumkuYetZsrAPLbA_11_6"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">115800249</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg"
      decimals="0"
      id="Tc_Dy16AHnSs0Ce6KPY2I0Xow_12_3"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">136613829</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug"
      decimals="0"
      id="Tc_PQYfgAIsb0mxvC0rPbjZmQ_12_6"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">115016323</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg"
      decimals="0"
      id="Tc_CV4X_3K2bUyorDePQ6_qng_13_3"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">577810</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug"
      decimals="0"
      id="Tc_BSLnTgPen0ms4y2DybJe8A_13_6"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">783926</us-gaap:DeferredTaxAssetsNet>
    <glyc:DeferredTaxLiabilitiesTaxDeferredExpenseOperatingLeaseLiabilitiesRightOfUseAssets
      contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg"
      decimals="0"
      id="Tc_nhDp2LaVz06e3vJoSxzmSg_16_3"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">433727</glyc:DeferredTaxLiabilitiesTaxDeferredExpenseOperatingLeaseLiabilitiesRightOfUseAssets>
    <glyc:DeferredTaxLiabilitiesTaxDeferredExpenseOperatingLeaseLiabilitiesRightOfUseAssets
      contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug"
      decimals="0"
      id="Tc_Fz2IB8aklk-et3V1H_ZF4w_16_6"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">639843</glyc:DeferredTaxLiabilitiesTaxDeferredExpenseOperatingLeaseLiabilitiesRightOfUseAssets>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg"
      decimals="0"
      id="Tc_avu4qAHO_UW2VCWMmD0ILg_17_3"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">144083</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug"
      decimals="0"
      id="Tc_wJ8_joiiZUuK9z9CmNVi-w_17_6"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">144083</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg"
      decimals="0"
      id="Tc_FdWShxjPUUua4QEkAhIgiA_18_3"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">577810</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="As_Of_12_31_2020_Lj_m2DtHHkSqtnW83Sjtug"
      decimals="0"
      id="Tc_hI4XEb_YxEu89LTIKx6aZA_18_6"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">783926</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_glyc_FederalAndStateAuthoritiesMember_onB_QxVk6kiCCtMYcUAFbg"
      decimals="-5"
      id="Narr_VyrVpc3W3E-iaPfinwkMoA"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">290000000.0</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="As_Of_12_31_2021_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_D-pk4UYBwUG2J1DzykZ-HQ"
      decimals="-5"
      id="Narr_hkjFWkzGCU69MUmjR6llvQ"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">10300000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="As_Of_12_31_2021_us-gaap_TaxCreditCarryforwardAxis_us-gaap_GeneralBusinessMember_ecyj2U3Yt0Wb9cFTtDT3zQ"
      decimals="-5"
      id="Narr_V6_Kw3YLlUa14VTG4Y5nEw"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">37700000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      id="Tb_UnVQ94czLUWE11eQtW9fFQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:79.99%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:42.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:14.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:14.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:14.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:42.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:14.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:14.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:14.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:42.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;U.S. Federal statutory tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:14.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:14.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:14.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:42.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;State taxes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:14.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:14.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:14.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:42.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research credit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:14.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 0.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:14.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 0.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:14.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 0.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:42.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Orphan drug credit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:14.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 6.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:14.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 9.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:14.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 8.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:42.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:14.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.3)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:14.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 0.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:14.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:42.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:14.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (34.1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:14.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (37.6)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:14.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (36.2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:42.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Provision for income taxes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:14.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:14.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:14.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      decimals="INF"
      id="Tc_F5quWnc3uES62G6XfSgstQ_2_2"
      unitRef="Unit_Standard_pure_o6l_rGctYUCSP0KoHptHcQ">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2020_To_12_31_2020_n4dAyZdoqEGSie7qc7FpOQ"
      decimals="INF"
      id="Tc_fTSnBhtrz0qzNPD8d98RDA_2_4"
      unitRef="Unit_Standard_pure_o6l_rGctYUCSP0KoHptHcQ">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2019_To_12_31_2019_pmIpEVmd-kmwrLI0XOvIXQ"
      decimals="INF"
      id="Tc_uEvTmQ33S0CIqAgAFXcMLg_2_6"
      unitRef="Unit_Standard_pure_o6l_rGctYUCSP0KoHptHcQ">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      decimals="3"
      id="Tc_7b4DMmM-a0i1hg2Oca1oug_3_2"
      unitRef="Unit_Standard_pure_o6l_rGctYUCSP0KoHptHcQ">0.059</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2020_To_12_31_2020_n4dAyZdoqEGSie7qc7FpOQ"
      decimals="3"
      id="Tc_29yZVNWCL0qTxaBoAnQwVw_3_4"
      unitRef="Unit_Standard_pure_o6l_rGctYUCSP0KoHptHcQ">0.057</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2019_To_12_31_2019_pmIpEVmd-kmwrLI0XOvIXQ"
      decimals="3"
      id="Tc_ezYifR7gN0SGMZlblVgAzg_3_6"
      unitRef="Unit_Standard_pure_o6l_rGctYUCSP0KoHptHcQ">0.057</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      decimals="3"
      id="Tc_JBgqZ3Uc_0q6qIbFPPUrBQ_4_2"
      unitRef="Unit_Standard_pure_o6l_rGctYUCSP0KoHptHcQ">0.009</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="Duration_1_1_2020_To_12_31_2020_n4dAyZdoqEGSie7qc7FpOQ"
      decimals="3"
      id="Tc_lbJX3aVJEE-9GsP11zqJ2A_4_4"
      unitRef="Unit_Standard_pure_o6l_rGctYUCSP0KoHptHcQ">0.007</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="Duration_1_1_2019_To_12_31_2019_pmIpEVmd-kmwrLI0XOvIXQ"
      decimals="3"
      id="Tc_WetBXf1rH0mqtioqr8k4fQ_4_6"
      unitRef="Unit_Standard_pure_o6l_rGctYUCSP0KoHptHcQ">0.008</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <glyc:EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      decimals="3"
      id="Tc_nfh-aO_Wskan3xEEamJehw_5_2"
      unitRef="Unit_Standard_pure_o6l_rGctYUCSP0KoHptHcQ">0.066</glyc:EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent>
    <glyc:EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent
      contextRef="Duration_1_1_2020_To_12_31_2020_n4dAyZdoqEGSie7qc7FpOQ"
      decimals="3"
      id="Tc_geEvh3Hhtk2ytUhVVqH29w_5_4"
      unitRef="Unit_Standard_pure_o6l_rGctYUCSP0KoHptHcQ">0.098</glyc:EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent>
    <glyc:EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent
      contextRef="Duration_1_1_2019_To_12_31_2019_pmIpEVmd-kmwrLI0XOvIXQ"
      decimals="3"
      id="Tc_jv1x-eWOMkK4D2bIXkqr-w_5_6"
      unitRef="Unit_Standard_pure_o6l_rGctYUCSP0KoHptHcQ">0.088</glyc:EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      decimals="3"
      id="Tc_7s0N_s0H80qcXP4qZvfy0w_6_2"
      unitRef="Unit_Standard_pure_o6l_rGctYUCSP0KoHptHcQ">-0.003</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="Duration_1_1_2020_To_12_31_2020_n4dAyZdoqEGSie7qc7FpOQ"
      decimals="3"
      id="Tc_eUI1M29hLkOXyhxQqHDnsA_6_4"
      unitRef="Unit_Standard_pure_o6l_rGctYUCSP0KoHptHcQ">0.004</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="Duration_1_1_2019_To_12_31_2019_pmIpEVmd-kmwrLI0XOvIXQ"
      decimals="3"
      id="Tc_l5rUup43ZkqfD6-hj__rxg_6_6"
      unitRef="Unit_Standard_pure_o6l_rGctYUCSP0KoHptHcQ">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      decimals="3"
      id="Tc_MgJ91dV200qXkNv67FU1vw_7_2"
      unitRef="Unit_Standard_pure_o6l_rGctYUCSP0KoHptHcQ">-0.341</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2020_To_12_31_2020_n4dAyZdoqEGSie7qc7FpOQ"
      decimals="3"
      id="Tc_VLmTcCrjfEawsS9h_IlT_w_7_4"
      unitRef="Unit_Standard_pure_o6l_rGctYUCSP0KoHptHcQ">-0.376</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2019_To_12_31_2019_pmIpEVmd-kmwrLI0XOvIXQ"
      decimals="3"
      id="Tc_bTJTrT8SjkGu3F-ko86NVA_7_6"
      unitRef="Unit_Standard_pure_o6l_rGctYUCSP0KoHptHcQ">-0.362</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <glyc:ResearchAndLicenseAgreementTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      id="Tb_Imwu8GL6xU6cxXKrXDtmwg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;11. &#160;Research and License Agreements&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Apollomics&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27pt;margin:0pt 0pt 6pt 0pt;"&gt;In January 2020, the Company entered into a collaboration and license agreement (the Agreement) with Apollomics (Hong Kong), Limited (Apollomics) for the development, manufacture and commercialization of products derived from two of the Company&#x2019;s compounds, GMI-1271 and GMI-1687 (the Products) for therapeutic and prophylactic uses (the Field) in China, Taiwan, Hong Kong and Macau (the Territory). Under the terms of the Agreement, the Company granted Apollomics:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:24.5pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;an exclusive license, with the right to sublicense, to develop, manufacture and have manufactured, distribute, market, promote, sell, have sold, offer for sale, import, label, package and otherwise the Products in the Field in the Territory; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:24.5pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;a non-exclusive license to conduct preclinical research with respect to Products in the Field outside of the Territory for the purposes of developing such Products for use in the Territory.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:6pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27pt;margin:0pt;"&gt;In June 2020, the Company and Apollomics entered into a clinical supply agreement pursuant to which the Company will manufacture and supply the Products at agreed upon prices. Apollomics has the option to begin manufacture of the Products after appropriate material transfer requirements are met. During the year ended December 30, 2021, the Company recognized $1.1 million as revenue from the sale of clinical supplies to Apollomics.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27pt;margin:0pt;"&gt;The Company evaluated the Agreement under the provisions of ASC 606 and identified two performance obligations under this revenue arrangement: the (i) delivery of functional licenses and (ii) manufacture and supply of the Products. The initial transaction price consists of a $9.0 million non-refundable up-front payment which was allocated to the delivered functional licenses and recognized in full as revenue in the first quarter of 2020 given that the performance obligation was satisfied upon inception. The Agreement contains various forms of variable consideration, including (i) up to $75.0 million in development milestones based on achievement of certain clinical and regulatory events, (ii) up to $105.0 million of sales-based commercial milestones based on achievement of certain annual net sales targets, (iii) sales-based royalties at specified percentages of net sales ranging from the high single digits to 15%, and (iv) manufacture and supply of clinical and commercial Products. The Company has fully constrained the development milestone consideration using the most likely amount method and will recognize that revenue when it is probable that recognition &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price. In September 2020, the Company received a non-refundable $1.0 million development milestone payment upon acceptance by Chinese regulatory authorities of a Phase 3 bridging study design to support registration in China. The Company recognized this $1.0 million payment as revenue in the quarter ended September 30, 2020. The Company did not recognize any milestone revenue under the Agreement for the year ended December 31, 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27pt;margin:0pt 0pt 6pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt; The Company will recognize revenue related to the sales-based commercial and royalty milestones and royalties at the later of (i) when the related sales occur or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied), as they were determined to relate predominantly to the licenses granted to Apollomics and, therefore, have been excluded from the transaction price. Lastly, the Company has determined that the consideration for the manufacturing and supply is all variable and is fully constrained. Variable consideration allocated to manufacturing and supply will be recognized at a point in time when the Product is delivered and when the title to the Product is transferred to the customer pursuant to the agreement. The Company reassesses the transaction price in each reporting period and upon the occurrence of a change in circumstances or final resolution of any particular event.&lt;/span&gt;&lt;/p&gt;</glyc:ResearchAndLicenseAgreementTextBlock>
    <glyc:RevenueReceivedFromSaleOfClinicalSupplies
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_glyc_ApollomicMember_u1SJvvGvK0azW3aP0YW7WQ"
      decimals="-5"
      id="Narr_qu2Iy01mqEK7ghM9WdRfnA"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">1100000</glyc:RevenueReceivedFromSaleOfClinicalSupplies>
    <glyc:UpFrontPaymentReceived
      contextRef="Duration_1_1_2020_To_3_31_2020_srt_CounterpartyNameAxis_glyc_ApollomicMember__UsntURv-UWFpyJ1frsxHw"
      decimals="-5"
      id="Narr_OvRLl3ZLXEGtBpANswgV2w"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">9000000.0</glyc:UpFrontPaymentReceived>
    <glyc:DevelopmentAndRegulatoryApprovalMilestonesClinicalAndRegulatoryEvents
      contextRef="Duration_1_1_2020_To_3_31_2020_srt_CounterpartyNameAxis_glyc_ApollomicMember_srt_RangeAxis_srt_MaximumMember_jz80Uqp0xkifz7ggXf9mng"
      decimals="-5"
      id="Narr_rmo959dQpUebSYJYeOZgPA"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">75000000.0</glyc:DevelopmentAndRegulatoryApprovalMilestonesClinicalAndRegulatoryEvents>
    <glyc:AchievementOfSpecifiedNetSalesThresholdsForAllLicensedProducts
      contextRef="Duration_1_1_2020_To_3_31_2020_srt_CounterpartyNameAxis_glyc_ApollomicMember_srt_RangeAxis_srt_MaximumMember_jz80Uqp0xkifz7ggXf9mng"
      decimals="-5"
      id="Narr_4ho0UoJGVkq7IWffAnchBQ"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">105000000.0</glyc:AchievementOfSpecifiedNetSalesThresholdsForAllLicensedProducts>
    <glyc:TieredPercentageOfAnnualNetSales
      contextRef="Duration_1_1_2020_To_3_31_2020_srt_CounterpartyNameAxis_glyc_ApollomicMember_srt_RangeAxis_srt_MaximumMember_jz80Uqp0xkifz7ggXf9mng"
      decimals="2"
      id="Narr_ZrgHpZekR0OYqS3PBoqZaw"
      unitRef="Unit_Standard_pure_o6l_rGctYUCSP0KoHptHcQ">0.15</glyc:TieredPercentageOfAnnualNetSales>
    <glyc:MilestoneRevenueRecognized
      contextRef="Duration_9_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_glyc_ApollomicMember_fv4inACjoUWDFNulm8LqCA"
      decimals="-5"
      id="Narr_wy8blxrMg0eTJjqw_AGmWw"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">1000000.0</glyc:MilestoneRevenueRecognized>
    <glyc:MilestoneRevenueRecognized
      contextRef="Duration_9_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_glyc_ApollomicMember_fv4inACjoUWDFNulm8LqCA"
      decimals="-5"
      id="Narr_hAJXFyocBk-fYOAYHdF6QA"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">1000000.0</glyc:MilestoneRevenueRecognized>
    <us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      id="Tb_qFSL-qx6xE-X6XIrjE7awg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;12. Employee Benefit Plan&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has a defined contribution plan under the Internal Revenue Code Section&#160;401(k). This plan covers substantially all employees who meet minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pre-tax basis. For the years ended December 31, 2021, 2020 and 2019, the Company matched 50%&lt;span style="white-space:pre-wrap;"&gt; up to the first 6%&lt;/span&gt;&lt;span style="white-space:pre-wrap;"&gt; of employee contributions. All matching contributions have been paid by the Company. The Company&#x2019;s matching contributions vest in full immediately. The total Company matching contributions were approximately $270,000, $252,000 and $219,000 for the years ended December 31, 2021, 2020 and 2019, respectively. &lt;/span&gt;&lt;/p&gt;</us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="Duration_1_1_2019_To_12_31_2019_pmIpEVmd-kmwrLI0XOvIXQ"
      decimals="2"
      id="Narr_ZPaXDh1KaUanw5Rzyqxt1g"
      unitRef="Unit_Standard_pure_o6l_rGctYUCSP0KoHptHcQ">0.50</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="Duration_1_1_2020_To_12_31_2020_n4dAyZdoqEGSie7qc7FpOQ"
      decimals="2"
      id="Narr_YOFHt0wZwUOOBe1mgJ63NQ"
      unitRef="Unit_Standard_pure_o6l_rGctYUCSP0KoHptHcQ">0.50</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      decimals="2"
      id="Narr_tfV4krDhxEm5aKoqnrbaJw"
      unitRef="Unit_Standard_pure_o6l_rGctYUCSP0KoHptHcQ">0.50</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MaximumMember_dvu4YMBVCkmKgIY5AJuxZA"
      decimals="2"
      id="Narr_CasoPUjj4kSXhj6jbuf6bA"
      unitRef="Unit_Standard_pure_o6l_rGctYUCSP0KoHptHcQ">0.06</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MaximumMember_w9j8fZvT2UmDwuBnDsgAcw"
      decimals="2"
      id="Narr_by1JU7-SD0Su8jRCmIlSKw"
      unitRef="Unit_Standard_pure_o6l_rGctYUCSP0KoHptHcQ">0.06</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_Bhd-nQulWU6ZbQQpkblCKw"
      decimals="2"
      id="Narr_FYDiHtX18kmnj7HTUInd9g"
      unitRef="Unit_Standard_pure_o6l_rGctYUCSP0KoHptHcQ">0.06</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      decimals="0"
      id="Narr_1XMh6z0qYEyncZAYyKtjSw"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">270000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="Duration_1_1_2020_To_12_31_2020_n4dAyZdoqEGSie7qc7FpOQ"
      decimals="0"
      id="Narr_lD9EdlNXUkqRcMNSVK_Lcw"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">252000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="Duration_1_1_2019_To_12_31_2019_pmIpEVmd-kmwrLI0XOvIXQ"
      decimals="0"
      id="Narr_juhJQnPXyEC_EGg5ZVx9Eg"
      unitRef="Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw">219000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:LossContingencyDisclosures
      contextRef="Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA"
      id="Tb_F_lTuqwzl0WkmORIuq8qFw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;13. Risks and Uncertainties&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;COVID-19&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27pt;margin:0pt;"&gt;In March 2020, the World Health Organization declared the novel coronavirus disease 2019, or COVID-19, outbreak a pandemic. In order to mitigate the spread of COVID-19, governments have imposed unprecedented restrictions on business operations, travel and gatherings, resulting in a global economic downturn and other adverse economic and societal impacts. The COVID-19 pandemic has also overwhelmed or otherwise led to changes in the operations of many healthcare facilities. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:27pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27pt;margin:0pt;"&gt;The impact of the COVID-19 pandemic on the Company&#x2019;s business and financial performance is uncertain and depends on various factors, including the duration of the pandemic, government restrictions and other actions, including relief measures and mass vaccination efforts, implemented to address the impact of the pandemic, and resulting impacts on the financial markets and overall economy. The imposition of &#x201c;lockdown,&#x201d; &#x201c;social distancing&#x201d; and &#x201c;shelter in place&#x201d; directives by state and federal governments in the United States as well as governments in other regions of the world in response to the COVID-19 pandemic, including in locations in which its Phase 3 clinical trial of uproleselan is being conducted, resulted in slowed clinical site initiation, patient recruitment and enrollment rates early in the pandemic. Enrollment rates have returned to forecasted levels since the lockdowns. However, COVID-19 infection rates continue to fluctuate, particularly with the emergence of variants, which could negatively affect completion of the trial. The Company is unable to determine the extent of the impact of the pandemic on its operations and financial condition going forward. These developments are highly uncertain and unpredictable, and may materially adversely affect the Company&#x2019;s financial position and results of operations. The Company continues to closely monitor the COVID-19 situation and any potential impact to its planned activities.&lt;/p&gt;</us-gaap:LossContingencyDisclosures>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>71
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( -E#8U0'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " #90V-4?6%4&^T    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M2L0P$(9?17)O)VU (71[6?&D(+B@> O)[&ZP:4(RTN[;F\;=+J(/(.22F3_?
M? /I=)#:1WR./F DB^EF=L.8I X;=B0*$B#I(SJ5ZIP8<W/OHU.4K_$ 0>D/
M=4!H.;\%AZ2,(@4+L HKD?6=T5)'5.3C&6_TB@^?<2@PHP$'=#A2@J9N@/7+
MQ'":APZN@ 5&&%WZ+J!9B:7Z)[9T@)V3<[)K:IJF>A(EEW=HX.WI\:6L6]DQ
MD1HUYE?)2CH%W+#+Y%>QO=\]L+[E;5MQD<^N$5)P*>[>%]<??E=AYXW=VW]L
M?!'L._CU+_HO4$L#!!0    ( -E#8U297)PC$ 8  )PG   3    >&PO=&AE
M;64O=&AE;64Q+GAM;.U:6W/:.!1^[Z_0>&?V;0O&-H&VM!-S:7;;M)F$[4X?
MA1%8C6QY9)&$?[]'-A#+E@WMDDVZFSP$+.G[SD5'Y^@X>?/N+F+HAHB4\GA@
MV2_;UKNW+][@5S(D$4$P&:>O\, *I4Q>M5II ,,X?<D3$L/<@HL(2W@4R]9<
MX%L:+R/6ZK3;W5:$:6RA&$=D8'U>+&A T%116F]?(+3E'S/X%<M4C66C 1-7
M02:YB+3R^6S%_-K>/F7/Z3H=,H%N,!M8('_.;Z?D3EJ(X53"Q,!J9S]6:\?1
MTDB @LE]E 6Z2?:CTQ4(,@T[.IU8SG9\]L3MGXS*VG0T;1K@X_%X.+;+THMP
M' 3@4;N>PIWT;+^D00FTHVG09-CVVJZ1IJJ-4T_3]WW?ZYMHG J-6T_3:W?=
MTXZ)QJW0> V^\4^'PZZ)QJO0=.MI)B?]KFNDZ19H0D;CZWH2%;7E0-,@ %AP
M=M;,T@.67BGZ=90:V1V[W4%<\%CN.8D1_L;%!-9ITAF6-$9RG9 %#@ WQ-%,
M4'RO0;:*X,*2TER0UL\IM5 :")K(@?5'@B'%W*_]]9>[R:0S>IU].LYKE']I
MJP&G[;N;SY/\<^CDGZ>3UTU"SG"\+ GQ^R-;88<G;CL3<CH<9T)\S_;VD:4E
M,L_O^0KK3CQG'U:6L%W/S^2>C'(CN]WV6'WV3T=N(]>IP+,BUY1&)$6?R"VZ
MY!$XM4D-,A,_")V&F&I0' *D"3&6H8;XM,:L$> 3?;>^",C?C8CWJV^:/5>A
M6$G:A/@01AKBG'/F<]%L^P>E1M'V5;S<HY=8%0&7&-\TJC4LQ=9XE<#QK9P\
M'1,2S90+!D&&ER0F$JDY?DU($_XKI=K^G-- \)0O)/I*D8]ILR.G=";-Z#,:
MP4:O&W6':-(\>OX%^9PU"AR1&QT"9QNS1B&$:;OP'J\DCIJMPA$K0CYB&38:
M<K46@;9QJ81@6A+&T7A.TK01_%FL-9,^8,CLS9%USM:1#A&27C="/F+.BY 1
MOQZ&.$J:[:)Q6 3]GE[#2<'H@LMF_;A^AM4S;"R.]T?4%TKD#R:G/^DR- >C
MFED)O816:I^JAS0^J!XR"@7QN1X^Y7IX"C>6QKQ0KH)[ ?_1VC?"J_B"P#E_
M+GW/I>^Y]#VATK<W(WUGP=.+6]Y&;EO$^ZXQVM<T+BAC5W+-R,=4KY,IV#F?
MP.S]:#Z>\>WZV22$KYI9+2,6D$N!LT$DN/R+RO JQ GH9%LE"<M4TV4WBA*>
M0AMNZ5/U2I77Y:^Y*+@\6^3IKZ%T/BS/^3Q?Y[3-"S-#MW)+ZK:4OK4F.$KT
ML<QP3A[+##MG/)(=MG>@'37[]EUVY".E,%.70[@:0KX#;;J=W#HXGIB1N0K3
M4I!OP_GIQ7@:XCG9!+E]F%=MY]C1T?OGP5&PH^\\EAW'B/*B(>ZAAIC/PT.'
M>7M?F&>5QE T%&ULK"0L1K=@N-?Q+!3@9& MH >#KU$"\E)58#%;Q@,KD*)\
M3(Q%Z'#GEUQ?X]&2X]NF9;5NKREW&6TB4CG":9@39ZO*WF6QP54=SU5;\K"^
M:CVT%4[/_EFMR)\,$4X6"Q)(8Y07IDJB\QE3ON<K2<15.+]%,[82EQB\X^;'
M<4Y3N!)VM@\",KF[.:EZ93%GIO+?+0P)+%N(61+B35WMU>>;G*YZ(G;ZEW?!
M8/+]<,E'#^4[YU_T74.N?O;=X_INDSM(3)QYQ1$!=$4"(Y4<!A87,N10[I*0
M!A,!S93)1/ "@F2F'("8^@N]\@RY*17.K3XY?T4L@X9.7M(E$A2*L P%(1=R
MX^_ODVIWC-?Z+(%MA%0R9-47RD.)P3TS<D/85"7SKMHF"X7;XE3-NQJ^)F!+
MPWING2TG_]M>U#VT%SU&\Z.9X!ZSAW.;>KC"1:S_6-8>^3+?.7#;.MX#7N83
M+$.D?L%]BHJ $:MBOKJO3_DEG#NT>_&!()O\UMND]MW@#'S4JUJE9"L1/TL'
M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M6LNT.%QS%G%E;H#?EU+JW8EIH/KH<_$/4$L#!!0    ( -E#8U0'A)L*0@4
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MCZSU&$QY%&:+1)6AU WDMR9_% 6\POARM7,5MZ[<5GI<<TS#(.$0V^-A5L9
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M4Q_E@=?FEZUL*J;-:[.;JT/#6>&,JG*.(4SF%1/U;+EP8_?-<B&/NA0UOV^
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M/6<%;RS _+Z54K^^V FZZ]?E+U!+ P04    " #90V-4$F@K)$X#  !2!P
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M"88(,,M:!>F.Z$] V:B-CC0>>FKVR$(M632TK-!DA5#[H0T0'8BZ]JQ_L&0
M@W7*;!'K0$,B4#,JVT+CG>$<2 W+.F#LE.Q "K]WW:EF1<PS,>RU.+&, Y[
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MM.3&0<\.9&\<W?)IPPDNS^CV7U!+ P04    " #90V-48CNH*:4%  !N#0
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M'BK$^$1,Q[DJ#1:979?=!V5-P1L]Y_N 6+;JL[4>3W.^\]SK@ %BK@1PC<<
M$()[95<D%3'*2 1/V!0\9_B$O_V" IX-$R7"O" >GC$[I5LL@QKT\N PK:($
M%)A%YB]6OH_"[/XEE(+5..12A7H.YY$'C+C$S!5 XZ(N<G=%J&&O;[4!@I8X
MXXXY/8F'KF!_H#;E!:@?E<$?@N E],]&/U>L<_]?'QI]#YQ @4!'RHIT6;O
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MU])@(W?;$B<G*&N _PLIS4&P!PRS>/474$L#!!0    ( -E#8U2)]%;@N (
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MV-# 9"@ID:Z3_$$H[(2+7\,F1Z"-^!W 91S%N*0P+]:YS!J;LEDS5@IU:U6
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M[*'UPX@A]9YA"%J&P.KM#K):_L0,N[I0\D 44H,T?+"F6FY03M08E'NC8%<
MG[EZ7^>RXN03>^#Z8F% (JXO\I;[QG$'SW#[ ?E5UF:KR<]UP8MC 0M0I=<G
MZ/2Y"5Z4^!//YR3T*0F\P']!7MC;%UIYX=^V[TA<U(N+K+CH&]WU,K?OS<E8
M OFTY01>=[+FM=%$KHF!E8V26B.TN%*\((8]$*8U)"BK"TB$DAE8W;.R80[8
M)606JW-.F"'@/UZMN (?D@-7L*;)6B*%?DM^^"X-O/#=_^P78X3_/#BV558X
M\WJ=_\&I_P&+H?@HL++>D!)]DC.E'J$2'9@J>KHSDF0T25/J1_%H,0YI&GHT
MC8?%6[83AI7B3U!4&Z;,FV8'_M?@^HXD"SRZ] <6G_I^1$,OZU?NP/TUQ**2
MRH@_70BZO22D4>KUKZ!3%@V<'[GF3.5;&T>I=EM6DT(U&Y*#Y\1(B2BA61+3
M,!E$10'UO)0F6=(OW1N9?WV#):FP(()*^40;ZGL!:#"PQ#1)4KJ,!YT^# [F
M((F4@JU$*8S@^B0@RR"E8>2=K"?)DBZSM'^_SG/5@%(K63<34K* !O&IE,S/
M:.0/ZQ\@%=0$Y#*Z3$^Y@S2DR=+OW_]UG$,GL!P"'(*;,I_&X> 4WU_2U/-H
M, K>;Q/YUNV=^V%,8Q\ %V0_CE9!C.=#'(-P6$54OT*M99+0=.2-!.S+@OC$
M[F_]G4K84>R_/6N? DIA6WPCUV\:S9\:>1Z%$+4@&?D,PD#3:.2O.X4UP#S:
MI.%_-&)78?H-3HXBZJ7ACR^L/(^%*;2?MZX?26R=_\H@+LX[L8\#QYE]\H-W
M+ZQTOS<VI0%IV QN(;-9_6AIDW=Z5!&W J8#Y1Q3L1I&*/1,3\@?=C#Y.,@J
MOH&*B4SKQC30%79*KJ$4.BWIB)VL>"GX'OPQ=?AI3](PKY0EJ25RPCE87=FJ
MY*2!@4"1Z_M;DD0>/6Y[U[;5C5J5:_=T?";9LH*<!9DW]V#N*4LT Y@^S^_G
MY!<.LEEI+8<Z;CBI3WH%UY2<0<,-Q]QJ7($+,+.4#DYH3U>%<>\L3.;)F'-<
MKH^(]TR4UF C77LB;7^:DVNRPQ[A!*!IIUH>=;36ERN^$36*@P@*B!6\@'=B
MYYU76> X0DN#3-/*.[(PG)//-E9Y Z$%2>O6N^,\80=P9[<QY6RD;MIT *E^
M:@^'YQ9PCZ"U!IP](DS0: &DK=T4Z !9HA:&EX#&56.LVC!1-C"T.Y"B#W4#
MAK^LA8:<KD .N/_3!( M;HU1 LY A(#696,38U(<VM ZE1(&9NAF]06R"J.#
M&)6'FBN]%3!%@(,WR&&3!.:^HLV ][7AJ@9]/T*PZ@95*CBY=Y<23<(TL*>$
M:8B <6+0;R/1LBD+PM9K>_"$46T:HU*-$3C>$$3!7UDT?UT>%A+87'[;R@";
M#$?1$^,A8T%>[F  PH&W#?ZIFQ (.;,MP07,U:EG:MZ$@?P!JA_:=1S1HZB3
MM2@=,CL<*P[ZU#9!\!Q;3#H\?6F4T(5H+XL.O$AT;PL,^.E7N+26L#&-K(FL
MZ4X#F-MWEP-P77:9R=: #"#"J_,86/R!P47/.63U."AZ@J1[KO8"QI"BL=7G
MV!/'E>DTZ7 5K_90'+HP]3I.6]C9_ZR)6WYL9MP5(&@+K[<5CS4*KBS <.3U
M]Q"6 H +M!2'L.>K*F;V*PKE,W/XDYILX=X6KD;STZ)FZX+!RCVN#L47N+SC
M@<>0+$1ADVG+]M@C%<_EIK87$M1KQ6LH'L:6D:G,M!KCA8LZL[K49+41N=@A
M4 V,!;87N9S4 L2O10X4)=2K/5>MSQX,@=M[96_OQRK:)M0K!N9"Z+AVW@+
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M\!\"7TGH&=TLIZ+4(7J]3E&1N+]5< ^HU(YN@%3--)\*SD#:;38(C9 ,TD!
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MK+R_QPQ(':8<_-_Q5^U0E$;?*N+M&LM))(JK7,EN,$/WU9W+M"OK787"U5&
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M@I0U[83E6V&+_%G&#UB,X&1\#'F6CY_A.]D%>A+Y3OX]T />R8YW$GDG_YO
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M4CVEO>SC[[_^\>SQDV<OU >*96K*/#Y_\6Y8 >&O-K1MAA&(\#V'W+[5]>^
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M($_>8HFJ8Z%EQ,0<1 N,.3"=-C*:IRL3&&Z(PJ_0>F-<.@#&\7P+910=2+#
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M'3!6,H9BW*Y/CTX.-BF&,;CIX<FUG9K[,_;V;QAY5.^=UO+WR:K?4J3(ZIU
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MR15@6#:NXZ'Q#NY\I]V3#H8/,/;0Y6]02P,$%     @ V4-C5#>]^4.: @
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MTMC6Y:>5_5>@<@YV?RVEV2\<0?_WF?T$4$L#!!0    ( -E#8U1LR@21X (
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M>?<\W#.UXI4F G)T]<^2D4-41[F=8&3=TMQ2&B3-=EO@*P7*&N#_7$JS%6R
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MT>A@3C6@UWX:&ZQ!S/%A9(W4<>"_'N;<GGWX6[CA>BU:@XJL4)1>3#&.>IC
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M0.J29.PYZS8COI5UW_NIO$=YC?*6$<O [+,%HK#M ;N'7+R$S"H0RS=BC_\
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M7K=NBRI_-2W[ /O@IM3#D=\[Q?-"G!""Z2!X?0&R;0%V>V//CW#D0<+1]&A
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MP'@'=UYKC2?#$TRO3_$;4$L#!!0    ( -E#8U3);,W P0(  !@)   9
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MF!2%WBC'50T++7C!T<(YW,HUXX9ZZ'S\G5;U^1TUH82)M>@LG,[1,2[L&9P
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M.#UA"QQ>Y'1"K[->[XW.9P-TL('\@,+A!GH][I!J[RT!IT\H>Q"2:2&?S],
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M?KBFUA*U,Z#]I5+V>>(.Z)K5R;]02P,$%     @ V4-C5#( 0UC] @  S@@
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MUCB/Y7>V_T+,@GSM+V*Q*'Z#O;%U+!#E0K+$@%4&"4W+O_C%%*(!@%X' !D
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M,-XAK]UV2D'\]/V)Y=)5MA6+9G'V>CG9J>H(ME(4XFU?=P>.:3@>A=N]<\_
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M$UWD'SOR$\6WV<OY%ZX43[+#B&"]83$/Z/MKSM7QQ Q0?G(:_P=02P,$%
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M<U7: =<!ZGO&F-P/] )ML3C[ U!+ P04    " #90V-4XM:/CN("   ?"0
M&0   'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6RU5MMNHS 0_14+K;2MM"W&
M7 )5$JD)W<M#I:K9[CX[, FH@%/;2=J_7]L02B."N@]Y =O,.>,S!SR,]XP_
MBPQ HM>RJ,3$RJ3<W-BV2#(HJ;AF&ZC4DQ7C)95JRM>VV'"@J0&5A4TP#NR2
MYI4U'9NU!SX=LZTL\@H>.!+;LJ3\;08%VT\LQSHL/.;K3.H%>SK>T#4L0#YM
M'KB:V2U+FI=0B9Q5B,-J8MTZ-[&#-<!$_,EA+SICI*4L&7O6DU_IQ,)Z1U!
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M7;$X#F!D(1GA'1P+OV]9_U%H8K<M3&UL=8<=EV8D#T?\"@^&A:./>;CA/%D
MIAP<#Q:#ISWF?(61YOMQ)M:S%DXF5+'M9!81DH;G"Z,K$%HTB\9>Y6 ]>-I[
M5M)\>^B7SGO8CY;OX#-=.V%M)YGA* HR<@[[?N!;V,%R\+3GC$_Q=Y9T;#O+
MS-U_CL#)!AP\"$^;T.2<\2]>!_#B_ER>K&UV>U=J1PNV\& [IYA\8MX2.3^<
M_W^AP_C]DUV'V?)]I7+#&P7]OX;*P64*'2L/NZC#B1:[;B/R(#1L:[K#+>P\
MF30!<'\MA'X],7N;?B^[_!=02P,$%     @ V4-C5#FW[/I_ @  V@8  !D
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M<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ V4-C5%%.%G6F!   $B0
M  \   !X;"]W;W)K8F]O:RYX;6S%FDMOVS@0@/\*X4NSAZQM/9(TJ ODU6R
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M4$L! A0#%     @ V4-C5 =!36*!    L0   !               ( !
M &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " #90V-4?6%4&^T    K @
M$0              @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4
M" #90V-4F5R<(Q &  "<)P  $P              @ '+ 0  >&PO=&AE;64O
M=&AE;64Q+GAM;%!+ 0(4 Q0    ( -E#8U3'B7QX$P8    :   8
M      " @0P(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4
M" #90V-4!X2;"D(%  #>$P  &               @(%5#@  >&PO=V]R:W-H
M965T<R]S:&5E=#(N>&UL4$L! A0#%     @ V4-C5-K;PPV7 @  ' D  !@
M             ("!S1,  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4
M Q0    ( -E#8U1O"^DM/P0  !D/   8              " @9H6  !X;"]W
M;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    " #90V-46T4C^1$%  !R
M%@  &               @($/&P  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL
M4$L! A0#%     @ V4-C5 \SR:JL!0  BA4  !@              ("!5B
M 'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( -E#8U02:"LD
M3@,  %('   8              " @3@F  !X;"]W;W)K<VAE971S+W-H965T
M-RYX;6Q02P$"% ,4    " #90V-48CNH*:4%  !N#0  &
M@(&\*0  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ V4-C
M5*'GHEF#$P  O38  !@              ("!ER\  'AL+W=O<FMS:&5E=',O
M<VAE970Y+GAM;%!+ 0(4 Q0    ( -E#8U2A)M!=+ ,   \(   9
M      " @5!#  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%
M  @ V4-C5+_QZ2J. @  J@8  !D              ("!LT8  'AL+W=O<FMS
M:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    " #90V-4L$%<3PT#  "7!P
M&0              @(%X20  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+
M 0(4 Q0    ( -E#8U2)]%;@N (  ) &   9              " @;Q,  !X
M;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ V4-C5-URBH'H
M"   QQ@  !D              ("!JT\  'AL+W=O<FMS:&5E=',O<VAE970Q
M-"YX;6Q02P$"% ,4    " #90V-4VS'!I7L2  #710  &0
M@('*6   >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( -E#
M8U1LN+G8E <  (@5   9              " @7QK  !X;"]W;W)K<VAE971S
M+W-H965T,38N>&UL4$L! A0#%     @ V4-C5-,,."06"   IA0  !D
M         ("!1W,  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4
M    " #90V-4F%1VF2D#   >!P  &0              @(&4>P  >&PO=V]R
M:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( -E#8U2#E?Q,5 4  #$,
M   9              " @?1^  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL
M4$L! A0#%     @ V4-C5$$NW$.0%    3\  !D              ("!?X0
M 'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    " #90V-4#*/?
M\( "  "J!0  &0              @(%&F0  >&PO=V]R:W-H965T<R]S:&5E
M=#(Q+GAM;%!+ 0(4 Q0    ( -E#8U3@XO0^1 (  $\%   9
M  " @?V;  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @
MV4-C5#>]^4.: @  B08  !D              ("!>)X  'AL+W=O<FMS:&5E
M=',O<VAE970R,RYX;6Q02P$"% ,4    " #90V-4;,H$D> "   #!P  &0
M            @(%)H0  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4
M Q0    ( -E#8U2IE57GP0(  (@&   9              " @6"D  !X;"]W
M;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ V4-C5"7MPYD_ P
M$@D  !D              ("!6*<  'AL+W=O<FMS:&5E=',O<VAE970R-BYX
M;6Q02P$"% ,4    " #90V-4DZ24$"(&  !Z&0  &0              @('.
MJ@  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( -E#8U1C
M3^R2>00  )L,   9              " @2>Q  !X;"]W;W)K<VAE971S+W-H
M965T,C@N>&UL4$L! A0#%     @ V4-C5/Q>H1*9 @  $0<  !D
M     ("!U[4  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( -E#8U22*JD)@0(  ,$'   9              "
M@9C#  !X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ V4-C
M5-YUC&Y^ @  -P8  !D              ("!4,8  'AL+W=O<FMS:&5E=',O
M<VAE970S-2YX;6Q02P$"% ,4    " #90V-49N9J:W,"  #'!@  &0
M        @($%R0  >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0
M   ( -E#8U3F-]A*H@,  *H.   9              " @:_+  !X;"]W;W)K
M<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ V4-C5 N;E/.O @  T@<
M !D              ("!B,\  'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q0
M2P$"% ,4    " #90V-4,3W?-UP#  "X"@  &0              @(%NT@
M>&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( -E#8U0R $-8
M_0(  ,X(   9              " @0'6  !X;"]W;W)K<VAE971S+W-H965T
M-# N>&UL4$L! A0#%     @ V4-C5!=^X9U: @  *P8  !D
M ("!-=D  'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"% ,4    " #9
M0V-4O=A$2/@#  ")$   &0              @('&VP  >&PO=V]R:W-H965T
M<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( -E#8U1<D-4[X 4  -P:   9
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M970T-RYX;6Q02P$"% ,4    " #90V-415(W'P,#   X"@  &0
M    @(%A^P  >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    (
M -E#8U3BUH^.X@(  !\)   9              " @9O^  !X;"]W;W)K<VAE
M971S+W-H965T-#DN>&UL4$L! A0#%     @ V4-C5"T8#'T]!   UPX  !D
M             ("!M $! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q02P$"
M% ,4    " #90V-4.;?L^G\"  #:!@  &0              @($H!@$ >&PO
M=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    ( -E#8U0BT;-Y^@(
M .P*   9              " @=X( 0!X;"]W;W)K<VAE971S+W-H965T-3(N
M>&UL4$L! A0#%     @ V4-C5.C4I&%  P  \@D  !D              ("!
M#PP! 'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q02P$"% ,4    " #90V-4
M#+&Q8K8"  "A"   &0              @(&&#P$ >&PO=V]R:W-H965T<R]S
M:&5E=#4T+GAM;%!+ 0(4 Q0    ( -E#8U0_UM[-*@,   P3   -
M      "  7,2 0!X;"]S='EL97,N>&UL4$L! A0#%     @ V4-C5)>*NQS
M    $P(   L              ( !R!4! %]R96QS+RYR96QS4$L! A0#%
M  @ V4-C5%%.%G6F!   $B0   \              ( !L18! 'AL+W=O<FMB
M;V]K+GAM;%!+ 0(4 Q0    ( -E#8U0/E%1(V@$  %D@   :
M  "  80; 0!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    (
M -E#8U0A7:<FS0$  "0@   3              "  98= 0!;0V]N=&5N=%]4
?>7!E<UTN>&UL4$L%!@     ^ #X Z1   )0? 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>120</ContextCount>
  <ElementCount>344</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>37</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="glyc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="glyc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/StatementBalanceSheets</Role>
      <ShortName>Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="glyc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00105 - Statement - Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/StatementBalanceSheetsParenthetical</Role>
      <ShortName>Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="glyc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00200 - Statement - Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/StatementStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="glyc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00300 - Statement - Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/StatementStatementsOfStockholdersEquity</Role>
      <ShortName>Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="glyc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00400 - Statement - Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/StatementStatementsOfCashFlows</Role>
      <ShortName>Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="glyc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>10101 - Disclosure - Description of the Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureDescriptionOfBusiness</Role>
      <ShortName>Description of the Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="glyc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>10201 - Disclosure - Going Concern</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureGoingConcern</Role>
      <ShortName>Going Concern</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="glyc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10301 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="glyc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10401 - Disclosure - Net Loss Per Share of Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureNetLossPerShareOfCommonStock</Role>
      <ShortName>Net Loss Per Share of Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="glyc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10501 - Disclosure - Prepaid Expenses and Other Current Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets</Role>
      <ShortName>Prepaid Expenses and Other Current Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="glyc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10601 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosurePropertyAndEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="glyc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10701 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureAccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="glyc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>10801 - Disclosure - Operating Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureOperatingLeases</Role>
      <ShortName>Operating Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="glyc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>10901 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureStockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="glyc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>11001 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="glyc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>11101 - Disclosure - Research and License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureResearchAndLicenseAgreements</Role>
      <ShortName>Research and License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="glyc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>11201 - Disclosure - Employee Benefit Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureEmployeeBenefitPlan</Role>
      <ShortName>Employee Benefit Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="glyc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>11301 - Disclosure - Risks and Uncertainties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureRisksAndUncertainties</Role>
      <ShortName>Risks and Uncertainties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="glyc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>20202 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="glyc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>30303 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="glyc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>30403 - Disclosure - Net Loss Per Share of Common Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureNetLossPerShareOfCommonStockTables</Role>
      <ShortName>Net Loss Per Share of Common Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://glyc.com/role/DisclosureNetLossPerShareOfCommonStock</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="glyc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>30503 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables</Role>
      <ShortName>Prepaid Expenses and Other Current Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://glyc.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="glyc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>30603 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosurePropertyAndEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://glyc.com/role/DisclosurePropertyAndEquipment</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="glyc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>30703 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureAccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://glyc.com/role/DisclosureAccruedExpenses</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="glyc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>30803 - Disclosure - Operating Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureOperatingLeasesTables</Role>
      <ShortName>Operating Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://glyc.com/role/DisclosureOperatingLeases</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="glyc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>30903 - Disclosure - Stockholders Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureStockholdersEquityTables</Role>
      <ShortName>Stockholders Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="glyc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>31003 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://glyc.com/role/DisclosureIncomeTaxes</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="glyc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>40201 - Disclosure - Going Concern (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureGoingConcernDetails</Role>
      <ShortName>Going Concern (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://glyc.com/role/DisclosureGoingConcern</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="glyc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>40301 - Disclosure - Summary of Significant Accounting Policies - Segment Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesSegmentInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Segment Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="glyc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>40302 - Disclosure - Summary of Significant Accounting Policies - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="glyc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>40303 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="glyc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>40304 - Disclosure - Summary of Significant Accounting Policies - Impairment of Long-Lived Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesImpairmentOfLongLivedAssetsDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Impairment of Long-Lived Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="glyc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>40305 - Disclosure - Summary of Significant Accounting Policies - Stock-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Stock-Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="glyc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>40401 - Disclosure - Net Loss Per Common Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureNetLossPerCommonShareDetails</Role>
      <ShortName>Net Loss Per Common Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="glyc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>40501 - Disclosure - Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails</Role>
      <ShortName>Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="glyc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>40601 - Disclosure - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosurePropertyAndEquipmentDetails</Role>
      <ShortName>Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://glyc.com/role/DisclosurePropertyAndEquipmentTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="glyc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>40701 - Disclosure - Accrued Expenses - Summary of Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails</Role>
      <ShortName>Accrued Expenses - Summary of Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="glyc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>40801 - Disclosure - Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureOperatingLeasesDetails</Role>
      <ShortName>Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://glyc.com/role/DisclosureOperatingLeasesTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="glyc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>40802 - Disclosure - Operating Leases - Components of lease expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureOperatingLeasesComponentsOfLeaseExpenseDetails</Role>
      <ShortName>Operating Leases - Components of lease expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="glyc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>40803 - Disclosure - Operating Leases - Maturities of lease liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureOperatingLeasesMaturitiesOfLeaseLiabilityDetails</Role>
      <ShortName>Operating Leases - Maturities of lease liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="glyc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>40901 - Disclosure - Stockholders' Equity - Equity Offerings (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureStockholdersEquityEquityOfferingsDetails</Role>
      <ShortName>Stockholders' Equity - Equity Offerings (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="glyc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>40903 - Disclosure - Stockholders' Equity - Incentive Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureStockholdersEquityIncentivePlansDetails</Role>
      <ShortName>Stockholders' Equity - Incentive Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="glyc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>40904 - Disclosure - Stockholders' Equity - Company's Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureStockholdersEquityCompanySStockOptionActivityDetails</Role>
      <ShortName>Stockholders' Equity - Company's Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="glyc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>40905 - Disclosure - Stockholders' Equity - Summary of RSU Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureStockholdersEquitySummaryOfRsuActivityDetails</Role>
      <ShortName>Stockholders' Equity - Summary of RSU Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="glyc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>40906 - Disclosure - Stockholders' Equity - Inducement Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureStockholdersEquityInducementPlanDetails</Role>
      <ShortName>Stockholders' Equity - Inducement Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="glyc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>40907 - Disclosure - Stockholders' Equity - Inducement Plan - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureStockholdersEquityInducementPlanStockOptionActivityDetails</Role>
      <ShortName>Stockholders' Equity - Inducement Plan - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="glyc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>40908 - Disclosure - Stockholders' Equity - Weighted-Average assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureStockholdersEquityWeightedAverageAssumptionsDetails</Role>
      <ShortName>Stockholders' Equity - Weighted-Average assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="glyc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>40909 - Disclosure - Stockholders' Equity - Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stockholders' Equity - Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="glyc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>41001 - Disclosure - Income Taxes - Schedule of Gross Deferred Tax Asset and Related Valuation Allowance (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureIncomeTaxesScheduleOfGrossDeferredTaxAssetAndRelatedValuationAllowanceDetail</Role>
      <ShortName>Income Taxes - Schedule of Gross Deferred Tax Asset and Related Valuation Allowance (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="glyc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>41002 - Disclosure - Income Taxes - NOLs and carryforwards (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureIncomeTaxesNolsAndCarryforwardsDetail</Role>
      <ShortName>Income Taxes - NOLs and carryforwards (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="glyc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>41003 - Disclosure - Income Taxes - Reconciliation Between Statutory Federal Income Tax Rate and Effective Income Tax Rate (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureIncomeTaxesReconciliationBetweenStatutoryFederalIncomeTaxRateAndEffectiveIncomeTaxRateDetail</Role>
      <ShortName>Income Taxes - Reconciliation Between Statutory Federal Income Tax Rate and Effective Income Tax Rate (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="glyc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>41101 - Disclosure - Research and License Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureResearchAndLicenseAgreementsDetails</Role>
      <ShortName>Research and License Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://glyc.com/role/DisclosureResearchAndLicenseAgreements</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="glyc-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>41201 - Disclosure - Employee Benefit Plan (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureEmployeeBenefitPlanDetail</Role>
      <ShortName>Employee Benefit Plan (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://glyc.com/role/DisclosureEmployeeBenefitPlan</ParentRole>
      <Position>54</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="glyc-20211231x10k.htm">glyc-20211231x10k.htm</File>
    <File>glyc-20211231.xsd</File>
    <File>glyc-20211231_cal.xml</File>
    <File>glyc-20211231_def.xml</File>
    <File>glyc-20211231_lab.xml</File>
    <File>glyc-20211231_pre.xml</File>
    <File>glyc-20211231xex10d13.htm</File>
    <File>glyc-20211231xex10d14.htm</File>
    <File>glyc-20211231xex10d19.htm</File>
    <File>glyc-20211231xex23d1.htm</File>
    <File>glyc-20211231xex31d1.htm</File>
    <File>glyc-20211231xex31d2.htm</File>
    <File>glyc-20211231xex32d1.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>glyc-20211231x10k006.jpg</File>
    <File>glyc-20211231x10k007.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="491">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="36">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>77
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "glyc-20211231x10k.htm": {
   "axisCustom": 0,
   "axisStandard": 17,
   "contextCount": 120,
   "dts": {
    "calculationLink": {
     "local": [
      "glyc-20211231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "glyc-20211231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "glyc-20211231x10k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "glyc-20211231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "glyc-20211231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "glyc-20211231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 398,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 33,
    "http://xbrl.sec.gov/dei/2021q4": 7,
    "total": 40
   },
   "keyCustom": 33,
   "keyStandard": 311,
   "memberCustom": 14,
   "memberStandard": 23,
   "nsprefix": "glyc",
   "nsuri": "http://glyc.com/20211231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00090 - Document - Document and Entity Information",
     "role": "http://glyc.com/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10401 - Disclosure - Net Loss Per Share of Common Stock",
     "role": "http://glyc.com/role/DisclosureNetLossPerShareOfCommonStock",
     "shortName": "Net Loss Per Share of Common Stock",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10501 - Disclosure - Prepaid Expenses and Other Current Assets",
     "role": "http://glyc.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets",
     "shortName": "Prepaid Expenses and Other Current Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10601 - Disclosure - Property and Equipment",
     "role": "http://glyc.com/role/DisclosurePropertyAndEquipment",
     "shortName": "Property and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10701 - Disclosure - Accrued Expenses",
     "role": "http://glyc.com/role/DisclosureAccruedExpenses",
     "shortName": "Accrued Expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10801 - Disclosure - Operating Leases",
     "role": "http://glyc.com/role/DisclosureOperatingLeases",
     "shortName": "Operating Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "glyc:DisclosureOfStockholdersEquityAndCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10901 - Disclosure - Stockholders' Equity",
     "role": "http://glyc.com/role/DisclosureStockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "glyc:DisclosureOfStockholdersEquityAndCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11001 - Disclosure - Income Taxes",
     "role": "http://glyc.com/role/DisclosureIncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "glyc:ResearchAndLicenseAgreementTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11101 - Disclosure - Research and License Agreements",
     "role": "http://glyc.com/role/DisclosureResearchAndLicenseAgreements",
     "shortName": "Research and License Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "glyc:ResearchAndLicenseAgreementTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11201 - Disclosure - Employee Benefit Plan",
     "role": "http://glyc.com/role/DisclosureEmployeeBenefitPlan",
     "shortName": "Employee Benefit Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyDisclosures",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11301 - Disclosure - Risks and Uncertainties",
     "role": "http://glyc.com/role/DisclosureRisksAndUncertainties",
     "shortName": "Risks and Uncertainties",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyDisclosures",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00100 - Statement - Balance Sheets",
     "role": "http://glyc.com/role/StatementBalanceSheets",
     "shortName": "Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:AssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "20202 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "glyc:ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30303 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "glyc:ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30403 - Disclosure - Net Loss Per Share of Common Stock (Tables)",
     "role": "http://glyc.com/role/DisclosureNetLossPerShareOfCommonStockTables",
     "shortName": "Net Loss Per Share of Common Stock (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:OtherCurrentAssetsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30503 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)",
     "role": "http://glyc.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables",
     "shortName": "Prepaid Expenses and Other Current Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:OtherCurrentAssetsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30603 - Disclosure - Property and Equipment (Tables)",
     "role": "http://glyc.com/role/DisclosurePropertyAndEquipmentTables",
     "shortName": "Property and Equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30703 - Disclosure - Accrued Expenses (Tables)",
     "role": "http://glyc.com/role/DisclosureAccruedExpensesTables",
     "shortName": "Accrued Expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30803 - Disclosure - Operating Leases (Tables)",
     "role": "http://glyc.com/role/DisclosureOperatingLeasesTables",
     "shortName": "Operating Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30903 - Disclosure - Stockholders Equity (Tables)",
     "role": "http://glyc.com/role/DisclosureStockholdersEquityTables",
     "shortName": "Stockholders Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31003 - Disclosure - Income Taxes (Tables)",
     "role": "http://glyc.com/role/DisclosureIncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "glyc:NetIncomeLossAndComprehensiveIncomeNetOfTax",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40201 - Disclosure - Going Concern (Details)",
     "role": "http://glyc.com/role/DisclosureGoingConcernDetails",
     "shortName": "Going Concern (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_6ZVfdDCn5UCsvmo46quH_A",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00105 - Statement - Balance Sheets (Parenthetical)",
     "role": "http://glyc.com/role/StatementBalanceSheetsParenthetical",
     "shortName": "Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_6ZVfdDCn5UCsvmo46quH_A",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_segment_SDPUnB8SLEWaCbvZFtu_Hw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40301 - Disclosure - Summary of Significant Accounting Policies - Segment Information (Details)",
     "role": "http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesSegmentInformationDetails",
     "shortName": "Summary of Significant Accounting Policies - Segment Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_segment_SDPUnB8SLEWaCbvZFtu_Hw",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_jja2ssufsk-400-VxFX0dA",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:MoneyMarketFundsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40302 - Disclosure - Summary of Significant Accounting Policies - Fair Value Measurements (Details)",
     "role": "http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails",
     "shortName": "Summary of Significant Accounting Policies - Fair Value Measurements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_jja2ssufsk-400-VxFX0dA",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:MoneyMarketFundsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "glyc:ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_XpvrdhTYnU29K3NXwMZg1w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40303 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details)",
     "role": "http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails",
     "shortName": "Summary of Significant Accounting Policies - Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "glyc:ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_XpvrdhTYnU29K3NXwMZg1w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "glyc:NumberOfLongLivedAssetsDeterminedToBeImpaired",
       "p",
       "us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "glyc:NumberOfLongLivedAssetsDeterminedToBeImpaired",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_item_g-Qg15KDVUyxut40CeCIjQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40304 - Disclosure - Summary of Significant Accounting Policies - Impairment of Long-Lived Assets (Details)",
     "role": "http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesImpairmentOfLongLivedAssetsDetails",
     "shortName": "Summary of Significant Accounting Policies - Impairment of Long-Lived Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "glyc:NumberOfLongLivedAssetsDeterminedToBeImpaired",
       "p",
       "us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "glyc:NumberOfLongLivedAssetsDeterminedToBeImpaired",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_item_g-Qg15KDVUyxut40CeCIjQ",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
       "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
       "p",
       "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40305 - Disclosure - Summary of Significant Accounting Policies - Stock-Based Compensation (Details)",
     "role": "http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails",
     "shortName": "Summary of Significant Accounting Policies - Stock-Based Compensation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_glyc_EmployeeStockOptionsAndRestrictedStockUnitsMember_XfZ7v3VAVk-r9VvuNg_XkA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40401 - Disclosure - Net Loss Per Common Share (Details)",
     "role": "http://glyc.com/role/DisclosureNetLossPerCommonShareDetails",
     "shortName": "Net Loss Per Common Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_glyc_EmployeeStockOptionsAndRestrictedStockUnitsMember_XfZ7v3VAVk-r9VvuNg_XkA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PrepaidExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40501 - Disclosure - Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details)",
     "role": "http://glyc.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails",
     "shortName": "Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PrepaidExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40601 - Disclosure - Property and Equipment (Details)",
     "role": "http://glyc.com/role/DisclosurePropertyAndEquipmentDetails",
     "shortName": "Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "glyc:AccruedResearchAndDevelopmentExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40701 - Disclosure - Accrued Expenses - Summary of Accrued Expenses (Details)",
     "role": "http://glyc.com/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails",
     "shortName": "Accrued Expenses - Summary of Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "glyc:AccruedResearchAndDevelopmentExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:SecurityDeposit",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40801 - Disclosure - Operating Leases (Details)",
     "role": "http://glyc.com/role/DisclosureOperatingLeasesDetails",
     "shortName": "Operating Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA",
      "decimals": "2",
      "lang": null,
      "name": "us-gaap:DebtInstrumentInterestRateIncreaseDecrease",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_o6l_rGctYUCSP0KoHptHcQ",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00200 - Statement - Statements of Operations and Comprehensive Loss",
     "role": "http://glyc.com/role/StatementStatementsOfOperationsAndComprehensiveLoss",
     "shortName": "Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40802 - Disclosure - Operating Leases - Components of lease expense (Details)",
     "role": "http://glyc.com/role/DisclosureOperatingLeasesComponentsOfLeaseExpenseDetails",
     "shortName": "Operating Leases - Components of lease expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40803 - Disclosure - Operating Leases - Maturities of lease liability (Details)",
     "role": "http://glyc.com/role/DisclosureOperatingLeasesMaturitiesOfLeaseLiabilityDetails",
     "shortName": "Operating Leases - Maturities of lease liability (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cGTT67gulkyrZ4UjnAS9fA",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40901 - Disclosure - Stockholders' Equity - Equity Offerings (Details)",
     "role": "http://glyc.com/role/DisclosureStockholdersEquityEquityOfferingsDetails",
     "shortName": "Stockholders' Equity - Equity Offerings (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "glyc:DisclosureOfStockholdersEquityAndCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_glyc_AtMarketOffering2017Member_xegFN2MRVUeT2e9ks4eOqg",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
       "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
       "p",
       "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_Bhd-nQulWU6ZbQQpkblCKw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40903 - Disclosure - Stockholders' Equity - Incentive Plans (Details)",
     "role": "http://glyc.com/role/DisclosureStockholdersEquityIncentivePlansDetails",
     "shortName": "Stockholders' Equity - Incentive Plans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member_jeH3ukS87UGj2TpOqDjAFA",
      "decimals": null,
      "lang": "en-US",
      "name": "glyc:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2020_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member_CPK9V-Op3UaIxCwH7D8lOQ",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40904 - Disclosure - Stockholders' Equity - Company's Stock Option Activity (Details)",
     "role": "http://glyc.com/role/DisclosureStockholdersEquityCompanySStockOptionActivityDetails",
     "shortName": "Stockholders' Equity - Company's Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
       "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member_jeH3ukS87UGj2TpOqDjAFA",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_eZd6RRkvHUKXyt8ofzDQvA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40905 - Disclosure - Stockholders' Equity - Summary of RSU Activity (Details)",
     "role": "http://glyc.com/role/DisclosureStockholdersEquitySummaryOfRsuActivityDetails",
     "shortName": "Stockholders' Equity - Summary of RSU Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_LNH3eNmn5kWst66eRhnJGQ",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_1_31_2020_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_OL9RAaPvWESWUYV6Drys3g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40906 - Disclosure - Stockholders' Equity - Inducement Plan (Details)",
     "role": "http://glyc.com/role/DisclosureStockholdersEquityInducementPlanDetails",
     "shortName": "Stockholders' Equity - Inducement Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_1_31_2020_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_OL9RAaPvWESWUYV6Drys3g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2020_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_NxJ0kAmhLEq77boNzSrSDA",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40907 - Disclosure - Stockholders' Equity - Inducement Plan - Stock Option Activity (Details)",
     "role": "http://glyc.com/role/DisclosureStockholdersEquityInducementPlanStockOptionActivityDetails",
     "shortName": "Stockholders' Equity - Inducement Plan - Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_GhGdoDUAg0O8Z5VKpubXGw",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_7hpUA7qidECXv0j5XUW-HA",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_6ZVfdDCn5UCsvmo46quH_A",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40908 - Disclosure - Stockholders' Equity - Weighted-Average assumptions (Details)",
     "role": "http://glyc.com/role/DisclosureStockholdersEquityWeightedAverageAssumptionsDetails",
     "shortName": "Stockholders' Equity - Weighted-Average assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_6ZVfdDCn5UCsvmo46quH_A",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40909 - Disclosure - Stockholders' Equity - Stock-Based Compensation Expense (Details)",
     "role": "http://glyc.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails",
     "shortName": "Stockholders' Equity - Stock-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Aswh0QD8T06Z70c7oH6rxw",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00300 - Statement - Statements of Stockholders' Equity",
     "role": "http://glyc.com/role/StatementStatementsOfStockholdersEquity",
     "shortName": "Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Aswh0QD8T06Z70c7oH6rxw",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41001 - Disclosure - Income Taxes - Schedule of Gross Deferred Tax Asset and Related Valuation Allowance (Detail)",
     "role": "http://glyc.com/role/DisclosureIncomeTaxesScheduleOfGrossDeferredTaxAssetAndRelatedValuationAllowanceDetail",
     "shortName": "Income Taxes - Schedule of Gross Deferred Tax Asset and Related Valuation Allowance (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_Y-IKW2I17UuI0k9SgPOepg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_D-pk4UYBwUG2J1DzykZ-HQ",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:TaxCreditCarryforwardAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41002 - Disclosure - Income Taxes - NOLs and carryforwards (Detail)",
     "role": "http://glyc.com/role/DisclosureIncomeTaxesNolsAndCarryforwardsDetail",
     "shortName": "Income Taxes - NOLs and carryforwards (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_D-pk4UYBwUG2J1DzykZ-HQ",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:TaxCreditCarryforwardAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_o6l_rGctYUCSP0KoHptHcQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41003 - Disclosure - Income Taxes - Reconciliation Between Statutory Federal Income Tax Rate and Effective Income Tax Rate (Detail)",
     "role": "http://glyc.com/role/DisclosureIncomeTaxesReconciliationBetweenStatutoryFederalIncomeTaxRateAndEffectiveIncomeTaxRateDetail",
     "shortName": "Income Taxes - Reconciliation Between Statutory Federal Income Tax Rate and Effective Income Tax Rate (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_o6l_rGctYUCSP0KoHptHcQ",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "glyc:ResearchAndLicenseAgreementTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_glyc_ApollomicMember_u1SJvvGvK0azW3aP0YW7WQ",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "glyc:RevenueReceivedFromSaleOfClinicalSupplies",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41101 - Disclosure - Research and License Agreements (Details)",
     "role": "http://glyc.com/role/DisclosureResearchAndLicenseAgreementsDetails",
     "shortName": "Research and License Agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "glyc:ResearchAndLicenseAgreementTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_glyc_ApollomicMember_u1SJvvGvK0azW3aP0YW7WQ",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "glyc:RevenueReceivedFromSaleOfClinicalSupplies",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
       "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_o6l_rGctYUCSP0KoHptHcQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41201 - Disclosure - Employee Benefit Plan (Detail)",
     "role": "http://glyc.com/role/DisclosureEmployeeBenefitPlanDetail",
     "shortName": "Employee Benefit Plan (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
       "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_o6l_rGctYUCSP0KoHptHcQ",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00400 - Statement - Statements of Cash Flows",
     "role": "http://glyc.com/role/StatementStatementsOfCashFlows",
     "shortName": "Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_kv08tV6aek2l8RXdsuRnXw",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10101 - Disclosure - Description of the Business",
     "role": "http://glyc.com/role/DisclosureDescriptionOfBusiness",
     "shortName": "Description of the Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10201 - Disclosure - Going Concern",
     "role": "http://glyc.com/role/DisclosureGoingConcern",
     "shortName": "Going Concern",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10301 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_DO7FlHsgaEKRc8NNXPxAUA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 37,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://glyc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r370",
      "r371",
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://glyc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r370",
      "r371",
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://glyc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r370",
      "r371",
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://glyc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://glyc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Document and Entity Information"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://glyc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r370",
      "r371",
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://glyc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://glyc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://glyc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://glyc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://glyc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://glyc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://glyc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://glyc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://glyc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://glyc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://glyc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://glyc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://glyc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://glyc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://glyc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://glyc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://glyc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://glyc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://glyc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://glyc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://glyc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://glyc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://glyc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://glyc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://glyc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r370",
      "r371",
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://glyc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://glyc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://glyc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://glyc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://glyc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "glyc_AccrualsForClinicalTrialExpensesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for Accruals for Clinical Trial Expenses.",
        "label": "Accruals For Clinical Trial Expenses [Policy Text Block]",
        "terseLabel": "Accruals for Clinical Trial Expenses"
       }
      }
     },
     "localname": "AccrualsForClinicalTrialExpensesPolicyTextBlock",
     "nsuri": "http://glyc.com/20211231",
     "presentation": [
      "http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "glyc_AccruedResearchAndDevelopmentExpenseCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://glyc.com/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Research And Development Expense Current",
        "terseLabel": "Accrued research and development expenses"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentExpenseCurrent",
     "nsuri": "http://glyc.com/20211231",
     "presentation": [
      "http://glyc.com/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "glyc_AchievementOfSpecifiedNetSalesThresholdsForAllLicensedProducts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of revenue to be received upon the achievement of specified net sales thresholds for all licensed products.",
        "label": "Achievement of Specified Net Sales Thresholds for all Licensed Products",
        "terseLabel": "Milestone payment upon achievement of specified net sales thresholds for all licensed products"
       }
      }
     },
     "localname": "AchievementOfSpecifiedNetSalesThresholdsForAllLicensedProducts",
     "nsuri": "http://glyc.com/20211231",
     "presentation": [
      "http://glyc.com/role/DisclosureResearchAndLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "glyc_ApollomicMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Apollomic.",
        "label": "Apollomics, Inc."
       }
      }
     },
     "localname": "ApollomicMember",
     "nsuri": "http://glyc.com/20211231",
     "presentation": [
      "http://glyc.com/role/DisclosureResearchAndLicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "glyc_ArrangementsAndNonarrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Research And License Agreements",
        "terseLabel": "Research and License Agreements"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsLineItems",
     "nsuri": "http://glyc.com/20211231",
     "presentation": [
      "http://glyc.com/role/DisclosureResearchAndLicenseAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "glyc_AtMarketOffering2017Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pertains to the sale of common stock under an at-the-market sales agreement under a shelf registration statement filed in September 2017.",
        "label": "At Market Offering 2017 [Member]",
        "terseLabel": "2017 Sales Agreement"
       }
      }
     },
     "localname": "AtMarketOffering2017Member",
     "nsuri": "http://glyc.com/20211231",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquityEquityOfferingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "glyc_AtMarketOffering2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pertains to the sale of common stock under an at-the-market sales agreement under a shelf registration statement filed in October 2020.",
        "label": "At Market Offering 2020 [Member]",
        "terseLabel": "2020 Sales Agreement"
       }
      }
     },
     "localname": "AtMarketOffering2020Member",
     "nsuri": "http://glyc.com/20211231",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquityEquityOfferingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "glyc_CommonStockValueAvailableForSaleUnderAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of common stock remaining available to be sold under the terms of the agreement at the end of the period.",
        "label": "Common Stock Value Available For Sale Under Agreement",
        "terseLabel": "Common stock available for sale under agreement"
       }
      }
     },
     "localname": "CommonStockValueAvailableForSaleUnderAgreement",
     "nsuri": "http://glyc.com/20211231",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquityEquityOfferingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "glyc_DeferredTaxAssetsAccruedBonus": {
     "auth_ref": [],
     "calculation": {
      "http://glyc.com/role/DisclosureIncomeTaxesScheduleOfGrossDeferredTaxAssetAndRelatedValuationAllowanceDetail": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from Accrued bonus.",
        "label": "Deferred Tax Assets, Accrued Bonus",
        "terseLabel": "Accrued bonus"
       }
      }
     },
     "localname": "DeferredTaxAssetsAccruedBonus",
     "nsuri": "http://glyc.com/20211231",
     "presentation": [
      "http://glyc.com/role/DisclosureIncomeTaxesScheduleOfGrossDeferredTaxAssetAndRelatedValuationAllowanceDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "glyc_DeferredTaxAssetsCapitalizedStartUpCosts": {
     "auth_ref": [],
     "calculation": {
      "http://glyc.com/role/DisclosureIncomeTaxesScheduleOfGrossDeferredTaxAssetAndRelatedValuationAllowanceDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences capitalized start up costs.",
        "label": "Deferred Tax Assets Capitalized Start Up Costs",
        "terseLabel": "Capitalized start-up costs"
       }
      }
     },
     "localname": "DeferredTaxAssetsCapitalizedStartUpCosts",
     "nsuri": "http://glyc.com/20211231",
     "presentation": [
      "http://glyc.com/role/DisclosureIncomeTaxesScheduleOfGrossDeferredTaxAssetAndRelatedValuationAllowanceDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "glyc_DeferredTaxAssetsPatentAmortization": {
     "auth_ref": [],
     "calculation": {
      "http://glyc.com/role/DisclosureIncomeTaxesScheduleOfGrossDeferredTaxAssetAndRelatedValuationAllowanceDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences patent amortization.",
        "label": "Deferred Tax Assets Patent Amortization",
        "terseLabel": "Patent amortization"
       }
      }
     },
     "localname": "DeferredTaxAssetsPatentAmortization",
     "nsuri": "http://glyc.com/20211231",
     "presentation": [
      "http://glyc.com/role/DisclosureIncomeTaxesScheduleOfGrossDeferredTaxAssetAndRelatedValuationAllowanceDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "glyc_DeferredTaxAssetsResearchAndOrphanDrugCredits": {
     "auth_ref": [],
     "calculation": {
      "http://glyc.com/role/DisclosureIncomeTaxesScheduleOfGrossDeferredTaxAssetAndRelatedValuationAllowanceDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from research and orphan drug credits.",
        "label": "Deferred Tax Assets Research And Orphan Drug Credits",
        "terseLabel": "Research and orphan drug credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsResearchAndOrphanDrugCredits",
     "nsuri": "http://glyc.com/20211231",
     "presentation": [
      "http://glyc.com/role/DisclosureIncomeTaxesScheduleOfGrossDeferredTaxAssetAndRelatedValuationAllowanceDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "glyc_DeferredTaxAssetsTaxDeferredExpenseOperatingLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://glyc.com/role/DisclosureIncomeTaxesScheduleOfGrossDeferredTaxAssetAndRelatedValuationAllowanceDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from operating lease liabilities.",
        "label": "Deferred Tax Assets Tax Deferred Expense Operating Lease Liabilities",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseOperatingLeaseLiabilities",
     "nsuri": "http://glyc.com/20211231",
     "presentation": [
      "http://glyc.com/role/DisclosureIncomeTaxesScheduleOfGrossDeferredTaxAssetAndRelatedValuationAllowanceDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "glyc_DeferredTaxLiabilitiesTaxDeferredExpenseOperatingLeaseLiabilitiesRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://glyc.com/role/DisclosureIncomeTaxesScheduleOfGrossDeferredTaxAssetAndRelatedValuationAllowanceDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from operating lease right-of-use assets.",
        "label": "Deferred Tax Liabilities Tax Deferred Expense Operating Lease Liabilities Right Of Use Assets",
        "negatedLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesTaxDeferredExpenseOperatingLeaseLiabilitiesRightOfUseAssets",
     "nsuri": "http://glyc.com/20211231",
     "presentation": [
      "http://glyc.com/role/DisclosureIncomeTaxesScheduleOfGrossDeferredTaxAssetAndRelatedValuationAllowanceDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "glyc_DevelopmentAndRegulatoryApprovalMilestonesClinicalAndRegulatoryEvents": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of development and regulatory specific approval milestones based on achievement of certain clinical and regulatory events.",
        "label": "Development And Regulatory Approval Milestones Clinical And Regulatory Events",
        "terseLabel": "Milestones based on achievement of certain clinical and regulatory events"
       }
      }
     },
     "localname": "DevelopmentAndRegulatoryApprovalMilestonesClinicalAndRegulatoryEvents",
     "nsuri": "http://glyc.com/20211231",
     "presentation": [
      "http://glyc.com/role/DisclosureResearchAndLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "glyc_DisclosureOfStockholdersEquityAndCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This note contains 1) the entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income and 2) the entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.",
        "label": "Disclosure Of Stockholders Equity And Compensation Related Costs Share Based Payments Text Block",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "DisclosureOfStockholdersEquityAndCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://glyc.com/20211231",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "glyc_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent": {
     "auth_ref": [],
     "calculation": {
      "http://glyc.com/role/DisclosureIncomeTaxesReconciliationBetweenStatutoryFederalIncomeTaxRateAndEffectiveIncomeTaxRateDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to orphan drug tax credit.",
        "label": "Effective Income Tax Rate Reconciliation Tax Credit Orphan Drug Percent",
        "terseLabel": "Orphan drug credit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent",
     "nsuri": "http://glyc.com/20211231",
     "presentation": [
      "http://glyc.com/role/DisclosureIncomeTaxesReconciliationBetweenStatutoryFederalIncomeTaxRateAndEffectiveIncomeTaxRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "glyc_EmployeeStockOptionsAndRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "n/a",
        "label": "Stock options and restricted stock units"
       }
      }
     },
     "localname": "EmployeeStockOptionsAndRestrictedStockUnitsMember",
     "nsuri": "http://glyc.com/20211231",
     "presentation": [
      "http://glyc.com/role/DisclosureNetLossPerCommonShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "glyc_EquityIncentivePlan2013Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pertaining to the 2013 Equity Incentive Plan.",
        "label": "2013 Equity Incentive Plan"
       }
      }
     },
     "localname": "EquityIncentivePlan2013Member",
     "nsuri": "http://glyc.com/20211231",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquityCompanySStockOptionActivityDetails",
      "http://glyc.com/role/DisclosureStockholdersEquityIncentivePlansDetails",
      "http://glyc.com/role/DisclosureStockholdersEquitySummaryOfRsuActivityDetails",
      "http://glyc.com/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "domainItemType"
    },
    "glyc_EquityInducementPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to inducement plan.",
        "label": "Inducement Plan"
       }
      }
     },
     "localname": "EquityInducementPlanMember",
     "nsuri": "http://glyc.com/20211231",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquityInducementPlanDetails",
      "http://glyc.com/role/DisclosureStockholdersEquityInducementPlanStockOptionActivityDetails",
      "http://glyc.com/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "domainItemType"
    },
    "glyc_FederalAndStateAuthoritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the U. S. government and the designated tax department of the state government entitled to levy and collect income taxes.",
        "label": "U.S. Federal And State"
       }
      }
     },
     "localname": "FederalAndStateAuthoritiesMember",
     "nsuri": "http://glyc.com/20211231",
     "presentation": [
      "http://glyc.com/role/DisclosureIncomeTaxesNolsAndCarryforwardsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "glyc_GoingConcernAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Going Concern"
       }
      }
     },
     "localname": "GoingConcernAbstract",
     "nsuri": "http://glyc.com/20211231",
     "xbrltype": "stringItemType"
    },
    "glyc_IncreaseDecreaseInOperatingLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://glyc.com/role/StatementStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the operating lease liabilities.",
        "label": "Increase Decrease In Operating Lease Liabilities",
        "verboseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiabilities",
     "nsuri": "http://glyc.com/20211231",
     "presentation": [
      "http://glyc.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "glyc_LaboratoryEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory equipment.",
        "label": "Laboratory Equipment"
       }
      }
     },
     "localname": "LaboratoryEquipmentMember",
     "nsuri": "http://glyc.com/20211231",
     "presentation": [
      "http://glyc.com/role/DisclosurePropertyAndEquipmentDetails",
      "http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "glyc_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due After Year Two",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo",
     "nsuri": "http://glyc.com/20211231",
     "presentation": [
      "http://glyc.com/role/DisclosureOperatingLeasesMaturitiesOfLeaseLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "glyc_LesseeOperatingLeaseNumberOfNewLeases": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of additional operating leases entered into during the period.",
        "label": "Lessee Operating Lease Number Of New Leases",
        "terseLabel": "Number of additional operating leases entered during the period"
       }
      }
     },
     "localname": "LesseeOperatingLeaseNumberOfNewLeases",
     "nsuri": "http://glyc.com/20211231",
     "presentation": [
      "http://glyc.com/role/DisclosureOperatingLeasesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "glyc_MilestoneRevenueRecognized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The milestone revenue recognized.",
        "label": "Milestone Revenue Recognized",
        "terseLabel": "Milestone revenue recognized based on achievement of certain clinical and regulatory events"
       }
      }
     },
     "localname": "MilestoneRevenueRecognized",
     "nsuri": "http://glyc.com/20211231",
     "presentation": [
      "http://glyc.com/role/DisclosureResearchAndLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "glyc_NetIncomeLossAndComprehensiveIncomeNetOfTax": {
     "auth_ref": [],
     "calculation": {
      "http://glyc.com/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss and comprehensive income for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income Loss And Comprehensive Income Net Of Tax",
        "negatedLabel": "Net loss",
        "totalLabel": "Net loss and comprehensive loss"
       }
      }
     },
     "localname": "NetIncomeLossAndComprehensiveIncomeNetOfTax",
     "nsuri": "http://glyc.com/20211231",
     "presentation": [
      "http://glyc.com/role/DisclosureGoingConcernDetails",
      "http://glyc.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "glyc_NewAccountingPronouncementsAdoptedPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that have been adopted during the period.",
        "label": "New Accounting Pronouncements Adopted Policy [Policy Text Block]",
        "terseLabel": "Adopted Accounting Standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsAdoptedPolicyPolicyTextBlock",
     "nsuri": "http://glyc.com/20211231",
     "presentation": [
      "http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "glyc_NumberOfLongLivedAssetsDeterminedToBeImpaired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of long-lived assets determined to be impaired.",
        "label": "Number Of Long Lived Assets Determined To Be Impaired",
        "terseLabel": "Number of long-lived assets determined to be impaired"
       }
      }
     },
     "localname": "NumberOfLongLivedAssetsDeterminedToBeImpaired",
     "nsuri": "http://glyc.com/20211231",
     "presentation": [
      "http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesImpairmentOfLongLivedAssetsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "glyc_PercentageOfTotalNumberOfCommonStockOutstandingOnLastBusinessDayOfPriorFiscalYearThatMayAutomaticallyIncreaseUnderPlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total automatic increase in number of shares of common stock reserved for issuance under the Plan on January 1 of each year, as a percent of the total number of common stock outstanding at December 31 of the prior year.",
        "label": "Percentage Of Total Number Of Common Stock Outstanding On Last Business Day Of Prior Fiscal Year That May Automatically Increase Under Plan",
        "terseLabel": "Automatic increase in number of shares reserved for issuance as a percentage of the total common stock outstanding at the end of the prior year"
       }
      }
     },
     "localname": "PercentageOfTotalNumberOfCommonStockOutstandingOnLastBusinessDayOfPriorFiscalYearThatMayAutomaticallyIncreaseUnderPlan",
     "nsuri": "http://glyc.com/20211231",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquityIncentivePlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "glyc_ResearchAndLicenseAgreementTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for research services and license agreements, including contracts and arrangements to be performed by or for others. Includes contingent payment receivables or liabilities for achievement of specific milestones.",
        "label": "Research And License Agreement Text Block",
        "terseLabel": "Research and License Agreements"
       }
      }
     },
     "localname": "ResearchAndLicenseAgreementTextBlock",
     "nsuri": "http://glyc.com/20211231",
     "presentation": [
      "http://glyc.com/role/DisclosureResearchAndLicenseAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "glyc_ResearchAndLicenseAgreementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "n/a",
        "label": "Research and License Agreements"
       }
      }
     },
     "localname": "ResearchAndLicenseAgreementsAbstract",
     "nsuri": "http://glyc.com/20211231",
     "xbrltype": "stringItemType"
    },
    "glyc_RevenueReceivedFromSaleOfClinicalSupplies": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of revenue from the sale of clinical supplies.",
        "label": "Revenue Received From Sale Of Clinical Supplies",
        "terseLabel": "Revenue from sale of clinical supplies"
       }
      }
     },
     "localname": "RevenueReceivedFromSaleOfClinicalSupplies",
     "nsuri": "http://glyc.com/20211231",
     "presentation": [
      "http://glyc.com/role/DisclosureResearchAndLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "glyc_RockvilleMarylandMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pertaining to Rockville, Maryland.",
        "label": "Rockville, Maryland"
       }
      }
     },
     "localname": "RockvilleMarylandMember",
     "nsuri": "http://glyc.com/20211231",
     "presentation": [
      "http://glyc.com/role/DisclosureOperatingLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "glyc_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the useful life of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Schedule Of Property Plant And Equipment Useful Life [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment Estimated Useful Lives"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock",
     "nsuri": "http://glyc.com/20211231",
     "presentation": [
      "http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedSharesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "n/a",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Authorized Shares Disclosure Abstract",
        "terseLabel": "Authorized shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedSharesDisclosureAbstract",
     "nsuri": "http://glyc.com/20211231",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquityIncentivePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfMonthlyInstallments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of monthly installments for Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Number of Monthly Installments",
        "terseLabel": "Number of monthly installments"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfMonthlyInstallments",
     "nsuri": "http://glyc.com/20211231",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquityIncentivePlansDetails",
      "http://glyc.com/role/DisclosureStockholdersEquityInducementPlanDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFairValueOfOptionExcludedFromUnrecognizedCompensationExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum fair value of option excluded from the unrecognized compensation expense under the share based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Fair Value Of Option Excluded From Unrecognized Compensation Expense",
        "terseLabel": "Maximum fair value of option excluded from the unrecognized compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFairValueOfOptionExcludedFromUnrecognizedCompensationExpense",
     "nsuri": "http://glyc.com/20211231",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquityInducementPlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMaximumSharesIssuedUponExerciseOfIncentiveStockOptions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award number of maximum shares issued upon exercise of incentive stock options.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Maximum Shares Issued Upon Exercise Of Incentive Stock Options",
        "terseLabel": "Maximum number of shares that may be issued pursuant to exercise of incentive stock"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMaximumSharesIssuedUponExerciseOfIncentiveStockOptions",
     "nsuri": "http://glyc.com/20211231",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquityIncentivePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingUnderlyingSharesVestPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period remaining underlying shares vest, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Remaining Underlying Shares Vest Period",
        "terseLabel": "Period remaining underlying shares vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingUnderlyingSharesVestPeriod",
     "nsuri": "http://glyc.com/20211231",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquityInducementPlanDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "glyc_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from date of termination of employment by reasons other than death, cause, or disability that any vested options shall expire, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period After Termination Of Employment",
        "terseLabel": "Period from date of termination that any vested options shall expire"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment",
     "nsuri": "http://glyc.com/20211231",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquityIncentivePlansDetails",
      "http://glyc.com/role/DisclosureStockholdersEquityInducementPlanDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "glyc_StockIncentivePlan2003Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pertains to the 2003 Stock Incentive Plan.",
        "label": "2003 Stock Incentive Plan"
       }
      }
     },
     "localname": "StockIncentivePlan2003Member",
     "nsuri": "http://glyc.com/20211231",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquityCompanySStockOptionActivityDetails",
      "http://glyc.com/role/DisclosureStockholdersEquityIncentivePlansDetails",
      "http://glyc.com/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "domainItemType"
    },
    "glyc_StockIssuedDuringPeriodSharesStockOptionsAndRestrictedStockUnitsVesting": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options and vesting of stock units exercised during the current period.",
        "label": "Stock Issued During Period Shares Stock Options And Restricted Stock Units Vesting",
        "terseLabel": "Exercise of options and vesting of restricted stock units, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsAndRestrictedStockUnitsVesting",
     "nsuri": "http://glyc.com/20211231",
     "presentation": [
      "http://glyc.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "glyc_StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsVesting": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of share options and vesting of stock units exercised during the current period.",
        "label": "Stock Issued During Period Value Stock Options And Restricted Stock Units Vesting",
        "terseLabel": "Exercise of options and vesting of restricted stock units"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsVesting",
     "nsuri": "http://glyc.com/20211231",
     "presentation": [
      "http://glyc.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "glyc_StockOptionsVestingBasedOnPerformanceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents a stock option award with vesting based on achievement of performance conditions.",
        "label": "Stock options vesting based on performance"
       }
      }
     },
     "localname": "StockOptionsVestingBasedOnPerformanceMember",
     "nsuri": "http://glyc.com/20211231",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquityInducementPlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "glyc_StockOptionsVestingBasedOnServiceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents a stock option award with vesting based on length of service.",
        "label": "Stock options vesting based on service"
       }
      }
     },
     "localname": "StockOptionsVestingBasedOnServiceMember",
     "nsuri": "http://glyc.com/20211231",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquityInducementPlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "glyc_TieredPercentageOfAnnualNetSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entitled royalty payments to be received based on a tiered percentage of annual net sales.",
        "label": "Tiered Percentage Of Annual Net Sales",
        "terseLabel": "Tiered percentage of annual net sales"
       }
      }
     },
     "localname": "TieredPercentageOfAnnualNetSales",
     "nsuri": "http://glyc.com/20211231",
     "presentation": [
      "http://glyc.com/role/DisclosureResearchAndLicenseAgreementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "glyc_UpFrontPaymentReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of up-front payment received under terms of the agreement.",
        "label": "Up Front Payment Received",
        "terseLabel": "Up-front payment received"
       }
      }
     },
     "localname": "UpFrontPaymentReceived",
     "nsuri": "http://glyc.com/20211231",
     "presentation": [
      "http://glyc.com/role/DisclosureResearchAndLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "glyc_VestingUponFDApprovalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting upon FDA approval of uproleselan in patients with relapsed/refractory acute myeloid leukemia.",
        "label": "Vesting upon FDA Approval"
       }
      }
     },
     "localname": "VestingUponFDApprovalMember",
     "nsuri": "http://glyc.com/20211231",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquityInducementPlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "glyc_VestingUponFirstCommercialSaleMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting upon the first commercial sale of uproleselan.",
        "label": "Vesting upon First Commercial Sale"
       }
      }
     },
     "localname": "VestingUponFirstCommercialSaleMember",
     "nsuri": "http://glyc.com/20211231",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquityInducementPlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ChiefExecutiveOfficerMember": {
     "auth_ref": [
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Executive Officer"
       }
      }
     },
     "localname": "ChiefExecutiveOfficerMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquityInducementPlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r39",
      "r41",
      "r66",
      "r67",
      "r160",
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureResearchAndLicenseAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r159",
      "r165",
      "r193",
      "r194",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r343",
      "r345",
      "r364",
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureEmployeeBenefitPlanDetail",
      "http://glyc.com/role/DisclosureResearchAndLicenseAgreementsDetails",
      "http://glyc.com/role/DisclosureStockholdersEquityEquityOfferingsDetails",
      "http://glyc.com/role/DisclosureStockholdersEquityIncentivePlansDetails",
      "http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails",
      "http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r159",
      "r165",
      "r193",
      "r194",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r343",
      "r345",
      "r364",
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r159",
      "r165",
      "r183",
      "r193",
      "r194",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r343",
      "r345",
      "r364",
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureEmployeeBenefitPlanDetail",
      "http://glyc.com/role/DisclosureResearchAndLicenseAgreementsDetails",
      "http://glyc.com/role/DisclosureStockholdersEquityEquityOfferingsDetails",
      "http://glyc.com/role/DisclosureStockholdersEquityIncentivePlansDetails",
      "http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails",
      "http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r159",
      "r165",
      "r183",
      "r193",
      "r194",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r343",
      "r345",
      "r364",
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureEmployeeBenefitPlanDetail",
      "http://glyc.com/role/DisclosureResearchAndLicenseAgreementsDetails",
      "http://glyc.com/role/DisclosureStockholdersEquityEquityOfferingsDetails",
      "http://glyc.com/role/DisclosureStockholdersEquityIncentivePlansDetails",
      "http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails",
      "http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r40",
      "r41",
      "r66",
      "r67",
      "r160",
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureResearchAndLicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r127",
      "r128",
      "r178",
      "r179",
      "r344",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureOperatingLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r127",
      "r128",
      "r178",
      "r179",
      "r344",
      "r351",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureOperatingLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r130",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquityInducementPlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquityInducementPlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureAccruedExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://glyc.com/role/StatementBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due after one year (or beyond the operating cycle if longer), including liabilities for compensation costs, fringe benefits other than pension and postretirement obligations, rent, contractual rights and obligations, and statutory obligations.",
        "label": "Accounts Payable and Accrued Liabilities, Noncurrent",
        "terseLabel": "Noncurrent accrued expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r30",
      "r314"
     ],
     "calculation": {
      "http://glyc.com/role/StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedBonusesCurrent": {
     "auth_ref": [
      "r8",
      "r9",
      "r33"
     ],
     "calculation": {
      "http://glyc.com/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Bonuses, Current",
        "terseLabel": "Accrued bonuses"
       }
      }
     },
     "localname": "AccruedBonusesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedEmployeeBenefitsCurrent": {
     "auth_ref": [
      "r8",
      "r9",
      "r33"
     ],
     "calculation": {
      "http://glyc.com/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Employee Benefits, Current",
        "terseLabel": "Accrued employee benefits"
       }
      }
     },
     "localname": "AccruedEmployeeBenefitsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://glyc.com/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://glyc.com/role/StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails",
      "http://glyc.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r8",
      "r9",
      "r33"
     ],
     "calculation": {
      "http://glyc.com/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accrued consulting and other professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r28",
      "r140"
     ],
     "calculation": {
      "http://glyc.com/role/DisclosurePropertyAndEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosurePropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r18",
      "r238",
      "r314"
     ],
     "calculation": {
      "http://glyc.com/role/StatementBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r69",
      "r70",
      "r71",
      "r235",
      "r236",
      "r237",
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r197",
      "r200",
      "r241",
      "r242"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r200",
      "r231",
      "r240"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Allocated Share-based Compensation Expense",
        "terseLabel": "Total stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Anti-dilutive securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureNetLossPerCommonShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureNetLossPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Anti-dilutive securities excluded from computation of earnings per share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureNetLossPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureNetLossPerCommonShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r64",
      "r109",
      "r118",
      "r124",
      "r132",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r273",
      "r277",
      "r288",
      "r312",
      "r314",
      "r328",
      "r337"
     ],
     "calculation": {
      "http://glyc.com/role/StatementBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r5",
      "r7",
      "r38",
      "r64",
      "r132",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r273",
      "r277",
      "r288",
      "r312",
      "r314"
     ],
     "calculation": {
      "http://glyc.com/role/StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r284"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Assets measured at fair value levels 2 or 3"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup": {
     "auth_ref": [
      "r137"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets held-for-sale that are not part of a disposal group.",
        "label": "Assets Held-for-sale, Not Part of Disposal Group",
        "terseLabel": "Assets held for sale"
       }
      }
     },
     "localname": "AssetsHeldForSaleNotPartOfDisposalGroup",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesImpairmentOfLongLivedAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r201",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquityInducementPlanDetails",
      "http://glyc.com/role/DisclosureStockholdersEquitySummaryOfRsuActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Accounting"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r3",
      "r25",
      "r60"
     ],
     "calculation": {
      "http://glyc.com/role/StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureGoingConcernDetails",
      "http://glyc.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r11",
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r55",
      "r60",
      "r62"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents, end of period",
        "periodStartLabel": "Cash and cash equivalents, beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r55",
      "r289"
     ],
     "calculation": {
      "http://glyc.com/role/StatementStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net change in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowOperatingActivitiesLesseeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Operating Activities, Lessee [Abstract]",
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities:"
       }
      }
     },
     "localname": "CashFlowOperatingActivitiesLesseeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureOperatingLeasesComponentsOfLeaseExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r69",
      "r70",
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquityEquityOfferingsDetails",
      "http://glyc.com/role/DisclosureStockholdersEquityIncentivePlansDetails",
      "http://glyc.com/role/DisclosureStockholdersEquityInducementPlanDetails",
      "http://glyc.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r17",
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r17",
      "r314"
     ],
     "calculation": {
      "http://glyc.com/role/StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock; $0.001 par value; 100,000,000 shares authorized; 52,313,894 shares issued and outstanding at December 31, 2021; 49,017,622 shares issued and outstanding at December 31, 2020"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock": {
     "auth_ref": [
      "r181",
      "r182",
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of an entity's employee compensation and benefit plans, excluding share-based compensation and including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, life insurance, severance, health care, unemployment and other benefit plans.",
        "label": "Compensation and Employee Benefit Plans, Other than Share-based Compensation [Text Block]",
        "terseLabel": "Employee Benefit Plan"
       }
      }
     },
     "localname": "CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureEmployeeBenefitPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Benefit Plan"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets [Abstract]",
        "terseLabel": "Deferred income tax assets:"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureIncomeTaxesScheduleOfGrossDeferredTaxAssetAndRelatedValuationAllowanceDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Liabilities [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureIncomeTaxesScheduleOfGrossDeferredTaxAssetAndRelatedValuationAllowanceDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "verboseLabel": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosurePropertyAndEquipmentDetails",
      "http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r99",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentInterestRateIncreaseDecrease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental percentage increase (decrease) in the stated rate on a debt instrument.",
        "label": "Debt Instrument, Interest Rate, Increase (Decrease)",
        "terseLabel": "Incremental borrowing rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureOperatingLeasesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r29"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.",
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "terseLabel": "Summary of Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r14",
      "r15",
      "r253",
      "r329",
      "r336"
     ],
     "calculation": {
      "http://glyc.com/role/DisclosureIncomeTaxesScheduleOfGrossDeferredTaxAssetAndRelatedValuationAllowanceDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Gross deferred income tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureIncomeTaxesScheduleOfGrossDeferredTaxAssetAndRelatedValuationAllowanceDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r254"
     ],
     "calculation": {
      "http://glyc.com/role/DisclosureIncomeTaxesScheduleOfGrossDeferredTaxAssetAndRelatedValuationAllowanceDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Gross deferred income tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureIncomeTaxesScheduleOfGrossDeferredTaxAssetAndRelatedValuationAllowanceDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r256"
     ],
     "calculation": {
      "http://glyc.com/role/DisclosureIncomeTaxesScheduleOfGrossDeferredTaxAssetAndRelatedValuationAllowanceDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred income tax asset/(liability)"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureIncomeTaxesScheduleOfGrossDeferredTaxAssetAndRelatedValuationAllowanceDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r256"
     ],
     "calculation": {
      "http://glyc.com/role/DisclosureIncomeTaxesScheduleOfGrossDeferredTaxAssetAndRelatedValuationAllowanceDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Net deferred income tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureIncomeTaxesScheduleOfGrossDeferredTaxAssetAndRelatedValuationAllowanceDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r261",
      "r262"
     ],
     "calculation": {
      "http://glyc.com/role/DisclosureIncomeTaxesScheduleOfGrossDeferredTaxAssetAndRelatedValuationAllowanceDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforward"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureIncomeTaxesScheduleOfGrossDeferredTaxAssetAndRelatedValuationAllowanceDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r261",
      "r262"
     ],
     "calculation": {
      "http://glyc.com/role/DisclosureIncomeTaxesScheduleOfGrossDeferredTaxAssetAndRelatedValuationAllowanceDetail": {
       "order": 8.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureIncomeTaxesScheduleOfGrossDeferredTaxAssetAndRelatedValuationAllowanceDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits": {
     "auth_ref": [
      "r261",
      "r262"
     ],
     "calculation": {
      "http://glyc.com/role/DisclosureIncomeTaxesScheduleOfGrossDeferredTaxAssetAndRelatedValuationAllowanceDetail": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureIncomeTaxesScheduleOfGrossDeferredTaxAssetAndRelatedValuationAllowanceDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r255"
     ],
     "calculation": {
      "http://glyc.com/role/DisclosureIncomeTaxesScheduleOfGrossDeferredTaxAssetAndRelatedValuationAllowanceDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureIncomeTaxesScheduleOfGrossDeferredTaxAssetAndRelatedValuationAllowanceDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r261",
      "r262"
     ],
     "calculation": {
      "http://glyc.com/role/DisclosureIncomeTaxesScheduleOfGrossDeferredTaxAssetAndRelatedValuationAllowanceDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedLabel": "Property and equipment"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureIncomeTaxesScheduleOfGrossDeferredTaxAssetAndRelatedValuationAllowanceDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Contribution Plan Disclosure [Line Items]",
        "terseLabel": "Defined Contribution Plan Disclosure"
       }
      }
     },
     "localname": "DefinedContributionPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureEmployeeBenefitPlanDetail",
      "http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "terseLabel": "Employer match contribution"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureEmployeeBenefitPlanDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay",
        "terseLabel": "Percent of employee contributions the company contributes a matching contribution"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureEmployeeBenefitPlanDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage employer matches of the employee's percentage contribution matched.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match",
        "terseLabel": "Company matching contribution percentage"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureEmployeeBenefitPlanDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedContributionPlanTable": {
     "auth_ref": [
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about defined contribution pension plans or defined contribution other postretirement plans, separately for pension plans and other postretirement benefit plans.",
        "label": "Defined Contribution Plan [Table]"
       }
      }
     },
     "localname": "DefinedContributionPlanTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureEmployeeBenefitPlanDetail",
      "http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r58",
      "r138"
     ],
     "calculation": {
      "http://glyc.com/role/StatementStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation",
        "verboseLabel": "Depreciation of property and equipment"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosurePropertyAndEquipmentDetails",
      "http://glyc.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r49",
      "r74",
      "r75",
      "r76",
      "r77",
      "r78",
      "r82",
      "r84",
      "r86",
      "r87",
      "r88",
      "r92",
      "r93",
      "r282",
      "r283",
      "r332",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic net loss per common share (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss Per Share of Common Stock"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r49",
      "r74",
      "r75",
      "r76",
      "r77",
      "r78",
      "r84",
      "r86",
      "r87",
      "r88",
      "r92",
      "r93",
      "r282",
      "r283",
      "r332",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted net loss per common share (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r89",
      "r90",
      "r91",
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "verboseLabel": "Net Loss Per Share of Common Stock"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureNetLossPerShareOfCommonStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r248"
     ],
     "calculation": {
      "http://glyc.com/role/DisclosureIncomeTaxesReconciliationBetweenStatutoryFederalIncomeTaxRateAndEffectiveIncomeTaxRateDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureIncomeTaxesReconciliationBetweenStatutoryFederalIncomeTaxRateAndEffectiveIncomeTaxRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r65",
      "r248",
      "r267"
     ],
     "calculation": {
      "http://glyc.com/role/DisclosureIncomeTaxesReconciliationBetweenStatutoryFederalIncomeTaxRateAndEffectiveIncomeTaxRateDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "U.S. Federal statutory tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureIncomeTaxesReconciliationBetweenStatutoryFederalIncomeTaxRateAndEffectiveIncomeTaxRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r248",
      "r267"
     ],
     "calculation": {
      "http://glyc.com/role/DisclosureIncomeTaxesReconciliationBetweenStatutoryFederalIncomeTaxRateAndEffectiveIncomeTaxRateDetail": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureIncomeTaxesReconciliationBetweenStatutoryFederalIncomeTaxRateAndEffectiveIncomeTaxRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent": {
     "auth_ref": [],
     "calculation": {
      "http://glyc.com/role/DisclosureIncomeTaxesReconciliationBetweenStatutoryFederalIncomeTaxRateAndEffectiveIncomeTaxRateDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureIncomeTaxesReconciliationBetweenStatutoryFederalIncomeTaxRateAndEffectiveIncomeTaxRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r248",
      "r267"
     ],
     "calculation": {
      "http://glyc.com/role/DisclosureIncomeTaxesReconciliationBetweenStatutoryFederalIncomeTaxRateAndEffectiveIncomeTaxRateDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State taxes"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureIncomeTaxesReconciliationBetweenStatutoryFederalIncomeTaxRateAndEffectiveIncomeTaxRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r248",
      "r267"
     ],
     "calculation": {
      "http://glyc.com/role/DisclosureIncomeTaxesReconciliationBetweenStatutoryFederalIncomeTaxRateAndEffectiveIncomeTaxRateDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "terseLabel": "Research credit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureIncomeTaxesReconciliationBetweenStatutoryFederalIncomeTaxRateAndEffectiveIncomeTaxRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Period for unrecognized compensation expense related to unvested options yet has not been recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquityIncentivePlansDetails",
      "http://glyc.com/role/DisclosureStockholdersEquityInducementPlanDetails",
      "http://glyc.com/role/DisclosureStockholdersEquitySummaryOfRsuActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r232"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options",
        "terseLabel": "Unrecognized compensation expense related to unvested service RSUs",
        "verboseLabel": "Unrecognized compensation expense related to unvested options"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquityInducementPlanDetails",
      "http://glyc.com/role/DisclosureStockholdersEquitySummaryOfRsuActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r232"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options",
        "terseLabel": "Unrecognized compensation expense related to unvested options"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquityIncentivePlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r45",
      "r46",
      "r47",
      "r69",
      "r70",
      "r71",
      "r73",
      "r79",
      "r81",
      "r95",
      "r133",
      "r167",
      "r168",
      "r235",
      "r236",
      "r237",
      "r264",
      "r265",
      "r281",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r346",
      "r347",
      "r348",
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquityEquityOfferingsDetails",
      "http://glyc.com/role/DisclosureStockholdersEquityIncentivePlansDetails",
      "http://glyc.com/role/DisclosureStockholdersEquityInducementPlanDetails",
      "http://glyc.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r284",
      "r285",
      "r286",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r161",
      "r162",
      "r163",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r285",
      "r316",
      "r317",
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r161",
      "r184",
      "r185",
      "r190",
      "r191",
      "r285",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r161",
      "r162",
      "r163",
      "r184",
      "r185",
      "r190",
      "r191",
      "r285",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r161",
      "r162",
      "r163",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r285",
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r161",
      "r162",
      "r163",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r316",
      "r317",
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosurePropertyAndEquipmentDetails",
      "http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://glyc.com/role/StatementStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedTerseLabel": "Loss on disposal of assets"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://glyc.com/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General And Administrative Expense",
        "terseLabel": "General and administrative expense"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r50"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and Administrative Expense"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralBusinessMember": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax credit carryforwards which include, but are not limited to, investment, alcohol fuels, low income housing, alternative fuels, alternative motor vehicles, hurricane relief, disabled access, renewable resources electricity production, employer social security, orphan drug, new markets, employer provided child care facilities and services, biodiesel fuels, low sulfur diesel fuel production, distilled spirits and the advanced nuclear power facilities credit.",
        "label": "General Business Tax Credit Carryforward [Member]",
        "terseLabel": "General Business Tax Credit Carryforward"
       }
      }
     },
     "localname": "GeneralBusinessMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureIncomeTaxesNolsAndCarryforwardsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GranteeStatusAxis": {
     "auth_ref": [
      "r196",
      "r198",
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by status of recipient to whom award is granted.",
        "label": "Grantee Status [Axis]"
       }
      }
     },
     "localname": "GranteeStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquitySummaryOfRsuActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GranteeStatusDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Status of recipient to whom award is granted.",
        "label": "Grantee Status [Domain]"
       }
      }
     },
     "localname": "GranteeStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquitySummaryOfRsuActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of Intangible Assets (Excluding Goodwill) [Abstract]",
        "terseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesImpairmentOfLongLivedAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r136",
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statements of Operations and Comprehensive Loss"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r142",
      "r145"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r145"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureIncomeTaxesNolsAndCarryforwardsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureIncomeTaxesNolsAndCarryforwardsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r65",
      "r249",
      "r251",
      "r258",
      "r266",
      "r268",
      "r269",
      "r270",
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r44",
      "r246",
      "r247",
      "r251",
      "r252",
      "r257",
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://glyc.com/role/StatementStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://glyc.com/role/StatementStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://glyc.com/role/StatementStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "auth_ref": [],
     "calculation": {
      "http://glyc.com/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "glyc_NetIncomeLossAndComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of nonoperating interest income (expense).",
        "label": "Interest Income (Expense), Nonoperating, Net",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r306",
      "r308"
     ],
     "calculation": {
      "http://glyc.com/role/DisclosureOperatingLeasesComponentsOfLeaseExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total operating lease cost"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureOperatingLeasesComponentsOfLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Abstract]",
        "terseLabel": "Components of lease expense"
       }
      }
     },
     "localname": "LeaseCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureOperatingLeasesComponentsOfLeaseExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Components of lease expense and related cash flows"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureOperatingLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeasePracticalExpedientLessorSingleLeaseComponent": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether practical expedient is elected to account for lease component and nonlease component as single lease component.",
        "label": "Lease, Practical Expedient, Lessor Single Lease Component [true false]"
       }
      }
     },
     "localname": "LeasePracticalExpedientLessorSingleLeaseComponent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureOperatingLeasesDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosurePropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Leases"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureOperatingLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureOperatingLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseDescriptionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Description [Abstract]",
        "terseLabel": "Operating leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseDescriptionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureOperatingLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether lessee has option to extend operating lease.",
        "label": "Lessee, Operating Lease, Existence of Option to Extend [true false]"
       }
      }
     },
     "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureOperatingLeasesDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether lessee has option to terminate operating lease.",
        "label": "Lessee, Operating Lease, Existence of Option to Terminate [true false]"
       }
      }
     },
     "localname": "LesseeOperatingLeaseExistenceOfOptionToTerminate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureOperatingLeasesDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Maturities of lease liabilities due"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureOperatingLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r307"
     ],
     "calculation": {
      "http://glyc.com/role/DisclosureOperatingLeasesMaturitiesOfLeaseLiabilityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://glyc.com/role/DisclosureOperatingLeasesMaturitiesOfLeaseLiabilityDetailsCalc2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureOperatingLeasesMaturitiesOfLeaseLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r307"
     ],
     "calculation": {
      "http://glyc.com/role/DisclosureOperatingLeasesMaturitiesOfLeaseLiabilityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureOperatingLeasesMaturitiesOfLeaseLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r307"
     ],
     "calculation": {
      "http://glyc.com/role/DisclosureOperatingLeasesMaturitiesOfLeaseLiabilityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureOperatingLeasesMaturitiesOfLeaseLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r307"
     ],
     "calculation": {
      "http://glyc.com/role/DisclosureOperatingLeasesMaturitiesOfLeaseLiabilityDetailsCalc2": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Present value adjustment"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureOperatingLeasesMaturitiesOfLeaseLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "verboseLabel": "Operating Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureOperatingLeases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r32",
      "r64",
      "r119",
      "r132",
      "r148",
      "r149",
      "r150",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r274",
      "r277",
      "r278",
      "r288",
      "r312",
      "r313"
     ],
     "calculation": {
      "http://glyc.com/role/StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r22",
      "r64",
      "r132",
      "r288",
      "r314",
      "r330",
      "r339"
     ],
     "calculation": {
      "http://glyc.com/role/StatementBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities &amp; stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r34",
      "r64",
      "r132",
      "r148",
      "r149",
      "r150",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r274",
      "r277",
      "r278",
      "r288",
      "r312",
      "r313",
      "r314"
     ],
     "calculation": {
      "http://glyc.com/role/StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r284"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure",
        "terseLabel": "Liabilities measured at fair value levels 2 or 3"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risks and Uncertainties"
       }
      }
     },
     "localname": "LossContingencyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyDisclosures": {
     "auth_ref": [
      "r146",
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for loss and gain contingencies. Describes any existing condition, situation, or set of circumstances involving uncertainty as of the balance sheet date (or prior to issuance of the financial statements) as to a probable or reasonably possible loss incurred by an entity that will ultimately be resolved when one or more future events occur or fail to occur, and typically discloses the amount of loss recorded or a range of possible loss, or an assertion that no reasonable estimate can be made.",
        "label": "Contingencies Disclosure [Text Block]",
        "terseLabel": "Risks and Uncertainties"
       }
      }
     },
     "localname": "LossContingencyDisclosures",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureRisksAndUncertainties"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MoneyMarketFundsAtCarryingValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.",
        "label": "Money Market Funds, at Carrying Value",
        "terseLabel": "Carrying value of cash held in money market fund"
       }
      }
     },
     "localname": "MoneyMarketFundsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r96",
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "Description of the Business"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureDescriptionOfBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://glyc.com/role/StatementStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://glyc.com/role/StatementStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r55",
      "r56",
      "r59"
     ],
     "calculation": {
      "http://glyc.com/role/StatementStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "negatedLabel": "Net cash flows used in operating activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureGoingConcernDetails",
      "http://glyc.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r42",
      "r43",
      "r47",
      "r48",
      "r59",
      "r64",
      "r72",
      "r74",
      "r75",
      "r76",
      "r77",
      "r80",
      "r81",
      "r85",
      "r109",
      "r117",
      "r120",
      "r123",
      "r125",
      "r132",
      "r148",
      "r149",
      "r150",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r283",
      "r288",
      "r331",
      "r341"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "verboseLabel": "Accounting Standards Not Yet Adopted"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number Of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesSegmentInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.",
        "label": "Office Equipment"
       }
      }
     },
     "localname": "OfficeEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosurePropertyAndEquipmentDetails",
      "http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingCostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Costs and Expenses [Abstract]",
        "terseLabel": "Costs and expenses:"
       }
      }
     },
     "localname": "OperatingCostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://glyc.com/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total costs and expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r109",
      "r117",
      "r120",
      "r123",
      "r125"
     ],
     "calculation": {
      "http://glyc.com/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "glyc_NetIncomeLossAndComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r302",
      "r308"
     ],
     "calculation": {
      "http://glyc.com/role/DisclosureOperatingLeasesComponentsOfLeaseExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureOperatingLeasesComponentsOfLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease Liabilities, Payments Due [Abstract]",
        "terseLabel": "Maturities of lease liability due"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureOperatingLeasesMaturitiesOfLeaseLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r298"
     ],
     "calculation": {
      "http://glyc.com/role/DisclosureOperatingLeasesMaturitiesOfLeaseLiabilityDetailsCalc2": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Present value of lease payments"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureOperatingLeasesMaturitiesOfLeaseLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r298"
     ],
     "calculation": {
      "http://glyc.com/role/StatementBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "verboseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r298"
     ],
     "calculation": {
      "http://glyc.com/role/StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "verboseLabel": "Lease liabilities, net of current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r299",
      "r304"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating cash outflows from operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureOperatingLeasesComponentsOfLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r297"
     ],
     "calculation": {
      "http://glyc.com/role/StatementBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://glyc.com/role/StatementStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Operating Lease Right Of Use Asset Amortization",
        "terseLabel": "Non-cash lease expense"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r305",
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureOperatingLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r259"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating losses"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureIncomeTaxesNolsAndCarryforwardsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of the Business"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r8",
      "r9",
      "r10",
      "r33"
     ],
     "calculation": {
      "http://glyc.com/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other accrued expenses"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentAssetsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for other current assets.",
        "label": "Other Current Assets [Text Block]",
        "terseLabel": "Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "localname": "OtherCurrentAssetsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "auth_ref": [
      "r4",
      "r6",
      "r135"
     ],
     "calculation": {
      "http://glyc.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Other Prepaid Expense, Current",
        "terseLabel": "Other prepaid expenses"
       }
      }
     },
     "localname": "OtherPrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://glyc.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.",
        "label": "Other Receivables, Net, Current",
        "terseLabel": "Other receivables"
       }
      }
     },
     "localname": "OtherReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Expenses"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://glyc.com/role/StatementStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r201",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquityCompanySStockOptionActivityDetails",
      "http://glyc.com/role/DisclosureStockholdersEquityIncentivePlansDetails",
      "http://glyc.com/role/DisclosureStockholdersEquityInducementPlanDetails",
      "http://glyc.com/role/DisclosureStockholdersEquityInducementPlanStockOptionActivityDetails",
      "http://glyc.com/role/DisclosureStockholdersEquitySummaryOfRsuActivityDetails",
      "http://glyc.com/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquityCompanySStockOptionActivityDetails",
      "http://glyc.com/role/DisclosureStockholdersEquityIncentivePlansDetails",
      "http://glyc.com/role/DisclosureStockholdersEquityInducementPlanDetails",
      "http://glyc.com/role/DisclosureStockholdersEquityInducementPlanStockOptionActivityDetails",
      "http://glyc.com/role/DisclosureStockholdersEquitySummaryOfRsuActivityDetails",
      "http://glyc.com/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r16",
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r16",
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "verboseLabel": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r16",
      "r314"
     ],
     "calculation": {
      "http://glyc.com/role/StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "verboseLabel": "Preferred stock; $0.001 par value; 5,000,000 shares authorized, no shares issued and outstanding at December 31, 2021 and December 31, 2020"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r5",
      "r23",
      "r24"
     ],
     "calculation": {
      "http://glyc.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://glyc.com/role/StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails",
      "http://glyc.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r4",
      "r6",
      "r134",
      "r135"
     ],
     "calculation": {
      "http://glyc.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid research and development expenses"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseNoncurrent": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://glyc.com/role/StatementBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.",
        "label": "Prepaid Expense, Noncurrent",
        "terseLabel": "Prepaid research and development expenses"
       }
      }
     },
     "localname": "PrepaidExpenseNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://glyc.com/role/StatementStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "auth_ref": [
      "r53",
      "r234"
     ],
     "calculation": {
      "http://glyc.com/role/StatementStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.",
        "label": "Proceeds from Issuance of Shares under Incentive and Share-based Compensation Plans, Including Stock Options",
        "terseLabel": "Proceeds from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r53",
      "r234"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Cash proceeds from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquityIncentivePlansDetails",
      "http://glyc.com/role/DisclosureStockholdersEquityInducementPlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r1",
      "r42",
      "r43",
      "r47",
      "r54",
      "r64",
      "r72",
      "r80",
      "r81",
      "r109",
      "r117",
      "r120",
      "r123",
      "r125",
      "r132",
      "r148",
      "r149",
      "r150",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r272",
      "r275",
      "r276",
      "r279",
      "r280",
      "r283",
      "r288",
      "r333"
     ],
     "calculation": {
      "http://glyc.com/role/StatementStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r28",
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosurePropertyAndEquipmentDetails",
      "http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r144",
      "r352",
      "r353",
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosurePropertyAndEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r27",
      "r139"
     ],
     "calculation": {
      "http://glyc.com/role/DisclosurePropertyAndEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosurePropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosurePropertyAndEquipmentDetails",
      "http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r12",
      "r13",
      "r141",
      "r314",
      "r334",
      "r340"
     ],
     "calculation": {
      "http://glyc.com/role/DisclosurePropertyAndEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://glyc.com/role/StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosurePropertyAndEquipmentDetails",
      "http://glyc.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r26",
      "r141",
      "r352",
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r12",
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Summary of Property and Equipment useful lives"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosurePropertyAndEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r12",
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosurePropertyAndEquipmentDetails",
      "http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Property and Equipment estimated useful lives"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r243",
      "r326",
      "r366"
     ],
     "calculation": {
      "http://glyc.com/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development [Member]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchMember": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.",
        "label": "Research Tax Credit Carryforward [Member]"
       }
      }
     },
     "localname": "ResearchMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureIncomeTaxesNolsAndCarryforwardsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "RSU [Member]",
        "terseLabel": "RSU"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquitySummaryOfRsuActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r19",
      "r168",
      "r238",
      "r314",
      "r338",
      "r349",
      "r350"
     ],
     "calculation": {
      "http://glyc.com/role/StatementBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r69",
      "r70",
      "r71",
      "r73",
      "r79",
      "r81",
      "r133",
      "r235",
      "r236",
      "r237",
      "r264",
      "r265",
      "r281",
      "r346",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "auth_ref": [
      "r107",
      "r108",
      "r116",
      "r121",
      "r122",
      "r126",
      "r127",
      "r129",
      "r177",
      "r178",
      "r327"
     ],
     "calculation": {
      "http://glyc.com/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.",
        "label": "Revenue from Contract with Customer, Including Assessed Tax",
        "verboseLabel": "Revenue from collaboration and license agreements"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r63",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Aggregate net proceeds from stock sale"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquityEquityOfferingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquityEquityOfferingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Summary of Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureAccruedExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureNetLossPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Potentially dilutive securities outstanding"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureNetLossPerShareOfCommonStockTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Gross Deferred Tax Asset and Related Valuation Allowance"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Reconciliations Between Statutory Federal Income Tax Rate and Effective Income Tax Rate of Income Tax Expense"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r200",
      "r230",
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r200",
      "r230",
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]",
        "terseLabel": "Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.",
        "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
        "terseLabel": "Summary of RSU Activity"
       }
      }
     },
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r28",
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosurePropertyAndEquipmentDetails",
      "http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": {
     "auth_ref": [
      "r244",
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A schedule reflecting the terms of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements.",
        "label": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]"
       }
      }
     },
     "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureResearchAndLicenseAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r201",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquityCompanySStockOptionActivityDetails",
      "http://glyc.com/role/DisclosureStockholdersEquityInducementPlanDetails",
      "http://glyc.com/role/DisclosureStockholdersEquityInducementPlanStockOptionActivityDetails",
      "http://glyc.com/role/DisclosureStockholdersEquitySummaryOfRsuActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r208",
      "r219",
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]",
        "terseLabel": "Company's Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Weighted-Average Fair Value of Options Granted"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecurityDeposit": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://glyc.com/role/StatementBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.",
        "label": "Security Deposit",
        "terseLabel": "Deposits"
       }
      }
     },
     "localname": "SecurityDeposit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureOperatingLeasesDetails",
      "http://glyc.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r110",
      "r111",
      "r112",
      "r113",
      "r114",
      "r115",
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://glyc.com/role/StatementStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Compensation",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incentive plans"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquityIncentivePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquitySummaryOfRsuActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]",
        "terseLabel": "Restricted Stock Units information"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquitySummaryOfRsuActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquitySummaryOfRsuActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquitySummaryOfRsuActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquitySummaryOfRsuActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquitySummaryOfRsuActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Unvested at end of period",
        "periodStartLabel": "Unvested at beginning of period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquitySummaryOfRsuActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "NUMBER OF SHARES"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquitySummaryOfRsuActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Unvested at end of period",
        "periodStartLabel": "Unvested at beginning of period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquitySummaryOfRsuActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "WEIGHTED-AVERAGE GRANT DATE FAIR VALUE"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquitySummaryOfRsuActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquitySummaryOfRsuActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquitySummaryOfRsuActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]",
        "terseLabel": "Weighted-average assumptions"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquityWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquityWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquityWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquityWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquityCompanySStockOptionActivityDetails",
      "http://glyc.com/role/DisclosureStockholdersEquityIncentivePlansDetails",
      "http://glyc.com/role/DisclosureStockholdersEquityInducementPlanDetails",
      "http://glyc.com/role/DisclosureStockholdersEquityInducementPlanStockOptionActivityDetails",
      "http://glyc.com/role/DisclosureStockholdersEquitySummaryOfRsuActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Increase in number of shares of common stock"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquityIncentivePlansDetails",
      "http://glyc.com/role/DisclosureStockholdersEquityInducementPlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "verboseLabel": "Common stock authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquityIncentivePlansDetails",
      "http://glyc.com/role/DisclosureStockholdersEquityInducementPlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "ADDITIONAL DISCLOSURES"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquityCompanySStockOptionActivityDetails",
      "http://glyc.com/role/DisclosureStockholdersEquityInducementPlanStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Outstanding options exercisable at end of period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquityCompanySStockOptionActivityDetails",
      "http://glyc.com/role/DisclosureStockholdersEquityInducementPlanStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted-average exercise price exercisable at end of period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquityCompanySStockOptionActivityDetails",
      "http://glyc.com/role/DisclosureStockholdersEquityInducementPlanStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r221"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based compensation arrangement by share-based payment award options exercises in period total intrinsic value",
        "terseLabel": "Intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquityIncentivePlansDetails",
      "http://glyc.com/role/DisclosureStockholdersEquityInducementPlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Options forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquityCompanySStockOptionActivityDetails",
      "http://glyc.com/role/DisclosureStockholdersEquityInducementPlanStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Options granted",
        "verboseLabel": "Stock options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquityCompanySStockOptionActivityDetails",
      "http://glyc.com/role/DisclosureStockholdersEquityInducementPlanDetails",
      "http://glyc.com/role/DisclosureStockholdersEquityInducementPlanStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average fair value of the options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquityWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r210",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding at end of period",
        "periodStartLabel": "Outstanding at beginning of period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquityCompanySStockOptionActivityDetails",
      "http://glyc.com/role/DisclosureStockholdersEquityInducementPlanStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "OUTSTANDING OPTIONS"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquityCompanySStockOptionActivityDetails",
      "http://glyc.com/role/DisclosureStockholdersEquityInducementPlanStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding at end of period",
        "periodStartLabel": "Outstanding at beginning of period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquityCompanySStockOptionActivityDetails",
      "http://glyc.com/role/DisclosureStockholdersEquityInducementPlanStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "WEIGHTED-AVERAGE EXERCISE PRICE"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquityCompanySStockOptionActivityDetails",
      "http://glyc.com/role/DisclosureStockholdersEquityInducementPlanStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest [Abstract]",
        "terseLabel": "VESTED AND EXPECTED TO VEST"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquityCompanySStockOptionActivityDetails",
      "http://glyc.com/role/DisclosureStockholdersEquityInducementPlanStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Outstanding options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquityCompanySStockOptionActivityDetails",
      "http://glyc.com/role/DisclosureStockholdersEquityInducementPlanStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquityCompanySStockOptionActivityDetails",
      "http://glyc.com/role/DisclosureStockholdersEquityInducementPlanStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period",
        "terseLabel": "Common stock shares issued"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquityInducementPlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r199",
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Equity Award [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquityInducementPlanDetails",
      "http://glyc.com/role/DisclosureStockholdersEquitySummaryOfRsuActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquityCompanySStockOptionActivityDetails",
      "http://glyc.com/role/DisclosureStockholdersEquityInducementPlanStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Options forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquityCompanySStockOptionActivityDetails",
      "http://glyc.com/role/DisclosureStockholdersEquityInducementPlanStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquityCompanySStockOptionActivityDetails",
      "http://glyc.com/role/DisclosureStockholdersEquityInducementPlanStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Upon first anniversary of start date"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquityIncentivePlansDetails",
      "http://glyc.com/role/DisclosureStockholdersEquityInducementPlanDetails",
      "http://glyc.com/role/DisclosureStockholdersEquitySummaryOfRsuActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "On the second anniversary of the date of grant"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheThreeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquitySummaryOfRsuActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Each month after the first anniversary"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquityIncentivePlansDetails",
      "http://glyc.com/role/DisclosureStockholdersEquityInducementPlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r201",
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedPaymentArrangementEmployeeMember": {
     "auth_ref": [
      "r198",
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Includes, but is not limited to, nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires.",
        "label": "Non-executive employees"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementEmployeeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquitySummaryOfRsuActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Percent of shares subject to option grant that will vest",
        "verboseLabel": "Vesting percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquityIncentivePlansDetails",
      "http://glyc.com/role/DisclosureStockholdersEquityInducementPlanDetails",
      "http://glyc.com/role/DisclosureStockholdersEquitySummaryOfRsuActivityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement By Share-based Payment Award Expiration Period",
        "terseLabel": "Expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquityIncentivePlansDetails",
      "http://glyc.com/role/DisclosureStockholdersEquityInducementPlanDetails",
      "http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r225",
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquityWeightedAverageAssumptionsDetails",
      "http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-average contractual term (years) exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquityCompanySStockOptionActivityDetails",
      "http://glyc.com/role/DisclosureStockholdersEquityInducementPlanStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-average contractual term outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquityCompanySStockOptionActivityDetails",
      "http://glyc.com/role/DisclosureStockholdersEquityInducementPlanStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-Average Remaining Contractual Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquityCompanySStockOptionActivityDetails",
      "http://glyc.com/role/DisclosureStockholdersEquityInducementPlanStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r207"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Fair value of shares vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquityIncentivePlansDetails",
      "http://glyc.com/role/DisclosureStockholdersEquityInducementPlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "verboseLabel": "Price per share"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquityEquityOfferingsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance, shares",
        "periodStartLabel": "Balance, shares"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r36",
      "r45",
      "r46",
      "r47",
      "r69",
      "r70",
      "r71",
      "r73",
      "r79",
      "r81",
      "r95",
      "r133",
      "r167",
      "r168",
      "r235",
      "r236",
      "r237",
      "r264",
      "r265",
      "r281",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r346",
      "r347",
      "r348",
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquityEquityOfferingsDetails",
      "http://glyc.com/role/DisclosureStockholdersEquityIncentivePlansDetails",
      "http://glyc.com/role/DisclosureStockholdersEquityInducementPlanDetails",
      "http://glyc.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquityEquityOfferingsDetails",
      "http://glyc.com/role/DisclosureStockholdersEquityTables",
      "http://glyc.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statements of Cash Flows"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheets"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statements of Stockholders' Equity"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r69",
      "r70",
      "r71",
      "r95",
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquityEquityOfferingsDetails",
      "http://glyc.com/role/DisclosureStockholdersEquityIncentivePlansDetails",
      "http://glyc.com/role/DisclosureStockholdersEquityTables",
      "http://glyc.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r16",
      "r17",
      "r167",
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock, net of issuance costs, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquityEquityOfferingsDetails",
      "http://glyc.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r16",
      "r17",
      "r167",
      "r168",
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Options exercised",
        "positiveLabel": "Shares issued from exercise of stock options",
        "terseLabel": "Options exercised",
        "verboseLabel": "Exercise of options, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquityCompanySStockOptionActivityDetails",
      "http://glyc.com/role/DisclosureStockholdersEquityIncentivePlansDetails",
      "http://glyc.com/role/DisclosureStockholdersEquityInducementPlanDetails",
      "http://glyc.com/role/DisclosureStockholdersEquityInducementPlanStockOptionActivityDetails",
      "http://glyc.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r16",
      "r17",
      "r167",
      "r168"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock, net of issuance costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r36",
      "r167",
      "r168"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r17",
      "r20",
      "r21",
      "r64",
      "r131",
      "r132",
      "r288",
      "r314"
     ],
     "calculation": {
      "http://glyc.com/role/StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/StatementBalanceSheets",
      "http://glyc.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity offerings"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquityEquityOfferingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r296",
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquityEquityOfferingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r296",
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquityEquityOfferingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r296",
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquityEquityOfferingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquityEquityOfferingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.",
        "label": "Substantial Doubt about Going Concern [Text Block]",
        "terseLabel": "Going Concern"
       }
      }
     },
     "localname": "SubstantialDoubtAboutGoingConcernTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureGoingConcern"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r259"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credits available to carry forward"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureIncomeTaxesNolsAndCarryforwardsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureIncomeTaxesNolsAndCarryforwardsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Tax Credit Carryforward [Line Items]",
        "terseLabel": "Tax Credit Carryforward"
       }
      }
     },
     "localname": "TaxCreditCarryforwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureIncomeTaxesNolsAndCarryforwardsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureIncomeTaxesNolsAndCarryforwardsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxCreditCarryforwardTable": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A listing of tax credit carryforwards available to reduce future taxable income including descriptions, amounts, expiration dates, limitations on use and the related deferred tax assets and valuation allowances.",
        "label": "Tax Credit Carryforward [Table]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureIncomeTaxesNolsAndCarryforwardsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r97",
      "r98",
      "r100",
      "r101",
      "r102",
      "r103",
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r303",
      "r308"
     ],
     "calculation": {
      "http://glyc.com/role/DisclosureOperatingLeasesComponentsOfLeaseExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease cost"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureOperatingLeasesComponentsOfLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquityIncentivePlansDetails",
      "http://glyc.com/role/DisclosureStockholdersEquityInducementPlanDetails",
      "http://glyc.com/role/DisclosureStockholdersEquitySummaryOfRsuActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquityIncentivePlansDetails",
      "http://glyc.com/role/DisclosureStockholdersEquityInducementPlanDetails",
      "http://glyc.com/role/DisclosureStockholdersEquitySummaryOfRsuActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r83",
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted weighted-average number of common shares outstanding (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r82",
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic weighted-average number of common shares outstanding (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://glyc.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 8
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123398962&loc=d3e400-110220"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/subtopic&trid=2127163"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "30",
   "Topic": "450",
   "URI": "http://asc.fasb.org/subtopic&trid=2127197"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "710",
   "URI": "http://asc.fasb.org/topic&trid=2127225"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "712",
   "URI": "http://asc.fasb.org/topic&trid=2197446"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=SL116886442-113899"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4549-113899"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "40",
   "Topic": "205",
   "URI": "http://asc.fasb.org/subtopic&trid=51888271"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=124258985&loc=SL117410129-209981"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r367": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r368": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r369": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8,17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r371": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r372": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r373": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r374": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r375": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>78
<FILENAME>0001558370-22-002737-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-22-002737-xbrl.zip
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MY>4D33SJR>09U)DA]S!U@FW& 7%.%OYS3R4I96(Q,LQ?1HKUX.SLK*=2#6E
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M/_6'Q8U[8AIW4D;2N$E43(OT,9WZH?Z\%&V+*Y_4=.4MWEF\OWGPD3SB5_#
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M-ZZ>.(95IW:BXX31R:*?_P=02P,$%     @ V4-C5.RJ;_<L#@  F;\  !4
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MV@*Y0"DELVLY5&QTP+&(0#@+@U2O"J_A,=I!B"8)):S,#P;\X'@QA")L?91
M6D<:+-MVH2*;/N(WE&<KFXW-M=E8K2&H)\G";"SPP?G*\(M4]%&=9U^D8E^D
MHBI/^R(5LA@-@XG//\)-2U2L1H!P-*2C0,4*(Q-F0 [A=V+67U^.YO,H?+-]
MOAT@; [AD(!+\6;P39/7BW!,O2-:V]SVGVR?K;$4^D$(%<L3G(^' >V$H[BD
MF<A?5:U$OOK]F49 QQ-B%WIOGIO8/L/F$K3;\O)@ LS!,.P?7CQ]1'Z*))YZ
M\^?P*HAIT7V65=9JA)YMMD8QY7*J";&^>'@Q]=#DZATY":V1/9Y,/ =%3$W8
MV+I/.VT#<2Q8)L0-@L4VC&+AO"<".RP6#H%9[;'<UP<'4!_<A/691N%+I]K$
M$DMA&@?YC7.^ 2K=%8*O;%+TEZ:L-$6ZY>0#BB9A-".^8BMN,KI#<)Q[YBB#
M*H-0\?O:D"!K0PZ['.1+,V5?F*MP7X3,_#TE_033=Q[&V\O:4F/Y^-_W@%#;
M7Y!/:<-4>3.ODW8P'X2@IU[YZH!H<&6LO#:RRAOCR1U1U%,_31DENU&J\+7*
MF?2<$.*]D&1-FG#=R%L;77SU/O>BM'&V-D:3&$7T15,O2+\=3[(B8;EEP!8Z
M\Q-W*GF\@(XAR3-//7 I)MKPUFW+U<?O5/(^#<)^JQ,)IH"UH5BAQC.;893$
M4X+8GTA[603^/)T*W,^="YQ>8H$3O'WQX7Z*#__2I2#OZPAKT+0Y2E?O-!\#
MH^4=[I10-T$<>0'V'".7)I6F[E2,/P]"'RO1#YS$/D2A@Y"+KPF)RR'X AW>
M7B_1K]O#J.,NA44">W"<WM<X-RZ#G1Z)[.N5;VI!KTK$=^7@B&;L5E2'\<Z5
M#-VV1RXSW&XP3LR5Y&3/T:WL#:,,/IM2VR-MS)I1WZ(0:\]+$,W4K>0-HW2E
MB%XPY:]-X)19X&59R$7XBI^1Z;J5Q$Z.5<P3#9XX4F\L4]J72;1\5#!3YBH.
M;IN!NA6A;L]'6I #;F+!G?WNS9+94I+'DPSZJW?'3USD4K_^>Q M7:+R\%?O
M]&,U# < GFZEKY/#$@!4A5=/K+3:1D[LO=$K+8HEQGYN66(L;VAELUO%]/O2
M8Z!+CPVAPDX?A<7V%7:,W=O95]C1M,V*R=NBP@X$R=9G).RO3G1Y=4*T2@=V
MCV*#N,PXB7%L!RY-V#?W5$S#9%M^D\( Q>"%*O0A:N8=4OX\$/9 L\O8D$1N
MW_NA.WB,H%L==BZ0 SE9V)E0KNX#476!ZC6Z"T2%E5[U,'7Z+IIIT/?).E=A
M3!)NG4B6Z%EY^J)8B ^1YZ2O<TRZ<D.D 1FT"NW*19&FYJ[*=K\"O76NCJ(:
MZ4'JARCJW,"9S,-\6L1=)P1;YDR9%'F=9-\^L:_=B>E#\A6!&+35 DOX%2F_
M??+/<%+Z6 '*8&R9*]KG&E"F_?!600,%LN3144 K)2"'?'P.Z5>C%QQ'ME.M
MH]+9K(.6<:/>:2/I=D5$NSI@DY]^&YQ127W0@43OPKE<,^H]!%\V!6H;'%20
MRV"(ILG&]UH4"+*LIW@1!BF;$MNGA<;,WE;2 ^ V.+9M%PT0%L!<0!OP8W4O
M>W6; !NV[!OFW+[BB!T1;NN$,]^]:.JJ4?.=,<\VV.E2:]M !:4R';=9)GNP
MNZ5GWP8#NT_YW3$[6MT8.C5D,+>"9!LLXW;2WC6EMT[R^6N^:U>Q%22##H+W
M)?FM* WA&GGZ38W2^4UWU2ODGR6OD*=?'Z:S6N5IK7Q>,'?'I>KIC?P4&(\6
ME:]6S*.U]+#</7*M<_6B.&\"(G)$QNPX73*W.:2"*^;"'A!OG!L0B+(:$M(#
MW&5T#K3"N^D-?8!<59>09 FVZ;_(KHEQCP@C0IKI*' OT1ORPSD%.U>^S!OP
M2CTA1#JD9+/,0RG,P''R&PJ(E>$3H$?NC-":6CCTK6(97DKVA>#W*W-3$C=P
M_-2SO]1"QFTJ+JO,TE]]!$,$8Q=+T+K[;T?AA!S;\LL,S8715#M#4$$=")HL
M.;KW&S/]^VR_(WP?^IBHU0L[BA9YDB3.O#4Y-_'D^/BTZB9FPUOI^.3/^_$M
MMNS M9SR)(53V(]/2&"[B)#KQ67$18Z=J$./UCH!*R^4'2\:';-Z8S@^63-#
MZA9Z'1\(>WX=-@D/BM4<E//$$S0Q5PI43)3[ND9N;A.FAF0QIX<PO^A7<Q\X
MS@Y?@I9%P)K1 1>-9ZYS@>82M.]!>7&,"37E)4 )G /#A+6Q8F%C+R"JK5$8
M&]EFIL"AYKB05 @(D@*4E#I6O =L*" /89PGF/@,F+U'-;2%X#>U8 T'&W <
M8J+6%'MIZM1?*$4.G48-EV]C@XUHC,EN;M,'RV]#C-?<7 Y'11W KD A7T48
M#<1 G(5)[3UVJ1X0$G\TK<0"I>[C1:7#E%O/H5&KT6N$LLNQ2DD%)R?')]5H
M43%X&B+*A[=6XX-)'F"?*)5R2HJ,D.?P 46$9[/K,$H?M)7,&-A\ AT+%D=Q
MB3KDKRIER%>_7U!)1-'<CN(%I^P\OQF<H)-^YM)%S,?<@'Z58M<CFB<$.;NT
M;JL ,OTYQ;X]>W5-@EGP1@$C$W&KT3ST_7#F.?PP5:U)GTY9*P%:AJAJJ/2V
M!NA*YNBITF]P@DKFE%,)W5ZYP5P M5\!:)6:[*Q1LF_)SM] XE*S\GOONJ3.
M^H*<%4B-:-]271>RGN[)T*MOGLDG3-8130'F.?ZM1^D^$K APNRDB<V54<^9
M$AS!>"3(! EQ=1SDO64/ASW9%.$+TM=S;/\IF<]]#S'E0:%SGR$$#0*ABJ[Q
M!P*_S\GT09PG\1<@L9C$:]EGB$ 71WBX&2=_60<$[B-Z37S:=S&:SZ/PS?;O
M/!_A. P0+F1CK=G5&T6:Q2U- _=Y_447<S61PK@LC)RI1T"E<(XG3W/D>!,/
MN?<HILH!/Y.^F%X>H0731KZ?AWK<ARAT$X<M!)N.V&>E %W<WY0&QMF^%+_5
MMI!GRK%8*FK=*;L^F6&7"#_CK'CV4)0F*!(AB.U7LB./@B"Q_4):6 QI[M,I
M6WXVPY9F++L/JQ<YJ.<H(&.D3_@II5Z>UH/IQ9!6/F;VIFNOJ9:7E#XT]96X
M!=Y+0@E%@1+%Q,5=]B$C7CQ;AM3[(- ^"+0S02"S*FRE>7G!HC8#])<QHHYF
M.40D5CZ#S1_AH)5OM-&='1/[/"\'4/R>61GC2?JCFDBHC LA&\6(S*@0 5P"
M2WN<M$L*C/27OD1D>+)!21*A%,)H46XDS'_:=% (%6*,RD@C!5JY?K\>9<P@
M_] R,G_[?U!+ P04    " #90V-4'%9LFV1A   ?=@4 %0   &=L>6,M,C R
M,3$R,S%?;&%B+GAM;.6]_7/D.(X@^ON+N/^!K^_%=7=$NKYZ9F^[=V<OLOQ1
MXW<NVV&[NG=>Q8L)6F(ZM:V4<O1A5\Y??P2ISQ0I44I)8+HC[G:JG0 (4  (
M@B3P[__KV\8GSRR*O3#XRW?OW[S[CK# "5TO>/K+=VE\0F/'\[[[7__QW_ZO
M?_^_3T[^\^/=%7%#)]VP("%.Q&C"7/+B)6OR$&ZW-""?611YOD\^1I[[Q CY
M^<V_O/G7=W_Z\.:G?_G7]^_(R4E&Z2.-.688$$'RPYOWQ2^G&=4P^(7\]/:G
MMQ_>??A ?O[E3S_]\N>?R/)S ?>9,[GRN@!]+_C]%_@_CWQ PH4-XE^^Q=Y?
MOELGR?:7MV]?7E[>O/ST)HR>./Z[]V__\_/5O;-F&WKB!7%" X=]1SC\+['X
MXU7HT$3,5 7]VV/DYP1^>EN,I86 _SK)P4[@3R?O/YS\]/[-M]C]3K)H0/^[
M7!CX@TJ<]S___/-;\6L.VH#LH,Q_=9,"H0K\Y[?RQ^_X%!/R[U'HLSNV(F*T
M7Y+=EOWEN]C;;'V@)?ZVCMA*/;0?16\!_VW GN"[PX3\#!/R_E]@0OY[]N<K
M^LC\[PA ?KF[U$KQ<XU6AO1V-BX?N"&Q0:Q6,6?D-TRH/XS?"F;&KS0U^-,5
M_U>-;?8M88'+W)QQH-2BB6(@H;F",M .G1I!'PPQC)H3$>>:&C/GS5/X_-9E
M'GB&]__X$_SS1/Y3S '_S[^?AMSW+1_C)*).DE,3,OSE.\7O;PM^ &09U9FB
MD9.3X/_LD#&#>.N$W,=LDQ-?SJ5$7T7A1LE -ERH^/'O_J._SV&-O8C%81HY
MK-='J'*EFQ<Y,G<:' *6#1:<?+G_[C_.\G6"!BXY#Q(OV9'+8!5&&^%#_UT2
MG_H+YUP\<*H*0>H_S_]]5>SEG[?ZVZQ?MSFP_N,"S/ZG'(6YI.(11^=P8F5;
M!D%*_3NV#2.55U&#X2F?BMU]):S"H"ACDP'])Y>P1 +/[6@B&L0>>+C.[]\$
M171 &K8;SF@/#L<Q*9EH<0$%/(Y.W++("]WSP#WCL5.+7'MP>-J@9'A?%6I
M*'J@X$"O!!*81R(N 7"\16M,KB=27!FN77@^NTXWCRQ22-,$F5]==6SFFKK_
M^ZQ*JAZ\\:6SR!C@B 2<]1O?L2</PO@@N:8;E6]2@V%]:S6[]>]=AT'XYBH&
M=-^]A"4 /+]7&IWE2=7U,G#"B*_@8@MYGW"/>!JF01+M3D-7K[T=6%C*;"1,
M7;=;41!4W8 ?G1K54!=$(),P(AD! A1FU:T'^NW2Y6NNM_)DFK=C[=/"8^E3
MAP!U3=( (^A0*R<Z[>%(I(Z%L7HN79?/1YS]SY47L/=:,96P6*K2PGA=312
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MML&R,J@MH/ BV3T6VK9! $H$+%I?K+Y,8VJO87K7F@2N48H6/PEKFG2<JZR
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M4/+U@7U+R$?^\7_'.FLTY7]DU=8\NOD4PM-RT(\HT/CD%CB$9S1M#!?O951
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MFF]6I#I8MJ 2/ER]?$\V(!$C9C<7Q)BDJ)];1I/S[K[GGKVQ(I#QNDQQG_%
MOQG?R&C%0.LIU27$7BLI'3A&!ZEV7E3=7\#+<Q34K8N"\:YM?3N*-:K3NJ5O
M@[=!>;K<3ZD]=B4_#Q)EU!9C=RSF@9L#S_*O>/  +3B?(M;Z(KT''L(>JX]
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M1QPP$6KW,( @HF<8S&VK4RBHDI)L9@R"L,W.8,09*0_F[NZ_V&7_I<N[E6V
MER\T<JLN#RH[RZ9]<9QNY-\&1PZ'#(+M(<:<JJZ(8O@(5D07A[)O'&ED Q$Q
M4B/4*(8CE?$L=#433MQOS'M:<]=ULGQF$7UBI%*MG<]E1IY\BF@P\.'4Z"XI
M;^-Y+Y^HJ(.RI2^8$9>)LZ*#<&=0/,45-PG-O=/HXV$[JHDF4.VS1AX,T7U-
M(DFK)RL:UF9#MFRBRG%%&%&,3.30\AJPA:YMIDG55#K*+T!9X=?RB\X/])N\
M;KP,#KB(V),:MD\:)+S:X_0BA>A/!O#9ZBV**_^<8'Z?'VXXV7V9<>Q9^!2%
M<:R8"S$5=]EEKTK@QUW+"^6*:H4+.%^M&.S^6%'(ZH[S"RXO</B$R"[G_?S
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MAH#TSKM3A-IC;RWT_"^^.UAI/OL&!&*700P48IL)88L)W#&'><]PZA!?L\3
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MOE(SD6OJ'R9B*9H/B.@W0F^!5XB%X)30]?AJ"_*%T3UGT9<.!9[^A($^832
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M6'/C??KACNI&E_'TC7"9JW.L8[O'92A0PZ:"M_18KB@-%5& DX]FY[D97/U
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M0/SPHL9W:W2@A+1 )_1KLP(,5R]:5\9]S<!?&YM+?AD1G&^V?KACK'6A[$,
M.TPT%5$=_'5A(X9T9JPUU/$Z#$[XSM=)1;-?EJ%8^%!*1*!<-F?-'OAXIAII
M1 -;*7L(:K I41.P9;?1QEWS]DA DC4C,>/3"?>F ZZD44RC'9QOPB\N341?
M2E'+S#ZE[3X?EANERX 'F*G8@MUPL:*'-0TP;O@>RHU5AC37Y(]RU^0P5FPQ
M[GGDG"+1GB4L*HP1P1GW,C1XO?>,)_D<Y7:9R/9 8L-,O& 51AO!V3%Z:O%_
MX(V*%SS)ZD6MYYJC#7%D/K5EFD9QE KZQ^/]M,Q/X=)D\C4;;9*>/Y.[)_/Y
MRL5$O_26[[KN6?3L.4PM.M]U/<L'<"!@_! FU*_^?AK&R768_(TE=SST?0J\
M?S*WI"21]CVU9NX1^<'Q7.@?H.KFT)B9W2<B2]H\@<KX(1E#1.=1%Z3@2KI,
M'N;5/"YGB.Q80DJ6%C5B$DD1+N(X6]L^Q)<@*D@0ISJQ[!O\FY&(^31["IWF
M7R+.OMK=_9=IYM&@B^;KF,DC+GW4N3LI)O\N]/V+:=K>#63BR,+V@Z9ZG@R(
MBH/C"?T/$ \QWU$PE;]6A&2K(!N3K\ HR3A]=8F/'I_C^LOGC^=WY.:"W/]U
M>:1OK<WG8YHWV/W'?[4.=H(WVWT'?XUN=>HWWD,]ZA%VO!MITK_D(>JK:'@W
MP:0<6;^[P3-3;VDU^X?9'_ZUK2SJZ9UG8:F/_8K6%95@B,O*?O>[UQ:.&TVW
MO%OW.GWD1=[O!,U-*CAX;9Y2.\GS.,O&\*_(7VID0W29!4=3><V?Y7P'[ F2
MLCA^TW3:+XZYG5+G+,AJHVB><W_XU^8VU=,[C\^LC_V*'*9*,$1OF=4N?L6N
MTFC")="K=))%?F+OR;V(JL_X=[F@7O0K]5-FQ6E;/RY?F\L]Z&/-G%/NP^(K
M<N 'R&]'?KI19D1P3H!U KP3P?PKOOP\YA?\[?SRTU\?SL].EK^>WRT_G9-/
M=\OK!W*V?#@G%\O+._+K\NK+^1]\8;'X"_^1EQ!;UXT_Y&)Q?"O$JS[A'/J]
M_JB'GV/,UQ_S7-2^U;,W?Z]M"1WX@3".7O](B^D@R2TZO$5=6*TYY!WZW?X
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MXO_B?\S_Q/\/;##_X_\ 4$L#!!0    ( -E#8U11BN_N*$0  !\6!0 5
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MA1VM(&V\60!G0L>&HY[CA"D<]H+94^A[C@<$%,C;GD01'D&"S/()1,]S..!
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MKFVQ98NP:(;%#8B'W9B D;#6>4)M!!"2%/ZO,-1&)TIL%?.%VAAJ,LWC,HP
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ML,QBVA([2@9C!]]AP60=S/P]"F/IJQOREZI@?=6?EK'7ML"K8*6+(6UV8$I
M\-ZS6([^VAXY7F8D#<#,3O*R1M"T)300BRGP$A2T=\]Q)5SNEPY$ESE<\RJX
M[='B0"W!D 7\P0JZ4*^DZ]W9 OXV&*05_ %0MBW@CMY 9,] ,;WB5SX1KM.N
M_#N<'1F.'6GT_;31]3#W =WH5J\5#<=TY#):FZG1[&LOO4[$PZ!:7X4*2Y/7
M@X.U2;,VQ:#LYXS&4NI.R@H=YB;4B8/%=69Q[7%1>CF@MT97X]W187:"W3@8
M7F>&)P,9I;<.C#6]@>[@C@^69M@6[OC@>"1J-<M:,@I0CEO@P!]?0O0K5>^1
M\'UU.--7UR[%)HK=SX5?,T5V=5K%^_GA6$H+ G=F1D*'7(=$-V(:U;#(:]>I
M*OCG$/SS@^T9"8I2?Z)6BWQEZ_E5EIXG -TL@K^_#@-,B-3VT8L@:K,7RNC@
MP5+)EFHN0$K7I7V=1S?Y+#IX/9+GF\.QK:[W:N)J/?@)R2<?Z'*BTBW9SG>&
MP_S&A)1O%'Q:/FRQZ*K3L)?B_/K!:-0:S6%O)&-E*[Z$/5&T"6K0DX.)*=CK
MR,)!Z:9&VRL>+95+'K^Z]CDTZ,G!W!28FRP<E.Z8UK-;-_D<G]/%PHY6X^DD
M3ILF<OS*F<@Q_Y853JW)\\]# L>!)W#\!JWEJYY12UL"QUQF@Y/Z93V'GZ%D
M<*R4,0;4;J#;I0I;&P;#W5Q%&[$#ERL3I(I/&4<^-AEDAH,**L9@'DX '(L]
M=)Z#%P<_ R^)X2*@-E$B5QWCF-$9RKL$$U>44E^G[GRUC7(3F\"@CB<VIC(H
M;CQ3L&Z<F]@ O)GZ)T/69!(P/N&M09!P#;\-Y9,$D"1#PK<J 7B&:DYCRLBY
M4\XX[+H>/ODT0O'-ZAY#*P)0!]*:DL;!SP<' T;UXZKT?5U!WPV[;Q=+/UP!
M0%U<\S=@-M)""^660IM% 106YP4SRIA=*F$<B%V/UBQ=4)SZNL?IO.O4$;I2
MQCBP6<HGPM7#\;A"8LQ22&1(]G' .R S6S 5WX9C<3-Y^X;_"_Q>6P:4VM@3
M#K D/KP>TBC^^$(_7[I> "A2(>42N.YU0V.)"Y]&G$0IUO\XF0/TQ'*@X\)
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M%#@Z>.]B>'96??&@<S.K?OY@97JMC .-PS0FI-$\RSIPM5G83@\.1J;7R/@
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MJK:L>700AJ?FO@ZWI&9E%X(]7H0!GI:I&81VRAF'(C\"N^CQ26<6<FUR4IN
M5]>#,%,9'#FI=06>M,U);0+>3/V3(5,_FC)R4I?W0.R$U+NEC06#:Y1L(IQ9
M8V7SA*8F@-7U2,G2!4?B:5T#9;N$IB: S5(^$:[>+#D)).X@H:E!^ HM3]O*
MVS?\7][#MNE,BQ;V!'^ZO))2F1(62;E$/^&^Z^YFM%Q&X9OMDU=)E.*]!JN1
M<)+.^?WLE$ ZG%X4)VAOC%XWM?UGVZ\?E[GK#0M@(2DE'?<V0KI^X(ZCI#1H
MP__:'K#AK_Y\08<YXRE<]WMOGIO:?LT:FEBNJHAC_7!WM9(6T\A0J/&'E\PG
MP,>:C.?>\B6\#1+TZF_=:KQ!"\;020Q>!BT:R"PIP+MKPES//3"]_0!.BMZS
M&D^GG@.BV@F%4=IL(C0 M$H14<G-HX/PGJ#=V\'[-+7P:T-2*(I.6C17I7EO
M#)M 4C9IN#>?\A6C<Q@C[(7PB6 IYA.N_+&4XR#/RTC>#G%6-8XBG<&]M;%J
MHZ]>,><)1-,P6MA!,_;L5#\P2)+.)-VF,GJ^-.25("-HVG40F!H5YJP]']XU
M@E>VKEYK1Q#3WGHP@NUJV$>@>2?JE#3KDYYM^"9K)=!4\Q. 9C[D; Z@H/X*
M_H0+XLFM-M^9\N_M'ZWUJ%3IQ6[A1P]D$[MLZ5D:J?'T1Q@D<Q_?S+%]'T^Z
M4LG-^<T#P;M3J]([SL*)^&@D;S*=W7XLO0@7SNQ\-(4=?0'1P@OP;\?3[(D'
M5('(=-4?KN)R G$YVQNZ:]&MTDN_6M/BR5"G[!7Z=OO[1_=N5"CII*&>U<+K
M<-V^E&(>S%9ZHS290TG^":CLEOF=/6>Y<E5*\KB0]IV70WN3;--2#Y\+W"O[
M,4OEN9U]4V1GO4N1DNOJ]@/%&\9@G3L.(W ?))$7Q)ZC) 6*P*?WUWJT:3<W
ME LSO$6RKCQ&H0. &]]!,,LG>X662,LI9KW])6@SU>3LNAP4N_;] =:]XKT!
M>B[.JHX.6^3R?FOS4FY7FV7R%_?7/KI6:F$,;4]NZXWAO&_&D.GL/HY3=0]9
MU7VCBLUIC[.,=D9X;C46%%=S@MN[5Z9J<YY_C\)8>KP9^4L'NJM69D'ZMB>Z
M)(^-KLU"X\.3VFS!ZP2BI&V!JL_MN0%TI='""M2<\6JS >0OR":^FS3R@EFF
MBVQ"%/'/B#>TQ[R5HZN"D6K.9[6'D_VP/[Q%NEB;Y7B::>7VP_%3%[C(W?4S
MB-:[]G+SMQ_HQVU_N?;^[!_ES51Y83EJHNO7EJ,CE7=I^!@YB?>&+B@+9O?^
MUC"[=U[0RKYN%9_O7]9OQ)G3HZ_?+D\OCD[.CA"M#XG 12[+&#"R<2!:,S$K
M58?!N<%;)9T],\"GJA2XFB,WEC)Z@'7CI+,&X,W4/QDRBD1]3#IK$!@4S6XM
M" 6%ZT6>0_,NXQI C:['944J5'IO2]M[("W=Q^,TB1,[<-&]3G6/UU,_9A[?
MU?!/ON]?0)^2[N,:>!-=COZRTW+UO,^^,QS*BS-1J1E0U'MX>+T/1[\'6^A&
MP<-\G=R4<["]9[$<_;6]A'Z9D30 ,SL!E-<Z>S9<EQXP5Q621O[2@>@RAVM>
M!;>]FCY02S!I =_7MZ)-, -._7;W?G-_[6#K:>QB@GV*/ >_Y3WMRL/#V9'A
MS"<:O3]M=#W,G4 WNM5K1<,Q';F,UF9J![\3[W%0K;="A:7)Z\'!VJ19FV)0
M]G-&8REU)X.!#G,3ZL3!XCJSN/:X*$T8V5NCJ_'OZ# [P6Y4 ?YZ,#QUAB<#
M&:5Y*XTUO>'MX Z&9M@.KFI?![=C_=7+48 2D0('_O@2HE\QKFDH_NIP;*IK
MAV(3Q>[GLJ^9(KLZK>+]_' LI06!.S,C/O4KC=/4FJ-!J48U+/':=>I@>YIL
MK^GJSY#G7HS*FB*@Y_5C.]=A@ F1VCYZFT%MGA49'3Q8*ME2S05(Z;JTK_/H
M)A7@)C- K'BW1OWF<&RKZ[V:N%H/7D+RN0>ZG*AT2[;SG>$POS$AY1L%GY8/
M6RRZZC3LI3B_?C :M49SV!O)6-F*+V%/%&V"&O3D8&(*]CJR<%"ZJ>G= X7,
M\:MKGT.#GE1A/M>?<6L(YB8+!Z4[IO6S$-WD%]Q2Q"B.TT6F+='$@A><B06+
M+W[./VG9FV^:G$UP^X^]7,Y3(VCQ'V_L!*Q3<G9RVY_9"V,&PWI^J+NFWTPS
M"O:Q_>+Z6CVET6P4N#] ,@_=T ]GK(2A'7QY'SC=4AL*-I']6LC6Z6]]*J)B
MO<K\H#&LU<U-B8O39DI7ZJS4NN63A6:AP]]#'S;C0\$F<.KL8L2O__+!=NBV
MHT'[2MV4@S"BB1?_=1<!<!] (4&<=&5"==\]&% W!L2M^^&Z'66/13?>F^>"
MP.UZ!BI_]V ^W<X_3-TK=2.>=NM&Q+_9T6#^2HNH)_&2TY.(?_T9?]4J?];*
MOWOP)K+&NG4";Z[7ED<^[@S\:3S=?D\9O;0<\SU&(O%;QHQI'%Z4SN0W^'6*
M^P".)G#X@$,B&D,?<A$I#Y-0:A@#?O<0[])+5$_](PGU11-JG:H"OD$%G.LE
MBBA8W'!3Y#48\ D$ "IO#M=P-^ -^.$2R91/XK6/J C4[ OX%.AVX6\JMU*O
MH2[Z? <!B&P?ZF+D+KS 0W-PXKT!'@)QU1TDA9I+/LCW4N3,V ^,1X D?\4X
M8NI< 76AVT%2/]<)<.M55O_:KEAEXXC:!5EV*=I"6=W,W"J<1=ED]6)_@'@S
M/. '*&[RGL._C>(8)' NF@ ?Z0?YU-80O-N!D_N0^%Q(QT='Q]LNI*P7%NX&
M<AWE/;'"J87[8A6=044LW!W+#EPK[Y"U[I&U[E+A7M+C75JK=2,F(ZJ%6D/+
MR(/('P:06/%XNDT&UOU#KKK&C3L<J)4'C.9"#O)=KQT5C)< K5J#V0,TX6L[
MBE9Y]BC2 DR@!>.XTYP,N\1JJP>S-I*$-UEWA+RVEUYB^V@6QPF3?R[Q-+[%
M%:&Z@V1)>PV8M5#FY<<3G.J#9+0(H\3[)P:-BQJ[U?:(%9S"*XT54$:(DI]M
M'"WG=G 3I;-K6,+C'#5H#>P12835H/1L7-<%TAVUH'5@_KM\[U?9?@;N%0C
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M\?U[5W8ZIZ;=^^[_@!,1(KP0B0K?_%=TS1C,GY],)J?3CJW3=T2>CW['GSM
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MIO.>."Q5SJ.D,C3B@QO'321(O6]<%(XX/!@<KCJ&VZII8>>YR<,+;@0O[?1
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MI<8_WSN_=K0&SP[Y]<-L2-E6O=@L2@TN4\EQTFWV/%,I2%RV6BX7&XUBM7(
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MMK3VHDY7<SB9FQ!=CPS +(3VB.S 9%7XP?$P%BD[G$JZFL'*>.L>F/LQ/AZ
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M%C!7/3^6&"!]S3[2)P8)V[-ITGQLN,D@)N^?>L Y@&R'5<+!9,,. "H&/S5
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MDBUF2KCM* ?&@_\,B)-6J4D?P<A_!G_XP\R*^%&T?#[1DKEJ@7%=; )@KR4
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M&X1Q.O._'2;N0F%9A+/,6'N BA!CT1; ;)$[SMYFZ[%3KJ&A/%QYD_[&"A"
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M.1\U]>3__HFW^X G=1R?/#C^>'STX>CHT>%/J_F?N#O[__[I6U)\E\7D3[9
MDC6NF_VM*#&O!!6]9]TDB"C*KY_@-H^^NJ.3TGRY#M6GDV?O0P&#3_T;+NZ]
MEO$=K[OC.TB5ON>R5AR?0N(JC &?FQVUSTZ?1;@ROTQ"N)Y%F,\@[_E8:<Q0
M/<^F/R'LPR65J;AAT*-OV.>P#[L!8H! NS5 RM6G</?-.$Q5$'Z[D8X.F7N:
M$AGG3)_  ,4>*T%5ZPRGV_'-I%5;@[$.YF>2R7!6#;QIQ NJIH/\B:3@+H0L
MVK^\E&#]MBZS:9[^KI1P,:^-HQX&8"3,$*^LIWWP=Y/&7NX<QB@6]C:K90S'
M40!V<$O_"QX/HG2O>5ED0B+:3I C98+(<B1^B"S[LU$I=JZ"/]M 9K1MD$E"
MJB,#Q!\.-W?TI [[3I]_E&YQ^,F7W"KQGB3JP_9?W$Z3]3/(D[C7H'LULCE]
M]M&1X%R8KZCA;PH!2?<%'F]Y@6^XHF'>PWN5SM_S5=R"$CZCLVJIG6+CZ QD
MHUEV1;:78QQ:,C>U!P"1K>O%ZU/Y\GJ=2])*Y4 9DGC8?%TQ2)G$UX;?F*AT
MYMA\DMUL6$ <:<.QO!8X B+AS&M%"MI"1J?)R ^;8,@_">E]$;E+;<6?/*A.
M]^/@\K?QAGV)XRP>[LM[^_+>;L=9_(8^ZRG:7U]OR+,K&.R&V6G9;OU-T@SL
M5?9]/7'O&%O@>CFF!OAC9-F4]%9US6$CV8<+]1B0>6&L8#55IT>:*">3=BGS
M^P;&ZTE^EWYBADX<X_):B28-O+KX ??HL5#VVYF3V<0(LC#C@J<3H6M15T"*
M8AU[TH'8)LL>,\F9S$2<DC*]5/H_'7"7#8\GBRA9 X"=M_557BP6,D;O!6T2
M?1MALR#-7O"\->47)$-!BA^P8%AYW5I,I%]K3Q*0AB,>C[$$..SD:'SR]1%&
M9$S #JR@P6F1S4L;=X[9K%L63)^=9.*A^^<>'X^_/CJR5[_Q&;L35#YNN- "
M=V$W28:Z\$*[GM/8AB7JG$$>S4YBH!LEF=E'3T;J4BT<FM/.D@Y"H),CYH"C
MEUKQ\,+F,F86_K/8?O__]%__7;6@JV059\[\FW(BPSJ_*OY+O A=7@5.^4CS
MGS@BCX[<.J/[1S%6*3,?2SHU82VVY\SH0AQ@L)Y=C_CH4/GC#SHR0)5Y<MR.
M>0_8@<./G#P]?/B70Y+;[H-P_=RT1X9Q-EH;+/.UF^UHNB1; (0KTLZIQJQ.
M)OB&;^#PA-;3_[4.WI%O2EH\%Z>-ARCDX.";5J0K=$(VU!M3A=7@W*O""E%&
M_<@H*Q8I/C)&MNHR,QVI;)RJ_&%WRXK=70*GK:(T6@.>S;&0]\ %06B8'#'O
MD$8&:;B:32X1UF>!_C8,L'!(L] F((A>TK79BGS[.M,ASY!A\NU,,QG EL'L
MS-"5.M<#OR5\6Y@CT"+MJ?[LX>BM?P4]9/&IZ]P(**3I2Z>Y,1RN<:')&##C
M,*F6UK^Q+C%,/ET':'.2'3'G>E>'_H\.@%RN'3<DX1*S+7 !P"JVOF_-LW0:
MU[F1?T!&L.VL;HSEQ044H5<(4Y73+]\0&UKG ^XF$_2"8YGKPBK*_1?)F%PY
M\]THFF8*QYQ,_;9YA[WNU(#$+73$E,/'OZQ2$H214 JR@'&'5G@V=H,EID4#
M7N<?QP.K7V]6BM-0A.\P5>9X=+E950P[VNA<&3)7QL&I^&+%G].>OY0NV[$T
M%&W/I@E)?45*,RO0VH8NS'G5N??B0[%/@IXVZ4+48#8V"-E,H(TH%FX;UBT@
MOS&'25DQD1Q=Z!F&@=4CI<(VG<O90UI:U;KQB_3BU76.P3UJX-NR8/PU\R=G
MI)9_RTMW0T+])CO^KI(X):&HY.6R$=^13G!KV3*#:F!LD?K4<S<ZV_).PJ"H
M8XDTTX!V6EI3S>P"D_Z4:S1N].>'<MU<)^2$U*68#V$4D56R C:2CV1KZ:)+
M)X2:7HR?*<I9L;!$BG3&B':2@T!:&KIQQNYADJ#ND(OZ5'F26;]4BY;T@AIZ
M!$9!9T=](E=T]\LE;UUR^7DLHNTV#K5H6(-&[E/F\C8?0GKONK%C(',Q6QZ"
M09WL[AGPM^3%5997EWE)2KAD"T*N-3T\M(6ZPL !/'9^+$J6?FPZV-F?O^M7
M2?KLMH6PW-?M2MO 9%R;]8+YAD%^I"C?"O IKJ1*CQBKTGXOFX73"N;C>+EA
MH5VRP; .ON%^LG13NF^QEDZMR24Y4<U2"+WP(FP5,I[SE&0GW?WI&#WU]+1'
M==K6 =WH/#FV^W[(7(PZNJQQ0]-CFI:GNS6_]97\.2+-U9P2*HK674$9;J0!
M=%DQ\[%,##4W^995I7&0@FGL%G1E+?:]@2H"(Y15B$2+7K0UCU/.&HV?Q$6.
M^JQ?PLH6] 82!)?R(F30Y4W$8,L/5^S\7PBS2')?D<" H"4^=J_JE86F9'TV
MQEH;W;KP[GIE+;UV=O$PY)3/6Q-.'0?G&D$ -H(N>IBHUZ3Z^[(R-BWU7'$J
ML@[R4&/0K[S(B"?DG=,]9_85\J &C1O:(==;EL"QI[6_AT!S='HSZ0JF$09I
MBE%7F!KE3R-KDC'?%Y@_(A,J>*!)T\Z1$<-ECZ?K>AP3M^,J-U!FK@7E@YY[
MP!%CFUM<590NGS<PVQ [F:&C57NC&W%/)ZPO_M7F>MAN&;HX_3G1[Q"8 5/1
M+?&JN_DO6:!W$M(;(BYQX$D(2MHUSLI43]Y1@"HDO^%$5I(S-EG$\8+T3Q1W
MII=J^DF323](!S,7P]HRX&'8#5K5Y.0+I;A2.[NH<323?6H"E73T#Y.&QPNV
M*6A#2]5"M\YOFMVJV=H8G-SLSSGQL4E6F%C6V^$!;A*4,?SC(<L'/V$=0EDT
MX.ED'9%O"@#SI %;YI?5_@*+IO&<X*IQUKTITE_D4/I'^RK>OHIW1ZMX88R$
M*@0QH[BQWG&3F\H^.9(S9;&TD>_0YDMV5#G_O.3BWC(C=^Z2= >3%_!?S"FF
M:)M83!+R""X&+C;+U65UH>-_[0.=T)1-8&EH+O0'*XSKH)H=3$ FG'B(T]RL
M<NKW<5@@:MMEU+E@,.3T[<YI]IJR0 YL71S(FVC\UMD?A/7N1"28ET2#!H&P
M;?.L*,F]Z<&EA$>P%Q,R_BMT\8WU)YJM7NE(DE_DD(@I[7O3E]F4CICY*S@_
MDF^'8 FC5$6>0&*6=+&;KG\RN+(A/[X7T&VW\>:JT$O=L!#U[0I\,,2UB8<6
MF2\T^)1H;545P CS&&^UPJ0CV#'!#LUJN'MK8R+44[38%0%]^H:2+Y774O(-
MKE$S/)F?"YP\T&R*^1Q8 -^D7N5ZSGG7NI IWN!]@+I@NRYTMNX+N-?TD,L\
MNRJ$V5L&P;OP(2&=^28BHMD=1)02/+K;R>D0&ZX\S9(=?!=R3N0R?(G^DKS&
M"<B"M4NJ$#J_SJBG.Y!XE9E!!NC]<1T&U@[F\YH=IF-/A?WCY.CXB:$(3L^_
M(X\1>&0=+LG^=CCMQ/7OCNCL,'C&=^Q>+:.$MPQK,AG<A:6QW:.K*_V L[#$
M+DR.@10,H= F@X^:DQD=C\E-.YAQ55J4!'-":RB&^-<\9?RTA)\\;08_87/!
MB_*G7(6^#9/1F@]%J4-NF ^,[AVM4DJ;>2Q]%7RWKL2X4A33-M))U;E5@?6T
MUR?C8J1 KB\_F$Q-5D@S[LG:!N<U^7J-@$H2D+0W@U)I>>4PQEPI@B9YZ*/X
M]"0 5\,*Z_0$K;-BD1OQ_DUT^KNRZ&'0E;\$.6YW/AT.@I.!!R&9 =%H+\AU
MRLJ<3SU+,99^@UC<1 46R%1@>E$%N('H[!DG+/E0)ZC,3?6OKYCE:"$%D^NJ
MEUTY/WL^E!EE0<.@46,#\A,2;AK_D;Q.VT@;(C.G'73>+<*B0H4"][0)D"KR
MJU%H7'.&I[0-^?N;LR^@*!$0,IANN^,F#$$O?PV1C;.  ['^UF&19/<7Z\O-
MB.*$EDX!#1.<]Y&, "UFG7>><2W5UY\Q57AL^86L(=_"F&B#&@0K/YZMHWX]
M:;YQ]TMFP5CZI7ZKX^#!U_\_G7>CM[BF?=L<X/C":PHHG 3X)_@92%R%Z<'P
MAB]!W+F.B!-)@B.G@6M3YSI(0-*E VN."4LCAPL_:(7G:9HR)U?,H4[X&_1"
M79-V#1^ZY'1E\'^O^?/7,A%S6J!R%%#JB;FF>[Y3;7K\T$1SR2E1%DU$H*5A
MT<.XZ_&(XXN#14;J:EALMP:7J7_=*[K(*&JV]/)83D1GE@N=Y?+?<3:J;#=;
M-U[N.N&IRB89PR0G3&./8:WF ?? A^/1*\X-E-/NY.CW8;*S'>H4KO.U(#2B
M8-GU Z*"^Q#<! O.NH%-D44@KSDK*@%6;+O-8HM"1^P@Q4,AX-:>*^=7Q)6=
MV,HZ*PY_'R("N2$RA8--*5+2Z=)5_/V2\7EZQ/'1:#G_ZL/\DQ'LX/)EPU<U
M.8+,)HC[R-?;KPUK\0-#HLX94)TW1LY,H6P!3/@Q53A(.CNV^3AS))-RE"H0
M22-HAL4/'SFE#ZWE7AP_O7VW3JKMT) *_*WBVE1)R_@JWI;MH3;<W,Y=&Q#5
M9'.W28<PK(KBA>/W,+X1,CT12CH#)!:K*?-KQ,F&(3942*:!HWO@UX]_X1;Q
MW.-%\2'?\G;C)-P-/S%\-_3)BV)NA6NS+R$1AXWOS</L2];NU/AS6C(T($>-
M,CY>T,P<W*"E*<3J$@C5 <G;F5"?1WUOD^GEXKM0-/'.!N>2:;"JGM?AZ']R
MJ64N="IH_[<2@Q@ ;H@^++K[V^?@L^S/XMH3J^R<P.*=M:&]BTKAWKNOWMV'
M:CB#0OD;FMRTS^'1H]ZUIX^KZAE'NM6'7\OGPTS::-Q,3<#(W7OW]N3Y?>Y1
M:5>DY>5&\-^-1V?O1O<<\%@A)_>_.GM7#/V#J V2;_L7S?EQ/PE^GTYQ<U]@
M]6STOC[^RW@;KA\@H3?G8WSPR>$3!>^/[CU]^)?1V:O1P\/'!\?'AU_?QZ5_
M]/0O8*:#">4[%';HWO'Q5\>/[AMJ>SKB6'$IL^&+*=I8K V&?O#U.WKK,I]G
M1@8"C#L'NBA4YP5RF@B(Z6>_XA;%'TX/Q/DU,CQ#U-2<O$:003['I"Z ="7-
MO-@LZ54;\"T@VM82Z;UW[P_>GKV[?TBO'08XK[W[ ,;E/$#S-1]9E?.*O3$Y
MU ?1S=S2X!CV!K:1'%,.]A7#RK$3.8^T #9[20[KX>')P</#K^T<!O&, #ZM
MJE6[2$+QHG%FW>@WZ-=GEI(UA*Q!Z^GW75X]*M,'P7<-;0U 3,!7LW7\?\/9
M^GA?#MZ7@[^8.<I_*%?BCOD0::C@/4Z-?@L_Q2PI>&BA6U*N5UI5"/BK=*PD
M-Z3TS<7NF"S_X$)X-_W9'Q C/T]B9/-B.\XE_,C@#3X^V>X-X@/')X>/NF[@
MT\.G!PPL8R_J,I_>'TM'W,&,$Z;AV_=>O#R_CV<\/3SI/N+!X=$!/UH\R8>/
MMGJ2#PU'_M2YD^0Q_E8.H_A_Y/YQ#S?:I)C1X^6YA(WWMKF!UJ>->D:QI-_)
M%AMNW)5+*XPH/YR].@":O&(L1*H>^(-#F0U[\_L&HF@" \E&$'QA\M8)[>&C
MPX>VM;PD7GBQQ;^4 &6>EWGM>[ZL.EH7S0?[=>=.-@H+EN&[BN%0)[@3V-\E
MG72TUTF[UDFG9;P5*2R"WA1T0A]7H=FK'(7DI^)M/%@ M1+.<T]$D!2^+F!D
M[;+WC] .%+29<O@;Y%J@JV/%&0-V8[<R9WR/0K@=%66HB%OVK_\>%H-9_Z@6
MWQ'I>6!2@S%3=!/#.@.\)]F+H;T*C6>:PTU?]>;-O;?ZZV+][.B0PI3C^^->
M88E?BAL\U\()VVD)B@U%Z4A)#B!3T'&O!2\V!RQ [G7%%8QYAHFJ05\C$Z@=
M[;Q8@T"SM@8[VZWEQHVF"H>J:IMKUX!&DJZC0"@K/T 20IXZIG*2GH>M8#JL
M(I0KH7AO6B5MJ+W.6$0E7(R^F/_UST^>'#U\=GSTEYL?*D6K5"IXB3Q[RB$H
MP^$?WT]@>?RWG_J-#I2@,-\T,W1YA.E?Y"#N2"IQZ%#>MH6HMTP*&0P\H=]F
MX4+W "<YN-;&H]W3^BHG?(=;5[;<DFQT77$V*,@#-YAJZ\I[3#>;!E!@I^1C
M*/C-2"@$FC!R3%-,TY!C027GFJM0^+42J!']G8%VAZ*QAF;M%0]NC9%K:32P
MKB)P!)?+M3/\NFGLG[^DT,,2(M8)\$"'+?IY@(.0H^IX5[ZTUSE9[C6Y0A:R
M4R3JI.P"1XL\T8AL%S+*#/\V;XLI;$-@L_-D=6D=LH=MQ#C87@+6V!^9[(YO
M0C:]*GCK6M7,<$NK(6>=DY=\Y0! DPKN)%??$^XJIT09]+..[=:=I9E:ZG!1
M)'UH&+5FS7GAB?AU/I:B%-3M11X=3"[[9G7H!@U+MI_;&6$)K3DVN*$W&^_L
M==9P@9R#%8DR7K\X&]U;%NOJ8\8RR1H^9_QNPVAAZ*3-FK.FI/OO<[+[Y>FK
MT;T9[8O^Y=A]0$#P]"_M!?,&WC<)3%+"AII+*I'QROAZ8T?P/70]+6 '\A+Y
M9K?/$[Q5B%!8CMBCF6;<P5Q48*V1OL!$4P7X[_JZ8/)Z?,&KMR&BB2#\RAUX
M7?'7>'SU6E,DK&K["&,99*D=\N1DL6&AL+0%#&E;D59WL!O"X,JB0J.+XEN*
M8&',0?-EKE,CQ=F5F')@EF9#EG'!8T.[(,!@#S(0$<WR6C9;4NH</\?:,#MJ
MU:)0NDE7?^=\)#U@V215]PXY[67,[(=:41\;.%"2CE6#!%8#UA6.9H5G8UH7
M5T+_1:$_*<=\!:H;;9[VW]SF J 6L=8^3,@$"D(A:[;(RSF$ 8UF@VW8XO0D
MB,,L=J1>D"F>%8@,3.5(X=@!S@/./)&'6,^)56/Z[Q@@:(]$VA,1UU6#<$6E
M0HM*P>-%DS4=3)W5=#Z8DYPUEWHOK0'2T:H T+6KL98O ) P:9!24W$%2(IL
MT44^SP+UP:QB\I?1OUK2]H*>$OB RGQ$*^;QL2DJ1RVN85X>/'F2U%U_X*RI
MP!).CMFOEGK.-CS6&5F8:396CM<N+"OX),QRW^+D;-@]>.F%VSY2B!4\!1;W
MJA8JLR;/#?_? STX7"-XPD0O WQ+[C6W9)8L@##G^J6 5A.%QTB8 ]9XGQ4?
M'5!\@OJPP:VCLW>GY)&$@!'T<S\&1#PCT,(=PD>=:[?0IO0P"QCZ2Y\2'!XR
MQ@5\*;[%'< M'Z^1T]ED<'(7 ^CUY*L'B=?H_,.N7Z@HNO4-WK_TR0:['\SS
M5].L+2LUSH,6;'3O\5\IR'_VX#Y""!#A 8?:6'P6VAG:TO0BP$@J5:RNM'>
M??T..05S05EC@MXE77[_/FVQ=X'!@%63#*87E>0 /THA7.=1=Y7]1"<'8"_/
MQ6#R+%!3F4TDQF,G' OKN#"/'A_UJ-:"+WJC=[R-Z6U-NQ_O'GJ1V5"H2 1Z
M8C!(*DU?N1&NR4^)L<FIT(@T%4\KFWHSP_DG5N6>O[S3KN2Z,U=(I]04\@Y0
M8D7>,X_HQ2P*%J]N=D,?[GJKL@64%NR&S^'V4'S&[06/ ,?,%F>QZ:)O;3U?
M8F?WDWTI?U_*OZ.=W>;G,9:RY,E<<5 W68)V#E4.YR H7"%9*@MM$[(*5+2
M*Z'L/63^C6';P*Q13:[,$V3AYLJT&GJ!\DC[?K,="5F6B#Z_OLPU/I*DO(P"
MD;16WEQR']Y,>?>*LE7.%O.W [)IF:]C7P.7L]2SN@MS'O@0V )(FD"ZP6 \
M0Q3ED]RN]*>*^MZK\_?-?62=7V=&UB_:'+ZE F/_P>$ Q3ZT >3/LI_)1<[S
MR655P2G6L0*(LL[7AZ/OJ[9H-$"/W756\D"X8:=("_#FHMMJ@:GSS/(XX69
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M> T'"W("V_7?9L7'?.K5DFE642#KFO[_U!8L'U.?FU7K>NK_^5<M^XKG%I%
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MN.P6BJ)9T0 KPHC3$H6U,!4S&0I=HE(& %Z(++OI/)B>13;1 F.7RK'L%K8
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M.\BTQ7W.CPV;(K+:NRCA=RS=\5(\1#XFL9!=JWTX G3'6)Q=@ F_>]B'CN=
M07Y!?\>2SDMFDSIU] W>GH1*B[ JF*4/%RUT WG MB"PQ#/E4  #W.)&8S@(
M  Z\RP-8Q,#@D*RZJ^&W")*X9.G?&7_YOX4L7L?GN4$?/NDDNVH"HJ.O+CH-
MURGJW^<\O\A"TZ-]H6E?:+J+A:9;-<0:3INUQ(N/G$YDF_@NMO!9 6KT5B=
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MYL9)$D7G9)/7\==U1Z">4AJN](%"D14O;N*]%35G%&NA#5A6]44QU:3]DEW
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M/.\TAL/W@::OMBAD7<+85!6'P>@@P>G7HMC;=W-V3?+<6*ZDK!/<+",QJ2Y
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M+<19!B /MQ)Q'Q=] AY^X>DQ#E+O*<';9$Z5NH;AP=7W!,@B_]C26TQ$,/B
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M^GWN3)%+@]FC.BB]'YBPY*9Z]N<&^LHU<FYJP2-7A;@*) *3MJYS3D:-@T#
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MHCJMRG;-<R+R,$T]*2!S.VU;YB/6]7*4:V-S.&]7K%U):;6T4'I_[G05%I.
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M]S:(>4,POJ*='-[W 9^^Y0^'(U=S1;$E0NMP<;C7/*F#[4?AL=^"I@W4*#[
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MLAEBY<R@AS-,X$GI1>4[Q@H5BU4O5CVP:JD+9"R^@)!3I)6$ 7K ^;T8X&*
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M4^!^#?[HJ=^;G%J&//$[HZY=?\!$W\]L: 'J@=/I$%9( <Z3S6Q/@QGLZYU
MM^\%[@DZ,X8[3GH<NN'W(I<E+C.(*Y(GNXDDHJUJNRHI=6Z"II*(C US&! K
M1--K#)'N#D40IK)H.\G7-/4Y/X1#[Y2?.;Z5O/I^@ <;<$.$E_ZJ6#<].:3$
M:9.MOMV%66^\!=. &3%>C =N]GU7-X?M'=6/'S1M3)Q6CLH1X=2^)?FFMF!E
M=[!\%82ZK:021ZT)2C8V,5/W&KQ-6SLY;X;(Y9TQPM1?KQ*>!Q6D%V1T&.F-
MBK_[P2$LB-_!#83>1#+&\]EV;_MUV^65- L*&_V@ZT"_@%N;V2Z$YH[:\M4
M_+()9<_]+;%Q),J$[\1'T=699AQB5N\"TOAZ]>IPL/0'T/;LV1':L1Y!J+/)
MY.*T26V+=M.4ZT+:[$MZ,K63,+V=1TBN<F9 *HMV<J\^%MJ8SJU[L-PRWI8@
MUB'FI ;[+:.W'5S^N)8\4S:^9/@(W 9;..WS5J+7*)'RD,MB#.#2PP%74TF4
M#N%<@*G^[<<A";S1,Y&.3ED?N"#(J)&T8".I@F  ?6?Q/<U%PG+E.9B.1VVR
MNM1NL)(6O93(02&[0J>B(Y%*49CGX"ELBI[U?.F+UV7P+#?[*H2V-RR7DE>:
MIALW0:>NZ$.K01CK+GQO@C6V.I:D/(KBK;%=AL.8 65^*Z #)F%CR9$EV18[
M@"-N_8T@$*%!G<T1@>7'F@YP%GLAK>^PSJ"% XD&6#ST1$H/1\'7M>Z@T<QB
M\"O;@BV=:\A\/ BIEHK'("B  F Z/&4>F?BU^U9IZ3+(481Y"'YONC=&)FN0
MGJ;>/FF*\T9;NQZ,==B:;3;0.L?;)7T9"1EG34='AR:\\?D^A;Z"6K4U'=(N
M'.S^B4)0/7(IM=$N<\^Y:*V-?C5\K4T(U?10D4LWH6%U)W43V5Q!HH<VV9)V
M(*\YKKLN?_N 4\P]5EIHJ)++>>I"UY+!IM39V NAU?M]@S)WW%4C4@3E((\7
MJ5FT, T-'7P?NRJ1DP%,60=VPFH\22R_G'9K.F=XV)<5NY>X92&%!+:2LI31
M0E=39P?:T"9-=[\W&"<K\8(=2=4@F)ECE5TKY<<Q<L>FC&F.+M;N@F#"*(D\
M(1[8'\W)PS%#F)]J0,$ZX$6<X5+;C?SO5NF86 K,/W+8+-"23#V?@"6Q0Z7"
M]N+30;]X6^1;$$:Z:!ALQK[,.]1F>Y2UT#:_HKK);T"%-:7E',.QNKD)E_?_
MB+\57N[U=V^RX>1[4COA?9Y<"4=K9_<;KS$/AXE4AV4\QT0]W1QN??PXK,GD
M:7SZ_9X89)48EB<5FC2R"%NG@3GNWO"]N6^D][-$E4MBZ0)CFZGXR;VM#QB(
M_[GY9,,<S%Z(*T:W[&8_-%\.&LW997>%Q(@+)B"=T"/.8<K" J=V+[1]R=/U
M8-6CW1VL^0%@?W:67)>U@/N%RM$H5\=]I'8\/M8!Q6P (LK,)#ZCPV&'FWVF
M'=]=AW (U?OH1=2\/G Y7H)5=Q^L^TX8TA'O,B2QM\!M6.H>9#>4'JLIJ)H8
M/WW@U0_7O;)$A86 MZ;1RF!W$@TF&Z $7)M-W6RC2#48OXJJ:!+;%5D'W<Z1
M3U%/03S]>O5-<+%J901;??7%*TWVM9*9]B2-E!78DM!EAJL4$H<&20 ;WNJ&
M:#<<=2]-Z$9H1G_W^MOPCUV"9R9W< .FW!MI-*3(65L0G0SC<%J8?*]7;7!L
M^_B 8FM_2X[QALCY:.KAV@AA@EPVHMZM$ S*Y]^ %UB\^1TS>YE KK0?#,6^
M:89CJ,:1_T UD_BT6X@AR*$\?">.M]IN].[&OS_J42#7/1+>7L'(:OH^FA#J
M+,I6K^5O?N#S*GPZPW)2%,94% 7S*N^"-PT[CN=.<,.(H3^O7*9RQ^2\RHQV
MZM?!5= )2T*^L)4D9](@B78(]W:U^66X*>?.DW"&?,4N'$43V>0!0A<45DS(
ML(7>:U^>$N83,@.Y>X1_+7K$:SU23%( Q_+4MXEKFW:@A].9SF"E(M/;GHI*
MVYZ_%.Z,R=A&OR;LIR?)JO5RJ<0OE?C'9=6:=3N\"SVZD,=WL,L5>\DDU9-N
M.Q0S[!*.WL$@V.2H/%,,T8P6K.?K,+68.358SIV/OVON2RB_(8W_]*&G(6>B
M-^XX,K6,7QJ?MAT8A#SL5XJ/X"=7KW)B^8._SPHU0%"1!:B;+MSPS&HCF5%]
M>.RY&31 #M(Y$PJM\]+5%Q.RW%0I3,$NFW.H*=DI;O*)*EXB?>XY:4'DV#\:
M^<E[924L0![W+)G3FU+1S\SLKDYUE9+H4,DQTQC9AZOL,NVFUH<8B5$=\O&,
M'Z>F&5NK4JU4$MVV\# E]M<^%[_D@JG$2C&B4_<WE)Q+TG9$_)^21\-D,Z7W
M5*9BR67=FX^4T^3QDRL^I3C6)7"" K3^*K@ ;YX.D^S"DO/O1ZOYLUL=:.3O
M"J)=:0<6Y@42J";L,C/#;Y+2;3NEQ+;Z(I*0TWT4U1T2DC8XS UE7U%.[@E.
M&AS= @8$*U'.6::0'J=$'BS[I(2 '_J6H0^&SQP@;_/@W>/J6U* N>1YR(TT
M+H7<L_$^L#MY6L"$%)OJ9C6K[C2_G=PN$&.5LLYT3C*2A[)^V+A$/"N7;F78
MM2^VA<T9_DG4B/2EPZ+;Y;?5^V*B='*]^C(%>$Q\WT._*QOOH,DA%81[ITR$
M U@L;&(+WA!!W2 /ZP[BL^1@+0I"QHH_3!>9'(R<L:.?+OTXBV4YRV*]EI;3
MX^M&T^'CTSXB/D:5D/-B4XM-S=G4L6PCTBB!@4XV17GOE#X6 LLM:4D16R+'
MSJ3K<K6O[Q98_F)XEPPOZ;UM0C1278$I+C<LZJ4C#:$&-[9R.-4BUE"B%</U
M=])G^]3P\C_,.J+WR<4)5A7EQO2*2&N.F]]]\ZUA>1F5UYC*TVS:MN^@;C)2
M4.1@5!)^)IUH"4 ^4RXXX8.W<(T/?H0CD3 MFH79H#<,\6,ME(%]$DA;O+BO
M#U2DE4I=6?VEER=D4I0[%<&U%SH?](E3IK=%LS0;*HUOV^1BIY9ES@R-'\)9
M8>8/?UJ4_P,P')Q (LUIIX@.75#ME4E3U54K%1(V"O*>HCCE6KY%,3R6&@_G
M@3R>R)I9,M<G1A\-9.VQ^X+CY9P DUK$C,U\?+9#=#8LRU-^8EAW<* 1 D9Z
M7E4&ZP&4(&QVX2>6N^C*HV?GOP/&55I,8CI(JM)U974.Q-JF%AI,-?R^:(VT
MO'8"C=*:I/JJ GVYL] Z_'+#)7.?U6)O4)\/ H3#;2&( @OHHV2HS_<QI[<C
M/Z^CR 0?%!XU4PU1X7DUK"-8DF<:-;A%1)](./![>CPMI>D$&AG3DW'\G*@<
M:"- !U>BK6U?;:G.KDL" 3MBK@I[@^4SZ'/K_O!62QOHZ]@PSM33MUON/+4V
M(7Y7.\H%+;_U:Y4"''AX,,BQ%O>=0M@WE/G:;H%Y;CLG_,S4=ZRD=M8T.RQ3
M__.LUHYO8N08%63<#W07#=Y%#E4F=/0P!<Z3I:AN,E^P:+"^C*JG3JBO\.A*
M $YL" DJV\\04[D.-[50^+&%Q.+@8'9)KGIWCH@5ZC[P#S+:@M8GLP7]$_83
M3FBC5-/#0T-SP_9(P9"L7OB])ZXH^LQ-'U8*$ 166I05',J\T5 Q=!4%8AS[
M</ C2>MIL=YWTQ+0FRS\9MUO;XKN,6%L7N:"<LF$'L)1J+T<)O;!C0ED>N]8
M1- ;EA/T4[K'\F6L@+/B\<:VE405V==ZM?-&#$B[OZ;*E6X1!'-M_&5H+GB:
M$G ?+6"5!:SROUL"+M-BR(4 9E3[2/ A;7#]BZO^]+##"L0WOB9W4!"AU-K.
M \EYQBDW5DKKI9O5L>,^%/+N4,+Z9Q^8CBI%86BB?7<\_P6A62Z)%I/.]1&L
M6Z0.YHJ=Y)J:80P"[6 @U0.LPGJGQM<8N>2 CJH+-&\J=JF@UMEV5RP]RK?0
M0#=HT">MIE6V;5_XXK4(]9K9.KB[^&\77WS0<S?>"N$B'[ST+*_A0S;#H+LN
M2\ H$T8PI<HV0'Q1?(! C;*?89$H9Y6)%N'X:D\ !X>\KSA-S[XK92M =4=?
M./X:"B2XKHKX83:.IY[5I$GJ ]1F@X#X%/@*HFWT_J]M99^44)L6G-\//9*A
M6YHZIZ7%3WDZV7 I=*2GBO*@E+O)WUV?5Z?]N0W&GU,B(+C%I7:IQ)OHE)^M
MPYI=8\FA:$N/ME*?70?@ "3S88B!?OTW3W!55T5X=6A%ZV3?Y.D9\HM/LV41
M1N3'*DS)JT_IE&V(8]&N3\<7S@P;5M)XR8TL71J@"QJ1+WO.9*!?U[-"(/V"
M@RR*>VI8.F]X<S=EJ2E/R51Y$\K1W1-[RSGB&?5E+XB)I13TGR*C%EYN<QZP
M*9AZ*5-\Y]I"Y3KV.M+903II*6TO9N7,:I"JJ8,G'+'_D49H-5)/H++88DN+
M+0V.*,\/AS1XSMS2^9;D(%OA75[.J<6VWMVVR%,*0P#=A2 >1(%<_,]P)Y[Z
M6(?LFC.* ^1[YB>M8%!WBKFNJ&TV0KIE+9;R\<4$%Q,<F& XP(KJIMO'&&!2
M\X'*J'73+0:T&-# @(3GJ#0*@*1'(;P[$:0P $7BW*8HCVM"*-"UN%C48E%#
M?&!#Q&[F<+4%5<@[:UP!^HP3W.V",%TL:"BPQ GW")R3AHR^35):Y"C=%  N
M.18+SN,I"<>3@HN^>T)[BALQMD\AC9A=\@D2S-A,A_V0.<ZQ.)=5@J/@9D<B
MD9K0040V<U]43,:+?B])07Y@K;-3;(E$B9^'>>NYR$7O@@]7M9<W59IKI%#C
M']?-2'QK0%W*N,W5#[&D,$[J6PUQ0I4W@>K-=O>-*Z2NT\[EG/W(([E8Y/WC
M0ME5>.BQ5ED6?0/ R8 *0U')F'2Q0>WKK)1]5[VCD0Y8J)IBT_2E_5F(Y,$@
M8:\#I"7!RDTIB3]7CJ24/'L!S;)(<4H94,EN9@J$%]=$QC@8$_(0-OWQ[9,=
M6;:^Q+BMPX]09R2&ITE8'5X"EGDB8BXR5BXI]Y46C<J#0!21Z4!P.=%;RX2=
MK73T2[F3L?F9P:F8CHMAI,KM>Z!>8>[I%'@EJ7R50D^J\!&&VDY87&Q,?Z33
MX"LN;T1FO[+:E^NR&S"'S'"%>$Y2*9 42WGD']6/X3V2<#SC*,CXH!(^-R&J
ME<B*"VW()44$R,6=LH1?B]$-PJ]H=,0 "^,Q<_'LR.Q84+HQ)A^%':2GCL I
MJYS+4WJ=B$5-=#'+";,\Y)NWD>^1_ :P6$LH!XY!*O6Q6O3 ;#T]]ZD'.!+-
M@[X 2"JD6G9>*4!5NXE8"(#%>NLF:JW?DW]X:D#NCQ<@]P+D?C+Z?TNR[=$/
M9B.WJERWFL9_HVXG@CI+N+VBB(I[>KI[LP=/+15W.;'V?KD+GEG7A^E['R=8
M_5R+*\?IX;5NI?,;G&$,&]1H7(&!)?>Y,LPUPSL<RK<%BS0A0K]#JV>NW$MW
M!9,AMP5)GRB*,.6.'#1(W16^4XT;50>H]$M)0TP"Y]4>-@^7AC;3*#8"[1L1
M%0MW<%-R0^WMMW4353[0K"H3AF09TBEA3KM#D5*J3[&^<?.;5-&*8P(7#C-&
M^;)4PR.5W<D[X.<XV]:""<^VE$LR6&1X. ]TR]X[^>O1_=FJ*)%+=\D,]#>/
M%(B&:S5B?KV<+/Z *%;?BY.35:"BG)Q7@?(.:^0Z$,QQ6 <45D%ZZ!MUFM$<
M\8JOBQW$@D0T*.G%P%:&"3QR)OV'_0,5"@D P^]5MJM]F%0FWU5'/BIL>56M
MH3B';_">%%I14[SW2>.L>CSF:/E(S"MISFT&Z;]$M2QC(/<Q_PN%TFFBWP*1
MC+GI61]Q]C,S<F;A]38YV",3G8_,,>43 O>FJ#;6(@T6>^F6+F^YAB^2$OX9
MUZOO]TCELLZGL;V+8-<<FM]3C4S3_+(@)2];*XJ,D GV)8APME8W>MQ9KI@&
MO1Y(U(4-Q+WX**X QK>7DU79%SZ<LX7VQ=LB,7&%T4OOLM*$:JV'B@J'.6[D
M!+\_<<$SQ7Z;[PKR Q2?G7D89,9@6>ZYLJ8%="<$*_%[)1<9MR%&),&%)' 0
M-O]HBK'78J(1XWKUJG4"D^%N(1$2R&N2R;UX]OEOI4\*%OCB\]?NA,4GGG_N
MA#FQ:Z<< AP$_%Z%D=-P T2*Q!,1'&.I**OD2%LKZZ9M1I3M (3_J3.RDR0K
MP76!B3X2?BZG.^1BR)OAG=FIQXW65886!KO3&C=Z9I3\P=3?U&, XHN;ACZP
M/?%-]))<>B:G+I^VB\4SJ)OP9-)5226OX4?H%-&5'1S$3(R;]-_=T'2&]8L2
ME3/"ATP@,ZVZDZ4=DUG";&QDQJYO=]"]F$6R^RD=UF$@9:9J'KC>]ZMOBF 0
MTL^4;_[:EZV(,\I,W*N1&9:K)Y]0&D>CIP+U73@;<8*8GRF\%^6A&D2%+#P9
MSNX031["O,9&H9%>R/?R$2K@YLT!G!PW?O5-IP2O*Z?9E,@F^H]8HB;,70,?
MJ*G[F[UW4(?L,MCUW/^;%%^+;;*9M2*J7\0C2HX.91=*:L]<R*'_BI0I+5K5
M:/2RHB;;%=/QR5C&MA+>7U4.%%#,.COB@Z-]:VA=CD8;:7XB6<$5H^M>2EM.
MS,**8D+26IAI7 D=RD?E%HEE=W^F.05W.OI0)5=!:])[&!FAN7!#U[3PT2T.
MX7!]A@G !K!P2TZ477''9HP&18#;B@33QI<R_M9QV-'A17<U_5'$(V WC\-K
MV@LR6&9E&YFDPWJ0KI4CG!H+.SO]6^9/P;X.M][6Q0_N@<D?LL?F6YI=/#,8
M66+)LQZ=1#-#WF>D1N+U]4$0F2E1TEUAB!^BM;$#91"0W!S.83K"4,+1U!*#
M04?YFVPT3S37O>BMA@_OZZT(T&Z4P(DI_)P.;^DH$]2,_==-*J-$74*<:^,H
M1X[-*;V.R? M-81IJO=W$U5)J-B8@4JG:[SG'U&J[_W;S>=XV+WQC_F(YIQ_
M=)L;"Y)T!;?]^B]BAGT5,UKDY3LG0PDB9P'>J2-_JDGY[._/%2*'OB8VDTG3
M0/0BE=-,ZWEBEXE\-C'/A=G(%&FJOGQMUGXO"E[/V%97A^=32!6LA<RHSZ*X
M\#!>0F1DU^Y*Z-!VQ18:B,!3=]9L'G[?A^.C*8>J$]\ !RM@1?Z/<IM9]+\O
M\D.'V-^H;RK(LN)OB'K%-<FG*J/7J]^YX"Y^N\1/PQ O2IG.?#?#*?EGX'@K
M*NY>3Z5-M\6&KEC)JD64+^<2,*VG7*E6/+@N72:>M1!WTG".<'T::G,7A_F/
MU]]?RV P$^(?<WMS^,/B#A!'8:I%0C@,F8GZWFE:!&W:=<7Q)+P;FEWF.DP(
M"G$8LLOM[ _A^+'NF0HP?;LG23[VR5*S7FK6'ZA2'G2++-),N@M67S/S4UCH
MPWF:9<3H,4N5PN4[R4)><K.%BOG(#N4IQ#(%TVH76RX4]'1OX)8(YUDG?>Y\
M%5&$L:>PNKK1'*+\.ORXN9%<J*"S7\]?]9.J]PGB7 .324]F> 6'BZ80YT>$
MAQOWX$':<78D3@6=ZES5S,4K]^ D)R13\QSIA3F@;>(<A>_.[D74OZN SAM+
M['#$SY2E+%(WZS;$RIX22VFNVROR)$2KPID6XTC)]-1$D%M3::#M@B/ Y=._
MA"N,N%4O^'HR,3.+XL%4FLJ5K"D*D _QC\@$P)MC]@5(N/](N%7=;RO.:"LG
M+2]S-KLH$S3%%P*1J9I/7/B) D;9&K_7(]81(EFOSXM%<N&85[R4H$>BY^YP
M'F06,PGYY _EBY KT$5 KH AIM$!B_.FL0E64I\MO/^2I)@@I_?.T@5N^JCE
M703'HI0 @/F+9M_5FB9*< )S?H?'J)YX"&'YF*3$!Y4)(+<F;'LKT#5)4O\6
M&-B>&?H2;ULSQ=E<FC@<>LQ9,JS"QU:+KX&*.$Z?;K)FNE!< 1+JXBQF3JWL
M;CQ9."QNBR:.6TXFVRU'@OJ>"I+[A!O[7;KUL37HX[?D++,T+.Z:VC?EV<JK
MAVHIA;;HI(=*C*3$1@]_MS5J15+R!M/4Y+OGAW#-;JD.R[;+"!;XWS'4DB>1
M:D1SJCDY#7A)\5/)-(+A4N80+)*S*Z+F.NQ8NUCMQHP'+V<7U^ +W;+1QIL9
MQ]A:RJ%R1(>/NHC.Q1,6UB'$XWC(<9*MSQY(3<?N3U8U/^1WDA\DU#67I[1-
M$J()36>Z!$8=&D:(Y#Z'+59V)1NIJ<S;R6S*NS,LJ)K:?C^,_9LZ^-<5Z]Z!
MT]EB3MN02"$(-Q1//Q\EN54IU#PX/4E0DYDDQ.KW8:#8_G4E<R;) $KK>B&2
MKC:_R@8"7X8MU(X$R'7)YF9[D/?"R6"5B-%SU-8Y,3MU&6F6(NG^H(:Y$\1-
MV'UXR*7)NP]K21ZQ,ZJK'95)MTE)7X:O?MNX;I0@MSB%-TFCG0A8!#=$(&>^
ME26G;-TFN "$-:"JNSHFXZ2Z)G+PO@3(L-H;N3&EX ,?K33ODV.8(Y[D"2>@
MS32CECW@?I6WQ[%Y1USR9[\I)76%?P;7W)&GR^8_4)E'B&. 0DGJF,*TCUR
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M9&Z#15>K[XM35Q WV?_YY^>?//O\^2?9ZL6SY\]Y;_UWD>_/5]\?Z=AX11#
M31ZNF5LLS*M-9WW#R>?HYW=Y"SB.-IL%R^!4RN"3*@9$FSI2I"75=;'*\!"<
M\M'4E)1,'L$]26T$ZKM6Y[O\/#UKS<B?L99!^7/]/G?1_J!\&-_*(\.?_= 0
M\VC>O%V]H4BRD/O[<'9TAM3[XML)Q,T+SE,X1O"&TF$S$."633::9.%.,[Y
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MSQQ S *92WR"'Z-A>U\)4=?_4-Z^+;R'[[GID#=)_I@/-YM@)B2X5'XE9]>
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M4F/*Y982<\FTI-KI.BM\^)G"M>:7PRYF_Q>9(\J1&0GOX[H-:D[T-@8;#*\
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M+P]]X]W,RPJLMJC:D6K8ILE]-@EXZO;#0!'^O_A,'7A7T )C T"D+Q#7\PQ
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M^ZN 0F$)PG=P*83GO@,Z['IYI?W[=7+9X7J??((YA.=[!P-BQIZ5]V6DVH^
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MYI-B1/TQ@A8BKPX&-0\JW@[[TUYWJ"EK*X,):R-7YT?MG$' %$P4/V<(".?
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MWP0!+C]:G7NT'H3?X/,REYHIZ))DAW<S^Q!+7>D$B72WC+T5TI+A4,-.&Z;
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M$"[,T24-4H-*@H>>*#J*T08W]G\9;SOA\,3C(FCHJ=([W\/<%$-+;>K:?M<
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M%V"\&"=(]),R!1[+]YDIS6LR6R"YC:57UUI(8PAIB\#1%3(;.U>DYI9AQ7Z
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M_"F#@\W.Y7""H."=5Z:<8WPTLV9+.P56@6*]L.)/".LMQWXU_#L?G?9WBBO
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MJI-Q <ZK@W02NIV5>%9"&VE-[*NNB"LNA$J<PW26S(UK/D)GU=E09T,K;8@
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MX;-3>6RN5C(O#K/;G2HV5R)IMPIT%'+%U78$XS3.:3QC-*[EY.*JVY)R&L]
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M99X$'D;3?,R^HM'<@!@I/W_*N0YFKX]!HS'U7<U8VYP'. ]DD@=L/72,60G
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MC#Z%R7ZW)LUP:@^1_5PQ:-Q&*BLJ[<RE#ZCOE,9-\9[TA3EA0+"^]M3XXHY
MR3(A)0E1*X:H.Y"'T2YLVL:4_L@?G>[L@D6J/=K7A]6:=[#.NQYY@*;,A6B=
MV,).7A2Y+SRZNE&A:RN@Q@5M1^*'G8$5^*G5F%H"BSJ>4=K#U*/*U?AG4BS6
MC P<?'Q<QSYZ9P"L&6VZC[$TP^I:<9,)&!'=G*CQP,#'AP]"NZ<',6G OM2J
M^31F/$: 4?^*21%]VKJ%KE+NT9O2"T\<YC3:UA+KAA$.0F8CQB'/$*-YJ8KL
MT=NB+F?^(YB#[UF$)VSRC\*#SV@<NY["5;1W@8N-A-P1W45[C.%_"HA(#SW=
MHR]+EF?"HU,]*)!R>@ZM*,SHG39*6\S#V P#5AWCMGUXZPA;P25;1/F)!M61
MQ+!#7LPJKF./%_,+LAOMP!<%0"Q/<#NW#.#\7!RZC8<:-PK$Z LL@XU8@&MY
M&YJ]0>2JC1$SZ4Q!?9,.Z5H!L_!Q>;#O&(8$7=^G_;<>F6]>2 KW4Y2< N-7
MX>YTOD#N*>G#:&RQ0*&]+E@W&-RS7/06VJ\0B]/GEAW="./IB4@1HO8N"[>*
M^E0S$*><D&["95$+'-B7NA/U]8LT%];VY#!9/W9EW$*U$F!M?[:C\3.8%+PD
M/73GT&A\V($7 PA05S;>>FAY@RVJ0,TI78:!/TT>H*2,D6J<% S:[R_J%8NY
M&'%;6'_LHXL*)FW%"V>D%VY">%Z\<)363& G9R(EII 2Y7DLSKN?IJ!F2K5A
MR6)Q'U/F/E]R#%&SB(@M73! +=J Q0/YCXE2DP5@8Y1%28G%537JY4.QI\5R
M+O"13:^G.U'N2MQ84+@"3C#!L&9W^7[4-&B6RB@ARE_PZQZ%/^$P'LH,A$PF
MG4OOX6)V7J"LO6R9,(,A8>Y5LN[+?*YSO:I,%]Z&,8ZX3R.20XH7O8076;^4
MA!>'C!?U"2]V@1=3PFZAAKS\@NDI_R[02PN?XT8E]E11_=CY%%-&2_<Z.KQ@
MK_E@DW&LB,JB**<I/D&H:$:X(3AO4#9NHXZPZ7G#*Y>;\##TL)$D?0!3T>)A
MU:I,B@^Q#1Z\"*Q<FWBI*3(-!25G2I>E GKPZ+ 7=AS+@"BH3J)_2P/_QH%[
M.L0<I:]A4[$D!/@RIK9,EKG$H TN=QB53JS?E)Z2IN8T,)M3=I:9D/44DK/6
M04;4N2V50Q,W\7DLBX;>V-?])'B9M%:-;#,JLR(=8PR&P!TJKS0:/'/]"Q$O
MGPZK=$OH$E,[;:.LZ6U5-HOMCBRK;4,4Q6)1[8H%69GWENTWKXYKE_7&8?/R
MK')5;S;::D$399[3\KBCK+R_6^%-NL/"9(N?==,U,A #2<$(!D%2A,ZB@9.
MS67MJ')Y4&\<P?QJ]:/&U^O+>NN@7N4D_ 0)5W>)A-F:@UGFHQ?D<S@$:6^
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MO, )E3WW]JM]7)U5 E5,Y1&8:+/8=<5ZNK;Z.EB)3%6/VNL28=_5/9-Z*:)
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M4KC4L$,3GH"H9"(5LI_I1@R0CR(48CN'8X<%!)(D;"J6+X2XMKB>P7B5 +"
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M,,F6Q7:C>D^ LMHNS41M4NZ@I&4*5Y.!_)%D,Z_U$[PI!+S98\!_[GWSA>7
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MR/@RXHP7&M\*+-]0/GRS,A[O%!"O>QY7K%ME0;LA$/*HW6P5:-.PB/=Y$/Y
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M/!),)BKO%3"J_!9F/:3T*0+*6-)(#,]PO)QA)9DFQQ(-E(PD,\Q8DEF&XDC
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MA1>L@:UH#E9XL::;L.8(=G$XZAGLV>N.2_^$"+8K)L"WT*E[4]D&CFC"3:C
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MX/2>0+R:T4W$=>C9OYT$EEEF6,XOL/SP#"%M ?P4S<T$$VP(1E&(IW0:@LM
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M.1=L-89_(MO-L41XHID9YLORN.FL)/J,L/U4[L[['EH[/C?C<_,Y_D+>>([
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MF]!#A^NVVA#*]G']UI]!'164!HV0#%<P3\%#W-S-/3$&P/D[VN0'U7R8H-Q
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MG8:01W(4=(W$E9A]=0A_)\C*>7'9SQ@F2JKG.^43-QK\\$PI"RD?!)>AGIT
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MW!E"""/58HHR<._!T;1"I"Q?0C6X.Q,=Z.*NO'1R^<VW>V4/Z+B0.)&C.(>
M>1F_A$-HGIF)PDEX'VYUH+?<GT"-B"?LA3G6"FJ:@ZL#;2@%<*CA-6;T-_P*
MF;:O9L8%ZWL/-A9*/,3Y$0K*GGS=CH&,;8BI\&%>*TY6.D7 $_ )FH0:R9@
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MO+XCXCUBS7#-I']9QC4%_$V$I%[V_X'"<L9RKU67VWH2J^41SEA\;0RP;X@
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MY8,"]V<H<(\'A5I/43+W0@5X> H\T $>G@$/00GILV B*&]_%D0$Y>W/@8A
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M_27Z\H.<>J]N]'O3/_9-0]1U?G[6[ G9A@VQ)8?^?64*_-VY +]'D/N'/2;
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M!5,_V_F^B3WR"SQ-Q^)B,=-1"&9; MEJRHB7IV-OJ!D;#<>9;Q*K -I<-38
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M(XI&;F[GI/JUIWU1OS3(:6CG=<LV'40.>2^,UH!PSWLA!RC"\/]W#E"$VO.
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M>1,!7L$GBQAL0)0F_@H,H;, AKR+@0],:.6Y\@G]5INKQL;-F]A KT*TD%>
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MT%L)V:2RY=1!CHYTT"Q<E$=(AZ/,Z4U.$)?[PG&YX"+G<TF"-Q0.7R-)D!6
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MY7EFM*Z5!ZRP('*3E>&([#KZD,1=2 'VYC![-8*73 YC6CZ((4N'-/B@B9?
M^PH^6<1@ Z(T\5=@")T%,&1C#'Q@:HKNBB;T6RP $.V$ABC:+UK8B<)2S9Y
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M!Y WAM,'*+!MC= 7X(.WC:S<V7E?47"W T@LI[?6N];[SB3M3O>B'E@/LSH
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MW(:242>4K, _]MHKHST50YT01RI";:!HBW%99W_]81+0#!Q%D03DKHHH"1G
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M-<^'UA$-L*WUHH?K3NZ/5)Y"X9*2[*S&@!<2K"3G\_UB'8Z,'(ZT*SEI;J[
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M5XZ-,EHDM%Q[?W?25M4!_N,+J:J:T$T/Z:+ "]HBTEBO9DN+EG_]N;_[BW=
MK*=J)F=1B^<%7ZTF 3V1"]%0I7YY8GW\_O,=$,L:M,-C(SU<<I.(4-1GFM$7
M"C! C)QJ\?76!W^]"Q8[VR+;;;QK:_Q;B6EI;H>?RLEV:CPIROFG"%NPE\\W
MX-MIAJ4$4Z_QHU%XW.P.1]%1WQY$^^SU3<%;5%PD1O'!\[S%\)/TPDYJ:5-F
MQ<6]4+&_H@M\C&RFJ:8='S52D[S:+"ZN;R/>HF)R*)%:W58[?/2Y7Z]/QWTU
M5;P;*F:>TDK.ZM+Q\40;Q7(M/J])">B63M6U?=MVN"#[/28$XA,/!>T!+W28
M#)]%<Q:R_[>=\&\J*!)*7.T D+U@9'/\_(4GS6$(OCF>H, X74+GSE3W(99N
M0<RT!VR.'X$C77QH#?(;?_GJQ\G>=E#4^80KK9BB ?")#V.U.XC%2>6-@%$[
M\D5WR\/HFIH]<2M-?&:?5D5KU(1:RL2H $4=>ZC =3;;/P2(;DQ"-9W@)+72
MY<>SAEBN--O%7DE$)(PP)TF(T?F%J?@)#'YC*H[L8:&NU;HK+M7CLG+DN;U,
M<#)JA9HX3<7!I^(A]V2S,L>FY##KL+L!*^"Y]<1I#Q$9M;:)_')VO"Z=C2CI
MIIG"^0\9:.(*45/53>@/S4UR(=-36_9LL5:ISGA2;>3M67R66=Q7<B$4)!J*
M.7:B8EYS#W6@1.K]7D=+5=OY-$DGKGV8-*\197S\?KLCU]$-52)R0%"M(5$U
M9$'S+GE!I50%PSW)H.E0E*$0&E#9YHIAF^AF"D ;08[ 0RWQ%A5 Q_;QICK*
M+D"N@(DBXAU!O)&.TYR*A7+2SMT3$^(!0<+[OILGR"AEHCG9#NSLT4T6E$NW
M-72= *#UH=,X -V.$1T_#*?<1X<I@ E_GKKI53. \H]H[D@\X#N' *56S8"[
M38K<.=XIE56]#WT]JB^"4LZ$I"\TRS:T[6490I!0'@=LQ^ $C2XJ *$$.$-A
M>S3$7<EF_4Z.235U JUL,03J!)U),G;NX:A.QM5)<VXN0FQ7@B@TP>DJS"P1
M'7X?"*@8"A+V('$F*6(^=E3Z\*;+?9V<=IBRN9)XQ!4WU7P(%C=RA#B,DLL:
MWKW9W591T%GI[0DR":K+%'H'+(:;,Z;PW;IA[IXEQ:>"7//M3<N;S:[8[XOV
MC@R*KE1O'VD 50%0-* V(N.-!T\$$QUU%44X=_PJ,( S1T?:($54G$9TI$V0
M) ,MU#HBUG96SLG(C;8X<NZ1;DL=YWJ:.]DYZE+NJ9.+IK$.*][*$;$9ZC\H
MF8UT+8!_I__C?8[T"CX4W7]#S]=D[^_H\=X8J$9HCTS!>5H1>$,DQ7"<KXE"
M Q-WUL:<=)JG[UD75\T0'$);H6BLB3:Q%L YKWPPUN$"VMEV-1)]>8%M*/PK
M<ONZ>_WII,#M\@V.QSL_^$GP%V=K#AT(]';8-\?0+'P'!K[-AE&&"DR TLH*
MVI5SPQ&T>X.N"SIL<DYSF*J^0.GLS0T+N$+WB+USPGD*_W=$331LQ7+VBB&9
M@ 9?HCI2B,D!H0_:Z=+VY")(<(?CL*6&B R:34>ZT&:=*)AH0BHZBF"BDX^B
M8_8]QD/+E8,3A50.;.FE: ,GI^X^V;L[CQ^JPL6B:Q"!G?T=O$7FWKN$XFW(
MWKX1WIC#)WD=^HJZ#7FE 5EPT!DAX$)3.#&N@EVUQ$3?W]G"2N^<KM.WFX?.
M2Y>6>ZST955".H/XNV/3]PT,XJ2C(+*.3XWJQO]?.;!Y#G9$,<IR0LC>)]!B
M4J 74 LB<!69 BPZ0 [5@18'E?"M5" O0RHRA.>QE8%(Q1XLUR(* G#21W@#
M-91@D06>D "U*4$VY>;G@3;=H68+H+FP$TA!4QJ@&;M\4#!FPNM3D!&@( --
MI( 2%:C\*X-4>%B;TX/EU*PAMJS2B*K+*J$^1%[E"!5"6>2(M(C1V #K:LRR
M_,P4'(LQX:LM]9/R4RJ!5$9);HX= %!+ P04    " #90V-4)O11O9J3   N
MMP  &    &=L>6,M,C R,3$R,S%X,3!K,# V+FIP9]R[!5R47;<W?!$**"%(
MMY*2TLV@2 N(""BM-$@W @,H2",@H-0@W=TUTMW=,71W,_.-][G#V^<Y[W/.
M^;[O?<]YQ]_&ZV*OM?;Z__?:>^UU70-B'#$/W)&7EI,&4% !  7Y#T!, 9(
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M$69(:E0Q"NU]U#8JW!ORHI8+*T/227SX)WJE[#E" 8>4N39$8U:J$>)[:+'
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ME&1,I[GC\15?F^FIB'J\,QV;]D!!NFX@B21!3 9^G8&4DKEB#\&#NQ_37)Y
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MJ:0Q88DIOTFN=?ZY'[D@+@JNT7(1 #^R3H9FC6Z97&?X[9Y1MTBY[%ZQ7VO
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M]I[UY7.]K)?AL#)(%A^0B?FTL3I8FN.AOJ>=5ZJB*U_>C_&L_OG6C525(9%
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MJ497.*JU[VUFADKZ4#<UYY+AI:GZV>WRZYGV-L(0HRS^Z]$Q$]<N8_[SL#K
MO"POMU4C5+"IR=2]_228LNT3; XTF%3]SM:%]GG5[/NN2S9]I[Z>>'B4S)9F
M].*<<4T'A=SXC!B+*G%A1V&;NT;_QQ;@9=V32Z(I?/0XXUN)3Q\]U?$\1?,1
MW!TLRIXO'O:R8<_?0P#OEJSC-A7A/<C" <(:=GDTC*)>9^A M$(S43%WN&R+
MC-2X*]:ACX\D[O1R5>QGFEN$+5Q9Q.WKEH@'93RBQR&4?O?!.Y^1+!2PCWF]
MW@HB!V:3J[:Y/8SX2-6UNG0T%!-(K[,Q&TF_.*#?I'V_O?Z"5WT?MR1-"GP-
MQ::V$-B!-^958,OH- UZB=QBA9!''5%S%@[2)S $')W$JN/[<MXOI/B8M-DB
MTEQ1,=J7-C6NG58R,X.IJ>XO/E 6)ADFCQRN:)O=T4(K3/A4.W1EAC#&7Y/-
M%98O2=X[E'\\=V>"2JGWY/9ML]L>T205A[>9!;%7Z<C:'@W->@G'LL956]]1
M3,X[G4P9LKKG'6L!OF>$W94H>?>[8/:GF<UH.$&,5N4(74)L4U\HOGE643LV
MKGVO$!4S6D%RI0*4=,YL,C%P*+L>(IY U;+)8D]F$(+<.F07J[$<S8::TP=%
MY=[RPAR(9-BF]AYZ?D:ID+*I=JK(WZA^.<+&)R:\ MLM_QP.=/)T$K-_FEUZ
M4_.9(?QEUG-II\1D+^+_-]\AS9Z*G],)>PRYP-',5L]+D#]S(T2F'%/4[7_R
M1Q+X,O!ZZTRX&KL4S<5Y?<KYBU+@YR>?/]H+8O ^S!H!:(^=WTI,*D8 8;?!
M%RO0]F?H1[\\J"6ZL7OEH@T>8X2KB3UZAUR$)#3''=#P)*RU?WR8#03J'7\"
M0Q% <6QT<LRU(<TNY/I&MN8_B+%PGB,M>8$UHY,10$S!&<9Q$I;I/S/'>1R)
M ,8>(7-M8'3RQVM#!'#<#UYC?=Z/\O-CZ1]-@R5!.PG3"O1Q/Y?=4^O,\LT[
M17'6,X'%C1D_G92V/50)>DH;"R?8&9C<STO0DJ/Q@;N"B6N*:4SU4WR_2ZT^
MFHAB'\%G7Y=6XQ=+'-[IW!][&DJEW'#QX32P;T7N.E;/Z65XGR>7;HP48"M0
MP:UY5J(P8C#()U "[S$MES3O'HCX[FM$A8LAKX>OS5%FEJY='Y"E8'D# >QN
MIY:(=&Z);NUPRXB/3 Y(4$:'70=:!Q/KDD$+(Q;Y S+>H1'XMLJR[WJ?+7Y-
MF9USL9#7H=Z5A59%C-D]8L\5&33LF.K;2_1:J;G%C$;,?"SDSFY3[8\'9N..
MI#386:+*Y!I#0YO-ZC&S\R2_#GYTKPK>\_(J(<-SV\N REZ'CQ"EU>SBQ:!%
M[,OJ$ONWO P5<=W!VSCAG\7A(S>#4C>%]0(Y+#M=HT=/<(A\N[VBC#BC9.@J
MA:@K46NRF=%ZCP4U7I1$/'"G<\6M[_*M]*$-SZV\7'QF6R%Z8%%7'&J:RPZK
M^B0G_"2'+FQ1_Z;RJNK /\3B?ZJ93$+.XN;P3D%'^)I$<6_!B\[NH&EDF$L!
M9K\&,+*A$((W5R["EI\/JR" @K@-4)3"/YI\A#R04?,CXZ8'_"EKXS;H;!]Y
M$LBWN/(%E'\-H6>Z"*#-M^W:SGK)W,WG%"[* =J,=#KA11'[9VM, 5Z,=]H'
M]QEAE^*\: ?-@2ZPLDR!Y$#FO[5,Z/(N'.7:7#,(CK2^#?G7@9ZGH"(%+P:?
MML%]RMB!7U^;$-EEC70"TE+N)F4"'<K*HZG)7G0'JD/'*?]_WZ3V$0)]#&(@
M3='/1]=FW\,TM0,!DXA$2!ZUO)MGZ=5 [,]W@\_0W)%BIC_4,U:"]R6P_S24
M$+XI;7H[Y,][2'@@ST_=$&E3E,0?-EP?K%\,K?UMT G"*L(;K3\Z!I8R,C:5
MTY(PK_X8)8OY7]U8W,?L=_$Y,R@%7^!8QA[J$6ZZ^<4L=GTNJ3R(2@D.+U(6
M/"7*(^?.X7@9?Q;_U.;H.O5$C/3QE]\'TY5V-UH$P$NTX-U!\#XON-%D$>\"
MD^;R"'*EZ(P #,=VPEBO]9N<3/+_]$]7!@%@0?Q!:_],AV:"[S()6>?9U'W=
M_!/O6/B/-Y4_">U]/7L/]\& 7S,A@+LR)XJ>:Z!12DYCM]4_J"Y; O]=YHK1
MDQ891-[(PY < F@>N([4J\8[_GA[(K'JAT\R/Q1=:7Z5^L51))KWUZ\;3TQR
M9&YY)'N*A"VK_N;>IS!2BX:O?DEV,V 'R((2L@SJ:Z8YN@,Z70>=Q8**+4X?
MP0M?O^,9$_V#^P*Z7V06>/8QKM'QKB^4X8QA6['7_>!<0=WNXS_GV*(= ?Q-
MYNSI%7)1/$)#'EB0"R0@Y9(1ZD"SB4M2(F;_(US"?B@>@'Z5@M\%W0'W2R"
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MME5TGW+HK,A7]OLV'/=+/8JY?6GUERA-R( Q4(WP=LLKJL//6?-)Z>=I3@B
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MR!':N<3N=9!S-;L7O[_B&QPCRMJ,UM0(M(I8CN=A>\N?[C*E@=FI-##=F[J
M.6O5O@$K*6/AL<2[OB1$ (63/[XQ?KJE(5PO/*#BZ@K=G4A#%D<(X G\:NYT
M:W1.HQG,*N19]5[/BDGRA$+Y_/@C_#I0O,GLQQ?0D=54D?;I%=,DT^D* H :
MAYTIERKO(E.'9P_-#SV\_'D$D/@_18]QVDF]WGUNK?\$66D9#*9?XF1<730A
MA5KLY6!UA(JL)'$XP9Y;%R\@>Q!3R%P<_#I6O, ?KDZCTX  1)4^;O%##C=_
ML.KA-P3W>(T<Z$W5[D\C_4_7(M+M[!P>GXJTQ!)_OLH5)M^*C)/+?PN387YD
M]+PN]>-W+0[/CG_R[M;/!B#_<R#^5XFYZ!Q^J8UOB7F?L96..BH$ 6"=!%R?
M(]=2IE7M_\/=>X9%U61MHQM!44 P@));!26+@I*A000$).>LY)R13",** )-
MSCEG)&=!09K<),E!<LZ93J?!9V:>],Z9=[[OSSD_^KJZ]JY=M>*]5E7MJNV4
MUFWR1&KOELNHN,$!J:?>=62!4-T[M$OBH])R#)"L#MD:R?R=J4W_LR_PC% ?
MN)$;A7CRNX=(1JS 2T,@Q"'C_S>>,3'S8N@_<'VI.H#>=Y2@DCQU&_IBP93[
M=4SM)38*J=!U$SY1BNL8E+S$EHH!-+!BA1W)2/_3?QTQP!H;]I>=C6!3(@@V
MF1@($_SP.Z>6^$>/S&Z,BY[-_R<WWP,XW@!I.38O_N?,31R6I.B>QEWX\)3W
M@S\OA6!_%\@A0Q.07\L<=K=J/4Y)6L;KVJ^AWBE_(GR$R&? -]M?.1VVNH;:
M@*&PG(RJUH_/L@<]329V\2$4%%*/NEVA\<*EF>9[#.0.<[I2J%!7K;JD?I[X
MM4ES-UL5(BW3"?>Y.,UM\+%F$B/64#Y!$-LL^GJWCU=9GM:YLCTGL3J,A#"^
M*A*F6VN;+5V22!=(OT[H\*1XT9VV9;K1=#+0&L:367P/ZZ3Q,)8W;%GU S]#
MQE$IKA\ 1AR&*H5@,0;D?5HN'$II%!?/PI4%_IP+S^:8TZ=)3_J2#ZWD%O5<
MUP;50CIGY3Y<>U;:815*\&(^QI^*LQKD=56,X9.'TXTF.%O:Q\*X!8@CCPK%
M'<0<M7M?CU_I6+$9>_TA'TL3!I@Q/TY'>V'5M]66?\K04GQ]VN+4*6.O23]I
ME3'ALO")AC<X-3V14HZAI?6A[)AKTN18C95:,U]P>DZG;6WJQRO?'DR]V_[N
M1)=))A%!)G[:-*$SJM,Z\Z B)#0I,#!30V[9*X_Y@!0GIO92 KWJ]3:R^S=9
MGYGL-K\+>69BH^OFE'+L+BUH5;,[_XE_G-^0]_5P#3)?-@#P(61DRXA[$6[Q
M4KFFG?>;+RB%[&)KJ(D36U=I*]JHZ\*8J@:%9."M.[8N"^.A\*=N 0 <^KPT
MN&7T8F1A\'289*+WF A@N,U#35!A9W&U/R76^?*\QNVP1QWV5V7$ /F*SX_-
MG:/[J\V,KU#B]-%I__1TYKQY0!OI]2?SR7/+G!G8SZ]KBN^Z_N3ME=9UHMDB
M%1K]?FD4Y6'/O33)&9?!DB:\0 <9S=-PEM&1]JH=Q8F5,<^.\8VPV06KK(_Q
M,>H'IZ=0>?,E)/W8BPF9/H*4Q%8&@B;J&]GDKT@4.36XDV[$:35PS(X9?OB^
M0-C2/O[@JW<SM)Y#8F!%?LR%0V]":[*T_-9..^4+Z\60+PO,EX."!W_N!:+)
M\I6/>"/R"UD=Y8K,^MH=J+2O'G9]8GZOK]PX2<,+KU 9\) V<<^FBHT1WA%F
MB+UL4")K*P+K[MTO<">Y8GY=;T1G<N+;)J'@9C^LRX@72D$]-TU&M7P3O\]Q
M=M11)CKKZ7W*^U8_K>] KL%F31>R2U]OL.ANT-#FYTD;1H&,/]);=/KZ8L>K
MMYF[DV+1M)&*-M>?!LU7NOF(X764M 47= 47C/,3O4OB<R8ST/Y<5T_I$65!
M*&GA6!81V7$)1]W@KASXT8:&9K2_$XVN*[N)A6G1Y0">64F*T.N&Q"V5O9(\
M^S3,^FE'#ZW3;")&]*Z9!3FRH7M%HQD+^GB"8ISDYZWH7VV3&,B#;BWG)P[+
MIG>:B9C2XX2ZE296O][DC/M6LQV5:L<JPRG<RA\5N4FTRU]NXD4F'_@ UQ$?
M+R"3*SYW[9.9?NBS&]-R<1,OGP=P?%61ME;PL>NU;KVJ^9X_MO:'FNAGN>LK
M,M3]5(F?"/*K8JE2[P:3YMRYA;?]..%LX8HVMLPY\0$*K1<Y+[FXV6JWL#$Y
MD)3(PJZTW?UC8UWM<3=!^361!;\>RA?S[.]@DX*<PV-A<\(-]4GNG?%:3"9Q
MSX44)UXD*>;<(8M4?F1YT$1MI]1)O%#S8]V\<Y:-@SPU--O^?F!'WN>Z1R(_
M8H4[WFX%O%/>$0OR+2^^B4I3%GN54Z"TN%+3Q%Q#P^$Z-U02_2TN[T4TNZ-U
MMJE ]%7/)UJV+<4]"=54)7LX"2:! S#?"D(:H2/9S^X25767-3*-E:@NJO"0
M6_J0&C! W<P??9EU*#BEN93ID"M!RB!7IM%I6$/O46_W]742)%*I;*BHN(CA
M^2V%#T640.E+Y\J!P#FRZOP*8!,@B\Y8 >MSVPC8UH=-2G+P!884N,P'5US)
MYX^3E([5B) +""WJ+JPG<;@;8*Q$:G]-@_SA=!W,(RE14,Q24T?JL+3;Z5K5
MR*:00>L/>NNE*K*/&<O<I]:99,U4SB\G\'':[AJ&\- MS.\$VAT4ZMA_\Y23
M=B?743!A#G],#V)-3B;?%)>8DY7B+GU G!D?/6$TYE*X^:10:E7Z,>G09U0:
MSR<,4/BA2*76+N&:YV/9FAU-D1F7 \.J2=;WV2%:>#P,M@SC9LB\JQ+?K+EI
MF)]E:6FP&=U6XVAL4UMHW1AI?C/G8U:E2UH3)2A&%T93UOSA6OC[T,J3]SO3
MK\ ?\Z3B.:UK:[GW-X2G.MW\'OF,_?QVF7?25REYJ'CH:F)1_FM7#_W*LBC"
M^/!'QC6&1A>5/:=9 W?6M'XD%'H2QUE5%,V(D2I'_6-T<*G>'P;9Y97Y-9NS
M]F.>5@ #A/;8G,Z!=HLF\'>@[-P8X(TQG>=8< ;X37IQCA^L6?G8)X QC_-W
MNQ+_CWYD%*'-=&2O["_SW*L3Q(<YC/E6#7Z->^CS^FAX;4U;QWK9BZQQ*%&;
MR6^XOH</A>^V\/W;^U3$1C#RHK8R<W'^%LK:+4*M<GC%2K"@G=42R9&  0B]
M5%P<"W38GY7U]E_>B(@R$W(EWX59J/861R0SA\^/(%9EK:\,JGJ*I04PR_SA
MO:.SB Y'F*#,S?W/YWP.4J[D_,T+#'Z@@RK0^;LYNBP[G]#B")O3'3G4U;4Q
M[/-:=AA !Q_M4S';2-XX;U.) 8K/WEV:RG*GS9)#'S90+%6,C*^B[Y;VXW6;
MW%S9%:-^QOO('F>F<DE@?_\I3$V)N&!\O=CZ"7?2[(08I92.#Y?04F>@X=Q.
M@<(!><Q4QS"KCGD20VA1V&Z+Y--R:WI][R=FC##KR96=B>,/6K,ZS&.F5F37
M55\)J8DTL],QX,?%'(?KQ-]F2N>;>*'*'7J]LHWLXYA:HR+SU6?8@8Q*XI<?
M,^-^L31)UWR'.R>#+\.>]-RGL/P9?;"J(5U\^[L3O?W8=SIIZ_8G-O=FHNWN
M0[N_GGQ 6G#9W%X]' X7S=$<;UONRF*B:Q)6,]/E-P!EFNJX)"M$*[N*?YA=
MF&76CW0.JO/STJG??3Q5@Y*3^W%P57%VI;PNPRRF33Z5!S[3[]>9*?50KSY
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M1[4'+XSXXL+C@Q%^<G)8#?8=&F  P<45:+V@4,29NJZ6W($*O4Y"^--X-F
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M%/H-0JZT$R)R>0]7_A&13I;0+NTG"H?OS@C<@)YU>1YYSN/6]POVD#/,.CE
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MRC6USKQ^1>1$.71W:20)3+GT>N! [UABJUPDN]Y>1Y(/E3D/[50.C4^XQ)9
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M@+[%>R(A"C70B4FY^*_@)P5H,C%B+X0_.3O9[&6?,*'8?0IL.2RP]T*?I!C
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MU(\[%O&F>&.^)B6)CI*N?P%02P,$%     @ V4-C5$<A9QC:?P  9(\  !@
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M=G1:7LT3 G.7,0Q".KY5^M,_0OLSLK\66-#_5F3_+;"_Q34'8"(C/7QXR+B
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M08NQ-0?65XY8"VF*Z_>9\&JW (H3W835Y64YJDR?@,O)9=Z$9<K$,980]1\
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MI2& YK3U9>(R.5V0>K^T)@_:$1.234Y.?<J;FGA==_4?JGHK&$\2%^/8"5;
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M+T43QT$H:H7"I7>*4#=2:?[:X.V6KVGWN?KU5IK^'AQC-UL_0WG2KM2.Q(U
MV.8GTZY?WMV>&RS[MSY-K[[NI0"&'=S(*&0-Z@]J?J91[=_J$GT2DSLE,ADM
MDQC+GMOQ$8OC^C+">9S._<M4'L::5W'B]-ED0<K=GIUT!NYEF[1/N7RW@;.M
MN0!CK,SH]TC6:FZ<)$&+-@R74%\,)\^<_J'#HB2A=[^%_]Y+1.?%_HR:3IX6
M^',%;"0= :P23]Q;(8 6!' [M6M". 6G[\0GG#,:\35[SB+#4/5+&QEP7!>B
M.#>4//GN'G.+KH< UA]^RZ0VYW=+2O9O/<7^$0<G\M<#HXGJZ%2)KJNKGQS.
M:V*L!;HL3SZ:D*99'F^UW!D@ .^-VZO&4U6F)XN4;^HV2\;0[Y7X^\H^5;4I
M>TT/="M1'XM0!-Y95_O3OXZG2R2AD^KO?(QK+ D*AE9?BE$=OGL)#OHBV1$/
M\X2I15J=ZOQXO8_/HT1L3@ E"[.(GCJB!*"?5XPYVZ^XEO>N?IH$#K$T8=4K
MF;]7U$JS^EF=.=MOF.ZA7]5LCL:W:\F^V1]IPJ4F'8TM:DVP1RK9*8FV*R)7
M_=F&].UZQP>#M:UA8;K8:[I8%?R3R=T6FYSRE&E>$K79Z<2IXPK3.%,XX74@
M>,>R%@&TNH!/^<+6K@,5)4\UYA' <KTD-'7FP:;CM2. "Q8;,)0C# &$Y\*?
MJ:$B@-&B; 2PTL )9Z@5R]V*<EWC^,(_^R1J]1O.P>\-&K^MV*8?.$9'Z_Q[
M(D0]RZB[M_20_-#$@ 2'A>FD4R*TWGADO(0A2_O,RH2%_8J1/+M1P]WQ7Z9]
MB<154ID-=2L?YH7*S$]J0P[$&%?OC!GZD.E8SQ7[!47=V0*^Y_"M$GD54Q X
M>T6,;19K]'G7##^%$\Y\XASF X?=-M7?0=[GX\.%<N]\UY\\, ME"^D$WZ@/
M68JGQ1G_/KY.VG9G"\-H]2)O5ZUNZE#5MD:\E95#?M,6H^@7!/!,HOI"L@,<
M,F>2LMJHHFPTMI:@]R5%<ASDF51_(S_1)E2FSU3BHHVW)R<2^,=_3 C\4\+O
M/[2<C1;6$\J"U:BW,+,5SD6C^_U%;O#4 J<?YP6LN.Q$+=JME7Q7A8ZJH3'2
MH:$RX5C>AU(T8F]_4,SYY.R47V/M^(G2E;@/5:H>Z&,#13L%#]@ 6('3V%XU
M6$<Y04I6];+)B%]<H,3BQ71-(8!0$\J?,Y>-(9.T/+U.S^(LAI')US/M?D_X
M*:_@$'8Z%T(KYL0%#3Z6@.*,U.B\WG"A(84J/'A;V1*8R(EJZNU4R&*5\P+#
MV,:"&(2)?(79PL2E77G>M=%@>W9RS4"-0\_+E26MR%3EHJ6V=<7S5(X<ETWC
M12\I)DMAVZ.Z92*8ZJ@? P*PY.&_*EQFT9N#'1G^%-J%[<?Y6_>VXBF%R8;
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M.',Q2F#IE[D,:B6TQ#&RCYH9)^@[LGGT#:IQ;KN7?X! 9]_7S>1,-P$^X*H
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M&\:74[1[YUN-)EZH1]MEZ<Y0R8MR4LS=BGGR&#_ESCVO_W[X-;*4ZAS*.7B
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M<C8WX-776S4]"O.VO]WR_@/X<_B=XMD1JB*^(VQG&?$ME1$IXJ(%E)]F:O\
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MQEYD\GB9^:SGM%"YZ*D3G<WPEY_NQ(P@]YUO#F:3E1_(S!4]=MBQR*#(:6!
MPX@>[<A0#$$0CQ"Y1E# OG!Q40^4B'^JER8Y[+MBW_>X_]BK[&7Z.MJS1X@>
MSH:S]E3R6][PNO3'*C'6="K+J]QPX8VJ]%3G**]]RVQ_*L^UU\P-2?@6J@,I
MP>LHJDB>&Y:?%A(22PH'4:ZVTS@=%/P<R74)-VYCM?UW];%["4FJ!#1&7W%G
MY7HD@#)J2!C)Q%04"Z-##6<L>Q/P H#W.S2O9EIT3[9:B[R%@AL$)">D8^<-
MFN@2KWYI+/3_8N$UF2%[_^8J$^T.)61CAKIABHN#D<B"<?N#+F)+A.^!#"&O
MR)2WE@L  &Q(P.?/+MG^Q"/%HN9 .D '=B".#.9:DM.=N%2BVK_C==>6<?//
M=3OCHYW"VE [VW3^JBAI/1/V1<"]T#KQ=9HP].X%K,MA6+ )(PA]J]?O2]&(
M!$N$5>&^IJYF=IV<LW?^4K]=G1WWCR;5!>UT 7]PS'2T&R?<IX_C?G5V95NM
MC>DNM0M(K7GVC7,[413LW%A#F=?7ZTTIWAY@YIRZ $1'R2P5*5$4,54 : >P
MK&VJ:-X+5K&I2S!U7<'[4^C'/S8>W$&V?Y1\K.H%/<5AE$E'[G.KEK3-@.SZ
M]M(*)G(3!B5.'_-:5N9S&R;C"5'QD@6EO3@^!Z(>8D$;8-3*#5-@%] /I/1[
MU?$_@+LK-QM-Q"_J+NU+&V-%@1X.J#_G%R97.8&<M09[YC+8YYHW>?XXMA2"
MDD-=P:NGZ0[-87LNG["LDI'"-6OQQ[.SF-LL%X=6/.+V03(F'YE4\.1(4]%-
M)__V1U8(B3,/0N_O:4=#8I@NZ7])5I?!,WU\Z)BYZ:W3O]-\C(_5Z>['45PE
MRI_%R[-QY2WA_ =Y2EX[1]+\HX8%GS'RB[O)W7]P)N,0^-I'P<S_J">@)F]I
MBH.KNL]&0AIP6?#/LN)<S 1*TYG) H/J/V4#B"J#V_D(A<00-[TTM8)=TC0%
M</VP]5\6Y7Q9D*#*X6J$_W#D(&S%'5,?R;LQ=?'SGP_VR(F)2<,+(RVB%E J
MO"@8_P>3Z@U<H[]O3<T_QBBXR"CG?B\+9],(%GM^,D!(2/87C272DJH^:C"9
M*X8=$TI$1!JVK=4Y4[O\UFTR_YX\@OTVT6%-QRQN'/=QS._[->S 0 ,7Z#,*
M6\8-)H3RCAFI2 +D_FJ[V?YHDLH#&OZ4X=C>$^.B&!^EQZ@8BB/A"]MQ]__!
M'$4$Z/\R#-U_?$(NM?P61E5DDD!I0C<U6?@\?;M99NTJO9O%11N1N N' )+,
M_AHD8':]<_R&)H%TIX[K62INS3TR))2F,8;%/@PI86<0]5,K[Z$ 6M,_*S6,
M,HAP#E9^^<WVB71CDO/NGX]M'W'@.)#[YQ!H!%E\TK\IB5=XZJ^%E1A:0;T"
M<9MJ(\WHE4/T'PH*GW<2A77M\:5R$$SS+G?;EH$/37MN!%]2'1VMNLTYYBRR
MLTQ)\9]& A<K03I8JZZE'Q1,1(3[7Y](^2H0CCPXX9]#4-'SM.%1.U!:4,.^
MO\)E"/ 'VG&?]T,A@3.9+DP"BR2PM" +!<(?!FQ!1+"6RQI KIERCQG;#W43
M91,1A*1?0DJN4.J\]IAA634_!@,Y)?II& )BO=(%IFK^.]H>RI^Y_P)02P,$
M%     @ V4-C5"7D VAU)0  +^8  !D   !G;'EC+3(P,C$Q,C,Q>&5X,3!D
M,3,N:'1M[5W[<]-(GO]7=.SM;%*E.'$2("0L54P(3&X@3"7AJ*NK^Z$MM>TF
MLMJK1XSWK[_OH[O5LF3'\6 F 6_5#F#+K7Y\'Y_OLU_^Q\[.63H4:23CX+?K
M#^^#6$?E2*9%$&52%/#I1!7#X%J/QR(-/L@L4TD2_)JI>""#X$6GV^WL=8Z>
M[NR\>@E#G9K?Z/0X.-@]V-W?V]\/]EX<'QX>=X^"UQ^"K4_7I]OT\)N/I]?_
M\\<9O_2/3[^^/S\-GNSL[GX^.-W=?7/]AK\X[.QU@^M,I+DJE$Y%LKM[=O$D
M>#(LBO'Q[NYD,NE,#CHZ&^Q>7^X.BU%RN)MHG<M.7,1/7KW$3^"_4L2O7HYD
M(8)H*+)<%O]\\NGZ[<X1/%&H(I&O7N[:/_G9GHZGKU[&ZC;(BVDB__ED)+*!
M2G<*/3X^V!L7)_#+7?AZYIFO.Q,5%\/C[M[>WT_&(HY5.MA)9+\X?MHY.JH^
MRM1@Z#[3O+3C3":B4+<2QU[P9N\-\.#8/M;7:;'3%R.53(__<:U&,@\NY"2X
MU".1_B/D3^#/7&:J_X\3>CI7_Y8P$(S)[S@V"\,O[;"W*E<]E:AB>CQ4<2Q3
M>."7OQWM[QV<O-S%!V$?QBU[$2529,<]70Q/9K>E;;W?9AF%_%KLB$0-8'#<
MX9EU]6HOX9_MPU?TSXFD,^GI)(9GS[X.8=G%+W_K/ML[Z>YUN@<O=WN\U&\^
MU0B8368+SN"NZ2YY1M]GXO?8Y-./%U>?WE^?7[P+7K^[/#O[<'9Q_7"V^:_:
MU2]E7JC^E#]2*;RX.#YXUF#2>^SS]6_G5T';9@>TVPOVX,FKK6(H USV_IY;
M]EVT25\=JP+6$[7-Y_4@DQ)5S!(#\I[O=T^V@]XT$&D<]&0QD3(-[(_OL1'O
MDFFD/\!!%"K*P^ \C3K+;,$W7OYIHF#M9EE+;<$V+7R%!5^*:"B3X/=.\#NH
MG;N7&L*+ J Y=:OB4B3!-U^Z3O,R*<1]CU[E@>SW983J(A!YH/O!ZW( C!(<
M=,, 0$8W6 >AGKEWO@%4<Z\I=QZ"C'B TJTAA0/\/TXIN+]@NSP[/;]^_?YJ
M?4ICB8UN+& A?7S^[>SR[/55@-0Z%EFA8&:QS%4F@[[.Z&.6#T&A YD.!*#L
MBFOPP[',X,D1/0KSOU41#Q%EJ@?(>R@SJ5(2&#C@S&\S#9P-ORNC8?5CG=)@
M<"ZCG'X8:1 !B-&: Y_@ W\U;:^TY6';GL.>E+F_P\@#W><G.4I!.9;T^B"_
M09L'=T9^A>TO%/QD7&9Y:;:U&(* <EH-!12+43< ;&B1B:C0V8/ #@NWZ^+C
MY^ :M^SMQ\NS$):!L\^!:C*!)(&RES8RTR/8!R:845F@NA!V"W):L5"IHYOZ
M[N-GA<;!"]@A4$VXBST9)'(@DF0:]'29QB&/A]O9UTFB)_GQ ]^\!PP9%[),
MK/)Q(J;'*DW@R'9ZB8YN_/'1@JT-7MFA])J&U%YE33-:.049)Y*FU&]9]I-7
MW0ZK@'L#I#.2L,2U0-=71B)V[D9* 9N&GG@E8LU]*1OQETC>3M;"URJ-DC*6
M0-XC#5^!B2Q1\,-C@$ESD!.%'*@HZ)4Y'$8.#!;C3^'Q/%=Y@9X:=LG(KS(J
M"9T4SC_"[,A#NG>68V#;3/ZKE'EAV?=TJ&0_.'-#?.SWX=GLFR,^]X;[ 3X[
M2U*%';/90>MNPS9D$4ID_,$0WHVKC"6)#A@&#J,/NTB^(Y6/:']@0@F\%<60
M)]%)\Z'_BK94)"3'0/P9A4M2"@:OM&YG$1&,Q V]()=)/Q"W0B6BETA?@9,2
M;J618:;+P5"7!6]"]<@?P#4:!&,YQH'V]P)X*,MQQ !LHALSG[M_CTMEB0OK
MS6%K>B!T:Y,<25DPF7F01!2!*A!]]QDW9$QI$]B]OQSO_M@";G]5 7>J1P!"
M<E+=RXNU\UFE;[&IH]$,D4T&ZGT1#C(8%'^(PFN06D$+D@;1 ?ZU!7J1[PX
M WID:1"$"1FRM7N9!1"&,">(S\9B6I,0/F_U61C\Y_Y!>+!WV.D^)YX!^0L$
MCE-LKBLN,\/Q308RO#,6*D:O!#[3?6H/)R_'S>U]@>@ Y4PD$G.XA1[#AL/[
M7^["3^XXEPC%42RR((9%PD(D&/:!&(]!ZA+'\DH6S7G#H&MET(-5&?3C) 4E
M,51C/-;/.KL)_LAT7$;%2B $^0(H4F69O-41BW7B/( 6 T )A3/P;N64])05
M[<! \_DNU1-0E( ^D)Z(HT$5C( 4Z4-4DDAS?; "P*8RUB>,+=*I"R>%H)-O
M9:+'_(\)KG3,*PV#&WC!SE!/0K++!F MP%? CF!?H)%P"S\!*013D]$P50!D
M0L0\:,A*T-@P ,P)A)5@S89KP:DGB8S(+H'!4,E/>87(Y E%J0HK1F@](+ML
MR*OG2Y(0ES(9*N X;Z?)I%.]LL IPNOY 1Z9-[8IV)R4,0AQH?1<AT/+IZ][
M ;+0H%8\?]S>2(^GO)GF)(#/;WSPN7#_MZK!8 .!NHH@42-%1P+X"'80IL3/
M;O.6&K&&I[4 =>$I(LU9(O"7&^1#_*C'E)W!A W5NLFA,C)XTQN;5(L:C62L
M8%[ 3R"JHD3GDH],^@Q48]]%X)"A.V+Z(JC<P:S\#$ZWWH8TQ\=@<,M(]5T&
M>\%\FDID&)%-D1K)O6&Q')!J7UG 62GB3J7L<1WREKQ.N(?>G&,-,X8#"DE-
MXN8R8@SM&GC4:G*(&5$"5,@2Y@ BM]K>V:6&P1T";#S6"H>V.YVW\98H"IVE
M<@H* H0_G+=%'L!B8SPNU)ILC"#6KD\:$$[+D#T))-,/#6N;:1!OHJC0Y3BQ
MT7%R]["L;)Y[J^*U"B_5J3PAG3=D3ET<CEU5M^TM[YU8',JE6#3\O="C!Q^.
MYO\.,_OCGHAN!AFZEG8BG>CL^&][]+\3;X7U+\R9H"RLG5';1IB/O&B_^<0/
M]L\&\\=B &@'6.5F1_2!@(Y%,A'3W.SJT5%G__#O)SV= 28U,?2]1GK )NG@
MH20=6#BXJJ>:512J0Y!F<C0F6)#) 6 LR<(78=,<F++0$F-/P*?.%>HVH[J-
MSR>LOOJ#->\O8C0^P:0;5NON.:, 0+ "&Z05!@B-RJ8G'!HP$\^F+9H0]#BH
M7U0L%A(895S3V*3&66?BGJ FPPV2Z4#.JA+MHV@<R PK1ST=*QFWC=\RKWZ9
MD5ZM-#4[W:SJ@5% 38**9= 0 *]RG ;V)&I,RD>;QL?=6".!Y0JQ@%9!6,FP
MUV"DL 4DA94N"X-;I,LI03,8)I:)PD^:6@Z_]9Q9]"WC"-"7-50&N@XXB?X&
M/T,=AY[(;5*]O!,(_CW?D44MJ'0QH(*V?0_/F":(+\5 *OY=(O!-(_I[#OS"
MSS#<H6W$?]U_(S?F[5K-V\-5S=O7Z%LMZ,<+5M ^S_I(AAI:AEKX,^"D#SH3
M"9N&'XG<+XF>[N$.Z]<@*L7WK#'C6T:(!='K2GS*CC-CP G:AAF"-L852DWS
MV AG:@>V7[>)1H:DD4A1+/2L>PU$PSJLQ@N=[KRF%Q":Y]V[I_G8:@9-!+K:
MC?0D107Z+8DG&#P!.4X"RO"^&*#"*)R%MM!HL2?D#T#/M&P8FNXXC;C%"C$>
M$\]+$F1Z*I)BNM.'-83D =PIQRB-@09R&":LEA!Z5HPD(3B69 [#-J-9%Y3H
M:J1EM.XPOG=+;:,\#2F<  (3;.H0_>_X.VW^.12PB2-!$27TN!H=EI<]^Z)9
M\N$'MY1"ZYJ=,/#C&+4U>31"@S! EV3JE@,BC#PTF$-C&AB$O@UDD%ZQ'QI1
M-U?3H2%=CG#;\;<"74%#21-&)Q,Z@E+\$MTHF749R8WW<KWB_>FJXOT2R$?F
ML"1111\_BPSY1JT81\WLD#S:A$=C!CX.ML1VT^DI<N-_M$Y,QE,E2.,,C B&
M: 5[I5JC%):2D0PU$/+ + ?E ''I2;#5VYX5,0YG<E Q1?,_4Q$B-,'FBT60
M@Q81[DD5] P2=BJ&R"97B)7P]8<T\%,?F;6HF&H:U=N0TVIO:S49G#X"6R/1
M4\DQO2I9)=^&=4?;S;GCZE&0LD<.#0*0J3)E*9 /&6]CJ! =M_#(](0E3MPR
M%CG8<#"5]A%R2HY7XPI:+ QG7H1FS1CB)=F#VPVS'Z/$BJ;.6F& BW@=8'6!
M[C'W._P:3IZ\658(V<67B!@ G18E[,.4MV4T@GDE8K+0M8<</DJ!K>SI]C,]
MJF'\6(S Z@?@$.D<\4.4"#7*0^OMJ^*J<,B6CCP*\/QJUN>5FX/$,!>B] SL
M9PQZX9MAL%G<C/X&A/X93D<.D"KXD[H]:2VI%A:?.!:O4RZQEB'?X.E&:*]5
M:#];56B?>YEIIX[9@TLB$SAB,*-7DMQJ0=X;D0UY-E(G;=JS/"XTY<(X<JHD
MM<I-PI@Q@3%N"\(PP9QP"O8666F^,OA%4,:9<0U@/AE8GB :OJ C-T#HB/$J
M&(9G1"_)_%TP4[H>(L!*4\G+&$D!? #,T@P*#;'V*&>G.XPI"P9?;5D>@D-E
M;6$B#;R-80:0G$JG-F)79#KI^ %Z>H$-^+:\8@[JMNE)I.P ;8'IKDQ4KM Z
M\>,+(T1A2N!G1?4\RZD6*:A8*QC%^V\.YSCYP1 <M(,A%#P->*>E!CI/2@"L
MB9S;&3)A;PBZ'ZI C#\NG,ZHAS/E'_VJ11;C/]Z 'B*=%M8HE![SJ6S995%^
M#\=#?/D8.IH/K=)0'#. @^2 0A4)H;!E&I6LJ:RT5T8%>#C$**L;E3I/5BHX
MIH)/^B,W&<I;B8N!]2FQDJ-6!<DKQ XHU =,L12R(6)GND<URR")$M#,BUJ(
M;O[^H8](97;W%.6'LID6 6(H$QHU+NWZJT#5G#&!+'5C8$O<<"J@E/)ZD,[C
M'O2),WK2M E,[_Z>-S-8&]QT;,9SH)0G$$D;%XKA/%'F\%9BRNRXX)R^-+9&
M9@W@SF1FN_,R>\_ 2D21SN(J$1"F_NTU[;=.>GT 8:6Y90C[AP8K["WIJ-_?
M!)LVP:9''FRRJ;)^@BQ:/)AF%KN 3%_))+92%-,(<PRN>W4 +%F-?=>KY"#!
MDREG.#0ACH<CPBK-E(1W[C1>0O-!=Q1@<^O![4M,2DS0#@-5GLE!:? :ZEL@
M/12+] 7IA"KP$>D8=MJ$\@%Z><ES9G4M^LT)8N<(V-@T:[5IGJ^>Y]J@L4N9
MCS&)U8*JY6V:UPL,&0Z7CG1,3EG$1O"G!&08>[9!F3>BLS;;J$YD34W?GA*;
MR\18U>QJLHYC,A6,;<#1/X*YAC^K@19AP<SN4\(U:)P*F-_DC$VS*GJ*,4_1
M'+Q*F'$E"S 3'E^F7_24829Z'F0J^XJP#C"4[MMIO7:>&.>+HOW3Y,:VFV_]
M7W,*XLB= ^;>G,FU^O6J7;C_GM)W;1N* U!,M+FO/L;W,KP:&W)=)9;QL.3D
MM^%R@L?.NTE;@B^34>$DM:67T*XDK)9A+1.7&.Z"+>8,-D)NK4+N:%4A=RV^
M!M?HV6!#=0EY-D.M?KXB%<B0S>%]2L[8 E]1^^DBQPZ2MLFQ<VJ[@(FB@@ZV
MC.8F/>[K;RYI[ROFC5'.]09YP9,@/(#6$#I@Y]?9A MG9M)Z4ZDX'H9&,\R5
MBGZ<OQNA #JIBX3MQS+U?$%.7*EZM+'FE<*R68 =+@]89S? 1=8C6V.S>>/5
M=MMYKGTWF?\UN<&^E$8N4TR-;70 -XGT,SQ\D6?EVQV^#B* =AE&J;G3FBO;
M/UV"9[M($ :A@?;0(PQ:ZD@AM)2@3%!>L0;SMAFH1>:SU<K&0JZ.JD4TNM !
M4LP0>(0FQ\-1*$".\7P_[^P';XG(ZN]@5Q+7CABW06TG,+&3?AAT]UZ\@(WO
M5ZX&4$[MD0"5SY'_#%^9P4"LP -(_:'CETP696;\Z[#/C%Q]UP:Z;91-.24J
MP: ON3LI+8NWW?(:.M/P=&CLQ<IB'B;A1.E(JC'I5 PNS"&CY=<_PJ8-E?<G
MAO7A;.$U&JT.C"\[G3@+/R(L=I.>*ZKF3VV;&07FY9@DF,NY9W=.Y6Y>!!IJ
M[.MXH^Q],=MG"8]2V:N0CTT]YF.T[KL91@A;CJR*6#GNAT% ?2=,UH[@/ 9@
M&RBC'4>G%]:5ED@\5)]4JT2H3"TP?R@DAN^%D2D%RQ"),H)UEM8WH&"=H.#%
MJJ  "/C,TLJO1L'<C0S:=&J$V1<@8 :&]_VRBEDM"H2J4QD85 [,@5\:+S0C
M5I(<M[*NRIP&]#W:%*?TH4E.Y0,XKZ7\\UMU(%Z5!&" (:\B##F+(,^BP! W
M-9?Y2B799BK4I2!28PZ:&AUK8M-F 0$06VJ4C!YD AMGS,YZOF!M%U4VM _\
MC#&+]A*B.2"L#I0\_W;-:[U5BQ2XXF0,]]2"$TMO96T?*8TJK^$#ER)'IQTR
MA'";JU.[N35?DGOIG5M^1XKL4(H$-66N@++!+ W1<ZYB$WC!/P5FW-Z"#!Z@
MDTGU,2*7EQD>&.5#V?"[)5O,P,+'Z7L[& P2 V >&ELQYP 4MU!T@]< CWN)
M]\ BW%@]Q<DJ:4Y&6Q8<[G6W;K;M]+;@$)R6,W6I53,92L>HP-2%+I#@R.%G
M8XB8R#'0M)\S(->6 8%ND2DES8D>G )JCSH&Q;_: T/J4&EI3,R,JPXSFKM)
MRIN=K7, DGRHG3P.P(K(Y3<@L[23*R"_6Z7+?%Y@U[@1."BTB9U\U]C)P29V
MLHF=/)#8R4^+-KM[*W?,L=89JJ+WE3MS-<CI%^XN=.68](X%KE5G-FZ96#LJ
M[-U$8Q'Y-O\>[<G<=+1*C4NW"CZU@[6661-\(\5I@_9#6?DBR*.N1CVT56-7
M-9N7&&]"W.2EVV#N!KO409N9;$ $U^PDH%XS]"DE1F@NES8>]AXF9_<S,:V\
M0%B,5-/ZK7#0 P5.J0]*@2D(4LY8B[0X,OLI$=SBXT6>?YHZ&MVR%9+3<C:6
MY'IY>^5N6%B&<&8J&4"F+\_2GD\.<Z&R6^EG1U>=#+7-L35TD=?Z(;FT-6L)
M#6 :6 WF-W5QV;M]!3P(K^N7.2#PNN_$5F,8G-E:@=@VS=FI$/N:#&(.C805
M9G6^\UG)44OAB3E'"6OP$Q69E*\""^(RD[ZSN"O$3"98J_]MPT]KY:>5FR]=
MD#0UY]X/SFV+@*4#T6^JACX89FAZ0]"P3$CN9JHH)#4K&RG*YD!U"0P$GQFE
MX%JQA<&LPY\LNX@\I6B'AGZYA*AG-+H6HEY'._*Z#U46DW4_9<XP#^:VRPN9
M[NY7IH -K=Q"UC) FL_.L6E3\H#7@NS^M-$-X>Q7G=7"Q#/3F% 2\0(6K>6"
MS&-3BI"O$'&IY?]1')@S)BMI2;M//HL2BQS8V49>:[/3%$BB35.PH;CI;4:Q
M)Z:6G-M]RAH0:5'4P14M./]]S]8*6T?/774'M3.J3M'TVJ@1VT;XK5?XK=S8
M"H3?E::Z'&X^9WHXWBW[WBSH8A:ZIG("Z1E[L6$.="J#K>YV, 6KDCF(;/16
M.6?S()(I\[G[UY8M >HWLB,RATC\S[>I.A-^G96JP# G+=:,6MJ&"54C!_NI
M[Q //3 4UHNOZDY1BM792#-^KORJA2KKO&0LQ**CZ?+R,_;@,2H!M1.G!!V+
MXPT31BY//0*2T"/.!+?9ZP5W+L5<?O2A8QY\3B6@N*4F:%DS2#:\NE9>7;E*
M'U$*^;(Q/GF><F7NO3I&MBH-"LG/./7GO0K,=C0S^Y1QWY.)GFRC8<L5E=S"
M*G:9]*8=B*L (<@]=^0&0E'MO5NQGJ#>;Z3,I8U/++L,:_"[ME,5D\S8"8L:
MQ%7YIF:>W_XBAM;IWZ>J'YF>$AV;E5H< <1<2-.,K]H?>V:Q%R^O>1W"6E_9
MT(3#JJX@)& +S^7 C486ML-I8K<V !38-H#D$Y$IQN9!G'%-NLE!F"$#[D)H
M1#XVN_%2'UV?YV;-;HAUS$C4"+G9E8;M"YLM3KR>B3:\Q#7Z)D:"8I\C2C/%
M]>;W!,!P3TUO1N,:&],!M(+M>G$2?)F7O5S%2F2V+J??!WB'^4Y<%.TW8@3S
M.,[$A%M9N[Z-N=_@,=?]8H)9.3:*9X*R]N-<E]A*QW6MX0IDGX(J@N"(8)]*
M7'/0_=%PILMD"C+7K(R[)N#,C!5#2\<<WNR&J^AH&C))3#S14!>]P_LWQL@B
M0:ZZ7AD/I#F^,JUJG_N4A:Z$25\?<>C4-&/(F^=HZJ[,<^/,)=\8EZ#Q'6;F
M0Z.(\ZJF&H^^?8?(<,';"^R ]:1/+YSKA7(K ,%AWQDD<B==>+*U74:2I#7L
MD==JLQD!5;_R5V4@B6]H3H:Z7@I(BD#597\U[48Z]B;T]UU#?X>;T-\F]/=
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M+&JAB]%Z 7DJ2ZM/0?-TK;'=5"3QT+#A4G#OMJBA:;KZZC;!@W\!4$L#!!0
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M'&FNZT5.L7=]?07&:^_TR5LV=D_D#T/DD\DC$SF3W.<(=-.DRY CB/=EC#/
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M3/M.I30).(5 JHBJ-RV[!2'EO!:CN^MB_Y;7]8+5#"/$@$B64W_YS_![T-!
MB=,R+=G8R*2X+.,W.%G(F?9C=DNC33O84,8J\"6QM<*_:)E4;=:O"Z2CYLT-
MV_LW>E-5;#6OO9>!8* K+!"RY$##55WM.J37SL&ZYU6#K8E1=5FL@T&IE/ 5
M^M9#_X8?K?%F-,+K,UP$/AA]N)0F>)YG. //<WH'D&&E"!,%DFOPN[;MX509
M?D%)*.0)O[3@BA/1!I(#20N)B-IHYGAP^L<,)73-#HB(ZMMIQN6"TGJYJYG"
M+_>\MD+)^84O0GF!0,0:Y>UB&;-]QYNB]%8!"ZN$UIXA_S^&N+O,$-?N.MWN
M9H;LH?^C0]_;;>@/^DYG#_T]]#=!O[/3T'>ZWE[U]]#?#/W#G8:^ZW6Z[E-"
M'_;8?S[8[^XT]CW;>>CG\%[V?W3H]W8/^EX#^LYA#Z&_Q^FSQVE_]W#:E.AN
M[_ ;?Y2VOZ[/[5+&WXMH%E:>_T&TAX7MGA#/AQ"#G2;$H=?K]Y_PF>5AY#_Y
M$6#C] ^\[G;WLF9%V11@/^*L."#AEZF2,Q$5E);*?Q&7K\?3>>,A\EHENIO/
M0NL(O/(U_*:RM,8( SE3H&@FE8:H[!NY( @4\ IE==UVU7JB:)[1\.[X-&:"
MB! 7QR"6YZ$/0*HX:N6S"-<M#U99#D="S'#F=>6S0KUC&[\^]( "L52EUP4E
M"LK#*3BAJ.4!5> Y99R.N=U#_>_9J/#?=B9L*8G6V,HM.%4BU_"2I-D0/B,?
MIG!^?O5T26RY3> MX9JE4M%VP8$%;SX*/(,-6>%M,_"J_:!Z3]3#(F:7KV&C
MU6GU1AWU.C?L%3VM^ZGJH94>J_7^K8Q,J1$H2KX8)-;XF$%N)(OJ+_O>P.PX
MRP>0NM_*+A\TJKZPLM%L_!=02P,$%     @ V4-C5"&&X+DD"0  @2P  !@
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MHR#N)FMYC'Z0MTIVY\\Y-^0I'F&B$:LT=:MG2^*"*7 /$D_=USR#@F>*%#:
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M$0H7&)41$,@B$-.DG%/T*E).\1S'<D*LN 9F>.92)5SX-1(T$"$7\T7<8W]
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M8RTR,#(Q,3(S,2YX<V102P$"% ,4    " #90V-4[*IO]RP.  "9OP  %0
M            @ $>$0  9VQY8RTR,#(Q,3(S,5]C86PN>&UL4$L! A0#%
M  @ V4-C5'Z"=)_&)0  &*\" !4              ( !?1\  &=L>6,M,C R
M,3$R,S%?9&5F+GAM;%!+ 0(4 Q0    ( -E#8U0<5FR;9&$  !]V!0 5
M          "  79%  !G;'EC+3(P,C$Q,C,Q7VQA8BYX;6Q02P$"% ,4
M" #90V-448KO[BA$   ?%@4 %0              @ $-IP  9VQY8RTR,#(Q
M,3(S,5]P<F4N>&UL4$L! A0#%     @ V4-C5/\(*B/ - , _GL; !4
M         ( !:.L  &=L>6,M,C R,3$R,S%X,3!K+FAT;5!+ 0(4 Q0    (
M -E#8U0F]%&]FI,  "ZW   8              "  5L@! !G;'EC+3(P,C$Q
M,C,Q>#$P:S P-BYJ<&=02P$"% ,4    " #90V-41R%G&-I_  !DCP  &
M            @ $KM 0 9VQY8RTR,#(Q,3(S,7@Q,&LP,#<N:G!G4$L! A0#
M%     @ V4-C5"7D VAU)0  +^8  !D              ( !.S0% &=L>6,M
M,C R,3$R,S%X97@Q,&0Q,RYH=&U02P$"% ,4    " #90V-44OP8@'(*  #Y
M6   &0              @ 'G604 9VQY8RTR,#(Q,3(S,7AE>#$P9#$T+FAT
M;5!+ 0(4 Q0    ( -E#8U0K26#Q#%8  $.G @ 9              "  9!D
M!0!G;'EC+3(P,C$Q,C,Q>&5X,3!D,3DN:'1M4$L! A0#%     @ V4-C5$)B
ME)<S!0  .R<  !@              ( !T[H% &=L>6,M,C R,3$R,S%X97@R
M,V0Q+FAT;5!+ 0(4 Q0    ( -E#8U0AAN"Y) D  ($L   8
M  "  3S !0!G;'EC+3(P,C$Q,C,Q>&5X,S%D,2YH=&U02P$"% ,4    " #9
M0V-4,U7\UC<)  "X+0  &               @ &6R04 9VQY8RTR,#(Q,3(S
M,7AE>#,Q9#(N:'1M4$L! A0#%     @ V4-C5/E%C$*F!P  [B,  !@
M         ( ! ],% &=L>6,M,C R,3$R,S%X97@S,F0Q+FAT;5!+!08
..#P /  <$  #?V@4    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
